Título	link	data	tipo	doi	issn	ISSN	Periódico	Qualis	FI (JCR)	H-index	media_citacao_3_anos	Resumo_antigo	Categorias	categories	Resumo	PUBMEDID	Periódico	ISSN	DOI	Tradução do título	Tradução do resumo
Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab – A Case- Controlled Study.	https://doi.org/10.1093/qjmed/hcaa206	19/06/2020	Preprint	10.1093/qjmed/hcaa206	-	-	-	-	-	-	-	-	['Tocilizumabe']	['Tocilizumab']	A high basal level of autophagic flux in bladder cancer (BC) cells prevents cell death and weakens chemotherapy efficacy. However, how autophagy influences cancer-associated immunosuppression in BC remains undetermined. In this study, we observed a negative correlation between the autophagy-related markers LC3-II and programmed death ligand-1 (PD-L1) in BC cells. The autophagy inhibitors chloroquine (CQ) and bafilomycin A1 (Baf-A1) increased PD-L1 expression in BC cells through the ERK-JNK-c-Jun signal-transduction pathway. Moreover, the treatment of BC cells with CQ and Baf-A1 inhibited hsa-microRNA-34a (miR-34a) expression and miR-34a overexpression in BC cells prevented the autophagy blockade-induced PD-L1 expression; a negative correlation between miR-34a and PD-L1 expression was observed during treatment with autophagy inhibitors. Furthermore, miR-34a overexpression induced the cytotoxic activity of natural killer cells against BC cells. Our results provide evidence that autophagy blockade and its regulatory pathway affect cancer-associated immunosuppression through PD-L1 elevation. Thus, the coadministration of autophagy inhibitors and a PD-L1 immune checkpoint blockade provides a potential therapeutic approach for treating BC.	33447849	QJM : monthly journal of the Association of Physicians	1460-2393	10.1093/qjmed/hcaa266	Resultados em pacientes com doença grave de COVID-19 tratados com tocilizumabe - um estudo de caso-controle. 	Um alto nível basal de fluxo autofágico em células de câncer de bexiga (BC) previne a morte celular e enfraquece a eficácia da quimioterapia. No entanto, como a autofagia influencia a imunossupressão associada ao câncer no CB permanece indeterminado. Neste estudo, observamos uma correlação negativa entre os marcadores relacionados à autofagia LC3-II e o ligante-1 de morte programada (PD-L1) em células BC. Os inibidores de autofagia cloroquina (CQ) e bafilomicina A1 (Baf-A1) aumentaram a expressão de PD-L1 em células BC através da via de transdução de sinal ERK-JNK-c-Jun. Além disso, o tratamento de células BC com CQ e Baf-A1 inibiu a expressão de hsa-microRNA-34a (miR-34a) e a superexpressão de miR-34a em células BC impediu a expressão de PD-L1 induzida pelo bloqueio de autofagia; uma correlação negativa entre a expressão de miR-34a e PD-L1 foi observada durante o tratamento com inibidores de autofagia. Além disso, a superexpressão de miR-34a induziu a atividade citotóxica de células natural killer contra células BC. Nossos resultados fornecem evidências de que o bloqueio da autofagia e sua via regulatória afetam a imunossupressão associada ao câncer através da elevação de PD-L1. Assim, a coadministração de inibidores de autofagia e um bloqueio de checkpoint imunológico PD-L1 fornece uma abordagem terapêutica potencial para o tratamento de BC.
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2	https://doi.org/10.1016/j.cell.2020.08.026	19/08/2020	Estudo pré-clínico	10.1016/j.cell.2020.08.026	0092-8674	928674	CELL (CAMBRIDGE)	A1	25.716	814	42.41	-	['Vacina ChAd-SARS-CoV-2-S']	['ChAd-SARS-CoV-2-S vaccine']	The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor. Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission and curtailing pandemic spread.	32931734	Cell	1097-4172	10.1016/j.cell.2020.08.026	Uma vacina contra ChAd intranasal de dose única protege o trato respiratório superior e inferior contra SARS-CoV- 	2 Avaliamos a atividade protetora de uma vacina vetorizada de adenovírus de chimpanzé que codifica uma proteína spike estabilizada por pré-fusão (ChAd-SARS-CoV-2-S) em estudos de desafio com coronavírus 2 de síndrome respiratória aguda grave (SARS-CoV-2) e camundongos expressando o receptor humano da enzima conversora de angiotensina 2. A dosagem intramuscular de ChAd-SARS-CoV-2-S induz respostas imunes humorais sistêmicas robustas e mediadas por células e protege contra infecção pulmonar, inflamação e patologia, mas não confere imunidade esterilizante, como evidenciado pela detecção de RNA viral e indução de anticorpos anti-inflamatórios. -anticorpos de nucleoproteína após desafio SARS-CoV-2. Em contraste, uma única dose intranasal de ChAd-SARS-CoV-2-S induz altos níveis de anticorpos neutralizantes, promove imunoglobulina A (IgA) sistêmica e mucosa e respostas de células T e previne quase inteiramente a infecção por SARS-CoV-2 em ambos as vias respiratórias superiores e inferiores. A administração intranasal de ChAd-SARS-CoV-2-S é um candidato para prevenir a infecção e transmissão por SARS-CoV-2 e reduzir a propagação da pandemia.
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge	https://doi.org/10.1038/s41467-020-17972-1	14/08/2020	Estudo pré-clínico	10.1038/s41467-020-17972-1	2041-1723	20411723	NATURE COMMUNICATIONS	A1	4.846	410	15.82	 Abstract The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease. Here, we find that a single vaccination with a replication-defective human type 5 adenovirus encoding the SARS-CoV-2 spike protein (Ad5-nCoV) protect mice completely against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. Additionally, a single vaccination with Ad5-nCoV protects ferrets from wild-type SARS-CoV-2 infection in the upper respiratory tract. This study suggests that the mucosal vaccination may provide a desirable protective efficacy and this delivery mode is worth further investigation in human clinical trials.	['Ad5-nCoV']	['Ad5-nCoV']	-	-	-	-	-	Uma única dose de uma vacina com vetor de adenovírus fornece proteção contra o desafio SARS-CoV-2 	-
A Thermostable mRNA Vaccine against COVID-19	https://doi.org/10.1016/j.cell.2020.07.024	23/07/2020	Estudo pré-clínico	10.1016/j.cell.2020.07.024	0092-8674	928674	CELL (CAMBRIDGE)	A1	25.716	814	42.41	-	['Vacina mRNA-LNP']	['mRNA-LNP vaccine']	-	-	-	-	-	Uma vacina de mRNA termoestável contra COVID-19 	-
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice	https://doi.org/10.1016/j.immuni.2020.07.019	30/07/2020	Estudo pré-clínico	10.1016/j.immuni.2020.07.019	1074-7613	10747613	IMMUNITY (CAMBRIDGE, MASS.)	A1	14.075	417	26.14	-	['Vacina mRNA-LNP', 'Vacina mRNA-LNP', 'Vacina mRNA-LNP', 'Vacina mRNA-LNP']	['mRNA-LNP vaccine', 'mRNA-LNP vaccine', 'mRNA-LNP vaccine', 'mRNA-LNP vaccine']	SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4	32783919	Immunity	1097-4180	10.1016/j.immuni.2020.07.019	Uma única imunização com vacinas de mRNA modificadas por nucleosídeos provoca fortes respostas imunes celulares e humorais contra SARS-CoV-2 em camundongos 	A infecção por SARS-CoV-2 emergiu como uma grave pandemia global. Devido à alta transmissibilidade do vírus e à alta taxa de morbidade e mortalidade associada ao COVID-19, o desenvolvimento de vacinas eficazes e seguras é uma das principais prioridades de pesquisa. Aqui, fornecemos uma avaliação detalhada da imunogenicidade de vacinas de mRNA (mRNA-LNP) encapsuladas em nanopartículas lipídicas que codificam a proteína spike SARS-CoV-2 de comprimento total ou o domínio de ligação ao receptor spike em camundongos. Demonstramos que uma única dose dessas vacinas induz fortes CD4 tipo 1
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques	https://doi.org/10.1038/s41586-020-2607-z	30/07/2020	Estudo pré-clínico	10.1038/s41586-020-2607-z	0028-0836	280836	NATURE (LONDON)	A1	17.897	1276	19.35	-	['Vacina (Ad26.COV2.S)', 'Vacina (Ad26.COV2.S)']	['Vaccine (Ad26.COV2.S)', 'Vaccine (Ad26.COV2.S)']	SARS-CoV-2 infection has emerged as a serious global pandemic. Because of the high transmissibility of the virus and the high rate of morbidity and mortality associated with COVID-19, developing effective and safe vaccines is a top research priority. Here, we provide a detailed evaluation of the immunogenicity of lipid nanoparticle-encapsulated, nucleoside-modified mRNA (mRNA-LNP) vaccines encoding the full-length SARS-CoV-2 spike protein or the spike receptor binding domain in mice. We demonstrate that a single dose of these vaccines induces strong type 1 CD4	33469218	Nature	1476-4687	10.1038/s41586-020-03100-y	A vacina Ad26 de dose única protege contra SARS-CoV-2 em macacos rhesus 	A infecção por SARS-CoV-2 emergiu como uma grave pandemia global. Devido à alta transmissibilidade do vírus e à alta taxa de morbidade e mortalidade associada ao COVID-19, o desenvolvimento de vacinas eficazes e seguras é uma das principais prioridades de pesquisa. Aqui, fornecemos uma avaliação detalhada da imunogenicidade de vacinas de mRNA (mRNA-LNP) encapsuladas em nanopartículas lipídicas que codificam a proteína spike SARS-CoV-2 de comprimento total ou o domínio de ligação ao receptor spike em camundongos. Demonstramos que uma única dose dessas vacinas induz fortes CD4 tipo 1
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates	https://www.nejm.org/doi/full/10.1056/NEJMoa2024671	28/07/2020	Estudo pré-clínico	10.1056/NEJMoa2024671	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']	-	-	-	-	-	Avaliação da vacina mRNA-1273 contra SARS-CoV-2 em primatas não humanos 	-
A human monoclonal antibody blocking SARS-CoV-2 infection	https://doi.org/10.1038/s41467-020-16256-y	04/05/2020	Estudo pré-clínico	10.1038/s41467-020-16256-y	2041-1723	20411723	NATURE COMMUNICATIONS	A1	4.846	410	15.82	 Abstract The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.	['Anticorpos']	['Antibodies']	-	-	-	-	-	Um anticorpo monoclonal humano bloqueando a infecção por SARS-CoV-2 	-
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis	https://wjes.biomedcentral.com/articles/10.1186/s13017-020-00305-4	20/04/2020	Estudo pré-clínico	https://wjes.biomedcentral.com/articles/10.1186/s13017-020-00305-4	1749-7922	17497922	WORLD JOURNAL OF EMERGENCY SURGERY	A1	1.736	51	7.7	 Abstract  Background COVID-19 threatens to quickly overwhelm our existing critical care infrastructure in the USA. Systemic tissue plasminogen activator (tPA) has been previously demonstrated to improve PaO 2/FiO 2 (mmHg) when given to critically ill patients with acute respiratory distress syndrome (ARDS). It is unclear to what extent tPA may impact population-based survival during the current US COVID-19 pandemic.  Methods A decision analytic Markov state transition model was created to simulate the life critically ill COVID-19 patients as they transitioned to either recovery or death. Two patient groups were simulated (50,000 patients in each group); (1) Patients received tPA immediately upon diagnosis of ARDS and (2) patients received standard therapy for ARDS. Base case critically ill COVID-19 patients were defined as having a refractory PaO 2/FiO 2 of &lt; 60 mmHg (salvage use criteria). Transition from severe to moderate to mild ARDS, recovery, and death were estimated. Markov model parameters were extracted from existing ARDS/COVID-19 literature.  Results The use of tPA was associated with reduced mortality (47.6% [tTPA] vs. 71.0% [no tPA]) for base case patients. When extrapolated to the projected COVID-19 eligible for salvage use tPA in the USA, peak mortality (deaths/100,000 patients) was reduced for both optimal social distancing (70.5 [tPA] vs. 75.0 [no tPA]) and no social distancing (158.7 [tPA] vs. 168.8 [no tPA]) scenarios.  Conclusions Salvage use of tPA may improve recovery of ARDS patients, thereby reducing COVID-19-related mortality and ensuring sufficient resources to manage this pandemic.	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']	Salvage use of tPA may improve recovery of ARDS patients, thereby reducing COVID-19-related mortality and ensuring sufficient resources to manage this pandemic.	32312290	World journal of emergency surgery : WJES	1749-7922	10.1186/s13017-020-00305-4	Uso de resgate de ativador de plasminogênio tecidual (tPA) no cenário da síndrome do desconforto respiratório agudo (SDRA) devido a COVID-19 nos EUA: uma análise de decisão de Markov O 	uso de resgate de tPA pode melhorar a recuperação de pacientes com SDRA, reduzindo assim a COVID-19- mortalidade relacionada e garantir recursos suficientes para gerenciar esta pandemia.
Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study	https://pubs.acs.org/doi/abs/10.1021/acs.jcim.0c00179	21/04/2020	Estudo pré-clínico	10.1021/acs.jcim.0c00179	1549-9596	15499596	JOURNAL OF CHEMICAL INFORMATION AND MODELING	A1	1.223	169	5.91	-	['Carfilzomibe', 'Elbasvir', 'Eravaciclina', 'Estreptomicina', 'Lopinavir', 'Valrubicina']	['Carfilzomib', 'Elbasvir', 'Eravacycline', 'Streptomycin', 'Lopinavir', 'Valrubicin']	The recent outbreak of novel coronavirus disease -19 (COVID-19) calls for and welcomes possible treatment strategies using drugs on the market. It is very efficient to apply computer-aided drug design techniques to quickly identify promising drug repurposing candidates, especially after the detailed 3D-structures of key virous proteins are resolved. Taking the advantage of a recently released crystal structure of COVID-19 protease in complex with a covalently-bonded inhibitor, N3,<sup>1</sup> I conducted virtual docking screening of approved drugs and drug candidates in clinical trials. For the top docking hits, I then performed molecular dynamics simulations followed by binding free energy calculations using an endpoint method called MM-PBSA-WSAS.<sup>2-4</sup> Several promising known drugs stand out as potential inhibitors of COVID-19 protease, including Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir. Carfilzomib, an approved anti-cancer drug acting as a proteasome inhibitor, has the best MM-PBSA-WSAS binding free energy, -13.82 kcal/mol. Streptomycin, an antibiotic and a charged molecule, also demonstrates some inhibitory effect, even though the predicted binding free energy of the charged form (-3.82 kcal/mol) is not nearly as low as that of the neutral form (-7.92 kcal/mol). One bioactive, PubChem 23727975, has a binding free energy of -12.86 kcal/mol. Detailed receptor-ligand interactions were analyzed and hot spots for the receptor-ligand binding were identified. I found that one hotspot residue HIS41, is a conserved residue across many viruses including COVID-19, SARS, MERS, and HCV. The findings of this study can facilitate rational drug design targeting the COVID-19 protease.	32510523	ChemRxiv : the preprint server for chemistry	2573-2293	10.26434/chemrxiv.11875446.v1	Identificação rápida de possível tratamento medicamentoso da doença de coronavírus -19 (COVID-19) por meio de estudo de reaproveitamento computacional 	de medicamentos É muito eficiente aplicar técnicas de design de drogas auxiliadas por computador para identificar rapidamente candidatos promissores para reaproveitamento de drogas, especialmente depois que as estruturas 3D detalhadas das principais proteínas virais são resolvidas. Aproveitando-se de uma estrutura cristalina da protease COVID-19 lançada recentemente em complexo com um inibidor de ligação covalente, N3,<sup>1</sup>, conduzi uma triagem virtual de ancoragem de medicamentos aprovados e candidatos a medicamentos em ensaios clínicos. Para os principais acertos de ancoragem, realizei simulações de dinâmica molecular seguidas de cálculos de energia livre de ligação usando um método de endpoint chamado MM-PBSA-WSAS.<sup>2-4</sup> Vários medicamentos conhecidos promissores se destacam como potenciais inibidores da COVID -19 protease, incluindo Carfilzomibe, Eravaciclina, Valrubicina, Lopinavir e Elbasvir. O carfilzomibe, um medicamento anticâncer aprovado que atua como inibidor de proteassoma, tem a melhor energia livre de ligação ao MM-PBSA-WSAS, -13,82 kcal/mol. A estreptomicina, um antibiótico e uma molécula carregada, também demonstra algum efeito inibitório, embora a energia livre de ligação prevista da forma carregada (-3,82 kcal/mol) não seja tão baixa quanto a da forma neutra (-7,92 kcal/mol) ). Um bioativo, PubChem 23727975, tem uma energia livre de ligação de -12,86 kcal/mol. As interações receptor-ligando detalhadas foram analisadas e os pontos quentes para a ligação receptor-ligante foram identificados. Descobri que um resíduo de hotspot HIS41 é um resíduo conservado em muitos vírus, incluindo COVID-19, SARS, MERS e HCV. As descobertas deste estudo podem facilitar o design racional de medicamentos visando a protease COVID-19.
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody	https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1729069	17/02/2020	Estudo pré-clínico	10.1080/22221751.2020.1729069	2222-1751	22221751	EMERGING MICROBES & INFECTIONS (ONLINE)	A1	3.322	68	13.11	-	['Anticorpos']	['Antibodies']	The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity of receptor-binding domain (RBD) in 2019-nCoV and SARS-CoV, it is urgent to assess the cross-reactivity of anti-SARS CoV antibodies with 2019-nCoV spike protein, which could have important implications for rapid development of vaccines and therapeutic antibodies against 2019-nCoV. Here, we report for the first time that a SARS-CoV-specific human monoclonal antibody, CR3022, could bind potently with 2019-nCoV RBD (KD of 6.3 nM). The epitope of CR3022 does not overlap with the ACE2 binding site within 2019-nCoV RBD. These results suggest that CR3022 may have the potential to be developed as candidate therapeutics, alone or in combination with other neutralizing antibodies, for the prevention and treatment of 2019-nCoV infections. Interestingly, some of the most potent SARS-CoV-specific neutralizing antibodies (e.g. m396, CR3014) that target the ACE2 binding site of SARS-CoV failed to bind 2019-nCoV spike protein, implying that the difference in the RBD of SARS-CoV and 2019-nCoV has a critical impact for the cross-reactivity of neutralizing antibodies, and that it is still necessary to develop novel monoclonal antibodies that could bind specifically to 2019-nCoV RBD.	32065055	Emerging microbes & infections	2222-1751	10.1080/22221751.2020.1729069	Ligação potente da nova proteína de pico de coronavírus de 2019 por um anticorpo monoclonal humano específico para o coronavírus 	SARS . Atualmente, no entanto, não há tratamento antiviral específico ou vacina. Considerando a identidade relativamente alta do domínio de ligação ao receptor (RBD) em 2019-nCoV e SARS-CoV, é urgente avaliar a reatividade cruzada de anticorpos anti-SARS CoV com a proteína spike 2019-nCoV, o que pode ter implicações importantes para rápido desenvolvimento de vacinas e anticorpos terapêuticos contra 2019-nCoV. Aqui, relatamos pela primeira vez que um anticorpo monoclonal humano específico para SARS-CoV, CR3022, pode se ligar potentemente ao 2019-nCoV RBD (KD de 6,3 nM). O epítopo de CR3022 não se sobrepõe ao sítio de ligação de ACE2 no 2019-nCoV RBD. Esses resultados sugerem que o CR3022 pode ter potencial para ser desenvolvido como terapia candidata, isoladamente ou em combinação com outros anticorpos neutralizantes, para a prevenção e tratamento de infecções por 2019-nCoV. Curiosamente, alguns dos anticorpos neutralizantes específicos de SARS-CoV mais potentes (por exemplo, m396, CR3014) que visam o local de ligação de ACE2 de SARS-CoV não conseguiram se ligar à proteína de pico de 2019-nCoV, o que implica que a diferença no RBD de SARS-CoV e 2019-nCoV tem um impacto crítico para a reatividade cruzada de anticorpos neutralizantes, e que ainda é necessário desenvolver novos anticorpos monoclonais que possam se ligar especificamente ao 2019-nCoV RBD.
Peptide-like and small-molecule inhibitors against Covid-19	https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1757510	20/04/2020	Estudo pré-clínico	10.1080/07391102.2020.1757510	0739-1102	7391102	JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS	A3	0.561	73	3.78	-	['Apicidina', 'Carfilzomibe', 'Darunavir', 'Dobutamina', 'Lopinavir', 'Nelfinavir', 'Ritonavir', 'Saquinavir', 'Teniposídeo']	['Apicidin', 'Carfilzomib', 'Darunavir', 'Dobutamine', 'Lopinavir', 'Nelfinavir', 'Ritonavir', 'Saquinavir', 'Teniposide']	Coronavirus disease strain (SARS-CoV-2) was discovered in 2019, and it is spreading very fast around the world causing the disease Covid-19. Currently, more than 1.6 million individuals are infected, and several thousand are dead across the globe because of Covid-19. Here, we utilized the 	32306822	Journal of biomolecular structure & dynamics	1538-0254	10.1080/07391102.2020.1757510	Os inibidores peptídicos e de pequenas moléculas contra a 	cepa da doença de coronavírus Covid-19 (SARS-CoV-2) foram descobertos em 2019 e estão se espalhando muito rapidamente pelo mundo causando a doença Covid-19. Atualmente, mais de 1,6 milhão de indivíduos estão infectados e vários milhares estão mortos em todo o mundo por causa do Covid-19. Aqui, utilizamos o
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease	https://doi.org/10.1016/j.tmaid.2020.101646	12/04/2020	Estudo pré-clínico	10.1016/j.tmaid.2020.101646	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Adeflavin', 'Coenzima A', 'Indinavir', 'Narcissoside', 'Remdesivir', 'Saquinavir', 'Zanamivir']	['Adeflavin', 'Coenzyme A', 'Indinavir', 'Narcissoside', 'Remdesivir', 'Saquinavir', 'Zanamivir']	Zanamivir, Indinavir, Saquinavir, and Remdesivir are among the exciting hits on the 3CL	32294562	Travel medicine and infectious disease	1873-0442	10.1016/j.tmaid.2020.101646	Uma busca por medicamentos para tratar o COVID-19 por meio de modelos de encaixe molecular in silico da glicoproteína de pico SARS-CoV-2 e da protease 3CL 	Zanamivir, Indinavir, Saquinavir e Remdesivir estão entre os sucessos emocionantes do 3CL
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19	https://doi.org/10.1016/j.lfs.2020.117477	28/02/2020	Estudo pré-clínico	10.1016/j.lfs.2020.117477	0024-3205	243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Cinamaldeído', 'Guanosina trifosfato', 'IDX-184', 'Remdesivir', 'Ribavirina', 'Sofosbuvir', 'Timoquinona']	['Cinmaldehyde', 'Guanosine triphosphate', 'IDX-184', 'Remdesivir', 'Ribavirin', 'Sofosbuvir', 'Thymoquinone']	-	-	-	-	-	Anti-HCV, inibidores de nucleotídeos, reaproveitamento contra COVID-19 	-
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods	https://doi.org/10.1016/j.apsb.2020.02.008	27/02/2020	Estudo pré-clínico	10.1016/j.apsb.2020.02.008	2211-3835	22113835	ACTA PHARMACEUTICA SINICA B	A1	2.200	65	13.74	-	['Cassine xylocarpa', 'Cloroquina', 'Derivados de andrografolideo', 'Gluconato de clorexidina', 'Limeciclina', 'Lopinavir', 'Platycodon grandiflorus', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Scutellaria baicalensis', 'Valganciclovir']	['Cassine xylocarpa', 'Chloroquine', 'Andrografolide derivatives', 'Chlorhexidine gluconate', 'Limecycline', 'Lopinavir', 'Platycodon grandiflorus', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Scutellaria baicalensis ', 'Valganciclovir']	-	-	-	-	-	Análise de alvos terapêuticos para SARS-CoV-2 e descoberta de potenciais medicamentos por métodos computacionais 	-
Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach	https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1751298	13/04/2020	Estudo pré-clínico	10.1080/07391102.2020.1751298	0739-1102	7391102	JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS	A3	0.561	73	3.78	-	['Darunavir', 'Derivados cumarínicos e flavonas (origem natural)', 'Remdesivir', 'Saquinavir']	['Darunavir', 'Coumarin derivatives and flavones (natural origin)', 'Remdesivir', 'Saquinavir']	Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL	32238094	Journal of biomolecular structure & dynamics	1538-0254	10.1080/07391102.2020.1751298	Identificação de inibidores de protease semelhantes à quimotripsina de SARS-CoV-2 por meio de abordagem computacional integrada 	Recentemente, o mundo testemunhou o surto de um novo coronavírus (SARS-CoV-2), o vírus que surgiu inicialmente em Wuhan, China para grande parte do mundo, resultando em uma emergência pública de interesse internacional. A importância funcional da protease do tipo Quimotripsina (3CL
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency	https://www.jbc.org/cgi/doi/10.1074/jbc.RA120.013679	13/04/2020	Estudo pré-clínico	10.1074/jbc.RA120.013679	0021-9258	219258	THE JOURNAL OF BIOLOGICAL CHEMISTRY (PRINT)	A1	1.871	528	5.02	-	['Remdesivir']	['Remdesivir']	Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analogue remdesivir (RDV). RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action. Here, we expressed and purified active SARS-CoV-2 RdRp composed of the nonstructural proteins nsp8 and nsp12. Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA. Incorporation of RDV-TP at position 	32284326	The Journal of biological chemistry	1083-351X	10.1074/jbc.RA120.013679	O remdesivir é um antiviral de ação direta que inibe a RNA polimerase dependente de RNA da síndrome respiratória aguda grave coronavírus 2 com alta potência 	Tratamentos eficazes para a doença do coronavírus 2019 (COVID-19) são urgentemente necessários para controlar esta pandemia atual, causada pela síndrome respiratória aguda grave coronavírus 2 (SARS-CoV-2). A replicação do SARS-CoV-2 depende da RNA polimerase dependente de RNA viral (RdRp), que é o provável alvo do análogo de nucleotídeo em investigação remdesivir (RDV). O RDV mostra atividade antiviral de amplo espectro contra vírus de RNA, e estudos anteriores com RdRps do vírus Ebola e coronavírus da síndrome respiratória do Oriente Médio (MERS-CoV) revelaram que a terminação tardia da cadeia é o mecanismo de ação plausível do RDV. Aqui, expressamos e purificamos o SARS-CoV-2 RdRp ativo composto pelas proteínas não estruturais nsp8 e nsp12. A cinética enzimática indicou que este RdRp incorpora eficientemente a forma trifosfato ativa de RDV (RDV-TP) no RNA. Incorporação de RDV-TP na posição
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease	https://doi.org/10.1016/j.lfs.2020.117627	03/04/2020	Estudo pré-clínico	10.1016/j.lfs.2020.117627	0024-3205	243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Agentes anti-tuberculose', 'Agentes anti-tuberculose', 'Antineoplásicos', 'Antineoplásicos', 'Antivirais', 'Antivirais', 'Nicotinamida', 'Nicotinamida', 'Ribavirina', 'Ribavirina', 'Telbivudina', 'Telbivudina', 'Vitamina B12', 'Vitamina B12', 'Vitaminas', 'Vitaminas']	['Anti-tuberculosis agents', 'Anti-tuberculosis agents', 'Antineoplastics', 'Antineoplastics', 'Antivirals', 'Antivirals', 'Nicotinamide', 'Nicotinamide', 'Ribavirin', 'Ribavirin', 'Telbivudine' , 'Telbivudine', 'Vitamin B12', 'Vitamin B12', 'Vitamins', 'Vitamins']	-	-	-	-	-	Triagem virtual e redirecionamento de medicamentos aprovados pela FDA contra a principal protease da COVID-19 	-
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro	https://doi.org/10.1016/j.antiviral.2020.104786	03/04/2020	Estudo pré-clínico	10.1016/j.antiviral.2020.104786	0166-3542	1663542	ANTIVIRAL RESEARCH	A1	2.213	134	9.13	-	['Emetine', 'Homoharringtonina (HHT)', 'Lopinavir', 'Remdesivir', 'Ritonavir']	['Emetine', 'Homoharringtonine (HHT)', 'Lopinavir', 'Remdesivir', 'Ritonavir']	An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 μM, 26.63 μM, 2.55 μM and 0.46 μM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 μM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 μM in combination with emetine at 0.195 μM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.	32251767	Antiviral research	1872-9096	10.1016/j.antiviral.2020.104786	Remdesivir , lopinavir, emetina e homoharringtonina inibem a replicação do SARS-CoV-2 in 	vitro Avaliamos o efeito antiviral in vitro de compostos que foram relatados anteriormente para inibir a replicação de coronavírus e compostos que estão atualmente sob avaliação em ensaios clínicos para pacientes com SARS-CoV-2. Relatamos o efeito antiviral de remdesivir, lopinavir, homorringtonina e emetina contra o vírus SARS-CoV-2 em células Vero E6 com a concentração efetiva estimada de 50% em 23,15 μM, 26,63 μM, 2,55 μM e 0,46 μM, respectivamente. Ribavirina ou favipiravir que são atualmente avaliados em ensaios clínicos não mostraram inibição a 100 μM. Sinergia entre remdesivir e emetina foi observada, e remdesivir a 6,25 μM em combinação com emetina a 0,195 μM pode atingir 64,9% de inibição no rendimento viral. A terapia combinada pode ajudar a reduzir a concentração efetiva de compostos abaixo das concentrações plasmáticas terapêuticas e proporcionar melhores benefícios clínicos.
Covid-19 treatment update: follow the scientific evidence	https://link.springer.com/article/10.1007/s11239-020-02120-9	27/04/2020	Editorial	https://link.springer.com/article/10.1007/s11239-020-02120-9	0929-5305	9295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Atualização do tratamento Covid-19: siga as evidências científicas 	-
Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19	https://doi.org/10.1016/j.onehlt.2020.100131	04/04/2020	Editorial	10.1016/j.onehlt.2020.100131	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of people with close contact with patients with positive COVID19 rtPCR, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at doses matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.	32292817	One health (Amsterdam, Netherlands)	2352-7714	10.1016/j.onehlt.2020.100131	Coalizão: Defesa de ensaios clínicos prospectivos para testar o potencial pós-exposição da hidroxicloroquina contra o COVID-19 	Nossa coalizão de especialistas em saúde pública, médicos e cientistas em todo o mundo quer chamar a atenção para a necessidade de protocolos de avaliação de alta qualidade do potencial efeito benéfico da hidroxicloroquina (HCQ) como medicamento pós-exposição para pessoas expostas. Na ausência de um medicamento ou vacina profilática pré ou pós-exposição aprovada e reconhecidamente eficaz para COVID-19, nem de qualquer medicamento terapêutico aprovado e validado, juntamente com a pressão social e política levantada pela publicidade, tanto em relação ao potencial efeito benéfico da hidroxicloroquina. HCQ), bem como os riscos potenciais do HCQ, pedimos os ensaios clínicos adequados imediatos. Especificamente, queremos dizer usar HCQ para pós-exposição de pessoas com contato próximo com pacientes com rtPCR COVID19 positivo, incluindo cuidadores domiciliares e médicos. Revisamos os mecanismos do efeito antiviral do HCQ, a relação risco-benefício levando em consideração o PK/PD do HCQ e os limites de eficácia. Estudamos seu uso como antimalárico, antiviral e imunomodulador e concluímos que o uso de HCQ em doses compatíveis com o tratamento padrão do Lúpus Eritematoso Sistêmico, que tem comprovada segurança e eficácia em termos de concentração de HCQ no sangue e nos tecidos adaptada ao peso corporal (2,3), a 6 mg/kg/dia 1 (dose de ataque) seguida de 5 mg/kg/dia, com limite máximo de 600 mg/dia em todos os casos, deve ser rapidamente avaliada clinicamente como pós -droga de exposição para pessoas expostas.
G6PD and chloroquine: selecting the treatment against SARS-CoV-2?	https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.15312	12/04/2020	Editorial	10.1111/jcmm.15312	1582-1838	15821838	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (PRINT)	A2	1.081	138	5.41	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of people with close contact with patients with positive COVID19 rtPCR, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at doses matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.	32281268	Journal of cellular and molecular medicine	1582-4934	10.1111/jcmm.15312	G6PD e cloroquina: selecionando o tratamento contra SARS-CoV-2? 	Nossa coalizão de especialistas em saúde pública, médicos e cientistas em todo o mundo quer chamar a atenção para a necessidade de protocolos de avaliação de alta qualidade do potencial efeito benéfico da hidroxicloroquina (HCQ) como medicamento pós-exposição para pessoas expostas. Na ausência de um medicamento ou vacina profilática pré ou pós-exposição aprovada e reconhecidamente eficaz para COVID-19, nem de qualquer medicamento terapêutico aprovado e validado, juntamente com a pressão social e política levantada pela publicidade, tanto em relação ao potencial efeito benéfico da hidroxicloroquina. HCQ), bem como os riscos potenciais do HCQ, pedimos os ensaios clínicos adequados imediatos. Especificamente, queremos dizer usar HCQ para pós-exposição de pessoas com contato próximo com pacientes com rtPCR COVID19 positivo, incluindo cuidadores domiciliares e médicos. Revisamos os mecanismos do efeito antiviral do HCQ, a relação risco-benefício levando em consideração o PK/PD do HCQ e os limites de eficácia. Estudamos seu uso como antimalárico, antiviral e imunomodulador e concluímos que o uso de HCQ em doses compatíveis com o tratamento padrão do Lúpus Eritematoso Sistêmico, que tem comprovada segurança e eficácia em termos de concentração de HCQ no sangue e nos tecidos adaptada ao peso corporal (2,3), a 6 mg/kg/dia 1 (dose de ataque) seguida de 5 mg/kg/dia, com limite máximo de 600 mg/dia em todos os casos, deve ser rapidamente avaliada clinicamente como pós -droga de exposição para pessoas expostas.
COVID-19: Important Therapy Considerations and Approaches in this Hour of Need	https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2396	08/04/2020	Editorial	10.1002/phar.2396	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of people with close contact with patients with positive COVID19 rtPCR, including home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at doses matching that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5 mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a post-exposure drug for exposed people.	32267556	Pharmacotherapy	1875-9114	10.1002/phar.2396	COVID -19: Considerações e abordagens terapêuticas importantes nesta hora de necessidade 	um medicamento pós-exposição para pessoas expostas. Na ausência de um medicamento ou vacina profilática pré ou pós-exposição aprovada e reconhecidamente eficaz para COVID-19, nem de qualquer medicamento terapêutico aprovado e validado, juntamente com a pressão social e política levantada pela publicidade, tanto em relação ao potencial efeito benéfico da hidroxicloroquina. HCQ), bem como os riscos potenciais do HCQ, pedimos os ensaios clínicos adequados imediatos. Especificamente, queremos dizer usar HCQ para pós-exposição de pessoas com contato próximo com pacientes com rtPCR COVID19 positivo, incluindo cuidadores domiciliares e médicos. Revisamos os mecanismos do efeito antiviral do HCQ, a relação risco-benefício levando em consideração o PK/PD do HCQ e os limites de eficácia. Estudamos seu uso como antimalárico, antiviral e imunomodulador e concluímos que o uso de HCQ em doses compatíveis com o tratamento padrão do Lúpus Eritematoso Sistêmico, que tem comprovada segurança e eficácia em termos de concentração de HCQ no sangue e nos tecidos adaptada ao peso corporal (2,3), a 6 mg/kg/dia 1 (dose de ataque) seguida de 5 mg/kg/dia, com limite máximo de 600 mg/dia em todos os casos, deve ser rapidamente avaliada clinicamente como pós -droga de exposição para pessoas expostas.
COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?	https://link.springer.com/article/10.1007/s00204-020-02734-1	08/04/2020	Editorial	https://link.springer.com/article/10.1007/s00204-020-02734-1	0340-5761	3405761	ARCHIVES OF TOXICOLOGY	A1	1.100	121	5.03	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	COVID-19 e lesão hepática induzida por drogas: um problema de abundância ou um ponto mesquinho? 	-
Guidelines for the pharmacological treatment of COVID-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology	https://doi.org/10.5935/0103-507X.20200039	18/05/2020	Diretriz para prática clínica	10.5935/0103-507X.20200039	0103-507X	0103507X	REVISTA BRASILEIRA DE TERAPIA INTENSIVA (IMPRESSO)	A4	0.521	23	1.54	-	['Antibióticos', 'Cloroquina', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Tocilizumabe']	['Antibiotics', 'Chloroquine', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Tocilizumab']	So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients; therefore such patients should ideally be treated in the context of clinical trials. The recommendations herein provided will be revised continuously aiming to capture newly generated evidence.	32667444	Revista Brasileira de terapia intensiva	1982-4335	10.5935/0103-507x.20200039	Diretrizes para o tratamento farmacológico da COVID-19. A força-tarefa/diretriz de consenso da Associação Brasileira de Medicina Intensiva, Sociedade Brasileira de Infectologia e Sociedade Brasileira de Pneumologia e Tisiologia 	Até o momento nenhuma intervenção farmacológica se mostrou eficaz e segura para justificar seu uso na rotina do tratamento da COVID- 19 pacientes; portanto, esses pacientes devem, idealmente, ser tratados no contexto de ensaios clínicos. As recomendações aqui fornecidas serão revisadas continuamente com o objetivo de capturar evidências recém-geradas.
Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched case-control study	https://onlinelibrary.wiley.com/doi/10.1111/ajt.16314	18/09/2020	Comunicação breve	10.1111/ajt.16314	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tocilizumab para COVID-19 grave em receptores de transplante de órgãos sólidos: um estudo de caso-controle pareado 	-
Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics	https://doi.org/10.1016/j.jfma.2020.08.022	25/09/2020	Comunicação breve	10.1016/j.jfma.2020.08.022	0929-6646	9296646	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (PRINT)	A1	0.779	59	2.92	-	['Hidroxicloroquina']	['Hydroxychloroquine']	Until now, there are no approved treatment against COVID-19. Hydroxychloroquine (HCQ) was hypothesized to be active against SARS-CoV2 via antiviral and anti-inflammatory effect; however, HCQ for COVID-19 in clinical use remained debating. In this preliminary report, we presented six patients with mild to moderate COVID-19. They were treated with HCQ for 14 days from the day of COVID-19 diagnosis. Serial viral load from respiratory specimens were performed every other day. Cytokine profile was checked before HCQ initiation and on the 14th day of HCQ treatment. All patients receiving HCQ completed 14-day course without complication. Among the six patients, the mean duration from symptom onset to last detectable viral load was 34 ± 12 days, which was similar to those without specific treatment in previous reports. Low level of interferon-gamma was noted in all patients of different stage of infection and three patients had elevation of IL-17 level. Prolonged virus shedding is still observed regardless HCQ. The impact of HCQ on cytokine kinetics remained unclear; however, IL-17 could be an inflammatory marker for disease status monitor and a potential therapeutic target.	32888840	Journal of the Formosan Medical Association = Taiwan yi zhi	0929-6646	10.1016/j.jfma.2020.08.022	Experiência do uso de hidroxicloroquina em pacientes com COVID-19: Uma perspectiva sobre carga viral e cinética de citocinas 	Até o momento, não há tratamento aprovado contra COVID-19. A hidroxicloroquina (HCQ) foi hipotetizada como ativa contra o SARS-CoV2 por meio de efeito antiviral e anti-inflamatório; no entanto, o HCQ para COVID-19 em uso clínico permaneceu em debate. Neste relatório preliminar, apresentamos seis pacientes com COVID-19 leve a moderado. Eles foram tratados com HCQ por 14 dias a partir do dia do diagnóstico de COVID-19. A carga viral seriada de amostras respiratórias foi realizada em dias alternados. O perfil de citocinas foi verificado antes do início do HCQ e no 14º dia de tratamento com HCQ. Todos os pacientes que receberam HCQ completaram o curso de 14 dias sem complicações. Entre os seis pacientes, a duração média desde o início dos sintomas até a última carga viral detectável foi de 34 ± 12 dias, semelhante àquelas sem tratamento específico em relatos anteriores. Baixo nível de interferon-gama foi observado em todos os pacientes de diferentes estágios de infecção e três pacientes tiveram elevação do nível de IL-17. A excreção prolongada de vírus ainda é observada independentemente do HCQ. O impacto do HCQ na cinética das citocinas permaneceu obscuro; no entanto, a IL-17 pode ser um marcador inflamatório para o monitor do estado da doença e um potencial alvo terapêutico.
A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort	https://doi.org/10.1007/s10096-020-04016-1	27/08/2020	Comunicação breve	10.1007/s10096-020-04016-1	0934-9723	9349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Ceftriaxona', 'Doxiciclina', 'Hidroxicloroquina', 'Lopinavir']	['Ceftriaxone', 'Doxycycline', 'Hydroxychloroquine', 'Lopinavir']	-	-	-	-	-	Uma nova abordagem para o gerenciamento de pacientes com COVID-19; resultados da coorte de lopinavir mais doxiciclina 	-
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension	https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1746200	31/03/2020	Carta do editor	10.1080/22221751.2020.1746200	2222-1751	22221751	EMERGING MICROBES & INFECTIONS (ONLINE)	A1	3.322	68	13.11	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Inibidores do sistema renina-angiotensina melhoram os resultados clínicos de pacientes com COVID-19 com hipertensão 	-
Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study	https://doi.org/10.1186/s13054-020-03215-8	08/08/2020	Carta do editor	10.1186/s13054-020-03215-8	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Plasmaferese']	['Plasmapheresis']	-	-	-	-	-	Plasmoterapia terapêutica em pacientes com pneumonia por COVID-19 em unidade de terapia intensiva: um estudo retrospectivo 	-
Efficacy of tocilizumab treatment in severely ill COVID-19 patients	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03224-7	27/07/2020	Carta do editor	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03224-7	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Azitromicina', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Prednisona', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Azithromycin', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Prednisone', 'Remdesivir', 'Ritonavir', 'Tocilizumab']	-	34631752	Frontiers in medicine	2296-858X	10.3389/fmed.2021.734838	Eficácia do tratamento com tocilizumabe em pacientes gravemente enfermos com COVID-19 	-
Argatroban for therapeutic anticoagulation for heparin resistanceassociated with Covid-19 infection	https://link.springer.com/article/10.1007/s11239-020-02251-z	24/08/2020	Carta do editor	https://link.springer.com/article/10.1007/s11239-020-02251-z	0929-5305	9295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	[]	[]	-	-	-	-	-	Argatroban para anticoagulação terapêutica para resistência à heparina associada à infecção por Covid-19 	-
“Toxic erythema” and eosinophilia associated to tocilizumab therapy in a COVID-19 patient	https://onlinelibrary.wiley.com/doi/10.1111/jdv.16620	09/05/2020	Carta do editor	10.1111/jdv.16620	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	“ Eritema tóxico” e eosinofilia associados à terapia com tocilizumabe em paciente com COVID-19 	-
Drug-induced vasculitis in a patient with COVID-19	https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16588	07/05/2020	Carta do editor	10.1111/jdv.16588	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Anti-histamínicos', 'Corticosteroides', 'Prednisolona']	['Antihistamines', 'Corticosteroids', 'Prednisolone']	-	-	-	-	-	Vasculite induzida por drogas em um paciente com COVID-19 	-
Favourable outcome of Coronavirus-19 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16781	05/05/2020	Carta do editor	10.1111/bjh.16781	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Teicoplanina']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Teicoplanin']	-	-	-	-	-	Resultado favorável do coronavírus-19 em uma menina de 1 ano com leucemia mieloide aguda e imunossupressão grave induzida por tratamento 	-
IL-6 blockade treatment for severe COVID-19 in two patients with multiple myeloma	https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16787	05/05/2020	Carta do editor	10.1111/bjh.16787	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Tocilizumabe']	['Tocilizumab']	-	32369612	British journal of haematology	1365-2141	10.1111/bjh.16787	Tratamento com bloqueio de IL-6 para COVID-19 grave em dois pacientes com mieloma múltiplo 	-
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	https://doi.org/10.1016/j.jinf.2020.04.017	23/04/2020	Carta do editor	10.1016/j.jinf.2020.04.017	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Baricitinibe']	['Baricitinib']	Personalizing the dose and duration of methylprednisolone according to the patient's disease severity assessed with demographic, clinical, and laboratory results may benefit mortality in severe COVID-19 patients receiving ventilatory support in the ICU. Hematologic disorders and malignancies, arterial blood pH and HCO3, neutrophil count, and NLR at admission were associated with mortality in our patient cohort.	32333918	The Journal of infection	1532-2742	10.1016/j.jinf.2020.04.017	Terapia com baricitinibe na COVID-19: um estudo piloto sobre segurança e impacto clínico 	Personalizar a dose e a duração da metilprednisolona de acordo com a gravidade da doença do paciente avaliada com resultados demográficos, clínicos e laboratoriais pode beneficiar a mortalidade em pacientes graves com COVID-19 que recebem suporte ventilatório em a UTI. Distúrbios hematológicos e malignidades, pH do sangue arterial e HCO3, contagem de neutrófilos e NLR na admissão foram associados à mortalidade em nossa coorte de pacientes.
Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19	https://doi.org/10.1016/S2352-3026(20)30109-5	09/04/2020	Carta do editor	10.1016/S2352-3026(20)30109-5	2352-3026	23523026	THE LANCET HAEMATOLOGY	A1	5.189	71	8.49	-	['Profilaxia para tromboembolismo']	['Prophylaxis for thromboembolism']	-	-	-	-	-	Atenção deve ser dada à profilaxia do tromboembolismo venoso no manejo da COVID-19 	-
Amiodarone in the COVID‑19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?	https://doi.org/10.1007/s40256-020-00429-7	01/08/2020	Artigo de opinião	10.1007/s40256-020-00429-7	1175-3277	11753277	AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS	A2	1.010	54	3.47	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Amiodarona na era COVID-19: tratamento apenas para pacientes sintomáticos ou medicamento para prevenir infecções? 	-
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients	https://doi.org/10.1186/s13054-020-03227-4	12/08/2020	Artigo de opinião	10.1186/s13054-020-03227-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Favipiravir', 'Nafamostato']	['Favipiravir', 'Nafamostat']	-	-	-	-	-	Eventos adversos associados ao tratamento com mesilato de nafamostat e favipiravir em pacientes com COVID-19 	-
An Inactivated Virus Candidate Vaccine to Prevent COVID-19	https://doi.org/10.1001/jama.2020.15539	13/08/2020	Artigo de opinião	10.1001/jama.2020.15539	0098-7484	987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Vacina de vírus inativado']	['Inactivated virus vaccine']	-	-	-	-	-	Uma vacina candidata a vírus inativada para prevenir o COVID-19 	-
The use of dexamethasone in the treatment of COVID-19	https://doi.org/10.1016/j.amsu.2020.07.004	09/07/2020	Artigo de opinião	10.1016/j.amsu.2020.07.004	2049-0801	20490801	ANNALS OF MEDICINE AND SURGERY	A4	0.373	30	1.78	-	['Dexametasona']	['Dexamethasone']	-	-	-	-	-	O uso de dexametasona no tratamento de COVID-19 	-
Critical COVID-19 disease, homeostasis, and the “surprise” of effective glucocorticoid therapy	https://doi.org/10.1016/j.clim.2020.108550	31/07/2020	Artigo de opinião	10.1016/j.clim.2020.108550	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']	MANAGEMENT OF CRITICAL COVID-19 IN THE INTENSIVE CARE UNIT The management of patients with severe to critical forms of Covid-19 in the intensive care unit includes oxygen therapy to treat the deep hypoxaemia induced by the disease, either delivered non-invasively (high concentration mask, high flow oxygen therapy, NIV) or invasively after oro-tracheal intubation in the most severe forms. The symptomatic management becomes then similar to that of an acute respiratory distress syndrome (ARDS) of other origin with the introduction of protective mechanical ventilation, sedation or even curarisation, and prone positioning in the most hypoxemic patients. Other organ failures, including haemodynamic and renal failures, should also be diagnosed and treated. Thrombo-prophylaxis at a higher than usual dose (intermediate or even curative dose) should also be initiated in the acute phase of the disease. Finally, specific treatment is mainly based on systemic corticosteroid therapy with dexamethasone 6 mg/d, possibly combined with tocilizumab. Other Covid-19-specific treatments have not yet been proven to be effective in critical care patients.	32745524	Clinical immunology (Orlando, Fla.)	1521-7035	10.1016/j.clim.2020.108550	Doença crítica de COVID-19, homeostase e a “surpresa” da terapia eficaz com glicocorticóides 	GERENCIAMENTO DE COVID-19 CRÍTICO NA UNIDADE DE TERAPIA INTENSIVA O manejo de pacientes com formas graves a críticas de Covid-19 na unidade de terapia intensiva inclui oxigenoterapia para tratar a hipoxemia profunda induzida pela doença, seja administrada de forma não invasiva (máscara de alta concentração, oxigenoterapia de alto fluxo, VNI) ou invasiva após intubação orotraqueal nas formas mais graves. O manejo sintomático torna-se então semelhante ao de uma síndrome do desconforto respiratório agudo (SDRA) de outra origem com a introdução de ventilação mecânica protetora, sedação ou mesmo curarização e posicionamento em decúbito ventral nos pacientes mais hipoxêmicos. Outras falências de órgãos, incluindo falências hemodinâmicas e renais, também devem ser diagnosticadas e tratadas. A tromboprofilaxia em dose maior que a usual (dose intermediária ou mesmo curativa) também deve ser iniciada na fase aguda da doença. Por fim, o tratamento específico baseia-se principalmente na corticoterapia sistêmica com dexametasona 6 mg/d, possivelmente associada ao tocilizumabe. Outros tratamentos específicos do Covid-19 ainda não foram comprovados como eficazes em pacientes de cuidados intensivos.
Vitamin D for COVID-19: a case to answer?	https://doi.org/10.1016/S2213-8587(20)30268-0	03/08/2020	Artigo de opinião	10.1016/S2213-8587(20)30268-0	2213-8587	22138587	THE LANCET DIABETES & ENDOCRINOLOGY	A1	9.767	132	11.05	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Vitamina D para COVID-19: um caso a responder? 	-
The effect of BCG vaccine in the era of COVID-19 pandemic	https://onlinelibrary.wiley.com/doi/abs/10.1111/sji.12947	22/07/2020	Artigo de opinião	10.1111/sji.12947	0300-9475	3009475	SCANDINAVIAN JOURNAL OF IMMUNOLOGY (PRINT)	A4	0.811	90	3.31	-	['Vacina BCG']	['BCG vaccine']	The emergency of the coronavirus disease 2019 (COVID-19) pandemic led to the off-label use of drugs without data on their toxicity profiles in patients with COVID-19, or on their concomitant use. Patients included in the COVID-19 Patient Registry of a tertiary hospital during the first wave were analyzed to evaluate the adverse drug reactions (ADRs) with the selected treatments. Twenty-one percent of patients (197 out of 933) had at least one ADR, with a total of 240 ADRs. Patients with ADRs were more commonly treated with multiple drugs for COVID-19 infection than patients without ADRs (	32698247	Scandinavian journal of immunology	1365-3083	10.1111/sji.12947	O efeito da vacina BCG na era da pandemia de COVID-19 	A emergência da pandemia da doença de coronavírus 2019 (COVID-19) levou ao uso off-label de medicamentos sem dados sobre seus perfis de toxicidade em pacientes com COVID-19, ou em seu uso concomitante. Os pacientes incluídos no Registro de Pacientes COVID-19 de um hospital terciário durante a primeira onda foram analisados para avaliar as reações adversas a medicamentos (RAMs) com os tratamentos selecionados. Vinte e um por cento dos pacientes (197 de 933) tiveram pelo menos uma RAM, com um total de 240 RAM. Pacientes com RAMs foram mais comumente tratados com vários medicamentos para infecção por COVID-19 do que pacientes sem RAMs.
Bacillus Calmette–Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality	https://doi.org/10.1016/j.vaccine.2020.06.083	03/07/2020	Artigo de opinião	10.1016/j.vaccine.2020.06.083	0264-410X	0264410X	VACCINE (GUILDFORD)	A2	1.392	191	4.02	-	['Cloroquina', 'Hidroxicloroquina', 'Vacina BCG']	['Chloroquine', 'Hydroxychloroquine', 'BCG Vaccine']	COVID-19 is affecting different countries all over the world with great variation in infection rate and death ratio. Some reports suggested a relation between the Bacillus Calmette-Guérin (BCG) vaccine and the malaria treatment to the prevention of SARS-CoV-2 infection. Some reports related infant's lower susceptibility to the COVID-19. Some other reports a higher risk in males compared to females in such COVID-19 pandemic. Also, some other reports claimed the possible use of chloroquine and hydroxychloroquine as prophylactic in such a pandemic. The present commentary is to discuss the possible relation between those factors and SARS-CoV-2 infection.	32654907	Vaccine	1873-2518	10.1016/j.vaccine.2020.06.083	Vacina Bacillus Calmette-Guérin, antimalárico, relação de idade e gênero com a disseminação e mortalidade 	do COVID-19 O COVID-19 está afetando diferentes países em todo o mundo, com grande variação na taxa de infecção e taxa de mortalidade. Alguns relatos sugeriram uma relação entre a vacina Bacillus Calmette-Guérin (BCG) e o tratamento da malária para a prevenção da infecção por SARS-CoV-2. Alguns relatos relacionaram a menor suscetibilidade do bebê ao COVID-19. Alguns outros relatam um risco maior em homens em comparação com mulheres nessa pandemia de COVID-19. Além disso, alguns outros relatos alegaram o possível uso de cloroquina e hidroxicloroquina como profiláticos em tal pandemia. O presente comentário é discutir a possível relação entre esses fatores e a infecção por SARS-CoV-2.
Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single-center experience	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03143-7	09/07/2020	Artigo de opinião	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03143-7	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Angiotensina II']	['Angiotensin II']	COVID-19 is affecting different countries all over the world with great variation in infection rate and death ratio. Some reports suggested a relation between the Bacillus Calmette-Guérin (BCG) vaccine and the malaria treatment to the prevention of SARS-CoV-2 infection. Some reports related infant's lower susceptibility to the COVID-19. Some other reports a higher risk in males compared to females in such COVID-19 pandemic. Also, some other reports claimed the possible use of chloroquine and hydroxychloroquine as prophylactic in such a pandemic. The present commentary is to discuss the possible relation between those factors and SARS-CoV-2 infection.	32646469	Critical care (London, England)	1466-609X	10.1186/s13054-020-03143-7	Tratamento com angiotensina II em pacientes com COVID-19: mais risco do que benefício? Uma experiência de centro único O 	COVID-19 está afetando diferentes países em todo o mundo, com grande variação na taxa de infecção e na taxa de mortalidade. Alguns relatos sugeriram uma relação entre a vacina Bacillus Calmette-Guérin (BCG) e o tratamento da malária para a prevenção da infecção por SARS-CoV-2. Alguns relatos relacionaram a menor suscetibilidade do bebê ao COVID-19. Alguns outros relatam um risco maior em homens em comparação com mulheres nessa pandemia de COVID-19. Além disso, alguns outros relatos alegaram o possível uso de cloroquina e hidroxicloroquina como profiláticos em tal pandemia. O presente comentário é discutir a possível relação entre esses fatores e a infecção por SARS-CoV-2.
Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses	https://doi.org/10.1016/j.antiviral.2020.104805	21/04/2020	Artigo de opinião	10.1016/j.antiviral.2020.104805	0166-3542	1663542	ANTIVIRAL RESEARCH	A1	2.213	134	9.13	-	['Ivermectina', 'Ivermectina', 'Ivermectina']	['Ivermectin', 'Ivermectin', 'Ivermectin']	-	-	-	-	-	Ivermectina e COVID-19: um relatório na Antiviral Research, amplo interesse, um aviso da FDA, duas cartas ao editor e as respostas dos autores 	-
COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution	https://doi.org/10.1016/j.onehlt.2020.100148	24/06/2020	Artigo de opinião	10.1016/j.onehlt.2020.100148	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Ivermectina']	['Ivermectin']	COVID-19 is affecting different countries all over the world with great variation in infection rate and death ratio. Some reports suggested a relation between the Bacillus Calmette-Guérin (BCG) vaccine and the malaria treatment to the prevention of SARS-CoV-2 infection. Some reports related infant's lower susceptibility to the COVID-19. Some other reports a higher risk in males compared to females in such COVID-19 pandemic. Also, some other reports claimed the possible use of chloroquine and hydroxychloroquine as prophylactic in such a pandemic. The present commentary is to discuss the possible relation between those factors and SARS-CoV-2 infection.	32632377	One health (Amsterdam, Netherlands)	2352-7714	10.1016/j.onehlt.2020.100148	COVID-19 e a corrida pela automedicação e autodosagem com ivermectina: uma palavra de cautela A 	COVID-19 está afetando diferentes países em todo o mundo, com grande variação na taxa de infecção e taxa de mortalidade. Alguns relatos sugeriram uma relação entre a vacina Bacillus Calmette-Guérin (BCG) e o tratamento da malária para a prevenção da infecção por SARS-CoV-2. Alguns relatos relacionaram a menor suscetibilidade do bebê ao COVID-19. Alguns outros relatam um risco maior em homens em comparação com mulheres nessa pandemia de COVID-19. Além disso, alguns outros relatos alegaram o possível uso de cloroquina e hidroxicloroquina como profiláticos em tal pandemia. O presente comentário é discutir a possível relação entre esses fatores e a infecção por SARS-CoV-2.
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin	https://doi.org/10.1016/j.tmaid.2020.101819	03/07/2020	Artigo de opinião	10.1016/j.tmaid.2020.101819	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	The methodological and reporting quality of guidelines for treating children with COVID-19 was not high. Recommendations were inconsistent across different guidelines. The supporting evidence from children with COVID-19 was very limited.	33316396	Travel medicine and infectious disease	1873-0442	10.1016/j.tmaid.2020.101954	Nenhuma evidência de benefícios clínicos do tratamento precoce de pacientes com COVID-19 com hidroxicloroquina e azitromicina 	A qualidade metodológica e de notificação das diretrizes para o tratamento de crianças com COVID-19 não foi alta. As recomendações eram inconsistentes em diferentes diretrizes. As evidências de apoio de crianças com COVID-19 foram muito limitadas.
Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models	https://www.nejm.org/doi/10.1056/NEJMp2020076	01/07/2020	Artigo de opinião	10.1056/NEJMp2020076	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Modelos de Infecção Humana Controlada (CHIM)']	['Models of Controlled Human Infection (CHIM)']	-	-	-	-	-	Acelerando o desenvolvimento de vacinas SARS-CoV-2 - O papel dos modelos de infecção humana controlada 	-
Ensuring Uptake of Vaccines against SARS-CoV-2	https://doi.org/10.1056/NEJMp2020926	26/06/2020	Artigo de opinião	10.1056/NEJMp2020926	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina']	['Vaccine']	-	-	-	-	-	Garantindo a aceitação de vacinas contra SARS-CoV-2 	-
Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic.	https://doi.org/10.6061/clinics/2020/e2022	08/06/2020	Artigo de opinião	10.6061/clinics/2020/e2022	1807-5932	18075932	CLINICS (USP, IMPRESSO)	A3	0.604	67	2.64	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Insuficiência adrenal e uso de glicocorticóides durante a pandemia de COVID-19. 	-
COVID-19 in patients with rheumatological diseases treated with anti-TNF.	http://dx.doi.org/10.1136/annrheumdis-2020-218171	16/06/2020	Artigo de opinião	10.1136/annrheumdis-2020-218171	0003-4967	34967	ANNALS OF THE RHEUMATIC DISEASES	A1	5.366	257	8.59	-	['Antagonistas de TNF', 'Azitromicina', 'Corticosteroides']	['TNF Antagonists', 'Azithromycin', 'Corticosteroids']	Since January 2020, the highly contagious novel coronavirus SARS-CoV-2 has caused a world pandemic. Severe coronavirus disease 2019 (COVID-19) leads to massive release of pro-inflammatory mediators, leading to diffuse damage to lung parenchyma, and development of acute respiratory distress syndrome (ARDS). Treatment with the highly potent glucocorticoid (GC), dexamethasone was found to be effective in reducing mortality in severely affected patients. In our review we discuss the regulation of the hypothalamic-pituitary-adrenal (HPA) axis in critical illness, the selection of a specific GC in critical illness- related GC insufficiency and the recent studies which investigate the HPA dysfunction in Covid-19 patients. Additionally, we focus on the mechanisms of anti-inflammatory and immunosuppressive effects of GCs, through their influence on innate and adaptive immune systems and relation of these effects in COVID-19. We also address the specific activation of the immune system with chronic endogenous glucocorticoid excess, as seen in patients with Cushing syndrome and finally we discuss the immune activation due to coronavirus infection and the possible mechanisms leading to improved outcomes of COVID-19 patients treated with GCs.	32546603	Annals of the rheumatic diseases	1468-2060	10.1136/annrheumdis-2020-218171	COVID-19 em pacientes com doenças reumatológicas tratados com anti-TNF. 	Desde janeiro de 2020, o novo coronavírus altamente contagioso SARS-CoV-2 causou uma pandemia mundial. A doença grave do coronavírus 2019 (COVID-19) leva à liberação maciça de mediadores pró-inflamatórios, levando a danos difusos ao parênquima pulmonar e ao desenvolvimento da síndrome do desconforto respiratório agudo (SDRA). O tratamento com o glicocorticóide altamente potente (GC), a dexametasona mostrou-se eficaz na redução da mortalidade em pacientes gravemente afetados. Em nossa revisão, discutimos a regulação do eixo hipotálamo-hipófise-adrenal (HPA) na doença crítica, a seleção de um GC específico na insuficiência de GC relacionada à doença crítica e os estudos recentes que investigam a disfunção do HPA em pacientes com Covid-19. Além disso, focamos nos mecanismos dos efeitos anti-inflamatórios e imunossupressores dos GCs, por meio de sua influência no sistema imunológico inato e adaptativo e relação desses efeitos na COVID-19. Também abordamos a ativação específica do sistema imunológico com excesso crônico de glicocorticóide endógeno, como visto em pacientes com síndrome de Cushing e, finalmente, discutimos a ativação imunológica devido à infecção por coronavírus e os possíveis mecanismos que levam a melhores resultados de pacientes com COVID-19 tratados com GCs .
Amplifying RNA Vaccine Development.	https://www.nejm.org/doi/10.1056/NEJMcibr2009737	18/06/2020	Artigo de opinião	10.1056/NEJMcibr2009737	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina de RNA']	['RNA vaccine']	-	-	-	-	-	Desenvolvimento de Vacina de RNA Amplificador. 	-
Convalescent Plasma and COVID-19.	https://doi.org/10.1001/jama.2020.10699	12/06/2020	Artigo de opinião	10.1001/jama.2020.10699	0098-7484	987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Plasma Convalescente e COVID-19. 	-
COVID-19 vaccine development pipeline gears up.	https://doi.org/10.1016/S0140-6736(20)31252-6	06/06/2020	Artigo de opinião	10.1016/S0140-6736(20)31252-6	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina']	['Vaccine']	The outbreak of coronavirus disease 2019 (COVID-19), triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the disruptive global consequences in terms of mortality and social and economic crises, have taught lessons that may help define strategies to better face future pandemics. Innate and intrinsic immunity form the front-line natural antiviral defense. They involve both tissue-resident and circulating cells, which can produce anti-viral molecules shortly after viral infection. Prototypes of these factors are type I interferons (IFN), antiviral cytokines with a long record of clinical use. During the last two years, there has been an impressive progress in understanding the mechanisms of both SARS-CoV-2 infection and the cellular and soluble antiviral responses occurring early after viral exposure. However, this information was not sufficiently translated into therapeutic approaches. Insufficient type I IFN activity probably accounts for disease progression in many patients. This results from both the multiple interfering mechanisms developed by SARS-CoV-2 to decrease type I IFN response and various pre-existing human deficits of type I IFN activity, inherited or auto-immune. Emerging data suggest that IFN-I-mediated boosting of patients' immunity, achieved directly through the exogenous administration of IFN-β early post viral infection, or indirectly following inoculation of heterologous vaccines (e.g., Bacillus Calmette Guerin), might play a role against SARS-CoV-2. We review how recent insights on the viral and human determinants of critical COVID-19 pneumonia can foster clinical studies of IFN therapy. We also discuss how early therapeutic use of IFN-β and prophylactic campaigns with live attenuated vaccines might prevent a first wave of new pandemic viruses.	32505245	Lancet (London, England)	1474-547X	10.1016/S0140-6736(20)31252-6	O pipeline de desenvolvimento de vacinas COVID-19 se prepara. 	O surto da doença de coronavírus 2019 (COVID-19), desencadeado pela síndrome respiratória aguda grave coronavírus 2 (SARS-CoV-2), e as consequências globais disruptivas em termos de mortalidade e crises sociais e econômicas, ensinaram lições que podem ajudar definir estratégias para melhor enfrentar futuras pandemias. A imunidade inata e intrínseca formam a defesa antiviral natural da linha de frente. Eles envolvem células residentes em tecidos e células circulantes, que podem produzir moléculas antivirais logo após a infecção viral. Protótipos desses fatores são os interferons tipo I (IFN), citocinas antivirais com um longo histórico de uso clínico. Durante os últimos dois anos, houve um progresso impressionante na compreensão dos mecanismos da infecção por SARS-CoV-2 e das respostas antivirais celulares e solúveis que ocorrem logo após a exposição viral. No entanto, essas informações não foram suficientemente traduzidas em abordagens terapêuticas. A atividade insuficiente do IFN tipo I provavelmente é responsável pela progressão da doença em muitos pacientes. Isso resulta dos múltiplos mecanismos de interferência desenvolvidos pelo SARS-CoV-2 para diminuir a resposta do IFN tipo I e vários déficits humanos pré-existentes da atividade do IFN tipo I, herdados ou autoimunes. Dados emergentes sugerem que o aumento da imunidade dos pacientes mediado por IFN-I, obtido diretamente através da administração exógena de IFN-β precoce pós-infecção viral, ou indiretamente após a inoculação de vacinas heterólogas (por exemplo, Bacillus Calmette Guerin), pode desempenhar um papel contra SARS-CoV-2. Revisamos como os insights recentes sobre os determinantes virais e humanos da pneumonia crítica por COVID-19 podem promover estudos clínicos da terapia com IFN. Também discutimos como o uso terapêutico precoce de IFN-β e campanhas profiláticas com vacinas vivas atenuadas podem prevenir uma primeira onda de novos vírus pandêmicos.
Covid‐19 and drug therapy, what we learned	https://doi.org/10.1007/s11096-020-01049-6	07/05/2020	Artigo de opinião	10.1007/s11096-020-01049-6	2210-7703	22107703	INTERNATIONAL JOURNAL OF CLINICAL PHARMACY	A4	0.501	63	2.41	-	['Antagonistas do Receptor da Angiotensina II', 'Azitromicina', 'Camostato', 'Cloroquina', 'Hidroxicloroquina', 'Interferon alfa', 'Ivermectina', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Angiotensin II Receptor Antagonists', 'Azithromycin', 'Camostat', 'Chloroquine', 'Hydroxychloroquine', 'Interferon alfa', 'Ivermectin', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir' , 'Tocilizumab', 'Umifenovir']	-	-	-	-	-	Covid-19 e terapia medicamentosa, o que aprendemos 	-
Metformin in COVID-19: A possible role beyond diabetes	https://doi.org/10.1016/j.diabres.2020.108183	29/04/2020	Artigo de opinião	10.1016/j.diabres.2020.108183	0168-8227	1688227	DIABETES RESEARCH AND CLINICAL PRACTICE (PRINT)	A3	1.677	122	6.69	-	['Metformina']	['Metformin']	The global COVID-19 (coronavirus disease 2019) pandemic, which was caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a significant loss of human life around the world. The SARS-CoV-2 has caused significant problems to medical systems and healthcare facilities due to its unexpected global expansion. Despite all of the efforts, developing effective treatments, diagnostic techniques, and vaccinations for this unique virus is a top priority and takes a long time. However, the foremost step in vaccine development is to identify possible antigens for a vaccine. The traditional method was time taking, but after the breakthrough technology of reverse vaccinology (RV) was introduced in 2000, it drastically lowers the time needed to detect antigens ranging from 5-15 years to 1-2 years. The different RV tools work based on machine learning (ML) and artificial intelligence (AI). Models based on AI and ML have shown promising solutions in accelerating the discovery and optimization of new antivirals or effective vaccine candidates. In the present scenario, AI has been extensively used for drug and vaccine research against SARS-COV-2 therapy discovery. This is more useful for the identification of potential existing drugs with inhibitory human coronavirus by using different datasets. The AI tools and computational approaches have led to speedy research and the development of a vaccine to fight against the coronavirus. Therefore, this paper suggests the role of artificial intelligence in the field of clinical trials of vaccines and clinical practices using different tools.	32360697	Diabetes research and clinical practice	1872-8227	10.1016/j.diabres.2020.108183	Metformina no COVID-19: um possível papel além do diabetes 	A pandemia global de COVID-19 (doença de coronavírus 2019), causada pelo coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2), resultou em uma perda significativa de humanos vida ao redor do mundo. O SARS-CoV-2 causou problemas significativos aos sistemas médicos e instalações de saúde devido à sua expansão global inesperada. Apesar de todos os esforços, o desenvolvimento de tratamentos eficazes, técnicas de diagnóstico e vacinas para esse vírus único é uma prioridade e leva muito tempo. No entanto, o primeiro passo no desenvolvimento de vacinas é identificar possíveis antígenos para uma vacina. O método tradicional era demorado, mas depois que a tecnologia inovadora de vacinologia reversa (RV) foi introduzida em 2000, ela reduz drasticamente o tempo necessário para detectar antígenos variando de 5-15 anos para 1-2 anos. As diferentes ferramentas de RV funcionam com base em aprendizado de máquina (ML) e inteligência artificial (IA). Modelos baseados em IA e ML mostraram soluções promissoras para acelerar a descoberta e otimização de novos antivirais ou candidatos a vacinas eficazes. No cenário atual, a IA tem sido amplamente utilizada para pesquisa de medicamentos e vacinas contra a descoberta da terapia SARS-COV-2. Isso é mais útil para a identificação de possíveis medicamentos existentes com coronavírus humano inibitório usando diferentes conjuntos de dados. As ferramentas de IA e as abordagens computacionais levaram a pesquisas rápidas e ao desenvolvimento de uma vacina para combater o coronavírus. Portanto, este artigo sugere o papel da inteligência artificial no campo de ensaios clínicos de vacinas e práticas clínicas usando diferentes ferramentas.
NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?	https://doi.org/10.1016/j.phrs.2020.104849	29/04/2020	Artigo de opinião	10.1016/j.phrs.2020.104849	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Anti-inflamatórios não esteroidais']	['Non-steroidal anti-inflammatory drugs']	-	-	-	-	-	AINEs em pacientes com infecções virais, incluindo Covid-19: vítimas ou agressores? 	-
Can melatonin reduce the severity of COVID-19 pandemic?	https://www.tandfonline.com/doi/full/10.1080/08830185.2020.1756284	29/04/2020	Artigo de opinião	10.1080/08830185.2020.1756284	0883-0185	8830185	INTERNATIONAL REVIEWS OF IMMUNOLOGY (PRINT)	A4	1.072	71	4.74	-	['Melatonina', 'Melatonina', 'Melatonina']	['Melatonin', 'Melatonin', 'Melatonin']	-	-	-	-	-	A melatonina pode reduzir a gravidade da pandemia de COVID-19? 	-
COVID-19 therapeutic options for patients with kidney disease	https://doi.org/10.1016/j.kint.2020.03.015	30/03/2020	Artigo de opinião	10.1016/j.kint.2020.03.015	0085-2538	852538	KIDNEY INTERNATIONAL	A1	4.063	288	7.69	-	['Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe']	['Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', ' Tocilizumab', 'Tocilizumab']	-	-	-	-	-	Opções terapêuticas COVID-19 para pacientes com doença renal 	-
The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement	https://doi.org/10.1016/j.micinf.2020.04.005	17/04/2020	Artigo de opinião	10.1016/j.micinf.2020.04.005	1286-4579	12864579	MICROBES AND INFECTION	A2	1.586	148	6.22	-	['Células Th17']	['Th17 Cells']	Increasing evidence points to host Th17 inflammatory responses as contributing to the severe lung pathology and mortality of lower respiratory tract infections from coronaviruses. This includes host inflammatory and cytokine responses to COVID-19 caused by the SARS-2 coronavirus (SARS CoV2). From studies conducted in laboratory animals, there are additional concerns about immune enhancement and the role of potential host immunopathology resulting from experimental human COVID-19 vaccines. Here we summarize evidence suggesting there may be partial overlap between the underlying immunopathologic processes linked to both coronavirus infection and vaccination, and a role for Th17 in immune enhancement and eosinophilic pulmonary immunopathology. Such findings help explain the link between viral-vectored coronavirus vaccines and immune enhancement and its reduction through alum adjuvants. Additional research may also clarify links between COVID-19 pulmonary immunopathology and heart disease.	32305501	Microbes and infection	1769-714X	10.1016/j.micinf.2020.04.005	O papel potencial das respostas imunes Th17 na imunopatologia do coronavírus e no aprimoramento imunológico induzido por vacinas 	Cada vez mais evidências apontam para as respostas inflamatórias Th17 do hospedeiro como contribuintes para a patologia pulmonar grave e a mortalidade de infecções do trato respiratório inferior por coronavírus. Isso inclui respostas inflamatórias e de citocinas do hospedeiro ao COVID-19 causado pelo coronavírus SARS-2 (SARS CoV2). A partir de estudos realizados em animais de laboratório, existem preocupações adicionais sobre o aprimoramento imunológico e o papel da potencial imunopatologia do hospedeiro resultante de vacinas experimentais humanas COVID-19. Aqui resumimos as evidências sugerindo que pode haver sobreposição parcial entre os processos imunopatológicos subjacentes ligados à infecção por coronavírus e à vacinação, e um papel para Th17 no aprimoramento imunológico e na imunopatologia pulmonar eosinofílica. Tais descobertas ajudam a explicar a ligação entre as vacinas de coronavírus com vetor viral e o aprimoramento imunológico e sua redução por meio de adjuvantes de alúmen. Pesquisas adicionais também podem esclarecer as ligações entre a imunopatologia pulmonar COVID-19 e doenças cardíacas.
Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?	https://www.ahajournals.org/doi/full/10.1161/JAHA.120.016509	01/04/2020	Artigo de opinião	10.1161/JAHA.120.016509	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Increasing evidence points to host Th17 inflammatory responses as contributing to the severe lung pathology and mortality of lower respiratory tract infections from coronaviruses. This includes host inflammatory and cytokine responses to COVID-19 caused by the SARS-2 coronavirus (SARS CoV2). From studies conducted in laboratory animals, there are additional concerns about immune enhancement and the role of potential host immunopathology resulting from experimental human COVID-19 vaccines. Here we summarize evidence suggesting there may be partial overlap between the underlying immunopathologic processes linked to both coronavirus infection and vaccination, and a role for Th17 in immune enhancement and eosinophilic pulmonary immunopathology. Such findings help explain the link between viral-vectored coronavirus vaccines and immune enhancement and its reduction through alum adjuvants. Additional research may also clarify links between COVID-19 pulmonary immunopathology and heart disease.	32233753	Journal of the American Heart Association	2047-9980	10.1161/JAHA.120.016509	Doença de coronavírus 2019 (COVID-19): Os inibidores da enzima conversora de angiotensina/bloqueadores do receptor de angiotensina têm um efeito bifásico? 	Evidências crescentes apontam para respostas inflamatórias Th17 do hospedeiro como contribuintes para a patologia pulmonar grave e mortalidade de infecções do trato respiratório inferior por coronavírus. Isso inclui respostas inflamatórias e de citocinas do hospedeiro ao COVID-19 causado pelo coronavírus SARS-2 (SARS CoV2). A partir de estudos realizados em animais de laboratório, existem preocupações adicionais sobre o aprimoramento imunológico e o papel da potencial imunopatologia do hospedeiro resultante de vacinas experimentais humanas COVID-19. Aqui resumimos as evidências sugerindo que pode haver sobreposição parcial entre os processos imunopatológicos subjacentes ligados à infecção por coronavírus e à vacinação, e um papel para Th17 no aprimoramento imunológico e na imunopatologia pulmonar eosinofílica. Tais descobertas ajudam a explicar a ligação entre as vacinas de coronavírus com vetor viral e o aprimoramento imunológico e sua redução por meio de adjuvantes de alúmen. Pesquisas adicionais também podem esclarecer as ligações entre a imunopatologia pulmonar COVID-19 e doenças cardíacas.
Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties	https://link.springer.com/article/10.1007/s40262-020-00891-1	18/04/2020	Artigo de opinião	https://link.springer.com/article/10.1007/s40262-020-00891-1	0312-5963	3125963	CLINICAL PHARMACOKINETICS	A1	1.274	169	5.4	-	['Cloroquina', 'Cloroquina', 'Cloroquina']	['Chloroquine', 'Chloroquine', 'Chloroquine']	Since in vitro studies and a preliminary clinical report suggested the efficacy of chloroquine for COVID-19-associated pneumonia, there is increasing interest in this old antimalarial drug. In this article, we discuss the pharmacokinetics and safety of chloroquine that should be considered in light of use in SARS-CoV-2 infections. Chloroquine is well absorbed and distributes extensively resulting in a large volume of distribution with an apparent and terminal half-life of 1.6 days and 2 weeks, respectively. Chloroquine is metabolized by cytochrome P450 and renal clearance is responsible for one third of total clearance. The lack of reliable information on target concentrations or doses for COVID-19 implies that for both adults and children, doses that proved effective and safe in malaria should be considered, such as 'loading doses' in adults (30 mg/kg over 48 h) and children (70 mg/kg over 5 days), which reported good tolerability. Here, plasma concentrations were < 2.5 μmol/L, which is associated with (minor) toxicity. While the influence of renal dysfunction, critical illness, or obesity seems small, in critically ill patients, reduced absorption may be anticipated. Clinical experience has shown that chloroquine has a narrow safety margin, as three times the adult therapeutic dosage for malaria can be lethal when given as a single dose. Although infrequent, poisoning in children is extremely dangerous where one to two tablets can potentially be fatal. In conclusion, the pharmacokinetic and safety properties of chloroquine suggest that chloroquine can be used safely for an acute virus infection, under corrected QT monitoring, but also that the safety margin is small, particularly in children.	32306288	Clinical pharmacokinetics	1179-1926	10.1007/s40262-020-00891-1	Cloroquina para SARS-CoV-2: Implicações de suas propriedades farmacocinéticas e de segurança 	únicas Neste artigo, discutimos a farmacocinética e a segurança da cloroquina que devem ser consideradas à luz do uso em infecções por SARS-CoV-2. A cloroquina é bem absorvida e distribuída extensivamente resultando em um grande volume de distribuição com meia-vida aparente e terminal de 1,6 dias e 2 semanas, respectivamente. A cloroquina é metabolizada pelo citocromo P450 e a depuração renal é responsável por um terço da depuração total. A falta de informações confiáveis sobre concentrações ou doses alvo para COVID-19 implica que, tanto para adultos quanto para crianças, devem ser consideradas doses que se mostraram eficazes e seguras na malária, como “doses de carga” em adultos (30 mg/kg em 48 h ) e crianças (70 mg/kg em 5 dias), que relataram boa tolerabilidade. Aqui, as concentrações plasmáticas foram < 2,5 μmol/L, o que está associado à toxicidade (menor). Embora a influência da disfunção renal, doença crítica ou obesidade pareça pequena, em pacientes críticos, a absorção reduzida pode ser antecipada. A experiência clínica mostrou que a cloroquina tem uma margem de segurança estreita, pois três vezes a dosagem terapêutica para malária em adultos pode ser letal quando administrada em dose única. Embora pouco frequente, o envenenamento em crianças é extremamente perigoso, onde um a dois comprimidos pode ser potencialmente fatal. Em conclusão, as propriedades farmacocinéticas e de segurança da cloroquina sugerem que a cloroquina pode ser usada com segurança para uma infecção viral aguda, sob monitoramento QT corrigido, mas também que a margem de segurança é pequena, principalmente em crianças.
Angiotensin Receptor Blockers and 2019-nCoV	https://doi.org/10.1016/j.phrs.2020.104832	15/04/2020	Artigo de opinião	10.1016/j.phrs.2020.104832	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Antagonistas do Receptor da Angiotensina II']	['Angiotensin II Receptor Antagonists']	-	-	-	-	-	Bloqueadores do Receptor de Angiotensina e 2019-nCoV 	-
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and reninangiotensin system blockers in SARS-CoV-2 infections	https://onlinelibrary.wiley.com/doi/full/10.1002/ddr.21672	17/04/2020	Artigo de opinião	10.1002/ddr.21672	0272-4391	2724391	DRUG DEVELOPMENT RESEARCH (PRINT)	A4	0.552	62	4.75	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Resposta a comentários recentes sobre o envolvimento da enzima conversora de angiotensina 2 (ACE2) e bloqueadores do sistema reninangiotensina em infecções por SARS-CoV-2 	-
Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action	https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16727	18/04/2020	Artigo de opinião	10.1111/bjh.16727	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Anticoagulantes']	['Anticoagulants']	Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in intensive care units appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.	32304577	British journal of haematology	1365-2141	10.1111/bjh.16727	Risco tromboembólico e terapia anticoagulante em pacientes com COVID-19: Evidências emergentes e apelo à ação 	Evidências emergentes mostram que a doença grave por coronavírus 2019 (COVID-19) pode ser complicada com coagulopatia, ou seja, coagulação intravascular disseminada, que tem um caráter bastante pró-trombótico com alto risco de tromboembolismo venoso. A incidência de tromboembolismo venoso entre pacientes com COVID-19 em unidades de terapia intensiva parece ser um pouco maior em comparação com a relatada em outros estudos, incluindo pacientes com outras doenças. O dímero D pode ajudar no reconhecimento precoce desses pacientes de alto risco e também prever o resultado. Dados preliminares mostram que em pacientes com COVID-19 grave, a terapia anticoagulante parece estar associada a menor mortalidade na subpopulação que atende aos critérios de coagulopatia induzida por sepse ou com dímero d marcadamente elevado. Recomendações recentes sugerem que todos os pacientes hospitalizados com COVID-19 devem receber tromboprofilaxia ou anticoagulação de intensidade terapêutica total, se tal indicação estiver presente.
Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients	https://link.springer.com/article/10.1007/s11739-020-02331-1	15/04/2020	Artigo de opinião	https://link.springer.com/article/10.1007/s11739-020-02331-1	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Acenocoumarol', 'Apixabana', 'Dabigatrana', 'Darunavir', 'Edoxabana', 'Heparina', 'Lopinavir', 'Ritonavir', 'Rivaroxabana', 'Varfarina']	['Acenocoumarol', 'Apixaban', 'Dabigatran', 'Darunavir', 'Edoxaban', 'Heparin', 'Lopinavir', 'Ritonavir', 'Rivaroxaban', 'Warfarin']	Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in intensive care units appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.	32440985	Internal and emergency medicine	1970-9366	10.1007/s11739-020-02373-5	Mudança de anticoagulantes orais para heparina parenteral em pacientes hospitalizados com SARS-CoV-2 	Evidências emergentes mostram que a doença grave por coronavírus 2019 (COVID-19) pode ser complicada com coagulopatia, ou seja, coagulação intravascular disseminada, que tem um caráter bastante pró-trombótico com alto risco de doença venosa tromboembolismo. A incidência de tromboembolismo venoso entre pacientes com COVID-19 em unidades de terapia intensiva parece ser um pouco maior em comparação com a relatada em outros estudos, incluindo pacientes com outras doenças. O dímero D pode ajudar no reconhecimento precoce desses pacientes de alto risco e também prever o resultado. Dados preliminares mostram que em pacientes com COVID-19 grave, a terapia anticoagulante parece estar associada a menor mortalidade na subpopulação que atende aos critérios de coagulopatia induzida por sepse ou com dímero d marcadamente elevado. Recomendações recentes sugerem que todos os pacientes hospitalizados com COVID-19 devem receber tromboprofilaxia ou anticoagulação de intensidade terapêutica total, se tal indicação estiver presente.
The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments	https://link.springer.com/article/10.1007/s10654-020-00628-1	15/04/2020	Artigo de opinião	https://link.springer.com/article/10.1007/s10654-020-00628-1	0393-2990	3932990	EUROPEAN JOURNAL OF EPIDEMIOLOGY	A1	3.920	120	10.4	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in intensive care units appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.	32296994	European journal of epidemiology	1573-7284	10.1007/s10654-020-00628-1	A dupla carga da doença de COVID-19 em pacientes cardiovasculares: condições sobrepostas podem levar a tratamentos sobrepostos 	Evidências emergentes mostram que a doença grave por coronavírus 2019 (COVID-19) pode ser complicada com coagulopatia, ou seja, coagulação intravascular disseminada, que tem um caráter bastante pró-trombótico com alto risco de tromboembolismo venoso. A incidência de tromboembolismo venoso entre pacientes com COVID-19 em unidades de terapia intensiva parece ser um pouco maior em comparação com a relatada em outros estudos, incluindo pacientes com outras doenças. O dímero D pode ajudar no reconhecimento precoce desses pacientes de alto risco e também prever o resultado. Dados preliminares mostram que em pacientes com COVID-19 grave, a terapia anticoagulante parece estar associada a menor mortalidade na subpopulação que atende aos critérios de coagulopatia induzida por sepse ou com dímero d marcadamente elevado. Recomendações recentes sugerem que todos os pacientes hospitalizados com COVID-19 devem receber tromboprofilaxia ou anticoagulação de intensidade terapêutica total, se tal indicação estiver presente.
Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology	https://doi.org/10.1016/j.clim.2020.108414	06/04/2020	Artigo de opinião	10.1016/j.clim.2020.108414	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	[]	[]	-	-	-	-	-	Algum possível papel dos inibidores da fosfodiesterase tipo 5 no tratamento de infecções graves por COVID19? Uma lição de urologia 	-
Amiodarone as a possible therapy for coronavirus infection	https://journals.sagepub.com/doi/full/10.1177/2047487320919233	16/04/2020	Artigo de opinião	10.1177/2047487320919233	2047-4873	20474873	EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY	A1	1.689	106	3.07	-	['Amiodarona']	['Amiodarone']	-	-	-	-	-	Amiodarona como possível terapia para infecção por coronavírus 	-
Why tocilizumab could be an efective treatment for severe COVID-19?	https://doi.org/10.1186/s12967-020-02339-3	14/04/2020	Artigo de opinião	10.1186/s12967-020-02339-3	1479-5876	14795876	JOURNAL OF TRANSLATIONAL MEDICINE (ONLINE)	A2	1.570	121	7.38	 Abstract A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Por que o tocilizumabe pode ser um tratamento eficaz para COVID-19 grave? 	-
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19	https://doi.org/10.1016/S1473-3099(20)30296-6	17/04/2020	Artigo de opinião	10.1016/S1473-3099(20)30296-6	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Cloroquina ou hidroxicloroquina para profilaxia de COVID-19 	-
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base	http://dx.doi.org/10.1016/S2213-2600(20)30172-7	15/04/2020	Artigo de opinião	10.1016/S2213-2600(20)30172-7	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Hidroxicloroquina']	['Hydroxychloroquine']	From the end of 2019, the world population has been faced the spread of the novel coronavirus SARS-CoV-2 responsible for COVID-19 infection. In approximately 14% of the patients affected by the novel coronavirus, the infection progresses with the development of pneumonia that requires mechanical ventilation. At the moment, there is no specific antiviral treatment recommended for the COVID-19 pandemic and the therapeutic strategies to deal with the infection are only supportive. In our opinion, mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 pneumonia, due to the broad pharmacological effects it shows, including anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties.	32304640	The Lancet. Respiratory medicine	2213-2619	10.1016/S2213-2600(20)30172-7	Hidroxicloroquina no manejo de pacientes críticos com COVID-19: a necessidade de uma base de evidências 	A partir do final de 2019, a população mundial enfrentou a disseminação do novo coronavírus SARS-CoV-2 responsável pela infecção por COVID-19. Em aproximadamente 14% dos pacientes acometidos pelo novo coronavírus, a infecção progride com o desenvolvimento de pneumonia que requer ventilação mecânica. No momento, não há tratamento antiviral específico recomendado para a pandemia de COVID-19 e as estratégias terapêuticas para lidar com a infecção são apenas de suporte. Em nossa opinião, o secretoma de células-tronco mesenquimais pode oferecer uma nova abordagem terapêutica no tratamento da pneumonia por COVID-19, devido aos amplos efeitos farmacológicos que apresenta, incluindo propriedades anti-inflamatórias, imunomoduladoras, regenerativas, pró-angiogênicas e antifibróticas.
Drug Evaluation during the Covid-19 Pandemic	https://doi.org/10.1056/NEJMp2009457	14/04/2020	Artigo de opinião	10.1056/NEJMp2009457	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Avaliação de medicamentos durante a pandemia de Covid-19 	-
Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and/or treatment?	https://doi.org/10.1016/j.jaad.2020.04.017	10/04/2020	Artigo de opinião	10.1016/j.jaad.2020.04.017	0190-9622	1909622	JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY	A1	1.948	217	4.29	-	['Hidroxicloroquina', 'Ivermectina']	['Hydroxychloroquine', 'Ivermectin']	-	-	-	-	-	Hidroxicloroquina e ivermectina: uma combinação sinérgica para quimioprofilaxia e/ou tratamento de COVID-19? 	-
Therapeutic Potential for Tetracyclines in the Treatment of COVID-19	https://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1002/phar.2395	08/04/2020	Artigo de opinião	10.1002/phar.2395	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Tetraciclinas']	['Tetracyclines']	-	-	-	-	-	Potencial Terapêutico das Tetraciclinas no Tratamento da COVID-19 	-
Considerations for statin therapy in patients with COVID-19	https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2397	08/04/2020	Artigo de opinião	10.1002/phar.2397	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Estatina']	['Statin']	-	-	-	-	-	Considerações para a terapia com estatinas em pacientes com COVID-19 	-
Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment	https://doi.org/10.1161/CIRCULATIONAHA.120.047521	08/04/2020	Artigo de opinião	10.1161/CIRCULATIONAHA.120.047521	0009-7322	97322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	Considerações para interações medicamentosas no QTc no tratamento exploratório de COVID-19 (doença de coronavírus 2019) 	-
Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients	https://doi.org/10.1093/cid/ciaa394	07/04/2020	Artigo de opinião	10.1093/cid/ciaa394	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.	['Hidroxicloroquina']	['Hydroxychloroquine']	Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.	32255489	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa394	Rumo à otimização da dosagem de hidroxicloroquina em pacientes da unidade de terapia intensiva COVID-19 A 	hidroxicloroquina (HCQ) parece ser um tratamento promissor para o COVID-19. No entanto, todos os ensaios clínicos em andamento com HCQ usam diferentes regimes de dosagem, resultando em várias concentrações. Estudos farmacocinéticos são, portanto, necessários para definir o regime de dosagem ideal.
Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial.	https://doi.org/10.1183/13993003.03725-2020	14/01/2021	Artigo completo publicado em periódico científico	10.1183/13993003.03725-2020	0903-1936	9031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Background Nitazoxanide is widely available and exerts broad-spectrum antiviral activity  in vitro. However, there is no evidence of its impact on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.  Methods In a multicentre, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of coronavirus disease 2019 (COVID-19) symptoms (dry cough, fever and/or fatigue) were enrolled. After confirmation of SARS-CoV-2 infection using reverse transcriptase PCR on a nasopharyngeal swab, patients were randomised 1:1 to receive either nitazoxanide (500 mg) or placebo, three times daily, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, laboratory tests, serum biomarkers of inflammation and hospitalisation rate. Adverse events were also assessed.  Results From June 8 to August 20, 2020, 1575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analysed. Median (interquartile range) time from symptom onset to first dose of study drug was 5 (4–5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. Swabs collected were negative for SARS-CoV-2 in 29.9% of patients in the nitazoxanide arm  versus 18.2% in the placebo arm (p=0.009). Viral load was reduced after nitazoxanide compared to placebo (p=0.006). The percentage viral load reduction from onset to end of therapy was higher with nitazoxanide (55%) than placebo (45%) (p=0.013). Other secondary outcomes were not significantly different. No serious adverse events were observed.  Conclusions In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.	['Nitazoxanida']	['Nitazoxanide']	In patients with mild COVID-19, symptom resolution did not differ between nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.	33361100	The European respiratory journal	1399-3003	10.1183/13993003.03725-2020	Uso precoce de nitazoxanida na doença leve de Covid-19: estudo randomizado controlado por placebo. 	Em pacientes com COVID-19 leve, a resolução dos sintomas não diferiu entre os grupos de nitazoxanida e placebo após 5 dias de terapia. No entanto, a terapia precoce com nitazoxanida foi segura e reduziu significativamente a carga viral.
Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.	https://onlinelibrary.wiley.com/doi/full/10.1111/trf.16177	30/10/2020	Artigo completo publicado em periódico científico	10.1111/trf.16177	0041-1132	411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Reações transfusionais associadas à terapia com plasma convalescente COVID-19 para SARS-CoV-2. 	-
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.	https://doi.org/10.1186/s12879-021-05773-w	14/01/2021	Artigo completo publicado em periódico científico	10.1186/s12879-021-05773-w	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.                                Methods                 We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching.                                Results                 Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available.                                Conclusions                 In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.              	['Hidroxicloroquina']	['Hydroxychloroquine']	In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.	33446136	BMC infectious diseases	1471-2334	10.1186/s12879-021-05773-w	Hidroxicloroquina no tratamento de pacientes ambulatoriais com COVID-19 levemente sintomático: um estudo observacional multicêntrico. 	Neste estudo observacional retrospectivo de pacientes não hospitalizados infectados com SARS-CoV-2, a exposição à hidroxicloroquina foi associada a uma diminuição da taxa de hospitalização subsequente. A exploração adicional de hidroxicloroquina nesta população ambulatorial levemente sintomática é justificada.
Corticosteroid treatment has no efect on hospital mortality in COVID‐19 patients.	https://doi.org/10.1038/s41598-020-80654-x	13/01/2021	Artigo completo publicado em periódico científico	10.1038/s41598-020-80654-x	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract Since the start of the novel coronavirus 2019 (COVID-19) pandemic, corticosteroid use has been the subject of debate. The available evidence is uncertain, and knowledge on the subject is evolving. The aim of our cohort study was to evaluate the association between corticosteroid therapy and hospital mortality, in patients hospitalized with COVID-19 after balancing for possible confounders. One thousand four hundred forty four patients were admitted to our hospital with a positive RT-PCR test for SARS-CoV-2, 559 patients (39%) were exposed to corticosteroids during hospital stay, 844 (61%) were not exposed to corticosteroids. In the cohort of patients exposed to corticosteroids, 171 (30.6%) died. In the cohort of patients not exposed to corticosteroids, 183 (21.7%) died (unadjusted  p &lt; 0.001). Nonetheless, exposure to corticosteroids was not associated with in-hospital mortality after balancing with overlap weight propensity score (adjusted  p = 0.25). Patients in the corticosteroids cohort had a reduced risk of ICU admission (adjusted  p &lt; 0.001). Treatment with corticosteroids did not affect hospital mortality in patients with COVID-19 after balancing for confounders. A possible advantage of corticosteroid therapy was to reduce Intensive Care Unit admission, which could be useful in reducing pressure on Intensive Care Units in times of limited resources, as during the COVID-19 pandemic.	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	O tratamento com corticosteroides não tem efeito na mortalidade hospitalar em pacientes com COVID-19. 	-
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.	https://www.nejm.org/doi/full/10.1056/NEJMoa2034201	13/01/2021	Artigo completo publicado em periódico científico	10.1056/NEJMoa2034201	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina (Ad26.COV2.S)', 'Vacina (Ad26.COV2.S)']	['Vaccine (Ad26.COV2.S)', 'Vaccine (Ad26.COV2.S)']	The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276.).	33440088	The New England journal of medicine	1533-4406	10.1056/NEJMoa2034201	Resultados provisórios de um estudo de fase 1-2a da vacina Ad26.COV2.S Covid-19. 	Os perfis de segurança e imunogenicidade de Ad26.COV2.S apoiam o desenvolvimento desta vacina candidata. (Financiado pela Johnson & Johnson e pela Autoridade de Pesquisa e Desenvolvimento Biomédico Avançado do Departamento de Saúde e Serviços Humanos; número COV1001 ClinicalTrials.gov, NCT04436276.).
The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.	https://doi.org/10.1371/journal.pone.0244128	31/12/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0244128	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	<jats:sec id="sec001"> Purpose To evaluate the efficacy and safety of methylprednisolone in treating the coronavirus disease 2019 (COVID-19) patients.<jats:sec id="sec002"> Methods A retrospective cohort study was conducted, and all COVID-19 patients were recruited who were admitted to the Yichang Third People’s Hospital from February 1 st to March 31 st, 2020. One-to-one propensity score matching (PSM) was used for minimizing confounding effects. The primary outcome was hospital mortality, with the secondary outcomes being the time needed for a positive SARS-CoV-2 nucleic acid test to turn negative and the length of hospital stay.<jats:sec id="sec003"> Results Totaling 367 patients with COVID-19 hospitalized at the Yichang Third People’s Hospital were identified, of whom 276 were mild or stable COVID-19, and 67 were serious or critically ill. Among them, 255 patients were treated using methylprednisolone, and 188 did not receive any corticosteroid-related treatment. After PSM, no statistically significant difference was found in the baseline characteristics between the two groups. Regarding the outcomes, there also were no statistically significant difference between the two groups. Patients without the use of methylprednisolone were more quickly to obtain negative results of their nasopharyngeal swab tests of SARS-CoV-2 nucleic acid after treatment, compared to those receiving methylprednisolone.<jats:sec id="sec004"> Conclusion Methylprednisolone could not improve the prognosis of patients with COVID-19, and the efficacy and safety of the use of methylprednisolone in patients with COVID-19 still remain uncertain, thus the use of corticosteroids clinically in patients with COVID-19 should be with cautions.	['Prednisona']	['Prednisone']	-	-	-	-	-	O uso de metilprednisolona em pacientes com COVID-19: um estudo de coorte retrospectivo combinado com escore de propensão. 	-
Efficacy Evaluation of Intravenous Immunoglobulin in Non-severe Patients with COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.	https://doi.org/10.1016/j.ijid.2021.01.009	09/01/2021	Artigo completo publicado em periódico científico	10.1016/j.ijid.2021.01.009	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Imunoglobulina']	['Immunoglobulin']	In non-severe patients with COVID-19, no benefit was observed with IVIG therapy beyond standard therapy.	33434674	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2021.01.009	Avaliação da eficácia da imunoglobulina intravenosa em pacientes não graves com COVID-19: um estudo de coorte retrospectivo baseado na correspondência de pontuação de propensão. 	Em pacientes não graves com COVID-19, nenhum benefício foi observado com a terapia IVIG além da terapia padrão.
Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study.	https://dx.doi.org/10.3390/jcm10010028	24/12/2020	Artigo completo publicado em periódico científico	https://dx.doi.org/10.3390/jcm10010028	2077-0383	20770383	JOURNAL OF CLINICAL MEDICINE	A1	1.040	75	4.84	 Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (p &lt; 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible.	['Plasma convalescente']	['Convalescent Plasma']	Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (	33374333	Journal of clinical medicine	2077-0383	10.3390/jcm10010028	Transfusão de plasma convalescente para o tratamento de COVID-19 - experiência da Polônia: um estudo multicêntrico. 	Como o tratamento ideal para o COVID-19 ainda é desconhecido, é importante explorar todas as formas potenciais de melhorar as chances de sobrevivência dos pacientes com COVID-19. O objetivo do estudo foi analisar a eficácia do plasma convalescente em pacientes com COVID-19. A população do estudo foi composta por 78 pacientes diagnosticados com COVID-19, selecionados do banco de dados nacional SARSTer, que receberam plasma convalescente. O impacto nos parâmetros clínicos e laboratoriais foi avaliado. Uma melhora clínica foi observada em 62 (79%) pacientes e 10 (13%) pacientes morreram de COVID-19. Não foram observados efeitos colaterais do tratamento com plasma convalescente. Quando o plasma foi administrado antes de 7 dias do diagnóstico, o tempo total de internação foi menor (
Impact of oral anticoagulation on clinical outcomes of COVID‐19: a nationwide cohort study of hospitalized patients in Germany.	https://doi.org/10.1007/s00392-020-01783-x	08/01/2021	Artigo completo publicado em periódico científico	10.1007/s00392-020-01783-x	1861-0684	18610684	CLINICAL RESEARCH IN CARDIOLOGY (PRINT)	A2	1.772	75	4.86	-	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes']	['Vitamin K antagonists (VKA)', 'Anticoagulants']	In a multivariable analysis, a therapy with both direct oral anticoagulants or vitamin-K antagonists-but not with antiplatelet therapy-was associated with improved clinical outcomes. ACE inhibitors did not impact outcomes. Prospective randomized trials are needed to verify this hypothesis.	33416918	Clinical research in cardiology : official journal of the German Cardiac Society	1861-0692	10.1007/s00392-020-01783-x	Impacto da anticoagulação oral nos resultados clínicos do COVID-19: um estudo de coorte nacional de pacientes hospitalizados na Alemanha. 	Em uma análise multivariada, uma terapia com anticoagulantes orais diretos ou antagonistas da vitamina K, mas não com terapia antiplaquetária, foi associada a melhores resultados clínicos. Os inibidores da ECA não afetaram os resultados. Ensaios prospectivos randomizados são necessários para verificar essa hipótese.
Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization.	https://dx.doi.org/10.3390/ijerph18010102	25/12/2020	Artigo completo publicado em periódico científico	https://dx.doi.org/10.3390/ijerph18010102	1660-4601	16604601	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH	A2	0.814	138	4.7	 Introduction: The Coronavirus disease 2019 (COVID-19) outbreak is a whole Earth health emergency related to a highly pathogenic human coronavirus responsible for severe acute respiratory syndrome (SARS-CoV-2). Despite the fact that the majority of infected patients were managed in outpatient settings, little is known about the clinical characteristics of COVID-19 patients not requiring hospitalization. The aim of our study was to describe the clinical comorbidity and the pharmacological therapies of COVID-19 patients managed in outpatient settings. Materials and Methods: We performed an observational, retrospective analysis of laboratory-confirmed COVID-19 patients managed in outpatient settings in Naples, Italy between 9 March and 1 May 2020. Data were sourced from the prospectively maintained Health Search (HS)/Thales database, shared by 128 primary care physicians (PCPs) in Naples, Italy. The clinical features and pharmacological therapies of COVID-19 patients not requiring hospitalization and managed in outpatient settings have been described. Results: A total of 351 laboratory-confirmed COVID-19 patients (mean age 54 ± 17 years; 193 males) with outpatient management were evaluated. Hypertension was the most prevalent comorbidity (35%). The distribution of cardiovascular comorbidities showed no gender-related differences. A total of 201 patients (57.3%) were treated with at least one experimental drug for COVID-19. Azithromycin, alone (42.78%) or in combination (27.44%), was the most widely used experimental anti-COVID drug in outpatient settings. Low Molecular Weight Heparin and Cortisone were prescribed in 24.87% and 19.4% of the study population, respectively. At multivariate regression model, diabetes (risk ratio (RR): 3.74; 95% CI 1.05 to 13.34; p = 0.04) and hypertension (RR: 1.69; 95% CI 1.05 to 2.7; p = 0.03) were significantly associated with the experimental anti-COVID drug administration. Moreover, only diabetes (RR: 2.43; 95% CI 1.01 to 5.8; p = 0.03) was significantly associated with heparin administration. Conclusions: Our data show a high prevalence of hypertension, more likely treated with renin–angiotensin–aldosterone system (RASS) inhibitors, among COVID-19 patients not requiring hospitalization. Experimental COVID-19 therapies have been prescribed to COVID-19 patients considered at risk for increased venous thromboembolism based on concomitant comorbidities, in particular diabetes and hypertension.	['Azitromicina', 'Corticosteroides', 'Heparina', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Azithromycin', 'Corticosteroids', 'Heparin', 'Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)']	-	-	-	-	-	Comorbidades cardiovasculares e tratamentos farmacológicos de pacientes com COVID-19 que não requerem hospitalização. 	-
Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.	https://doi.org/10.1016/j.onehlt.2021.100214	05/01/2021	Artigo completo publicado em periódico científico	10.1016/j.onehlt.2021.100214	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Estudo de coorte pareado sobre a eficácia do tocilizumabe em pacientes com COVID-19. 	-
Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.	https://doi.org/10.1371/journal.pone.0244853	07/01/2021	Artigo completo publicado em periódico científico	10.1371/journal.pone.0244853	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	<jats:sec id="sec001"> Background Cytokine release syndrome (CRS) plays a pivotal role in the pathophysiology and progression of Coronavirus disease-2019 (COVID-19). Therapeutic plasma exchange (TPE) by removing the pathogenic cytokines is hypothesized to dampen CRS.<jats:sec id="sec002"> Objective To evaluate the outcomes of the patients with COVID-19 having CRS being treated with TPE compared to controls on the standard of care.<jats:sec id="sec003"> Methodology Retrospective propensity score-matched analysis in a single centre from 1st April to 31st July 2020. We retrospectively analyzed data of 280 hospitalized patients developing CRS initially. PSM was used to minimize bias from non-randomized treatment assignment. Using PSM 1:1, 90 patients were selected and assigned to 2 equal groups. Forced matching was done for disease severity, routine standard care and advanced supportive care. Many other Co-variates were matched. Primary outcome was 28 days overall survival. Secondary outcomes were duration of hospitalization, CRS resolution time and timing of viral clearance on Polymerase chain reaction testing.<jats:sec id="sec004"> Results After PS-matching, the selected cohort had a median age of 60 years (range 32–73 in TPE, 37–75 in controls), p = 0.325 and all were males. Median symptoms duration was 7 days (range 3–22 days’ TPE and 3–20 days controls), p = 0.266. Disease severity in both groups was 6 (6.6%) moderate, 40 (44.4%) severe and 44 (49%) critical. Overall, 28-day survival was significantly superior in the TPE group (91.1%), 95% CI 78.33–97.76; as compared to PS-matched controls (61.5%), 95% CI 51.29–78.76 (log rank 0.002), p&lt;0.001. Median duration of hospitalization was significantly reduced in the TPE treated group (10 days vs 15 days) (p&lt; 0.01). CRS resolution time was also significantly reduced in the TPE group (6 days vs. 12 days) (p&lt; 0.001). In 71 patients who underwent TPE, the mortality was 0 (n = 43) if TPE was done within the first 12 days of illness while it was 17.9% (deaths 5, n = 28 who received it after 12 th day (p = 0.0045).<jats:sec id="sec005"> Conclusion An earlier use of TPE was associated with improved overall survival, early CRS resolution and time to discharge compared to SOC for COVID-19 triggered CRS in this selected cohort of PS-matched male patients from one major hospital in Pakistan.	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	A troca de plasma terapêutica para a doença de coronavírus-2019 desencadeou a síndrome de liberação de citocinas; um estudo de controle retrospectivo com correspondência de propensão. 	-
Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.	https://doi.org/10.1016/j.cct.2021.106272	07/01/2021	Artigo completo publicado em periódico científico	10.1016/j.cct.2021.106272	1551-7144	15517144	CONTEMPORARY CLINICAL TRIALS	A3	0.867	65	2.26	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']	-	-	-	-	-	Remdesivir para o tratamento de COVID-19: Uma revisão sistemática e meta-análise de ensaios clínicos randomizados. 	-
Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.	https://doi.org/10.1186/s13054-020-03422-3	04/01/2021	Artigo completo publicado em periódico científico	10.1186/s13054-020-03422-3	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 Critically ill patients with coronavirus disease 19 (COVID-19) have a high fatality rate likely due to a dysregulated immune response. Corticosteroids could attenuate this inappropriate response, although there are still some concerns regarding its use, timing, and dose.                                Methods                 This is a nationwide, prospective, multicenter, observational, cohort study in critically ill adult patients with COVID-19 admitted into Intensive Care Units (ICU) in Spain from 12th March to 29th June 2020. Using a multivariable Cox model with inverse probability weighting, we compared relevant outcomes between patients treated with early corticosteroids (before or within the first 48 h of ICU admission) with those who did not receive early corticosteroids (delayed group) or any corticosteroids at all (never group). Primary endpoint was ICU mortality. Secondary endpoints included 7-day mortality, ventilator-free days, and complications.                                Results                 A total of 691 patients out of 882 (78.3%) received corticosteroid during their hospital stay. Patients treated with early-corticosteroids (n = 485) had lower ICU mortality (30.3% vs. never 36.6% and delayed 44.2%) and lower 7-day mortality (7.2% vs. never 15.2%) compared to non-early treated patients. They also had higher number of ventilator-free days, less length of ICU stay, and less secondary infections than delayed treated patients. There were no differences in medical complications between groups. Of note, early use of moderate-to-high doses was associated with better outcomes than low dose regimens.                                Conclusion                 Early use of corticosteroids in critically ill patients with COVID-19 is associated with lower mortality than no or delayed use, and fewer complications than delayed use.              	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Corticosteroides precoces estão associados a menor mortalidade em pacientes críticos com COVID-19: um estudo de coorte. 	-
Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.	https://doi.org/10.1016/j.intimp.2020.107329	26/12/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107329	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon', 'Lopinavir', 'Ritonavir']	['Interferon', 'Lopinavir', 'Ritonavir']	Interferon Beta-1a (IFN-β1-a), an immunomodulatory mediator with antiviral effects, has shown in vivo and in vitro activities especially on coronavirus including SARS-CoV-2. COVID-19 defined as the disease caused by infection with SARS-CoV-2. The virus has been illustrated inhibits the production of IFN-β1-a from inflammatory cells. We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units of IFN-β1-a and Lopinavir 400 mg and Ritonavir 100 mg every 12 h (case group) for 14 days besides standard care and age- and sex- matched COVID-19 patients with receiving lopinavir/ritonavir (control group) at Masih Daneshvari Hospital as a designated hospital for COVID-19 between Feb 19 and Apr 30, 2020. Multivariate analysis was done to determine the impact of IFN-β1-a on outcome and all-cause mortality. 152 cases in IFN-β1-a group and 304 cases as control group were included. IFN-β1-a group stayed at hospital longer and required noninvasive ventilation more than control group (13 vs. 6 days, p = 0.001) and (34% vs. 24%, p = 0.04), respectively. During treatment, 57 (12.5%) patients died. The death rate in case and control groups was 11% and 13% respectively. In multivariate analysis, not receiving IFN-β1-a (HR 5.12, 95% CI: 2.77-9.45), comorbidity (HR 2.28, 95% CI: 1.13-4.60) and noninvasive ventilation (HR 2.77, 95% CI: 1.56-4.93) remained significantly associated with all-cause mortality. In this study, risk of death decreased by using IFN-β1-a in COVID-19 patients. More clinical study will be necessary to measure efficacy of IFN-β1-a in COVID-19 treatment.	33412395	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.107329	A terapia combinada de IFNβ1 com lopinavir-ritonavir aumenta a oxigenação, a sobrevida e a alta de pacientes internados infectados com COVID-19. 	O interferon beta-1a (IFN-β1-a), um mediador imunomodulador com efeitos antivirais, mostrou atividades in vivo e in vitro, especialmente em coronavírus, incluindo SARS-CoV-2. A COVID-19 é definida como a doença causada pela infecção pelo SARS-CoV-2. O vírus foi ilustrado inibe a produção de IFN-β1-a a partir de células inflamatórias. Realizamos um estudo retrospectivo de todos os pacientes adultos hospitalizados confirmados com COVID-19 que receberam a combinação de três doses de 12 milhões de unidades internacionais de IFN-β1-a e Lopinavir 400 mg e Ritonavir 100 mg a cada 12 h (grupo caso) por 14 dias além atendimento padrão e pacientes com COVID-19 pareados por idade e sexo que receberam lopinavir/ritonavir (grupo controle) no Hospital Masih Daneshvari como hospital designado para COVID-19 entre 19 de fevereiro e 30 de abril de 2020. A análise multivariada foi feita para determinar o impacto do IFN-β1-a no desfecho e na mortalidade por todas as causas. 152 casos no grupo IFN-β1-a e 304 casos como grupo controle foram incluídos. O grupo IFN-β1-a permaneceu mais tempo no hospital e necessitou de ventilação não invasiva mais do que o grupo controle (13 vs. 6 dias, p = 0,001) e (34% vs. 24%, p = 0,04), respectivamente. Durante o tratamento, 57 (12,5%) pacientes morreram. A taxa de mortalidade nos grupos caso e controle foi de 11% e 13%, respectivamente. Na análise multivariada, não receber IFN-β1-a (HR 5,12, IC 95%: 2,77-9,45), comorbidade (HR 2,28, IC 95%: 1,13-4,60) e ventilação não invasiva (HR 2,77, IC 95%: 1,56- 4,93) permaneceu significativamente associado à mortalidade por todas as causas. Neste estudo, o risco de morte diminuiu com o uso de IFN-β1-a em pacientes com COVID-19. Mais estudos clínicos serão necessários para medir a eficácia do IFN-β1-a no tratamento com COVID-19.
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.	https://www.nejm.org/doi/full/10.1056/NEJMoa2033700	06/01/2021	Artigo completo publicado em periódico científico	10.1056/NEJMoa2033700	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Terapia com plasma de alto título precoce para prevenir Covid-19 grave em adultos mais velhos. 	-
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.	https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472	05/01/2021	Artigo completo publicado em periódico científico	10.1002/sctm.20-0472	2157-6564	21576564	STEM CELLS TRANSLATIONAL MEDICINE	A1	1.412	80	7.67	 Abstract                Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-MSC) infusions in subjects with COVID-19 ARDS. A double-blind, phase 1/2a, randomized, controlled trial was performed. Randomization and stratification by ARDS severity was used to foster balance among groups. All subjects were analyzed under intention to treat design. Twenty-four subjects were randomized 1:1 to either UC-MSC treatment (n = 12) or the control group (n = 12). Subjects in the UC-MSC treatment group received two intravenous infusions (at day 0 and 3) of 100 ± 20 × 106 UC-MSCs; controls received two infusions of vehicle solution. Both groups received best standard of care. Primary endpoint was safety (adverse events [AEs]) within 6 hours; cardiac arrest or death within 24 hours postinfusion). Secondary endpoints included patient survival at 31 days after the first infusion and time to recovery. No difference was observed between groups in infusion-associated AEs. No serious adverse events (SAEs) were observed related to UC-MSC infusions. UC-MSC infusions in COVID-19 ARDS were found to be safe. Inflammatory cytokines were significantly decreased in UC-MSC-treated subjects at day 6. Treatment was associated with significantly improved patient survival (91% vs 42%, P = .015), SAE-free survival (P = .008), and time to recovery (P = .03). UC-MSC infusions are safe and could be beneficial in treating subjects with COVID-19 ARDS.	['Acetato de icatibanto', 'Ácido alfa lipóico', 'Ácido ascórbico', 'Aprepitanto', 'Auxora', 'Azitromicina', 'Azivudina', 'Baloxavir marboxil', 'Bromexina', 'Cloroquina', 'Cobicistato', 'Colchicina', 'Corticosteroides', 'Daclatasvir', 'Darunavir', 'Dexametasona', 'Difosfonato de metila (99-mTc)', 'Fator estimulador de colônias de granulócitos humano recombinante', 'Favipiravir', 'Hidroxicloroquina', 'Imunoglobulina', 'Inibidor de C1 esterase/calicreína', 'Interferon alfa', 'Interferon beta', 'Interferon gama', 'Lincocin', 'Lopinavir', 'N-acetilcisteína', 'Novaferon', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Sofosbuvir', 'Solução salina eletrolisada', 'Terapia celular', 'Tocilizumabe', 'Triazavirina', 'Umifenovir', 'Vilobelimabe', 'Vitamina D (25-hidroxivitamina D)']	['Icatibant acetate', 'Alpha lipoic acid', 'Ascorbic acid', 'Aprepitant', 'Auxora', 'Azithromycin', 'Azivudine', 'Baloxavir marboxil', 'Bromhexine', 'Chloroquine', 'Cobicistat' , 'Colchicine', 'Corticosteroids', 'Daclatasvir', 'Darunavir', 'Dexamethasone', 'Methyl diphosphonate (99-mTc)', 'Recombinant human granulocyte colony stimulating factor', 'Favipiravir', 'Hydroxychloroquine' , 'Immunoglobulin', 'C1 esterase/kallikrein inhibitor', 'Interferon alpha', 'Interferon beta', 'Interferon gamma', 'Lincocin', 'Lopinavir', 'N-acetylcysteine', 'Novaferon', 'Convalescent plasma ', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Sofosbuvir', 'Electrolyzed saline', 'Cell therapy', 'Tocilizumab', 'Triazavirin', 'Umifenovir', 'Vilobelimab', 'Vitamin D (25 -hydroxyvitamin D)']	-	-	-	-	-	Células-tronco mesenquimais do cordão umbilical para síndrome do desconforto respiratório agudo COVID-19: um estudo duplo-cego, fase 1/2a, randomizado controlado. 	-
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications.	https://doi.org/10.2147/IDR.S289037	29/12/2020	Artigo completo publicado em periódico científico	10.2147/IDR.S289037	1178-6973	11786973	INFECTION AND DRUG RESISTANCE	A1	0.944	44	4.55	-	['Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Azitromicina', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Azithromycin', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Prednisone', 'Prednisone', 'Prednisone', 'Prednisone', 'Prednisone' , 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', ' Tocilizumab', 'Tocilizumab', 'Tocilizumab']	A novel coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China, and quickly spread globally. Several treatments have been proposed, many of which have proven ineffective. Consequently, there is a need to review the published evidence of drug clinical trials to guide future prescribing. A systematic review of published clinical trials and retrospective observational studies was carried out. The search was made using PubMed, Embase, MEDLINE, and China National Knowledge Infrastructure (CNKI) databases. Articles published between January 2020 and October 2020 and written in the English language were retrieved and included in the study. Researches that used traditional medicine, in-vitro and in-vivo animal studies, as well as reviews were excluded. Seventy-three relevant articles that fulfilled the inclusion criteria were finally selected and reviewed. Hydroxychloroquine, chloroquine, and azithromycin produced no clinical evidence of efficacy in randomized controlled clinical trials (RCT). However, retrospective observational studies reported the efficacy of remdesivir and lopinavir/ritonavir in reducing viral load, although there have been concerns with lopinavir/ritonavir and, more recently, remdesivir. Recently, tocilizumab, dexamethasone, and methylprednisolone significantly relieved lung inflammation and decreased mortality in patients with severe COVID-19. In addition, convalescent plasma was effective in boosting strong immunity among patients with mild COVID-19. There is currently no single worldwide approved therapeutic option for patients with COVID-19 despite the initial hype with medicines, including hydroxychloroquine. Nonetheless, dexamethasone has shown promise in symptomatic treatment and convalescent plasma in boosting immunity. New treatments are currently being researched, and the findings will be reported accordingly to provide evidence-based guidance for prescribers and policymakers.	33402839	Infection and drug resistance	1178-6973	10.2147/IDR.S289037	Revisão Sistemática das Opções Terapêuticas para COVID-19: Evidência Clínica da Eficácia e Implicações de Medicamentos. 	Um novo coronavírus-2 (SARS-CoV-2) foi identificado pela primeira vez em Wuhan, China, e rapidamente se espalhou globalmente. Vários tratamentos foram propostos, muitos dos quais se mostraram ineficazes. Consequentemente, há uma necessidade de revisar as evidências publicadas de ensaios clínicos de medicamentos para orientar futuras prescrições. Foi realizada uma revisão sistemática de ensaios clínicos publicados e estudos observacionais retrospectivos. A busca foi feita nas bases de dados PubMed, Embase, MEDLINE e China National Knowledge Infrastructure (CNKI). Os artigos publicados entre janeiro de 2020 e outubro de 2020 e escritos na língua inglesa foram recuperados e incluídos no estudo. Foram excluídas pesquisas que utilizaram medicina tradicional, estudos in vitro e in vivo com animais, bem como revisões. Setenta e três artigos relevantes que preencheram os critérios de inclusão foram finalmente selecionados e revisados. Hidroxicloroquina, cloroquina e azitromicina não produziram evidências clínicas de eficácia em ensaios clínicos controlados randomizados (RCT). No entanto, estudos observacionais retrospectivos relataram a eficácia de remdesivir e lopinavir/ritonavir na redução da carga viral, embora tenha havido preocupações com lopinavir/ritonavir e, mais recentemente, remdesivir. Recentemente, tocilizumabe, dexametasona e metilprednisolona aliviaram significativamente a inflamação pulmonar e diminuíram a mortalidade em pacientes com COVID-19 grave. Além disso, o plasma convalescente foi eficaz em aumentar a imunidade forte entre pacientes com COVID-19 leve. Atualmente, não há uma única opção terapêutica aprovada em todo o mundo para pacientes com COVID-19, apesar do hype inicial com medicamentos, incluindo a hidroxicloroquina. No entanto, a dexametasona mostrou-se promissora no tratamento sintomático e no plasma convalescente no aumento da imunidade. Novos tratamentos estão sendo pesquisados atualmente, e os resultados serão relatados de acordo para fornecer orientação baseada em evidências para prescritores e formuladores de políticas.
Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.	https://doi.org/10.1093/cid/ciaa677	05/07/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa677	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   In patients with severe coronavirus disease 2019 (COVID-19), data are scarce and conflicting regarding whether chronic use of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) influences disease outcomes. In patients with severe COVID-19, we assessed the association between chronic ACEI/ARB use and the occurrence of kidney, lung, heart, and liver dysfunctions and the severity of the inflammatory reaction as evaluated by biomarkers kinetics, and their association with disease outcomes.                                                  Methods                   We performed a retrospective longitudinal cohort study on consecutive patients with newly diagnosed severe COVID-19. Independent predictors were assessed through receiver operating characteristic analysis, time-series analysis, logistic regression analysis, and multilevel modeling for repeated measures.                                                  Results                   On the 149 patients included in the study 30% (44/149) were treated with ACEI/ARB. ACEI/ARB use was independently associated with the following biochemical variations: phosphorus &amp;gt;40 mg/L (odds ratio [OR], 3.35, 95% confidence interval [CI], 1.83–6.14), creatinine &amp;gt;10.1 mg/L (OR, 3.22, 2.28–4.54), and urea nitrogen (UN) &amp;gt;0.52 g/L (OR, 2.65, 95% CI, 1.89–3.73). ACEI/ARB use was independently associated with acute kidney injury stage ≥1 (OR, 3.28, 95% CI, 2.17–4.94). The daily dose of ACEI/ARB was independently associated with altered kidney markers with an increased risk of +25 to +31% per each 10 mg increment of lisinopril-dose equivalent. In multivariable multilevel modeling, UN &amp;gt;0.52 g/L was independently associated with the risk of acute respiratory failure (OR, 3.54, 95% CI, 1.05–11.96).                                                  Conclusions                   Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of acute kidney injury. In these patients, the increase in UN associated with ACEI/ARB use could predict the development of acute respiratory failure.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Patients chronically treated with ACEI/ARB who have severe COVID-19 are at increased risk of acute kidney injury. In these patients, the increase in UN associated with ACEI/ARB use could predict the development of acute respiratory failure.	32623470	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa677	O uso prolongado de inibidor da ECA/BRA está associado a disfunção renal grave e lesão renal aguda em pacientes com COVID-19 grave: resultados de uma coorte de centro de referência no nordeste da França. 	Pacientes tratados cronicamente com IECA/BRA que têm COVID-19 grave têm risco aumentado de lesão renal aguda. Nesses pacientes, o aumento do UN associado ao uso de IECA/BRA poderia predizer o desenvolvimento de insuficiência respiratória aguda.
Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy.	https://doi.org/10.1016/j.jacl.2020.12.008	21/12/2020	Artigo completo publicado em periódico científico	10.1016/j.jacl.2020.12.008	1933-2874	19332874	JOURNAL OF CLINICAL LIPIDOLOGY	A1	1.281	62	3.57	-	['Estatina']	['Statin']	Our results did not confirm the supposed favorable effects of statin therapy on COVID-19 outcomes. Conversely, they suggest that statin use should be considered as a proxy of underlying comorbidities, which indeed expose to increased risks of more severe COVID-19.	33390341	Journal of clinical lipidology	1933-2874	10.1016/j.jacl.2020.12.008	Impacto do uso prévio de estatinas nos resultados clínicos em pacientes com COVID-19: dados de hospitais terciários de referência durante a pandemia de COVID-19 na Itália. 	Nossos resultados não confirmaram os supostos efeitos favoráveis da terapia com estatinas nos resultados do COVID-19. Por outro lado, eles sugerem que o uso de estatinas deve ser considerado como um proxy de comorbidades subjacentes, que de fato expõem a riscos aumentados de COVID-19 mais grave.
Low vitamin D status is associated with coronavirus disease 2019 outcomes: A systematic review and meta-analysis	https://doi.org/10.1016/j.ijid.2020.12.077	01/01/2021	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.12.077	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	O baixo status de vitamina D está associado aos resultados da doença por coronavírus 2019: uma revisão sistemática e meta-análise 	-
Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study.	https://doi.org/10.1016/j.diabres.2020.108619	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.diabres.2020.108619	0168-8227	1688227	DIABETES RESEARCH AND CLINICAL PRACTICE (PRINT)	A3	1.677	122	6.69	-	['Metformina']	['Metformin']	-	-	-	-	-	Associação de metformina com mortalidade ou SDRA em pacientes com COVID-19 e diabetes tipo 2: um estudo de coorte retrospectivo. 	-
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.	https://www.nejm.org/doi/full/10.1056/NEJMoa2035389	30/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2035389	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']	-	-	-	-	-	Eficácia e segurança da vacina mRNA-1273 SARS-CoV-2. 	-
Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.	https://doi.org/10.1016/j.diabet.2020.101220	23/12/2020	Artigo completo publicado em periódico científico	10.1016/j.diabet.2020.101220	1262-3636	12623636	DIABETES & METABOLISM	A2	1.834	94	4.51	-	['Estatina']	['Statin']	-	-	-	-	-	Estatinas e resultados clínicos com COVID-19: Meta-análises de estudos observacionais. 	-
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir.	https://doi.org/10.1016/j.jiph.2020.12.017	29/12/2020	Artigo completo publicado em periódico científico	10.1016/j.jiph.2020.12.017	1876-0341	18760341	JOURNAL OF INFECTION AND PUBLIC HEALTH	A3	1.277	46	6.31	-	['Favipiravir', 'Hidroxicloroquina']	['Favipiravir', 'Hydroxychloroquine']	HCQ with or without favipiravir treatment is associated with reduced risk of ICU admission compared to favipiravir alone in mild to moderate COVID-19 adult patients.	33647553	Journal of infection and public health	1876-035X	10.1016/j.jiph.2020.12.017	Comparando as taxas de admissão na UTI de pacientes leves/moderados com COVID-19 tratados com hidroxicloroquina, favipiravir e hidroxicloroquina mais favipiravir. 	HCQ com ou sem tratamento com favipiravir está associado a um risco reduzido de admissão na UTI em comparação com o favipiravir sozinho em pacientes adultos com COVID-19 leve a moderado.
Tocilizumab in the Management of COVID-19: A Preliminary Report.	https://doi.org/10.1016/j.amjms.2020.11.005	08/11/2020	Artigo completo publicado em periódico científico	10.1016/j.amjms.2020.11.005	0002-9629	29629	THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES (PRINT)	A2	0.628	92	1.74	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tocilizumab na gestão do COVID-19: um relatório preliminar. 	-
Effects of Tocilizumab in COVID-19 patients: a cohort study.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05701-4	22/12/2020	Artigo completo publicado em periódico científico	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05701-4	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressive respiratory failure from SARS-CoV-2.                                Methods                 A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020.                                Results                 Most patients were male (66.7%), Hispanic (63.3%) or Black (23.3%), with a median age of 54 years. Tocilizumab was administered at a median of 8 days (range 1–21) after initial symptoms and 2 days (range 0–12) after hospital admission. Within 30 days from receiving tocilizumab, 36 patients (60.0%) demonstrated clinical improvement, 9 (15.0%) died, 33 (55.0%) were discharged alive, and 18 (30.0%) remained hospitalized. Successful extubation occurred in 13 out of 29 patients (44.8%). Infectious complications occurred in 16 patients (26.7%) at a median of 10.5 days. After tocilizumab was administered, there was a slight increase in PaO 2/FiO 2 and an initial reduction in CRP, but this effect was not sustained beyond day 10.                                Conclusions                 Majority of patients demonstrated clinical improvement and were successfully discharged alive from the hospital after receiving tocilizumab. We observed a rebound effect with CRP, which may suggest the need for higher or subsequent doses to adequately manage cytokine storm. Based on our findings, we believe that tocilizumab may have a role in the early treatment of COVID-19, however larger randomized controlled studies are needed to confirm this.              	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Efeitos do Tocilizumab em pacientes com COVID-19: um estudo de coorte. 	-
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.	https://www.nejm.org/doi/full/10.1056/NEJMoa2033130	22/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2033130	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Bamlanivimabe', 'Bamlanivimabe']	['Bamlanivimab', 'Bamlanivimab']	-	-	-	-	-	Um anticorpo monoclonal neutralizante para pacientes hospitalizados com Covid-19. 	-
QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study.	https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13767	15/10/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13767	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Hidroxicloroquina']	['Hydroxychloroquine']	In patients treated with HCQ, QTc prolongation was associated with the presence of traditional risk factors such as hypokalaemia and furosemide treatment.	33063447	International journal of clinical practice	1742-1241	10.1111/ijcp.13767	Prolongamento do intervalo QTc entre pacientes com COVID-19 tratados com sulfato de hidroxicloroquina: um estudo observacional. 	Em pacientes tratados com HCQ, o prolongamento do intervalo QTc foi associado à presença de fatores de risco tradicionais, como hipocalemia e tratamento com furosemida.
Corticosteroid therapy in critically ill patients with COVID‑19: a multicenter, retrospective study.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03429-w	18/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03429-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 Corticoid therapy has been recommended in the treatment of critically ill patients with COVID-19, yet its efficacy is currently still under evaluation. We investigated the effect of corticosteroid treatment on 90-day mortality and SARS-CoV-2 RNA clearance in severe patients with COVID-19.                                Methods                 294 critically ill patients with COVID-19 were recruited between December 30, 2019 and February 19, 2020. Logistic regression, Cox proportional-hazards model and marginal structural modeling (MSM) were applied to evaluate the associations between corticosteroid use and corresponding outcome variables.                                Results                 Out of the 294 critically ill patients affected by COVID-19, 183 (62.2%) received corticosteroids, with methylprednisolone as the most frequently administered corticosteroid (175 accounting for 96%). Of those treated with corticosteroids, 69.4% received corticosteroid prior to ICU admission. When adjustments and subgroup analysis were not performed, no significant associations between corticosteroids use and 90-day mortality or SARS-CoV-2 RNA clearance were found. However, when stratified analysis based on corticosteroid initiation time was performed, there was a significant correlation between corticosteroid use (≤ 3 day after ICU admission) and 90-day mortality (logistic regression adjusted for baseline: OR 4.49, 95% CI 1.17–17.25,  p = 0.025; Cox adjusted for baseline and time varying variables: HR 3.89, 95% CI 1.94–7.82,  p &lt; 0.001; MSM adjusted for baseline and time-dependent variants: OR 2.32, 95% CI 1.16–4.65,  p = 0.017). No association was found between corticosteroid use and SARS-CoV-2 RNA clearance even after stratification by initiation time of corticosteroids and adjustments for confounding factors (corticosteroids use ≤ 3 days initiation vs no corticosteroids use) using MSM were performed.                                Conclusions                 Early initiation of corticosteroid use (≤ 3 days after ICU admission) was associated with an increased 90-day mortality. Early use of methylprednisolone in the ICU is therefore not recommended in patients with severe COVID-19.              	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']	in our multicenter retrospective cohort of COVID-19 patients undergoing MV, early corticosteroid therapy was independently associated with VA-LRTI.	35630429	Microorganisms	2076-2607	10.3390/microorganisms10050984	Corticoterapia em pacientes críticos com COVID-19: um estudo multicêntrico, retrospectivo. 	em nossa coorte retrospectiva multicêntrica de pacientes com COVID-19 submetidos a VM, a terapia precoce com corticosteróides foi independentemente associada a AV-LRTI.
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.	https://www.nejm.org/doi/full/10.1056/NEJMoa2035002	17/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2035002	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['REGN-COV2']	['REGN-COV2']	In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline. Safety outcomes were similar in the combined REGN-COV2 dose groups and the placebo group. (Funded by Regeneron Pharmaceuticals and the Biomedical and Advanced Research and Development Authority of the Department of Health and Human Services; ClinicalTrials.gov number, NCT04425629.).	33332778	The New England journal of medicine	1533-4406	10.1056/NEJMoa2035002	REGN-COV2, um coquetel de anticorpos neutralizantes, em pacientes ambulatoriais com Covid-19. 	Nesta análise interina, o coquetel de anticorpos REGN-COV2 reduziu a carga viral, com maior efeito em pacientes cuja resposta imune ainda não havia sido iniciada ou que apresentavam alta carga viral na linha de base. Os resultados de segurança foram semelhantes nos grupos de dose combinada de REGN-COV2 e no grupo placebo. (Financiado pela Regeneron Pharmaceuticals e pela Autoridade de Pesquisa e Desenvolvimento Biomédico e Avançado do Departamento de Saúde e Serviços Humanos; número ClinicalTrials.gov, NCT04425629.).
Tocilizumab in the Treatment of Critical COVID-19 Pneumonia: A Retrospective Cohort Study of Mechanically Ventilated Patients.	https://doi.org/10.1016/j.ijid.2020.12.021	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.12.021	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']	When controlling for age, severity of illness, and co-morbidities, tocilizumab was not associated with reduction in mortality in this retrospective cohort study of mechanically ventilated patients with COVID-19 pneumonia. Further studies are needed to determine the role of tocilizumab in the treatment of COVID-19.	33333252	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.12.021	Tocilizumab no tratamento da pneumonia crítica por COVID-19: um estudo de coorte retrospectivo de pacientes ventilados mecanicamente. 	Ao controlar a idade, gravidade da doença e comorbidades, o tocilizumabe não foi associado à redução da mortalidade neste estudo de coorte retrospectivo de pacientes ventilados mecanicamente com pneumonia por COVID-19. Mais estudos são necessários para determinar o papel do tocilizumab no tratamento da COVID-19.
Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: A systematic review with meta-analysis.	https://doi.org/10.18632/aging.202195	16/11/2020	Artigo completo publicado em periódico científico	10.18632/aging.202195	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Plasma convalescente']	['Convalescent Plasma']	We reviewed the scientific literature from four databases published from December 8, 2019 to August 20, 2020. Statistical analyses were performed with STATA (version 15.1; Stata Corporation, College Station, TX, USA). The frequency with 95% confidence intervals (CI) was assessed using fixed effect model in analyzing the overall mortality and p <0.05 was considered statistically significant.	33323550	Aging	1945-4589	10.18632/aging.202195	Segurança e eficácia da terapia com plasma convalescente em pacientes graves e críticos com COVID-19: uma revisão sistemática com meta-análise. 	Revisamos a literatura científica de quatro bases de dados publicadas de 8 de dezembro de 2019 a 20 de agosto de 2020. As análises estatísticas foram realizadas com o STATA (versão 15.1; Stata Corporation, College Station, TX, EUA). A frequência com intervalo de confiança (IC) de 95% foi avaliada pelo modelo de efeito fixo na análise da mortalidade geral e p<0,05 foi considerado estatisticamente significativo.
Coagulation dysfunction in ICU patients with coronavirus disease 2019 in Wuhan, China: A retrospective observational study of 75 fatal cases.	https://doi.org/10.18632/aging.202223	09/12/2020	Artigo completo publicado em periódico científico	10.18632/aging.202223	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Anticoagulantes']	['Anticoagulants']	Coagulation dysfunction in critically ill patients with coronavirus disease 2019 (COVID-19) has not been well described, and the efficacy of anticoagulant therapy is unclear. In this study, we retrospectively reviewed 75 fatal COVID-19 cases who were admitted to the intensive care unit at Jinyintan Hospital (Wuhan, China). The median age of the cases was 67 (62-74) years, and 47 (62.7%) were male. Fifty patients (66.7%) were diagnosed with disseminated intra-vascular coagulation. Approximately 90% of patients had elevated D-dimer and fibrinogen degradation products, which decreased continuously after anticoagulant treatment and was accompanied by elevated albumin (all 	33318314	Aging	1945-4589	10.18632/aging.202223	Disfunção da coagulação em pacientes de UTI com doença de coronavírus 2019 em Wuhan, China: Um estudo observacional retrospectivo de 75 casos fatais. 	A disfunção da coagulação em pacientes críticos com doença por coronavírus 2019 (COVID-19) não foi bem descrita e a eficácia da terapia anticoagulante não é clara. Neste estudo, revisamos retrospectivamente 75 casos fatais de COVID-19 que foram admitidos na unidade de terapia intensiva do Hospital Jinyintan (Wuhan, China). A idade mediana dos casos foi de 67 (62-74) anos, sendo 47 (62,7%) do sexo masculino. Cinquenta pacientes (66,7%) foram diagnosticados com coagulação intravascular disseminada. Aproximadamente 90% dos pacientes tinham produtos de degradação de dímero D e fibrinogênio elevados, que diminuíram continuamente após o tratamento anticoagulante e foi acompanhado por albumina elevada (todos
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. A Randomized Trial.	https://www.acpjournals.org/doi/10.7326/M20-6519	08/12/2020	Artigo completo publicado em periódico científico	10.7326/M20-6519	0003-4819	34819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Hidroxicloroquina como profilaxia pós-exposição para prevenir a infecção por coronavírus 2 da síndrome respiratória aguda grave. Um Julgamento Randomizado. 	-
Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial.	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w	14/12/2020	Artigo completo publicado em periódico científico	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract                  Background                 Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19, there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB) on COVID-19 disease.                                Methods                 Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into the study for the final analysis at significance level of 0.05.                                Results                 The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups, respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB group was significantly less than KALETRA arm (7.2 versus 9.6 days;  P = 0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA groups respectively) ( P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19.                                Conclusion                 Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using larger sample size and multicenter design.                                Trial registration                 <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://irct.ir/search/result?query=Evaluation+of+the+effect+of+Arbidol+drug+in+the+treatment+of+hospitalized+patients+with+COVID-19">IRCT20180725040596N2</jats:ext-link> on 18 April 2020.              	['Umifenovir']	['Umifenovir']	-	-	-	-	-	Efeito do Arbidol (Umifenovir) no COVID-19: um estudo controlado randomizado. 	-
Corticosteroid use in COVID‑19 patients: a systematic review and meta‑analysis on clinical outcomes.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03400-9	14/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03400-9	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 In the current SARS-CoV-2 pandemic, there has been worldwide debate on the use of corticosteroids in COVID-19. In the recent RECOVERY trial, evaluating the effect of dexamethasone, a reduced 28-day mortality in patients requiring oxygen therapy or mechanical ventilation was shown. Their results have led to considering amendments in guidelines or actually already recommending corticosteroids in COVID-19. However, the effectiveness and safety of corticosteroids still remain uncertain, and reliable data to further shed light on the benefit and harm are needed.                                Objectives                 The aim of this systematic review and meta-analysis was to evaluate the effectiveness and safety of corticosteroids in COVID-19.                                Methods                 A systematic literature search of RCTS and observational studies on adult patients was performed across Medline/PubMed, Embase and Web of Science from December 1, 2019, until October 1, 2020, according to the PRISMA guidelines. Primary outcomes were short-term mortality and viral clearance (based on RT-PCR in respiratory specimens). Secondary outcomes were: need for mechanical ventilation, need for other oxygen therapy, length of hospital stay and secondary infections.                                Results                 Forty-four studies were included, covering 20.197 patients. In twenty-two studies, the effect of corticosteroid use on mortality was quantified. The overall pooled estimate (observational studies and RCTs) showed a significant reduced mortality in the corticosteroid group (OR 0.72 (95%CI 0.57–0.87). Furthermore, viral clearance time ranged from 10 to 29 days in the corticosteroid group and from 8 to 24 days in the standard of care group. Fourteen studies reported a positive effect of corticosteroids on need for and duration of mechanical ventilation. A trend toward more infections and antibiotic use was present.                                Conclusions                 Our findings from both observational studies and RCTs confirm a beneficial effect of corticosteroids on short-term mortality and a reduction in need for mechanical ventilation. And although data in the studies were too sparse to draw any firm conclusions, there might be a signal of delayed viral clearance and an increase in secondary infections.              	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Uso de corticosteróides em pacientes com COVID-19: uma revisão sistemática e meta-análise sobre resultados clínicos. 	-
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824,650 Patients with Hypertension from a US integrated Healthcare System.	https://www.ahajournals.org/doi/10.1161/JAHA.120.019669	14/12/2020	Artigo completo publicado em periódico científico	10.1161/JAHA.120.019669	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             Background            <jats:p xml:lang="en">Previous reports suggest that the use of angiotensin‐converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) may upregulate angiotensin‐converting enzyme 2 receptors and increase severe acute respiratory syndrome coronavirus 2 infectivity. We evaluated the association between ACEI or ARB use and coronavirus disease 2019 (COVID‐19) infection among patients with hypertension.                    <jats:sec xml:lang="en">             Methods and Results            <jats:p xml:lang="en">              We identified patients with hypertension as of March 1, 2020 (index date) from Kaiser Permanente Southern California. Patients who received ACEIs, ARBs, calcium channel blockers, beta blockers, thiazide diuretics (TD), or no therapy were identified using outpatient pharmacy data covering the index date. Outcome of interest was a positive reverse transcription polymerase chain reaction test for COVID‐19 between March 1 and May 6, 2020. Patient sociodemographic and clinical characteristics were identified within 1 year preindex date. Among 824 650 patients with hypertension, 16 898 (2.0%) were tested for COVID‐19. Of those tested, 1794 (10.6%) had a positive result. Overall, exposure to ACEIs or ARBs was not statistically significantly associated with COVID‐19 infection after propensity score adjustment (odds ratio [OR], 1.06; 95% CI, 0.90–1.25) for ACEIs versus calcium channel blockers/beta blockers/TD; OR, 1.10; 95% CI, 0.91–1.31 for ARBs versus calcium channel blockers/beta blockers/TD). The associations between ACEI use and COVID‐19 infection varied in different age groups (               P              ‐interaction=0.03). ACEI use was associated with lower odds of COVID‐19 among those aged ≥85 years (OR, 0.30; 95% CI, 0.12–0.77). Use of no antihypertensive medication was significantly associated with increased odds of COVID‐19 infection compared with calcium channel blockers/beta blockers/TD (OR, 1.32; 95% CI, 1.11–1.56).                                <jats:sec xml:lang="en">             Conclusions            <jats:p xml:lang="en">Neither ACEI nor ARB use was associated with increased likelihood of COVID‐19 infection. Decreased odds of COVID‐19 infection among adults ≥85 years using ACEIs warrants further investigation.          	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Uso de inibidores da enzima conversora de angiotensina ou bloqueadores do receptor de angiotensina e infecção por COVID-19 entre 824.650 pacientes com hipertensão de um sistema de saúde integrado dos EUA. 	-
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.	https://www.nejm.org/doi/10.1056/NEJMoa2031994	11/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2031994	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Baricitinibe', 'Baricitinibe', 'Baricitinibe']	['Baricitinib', 'Baricitinib', 'Baricitinib']	-	-	-	-	-	Baricitinibe mais Remdesivir para Adultos Hospitalizados com Covid-19. 	-
Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study	https://doi.org/10.1016/j.cmi.2020.12.003	10/12/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.12.003	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Hidroxicloroquina']	['Hydroxychloroquine']	HCQ prophylactic use at a usual dose did not prevent COVID-19 in patients with rheumatic disease.	33316402	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases	1469-0691	10.1016/j.cmi.2020.12.003	Efeito da pré-exposição à hidroxicloroquina na infecção por SARS-CoV-2 em pacientes com doença reumática: Um estudo de coorte 	populacional O uso profilático de HCQ em uma dose usual não preveniu o COVID-19 em pacientes com doença reumática.
Anakinra treatment in critically ill COVID‑19 patients: a prospective cohort study.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03364-w	10/12/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03364-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation.                                Methods                 In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day − 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment.                                Results                 Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) ( p = 0.0002), ferritin ( p = 0.009), and temperature ( p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature ( p = 0.03), white blood cell counts ( p = 0.02), and plasma levels of ferritin ( p = 0.003), procalcitonin ( p = 0.001), creatinine ( p = 0.01), and bilirubin ( p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results.                                Conclusions                 Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.              	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']	-	-	-	-	-	Tratamento com Anakinra em pacientes criticamente doentes com COVID-19: um estudo de coorte prospectivo. 	-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.	https://www.nejm.org/doi/10.1056/NEJMoa2034577	10/12/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2034577	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162']	['BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine']	-	-	-	-	-	Segurança e eficácia da vacina BNT162b2 mRNA Covid-19. 	-
Repurposed Tocilizumab in Patients with Severe COVID-19.	https://doi.org/10.4049/jimmunol.2000981	09/12/2020	Artigo completo publicado em periódico científico	10.4049/jimmunol.2000981	0022-1767	221767	THE JOURNAL OF IMMUNOLOGY (1950)	A1	1.964	387	5.25	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tocilizumab reaproveitado em pacientes com COVID-19 grave. 	-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.	https://doi.org/10.1016/S0140-6736(20)32661-1	08/12/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)32661-1	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 Vaccine', 'ChAdOx1 nCoV-19 Vaccine', 'ChAdOx1 nCoV-19 Vaccine']	-	-	-	-	-	Segurança e eficácia da vacina ChAdOx1 nCoV-19 (AZD1222) contra SARS-CoV-2: uma análise provisória de quatro ensaios clínicos randomizados no Brasil, África do Sul e Reino Unido. 	-
The role of methylprednisolone on preventing disease progression for hospitalized patients with severe COVID-19.	https://doi.org/10.1111/eci.13412	20/09/2020	Artigo completo publicado em periódico científico	10.1111/eci.13412	0014-2972	142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Prednisona']	['Prednisone']	Data from the limited sample showed that the early use of low or medium doses of methylprednisolone has a positive effect for patients with severe COVID-19 younger than 65 years old, and excessive immune response and cytokine storm may be some of the reasons for the effectiveness.	32954492	European journal of clinical investigation	1365-2362	10.1111/eci.13412	O papel da metilprednisolona na prevenção da progressão da doença para pacientes hospitalizados com COVID-19 grave. 	Os dados da amostra limitada mostraram que o uso precoce de doses baixas ou médias de metilprednisolona tem um efeito positivo para pacientes com COVID-19 grave com menos de 65 anos, e a resposta imune excessiva e a tempestade de citocinas podem ser algumas das razões para a eficácia .
COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study.	https://doi.org/10.1016/j.ijid.2020.11.198	26/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.198	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Tratamento com plasma convalescente COVID-19 de casos moderados e graves de infecção por SARS-CoV-2: um estudo de intervenção multicêntrico. 	-
Hydroxychloroquine/Azithromycin treatment, QT interval and ventricular arrhythmias in hospitalized patients with COVID‐19.	https://onlinelibrary.wiley.com/doi/abs/10.1111/ijcp.13896	05/12/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13896	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	Tratamento com hidroxicloroquina/azitromicina, intervalo QT e arritmias ventriculares em pacientes hospitalizados com COVID-19. 	-
Cyclosporine A plus low‐dose steroid treatment in COVID‐19 improves clinical outcomes in patients with moderate to severe disease. A pilot study.	https://onlinelibrary.wiley.com/doi/10.1111/joim.13223	03/12/2020	Artigo completo publicado em periódico científico	10.1111/joim.13223	0954-6820	9546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Ciclosporina', 'Esteroides']	['Cyclosporin', 'Steroidal']	CsA used as an adjuvant to steroid treatment for COVID-19 patients showed to improve outcomes and reduce mortality, mainly in those with moderate to severe disease. Further investigation through controlled clinical trials is warranted.	33274479	Journal of internal medicine	1365-2796	10.1111/joim.13223	Ciclosporina A mais tratamento com esteróides em baixa dose no COVID-19 melhora os resultados clínicos em pacientes com doença moderada a grave. Um estudo piloto. 	A CsA usada como adjuvante ao tratamento com esteróides para pacientes com COVID-19 mostrou melhorar os resultados e reduzir a mortalidade, principalmente naqueles com doença moderada a grave. É necessária uma investigação mais aprofundada através de ensaios clínicos controlados.
Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users.	https://doi.org/10.1093/ofid/ofaa455	25/09/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa455	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   The preventive effect that tenofovir/emtricitabine (FTC) could have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human immunodeficiency virus-negative people is unknown. The objective of this study was to analyze the seroprevalence and clinical manifestations of COVID-19 among users of pre-exposure prophylaxis (PrEP), disoproxil fumarate/FTC (TDF/FTC), or tenofovir alafenamide (TAF)/FTC and to compare it to that of a control group.                                                  Methods                   An observational descriptive study of the seroprevalence of antibodies for SARS-CoV-2 among men who have sex with men and transgender women without use of PrEP (Group 1; n = 250) and PrEP users with TDF/FTC (n = 409) or TAF/FTC (n = 91) (Group 2; n = 500) was conducted from May11, 2020 to June 27, 2020. All participants were provided with a structured questionnaire that collected information on the variables to be analyzed, and testing for immunoglobulin G antibodies to SARS-CoV-2 (chemiluminescent microparticle immunoassay) was then carried out.                                                  Results                   The seroprevalence of SARS-CoV-2 was 9.2% (95% confidence interval [CI], 5.9–13.5) in the group without PrEP and 15.0% (95% CI, 12.0–18.4) in the group with PrEP (P = .026). Among users of TDF/FTC it was 14.7% (95% CI, 11.4–18.5), and in users of TAF/FTC it was 16.5% (95% CI, 9.5–25.7) (P = .661). In those who tested positive for SARS-CoV-2 and receiving PrEP, 57.4% manifested symptoms, compared with 78.3% in the control group (P = .070). In users of TDF/FTC the figure was 53.3% and in users of TAF/FTC the figure was 73.3% (P = .100). The duration of symptoms was 11.5 days in the control group, 9.0 days in PrEP users (P = .116), 7.0 days in users of TDF/FTC, and 13.0 days in users of TAF/FTC (P = .100).                                                  Conclusions                   Users of PrEP, TDF/FTC, or TAF/FTC presented a higher seroprevalence to SARS-CoV-2 than the control group. No statistically significant differences were found in relation to clinical manifestations. The PrEP users should use the same prevention measures as those indicated for the general population.               	['Tenofovir']	['Tenofovir']	Users of PrEP, TDF/FTC, or TAF/FTC presented a higher seroprevalence to SARS-CoV-2 than the control group. No statistically significant differences were found in relation to clinical manifestations. The PrEP users should use the same prevention measures as those indicated for the general population.	33200081	Open forum infectious diseases	2328-8957	10.1093/ofid/ofaa455	Eficácia preventiva do tenofovir/emtricitabina contra o coronavírus da síndrome respiratória aguda grave 2 entre usuários de profilaxia pré-exposição. 	Usuários de PrEP, TDF/FTC ou TAF/FTC apresentaram maior soroprevalência para SARS-CoV-2 do que o grupo controle. Não foram encontradas diferenças estatisticamente significativas em relação às manifestações clínicas. Os usuários de PrEP devem utilizar as mesmas medidas de prevenção indicadas para a população em geral.
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.	https://doi.org/10.1016/j.ijid.2020.11.191	02/12/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.191	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Ivermectina', 'Ivermectina']	['Ivermectin', 'Ivermectin']	Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.	33278625	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.11.191	Um curso de cinco dias de ivermectina para o tratamento de COVID-19 pode reduzir a duração da doença. 	A ivermectina, um agente antiparasitário aprovado pela Food and Drug Administration dos EUA, inibe a replicação do coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) in vitro. Um estudo randomizado, duplo-cego e controlado por placebo foi realizado para determinar a rapidez da eliminação viral e a segurança da ivermectina entre pacientes adultos com SARS-CoV-2. O estudo incluiu 72 pacientes hospitalizados em Dhaka, Bangladesh, que foram divididos em três grupos: ivermectina oral isolada (12 mg uma vez ao dia por 5 dias), ivermectina oral em combinação com doxiciclina (12 mg de ivermectina em dose única e 200 mg de doxiciclina em dia 1, seguido de 100 mg a cada 12 h pelos próximos 4 dias) e um grupo controle placebo. Os sintomas clínicos de febre, tosse e dor de garganta foram comparáveis entre os três grupos. A depuração virológica foi mais precoce no braço de tratamento de 5 dias com ivermectina quando comparado ao grupo placebo (9,7 dias vs 12,7 dias; p = 0,02), mas este não foi o caso do braço de ivermectina + doxiciclina (11,5 dias; p = 0,27) . Não houve eventos adversos graves de medicamentos registrados no estudo. Um curso de 5 dias de ivermectina mostrou-se seguro e eficaz no tratamento de pacientes adultos com COVID-19 leve. Ensaios maiores serão necessários para confirmar essas descobertas preliminares.
Association between renin-angiotensin-aldosterone system inhibitor use and covid-19 hospitalization and death: a 1,4 million patient nation-wide registry analysis.	https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.2060	22/11/2020	Artigo completo publicado em periódico científico	10.1002/ejhf.2060	1388-9842	13889842	EUROPEAN JOURNAL OF HEART FAILURE	A1	5.231	144	6.95	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Associação entre uso de inibidor do sistema renina-angiotensina-aldosterona e hospitalização e morte por covid-19: uma análise de registro nacional de 1,4 milhão de pacientes. 	-
A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin.	https://doi.org/10.1016/j.ijantimicag.2020.106248	28/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106248	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Ivermectina']	['Ivermectin']	As COVID-19 (coronavirus disease 2019) continues to rapidly spread throughout the world, the incidence varies greatly among different countries. These differences raise the question whether nations with a lower incidence share any medical commonalities that could be used not only to explain that lower incidence but also to provide guidance for potential treatments elsewhere. Such a treatment would be particularly valuable if it could be used as a prophylactic against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) transmission, thereby effectively slowing the spread of the disease while we await the wide availability of safe and effective vaccines. Here, we show that countries with routine mass drug administration of prophylactic chemotherapy including ivermectin have a significantly lower incidence of COVID-19. Prophylactic use of ivermectin against parasitic infections is most common in Africa and we hence show that the reported correlation is highly significant both when compared among African nations as well as in a worldwide context. We surmise that this may be connected to ivermectin's ability to inhibit SARS-CoV-2 replication, which likely leads to lower infection rates. However, other pathways must exist to explain the persistence of such an inhibitory effect after serum levels of ivermectin have declined. It is suggested that ivermectin be evaluated for potential off-label prophylactic use in certain cases to help bridge the time until a safe and effective vaccine becomes available.	33259913	International journal of antimicrobial agents	1872-7913	10.1016/j.ijantimicag.2020.106248	Profilaxia COVID-19? Menor incidência associada à administração profilática de Ivermectina. 	Como o COVID-19 (doença do coronavírus 2019) continua a se espalhar rapidamente pelo mundo, a incidência varia muito entre os diferentes países. Essas diferenças levantam a questão de saber se os países com menor incidência compartilham quaisquer semelhanças médicas que possam ser usadas não apenas para explicar essa menor incidência, mas também para fornecer orientação para possíveis tratamentos em outros lugares. Tal tratamento seria particularmente valioso se pudesse ser usado como profilático contra a transmissão de SARS-CoV-2 (síndrome respiratória aguda grave coronavírus 2), retardando efetivamente a propagação da doença enquanto aguardamos a ampla disponibilidade de vacinas seguras e eficazes . Aqui, mostramos que países com administração em massa rotineira de quimioterapia profilática, incluindo ivermectina, têm uma incidência significativamente menor de COVID-19. O uso profilático de ivermectina contra infecções parasitárias é mais comum na África e, portanto, mostramos que a correlação relatada é altamente significativa tanto quando comparada entre nações africanas quanto em um contexto mundial. Supomos que isso possa estar relacionado à capacidade da ivermectina de inibir a replicação do SARS-CoV-2, o que provavelmente leva a taxas de infecção mais baixas. No entanto, outras vias devem existir para explicar a persistência de tal efeito inibitório após os níveis séricos de ivermectina terem diminuído. Sugere-se que a ivermectina seja avaliada para potencial uso profilático off-label em certos casos para ajudar a reduzir o tempo até que uma vacina segura e eficaz esteja disponível.
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.	https://www.tandfonline.com/doi/full/10.1080/17512433.2021.1856655	30/11/2020	Artigo completo publicado em periódico científico	10.1080/17512433.2021.1856655	1751-2433	17512433	EXPERT REVIEW OF CLINICAL PHARMACOLOGY	A3	0.927	46	3.94	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']	-	-	-	-	-	Revisão rápida de eventos adversos suspeitos de medicamentos devido ao remdesivir no banco de dados da OMS; descobertas e implicações. 	-
A Case–Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers.	https://link.springer.com/article/10.1007/s10875-020-00925-0	26/11/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s10875-020-00925-0	0271-9142	2719142	JOURNAL OF CLINICAL IMMUNOLOGY	A3	1.522	101	4.54	-	['Vacina influenza', 'Vacina influenza']	['Influenza vaccine', 'Influenza vaccine']	-	-	-	-	-	Um estudo de caso-controle da vacina contra a gripe de 2019 e incidência de COVID-19 entre profissionais de saúde. 	-
Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study.	https://www.tandfonline.com/doi/full/10.1080/17476348.2021.1856659	11/11/2020	Artigo completo publicado em periódico científico	10.1080/17476348.2021.1856659	1747-6348	17476348	EXPERT REVIEW OF RESPIRATORY MEDICINE	A3	0.939	47	3.79	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Tratamento com corticosteróides em pacientes graves com COVID-19: um estudo de correspondência de escore de propensão. 	-
The effectiveness of early anticoagulant treatment in Covid-19 patients.	https://journals.sagepub.com/doi/abs/10.1177/0268355520975595	27/11/2020	Artigo completo publicado em periódico científico	10.1177/0268355520975595	0268-3555	2683555	PHLEBOLOGY (LONDON)	A4	0.504	52	1.79	  Objectives  Coronavirus disease 2019 (Covid-19) is an emerging, fast-spreading and worldwide infectious disease that would be deteriorated with the precipitation of systemic or local thrombosis. The aim of current study was evaluating the effects of early anticoagulant treatment in hospitalized Covid-19 patients.   Method  The present retrospective and comparative cohort study investigated 413 hospitalized Covid-19 patients treated with or without Low Molecular Weight Heparin (LMWH) (n = 187 and 226, respectively) in the Covid Clinics of Gulhane Education and Research Hospital in Ankara, Turkey, between March 18 and May 03, 2020. The treatment groups were consisted of the patients evaluated before and after The Covid-19 Treatment Guide update on April 12, 2020 that included the anticoagulant treatment thereafter.   Results  The mean age of all 413 patients (204 male and 209 female) at disease onset was 50.6 ± 16.7 years. The LMWH-treated patients had significantly higher coagulation markers such as d-dimer and platelet count than LMWH-untreated patients (p values &lt; 0.05). The inflammatory markers, ferritin, interleukin-6 and procalcitonin were significantly increased in LMWH-untreated patients (p values &lt; 0.05). The presence of any comorbidity was significantly more common in LMWH-treated patients compared to LMWH-untreated group (39.6% vs 19.9%, respectively; p &lt; 0.001). Hypertension and diabetes mellitus were the most frequent comorbidities in both groups. The number of intensive care unit (ICU) transfer and longer length of hospital stay were more commonly observed in LMWH-untreated patients (p values &lt;0.05).   Conclusions  Early anticoagulant treatment with relatively higher doses of LMWH may improve the clinical outcome of Covid-19 patients and shorten the length of hospital stay. 	['Heparina']	['Heparin']	-	-	-	-	-	A eficácia do tratamento anticoagulante precoce em pacientes com Covid-19. 	-
Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial	https://doi.org/10.1007/s12011-020-02512-1	27/11/2020	Artigo completo publicado em periódico científico	10.1007/s12011-020-02512-1	0163-4984	1634984	BIOLOGICAL TRACE ELEMENT RESEARCH	A3	0.649	88	4.18	-	['Hidroxicloroquina', 'Zinco']	['Hydroxychloroquine', 'Zinc']	No specific treatment for COVID-19 infection is available up till now, and there is a great urge for effective treatment to reduce morbidity and mortality during this pandemic. We aimed to evaluate the effect of combining chloroquine/hydroxychloroquine (CQ/HCQ) and zinc in the treatment of COVID-19 patients. This was a randomized clinical trial conducted at three major University hospitals in Egypt. One hundred ninety-one patients with a confirmed diagnosis of COVID-19 infection were randomized into two groups: group I (96) patients received both HCQ and zinc, and group II (95) received HCQ only. The primary endpoints were the recovery within 28 days, the need for mechanical ventilation, and death. The two groups were matched for age and gender. They had no significant difference regarding any of the baseline laboratory parameters or clinical severity grading. Clinical recovery after 28 days was achieved by 79.2% in the zinc group and 77.9% in zinc-free treatment group, without any significant difference (p = 0.969). The need for mechanical ventilation and the overall mortality rates did not show any significant difference between the 2 groups either (p = 0.537 and 0.986, respectively). The age of the patient and the need for mechanical ventilation were the only risk factors associated with the patients' mortality by the univariate regression analysis (p = 0.001 and < 0.001, respectively). Zinc supplements did not enhance the clinical efficacy of HCQ. More randomized studies are needed to evaluate the value of adding zinc to other therapies for COVID 19. ClinicalTrials.gov Identifier: NCT04447534.	33247380	Biological trace element research	1559-0720	10.1007/s12011-020-02512-1	Os suplementos de zinco aumentam a eficácia clínica da hidroxicloroquina?: um estudo randomizado e multicêntrico 	Nenhum tratamento específico para a infecção por COVID-19 está disponível até agora, e há uma grande necessidade de um tratamento eficaz para reduzir a morbidade e a mortalidade durante esta pandemia. Nosso objetivo foi avaliar o efeito da combinação de cloroquina/hidroxicloroquina (CQ/HCQ) e zinco no tratamento de pacientes com COVID-19. Este foi um ensaio clínico randomizado realizado em três grandes hospitais universitários no Egito. Cento e noventa e um pacientes com diagnóstico confirmado de infecção por COVID-19 foram randomizados em dois grupos: grupo I (96) pacientes receberam HCQ e zinco, e grupo II (95) recebeu apenas HCQ. Os desfechos primários foram a recuperação em 28 dias, a necessidade de ventilação mecânica e o óbito. Os dois grupos foram pareados por idade e sexo. Eles não tiveram diferença significativa em relação a qualquer um dos parâmetros laboratoriais basais ou classificação de gravidade clínica. A recuperação clínica após 28 dias foi alcançada em 79,2% no grupo de zinco e 77,9% no grupo de tratamento sem zinco, sem diferença significativa (p = 0,969). A necessidade de ventilação mecânica e as taxas de mortalidade geral também não mostraram diferença significativa entre os 2 grupos (p = 0,537 e 0,986, respectivamente). A idade do paciente e a necessidade de ventilação mecânica foram os únicos fatores de risco associados à mortalidade dos pacientes pela análise de regressão univariada (p = 0,001 e < 0,001, respectivamente). Os suplementos de zinco não aumentaram a eficácia clínica do HCQ. São necessários mais estudos randomizados para avaliar o valor da adição de zinco a outras terapias para COVID 19. ClinicalTrials.gov Identificador: NCT04447534.
Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019.	https://doi.org/10.1093/ofid/ofaa519	27/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa519	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   There is growing concern about the potential harmful effects of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19) and cardiovascular diseases (CVDs). The aim of this study was to evaluate the association between recent exposure to ACEIs/ARBs and in-hospital mortality in patients with COVID-19.                                                  Methods                   We used data from a nationwide cohort of patients with COVID-19 from the health insurance claims data of South Korea, which were released for research purposes for public health by the Ministry of Health and Welfare of South Korea. Patients with COVID-19 were identified using the relevant diagnostic code. Propensity score matching (1:1) was carried out among patients with CVD according to the type of medication (ACEIs/ARBs vs other), and the risk of death was assessed.                                                  Results                   A total of 4936 patients with COVID-19 were analyzed, of whom 1048 (21.2%) had CVD. Of the 1048 patients with CVD, 864 (82.4%) received at least 1 antihypertensive medication before the diagnosis of COVID-19, including 359 (41.6%) who received ACEIs/ARBs and 505 (58.4%) who received drugs other than ACEIs/ARBs. Using the propensity scores for ACEI/ARB use, we matched 305 pairs of patients receiving ACEIs/ARBs and patients receiving other drugs. Recent use of ACEIs/ARBs was not significantly associated with in-hospital mortality in unadjusted analysis (odds ratio [OR], 0.62; 95% CI, 0.33–1.14) or propensity score matching analysis (OR, 1.00; 95% CI, 0.46–2.16).                                                  Conclusions                   In patients with COVID-19 and underlying CVDs, the recent use of ACEIs/ARBs was not significantly associated with in-hospital mortality. These findings do not support stopping or modifying ACEIs/ARBs in patients during the current COVID-19 pandemic.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Efeitos do uso recente de inibidores do sistema renina-angiotensina na mortalidade de pacientes com doença de coronavírus 2019. 	-
Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study.	https://doi.org/10.1093/ofid/ofaa486	14/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa486	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                This is a retrospective cohort study of hospitalized adults with coronavirus disease 2019 (COVID-19). Fifty-seven patients received treatment alone, and 35 patients received treatment with adjunctive prednisolone. A combination of corticosteroids and antivirals was associated with lower risk of clinical progression and invasive mechanical ventilation or death in early COVID-19 pneumonia.	['Antivirais', 'Corticosteroides']	['Antivirals', 'Corticosteroids']	This is a retrospective cohort study of hospitalized adults with coronavirus disease 2019 (COVID-19). Fifty-seven patients received treatment alone, and 35 patients received treatment with adjunctive prednisolone. A combination of corticosteroids and antivirals was associated with lower risk of clinical progression and invasive mechanical ventilation or death in early COVID-19 pneumonia.	33235888	Open forum infectious diseases	2328-8957	10.1093/ofid/ofaa486	Antivirais com corticosteróides adjuvantes impedem a progressão clínica da pneumonia precoce por coronavírus 2019: um estudo de coorte retrospectivo. 	Este é um estudo de coorte retrospectivo de adultos hospitalizados com doença de coronavírus 2019 (COVID-19). Cinquenta e sete pacientes receberam tratamento isolado e 35 pacientes receberam tratamento com prednisolona adjuvante. Uma combinação de corticosteróides e antivirais foi associada a menor risco de progressão clínica e ventilação mecânica invasiva ou morte na pneumonia precoce por COVID-19.
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.	https://www.nejm.org/doi/full/10.1056/NEJMoa2031304	24/11/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2031304	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Um ensaio randomizado de plasma convalescente na pneumonia grave Covid-19. 	-
Evidence for treatment with estradiol for women with SARS-CoV-2 infection.	https://doi.org/10.1186/s12916-020-01851-z	25/11/2020	Artigo completo publicado em periódico científico	10.1186/s12916-020-01851-z	1741-7015	17417015	BMC MEDICINE	A1	3.405	155	10.07	 Abstract                  Background                 Given that an individual’s age and gender are strongly predictive of coronavirus disease 2019 (COVID-19) outcomes, do such factors imply anything about preferable therapeutic options?                                Methods                 An analysis of electronic health records for a large (68,466-case), international COVID-19 cohort, in 5-year age strata, revealed age-dependent sex differences. In particular, we surveyed the effects of systemic hormone administration in women. The primary outcome for estradiol therapy was death. Odds ratios (ORs) and Kaplan-Meier survival curves were analyzed for 37,086 COVID-19 women in two age groups: pre- (15–49 years) and peri-/post-menopausal (&gt; 50 years).                                Results                 The incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is higher in women than men (by about + 15%) and, in contrast, the fatality rate is higher in men (about + 50%). Interestingly, the relationships between these quantities are linked to age: pre-adolescent girls and boys had the same risk of infection and fatality rate, while adult premenopausal women had a significantly higher risk of infection than men in the same 5-year age stratum (about 16,000 vs. 12,000 cases). This ratio changed again in peri- and postmenopausal women, with infection susceptibility converging with men. While fatality rates increased continuously with age for both sexes, at 50 years, there was a steeper increase for men. Thus far, these types of intricacies have been largely neglected. Because the hormone 17ß-estradiol influences expression of the human angiotensin-converting enzyme 2 (ACE2) protein, which plays a role in SARS-CoV-2 cellular entry, propensity score matching was performed for the women’s sub-cohort, comparing users vs. non-users of estradiol. This retrospective study of hormone therapy in female COVID-19 patients shows that the fatality risk for women &gt; 50 years receiving estradiol therapy (user group) is reduced by more than 50%; the OR was 0.33, 95% CI [0.18, 0.62] and the hazard ratio (HR) was 0.29, 95% CI [0.11,0.76]. For younger, pre-menopausal women (15–49 years), the risk of COVID-19 fatality is the same irrespective of estradiol treatment, probably because of higher endogenous estradiol levels.                                Conclusions                 As of this writing, still no effective drug treatment is available for COVID-19; since estradiol shows such a strong improvement regarding fatality in COVID-19, we suggest prospective studies on the potentially more broadly protective roles of this naturally occurring hormone.              	['Estradiol', 'Estradiol', 'Estradiol']	['Estradiol', 'Estradiol', 'Estradiol']	-	-	-	-	-	Evidência para tratamento com estradiol para mulheres com infecção por SARS-CoV-2. 	-
A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.	https://www.nejm.org/doi/full/10.1056/NEJMoa2021801	24/11/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021801	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Um estudo randomizado em cluster de hidroxicloroquina para prevenção do Covid-19. 	-
The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort.	https://doi.org/10.1016/j.thromres.2020.10.031	05/11/2020	Artigo completo publicado em periódico científico	10.1016/j.thromres.2020.10.031	0049-3848	493848	THROMBOSIS RESEARCH	A3	1.678	118	5.91	-	['Anticoagulantes']	['Anticoagulants']	-	-	-	-	-	O efeito da anticoagulação nos resultados clínicos da nova pneumonia por coronavírus (COVID-19) em uma coorte dos EUA. 	-
Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities.	https://doi.org/10.18632/aging.202172	24/11/2020	Artigo completo publicado em periódico científico	10.18632/aging.202172	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Corticosteroides']	['Corticosteroids']	COVID-19 exhibits both variability and rapid progression, particularly in patients with comorbidities such as diabetes, hypertension or cancer. To determine how these underlying disorders exacerbate pneumonia in COVID-19, we evaluated 79 patients with severe COVID-19 and grouped them according to whether or not they had comorbidities. Clinical information, laboratory examinations, immunological function, and treatment outcomes were retrospectively analyzed. Our study revealed that severe COVID-19 patients with comorbidities had higher levels of inflammatory indices, including blood interferon-γ, interleukin (IL)-6 and c-reactive protein levels as well as the erythrocyte sedimentation rate. These were accompanied by lymphopenia, hypokalemia, hypoalbuminemia, a decrease in either CD4+ T cells or lymphocyte count, and coagulation disorders, which were closely related to poor prognosis. Patients with comorbidities also had longer disease remission times (27 ± 6.7 days) than those without comorbidities (20 ± 6.5 days). Cox multivariate analysis indicated that glucocorticoid therapy and IL-6 were independent prognostic factors. Our findings suggest that coexisting comorbidities aggravate COVID-19 through the excessive release of inflammatory factors and that glucocorticoid therapy may be beneficial.	33232277	Aging	1945-4589	10.18632/aging.202172	Estimativa da liberação de fatores inflamatórios e uso de terapia com glicocorticóides para pacientes com COVID-19 com comorbidades. 	O COVID-19 exibe variabilidade e progressão rápida, particularmente em pacientes com comorbidades como diabetes, hipertensão ou câncer. Para determinar como esses distúrbios subjacentes exacerbam a pneumonia no COVID-19, avaliamos 79 pacientes com COVID-19 grave e os agrupamos de acordo com a presença ou não de comorbidades. Informações clínicas, exames laboratoriais, função imunológica e resultados do tratamento foram analisados retrospectivamente. Nosso estudo revelou que pacientes graves com COVID-19 com comorbidades apresentaram níveis mais altos de índices inflamatórios, incluindo níveis sanguíneos de interferon-γ, interleucina (IL)-6 e proteína c-reativa, bem como a velocidade de hemossedimentação. Estes foram acompanhados por linfopenia, hipocalemia, hipoalbuminemia, diminuição das células T CD4+ ou da contagem de linfócitos e distúrbios de coagulação, que estavam intimamente relacionados ao mau prognóstico. Os pacientes com comorbidades também apresentaram tempos de remissão da doença mais longos (27 ± 6,7 dias) do que aqueles sem comorbidades (20 ± 6,5 dias). A análise multivariada de Cox indicou que a terapia com glicocorticóides e IL-6 foram fatores prognósticos independentes. Nossos achados sugerem que comorbidades coexistentes agravam a COVID-19 por meio da liberação excessiva de fatores inflamatórios e que a terapia com glicocorticóides pode ser benéfica.
Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.	https://doi.org/10.1016/j.rmed.2020.106188	07/11/2020	Artigo completo publicado em periódico científico	10.1016/j.rmed.2020.106188	0954-6111	9546111	RESPIRATORY MEDICINE	A2	1.112	127	3.99	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Eficácia da troca de plasma terapêutica no tratamento da síndrome de liberação de citocinas penn classe 3 e 4 complicando o COVID-19. 	-
Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A Natural Clinical Trial.	https://doi.org/10.1111/ijcp.13856	24/11/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13856	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Azitromicina', 'Azitromicina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Hydroxychloroquine', 'Hydroxychloroquine']	This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly. It also shows some manageable side effects mostly those related to heart rhythm. In the absence of FDA-approved medications to treat COVID-19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms can be useful.	33231925	International journal of clinical practice	1742-1241	10.1111/ijcp.13856	Avaliação do tratamento COVID-19 contendo hidroxicloroquina e azitromicina: um ensaio clínico natural. 	Este estudo natural mostrou que o regime COVID-19 contendo HCQ e azitromicina pode ser útil para promover a recuperação da maioria dos pacientes e reduzir significativamente seus sinais e sintomas. Ele também mostra alguns efeitos colaterais gerenciáveis, principalmente aqueles relacionados ao ritmo cardíaco. Na ausência de medicamentos aprovados pela FDA para tratar o COVID-19, o reaproveitamento de HCQ e azitromicina para controlar os sinais e sintomas da doença pode ser útil.
Therapeutic potential of ivermectin as add-on treatment in COVID 19: A systematic review and meta-analysis.	https://doi.org/10.18433/jpps31457	23/11/2020	Artigo completo publicado em periódico científico	10.18433/jpps31457	1482-1826	14821826	JOURNAL OF PHARMACY & PHARMACEUTICAL SCIENCES	A3	0.547	81	3.2	 The current management of COVID-19 is mostly limited to general supportive care and symptomatic treatment. Ivermectin is a broad-spectrum anti-parasitic drug used widely for the treatment of onchocerciasis and lymphatic filariasis. Apart from its anti-parasitic effect it also exhibits antiviral activity against a number of viruses both in vitro and in vivo. Hence, we conducted this systematic review and meta-analysis to assess the currently available data on the therapeutic potential of ivermectin for the treatment of COVID‐19 as add on therapy. A total of 629 patients were included in the 4 studies and all were COVID-19 RT-PCR positive. Among them, 397 patients received ivermectin along with usual therapy. The random effect model showed the overall pooled OR to be 0.53 (95%CI: 0.29 to0.96) for the primary outcome (all-cause mortality) which was statistically significant (P=0.04). Similarly, the random effect model revealed that adding ivermectin led to significant clinical improvement compared to usual therapy (OR=1.98, 95% CI: 1.11 to 3.53, P=0.02).  However, this should be inferred cautiously as the quality of evidence is very low. Currently, many clinical trials are on-going, and definitive evidence for repurposing this drug for COVID-19 patients will emerge only in the future.	['Ivermectina']	['Ivermectin']	The current management of COVID-19 is mostly limited to general supportive care and symptomatic treatment. Ivermectin is a broad-spectrum anti-parasitic drug used widely for the treatment of onchocerciasis and lymphatic filariasis. Apart from its anti-parasitic effect it also exhibits antiviral activity against a number of viruses both in vitro and in vivo. Hence, we conducted this systematic review and meta-analysis to assess the currently available data on the therapeutic potential of ivermectin for the treatment of COVID-19 as add on therapy. A total of 629 patients were included in the 4 studies and all were COVID-19 RT-PCR positive. Among them, 397 patients received ivermectin along with usual therapy. The random effect model showed the overall pooled OR to be 0.53 (95%CI: 0.29 to0.96) for the primary outcome (all-cause mortality) which was statistically significant (P=0.04). Similarly, the random effect model revealed that adding ivermectin led to significant clinical improvement compared to usual therapy (OR=1.98, 95% CI: 1.11 to 3.53, P=0.02).  However, this should be inferred cautiously as the quality of evidence is very low. Currently, many clinical trials are on-going, and definitive evidence for repurposing this drug for COVID-19 patients will emerge only in the future.	33227231	Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques	1482-1826	10.18433/jpps31457	Potencial terapêutico da ivermectina como tratamento complementar no COVID 19: uma revisão sistemática e meta-análise. 	O gerenciamento atual do COVID-19 é principalmente limitado a cuidados gerais de suporte e tratamento sintomático. A ivermectina é um fármaco antiparasitário de amplo espectro amplamente utilizado para o tratamento de oncocercose e filariose linfática. Além de seu efeito antiparasitário, também exibe atividade antiviral contra vários vírus in vitro e in vivo. Portanto, realizamos esta revisão sistemática e meta-análise para avaliar os dados atualmente disponíveis sobre o potencial terapêutico da ivermectina para o tratamento de COVID-19 como terapia complementar. Um total de 629 pacientes foram incluídos nos 4 estudos e todos foram positivos para COVID-19 RT-PCR. Entre eles, 397 pacientes receberam ivermectina junto com a terapia usual. O modelo de efeito aleatório mostrou que o OR geral agrupado foi de 0,53 (IC 95%: 0,29 a 0,96) para o desfecho primário (mortalidade por todas as causas), que foi estatisticamente significativo (P = 0,04). Da mesma forma, o modelo de efeito aleatório revelou que a adição de ivermectina levou a uma melhora clínica significativa em comparação com a terapia usual (OR = 1,98, IC 95%: 1,11 a 3,53, P = 0,02). No entanto, isso deve ser inferido com cautela, pois a qualidade da evidência é muito baixa. Atualmente, muitos ensaios clínicos estão em andamento e evidências definitivas para redirecionar esse medicamento para pacientes com COVID-19 surgirão apenas no futuro.
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality	https://doi.org/10.1055/s-0040-1720978	13/11/2020	Artigo completo publicado em periódico científico	10.1055/s-0040-1720978	0340-6245	3406245	THROMBOSIS AND HAEMOSTASIS	A1	1.745	195	5.58	 Abstract           Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.           Objective We wanted to investigate whether anticoagulation improves survival in COVID-19 and if this improvement in survival is associated with disease severity.           Methods This is a cohort study simulating an intention-to-treat clinical trial, by analyzing the effect on mortality of anticoagulation therapy chosen in the first 48 hours of hospitalization. We analyzed 3,625 COVID-19+ inpatients, controlling for age, gender, glomerular filtration rate, oxygen saturation, ventilation requirement, intensive care unit admission, and time period, all determined during the first 48 hours.           Results Adjusted logistic regression analyses demonstrated a significant decrease in mortality with prophylactic use of apixaban (odds ratio [OR] 0.46, p = 0.001) and enoxaparin (OR = 0.49, p = 0.001). Therapeutic apixaban was also associated with decreased mortality (OR 0.57, p = 0.006) but was not more beneficial than prophylactic use when analyzed over the entire cohort or within D-dimer stratified categories. Higher D-dimer levels were associated with increased mortality (p &lt; 0.0001). When adjusted for these same comorbidities within D-dimer strata, patients with D-dimer levels &lt; 1 µg/mL did not appear to benefit from anticoagulation while patients with D-dimer levels &gt; 10 µg/mL derived the most benefit. There was no increase in transfusion requirement with any of the anticoagulants used.           Conclusion We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.	['Apixabana', 'Enoxaparina']	['Apixaban', 'Enoxaparin']	 We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.	33186991	Thrombosis and haemostasis	2567-689X	10.1055/s-0040-1720978	Anticoagulação na COVID-19: Efeito da enoxaparina, heparina e apixabana na 	mortalidade
Renin–angiotensin system inhibitors and mortality in patients with COVID‐19.	https://doi.org/10.1007/s15010-020-01550-0	22/11/2020	Artigo completo publicado em periódico científico	10.1007/s15010-020-01550-0	0300-8126	3008126	INFECTION	A4	1.119	80	4.01	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Inibidores do sistema renina-angiotensina e mortalidade em pacientes com COVID-19. 	-
High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia.	https://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13458	20/11/2020	Artigo completo publicado em periódico científico	10.1111/eci.13458	0014-2972	142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Prednisona']	['Prednisone']	In nonintubated patients with severe COVID-19 pneumonia, methylprednisolone was associated with reduced need for mechanical ventilation and less-intensive care resource utilization without excess complications.	33219551	European journal of clinical investigation	1365-2362	10.1111/eci.13458	Metilprednisolona em altas doses em pacientes não intubados com pneumonia grave por COVID-19. 	Em pacientes não intubados com pneumonia grave por COVID-19, a metilprednisolona foi associada à redução da necessidade de ventilação mecânica e utilização de recursos de cuidados menos intensivos sem excesso de complicações.
Adverse impact of renin–angiotensin system blockade on the clinical course in hospitalized patients with severe COVID‐19: a retrospective cohort study.	https://doi.org/10.1038/s41598-020-76915-4	20/11/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-76915-4	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract The association between angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) and the risk of mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19) was investigated. This retrospective cohort study was performed in all hospitalized patients with COVID-19 in tertiary hospitals in Daegu, Korea. Patients were classified based on whether they received ACE-I or ARB before COVID-19 diagnosis. The analysis of the primary outcome, in-hospital mortality, was performed using the Cox proportional hazards regression model. Of 130 patients with COVID-19, 30 (23.1%) who received ACE-I or ARB exhibited an increased risk of in-hospital mortality (adjusted hazard ratio, 2.20; 95% confidence interval [CI], 1.10–4.38;  P = 0.025). ACE-I or ARB was also associated with severe complications, such as acute respiratory distress syndrome (ARDS) (adjusted odds ratio [aOR], 2.58; 95% CI, 1.02–6.51;  P = 0.045) and acute kidney injury (AKI) (aOR, 3.06; 95% CI, 1.15–8.15;  P = 0.026). Among the patients with ACE-I or ARB therapy, 8 patients (26.7%) used high equivalent doses of ACE-I or ARB and they had higher in-hospital mortality and an increased risk of ARDS and AKI (all,  P &lt; 0.05). ACE-I or ARB therapy in patients with severe COVID-19 was associated with the occurrence of severe complications and increased in-hospital mortality. The potentially harmful effect of ACE-I or ARB therapy may be higher in patients who received high doses.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	The association between angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) and the risk of mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19) was investigated. This retrospective cohort study was performed in all hospitalized patients with COVID-19 in tertiary hospitals in Daegu, Korea. Patients were classified based on whether they received ACE-I or ARB before COVID-19 diagnosis. The analysis of the primary outcome, in-hospital mortality, was performed using the Cox proportional hazards regression model. Of 130 patients with COVID-19, 30 (23.1%) who received ACE-I or ARB exhibited an increased risk of in-hospital mortality (adjusted hazard ratio, 2.20; 95% confidence interval [CI], 1.10-4.38; P = 0.025). ACE-I or ARB was also associated with severe complications, such as acute respiratory distress syndrome (ARDS) (adjusted odds ratio [aOR], 2.58; 95% CI, 1.02-6.51; P = 0.045) and acute kidney injury (AKI) (aOR, 3.06; 95% CI, 1.15-8.15; P = 0.026). Among the patients with ACE-I or ARB therapy, 8 patients (26.7%) used high equivalent doses of ACE-I or ARB and they had higher in-hospital mortality and an increased risk of ARDS and AKI (all, P < 0.05). ACE-I or ARB therapy in patients with severe COVID-19 was associated with the occurrence of severe complications and increased in-hospital mortality. The potentially harmful effect of ACE-I or ARB therapy may be higher in patients who received high doses.	33219294	Scientific reports	2045-2322	10.1038/s41598-020-76915-4	Impacto adverso do bloqueio do sistema renina-angiotensina no curso clínico em pacientes hospitalizados com COVID-19 grave: um estudo de coorte retrospectivo. 	A associação entre inibidor da enzima conversora de angiotensina (IECA) ou bloqueador do receptor de angiotensina II (BRA) e o risco de mortalidade em pacientes hospitalizados com doença grave por coronavírus 2019 (COVID-19) foi investigada. Este estudo de coorte retrospectivo foi realizado em todos os pacientes hospitalizados com COVID-19 em hospitais terciários em Daegu, Coréia. Os pacientes foram classificados com base se receberam ACE-I ou BRA antes do diagnóstico de COVID-19. A análise do desfecho primário, mortalidade intra-hospitalar, foi realizada por meio do modelo de regressão de riscos proporcionais de Cox. Dos 130 pacientes com COVID-19, 30 (23,1%) que receberam IECA ou BRA apresentaram um risco aumentado de mortalidade hospitalar (razão de risco ajustada, 2,20; intervalo de confiança de 95% [CI], 1,10-4,38; P = 0,025). O IECA ou BRA também foi associado a complicações graves, como síndrome do desconforto respiratório agudo (SDRA) (razão de chances ajustada [aOR], 2,58; IC 95%, 1,02-6,51; P = 0,045) e lesão renal aguda (LRA) (aOR, 3,06; IC 95%, 1,15-8,15; P = 0,026). Entre os pacientes em terapia com IECA ou BRA, 8 pacientes (26,7%) usaram altas doses equivalentes de IECA ou BRA e tiveram maior mortalidade hospitalar e risco aumentado de SDRA e LRA (todos, P < 0,05) . A terapia com IECA ou BRA em pacientes com COVID-19 grave foi associada à ocorrência de complicações graves e aumento da mortalidade hospitalar. O efeito potencialmente prejudicial da terapia com IECA ou BRA pode ser maior em pacientes que receberam altas doses.
Comparison of Infection Risks and Clinical Outcomes in Patients with and without SARS-CoV-2 Lung Infection under Renin-Angiotensin-Aldosterone-System Blockade - Systematic Review and Meta-Analysis.	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14660	20/11/2020	Artigo completo publicado em periódico científico	10.1111/bcp.14660	0306-5251	3065251	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (PRINT)	A1	1.055	153	3.73	-	[]	[]	-	-	-	-	-	Comparação de Riscos de Infecção e Resultados Clínicos em Pacientes com e sem Infecção Pulmonar por SARS-CoV-2 sob Bloqueio do Sistema Renina-Angiotensina-Aldosterona - Revisão Sistemática e Meta-análise. 	-
Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital.	https://doi.org/10.1016/j.clnu.2020.10.055	02/11/2020	Artigo completo publicado em periódico científico	10.1016/j.clnu.2020.10.055	0261-5614	2615614	CLINICAL NUTRITION (EDINBURGH)	A1	1.553	150	6.65	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	Very low 25(OH)vitamin D levels were highly prevalent and suggestive of deficiency among our hospitalized severe COVID-19 patients, but low 25(OH)vitamin D levels were not associated with outcome variables. Whether 25(OH)vitamin D adequacy may influence clinical outcomes in COVID-19 and the unexpected correlation between higher 25(OH)vitamin D levels and mortality require further investigations by large intervention trials.	33187772	Clinical nutrition (Edinburgh, Scotland)	1532-1983	10.1016/j.clnu.2020.10.055	Deficiência de vitamina D 25OH em pacientes com COVID-19 internados em um hospital terciário de referência. 	Níveis muito baixos de 25(OH)vitamina D foram altamente prevalentes e sugestivos de deficiência entre nossos pacientes graves hospitalizados com COVID-19, mas níveis baixos de 25(OH)vitamina D não foram associados a variáveis de resultado. Se a adequação de 25(OH)vitamina D pode influenciar os resultados clínicos no COVID-19 e a correlação inesperada entre níveis mais altos de 25(OH)vitamina D e mortalidade requerem investigações adicionais por grandes ensaios de intervenção.
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: an observational cohort study.	https://doi.org/10.1016/j.jaci.2020.11.006	06/11/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.11.006	0091-6749	916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Anakinra', 'Prednisona']	['Anakinra', 'Prednisone']	In patients with moderate hyperinflammatory state associated with severe COVID-19 pneumonia, treatment with anakinra after non-response to corticosteroids or corticosteroids plus tocilizumab therapy may be an option for the management of these patients and may improve their prognosis.	33400157	Internal and emergency medicine	1970-9366	10.1007/s11739-020-02600-z	Anakinra combinado com metilprednisolona em pacientes com pneumonia grave por COVID-19 e hiperinflamação: um estudo de coorte observacional. 	Em pacientes com estado hiperinflamatório moderado associado à pneumonia grave por COVID-19, o tratamento com anakinra após a não resposta a corticosteroides ou corticosteroides mais terapia com tocilizumabe pode ser uma opção para o manejo desses pacientes e pode melhorar seu prognóstico.
Risk factors of mortality and contribution of treatment in patients infected with COVID-19: a retrospective propensity score matched study.	https://www.tandfonline.com/doi/full/10.1080/03007995.2020.1853508	19/11/2020	Artigo completo publicado em periódico científico	10.1080/03007995.2020.1853508	0300-7995	3007995	CURRENT MEDICAL RESEARCH AND OPINION	A1	0.689	111	2.34	-	['Corticosteroides', 'Glicirrizinato de amônio', 'Imunoglobulina', 'Timosina']	['Corticosteroids', 'Ammonium Glycyrrhizinate', 'Immunoglobulin', 'Thymosin']	For in-hospital patients with COVID-19 of all severity levels, a high risk for fatal outcome was observed in those treated with glucocorticoids, immunoglobulin, thymosin, and ammonium glycyrrhizinate. The results of this study do not support immunomodulatory therapy in patients admitted to the hospital with COVID-19. Further prospective studies are essential to clarify our findings, especially for non-critically ill patients.	33210547	Current medical research and opinion	1473-4877	10.1080/03007995.2020.1853508	Fatores de risco de mortalidade e contribuição do tratamento em pacientes infectados com COVID-19: um estudo retrospectivo de escore de propensão. 	Para pacientes internados com COVID-19 de todos os níveis de gravidade, um alto risco de desfecho fatal foi observado naqueles tratados com glicocorticóides, imunoglobulina, timosina e glicirrizinato de amônio. Os resultados deste estudo não suportam a terapia imunomoduladora em pacientes internados no hospital com COVID-19. Mais estudos prospectivos são essenciais para esclarecer nossos achados, especialmente para pacientes não críticos.
BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers.	https://doi.org/10.1172/JCI145157	19/11/2020	Artigo completo publicado em periódico científico	10.1172/JCI145157	0021-9738	219738	THE JOURNAL OF CLINICAL INVESTIGATION	A1	5.527	505	14.12	-	['Vacina BCG']	['BCG vaccine']	BACKGROUNDSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 1 million deaths worldwide; thus, there is an urgent need to develop preventive and therapeutic strategies. The antituberculosis vaccine bacillus Calmette-Guérin (BCG) demonstrates nonspecific, protective innate immune-boosting effects. Here, we determined whether a history of BCG vaccination was associated with decreased SARS-CoV-2 infection and seroconversion in a longitudinal, retrospective observational study of a diverse cohort of health care workers (HCWs).METHODSWe assessed SARS-CoV-2 seroprevalence and collected medical questionnaires, which included information on BCG vaccination status and preexisting demographic and clinical characteristics, from an observational cohort of HCWs in a multisite Los Angeles health care organization. We used multivariate analysis to determine whether a history of BCG vaccination was associated with decreased rates of SARS-CoV-2 infection and seroconversion.RESULTSOf the 6201 HCWs, 29.6% reported a history of BCG vaccination, whereas 68.9% had not received BCG vaccination. Seroprevalence of anti-SARS-CoV-2 IgG as well as the incidence of self-reported clinical symptoms associated with coronavirus disease 2019 (COVID-19) were markedly decreased among HCWs with a history of BCG vaccination compared with those without BCG vaccination. After adjusting for age and sex, we found that a history of BCG vaccination, but not meningococcal, pneumococcal, or influenza vaccination, was associated with decreased SARS-CoV-2 IgG seroconversion.CONCLUSIONSA history of BCG vaccination was associated with a decrease in the seroprevalence of anti-SARS-CoV-2 IgG and a lower number of participants who self-reported experiencing COVID-19-related clinical symptoms in this cohort of HCWs. Therefore, large randomized, prospective clinical trials of BCG vaccination are urgently needed to confirm whether BCG vaccination can confer a protective effect against SARS-CoV-2 infection.	33211672	The Journal of clinical investigation	1558-8238	145157	O histórico de vacinação com BCG está associado à diminuição da soroprevalência de SARS-CoV-2 em uma coorte diversificada de profissionais de saúde. 	ANTECEDENTES O coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) causou mais de 1 milhão de mortes em todo o mundo; assim, há uma necessidade urgente de desenvolver estratégias preventivas e terapêuticas. A vacina antituberculose bacilo Calmette-Guérin (BCG) demonstra efeitos protetores inespecíficos de reforço da imunidade inata. Aqui, determinamos se um histórico de vacinação com BCG estava associado à diminuição da infecção por SARS-CoV-2 e soroconversão em um estudo observacional longitudinal e retrospectivo de uma coorte diversificada de profissionais de saúde (HCWs). MÉTODOSAvaliamos a soroprevalência e a soroprevalência de SARS-CoV-2 coletaram questionários médicos, que incluíam informações sobre o status de vacinação BCG e características demográficas e clínicas preexistentes, de uma coorte observacional de profissionais de saúde em uma organização de saúde de vários locais de Los Angeles. Usamos análise multivariada para determinar se um histórico de vacinação BCG estava associado a taxas reduzidas de infecção por SARS-CoV-2 e soroconversão. RESULTADOSDos 6.201 profissionais de saúde, 29,6% relataram histórico de vacinação BCG, enquanto 68,9% não receberam a vacinação BCG. A soroprevalência de IgG anti-SARS-CoV-2, bem como a incidência de sintomas clínicos autorrelatados associados à doença por coronavírus 2019 (COVID-19) foram marcadamente diminuídas entre os profissionais de saúde com histórico de vacinação BCG em comparação com aqueles sem vacinação BCG. Após o ajuste para idade e sexo, descobrimos que uma história de vacinação BCG, mas não meningocócica, pneumocócica ou vacina contra influenza, estava associada à diminuição da soroconversão de IgG para SARS-CoV-2. soroprevalência de IgG anti-SARS-CoV-2 e um número menor de participantes que relataram sintomas clínicos relacionados ao COVID-19 nesta coorte de profissionais de saúde. Portanto, grandes ensaios clínicos prospectivos e randomizados da vacinação com BCG são urgentemente necessários para confirmar se a vacinação com BCG pode conferir um efeito protetor contra a infecção por SARS-CoV-2.
Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study.	https://doi.org/10.1093/ofid/ofaa563	19/11/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa563	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract  Background This study was conducted to evaluate the impact of low-molecular-weight heparin (LMWH) on the outcome of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia.  Methods This is a prospective observational study including consecutive patients with laboratory-confirmed SARS-CoV-2 pneumonia admitted to the University Hospital of Pisa (March 4–April 30, 2020). Demographic, clinical, and outcome data were collected. The primary endpoint was 30-day mortality. The secondary endpoint was a composite of death or severe acute respiratory distress syndrome (ARDS). Low-molecular-weight heparin, hydroxychloroquine, doxycycline, macrolides, antiretrovirals, remdesivir, baricitinib, tocilizumab, and steroids were evaluated as treatment exposures of interest. First, a Cox regression analysis, in which treatments were introduced as time-dependent variables, was performed to evaluate the association of exposures and outcomes. Then, a time-dependent propensity score (PS) was calculated and a PS matching was performed for each treatment variable.  Results Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%) patients. Overall, 244 (77.5%) patients received LMWH, 238 (75.5%) received hydroxychloroquine, 201 (63.8%) received proteases inhibitors, 150 (47.6%) received doxycycline, 141 (44.8%) received steroids, 42 (13.3%) received macrolides, 40 (12.7%) received baricitinib, 13 (4.1%) received tocilizumab, and 13 (4.1%) received remdesivir. At multivariate analysis, LMWH was associated with a reduced risk of 30-day mortality (hazard ratio [HR], 0.36; 95% confidence interval [CI], 0.21–0.6; P &amp;lt; .001) and composite endpoint (HR, 0.61; 95% CI, 0.39–0.95; P = .029). The PS-matched cohort of 55 couples confirmed the same results for both primary and secondary endpoint.  Conclusions This study suggests that LMWH might reduce the risk of in-hospital mortality and severe ARDS in coronavirus disease 2019. Randomized controlled trials are warranted to confirm these preliminary findings.	['Heparina']	['Heparin']	-	-	-	-	-	Papel da heparina de baixo peso molecular em pacientes hospitalizados com pneumonia por SARS-CoV-2: um estudo observacional prospectivo. 	-
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients	https://doi.org/10.1371/journal.pone.0242184	11/11/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0242184	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	 Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.	['Ivermectina']	['Ivermectin']	[This corrects the article DOI: 10.1371/journal.pone.0242184.].	35551297	PloS one	1932-6203	10.1371/journal.pone.0268667	Falta de eficácia de doses padrão de ivermectina em pacientes graves com COVID-19 	[Isso corrige o artigo DOI: 10.1371/journal.pone.0242184.].
The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study.	https://doi.org/10.1016/j.intimp.2020.107143	31/10/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107143	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Timosina']	['Thymosin']	There was no association between use of thymosin α1 and decreased mortality in critically ill COVID-19 patients. Subgroups analysis and phenotype analysis also showed no differences on mortality after thymosin α1 therapy.	33208294	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.107143	O efeito da timosina α1 na mortalidade de pacientes críticos com COVID-19: Um estudo retrospectivo multicêntrico. 	Não houve associação entre o uso de timosina α1 e diminuição da mortalidade em pacientes criticamente doentes com COVID-19. A análise de subgrupos e a análise do fenótipo também não mostraram diferenças na mortalidade após a terapia com timosina α1.
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.	https://doi.org/10.1186/s12979-020-00207-8	14/11/2020	Artigo completo publicado em periódico científico	10.1186/s12979-020-00207-8	1742-4933	17424933	IMMUNITY & AGEING	A2	1.697	50	7.3	 Abstract                  Background                 Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the world has been placed. In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities have been the most risky population. Although most patients present a mild to moderate disease, some have developed severe symptoms. One of the possible mechanisms underlying rapid disease progression is a cytokine storm, in which interleukin (IL) -6 seems to be a major mediator. Itolizumab is a humanized recombinant anti-CD6 monoclonal antibody (MAb), with the ability of reducing serum interferon gamma (INF-γ), tumour necrosis factor alpha (TNFα) and IL-6. Based on these previous results in patients with psoriasis and rheumatoid arthritis, an expanded access clinical trial was approved by the Cuban regulatory agency for COVID-19 critically, severely and moderately ill patients.                                Results                 We show here a short kinetic of IL-6 serum concentration in the first 24 COVID-19 patients treated with itolizumab. Most of patients were elderly with multiple comorbidities. We found that with one itolizumab dose, the circulating IL-6 decreased in critically and severely ill patients, whereas in moderately ill patients the values didn’t rise as compared to their low baseline levels.                                Conclusion                 These findings suggest that itolizumab could be an attractive therapeutic option to decrease the negative outcome of the cytokine storm in COVID-19 patients.                                Trial registration                 CECMED IIC RD-EC 179, RPCEC00000311. Registered 4 May 2020 - Retrospectively registered, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rpcec.sld.cu/ensayos/RPCEC00000311-Sp">http://rpcec.sld.cu/ensayos/RPCEC00000311-Sp</jats:ext-link> or <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://rpcec.sld.cu/trials/RPCEC00000311-En">http://rpcec.sld.cu/trials/RPCEC00000311-En</jats:ext-link>              	['Itolizumabe']	['Itolizumab']	CECMED IIC RD-EC 179, RPCEC00000311. Registered 4 May 2020 - Retrospectively registered, http://rpcec.sld.cu/ensayos/RPCEC00000311-Sp or http://rpcec.sld.cu/trials/RPCEC00000311-En.	33292350	Immunity & ageing : I & A	1742-4933	10.1186/s12979-020-00207-8	Um anticorpo monoclonal anti-CD6 (itolizumab) reduz a IL-6 circulante em pacientes idosos com COVID-19 grave. 	CECMED IIC RD-EC 179, RPCEC00000311. Registrado em 4 de maio de 2020 - Registrado retrospectivamente, http://rpcec.sld.cu/ensayos/RPCEC00000311-Sp ou http://rpcec.sld.cu/trials/RPCEC00000311-En.
Comparative analysis between the use of renin–angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.	https://doi.org/10.1016/j.medcli.2020.07.004	25/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.07.004	0025-7753	257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	RAS inhibitor treatment prior to admission in patients with COVID-19 respiratory infection was associated with lower risk of the primary composite endpoint and did not show neither impact on mortality nor need for invasive mechanical ventilation, even if these drugs were prescribed during hospitalization.	33209988	Medicina clinica (English ed.)	2387-0206	10.1016/j.medcle.2020.07.013	Análise comparativa entre o uso de antagonistas do sistema renina-angiotensina e desfechos clínicos de pacientes hospitalizados com infecção respiratória por COVID-19. 	O tratamento com inibidor do RAS antes da admissão em pacientes com infecção respiratória por COVID-19 foi associado a menor risco do desfecho composto primário e não mostrou impacto na mortalidade nem necessidade de ventilação mecânica invasiva, mesmo que esses medicamentos tenham sido prescritos durante a internação.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002): a single-blind, randomised, controlled, phase 2/3 trial.	https://doi.org/10.1016/S0140-6736(20)32466-1	18/11/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)32466-1	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina ChAdOx1 nCoV-19']	['ChAdOx1 nCoV-19 vaccine']	-	-	-	-	-	Segurança e imunogenicidade da vacina ChAdOx1 nCoV-19 administrada em um regime de reforço inicial em adultos jovens e idosos (COV002): um estudo de fase 2/3 simples-cego, randomizado, controlado. 	-
Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19.	https://doi.org/10.1093/ofid/ofaa481	13/10/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa481	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   Remdesivir has been associated with accelerated recovery of severe coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients requiring mechanical ventilation is uncertain.                                                  Methods                   All consecutive intensive care unit (ICU) patients requiring mechanical ventilation due to COVID-19 were enrolled. Univariate and multivariable Cox models were used to explore the possible association between in-hospital death or hospital discharge, considered competing-risk events, and baseline or treatment-related factors, including the use of remdesivir. The rate of extubation and the number of ventilator-free days were also calculated and compared between treatment groups.                                                  Results                   One hundred thirteen patients requiring mechanical ventilation were observed for a median of 31 days of follow-up; 32% died, 69% were extubated, and 66% were discharged alive from the hospital. Among 33 treated with remdesivir (RDV), lower mortality (15.2% vs 38.8%) and higher rates of extubation (88% vs 60%), ventilator-free days (median [interquartile range], 11 [0–16] vs 5 [0–14.5]), and hospital discharge (85% vs 59%) were observed. Using multivariable analysis, RDV was significantly associated with hospital discharge (hazard ratio [HR], 2.25; 95% CI, 1.27–3.97; P = .005) and with a nonsignificantly lower mortality (HR, 0.73; 95% CI, 0.26–2.1; P = .560). RDV was also independently associated with extubation (HR, 2.10; 95% CI, 1.19–3.73; P = .011), which was considered a competing risk to death in the ICU in an additional survival model.                                                  Conclusions                   In our cohort of mechanically ventilated patients, RDV was not associated with a significant reduction of mortality, but it was consistently associated with shorter duration of mechanical ventilation and higher probability of hospital discharge, independent of other risk factors.               	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Uso de remdesivir em pacientes que necessitam de ventilação mecânica devido ao COVID-19. 	-
Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study.	https://doi.org/10.1111/cpr.12947	17/11/2020	Artigo completo publicado em periódico científico	10.1111/cpr.12947	0960-7722	9607722	CELL PROLIFERATION (PRINT)	A2	1.421	80	7.54	-	['Terapia celular']	['Cell Therapy']	Intravenous transplantation of UC-MSCs was safe and feasible for treatment of patients with severe and critically severe COVID-19 pneumonia.	33205469	Cell proliferation	1365-2184	10.1111/cpr.12947	Segurança e viabilidade de células-tronco mesenquimais do cordão umbilical em pacientes com pneumonia por COVID-19: um estudo piloto. 	O transplante intravenoso de UC-MSCs foi seguro e viável para o tratamento de pacientes com pneumonia grave e criticamente grave por COVID-19.
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years	https://doi.org/10.1016/S1473-3099(20)30843-4	17/11/2020	Artigo completo publicado em periódico científico	10.1016/S1473-3099(20)30843-4	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['CoronaVac']	['CoronaVac']	Chinese National Key Research and Development Program and Beijing Science and Technology Program.	33217362	The Lancet. Infectious diseases	1474-4457	10.1016/S1473-3099(20)30843-4	Segurança, tolerabilidade e imunogenicidade de uma vacina inativada contra SARS-CoV-2 em adultos saudáveis com idades entre 18 e 59 anos 	Programa Nacional de Pesquisa e Desenvolvimento da China e Programa de Ciência e Tecnologia de Pequim.
Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial.	https://doi.org/10.1016/j.ijid.2020.11.142	08/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.142	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Favipiravir', 'Favipiravir', 'Favipiravir']	['Favipiravir', 'Favipiravir', 'Favipiravir']	Chinese National Key Research and Development Program and Beijing Science and Technology Program.	33601033	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2021.02.035	Eficácia e segurança do favipiravir, um inibidor oral de RNA polimerase dependente de RNA, em COVID-19 leve a moderado: um ensaio clínico randomizado, comparativo, aberto, multicêntrico, de fase 3. 	Programa Nacional de Pesquisa e Desenvolvimento da China e Programa de Ciência e Tecnologia de Pequim.
Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety.	https://doi.org/10.1016/j.jsps.2020.11.003	13/11/2020	Artigo completo publicado em periódico científico	10.1016/j.jsps.2020.11.003	1319-0164	13190164	SAUDI PHARMACEUTICAL JOURNAL	A2	0.613	57	4.71	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	The COVID-19 pandemic has required clinicians to urgently identify new treatment options or the re-purposing of existing drugs. Of particular interest are chloroquine (CQ) and hydroxychloroquine (HCQ). The aims of this systematic review are to systematically identify and collate 24 studies describing the use of CQ and HCQ in human clinical trials and to provide a detailed synthesis of evidence of its efficacy and safety. Of clinical trials, 100% showed no significant difference in the probability of viral transmission or clearance in prophylaxis or therapy, respectively, compared to the control group. Among observational studies employing an endpoint specific to efficacy, 58% concurred with the finding of no significant difference in the attainment of outcomes. Three-fifths of clinical trials and half of observational studies examining an indicator unique to drug safety discovered a higher probability of adverse events in those treated patients suspected of, and diagnosed with, COVID-19. Of the total papers focusing on cardiac side-effects, 44% found a greater incidence of QTc prolongation and/or arrhythmias, 44% found no evidence of a significant difference, and 11% mixed results. The strongest available evidence points towards the inefficacy of CQ and HCQ in prophylaxis or in the treatment of hospitalised COVID-19 patients.	33204210	Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society	1319-0164	10.1016/j.jsps.2020.11.003	Cloroquina, hidroxicloroquina e COVID-19: revisão sistemática e síntese narrativa de eficácia e segurança. 	A pandemia de COVID-19 exigiu que os médicos identificassem com urgência novas opções de tratamento ou a redefinição de medicamentos existentes. De particular interesse são a cloroquina (CQ) e a hidroxicloroquina (HCQ). Os objetivos desta revisão sistemática são identificar e agrupar sistematicamente 24 estudos que descrevem o uso de CQ e HCQ em ensaios clínicos em humanos e fornecer uma síntese detalhada de evidências de sua eficácia e segurança. Dos ensaios clínicos, 100% não mostraram diferença significativa na probabilidade de transmissão viral ou depuração na profilaxia ou terapia, respectivamente, em relação ao grupo controle. Entre os estudos observacionais que empregam um desfecho específico para eficácia, 58% concordaram com a constatação de que não houve diferença significativa na obtenção de resultados. Três quintos dos ensaios clínicos e metade dos estudos observacionais que examinaram um indicador exclusivo da segurança de medicamentos descobriram uma maior probabilidade de eventos adversos nos pacientes tratados com suspeita e diagnóstico de COVID-19. Do total de artigos com foco nos efeitos colaterais cardíacos, 44% encontraram maior incidência de prolongamento do intervalo QTc e/ou arritmias, 44% não encontraram evidência de diferença significativa e 11% resultados mistos. A evidência mais forte disponível aponta para a ineficácia de CQ e HCQ na profilaxia ou no tratamento de pacientes hospitalizados com COVID-19.
Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.	https://onlinelibrary.wiley.com/doi/full/10.1111/imj.15002	16/11/2020	Artigo completo publicado em periódico científico	10.1111/imj.15002	1444-0903	14440903	INTERNAL MEDICINE JOURNAL (PRINT)	A4	0.590	74	1.53	-	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Use of ACEI or ARB was not associated with a heightened susceptibility for a positive diagnosis of COVID-19. Furthermore, they were not associated with increased illness severity or mortality due to COVID-19. Randomised controlled trials are needed to address definitively the potential benefits or harms of RAS inhibitors in patients with COVID-19.	33191600	Internal medicine journal	1445-5994	10.1111/imj.15002	Inibição do sistema renina-angiotensina e risco de infecção e mortalidade no COVID-19: uma revisão sistemática e meta-análise. 	O uso de IECA ou BRA não foi associado a uma maior suscetibilidade para um diagnóstico positivo de COVID-19. Além disso, eles não foram associados ao aumento da gravidade ou mortalidade da doença devido ao COVID-19. Ensaios controlados randomizados são necessários para abordar definitivamente os potenciais benefícios ou danos dos inibidores do RAS em pacientes com COVID-19.
Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review.	https://www.tandfonline.com/doi/full/10.1080/14787210.2021.1848545	13/11/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2021.1848545	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	-	-	-	-	-	Eficácia e segurança do lopinavir/ritonavir no tratamento do COVID-19: Uma revisão sistemática. 	-
Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.	https://doi.org/10.1016/j.amsu.2020.11.027	10/11/2020	Artigo completo publicado em periódico científico	10.1016/j.amsu.2020.11.027	2049-0801	20490801	ANNALS OF MEDICINE AND SURGERY	A4	0.373	30	1.78	-	['Dexametasona', 'Prednisona']	['Dexamethasone', 'Prednisone']	Parenteral Methylprednisolone is associated with a better improvement in the severity of moderate and severe COVID-19 compared to dexamethasone. Both steroids cause a similar increase in blood glucose levels, indicating that either steroid holds the risk of hyperglycemia and its potential complications. A longer duration of steroids is not associated with a significant difference in outcome compared to shorter duration of steroids, it also has a hyperglycemia risk similar to the latter.	35443522	The Journal of the Association of Physicians of India	0004-5772	10.1002/jmv.26674	Comparação da eficácia de dexametasona e metilprednisolona na doença covid 19 moderada a grave. 	A metilprednisolona parenteral está associada a uma melhor melhora na gravidade do COVID-19 moderado e grave em comparação com a dexametasona. Ambos os esteróides causam um aumento semelhante nos níveis de glicose no sangue, indicando que qualquer um dos esteróides possui o risco de hiperglicemia e suas possíveis complicações. Uma duração mais longa de esteróides não está associada a uma diferença significativa no resultado em comparação com uma duração mais curta de esteróides, também apresenta um risco de hiperglicemia semelhante a este último.
Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.	https://doi.org/10.1007/s10072-020-04887-4	13/11/2020	Artigo completo publicado em periódico científico	10.1007/s10072-020-04887-4	1590-1874	15901874	NEUROLOGICAL SCIENCES (TESTO STAMPATO)	A3	0.847	76	2.69	-	['Heparina']	['Heparin']	The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae.	33185785	Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology	1590-3478	10.1007/s10072-020-04887-4	Heparina de baixo peso molecular em pacientes com COVID-19 previne delirium e encurta a hospitalização. 	O uso de HBPM pode ajudar a prevenir a ocorrência de delirium em pacientes com COVID-19, com possível redução do tempo de internação e sequelas.
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.	https://doi.org/10.1186/s12916-020-01832-2	16/11/2020	Artigo completo publicado em periódico científico	10.1186/s12916-020-01832-2	1741-7015	17417015	BMC MEDICINE	A1	3.405	155	10.07	 Abstract  Background Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay.  Methods We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference &gt; 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100.  Results A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays.  Conclusions In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed.	['Metformina']	['Metformin']	In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed.	33190637	BMC medicine	1741-7015	10.1186/s12916-020-01832-2	Mortalidade e outros resultados adversos em pacientes com diabetes mellitus tipo 2 admitidos por COVID-19 em associação com medicamentos hipoglicemiantes: um estudo de coorte nacional. 	Em pacientes com diabetes mellitus tipo 2 admitidos por COVID-19, os medicamentos para baixar a glicose em casa não mostraram associação significativa com mortalidade e resultados adversos. Dada a estreita relação entre diabetes e COVID-19 e as evidências limitadas sobre o papel dos medicamentos para baixar a glicose, são necessários estudos prospectivos.
Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients.	https://doi.org/10.1183/13993003.01811-2020	01/07/2020	Artigo completo publicado em periódico científico	10.1183/13993003.01811-2020	0903-1936	9031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Background Coronavirus disease 2019 (COVID-19) may predispose to venous thromboembolism. We determined factors independently associated with computed tomography pulmonary angiography (CTPA)-confirmed pulmonary embolism (PE) in hospitalised severe COVID-19 patients.  Methods Among all (n=349) patients hospitalised for COVID-19 in a university hospital in a French region with a high rate of COVID-19, we analysed patients who underwent CTPA for clinical signs of severe disease (oxygen saturation measured by pulse oximetry ≤93% or breathing rate ≥30 breaths·min −1) or rapid clinical worsening. Multivariable analysis was performed using Firth penalised maximum likelihood estimates.  Results 162 (46.4%) patients underwent CTPA (mean± sd age 65.6±13.0 years; 67.3% male (95% CI 59.5–75.5%). PE was diagnosed in 44 (27.2%) patients. Most PEs were segmental and the rate of PE-related right ventricular dysfunction was 15.9%. By multivariable analysis, the only two significant predictors of CTPA-confirmed PE were D-dimer level and the lack of any anticoagulant therapy (OR 4.0 (95% CI 2.4–6.7) per additional quartile and OR 4.5 (95% CI 1.1–7.4), respectively). Receiver operating characteristic curve analysis identified a D-dimer cut-off value of 2590 ng·mL −1 to best predict occurrence of PE (area under the curve 0.88, p&lt;0.001, sensitivity 83.3%, specificity 83.8%). D-dimer level &gt;2590 ng·mL −1 was associated with a 17-fold increase in the adjusted risk of PE.  Conclusion Elevated D-dimers (&gt;2590 ng·mL −1) and absence of anticoagulant therapy predict PE in hospitalised COVID-19 patients with clinical signs of severity. These data strengthen the evidence base in favour of systematic anticoagulation, and suggest wider use of D-dimer guided CTPA to screen for PE in acutely ill hospitalised patients with COVID-19.	['Heparina']	['Heparin']	Elevated D-dimers (>2590 ng·mL	32907890	The European respiratory journal	1399-3003	10.1183/13993003.01811-2020	Dímeros D elevados e falta de anticoagulação predizem EP em pacientes graves com COVID-19. 	D-dímeros elevados (>2590 ng·mL
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.	https://doi.org/10.1016/j.clim.2020.108631	12/11/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108631	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Tocilizumabe']	['Tocilizumab']	Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.	33189888	Clinical immunology (Orlando, Fla.)	1521-7035	10.1016/j.clim.2020.108631	Eficácia e segurança do tocilizumab intravenoso no tratamento da síndrome hiperinflamatória associada ao COVID-19: coorte observacional do Covizumab-6. 	Embora o evento inicial no COVID-19 seja uma infecção viral, alguns pacientes apresentam uma resposta inflamatória excessivamente exuberante, levando à lesão pulmonar aguda (LPA) e à síndrome do desconforto respiratório do adulto (SDRA). Como a IL-6 desempenha um papel crítico na resposta inflamatória, avaliamos a eficácia e a segurança do tocilizumabe (TCZ) neste estudo observacional de centro único em todos os pacientes internados com Covid-19 com SARS-CoV-2 comprovado em rápida progressão infecção para prevenir ALI e SDRA. 104 pacientes com COVID-19 tratados com TCZ tiveram uma taxa de mortalidade menor (5,8%) em comparação com a taxa de mortalidade regional (11%), mortalidade de pacientes hospitalizados (10%) e um pouco menor do que pacientes hospitalizados tratados com nosso padrão de cuidar sozinho (6%). Descobrimos que o TCZ diminuiu rapidamente os reagentes de fase aguda, a ferritina e a liberação hepática de proteínas. D-dímero diminuiu lentamente. Não observamos preocupações específicas de segurança. A administração precoce de antagonistas de IL6-R em pacientes com COVID-19 com resposta hiperinflamatória iminente pode ser um tratamento seguro e eficaz para prevenir, admissão na UTI e outras complicações.
Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.	https://doi.org/10.1093/cid/ciaa1703	09/11/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1703	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   We evaluated an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for immunogenicity and safety in adults aged 18–59 years.                                                  Methods                   In this randomized, double-blinded, controlled trial, healthy adults received a medium dose (MD) or a high dose (HD) of the vaccine at an interval of either 14 days or 28 days. Neutralizing antibody (NAb) and anti-S and anti-N antibodies were detected at different times, and adverse reactions were monitored for 28 days after full immunization.                                                  Results                   A total of 742 adults were enrolled in the immunogenicity and safety analysis. Among subjects in the 0, 14 procedure, the seroconversion rates of NAb in MD and HD groups were 89% and 96% with geometric mean titers (GMTs) of 23 and 30, respectively, at day 14 and 92% and 96% with GMTs of 19 and 21, respectively, at day 28 after immunization. Anti-S antibodies had GMTs of 1883 and 2370 in the MD group and 2295 and 2432 in the HD group. Anti-N antibodies had GMTs of 387 and 434 in the MD group and 342 and 380 in the HD group. Among subjects in the 0, 28 procedure, seroconversion rates for NAb at both doses were both 95% with GMTs of 19 at day 28 after immunization. Anti-S antibodies had GMTs of 937 and 929 for the MD and HD groups, and anti-N antibodies had GMTs of 570 and 494 for the MD and HD groups, respectively. No serious adverse events were observed during the study period.                                                  Conclusions                   Adults vaccinated with inactivated SARS-CoV-2 vaccine had NAb as well as anti-S/N antibody and had a low rate of adverse reactions.                                                  Clinical Trials Registration                   NCT04412538.               	['Vacina de vírus inativado']	['Inactivated virus vaccine']	-	-	-	-	-	Ensaio de fase II randomizado, duplo-cego e controlado por placebo de uma vacina inativada SARS-CoV-2 em adultos saudáveis. 	-
Prophylactic or therapeutic doses of heparins for COVID‐19 infection? A retrospective study.	https://doi.org/10.1007/s40520-020-01750-6	16/11/2020	Artigo completo publicado em periódico científico	10.1007/s40520-020-01750-6	1720-8319	17208319	AGING CLINICAL AND EXPERIMENTAL RESEARCH	A4	0.911	78	4.02	-	['Heparina']	['Heparin']	-	-	-	-	-	Doses profiláticas ou terapêuticas de heparinas para infecção por COVID-19? Um estudo retrospectivo. 	-
Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study.	https://doi.org/10.1016/j.ijid.2020.11.149	16/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.149	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']	ISRCTN74727214.	33217576	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.11.149	Anakinra em pacientes hospitalizados com pneumonia grave por COVID-19 que requerem oxigenoterapia: resultados de um estudo prospectivo, aberto e intervencionista. 	ISRCTN74727214.
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial.	https://doi.org/10.1016/j.intimp.2020.107205	13/11/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107205	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Imunoglobulina', 'Imunoglobulina']	['Immunoglobulin', 'Immunoglobulin']	Our findings did not support the use of IVIg in combination with hydroxychloroquine and lopinavir/ritonavir in treatment of severe COVID-19 cases.	33214093	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.107205	Avaliando os efeitos da imunoglobulina intravenosa (IVIg) no manejo de casos graves de COVID-19: um estudo controlado randomizado. 	Nossos achados não apoiaram o uso de IVIg em combinação com hidroxicloroquina e lopinavir/ritonavir no tratamento de casos graves de COVID-19.
Prevalence of Diabetes, Management and Outcomes among Covid-19 Adult Patients Admitted in a Specialized Tertiary Hospital in Riyadh	https://doi.org/10.1016/j.diabres.2020.108538	12/11/2020	Artigo completo publicado em periódico científico	10.1016/j.diabres.2020.108538	0168-8227	1688227	DIABETES RESEARCH AND CLINICAL PRACTICE (PRINT)	A3	1.677	122	6.69	-	['Azitromicina', 'Dexametasona', 'Hidroxicloroquina']	['Azithromycin', 'Dexamethasone', 'Hydroxychloroquine']	-	-	-	-	-	Prevalência de Diabetes, Manejo e Resultados entre Pacientes Adultos Covid-19 Internados em um Hospital Terciário Especializado em Riad 	-
Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.	https://doi.org/10.1007/s10875-020-00911-6	14/11/2020	Artigo completo publicado em periódico científico	10.1007/s10875-020-00911-6	0271-9142	2719142	JOURNAL OF CLINICAL IMMUNOLOGY	A3	1.522	101	4.54	-	['Tocilizumabe']	['Tocilizumab']	These data could be helpful for the design of future trials aiming to counter COVID-19-induced inflammation, especially before patients require admission to the intensive care unit.	33188624	Journal of clinical immunology	1573-2592	10.1007/s10875-020-00911-6	Tocilizumab para pneumonia grave por COVID-19: uma análise de pontuação de propensão. 	Esses dados podem ser úteis para o desenho de estudos futuros com o objetivo de combater a inflamação induzida por COVID-19, especialmente antes que os pacientes precisem ser admitidos na unidade de terapia intensiva.
Mortality risk assessment in Spain and Italy, insights of the HOPE COVID‐19 registry.	https://doi.org/10.1007/s11739-020-02543-5	09/11/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02543-5	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Interferon', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Interferon', 'Interferon', 'Interferon', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', ' Tocilizumab', 'Tocilizumab', 'Tocilizumab']	Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-OR	33165755	Internal and emergency medicine	1970-9366	10.1007/s11739-020-02543-5	Avaliação do risco de mortalidade na Espanha e na Itália, insights do registro HOPE COVID-19. 	Recentemente, o surto de doença por coronavírus (COVID-19) foi declarado uma pandemia. Apesar de sua extensão agressiva e morbidade e mortalidade significativas, os fatores de risco são pouco caracterizados fora da China. Projetamos um registro, HOPE COVID-19 (NCT04334291), avaliando dados de 1.021 pacientes que receberam alta (vivos ou mortos) após COVID-19, de 23 hospitais em 4 países, entre 8 de fevereiro e 1 de abril. O desfecho primário foi a mortalidade por todas as causas com o objetivo de produzir uma calculadora de pontuação de risco de mortalidade. A idade mediana foi de 68 anos (IQR 52-79), e 59,5% eram do sexo masculino. As comorbidades mais frequentes foram hipertensão (46,8%) e dislipidemia (35,8%). Uma doença cardíaca ou pulmonar relevante foi descrita em 20%. E doença renal, neurológica ou oncológica, respectivamente, foram detectadas em quase 10%. Os sintomas mais comuns foram febre, tosse e dispneia na admissão. 311 pacientes morreram e 710 receberam alta vivos. Na análise multivariada de óbito, levantaram como mais relevantes: idade, hipertensão, obesidade, insuficiência renal, qualquer doença imunossupressora, saturação 02 < 92% e proteína C reativa elevada (AUC = 0,87; teste de Hosmer-Lemeshow, p > 0,999; bootstrap-otimista: 0,0018). Fornecemos um escore clínico simples para estimar a probabilidade de morte, dividindo os pacientes em quatro graus (I-IV) de probabilidade crescente. Hidroxicloroquina (79,2%) e antivirais (67,6%) foram os medicamentos específicos mais utilizados. Após um ajuste do escore de propensão, os resultados sugeriram uma ligeira melhora nas taxas de mortalidade (OR ajustado
Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial.	https://doi.org/10.1016/j.ijantimicag.2020.106216	02/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106216	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Artemisinina', 'Piperaquina']	['Artemisinin', 'Piperaquine']	-	-	-	-	-	Segurança e eficácia da Artemisinina-Piperaquina para o tratamento de COVID-19: um estudo aberto, não randomizado e controlado. 	-
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Control Study, Mayo Clinic Proceedings	https://doi.org/10.1016/j.mayocp.2020.08.038	14/06/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.08.038	0025-6196	256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Lenzilumabe']	['Lenzilumab']	-	-	-	-	-	Neutralização de GM-CSF com Lenzilumab em pneumonia grave por COVID-19: um estudo de caso-controle, Mayo Clinic Proceedings 	-
Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience	https://doi.org/10.1093/ofid/ofaa319	08/06/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa319	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract  Background The US Food and Drug Administration issued an Emergency Use Authorization for remdesivir use in patients with severe COVID-19.  Methods We utilized data from 2 quaternary acute care hospitals. The outcomes of interest were the impact of remdesivir on in-hospital death by day 28 and time to recovery, clinical improvement, and discharge. We utilized Cox proportional hazards models and stratified log-rank tests.  Results Two hundred twenty-four patients were included in the study. The median age was 59 years; 67.0% were male; 17/125 patients (13.6%) who received supportive care and 7/99 patients (7.1%) who received remdesivir died. The unadjusted risk for 28-day in-hospital death was lower for patients who received remdesivir compared with patients who received supportive care (hazard ratio [HR], 0.42; 95% CI, 0.16–1.08). Although this trend remained the same after adjusting for age, sex, race, and oxygen requirements on admission (adjusted HR [aHR], 0.49; 95% CI, 0.19–1.28), as well as chronic comorbidities and use of corticosteroids (aHR, 0.44; 95% CI, 0.16–1.23), it did not reach statistical significance. The use of remdesivir was not associated with an increased risk of acute kidney injury (AKI) or liver test abnormalities. Although not statistically significant, the rate ratios for time to recovery, clinical improvement, and discharge were higher in women and black or African American patients.  Conclusions Patients on remdesivir had lower, albeit not significant, all-cause in-hospital mortality, and the use of remdesivir did not increase the risk for AKI. Promising signals from this study need to be confirmed by future placebo-controlled randomized clinical trials.	['Remdesivir']	['Remdesivir']	Patients on remdesivir had lower, albeit not significant, all-cause in-hospital mortality, and the use of remdesivir did not increase the risk for AKI. Promising signals from this study need to be confirmed by future placebo-controlled randomized clinical trials.	33117850	Open forum infectious diseases	2328-8957	10.1093/ofid/ofaa319	remdesivir em comparação com cuidados de suporte em pacientes hospitalizados com COVID-19 grave: uma experiência em um único 	centro . Sinais promissores deste estudo precisam ser confirmados por futuros ensaios clínicos randomizados controlados por placebo.
The efect of tocilizumab on cytokine release syndrome in COVID‐19 patients.	https://doi.org/10.1007/s43440-020-00186-z	09/11/2020	Artigo completo publicado em periódico científico	10.1007/s43440-020-00186-z	1734-1140	17341140	PHARMACOLOGICAL REPORTS	A3	0.625	87	3.5	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	O efeito do tocilizumab na síndrome de liberação de citocinas em pacientes com COVID-19. 	-
Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.	https://doi.org/10.1016/j.ijid.2020.11.008	04/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.11.008	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Favipiravir', 'Interferon beta']	['Favipiravir', 'Interferon beta']	No differences in clinical outcomes were found between favipiravir plus inhaled interferon beta-1b and hydroxychloroquine in adults hospitalized with moderate to severe COVID-19 pneumonia.	33181328	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.11.008	Ensaio Aberto Randomizado Controlado sobre o Uso de Favipiravir Combinado com Interferon Beta-1b Inalado em Pacientes Hospitalizados com Pneumonia COVID-19 Moderada a Grave. 	Não foram encontradas diferenças nos resultados clínicos entre favipiravir mais interferon beta-1b inalado e hidroxicloroquina em adultos hospitalizados com pneumonia por COVID-19 moderada a grave.
Corticosteroid therapy for coronavirus disease 2019‑related acute respiratory distress syndrome: a cohort study with propensity score analysis.	https://doi.org/10.1186/s13054-020-03340-4	10/11/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03340-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract  Background The impact of corticosteroid therapy on outcomes of patients with coronavirus disease 2019 (COVID-19) is highly controversial. We aimed to compare the risk of death between COVID-19-related ARDS patients with corticosteroid treatment and those without.  Methods In this single-center retrospective observational study, patients with ARDS caused by COVID-19 between January 20, 2020, and February 24, 2020, were enrolled. The primary outcome was 60-day in-hospital death. The exposure was prescribed systemic corticosteroids or not. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for 60-day in-hospital mortality.  Results A total of 382 patients [60.7 ± 14.1 years old (mean ± SD), 61.3% males] were analyzed. The median of sequential organ failure assessment (SOFA) score was 2.0 (IQR 2.0–3.0). Of these cases, 94 (24.6%) patients had invasive mechanical ventilation. The number of patients received systemic corticosteroids was 226 (59.2%), and 156 (40.8%) received standard treatment. The maximum dose of corticosteroids was 80.0 (IQR 40.0–80.0) mg equivalent methylprednisolone per day, and duration of corticosteroid treatment was 7.0 (4.0–12.0) days in total. In Cox regression analysis using corticosteroid treatment as a time-varying variable, corticosteroid treatment was associated with a significant reduction in risk of in-hospital death within 60 days after adjusting for age, sex, SOFA score at hospital admission, propensity score of corticosteroid treatment, comorbidities, antiviral treatment, and respiratory supports (HR 0.42; 95% CI 0.21, 0.85;  p = 0.0160). Corticosteroids were not associated with delayed viral RNA clearance in our cohort.  Conclusion In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.	['Dexametasona', 'Prednisolona', 'Prednisona']	['Dexamethasone', 'Prednisolone', 'Prednisone']	In this clinical practice setting, low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS.	33172477	Critical care (London, England)	1466-609X	10.1186/s13054-020-03340-4	Terapia com corticosteroides para síndrome do desconforto respiratório agudo relacionado à doença de coronavírus 2019: um estudo de coorte com análise de escore de propensão. 	Neste cenário de prática clínica, o tratamento com baixas doses de corticosteroides foi associado à redução do risco de morte hospitalar em 60 dias em pacientes com COVID-19 que desenvolveram SDRA.
CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ARDS.	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03328-0	02/11/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03328-0	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract                  Background                 COVID-19-related ARDS has unique features when compared with ARDS from other origins, suggesting a distinctive inflammatory pathogenesis. Data regarding the host response within the lung are sparse. The objective is to compare alveolar and systemic inflammation response patterns, mitochondrial alarmin release, and outcomes according to ARDS etiology (i.e., COVID-19 vs. non-COVID-19).                                Methods                 Bronchoalveolar lavage fluid and plasma were obtained from 7 control, 7 non-COVID-19 ARDS, and 14 COVID-19 ARDS patients. Clinical data, plasma, and epithelial lining fluid (ELF) concentrations of 45 inflammatory mediators and cell-free mitochondrial DNA were measured and compared.                                Results                 COVID-19 ARDS patients required mechanical ventilation (MV) for significantly longer, even after adjustment for potential confounders. There was a trend toward higher concentrations of plasma CCL5, CXCL2, CXCL10, CD40 ligand, IL-10, and GM-CSF, and ELF concentrations of CXCL1, CXCL10, granzyme B, TRAIL, and EGF in the COVID-19 ARDS group compared with the non-COVID-19 ARDS group. Plasma and ELF CXCL10 concentrations were independently associated with the number of ventilator-free days, without correlation between ELF CXCL-10 and viral load. Mitochondrial DNA plasma and ELF concentrations were elevated in all ARDS patients, with no differences between the two groups. ELF concentrations of mitochondrial DNA were correlated with alveolar cell counts, as well as IL-8 and IL-1β concentrations.                                Conclusion                 CXCL10 could be one key mediator involved in the dysregulated immune response. It should be evaluated as a candidate biomarker that may predict the duration of MV in COVID-19 ARDS patients. Targeting the CXCL10-CXCR3 axis could also be considered as a new therapeutic approach.                                Trial registration                 ClinicalTrials.gov, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03955887">NCT03955887</jats:ext-link>              	['CXCL10']	['CXCL10']	The type of antihypertensive agent being used had no effect on the clinical course and mortality in hypertensive patients with COVID-19. The use of these agents should be maintained for the treatment of hypertension during hospitalization.	33849612	Critical care (London, England)	1466-609X	10.1186/s13054-021-03559-9	O CXCL10 pode levar a uma duração mais longa da ventilação mecânica durante a SDRA COVID-19. 	O tipo de agente anti-hipertensivo utilizado não teve efeito sobre o curso clínico e mortalidade em pacientes hipertensos com COVID-19. O uso desses agentes deve ser mantido para o tratamento da hipertensão durante a internação.
Therapeutic Plasma Exchange followed by Convalescent Plasma transfusion in critical COVID-19- an exploratory study.	https://doi.org/10.1016/j.ijid.2020.10.085	02/11/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.10.085	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Plasma convalescente']	['Convalescent Plasma']	The pathophysiology of severe coronavirus disease 2019 (COVID-19) is primarily a host immune interplay to virus invasion. The therapeutic options have been explored either against hyperinflammation from dysregulated adaptive immunity or direct virus neutralization using antibodies from convalescent plasma (CP) of a recovered patient. The therapeutic plasma exchange (TPE) for removal of excessive inflammatory cytokines has been tried with success in COVID-19. We undertook this exploratory study to evaluate safety and efficacy of TPE followed by CP transfusion in 14 patients with critical COVID-19 requiring invasive mechanical ventilation (IMV). All patients showed improvement in symptoms and decrease of inflammatory markers especially CRP (p = 0.03). 10 patients were liberated from IMV after a median of 5.5 (3-36) days, post sequential therapy. Day 7 and Day 28 mortality was 21.4% and 28.6% respectively. The median duration ICU and hospital LOS were 12 (5-42) days and 18 (12-47) days respectively. No patient developed transfusion-associated complications, but three patients developed secondary bacterial sepsis within 14 days of therapy, and one died. This case series demonstrated the sequential use of TPE followed by CP transfusion as a therapeutic option in critical COVID-19.	33157287	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.10.085	Troca de plasma terapêutica seguida de transfusão de plasma convalescente em COVID-19 crítico - um estudo exploratório. 	A fisiopatologia da doença grave por coronavírus 2019 (COVID-19) é principalmente uma interação imune do hospedeiro à invasão do vírus. As opções terapêuticas têm sido exploradas tanto contra hiperinflamação por imunidade adaptativa desregulada ou neutralização direta do vírus usando anticorpos do plasma convalescente (CP) de um paciente recuperado. A troca de plasma terapêutica (TPE) para remoção de citocinas inflamatórias excessivas foi tentada com sucesso no COVID-19. Realizamos este estudo exploratório para avaliar a segurança e eficácia do TPE seguido de transfusão de CP em 14 pacientes com COVID-19 crítico que requerem ventilação mecânica invasiva (IMV). Todos os pacientes apresentaram melhora dos sintomas e diminuição dos marcadores inflamatórios, principalmente PCR (p = 0,03). 10 pacientes foram liberados da VMI após uma mediana de 5,5 (3-36) dias, pós terapia sequencial. A mortalidade no dia 7 e no dia 28 foi de 21,4% e 28,6%, respectivamente. A duração mediana de UTI e internação hospitalar foi de 12 (5-42) dias e 18 (12-47) dias, respectivamente. Nenhum paciente desenvolveu complicações associadas à transfusão, mas três pacientes desenvolveram sepse bacteriana secundária dentro de 14 dias de terapia e um morreu. Esta série de casos demonstrou o uso sequencial de TPE seguido de transfusão de CP como opção terapêutica na COVID-19 crítica.
Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.	https://doi.org/10.1038/s41598-020-76258-0	05/11/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-76258-0	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract               Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization’s List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	Chloroquine (CQ) and hydroxychloroquine (HCQ) are on the World Health Organization's List of Essential Medications for treating non-resistant malaria, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, both drugs are currently used off-label in hospitals worldwide and in numerous clinical trials for the treatment of SARS-CoV-2 infection. However, CQ and HCQ use has been associated with cardiac side effects, which is of concern due to the higher risk of COVID-19 complications in patients with heart related disorders, and increased mortality associated with COVID-19 cardiac complications. In this study we analyzed over thirteen million adverse event reports form the United States Food and Drug Administration Adverse Event Reporting System to confirm and quantify the association of cardiac side effects of CQ and HCQ. Additionally, we identified several confounding factors, including male sex, NSAID coadministration, advanced age, and prior diagnoses contributing to drug related cardiotoxicity. These findings may help guide therapeutic decision making and ethical trial design for COVID-19 treatment.	33154498	Scientific reports	2045-2322	10.1038/s41598-020-76258-0	Eventos adversos cardíacos associados à exposição à cloroquina e hidroxicloroquina em 20 anos de relatórios de vigilância de segurança de medicamentos. 	A cloroquina (CQ) e a hidroxicloroquina (HCQ) estão na Lista de Medicamentos Essenciais da Organização Mundial da Saúde para o tratamento da malária não resistente, artrite reumatoide (AR) e lúpus eritematoso sistêmico (LES). Além disso, ambos os medicamentos são atualmente usados off-label em hospitais em todo o mundo e em vários ensaios clínicos para o tratamento da infecção por SARS-CoV-2. No entanto, o uso de CQ e HCQ tem sido associado a efeitos colaterais cardíacos, o que é preocupante devido ao maior risco de complicações do COVID-19 em pacientes com distúrbios relacionados ao coração e ao aumento da mortalidade associada às complicações cardíacas do COVID-19. Neste estudo, analisamos mais de treze milhões de notificações de eventos adversos do Sistema de Notificação de Eventos Adversos da Food and Drug Administration dos Estados Unidos para confirmar e quantificar a associação de efeitos colaterais cardíacos de CQ e HCQ. Além disso, identificamos vários fatores de confusão, incluindo sexo masculino, coadministração de AINEs, idade avançada e diagnósticos anteriores que contribuem para a cardiotoxicidade relacionada à droga. Esses achados podem ajudar a orientar a tomada de decisões terapêuticas e o design de ensaios éticos para o tratamento com COVID-19.
Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.	https://doi.org/10.1016/j.lfs.2020.118663	26/10/2020	Artigo completo publicado em periódico científico	10.1016/j.lfs.2020.118663	0024-3205	243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']	Remdesivir showed a better 14 days mortality profile, clinical recovery, and discharge rate. Overall clinical improvement and clinical recovery were earlier among the remdesivir group. 10-day remdesivir showed more adverse outcome than 5-day course with no significant benefits.	33121991	Life sciences	1879-0631	10.1016/j.lfs.2020.118663	Remdesivir: Um potencial divisor de águas ou apenas um mito? Uma revisão sistemática e meta-análise. 	O remdesivir apresentou melhor perfil de mortalidade em 14 dias, recuperação clínica e taxa de alta. A melhora clínica geral e a recuperação clínica foram mais precoces no grupo remdesivir. O remdesivir de 10 dias mostrou resultados mais adversos do que o curso de 5 dias, sem benefícios significativos.
Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.	https://doi.org/10.1016/j.imlet.2020.10.009	05/11/2020	Artigo completo publicado em periódico científico	10.1016/j.imlet.2020.10.009	0165-2478	1652478	IMMUNOLOGY LETTERS	A4	0.869	97	4.04	-	['Tocilizumabe']	['Tocilizumab']	As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients requiring intensive care were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary, these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls.	33161002	Immunology letters	1879-0542	10.1016/j.imlet.2020.10.009	Melhora vascular pulmonar em pacientes graves com COVID-19 tratados com tocilizumabe. 	A partir de outubro de 2020, o gerenciamento da doença de coronavírus 2019 (COVID-19) é baseado em cuidados de suporte e terapias off-label ou de uso compassivo. Em março de 2020, o tocilizumab - um anticorpo monoclonal anti-receptor de IL-6 - foi sugerido como tratamento imunomodulador no COVID-19 grave porque a síndrome hiperinflamatória ocorre em muitos pacientes de forma semelhante à síndrome de liberação de citocinas que se desenvolve após a terapia com células CAR-T. Em nosso estudo observacional retrospectivo, 20 pacientes graves com COVID-19 que necessitavam de terapia intensiva foram tratados com tocilizumabe além da terapia padrão de atendimento (SOC) e comparados com 13 pacientes com COVID-19 que receberam apenas SOC. O estado clínico respiratório, os marcadores inflamatórios e o escore radiológico vascular melhoraram após uma semana da administração de tocilizumabe. Ao contrário, esses parâmetros permaneceram estáveis ou pioraram em pacientes que receberam apenas SOC. Apesar das principais limitações do estudo, a melhora do gradiente de oxigênio alvéolo-arterial, bem como o escore radiológico vascular após uma semana, pode explicar a melhora da perfusão vascular pulmonar e pode explicar a recuperação mais rápida dos pacientes com COVID-19 que receberam tocilizumabe em comparação com os controles.
Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: results of the ACE-CoV study.	https://onlinelibrary.wiley.com/doi/10.1111/fcp.12613	28/10/2020	Artigo completo publicado em periódico científico	10.1111/fcp.12613	0767-3981	7673981	FUNDAMENTAL & CLINICAL PHARMACOLOGY	A4	0.534	77	2.61	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Data are lacking on the impact of ACEI/ARB exposure on unfavorable outcome in the population of patients hospitalized for COVID-19 with hypertension/cardiovascular disease, particularly in Europe. The ACE-CoV study was designed to assess this question. The study was conducted in the Covid-Clinic-Toul cohort, which contains data about all patients hospitalized at Toulouse University hospital, France with a SARS-CoV-2 infection since March, 2020. We selected the patients with a history of cardiovascular disease (heart failure or coronary disease) and/or arterial hypertension. We conducted a subgroup analysis in patients with arterial hypertension. ACEI/ARB exposures at admission were assessed. The outcome was composite: admission to intensive care unit, need of mechanical ventilation or death during the 14 days after admission to hospital. We used logistic regression models with propensity scores (PS) weighted by overlap weighting (OW) and inverse probability of treatment weighting (IPTW). Between March 2020 and April 20, 2020, the Covid-Clinic-Toul included 263 patients. Among them, 111 were included in the ACE-CoV study population. In OW-PS-adjusted analyses, the association of exposure to ACEIs or ARBs with outcome occurrence was OR: 1.56 (95% CI: 0.73-3.33). It was 0.99 (95% CI: 0.68-1.45) for ACEIs and 1.64 (95% CI: 0.77-3.50) for ARBs. Analyses with weighting by the IPTW-PS method gave similar results. Results were similar when considering the subgroup of patients with arterial hypertension. The ACE-CoV study found no association between exposure to ACEIs or ARBs and unfavorable outcome in hospitalized patients for COVID-19 with a history of cardiovascular disease/arterial hypertension.	33111329	Fundamental & clinical pharmacology	1472-8206	10.1111/fcp.12613	Resultado de pacientes hospitalizados por COVID-19 e exposição a inibidores da enzima conversora de angiotensina e bloqueadores dos receptores de angiotensina na França: resultados do estudo ACE-CoV. 	Faltam dados sobre o impacto da exposição a IECA/BRA no desfecho desfavorável na população de pacientes hospitalizados por COVID-19 com hipertensão/doença cardiovascular, particularmente na Europa. O estudo ACE-CoV foi projetado para avaliar essa questão. O estudo foi realizado na coorte Covid-Clinic-Toul, que contém dados sobre todos os pacientes internados no hospital da Universidade de Toulouse, França, com infecção por SARS-CoV-2 desde março de 2020. Selecionamos os pacientes com histórico de doença cardiovascular ( insuficiência cardíaca ou doença coronária) e/ou hipertensão arterial. Realizamos uma análise de subgrupo em pacientes com hipertensão arterial. As exposições de IECA/BRA na admissão foram avaliadas. O desfecho foi composto: admissão em unidade de terapia intensiva, necessidade de ventilação mecânica ou óbito durante os 14 dias após a admissão no hospital. Usamos modelos de regressão logística com escores de propensão (PS) ponderados por ponderação de sobreposição (OW) e probabilidade inversa de ponderação de tratamento (IPTW). Entre março de 2020 e 20 de abril de 2020, a Covid-Clinic-Toul incluiu 263 pacientes. Entre eles, 111 foram incluídos na população do estudo ACE-CoV. Nas análises ajustadas por OW-PS, a associação da exposição a IECAs ou BRAs com a ocorrência do desfecho foi OR: 1,56 (IC 95%: 0,73-3,33). Foi 0,99 (IC 95%: 0,68-1,45) para IECA e 1,64 (IC 95%: 0,77-3,50) para BRA. As análises com ponderação pelo método IPTW-PS apresentaram resultados semelhantes. Os resultados foram semelhantes ao considerar o subgrupo de pacientes com hipertensão arterial. O estudo ACE-CoV não encontrou associação entre exposição a IECAs ou BRAs e desfecho desfavorável em pacientes hospitalizados por COVID-19 com histórico de doença cardiovascular/hipertensão arterial.
Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes:  Prospective Cohort Study.	https://link.springer.com/article/10.1007/s40121-020-00363-w	02/11/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00363-w	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Anti-inflamatórios não esteroidais', 'Anti-inflamatórios não esteroidais', 'Ibuprofeno', 'Ibuprofeno']	['Non-steroidal anti-inflammatory drugs', 'Non-steroidal anti-inflammatory drugs', 'Ibuprofen', 'Ibuprofen']	-	-	-	-	-	O uso de ibuprofeno e AINE em pacientes infectados com COVID-19 não está associado a piores resultados: estudo de coorte prospectivo. 	-
Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: Systematic review and meta‐analysis including network meta‐analysis	https://doi.org/10.1002/rmv.2187	31/10/2020	Artigo completo publicado em periódico científico	10.1002/rmv.2187	1052-9276	10529276	REVIEWS IN MEDICAL VIROLOGY (PRINT)	A1	2.371	96	9.42	-	['Remdesivir']	['Remdesivir']	Remdesivir can help improve the clinical outcome of hospitalized patients with COVID-19 and a 5 day regimen, instead of a 10 day regimen, may be sufficient for treatment. Moreover, remdesivir appears as tolerable as other comparators or placebo.	33758946	The Journal of antimicrobial chemotherapy	1460-2091	10.1093/jac/dkab093	remdesivir em pacientes hospitalizados com Covid-19: Revisão sistemática e metanálise, incluindo metanálise de rede 	pode ser suficiente para o tratamento. Além disso, o remdesivir parece tão tolerável quanto outros comparadores ou placebo.
Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial	https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13185	09/10/2020	Artigo completo publicado em periódico científico	10.1111/joim.13185	0954-6820	9546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Preditores clínicos do título de anticorpos do doador e correlação com a resposta do anticorpo do receptor em um ensaio clínico de plasma convalescente COVID-19 	-
Blood ozonization in patients with mild to moderate COVID‑19 pneumonia: a single centre experience	https://doi.org/10.1007/s11739-020-02542-6	01/11/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02542-6	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Ozonioterapia']	['Ozone Therapy']	Remdesivir can help improve the clinical outcome of hospitalized patients with COVID-19 and a 5 day regimen, instead of a 10 day regimen, may be sufficient for treatment. Moreover, remdesivir appears as tolerable as other comparators or placebo.	33534080	Internal and emergency medicine	1970-9366	10.1007/s11739-021-02630-1	Ozonização do sangue em pacientes com pneumonia leve a moderada por COVID-19: uma experiência em um único centro 	O remdesivir pode ajudar a melhorar o resultado clínico de pacientes hospitalizados com COVID-19 e um regime de 5 dias, em vez de um regime de 10 dias, pode ser suficiente para o tratamento. Além disso, o remdesivir parece tão tolerável quanto outros comparadores ou placebo.
Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study	https://link.springer.com/article/10.1007/s00394-020-02411-0	30/10/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s00394-020-02411-0	1436-6207	14366207	EUROPEAN JOURNAL OF NUTRITION (PRINT)	A1	1.061	103	5.34	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	This study suggests that serum vitamin D status might provide useful information regarding the clinical course, extent of lung involvement and outcome of patients with COVID-19. However, further studies with larger sample size are needed to confirm these findings.	33123774	European journal of nutrition	1436-6215	10.1007/s00394-020-02411-0	Possível associação do status de vitamina D com envolvimento pulmonar e desfecho em pacientes com COVID-19: um estudo retrospectivo 	Este estudo sugere que o status sérico de vitamina D pode fornecer informações úteis sobre o curso clínico, extensão do envolvimento pulmonar e desfecho de pacientes com COVID-19 . No entanto, mais estudos com maior tamanho amostral são necessários para confirmar esses achados.
Metformin is associated with Decreased 30-day Mortality among Nursing Home Residents Infected with SARS-CoV2	https://doi.org/10.1016/j.jamda.2020.10.031	23/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jamda.2020.10.031	1525-8610	15258610	JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (PRINT)	A1	2.023	102	5.45	-	['Metformina']	['Metformin']	Our data suggest a reduction in 30-day mortality following SARS-CoV-2 infection in residents who were on metformin-containing diabetes regimens. These findings suggest a relative survival benefit in nursing home residents on metformin, potentially through its mTOR inhibition effects. A prospective study should investigate the therapeutic benefits of metformin among persons with COVID-19.	33232684	Journal of the American Medical Directors Association	1538-9375	10.1016/j.jamda.2020.10.031	A metformina está associada à diminuição da mortalidade em 30 dias entre os residentes de lares de idosos infectados com SARS-CoV2 	Nossos dados sugerem uma redução na mortalidade em 30 dias após a infecção por SARS-CoV-2 em residentes que estavam em regimes de diabetes contendo metformina. Esses achados sugerem um benefício relativo de sobrevivência em residentes de asilos em metformina, potencialmente através de seus efeitos de inibição de mTOR. Um estudo prospectivo deve investigar os benefícios terapêuticos da metformina entre pessoas com COVID-19.
Statin Use and In-Hospital Mortality in Diabetics with COVID-19	Doi: 10.1161/jaha.120.018475	23/10/2020	Artigo completo publicado em periódico científico	Doi: 10.1161/jaha.120.018475	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             Background            <jats:p xml:lang="en">Severe coronavirus disease 2019 (COVID‐19) is characterized by a proinflammatory state with high mortality. Statins have anti‐inflammatory effects and may attenuate the severity of COVID‐19.                    <jats:sec xml:lang="en">             Methods and Results            <jats:p xml:lang="en">              An observational study of all consecutive adult patients with COVID‐19 admitted to a single center located in Bronx, New York, was conducted from March 1, 2020, to May 2, 2020. Patients were grouped as those who did and those who did not receive a statin, and in‐hospital mortality was compared by competing events regression. In addition, propensity score matching and inverse probability treatment weighting were used in survival models to examine the association between statin use and death during hospitalization. A total of 4252 patients were admitted with COVID‐19. Diabetes mellitus modified the association between statin use and in‐hospital mortality. Patients with diabetes mellitus on a statin (n=983) were older (69±11 versus 67±14 years;               P              &lt;0.01), had lower inflammatory markers (C‐reactive protein, 10.2; interquartile range, 4.5–18.4 versus 12.9; interquartile range, 5.9–21.4 mg/dL;               P              &lt;0.01) and reduced cumulative in‐hospital mortality (24% versus 39%;               P              &lt;0.01) than those not on a statin (n=1283). No difference in hospital mortality was noted in patients without diabetes mellitus on or off statin (20% versus 21%;               P              =0.82). Propensity score matching (hazard ratio, 0.88; 95% CI, 0.83–0.94;               P              &lt;0.01) and inverse probability treatment weighting (HR, 0.88; 95% CI, 0.84–0.92;               P              &lt;0.01) showed a 12% lower risk of death during hospitalization for statin users than for nonusers.                                <jats:sec xml:lang="en">             Conclusions            <jats:p xml:lang="en">Statin use was associated with reduced in‐hospital mortality from COVID‐19 in patients with diabetes mellitus. These findings, if validated, may further reemphasize administration of statins to patients with diabetes mellitus during the COVID‐19 era.          	['Estatina']	['Statin']	-	-	-	-	-	Uso de estatinas e mortalidade hospitalar em diabéticos com COVID-19 	-
Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis	https://doi.org/10.1016/j.chest.2020.10.054	21/10/2020	Artigo completo publicado em periódico científico	10.1016/j.chest.2020.10.054	0012-3692	123692	CHEST (AMERICAN COLLEGE OF CHEST PHYSICIANS)	A1	2.264	302	4.41	-	['Corticosteroides', 'Dexametasona', 'Prednisolona', 'Prednisona']	['Corticosteroids', 'Dexamethasone', 'Prednisolone', 'Prednisone']	-	-	-	-	-	Impacto dos Corticosteróides nos Resultados da COVID-19: Revisão Sistemática e Meta-análise 	-
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial	https://doi.org/10.1186/s12967-020-02573-9	21/10/2020	Artigo completo publicado em periódico científico	10.1186/s12967-020-02573-9	1479-5876	14795876	JOURNAL OF TRANSLATIONAL MEDICINE (ONLINE)	A2	1.570	121	7.38	 Abstract                  Background                 Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.                                Methods                 A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.                                Results                 In the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6–24.0,  P = 0.52) and 22.4% (97.5% CI: 17.2–28.3,  P &lt; 0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.                                Conclusions                 Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.                  Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092).              	['Tocilizumabe']	['Tocilizumab']	The worldwide pandemic of 2019 novel coronavirus disease (COVID-19) has posed the most substantial and severe public health issue for several generations, and therapeutic options have not yet been optimised. Vitamin D (in its "parent" form, cholecalciferol) has been proposed in the pharmacological management of COVID-19 by various sources. We aimed to determine whether COVID-19 mortality was affected by serum 25-hydroxyvitamin D (25(OH)D) levels, vitamin D status, or cholecalciferol therapy, and to elucidate any other predictors of COVID-19 mortality. Patients hospitalised with COVID-19 were opportunistically recruited from three UK hospitals, and their data were collected retrospectively. Logistic regression was used to determine any relationships between COVID-19 mortality and potential predictors, including 25(OH)D levels and cholecalciferol booster therapy. A total of 986 participants with COVID-19 were studied, of whom 151 (16.0%) received cholecalciferol booster therapy. In the primary cohort of 444 patients, cholecalciferol booster therapy was associated with a reduced risk of COVID-19 mortality, following adjustment for potential confounders (OR	34674735	Journal of translational medicine	1479-5876	10.1186/s12967-021-03094-9	Tocilizumabe para pacientes com pneumonia por COVID-19. O estudo prospectivo de braço único TOCIVID-19 	A pandemia mundial de 2019 da doença do novo coronavírus (COVID-19) representou o problema de saúde pública mais substancial e grave por várias gerações, e as opções terapêuticas ainda não foram otimizadas. A vitamina D (em sua forma "pai", colecalciferol) foi proposta no manejo farmacológico do COVID-19 por várias fontes. Nosso objetivo foi determinar se a mortalidade por COVID-19 foi afetada pelos níveis séricos de 25-hidroxivitamina D (25(OH)D), status de vitamina D ou terapia com colecalciferol e elucidar quaisquer outros preditores de mortalidade por COVID-19. Pacientes hospitalizados com COVID-19 foram recrutados de forma oportunista em três hospitais do Reino Unido e seus dados foram coletados retrospectivamente. A regressão logística foi usada para determinar quaisquer relações entre a mortalidade por COVID-19 e potenciais preditores, incluindo níveis de 25(OH)D e terapia de reforço com colecalciferol. Um total de 986 participantes com COVID-19 foram estudados, dos quais 151 (16,0%) receberam terapia de reforço com colecalciferol. Na coorte primária de 444 pacientes, a terapia de reforço com colecalciferol foi associada a um risco reduzido de mortalidade por COVID-19, após ajuste para possíveis fatores de confusão (OR
Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study	https://doi.org/10.1016/j.ijid.2020.10.062	27/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.10.062	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	The viral shedding duration was similar between HCQ and LPV/r treatment groups. There was no benefit in improving viral clearance compared to the control group.	33127507	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.10.062	Comparação do efeito antiviral para casos leves a moderados de COVID-19 entre lopinavir/ritonavir versus hidroxicloroquina: um estudo de coorte nacional pareado com escore de propensão 	A duração da disseminação viral foi semelhante entre os grupos de tratamento com HCQ e LPV/r. Não houve benefício em melhorar a depuração viral em comparação com o grupo controle.
Comparative Effectiveness of Lopinavir/Ritonavir-Based Regimens in COVID-19	https://doi.org/10.1111/1440-1681.13425	22/10/2020	Artigo completo publicado em periódico científico	10.1111/1440-1681.13425	0305-1870	3051870	CLINICAL & EXPERIMENTAL PHARMACOLOGY & PHYSIOLOGY	A4	0.584	107	2.82	-	['Interferon', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	['Interferon', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	The coronavirus disease 2019 (COVID-19) is an epidemic disease caused by the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and spreading throughout the world rapidly. Here we evaluated the efficacy of the Lopinavir/Ritonavir (LPV/r) and its combination with other drugs in the treatment of COVID-19. We included 170 confirmed COVID-19 patients who had been cured and discharged. Their antiviral therapies were LPV/r alone or combinations with interferon (IFN), Novaferon and Arbidol. We evaluated the medication efficacy by comparing the time of the negative nucleic acid conversion and the length of hospitalization mainly. The LPV/r + Novaferon [6.00 (4.00-8.00) and 7.50 (5.00-10.00) days] had shorter time of the negative nucleic acid conversion (P = .0036) and shorter time of hospitalization (P < .001) compared with LPV/r alone [9.00 (5.00-12.00) and 12.00 (11.00-15.00) days] and LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days]. On the contrary, LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days] had shorter time of the negative nucleic acid conversion (P = .031) and shorter time of hospitalization (P < .001) compared with LPV/r + IFN +Novaferon [10.00 (8.00-11.25) and 13.50 (11.50-17.00) days] and LPV/r + IFN +Arbidol [14.00 (9.75-19.00) and 19.50 (13.25-24.00) days]. In conclusion, the combination of LPV/r and Novaferon may have better efficacy against COVID-19. However, adding IFN based on LPV/r + Novaferon or adding Arbidol based on LPV/r + IFN may not improve the efficacy.	33090501	Clinical and experimental pharmacology & physiology	1440-1681	10.1111/1440-1681.13425	COVID -19 	Aqui avaliamos a eficácia do Lopinavir/Ritonavir (LPV/r) e sua combinação com outros medicamentos no tratamento do COVID-19. Incluímos 170 pacientes confirmados com COVID-19 que foram curados e receberam alta. Suas terapias antivirais foram LPV/r sozinho ou combinações com interferon (IFN), Novaferon e Arbidol. Avaliamos a eficácia da medicação comparando o tempo de conversão negativa do ácido nucleico e o tempo de internação principalmente. O LPV/r + Novaferon [6,00 (4,00-8,00) e 7,50 (5,00-10,00) dias] teve menor tempo de conversão negativa de ácido nucleico (P = 0,0036) e menor tempo de hospitalização (P < 0,001) em comparação com LPV/r sozinho [9,00 (5,00-12,00) e 12,00 (11,00-15,00) dias] e LPV/r + IFN [9,00 (7,25-11,00) e 12,00 (10,00-13,50) dias]. Ao contrário, LPV/r + IFN [9,00 (7,25-11,00) e 12,00 (10,00-13,50) dias] teve menor tempo de conversão negativa de ácido nucleico (P = 0,031) e menor tempo de hospitalização (P < 0,001 ) em comparação com LPV/r + IFN + Novaferon [10,00 (8,00-11,25) e 13,50 (11,50-17,00) dias] e LPV/r + IFN + Arbidol [14,00 (9,75-19,00) e 19,50 (13,25-24,00) dias] . Em conclusão, a combinação de LPV/r e Novaferon pode ter melhor eficácia contra o COVID-19. No entanto, a adição de IFN com base em LPV/r + Novaferon ou a adição de Arbidol com base em LPV/r + IFN pode não melhorar a eficácia.
Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis	https://doi.org/10.1016/j.tmaid.2020.101906	27/11/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101906	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina', 'Ivermectina', 'Nitazoxanida', 'Oseltamivir', 'Prednisona', 'Zinco']	['Azithromycin', 'Hydroxychloroquine', 'Ivermectin', 'Nitazoxanide', 'Oseltamivir', 'Prednisone', 'Zinc']	This work adds to the growing literature of studies that have found substantial benefit for use of HCQ combined with other agents in the early outpatient treatment of COVID-19, and adds the possibility of steroid use to enhance treatment efficacy.	33137493	Travel medicine and infectious disease	1873-0442	10.1016/j.tmaid.2020.101906	Risco de Hospitalização para Pacientes Ambulatoriais Covid-19 Tratados com Vários Regimes Medicamentosos no Brasil: Análise 	Comparativa e acrescenta a possibilidade de uso de esteróides para aumentar a eficácia do tratamento.
COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin a retrospective case series study	https://doi.org/10.1016/j.ijantimicag.2020.106214	26/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106214	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Azitromicina', 'Hidroxicloroquina', 'Zinco']	['Azithromycin', 'Hydroxychloroquine', 'Zinc']	-	-	-	-	-	Pacientes ambulatoriais COVID-19 – tratamento precoce estratificado de risco com zinco mais hidroxicloroquina em baixa dose e azitromicina um estudo retrospectivo de série de casos 	-
Safely Administering Potential QTc Prolonging Therapy Across a Large Healthcare System in the COVID-19 Era	https://doi.org/10.1161/CIRCEP.120.008937	01/10/2020	Artigo completo publicado em periódico científico	10.1161/CIRCEP.120.008937	1941-3149	19413149	CIRCULATION. ARRHYTHMIA AND ELECTROPHYSIOLOGY	A1	2.471	113	5.0	              Background:             The severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) has resulted in a global pandemic. Hydroxychloroquine±azithromycin have been widely used to treat coronavirus disease 2019 (COVID-19) despite a paucity of evidence regarding efficacy. The incidence of torsade de pointes remains unknown. Widespread use of these medications forced overwhelmed health care systems to search for ways to effectively monitor these patients while simultaneously trying to minimize health care provider exposure and use of personal protective equipment.                                  Methods:             Patients with COVID-19 positive who received hydroxychloroquine±azithromycin across 13 hospitals between March 1 and April 15 were included in this study. A comprehensive search of the electronic medical records was performed using a proprietary python script to identify any mention of QT prolongation, ventricular tachy-arrhythmias and cardiac arrest.                                  Results:             The primary outcome of torsade de pointes was observed in 1 (0.015%) out of 6476 hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin. Sixty-seven (1.03%) had hydroxychloroquine±azithromycin held or discontinued due to an average QT prolongation of 60.5±40.5 ms from a baseline QTc of 473.7±35.9 ms to a peak QTc of 532.6±31.6 ms. Of these patients, hydroxychloroquine±azithromycin were discontinued in 58 patients (86.6%), while one or more doses of therapy were held in the remaining nine (13.4%). A simplified approach to monitoring for QT prolongation and arrythmia was implemented on April 5. There were no deaths related to the medications with the simplified monitoring approach and health care provider exposure was reduced.                                  Conclusions:             The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy.          	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	The risk of torsade de pointes is low in hospitalized patients with COVID-19 receiving hydroxychloroquine±azithromycin therapy.	33003964	Circulation. Arrhythmia and electrophysiology	1941-3084	10.1161/CIRCEP.120.008937	Administrar com segurança a potencial terapia de prolongamento do QTc em um grande sistema de saúde na era COVID-19 	O risco de torsade de pointes é baixo em pacientes hospitalizados com COVID-19 recebendo terapia com hidroxicloroquina±azitromicina.
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2029849	28/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2029849	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Bamlanivimabe']	['Bamlanivimab']	-	-	-	-	-	Anticorpo neutralizante SARS-CoV-2 LY-CoV555 em pacientes ambulatoriais com Covid-19 	-
Vitamin D and survival in COVID-19 patients: A quasi-experimental study	https://doi.org/10.1016/j.jsbmb.2020.105771	13/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jsbmb.2020.105771	0960-0760	9600760	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY	A2	1.072	133	4.92	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Vitamina D e sobrevivência em pacientes com COVID-19: um estudo quase experimental 	-
Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness	https://doi.org/10.1016/j.ijid.2020.09.1486	06/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1486	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Corticosteroides', 'Prednisona', 'Tocilizumabe']	['Corticosteroids', 'Prednisone', 'Tocilizumab']	In patients with severe COVID-19 receiving TCZ due to systemic host-immune inflammatory response syndrome, the use of CS in addition to TCZ therapy, showed a beneficial effect in preventing in-hospital mortality.	33035673	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.09.1486	Efeito benéfico dos corticosteróides na prevenção da mortalidade em pacientes que recebem tocilizumabe para tratar doença 	grave de COVID-19 efeito na prevenção da mortalidade intra-hospitalar.
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial	https://doi.org/10.1016/j.intimp.2020.107102	13/10/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.107102	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Tocilizumabe']	['Tocilizumab']	Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patients with severe and critical COVID-19. Tocilizumab was added to the standard care of therapy at a dose of 324 mg (<100 kg bodyweight) or 486 mg (≥100 kg bodyweight). The study endpoints were all-cause mortality rate, changes in oxygen-support level, oxygen saturation, body temperature, respiratory rate, and laboratory variables during the study, and drug safety. Of 126 patients enrolled, 86 had severe and 40 had critical disease. Most patients were male (63.49%) and aged below 65 (78.57%). By day 14 of the study, 4.65% (4/86) of severe patients and 50.00% (20/40) of critical patients died. By the end, 6.98% (6/86) of severe patients and 60.00% (24/40) of critical patients died.Outcomes concerning three additional endpoints (oral temperature, oxygen saturation, and respiratory rate)were significantly improved as early as three days after tocilizumab administration in both groups of subjects, more considerably in severe patients. Significant improvement in the required level of oxygenation was reported in severe patients seven days after tocilizumab administration. No tocilizumab-related serious adverse event occurred in this study. Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 patients, particularly if used in the early stages of respiratory failure.	33075713	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.107102	Tocilizumabe subcutâneo em adultos com COVID-19 grave e crítico: um estudo multicêntrico não controlado prospectivo aberto 	Potenciais abordagens terapêuticas na doença de coronavírus 2019 (COVID-19) incluem agentes antivirais e imunomoduladores; no entanto, nenhum medicamento imunomodulador foi aprovado. Este estudo multicêntrico, prospectivo, aberto e não controlado teve como objetivo avaliar o uso de tocilizumabe subcutâneo em pacientes adultos com COVID-19 grave e crítico. O tocilizumabe foi adicionado ao tratamento padrão na dose de 324 mg (<100 kg de peso corporal) ou 486 mg (≥100 kg de peso corporal). Os desfechos do estudo foram taxa de mortalidade por todas as causas, alterações no nível de suporte de oxigênio, saturação de oxigênio, temperatura corporal, frequência respiratória e variáveis laboratoriais durante o estudo e segurança do medicamento. Dos 126 pacientes inscritos, 86 tinham doença grave e 40 tinham doença crítica. A maioria dos pacientes era do sexo masculino (63,49%) e com idade inferior a 65 anos (78,57%). No dia 14 do estudo, 4,65% (4/86) dos pacientes graves e 50,00% (20/40) dos pacientes críticos morreram. No final, 6,98% (6/86) dos pacientes graves e 60,00% (24/40) dos pacientes críticos morreram. dias após a administração de tocilizumabe em ambos os grupos de indivíduos, mais consideravelmente em pacientes graves. Melhora significativa no nível necessário de oxigenação foi relatada em pacientes graves sete dias após a administração de tocilizumabe. Nenhum evento adverso grave relacionado ao tocilizumabe ocorreu neste estudo. O tocilizumabe subcutâneo pode melhorar alguns parâmetros clínicos e reduzir o risco de morte em pacientes com COVID-19, principalmente se usado nos estágios iniciais da insuficiência respiratória.
Efficacy and safety of tocilizumab in COVID-19 patients	https://doi.org/10.18632/aging.103988	08/10/2020	Artigo completo publicado em periódico científico	10.18632/aging.103988	1945-4589	19454589	AGING (ALBANY)	A1	1.212	103	5.36	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Eficácia e segurança do tocilizumabe em pacientes com COVID-19 	-
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2028836	21/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2028836	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Eficácia do Tocilizumab em Pacientes Hospitalizados com Covid-19 	-
Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies	https://doi.org/10.1007/s00228-020-03017-5	13/10/2020	Artigo completo publicado em periódico científico	10.1007/s00228-020-03017-5	0031-6970	316970	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.732	114	2.61	-	['Tocilizumabe']	['Tocilizumab']	Tocilizumab may have potential effectiveness to treat COVID-19 according to the results of this study. However, more large-scale studies are needed for more accurate conclusions.	33051695	European journal of clinical pharmacology	1432-1041	10.1007/s00228-020-03017-5	Tocilizumab para o tratamento de COVID-19: uma revisão sistêmica e meta-análise de estudos retrospectivos O 	tocilizumab pode ter eficácia potencial no tratamento de COVID-19 de acordo com os resultados deste estudo. No entanto, mais estudos em larga escala são necessários para conclusões mais precisas.
Association of Anticoagulation Dose and Survival in Hospitalized COVID-19 Patients: A Retrospective Propensity Score Weighted Analysis	https://doi.org/10.1111/ejh.13533	11/10/2020	Artigo completo publicado em periódico científico	10.1111/ejh.13533	0902-4441	9024441	EUROPEAN JOURNAL OF HAEMATOLOGY	A3	1.057	88	3.2	-	['Argatrobana', 'Enoxaparina', 'Fondaparinux', 'Heparina']	['Argatroban', 'Enoxaparin', 'Fondaparinux', 'Heparin']	Higher doses of AC were associated with lower mortality in hospitalized COVID-19 patients. Prospective evaluation of efficacy and risk of AC in COVID-19 is warranted.	33043484	European journal of haematology	1600-0609	10.1111/ejh.13533	Associação de Dose de Anticoagulação e Sobrevivência em Pacientes Hospitalizados com COVID-19: Uma Análise Ponderada do Escore de Propensão Retrospectiva 	Doses mais altas de AC foram associadas a menor mortalidade em pacientes hospitalizados com COVID-19. A avaliação prospectiva da eficácia e risco de CA no COVID-19 é garantida.
Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients	https://doi.org/10.1016/j.ijid.2020.10.031	10/10/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.10.031	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Hidroxicloroquina']	['Hydroxychloroquine']	Our results show that hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.	33075525	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.10.031	Resultado de segurança da hidroxicloroquina dentro do protocolo terapêutico aprovado para pacientes ambulatoriais 	com COVID-19 efeitos colaterais mínimos.
QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study	https://doi.org/10.1111/ijcp.13767	15/10/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13767	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Prolongamento do intervalo QTc entre pacientes com COVID-19 tratados com sulfato de hidroxicloroquina: um estudo observacional 	-
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics	https://doi.org/10.1038/s41467-020-19056-6	20/10/2020	Artigo completo publicado em periódico científico	10.1038/s41467-020-19056-6	2041-1723	20411723	NATURE COMMUNICATIONS	A1	4.846	410	15.82	 Abstract Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2.	['Hidroxicloroquina']	['Hydroxychloroquine']	Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study inclusion if they had moderately severe COVID-19 at admission. Treatment with hydroxychloroquine did not result in a significantly greater rate of decline in SARS-CoV-2 oropharyngeal viral load compared to standard care alone during the first five days. Our results suggest no important antiviral effect of hydroxychloroquine in humans infected with SARS-CoV-2.	33082342	Nature communications	2041-1723	10.1038/s41467-020-19056-6	Um estudo controlado randomizado pragmático relata a falta de eficácia da hidroxicloroquina na cinética viral da doença de coronavírus 	2019 além do tratamento padrão ou apenas do tratamento padrão (ClinicalTrials.gov Identifier, NCT04316377). Todos os pacientes positivos para coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) com 18 anos de idade ou mais foram elegíveis para inclusão no estudo se tivessem COVID-19 moderadamente grave na admissão. O tratamento com hidroxicloroquina não resultou em uma taxa significativamente maior de declínio na carga viral orofaríngea do SARS-CoV-2 em comparação com o tratamento padrão isolado durante os primeiros cinco dias. Nossos resultados sugerem nenhum efeito antiviral importante da hidroxicloroquina em humanos infectados com SARS-CoV-2.
Statin use is associated with lower disease severity in COVID‑19 infection	https://doi.org/10.1038/s41598-020-74492-0	15/10/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-74492-0	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract We aim to study the association of hyperlipidemia and statin use with COVID-19 severity. We analysed a retrospective cohort of 717 patients admitted to a tertiary centre in Singapore for COVID-19 infection. Clinical outcomes of interest were oxygen saturation ≤ 94% requiring supplemental oxygen, intensive-care unit (ICU) admission, invasive mechanical-ventilation and death. Patients on long term dyslipidaemia medications (statins, fibrates or ezetimibe) were considered to have dyslipidaemia. Logistic regression models were used to study the association between dyslipidaemia and clinical outcomes adjusted for age, gender and ethnicity. Statin treatment effect was determined, in a nested case–control design, through logistic treatment models with 1:3 propensity matching for age, gender and ethnicity. All statistical tests were two-sided, and statistical significance was taken as  p &lt; 0.05. One hundred fifty-six (21.8%) patients had dyslipidaemia and 97% of these were on statins. Logistic treatment models showed a lower chance of ICU admission for statin users when compared to non-statin users (ATET: Coeff (risk difference): − 0.12 (− 0.23, − 0.01);  p = 0.028). There were no other significant differences in other outcomes. Statin use was independently associated with lower ICU admission. This supports current practice to continue prescription of statins in COVID-19 patients.	['Estatina', 'Ezetimiba', 'Fibratos']	['Statin', 'Ezetimibe', 'Fibrates']	-	-	-	-	-	O uso de estatinas está associado a menor gravidade da doença na infecção por COVID-19 	-
High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study	https://doi.org/10.1007/s10096-020-04078-1	20/10/2020	Artigo completo publicado em periódico científico	10.1007/s10096-020-04078-1	0934-9723	9349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Hidrocortisona', 'Prednisolona']	['Hydrocortisone', 'Prednisolone']	-	-	-	-	-	Doses altas versus padrão de corticosteroides em COVID-19 grave: um estudo de coorte retrospectivo 	-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	https://doi.org/10.1016/S1473-3099(20)30831-8	15/10/2020	Artigo completo publicado em periódico científico	10.1016/S1473-3099(20)30831-8	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['Vacina BBIBP-CorV']	['BBIBP-CorV vaccine']	National Program on Key Research Project of China, National Mega projects of China for Major Infectious Diseases, National Mega Projects of China for New Drug Creation, and Beijing Science and Technology Plan.	33069281	The Lancet. Infectious diseases	1474-4457	10.1016/S1473-3099(20)30831-8	Segurança e imunogenicidade de uma vacina inativada contra SARS-CoV-2, BBIBP-CorV: um estudo de fase 1/2 randomizado, duplo-cego, controlado por placebo, 	programa nacional no projeto de pesquisa chave da China, mega projetos nacionais da China para infecções graves Doenças, Mega Projetos Nacionais da China para Criação de Novos Medicamentos e Plano de Ciência e Tecnologia de Pequim.
Cohort study to evaluate effect of vitamin D, magnesium, and vitamin B12 in combination on severe outcome progression in older patients with coronavirus (COVID-19)	https://doi.org/10.1016/j.nut.2020.111017	08/09/2020	Artigo completo publicado em periódico científico	10.1016/j.nut.2020.111017	0899-9007	8999007	NUTRITION	A1	0.892	150	4.65	-	['Magnésio', 'Vitamina B12', 'Vitamina D (25-hidroxivitamina D)']	['Magnesium', 'Vitamin B12', 'Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Estudo de coorte para avaliar o efeito da vitamina D, magnésio e vitamina B12 em combinação na progressão grave do resultado em pacientes idosos com coronavírus (COVID-19) 	-
Preemptive interleukin‐6 blockade in patients with COVID‐19	https://doi.org/10.1038/s41598-020-74001-3	08/10/2020	Artigo completo publicado em periódico científico	10.1038/s41598-020-74001-3	2045-2322	20452322	SCIENTIFIC REPORTS	A2	1.005	242	4.81	 Abstract Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identified outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score &lt; 3 fulfilling pre-defined criteria were treated with tocilizumab. Serial plasma biomarkers and nasopharyngeal swabs were collected. Of 193 patients admitted with COVID-19, 64 met the inclusion criteria. After tocilizumab, 49 (76.6%) had an early favorable response. Adjusted predictors of response were gender, SOFA score, neutrophil/lymphocyte ratio, Charlson comorbidity index and systolic blood pressure. At week-4, 56.1% of responders and 30% of non-responders had cleared the SARS-CoV-2 from nasopharynx. Temporal profiles of interleukin-6, C-reactive protein, neutrophil/lymphocyte ratio, NT-ProBNP, D-dimer, and cardiac-troponin-I differed according to tocilizumab response and discriminated final in-hospital outcome. No deaths or disease recurrences were observed. Preemptive therapy with tocilizumab was safe and associated with favorable outcomes in most patients. Biological and clinical markers predicted outcomes.	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Bloqueio preventivo da interleucina-6 em pacientes com COVID-19 	-
Remdesivir for the Treatment of Covid-19 — Final Report	https://www.nejm.org/doi/full/10.1056/NEJMoa2007764	08/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007764	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	-	-	-	-	-	Remdesivir para o Tratamento da Covid-19 — Relatório Final 	-
Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)	https://doi.org/10.1016/j.chest.2020.10.009	02/10/2020	Artigo completo publicado em periódico científico	10.1016/j.chest.2020.10.009	0012-3692	123692	CHEST (AMERICAN COLLEGE OF CHEST PHYSICIANS)	A1	2.264	302	4.41	-	['Ivermectina']	['Ivermectin']	-	-	-	-	-	Uso de ivermectina está associado a menor mortalidade em pacientes hospitalizados com COVID-19 (estudo ICON) 	-
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia	https://doi.org/10.1016/j.jmii.2020.09.003	05/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jmii.2020.09.003	1684-1182	16841182	JOURNAL OF MICROBIOLOGY, IMMUNOLOGY AND INFECTION	A4	1.748	63	7.83	-	['Azitromicina', 'Ciclesonida', 'Hidroxicloroquina']	['Azithromycin', 'Ciclesonide', 'Hydroxychloroquine']	No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.	33054978	Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi	1995-9133	10.1016/j.jmii.2020.09.003	Terapia tripla com hidroxicloroquina, azitromicina e ciclesonida para pneumonia por COVID-19 	Nenhuma terapia específica está disponível para COVID-19. Relatamos a eficácia e os efeitos adversos da terapia tripla com hidroxicloroquina, azitromicina e ciclesonida em pacientes com pneumonia por COVID-19. A condição clínica dos pacientes melhorou em 5 dias em resposta à terapia.
Hydroxychloroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality	https://doi.org/10.1002/phar.2467	12/10/2020	Artigo completo publicado em periódico científico	10.1002/phar.2467	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Hidroxicloroquina em pacientes hospitalizados com COVID-19: experiência do mundo real avaliando mortalidade 	-
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2022926	08/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2022926	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Efeito da Hidroxicloroquina em Pacientes Hospitalizados com Covid-19 	-
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men	https://doi.org/10.1111/jdv.16953	25/09/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16953	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Bicalutamida', 'Bicalutamida', 'Bicalutamida', 'Bicalutamida', 'Dutasterida', 'Dutasterida', 'Dutasterida', 'Dutasterida', 'Espironolactona', 'Espironolactona', 'Espironolactona', 'Espironolactona', 'Finasterida', 'Finasterida', 'Finasterida', 'Finasterida']	['Bicalutamide', 'Bicalutamide', 'Bicalutamide', 'Bicalutamide', 'Dutasteride', 'Dutasteride', 'Dutasteride', 'Dutasteride', 'Spironolactone', 'Spironolactone', 'Spironolactone', 'Spironolactone', ' Finasteride', 'Finasteride', 'Finasteride', 'Finasteride']	Comparison of hospitalization and mortality were not statistically significant. It seems that a respect to similar effect on mortality and hospitalization. ATV regimen is superior to Kaletra especially for better GI tolerance and less daily pills.	32977363	Journal of the European Academy of Dermatology and Venereology : JEADV	1468-3083	10.1111/jdv.16953	Antiandrógenos podem proteger contra desfechos graves de COVID-19: resultados de um estudo de coorte prospectivo de 77 homens hospitalizados 	Comparação de hospitalização e mortalidade não foram estatisticamente significativas. Parece que um efeito semelhante sobre a mortalidade e hospitalização. O regime ATV é superior ao Kaletra, especialmente para melhor tolerância GI e menos pílulas diárias.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates	https://www.nejm.org/doi/full/10.1056/NEJMoa2027906	14/10/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2027906	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162']	['BNT162 vaccine', 'BNT162 vaccine', 'BNT162 vaccine']	The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).	33053279	The New England journal of medicine	1533-4406	10.1056/NEJMoa2027906	Segurança e imunogenicidade de duas vacinas candidatas à Covid-19 baseadas em 	RNA A Alemanha e os Estados Unidos apoiam a seleção do BNT162b2 para o avanço para uma avaliação de segurança e eficácia da fase 2-3 crucial. (Financiado por BioNTech e Pfizer; número ClinicalTrials.gov, NCT04368728.).
Tocilizumab Therapy of COVID-19: A Comparison of Subcutaneous and Intravenous Therapies	https://doi.org/10.1016/j.ijid.2020.09.1447	22/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1447	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']	At the doses used in this study, IV tocilizumab is preferred over SC therapy to treat cytokine storm syndrome due to COVID-19.	33002613	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.09.1447	Terapia com tocilizumabe para COVID-19: uma comparação de terapias subcutâneas e intravenosas 	Nas doses usadas neste estudo, o tocilizumabe IV é preferível à terapia SC para tratar a síndrome da tempestade de citocinas devido ao COVID-19.
Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation	https://doi.org/10.1186/s13054-020-03306-6	29/09/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03306-6	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract  Background The severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is extremely variable, ranging from asymptomatic patients to those who develop severe acute respiratory distress syndrome (ARDS). As for now, there are still no really effective therapies for coronavirus disease 2019 (COVID-19). Some evidences suggest that tocilizumab (TCZ) may avoid the progression of severe COVID-19. The aim of this retrospective case-control study was to analyze the efficacy and safety of TCZ in patients with COVID-19 ARDS undergoing noninvasive mechanical ventilation (NIV).  Methods Seventy-nine consecutive patients with severe COVID-19 pneumonia and worsening acute respiratory failure (ARF) were admitted to the Pulmonology Unit of Azienda USL of Reggio Emilia-IRCCS. All patients were inflamed (elevated CRP and IL-6 levels) and received NIV at admission according to the presence of a pO 2/FiO 2 ratio ≤ 200 mmHg. The possibility of being treated with TCZ depended on the drug availability. The primary outcome was the in-hospital mortality rate. A secondary composite outcome of worsening was represented by the patients who died in the pulmonology unit or were intubated.  Results Out of 79 patients, 41 were treated with TCZ. Twenty-eight patients received intravenous (IV) TCZ and 13 patients received subcutaneous (SC) TCZ. In-hospital overall mortality rate was 38% (30/79 patients). The probabilities of dying and being intubated during the follow-up using Kaplan-Meier method were significantly lower in total patients treated with TCZ compared to those of patients not treated with TCZ (log-rank  p value = 0.006 and 0.036, respectively). However, using Cox multivariate analyses adjusted for age and Charlson comorbidity index only the association with the reduced risk of being intubated or dying maintained the significance (HR 0.44, 95%CI 0.22–0.89,  p = 0.022). Two patients treated with TCZ developed cavitating lung lesions during the follow-up.  Conclusions This study shows that TCZ treatment may be effective in COVID-19 patients with severe respiratory impairment receiving NIV. More data on safety are required. Randomized controlled trials are needed to confirm these results.	['Tocilizumabe']	['Tocilizumab']	This study shows that TCZ treatment may be effective in COVID-19 patients with severe respiratory impairment receiving NIV. More data on safety are required. Randomized controlled trials are needed to confirm these results.	32993751	Critical care (London, England)	1466-609X	10.1186/s13054-020-03306-6	Eficácia do tocilizumabe em pacientes com SDRA COVID-19 submetidos à ventilação não invasiva 	Este estudo mostra que o tratamento com TCZ pode ser eficaz em pacientes com COVID-19 com insuficiência respiratória grave recebendo VNI. São necessários mais dados sobre segurança. Ensaios controlados randomizados são necessários para confirmar esses resultados.
IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: na observational study	https://doi.org/10.1016/j.jaci.2020.09.018	17/09/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.09.018	0091-6749	916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Níveis séricos de IL-6 predizem gravidade e resposta ao Tocilizumab no COVID-19: um estudo observacional 	-
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size	https://doi.org/10.1016/j.biopha.2020.110825	30/09/2020	Artigo completo publicado em periódico científico	10.1016/j.biopha.2020.110825	0753-3322	7533322	BIOMEDICINE & PHARMACOTHERAPY	A2	1.194	109	7.17	-	['Favipiravir', 'Tocilizumabe']	['Favipiravir', 'Tocilizumab']	-	-	-	-	-	Tocilizumab combinado com favipiravir no tratamento de COVID-19: um estudo multicêntrico em uma pequena amostra 	-
Anticoagulation outcomes in hospitalized Covid‐19 patients: A systematic review and meta‐analysis of case‐control and cohort studies	https://doi.org/10.1002/rmv.2180	06/10/2020	Artigo completo publicado em periódico científico	10.1002/rmv.2180	1052-9276	10529276	REVIEWS IN MEDICAL VIROLOGY (PRINT)	A1	2.371	96	9.42	-	['Anticoagulantes']	['Anticoagulants']	Findings support the association of AC with mortality in Covid-19 patients. The results, synthesized from mostly low-quality studies, show that prophylactic and therapeutic AC might reduce mortality in Covid-19 patients. Findings suggest that therapeutic doses might be associated with better survival compared to prophylactic doses.	33022834	Reviews in medical virology	1099-1654	10.1002/rmv.2180	Resultados da anticoagulação em pacientes hospitalizados com Covid-19: uma revisão sistemática e meta-análise de estudos de caso-controle e coorte 	. Os resultados, sintetizados principalmente a partir de estudos de baixa qualidade, mostram que o AC profilático e terapêutico pode reduzir a mortalidade em pacientes com Covid-19. Os resultados sugerem que as doses terapêuticas podem estar associadas a uma melhor sobrevida em comparação com as doses profiláticas.
Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review and meta-analysis	https://doi.org/10.1016/j.ijid.2020.09.1443	28/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1443	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Plasma convalescente']	['Convalescent Plasma']	Based on the outcomes of RCTs, CBPs may not decrease all-cause mortality. Furthermore, compared with later initiation of CBP therapy, earlier initiation of this therapy may decrease the rate of mortality.	33002611	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.09.1443	Efeito de produtos sanguíneos convalescentes para pacientes com infecções respiratórias agudas graves de etiologia viral: uma revisão sistemática e meta-análise 	Com base nos resultados de RCTs, CBPs podem não diminuir a mortalidade por todas as causas. Além disso, em comparação com o início tardio da terapia com CBP, o início precoce dessa terapia pode diminuir a taxa de mortalidade.
Is oseltamivir suitable for fighting against COVID-19: In silico assessment,in vitro and retrospective study	https://doi.org/10.1016/j.bioorg.2020.104257	02/09/2020	Artigo completo publicado em periódico científico	10.1016/j.bioorg.2020.104257	0045-2068	452068	BIOORGANIC CHEMISTRY (PRINT)	A2	0.728	66	5.22	-	['Oseltamivir']	['Oseltamivir']	We consider that oseltamivir isn't suitable for the treatment of COVID-19. During the outbreak of novel coronavirus, when oseltamivir is not effective for the patients after they take it, health workers should be highly vigilant about the possibility of COVID-19.	32927129	Bioorganic chemistry	1090-2120	10.1016/j.bioorg.2020.104257	O oseltamivir é adequado para combater o COVID-19: Avaliação in silico, estudo in vitro e retrospectivo 	Consideramos que o oseltamivir não é adequado para o tratamento do COVID-19. Durante o surto do novo coronavírus, quando o oseltamivir não é eficaz para os pacientes depois de tomá-lo, os profissionais de saúde devem estar altamente vigilantes sobre a possibilidade de COVID-19.
Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study	https://doi.org/10.1186/s12879-020-05425-5	02/10/2020	Artigo completo publicado em periódico científico	10.1186/s12879-020-05425-5	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract  Background The global pandemic of coronavirus disease 2019 (COVID-19) infection is ongoing and associated with high mortality. The aim of this study was to investigate the efficacy and safety of subcutaneous injection of interferon alpha-2b (IFN alpha-2b) combined with lopinavir/ritonavir (LPV/r) in the treatment of COVID-19 infection, compared with that of using LPV/r alone.  Methods Patients diagnosed with laboratory-confirmed COVID-19 infection in Wuhan Red Cross hospital during the period from January 23, 2020 to March 19, 2020 were included. The length of stay, the time to viral clearance and adverse reactions during hospitalization were compared between patients using oral LPV/r and combined therapy of LPV/r and subcutaneous injection of IFN alpha-2b.  Results A total of 22 patients were treated with LPV/r alone and 19 with combined therapy with subcutaneous injection of IFN alpha-2b. The average length of hospitalization in the combination group was shorter than that of LPV/r group (16 ± 9.7 vs 23 ± 10.5 days;  P = 0.028). Moreover, the days of hospitalization in early intervention group decreased from 25 ± 8.5 days to 10 ± 2.9 days compared with delayed intervention group ( P = 0.001). Combined therapy with IFN alpha-2b also significantly reduced the duration of detectable virus in the upper respiratory tract. No patient in each group was transferred to intensive care unit (ICU) or died during the treatment. There was no significant difference in the adverse effect composition between two groups.  Conclusions Subcutaneous injection of IFN alpha-2b combined with LPV/r shortened the length of hospitalization and accelerated viral clearance in COVID-19 patients, which deserves further investigation in clinical practice.	['Interferon alfa', 'Lopinavir', 'Ritonavir']	['Interferon alpha', 'Lopinavir', 'Ritonavir']	Subcutaneous injection of IFN alpha-2b combined with LPV/r shortened the length of hospitalization and accelerated viral clearance in COVID-19 patients, which deserves further investigation in clinical practice.	33008327	BMC infectious diseases	1471-2334	10.1186/s12879-020-05425-5	Injeção subcutânea de IFN alfa-2b para COVID-19: um estudo observacional 	A injeção subcutânea de IFN alfa-2b combinada com LPV/r reduziu o tempo de hospitalização e acelerou a eliminação viral em pacientes com COVID-19, o que merece mais investigação na prática clínica.
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	https://doi.org/10.1016/S0140-6736(20)32013-4	05/10/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)32013-4	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	-	-	-	-	-	Lopinavir-ritonavir em pacientes internados no hospital com COVID-19 (RECOVERY): um estudo de plataforma randomizado, controlado, aberto 	-
Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension	https://doi.org/10.1111/jch.14038	02/10/2020	Artigo completo publicado em periódico científico	10.1111/jch.14038	1524-6175	15246175	THE JOURNAL OF CLINICAL HYPERTENSION (GREENWICH, CONN.)	A3	0.875	70	2.17	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Hypertension is proved to be associated with severity and mortality in coronavirus disease 2019 (COVID-19). However, little is known about the effects of pre-admission and/or in-hospital antihypertension treatments on clinical outcomes. Thus, this study aimed to investigate the association between in-hospital blood pressure (BP) control and COVID-19-related outcomes and to compare the effects of different antihypertension treatments. This study included 2864 COVID-19 patients and 1628 were hypertensive. Patients were grouped according to their BP during hospitalization and records of medication application. Patients with higher BP showed worse cardiac and renal functions and clinical outcomes. After adjustment, subjects with pre-admission usage of renin-angiotensin-aldosterone system (RAAS) inhibitors (HR = 0.35, 95%CI 0.14-0.86, P = .022) had a lower risk of adverse clinical outcomes, including death, acute respiratory distress syndrome, respiratory failure, septic shock, mechanical ventilation, and intensive care unit admission. Particularly, hypertension patients receiving RAAS inhibitor treatment either before (HR = 0.35, 95%CI 0.13-0.97, P = .043) or after (HR = 0.18, 95%CI 0.04-0.86, P = .031) admission showed a significantly lower risk of adverse clinical outcomes than those receiving application of other antihypertensive medicines. Furthermore, consecutive application of RAAS inhibitors in COVID-19 patients with hypertension showed better clinical outcomes (HR = 0.10, 95%CI 0.01-0.83, P = .033) than non-RAAS inhibitors users. We revealed that COVID-19 patients with poor BP control during hospitalization had worse clinical outcomes. Compared with other antihypertension medicines, RAAS inhibitors were beneficial for improving clinical outcomes in COVID-19 patients with hypertension. Our findings provide direct evidence to support the administration of RAAS inhibitors to COVID-19 patients with hypertension before and after admission.	33006442	Journal of clinical hypertension (Greenwich, Conn.)	1751-7176	10.1111/jch.14038	Influência do controle da pressão arterial e aplicação de inibidores do sistema renina-angiotensina-aldosterona nos desfechos em pacientes com COVID-19 com hipertensão A 	hipertensão está comprovadamente associada à gravidade e mortalidade na doença por coronavírus 2019 (COVID-19). No entanto, pouco se sabe sobre os efeitos dos tratamentos anti-hipertensivos pré-admissão e/ou intra-hospitalares nos desfechos clínicos. Assim, este estudo teve como objetivo investigar a associação entre o controle da pressão arterial (PA) intra-hospitalar e os desfechos relacionados à COVID-19 e comparar os efeitos de diferentes tratamentos anti-hipertensivos. Este estudo incluiu 2.864 pacientes com COVID-19 e 1.628 eram hipertensos. Os pacientes foram agrupados de acordo com a PA durante a internação e registros de aplicação de medicamentos. Pacientes com PA mais alta apresentaram pior função cardíaca e renal e desfechos clínicos. Após o ajuste, os indivíduos com uso pré-admissão de inibidores do sistema renina-angiotensina-aldosterona (RAAS) (HR = 0,35, IC 95% 0,14-0,86, P = 0,022) apresentaram menor risco de desfechos clínicos adversos, incluindo morte, síndrome do desconforto respiratório, insuficiência respiratória, choque séptico, ventilação mecânica e internação em unidade de terapia intensiva. Particularmente, pacientes com hipertensão que receberam tratamento com inibidor de RAAS antes (HR = 0,35, IC 95% 0,13-0,97, P = 0,043) ou após (HR = 0,18, IC 95% 0,04-0,86, P = 0,031) menor risco de resultados clínicos adversos do que aqueles que recebem aplicação de outros medicamentos anti-hipertensivos. Além disso, a aplicação consecutiva de inibidores do RAAS em pacientes com COVID-19 com hipertensão mostrou melhores resultados clínicos (HR = 0,10, IC 95% 0,01-0,83, P = 0,033) do que os usuários não inibidores do RAAS. Revelamos que pacientes com COVID-19 com controle inadequado da pressão arterial durante a hospitalização tiveram piores resultados clínicos. Em comparação com outros medicamentos anti-hipertensivos, os inibidores do RAAS foram benéficos para melhorar os resultados clínicos em pacientes com COVID-19 com hipertensão. Nossos achados fornecem evidências diretas para apoiar a administração de inibidores do SRAA a pacientes com COVID-19 com hipertensão antes e após a admissão.
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Ii Receptor Blockers and Prognosis of Hypertensive Patients Hospitalized With Covid-19	https://onlinelibrary.wiley.com/doi/10.1111/imj.15078	06/10/2020	Artigo completo publicado em periódico científico	10.1111/imj.15078	1444-0903	14440903	INTERNAL MEDICINE JOURNAL (PRINT)	A4	0.590	74	1.53	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Inibidores da Enzima Conversora da Angiotensina ou Bloqueadores do Receptor da Angiotensina II e Prognóstico de Pacientes Hipertensos Hospitalizados com Covid-19 	-
RAAS inhibitors are not associated with mortality in COVID-19 patients: findings from an observational multicenter study in Italy and a meta-analysis of 19 studies	https://doi.org/10.1016/j.vph.2020.106805	28/09/2020	Artigo completo publicado em periódico científico	10.1016/j.vph.2020.106805	1537-1891	15371891	VASCULAR PHARMACOLOGY	A2	1.308	100	6.03	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Os inibidores do SRAA não estão associados à mortalidade em pacientes com COVID-19: achados de um estudo multicêntrico observacional na Itália e uma meta-análise de 19 estudos 	-
Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study	https://doi.org/10.1016/j.jsps.2020.09.019	01/10/2020	Artigo completo publicado em periódico científico	10.1016/j.jsps.2020.09.019	1319-0164	13190164	SAUDI PHARMACEUTICAL JOURNAL	A2	0.613	57	4.71	-	['Hidroxicloroquina']	['Hydroxychloroquine']	HCQ had a modest effect on hospital length stay and days in ICU compared with SC. However, these results need to be interpreted with caution. Larger observational studies and RCTs that evaluate the efficacy of HCQ in COVID-19 patients in the Saudi population are urgently needed.	33020690	Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society	1319-0164	10.1016/j.jsps.2020.09.019	Comparando o impacto dos regimes à base de hidroxicloroquina e do tratamento padrão nos resultados dos pacientes com COVID-19: um estudo de coorte retrospectivo 	HCQ teve um efeito modesto na permanência hospitalar e nos dias na UTI em comparação com SC. No entanto, esses resultados precisam ser interpretados com cautela. Estudos observacionais maiores e ECRs que avaliam a eficácia do HCQ em pacientes com COVID-19 na população saudita são urgentemente necessários.
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19	https://doi.org/10.1016/j.cmi.2020.09.045	29/09/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.09.045	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides', 'Dexametasona', 'Hidrocortisona', 'Prednisolona', 'Prednisona']	['Corticosteroids', 'Dexamethasone', 'Hydrocortisone', 'Prednisolone', 'Prednisone']	-	-	-	-	-	Tratamento com doses baixas a moderadas de corticosteroides em adultos hospitalizados com COVID-19 	-
Effects of Short-Term Low-Dose Glucocorticoids for Patients with Mild COVID-19	https://doi.org/10.1155/2020/2854186	24/09/2020	Artigo completo publicado em periódico científico	10.1155/2020/2854186	2314-6133	23146133	BIOMED RESEARCH INTERNATIONAL	A3	0.647	147	3.5	  Objectives. To evaluate the role of short-term low-dose glucocorticoids in mild COVID-19 patients.  Methods. We conducted a retrospective, cross-sectional, single-center study in Kunming, China. A total of 33 mild COVID-19 cases were divided into two treatment groups (with and without glucocorticoids, methylprednisolone, were used in this setting), and the absolute value of peripheral blood lymphocyte count; CD3+, CD4+, and CD8+ T cell counts; and the time to achieve negative transformation of a nucleic acid pharyngeal swab were recorded. Peripheral blood lymphocyte and T cell counts were compared between the treatment group and 25 healthy individuals. At the point of time when there was a 50% accumulation conversion rate (positive to negative nucleic acid on pharyngeal swab), and the nucleic acid turned negative in half of the patients in two groups, the peripheral blood lymphocyte and T cell counts were compared between treatment groups.  Results. The mean cumulative time for the 50% negative conversion rate of the nucleic acid in the pharyngeal swab was <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mn>17.7</mml:mn><mml:mo>±</mml:mo><mml:mn>5.1</mml:mn></mml:math> days and <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mn>13.9</mml:mn><mml:mo>±</mml:mo><mml:mn>5.4</mml:mn></mml:math> days in the glucocorticoid group and the nonglucocorticoid group, respectively. The absolute peripheral blood lymphocyte count and the T cell subset count in the glucocorticoid group were lower than those in the nonglucocorticoid group. When the nucleic acid turned negative in half of the patients, the absolute value of peripheral blood lymphocyte count and CD4+ T cells of the glucocorticoid group and the nonglucocorticoid group was not significantly different; the CD3+ and CD8+ T cells in the glucocorticoid group were lower than those in the nonglucocorticoid group. The absolute peripheral blood lymphocyte count, CD3+ T cells, and CD4+ T cells in the glucocorticoid group were lower than those of the healthy group during the whole disease period, and CD8+ T cells returned to normal at 19-21 days of the disease period. There was no significant difference between the nonglucocorticoid group and the healthy group for absolute peripheral blood lymphocyte and CD8+ T cells; moreover, CD3+ T cells and CD4+ T cells were lower in the nonglucocorticoid group than those in the healthy group from the day of admission to the 18th day and returned to normal at the period of 19-21 days. The absolute peripheral lymphocyte count (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.048</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.727</mml:mn></mml:math>) and T cell subset count (CD3: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.042</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.655</mml:mn></mml:math>; CD4: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7"><mml:mi>P</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M8"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.599</mml:mn></mml:math>; and CD8: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M9"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.034</mml:mn></mml:math>, effect size <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M10"><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>0.550</mml:mn></mml:math>) in the nonglucocorticoid group were higher than those in the glucocorticoid group, and the difference between the groups was statistically significant.  Conclusions. This study found that the use of short-term, low-dose glucocorticoids does not negatively influence the clinical outcome, without affecting the final clearance of viral nucleic acid in mild COVID-19 patients.	['Prednisona']	['Prednisone']	This study found that the use of short-term, low-dose glucocorticoids does not negatively influence the clinical outcome, without affecting the final clearance of viral nucleic acid in mild COVID-19 patients.	33015160	BioMed research international	2314-6141	10.1155/2020/2854186	Efeitos dos glicocorticóides de baixa dose de curto prazo para pacientes com COVID-19 	leve Pacientes COVID-19.
SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels	https://doi.org/10.1371/journal.pone.0239252	17/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0239252	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	Until treatment and vaccine for coronavirus disease-2019 (COVID-19) becomes widely available, other methods of reducing infection rates should be explored. This study used a retrospective, observational analysis of deidentified tests performed at a national clinical laboratory to determine if circulating 25-hydroxyvitamin D (25(OH)D) levels are associated with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) positivity rates. Over 190,000 patients from all 50 states with SARS-CoV-2 results performed mid-March through mid-June, 2020 and matching 25(OH)D results from the preceding 12 months were included. Residential zip code data was required to match with US Census data and perform analyses of race/ethnicity proportions and latitude. A total of 191,779 patients were included (median age, 54 years [interquartile range 40.4-64.7]; 68% female. The SARS-CoV-2 positivity rate was 9.3% (95% C.I. 9.2-9.5%) and the mean seasonally adjusted 25(OH)D was 31.7 (SD 11.7). The SARS-CoV-2 positivity rate was higher in the 39,190 patients with "deficient" 25(OH)D values (<20 ng/mL) (12.5%, 95% C.I. 12.2-12.8%) than in the 27,870 patients with "adequate" values (30-34 ng/mL) (8.1%, 95% C.I. 7.8-8.4%) and the 12,321 patients with values ≥55 ng/mL (5.9%, 95% C.I. 5.5-6.4%). The association between 25(OH)D levels and SARS-CoV-2 positivity was best fitted by the weighted second-order polynomial regression, which indicated strong correlation in the total population (R2 = 0.96) and in analyses stratified by all studied demographic factors. The association between lower SARS-CoV-2 positivity rates and higher circulating 25(OH)D levels remained significant in a multivariable logistic model adjusting for all included demographic factors (adjusted odds ratio 0.984 per ng/mL increment, 95% C.I. 0.983-0.986; p<0.001). SARS-CoV-2 positivity is strongly and inversely associated with circulating 25(OH)D levels, a relationship that persists across latitudes, races/ethnicities, both sexes, and age ranges. Our findings provide impetus to explore the role of vitamin D supplementation in reducing the risk for SARS-CoV-2 infection and COVID-19 disease.	32941512	PloS one	1932-6203	10.1371/journal.pone.0239252	Taxas de positividade do SARS-CoV-2 associadas aos níveis circulantes de 25-hidroxivitamina D 	Até que o tratamento e a vacina para a doença de coronavírus-2019 (COVID-19) se tornem amplamente disponíveis, outros métodos para reduzir as taxas de infecção devem ser explorados. Este estudo usou uma análise retrospectiva e observacional de testes desidentificados realizados em um laboratório clínico nacional para determinar se os níveis circulantes de 25-hidroxivitamina D (25(OH)D) estão associados à positividade do coronavírus 2 (SARS-CoV-2) para doença respiratória aguda grave cotações. Mais de 190.000 pacientes de todos os 50 estados com resultados de SARS-CoV-2 realizados de meados de março a meados de junho de 2020 e resultados de 25(OH)D correspondentes dos 12 meses anteriores foram incluídos. Os dados do código postal residencial eram necessários para corresponder aos dados do Censo dos EUA e realizar análises de proporções de raça/etnia e latitude. Um total de 191.779 pacientes foram incluídos (idade mediana, 54 anos [intervalo interquartil 40,4-64,7]; 68% do sexo feminino. A taxa de positividade para SARS-CoV-2 foi de 9,3% (IC 95% 9,2-9,5%) e a média ajustada sazonalmente 25(OH)D foi de 31,7 (SD 11,7). A taxa de positividade para SARS-CoV-2 foi maior nos 39.190 pacientes com valores de 25(OH)D "deficientes" (<20 ng/mL) (12,5%, 95% CI 12,2-12,8%) do que nos 27.870 pacientes com valores "adequados" (30-34 ng/mL) (8,1%, IC 95% 7,8-8,4%) e os 12.321 pacientes com valores ≥55 ng/mL (5,9%, 95% CI 5,5-6,4%). A associação entre os níveis de 25(OH)D e a positividade para SARS-CoV-2 foi melhor ajustada pela regressão polinomial de segunda ordem ponderada, que indicou forte correlação na população total (R2 = 0,96) e em análises estratificadas por todos os fatores demográficos estudados. A associação entre taxas mais baixas de positividade para SARS-CoV-2 e níveis mais altos de 25(OH)D circulante permaneceu significativa em um modelo logístico multivariável ajustado para todos os fatores demográficos incluídos (ajustado o razão dds 0,984 por incremento de ng/mL, 95% CI 0,983-0,986; p<0,001). A positividade do SARS-CoV-2 está forte e inversamente associada aos níveis circulantes de 25(OH)D, uma relação que persiste em latitudes, raças/etnias, ambos os sexos e faixas etárias. Nossas descobertas fornecem impulso para explorar o papel da suplementação de vitamina D na redução do risco de infecção por SARS-CoV-2 e doença de COVID-19.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses	https://doi.org/10.1038/s41586-020-2814-7	30/09/2020	Artigo completo publicado em periódico científico	10.1038/s41586-020-2814-7	0028-0836	280836	NATURE (LONDON)	A1	17.897	1276	19.35	-	['Vacina BNT162']	['BNT162 vaccine']	-	-	-	-	-	A vacina COVID-19 BNT162b1 provoca anticorpos humanos e respostas de células T TH1 	-
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study	https://doi.org/10.2337/dc20-1521	29/09/2020	Artigo completo publicado em periódico científico	10.2337/dc20-1521	0149-5992	1495992	DIABETES CARE	A1	6.528	380	12.25	                    OBJECTIVE                   Poor outcomes have been reported in patients with type 2 diabetes and coronavirus disease 2019 (COVID-19); thus, it is mandatory to explore novel therapeutic approaches for this population.                                                  RESEARCH DESIGN AND METHODS                   In a multicenter, case-control, retrospective, observational study, sitagliptin, an oral and highly selective dipeptidyl peptidase 4 inhibitor, was added to standard of care (e.g., insulin administration) at the time of hospitalization in patients with type 2 diabetes who were hospitalized with COVID-19. Every center also recruited at a 1:1 ratio untreated control subjects matched for age and sex. All patients had pneumonia and exhibited oxygen saturation &amp;lt;95% when breathing ambient air or when receiving oxygen support. The primary end points were discharge from the hospital/death and improvement of clinical outcomes, defined as an increase in at least two points on a seven-category modified ordinal scale. Data were collected retrospectively from patients receiving sitagliptin from 1 March through 30 April 2020.                                                  RESULTS                   Of the 338 consecutive patients with type 2 diabetes and COVID-19 admitted in Northern Italy hospitals included in this study, 169 were on sitagliptin, while 169 were on standard of care. Treatment with sitagliptin at the time of hospitalization was associated with reduced mortality (18% vs. 37% of deceased patients; hazard ratio 0.44 [95% CI 0.29–0.66]; P = 0.0001), with an improvement in clinical outcomes (60% vs. 38% of improved patients; P = 0.0001) and with a greater number of hospital discharges (120 vs. 89 of discharged patients; P = 0.0008) compared with patients receiving standard of care, respectively.                                                  CONCLUSIONS                   In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.               	['Sitagliptina']	['Sitagliptin']	In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment. The effects of sitagliptin in patients with type 2 diabetes and COVID-19 should be confirmed in an ongoing randomized, placebo-controlled trial.	32994187	Diabetes care	1935-5548	10.2337/dc20-1521	O tratamento com sitagliptina no momento da hospitalização foi associado à redução da mortalidade em pacientes com diabetes tipo 2 e COVID-19: um estudo 	multicêntrico, caso-controle, retrospectivo e observacional 2 admitidos no hospital por COVID-19, o tratamento com sitagliptina no momento da hospitalização foi associado à redução da mortalidade e melhores resultados clínicos em comparação com o tratamento padrão. Os efeitos da sitagliptina em pacientes com diabetes tipo 2 e COVID-19 devem ser confirmados em um estudo randomizado controlado por placebo em andamento.
Ivermectin treatment may improve the prognosis of patients with COVID-19	https://doi.org/10.1016/j.arbres.2020.08.007	24/09/2020	Artigo completo publicado em periódico científico	10.1016/j.arbres.2020.08.007	0300-2896	3002896	ARCHIVOS DE BRONCONEUMOLOGÍA (ED. IMPRESA)	A4	0.262	52	0.98	-	['Ivermectina']	['Ivermectin']	-	-	-	-	-	O tratamento com ivermectina pode melhorar o prognóstico de pacientes com COVID-19 	-
The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy	https://doi.org/10.1016/j.ijcard.2020.09.062	24/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.09.062	0167-5273	1675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Antagonistas do Receptor da Angiotensina II', 'Heparina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Heparin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	This study can contribute to understand the reasons behind the high mortality rate of patients in Lombardy, a region which accounts for >50% of total Italian deaths. Based on our findings, we support that daily intake of antihypertensive medications in the setting of COVID-19 should not be discontinued and that a timely LMWH administration in ED has shown to decrease in-hospital mortality.	32980434	International journal of cardiology	1874-1754	10.1016/j.ijcard.2020.09.062	O papel do tratamento anti-hipertensivo, comorbidades e introdução precoce de HBPM no cenário de COVID-19: Um estudo retrospectivo e observacional no norte da Itália 	Este estudo pode contribuir para entender as razões por trás da alta taxa de mortalidade de pacientes na Lombardia, uma região que representa mais de 50% do total de mortes italianas. Com base em nossos achados, apoiamos que a ingestão diária de medicamentos anti-hipertensivos no cenário de COVID-19 não deve ser descontinuada e que a administração oportuna de HBPM na emergência demonstrou diminuir a mortalidade hospitalar.
Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities	https://link.springer.com/article/10.1007/s11906-020-01101-w	10/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11906-020-01101-w	1522-6417	15226417	CURRENT HYPERTENSION REPORTS (PRINT)	A3	1.413	79	5.79	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	In total, 25 observational studies were included. ACE inhibitors and ARBs were not associated with increased odds for SARS-CoV-2 infection, admission to hospital, severe or critical illness, admission to ICU, and SARS-CoV-2-related death. In Asian countries, the use of ACE inhibitors/ARBs decreased the odds for severe or critical illness and death (OR = 0.37, 95% CI 0.16-0.89, I	32910274	Current hypertension reports	1534-3111	10.1007/s11906-020-01101-w	Inibidores do Sistema Renina-Angiotensina e COVID-19: Revisão Sistemática e Meta-análise. Evidência de disparidades geográficas significativas 	No total, 25 estudos observacionais foram incluídos. Os inibidores da ECA e os BRAs não foram associados a maiores chances de infecção por SARS-CoV-2, internação hospitalar, doença grave ou crítica, internação em UTI e morte relacionada a SARS-CoV-2. Nos países asiáticos, o uso de inibidores da ECA/BRA diminuiu as chances de doença grave ou crítica e morte (OR = 0,37, IC 95% 0,16-0,89, I
Ibuprofen use and clinical outcomes in COVID-19 patients	https://doi.org/10.1016/j.cmi.2020.06.003	11/06/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.06.003	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Ibuprofeno', 'Paracetamol']	['Ibuprofen', 'Paracetamol']	-	-	-	-	-	Uso de ibuprofeno e resultados clínicos em pacientes com COVID-19 	-
Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients	https://doi.org/10.1016/j.ijid.2020.09.1460	23/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.09.1460	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	-	-	-	-	-	O uso precoce de hidroxicloroquina, mas não de cloroquina, reduz a admissão na UTI em pacientes com COVID-19 	-
Assessing QT interval in COVID-19 patients: Safety of Hydroxychloroquine-azithromycin combination regimen	https://doi.org/10.1016/j.ijcard.2020.09.038	18/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.09.038	0167-5273	1675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	The HCQ/AZT combination therapy causes a significantly increase of QT interval compared to HCQ alone. Older patients under such regimen are at higher risk of experiencing QT prolongation. The use of such drugs may be considered as safe relating to arrhythmic risk in the treatment of COVID-19 patients as no arrhythmic fatalities occurred.	32956782	International journal of cardiology	1874-1754	10.1016/j.ijcard.2020.09.038	Avaliação do intervalo QT em pacientes com COVID-19: segurança do regime combinado de hidroxicloroquina-azitromicina 	A terapia combinada HCQ/AZT causa um aumento significativo do intervalo QT em comparação com o HCQ sozinho. Pacientes idosos sob tal regime correm maior risco de apresentar prolongamento do intervalo QT. O uso de tais medicamentos pode ser considerado seguro em relação ao risco arrítmico no tratamento de pacientes com COVID-19, pois não ocorreram fatalidades arrítmicas.
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients	https://doi.org/10.1007/s11739-020-02505-x	30/09/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02505-x	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	 Abstract This study investigates the association between the treatment with hydroxychloroquine and mortality in patients admitted with COVID-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with COVID-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with hydroxychloroquine, azithromycin, heparin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1449 had been discharged home from the hospitals, 240 were still admitted, and 85 had been transferred to hospitals not included in the study. Median follow-up time was 8 (IQR 5–12) days. Hydroxychloroquine had been used in 1857 patients. Hydroxychloroquine was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI): 0.44 (0.29–0.67). This association remained significant when saturation of oxygen &lt; 90% and temperature &gt; 37 °C were added to de model with OR 0.45 (0.30–0.68)  p &lt; 0.001, and also when all the other drugs, and time of admission, were included as covariates. The association between hydroxychloroquine and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized-controlled trials to assess the causal effects of hydroxychloroquine in different therapeutic regimes are required.	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	A associação do tratamento com hidroxicloroquina e mortalidade hospitalar em pacientes com COVID-19 	-
Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients	https://doi.org/10.1093/ofid/ofaa446	23/09/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa446	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   Effective therapies to combat coronavirus 2019 (COVID-19) are urgently needed. Hydroxychloroquine (HCQ) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the clinical benefit of HCQ in treating COVID-19 is unclear. Randomized controlled trials are needed to determine the safety and efficacy of HCQ for the treatment of hospitalized patients with COVID-19.                                                  Methods                   We conducted a multicenter, double-blind randomized clinical trial of HCQ among patients hospitalized with laboratory-confirmed COVID-19. Subjects were randomized in a 1:1 ratio to HCQ or placebo for 5 days and followed for 30 days. The primary efficacy outcome was a severe disease progression composite end point (death, intensive care unit admission, mechanical ventilation, extracorporeal membrane oxygenation, and/or vasopressor use) at day 14.                                                  Results                   A total of 128 patients were included in the intention-to-treat analysis. Baseline demographic, clinical, and laboratory characteristics were similar between the HCQ (n = 67) and placebo (n = 61) arms. At day 14, 11 (16.4%) subjects assigned to HCQ and 6 (9.8%) subjects assigned to placebo met the severe disease progression end point, but this did not achieve statistical significance (P = .350). There were no significant differences in COVID-19 clinical scores, number of oxygen-free days, SARS-CoV-2 clearance, or adverse events between HCQ and placebo. HCQ was associated with a slight increase in mean corrected QT interval, an increased D-dimer, and a trend toward an increased length of stay.                                                  Conclusions                   In hospitalized patients with COVID-19, our data suggest that HCQ does not prevent severe outcomes or improve clinical scores. However, our conclusions are limited by a relatively small sample size, and larger randomized controlled trials or pooled analyses are needed.               	['Hidroxicloroquina']	['Hydroxychloroquine']	In hospitalized patients with COVID-19, our data suggest that HCQ does not prevent severe outcomes or improve clinical scores. However, our conclusions are limited by a relatively small sample size, and larger randomized controlled trials or pooled analyses are needed.	33134417	Open forum infectious diseases	2328-8957	10.1093/ofid/ofaa446	Tratando Covid-19 com Hidroxicloroquina (TEACH): um estudo multicêntrico, duplo-cego e controlado randomizado em pacientes 	hospitalizados No entanto, nossas conclusões são limitadas por um tamanho de amostra relativamente pequeno, e são necessários ensaios controlados randomizados maiores ou análises agrupadas.
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis	https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01412-z	24/09/2020	Artigo completo publicado em periódico científico	https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01412-z	1743-422X	1743422X	VIROLOGY JOURNAL	A3	1.091	88	4.9	 Abstract  Background The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that enzyme. We have conducted this systematic review and meta-analysis on efficacy and safety of the drug FVP as a treatment for COVID-19.  Methods Databases like Pubmed, Pubmed Central, Scopus, Embase, Google Scholar, preprint sites, and clinicaltirals.gov were searched. The studies with the standard of care (SOC) and FVP as a treatment drug were considered as the treatment group and the SOC with other antivirals and supportive care as the control group. Quantitative synthesis was done using RevMan 5.4. Clinical improvement, negative conversion of reverse transcription-polymerase chain reaction (RT-PCR), adverse effects, and oxygen requirements were studied.  Results We identified a total of 1798 studies after searching the electronic databases. Nine in the qualitative studies and four studies in the quantitative synthesis met the criteria. There was a significant clinical improvement in the FVP group on the 14th day compared to the control group (RR 1.29, 1.08–1.54). Clinical deterioration rates were less likely in the FVP group though statistically not significant (OR 0.59, 95% CI 0.30–1.14) at the endpoint of study (7–15 days). The meta-analysis showed no significant differences between the two groups on viral clearance (day 14: RR 1.06, 95% CI 0.84–1.33), non-invasive ventilation or oxygen requirement (OR 0.76, 95% CI 0.42–1.39), and adverse effects (OR 0.69, 0.13–3.57). There are 31 randomized controlled trials (RCTs) registered in different parts of the world focusing FVP for COVID-19 treatment.  Conclusion There is a significant clinical and radiological improvement following treatment with FVP in comparison to the standard of care with no significant differences on viral clearance, oxygen support requirement and side effect profiles.	['Favipiravir']	['Favipiravir']	-	-	-	-	-	Favipiravir versus outro antiviral ou padrão de tratamento para o tratamento com COVID-19: uma revisão sistemática rápida e meta-análise 	-
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study	https://doi.org/10.1053/j.gastro.2020.05.053	21/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.053	0016-5085	165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Famotidina']	['Famotidine']	Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 continues to grow and spread throughout the world since being declared a pandemic. Despite extensive scientific research globally including repurposing of several existing drugs, there is no effective or proven therapy for this enigmatic disease which is still largely managed empirically This systematic review evaluated the role of hydroxychloroquine (HCQ) in the treatment of COVID-19 infection and was conducted using Cochrane methodology for systematic reviews of interventional studies including risk of bias assessment and grading of the quality of evidence. Only prospective clinical trials randomly assigning COVID-19 patients to HCQ plus standard of care therapy (test arm) versus placebo/standard of care (control arm) were included. Data were pooled using the random-effects model and expressed as risk ratio (RR) with 95% confidence interval (CI). A total of 10,492 patients from 19 randomised controlled trials were included. The use of HCQ was not associated with higher rates of clinical improvement (RR = 1.00, 95% CI: 0.96-1.03, p = 0.79) or reduction in all-cause mortality by Day14 (RR = 1.07, 95% CI: 0.97-1.19, p = 0.19) or Day28 (RR = 1.08, 95% CI: 0.99-1.19, p = 0.09) compared to placebo/standard of care. There was no significant difference in serious adverse events between the two arms (RR = 1.01, 95% CI: 0.85-1.19, p = 0.95). There is low-to-moderate certainty evidence that HCQ therapy is generally safe but does not reduce mortality or enhance recovery in patients with COVID-19 infection.	32446698	Gastroenterology	1528-0012	10.1053/j.gastro.2020.05.053	O uso de famotidina está associado a melhores resultados clínicos em pacientes hospitalizados com COVID-19: um estudo de coorte retrospectivo com pontuação de propensão A 	doença de coronavírus 2019 (COVID-19) causada pela nova síndrome respiratória aguda grave coronavírus 2 continua a crescer e se espalhar por todo o mundo desde que foi declarou uma pandemia. Apesar da extensa pesquisa científica global, incluindo o reaproveitamento de vários medicamentos existentes, não há terapia eficaz ou comprovada para esta doença enigmática que ainda é amplamente gerenciada empiricamente Esta revisão sistemática avaliou o papel da hidroxicloroquina (HCQ) no tratamento da infecção por COVID-19 e foi conduzido usando a metodologia Cochrane para revisões sistemáticas de estudos de intervenção, incluindo avaliação do risco de viés e classificação da qualidade da evidência. Apenas ensaios clínicos prospectivos que atribuíram aleatoriamente pacientes com COVID-19 a HCQ mais terapia padrão de tratamento (braço de teste) versus placebo/padrão de tratamento (braço de controle) foram incluídos. Os dados foram agrupados usando o modelo de efeitos aleatórios e expressos como razão de risco (RR) com intervalo de confiança de 95% (IC). Um total de 10.492 pacientes de 19 ensaios clínicos randomizados foram incluídos. O uso de HCQ não foi associado a maiores taxas de melhora clínica (RR = 1,00, IC 95%: 0,96-1,03, p = 0,79) ou redução na mortalidade por todas as causas no Dia 14 (RR = 1,07, IC 95%: 0,97- 1,19, p = 0,19) ou Dia 28 (RR = 1,08, IC 95%: 0,99-1,19, p = 0,09) em comparação com placebo/padrão de tratamento. Não houve diferença significativa em eventos adversos graves entre os dois braços (RR = 1,01, IC 95%: 0,85-1,19, p = 0,95). Há evidências de certeza baixa a moderada de que a terapia com HCQ é geralmente segura, mas não reduz a mortalidade ou melhora a recuperação em pacientes com infecção por COVID-19.
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform	https://doi.org/10.1016/S2213-2600(20)30415-X	24/09/2020	Artigo completo publicado em periódico científico	10.1016/S2213-2600(20)30415-X	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Risco de morte relacionada ao COVID-19 entre pacientes com doença pulmonar obstrutiva crônica ou asma prescritos com corticosteroides inalatórios: um estudo de coorte observacional usando a plataforma OpenSAFELY 	-
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study	https://doi.org/10.1016/j.cmi.2020.09.014	21/09/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.09.014	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides', 'Dexametasona', 'Prednisona']	['Corticosteroids', 'Dexamethasone', 'Prednisone']	-	-	-	-	-	Eficácia do tratamento com corticosteroides para pacientes hospitalizados com COVID-19 grave: um estudo multicêntrico 	-
Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study.	https://doi.org/10.1007/s40121-020-00337-y	28/09/2020	Artigo completo publicado em periódico científico	10.1007/s40121-020-00337-y	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Efeito da terapia com corticosteroides na duração da liberação de SARS-CoV-2 em pacientes com COVID-19 leve: um estudo de coorte retrospectivo. 	-
Vitamin D sufficiency, a serum 25hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection	https://doi.org/10.1371/journal.pone.0239799	25/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0239799	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Suficiência de vitamina D, uma 25hidroxivitamina D sérica de pelo menos 30 ng/mL reduziu o risco de resultados clínicos adversos em pacientes com infecção por COVID-19 	-
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults	https://www.nejm.org/doi/full/10.1056/NEJMoa2028436	29/09/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2028436	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']	-	-	-	-	-	Segurança e imunogenicidade da vacina SARS-CoV-2 mRNA-1273 em adultos mais velhos 	-
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study	https://doi.org/10.1016/j.ebiom.2020.102999	16/09/2020	Artigo completo publicado em periódico científico	10.1016/j.ebiom.2020.102999	2352-3964	23523964	EBIOMEDICINE	A1	2.663	79	7.76	-	['Tocilizumabe']	['Tocilizumab']	Instituto de salud Carlos III (Spain).	32950003	EBioMedicine	2352-3964	10.1016/j.ebiom.2020.102999	Impacto do bloqueio de interleucina-6 com tocilizumab na cinética viral SARS-CoV-2 e respostas de anticorpos em pacientes com COVID-19: Um estudo de coorte prospectivo 	Instituto de salud Carlos III (Espanha).
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial	https://doi.org/10.1183/13993003.02808-2020	17/09/2020	Artigo completo publicado em periódico científico	10.1183/13993003.02808-2020	0903-1936	9031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Introduction There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.  Methods We conducted a single-blind, randomised controlled clinical trial involving severe hospitalised patients with confirmed COVID-19 at the early pulmonary phase of the illness in Iran. The patients were randomly allocated in a 1:1 ratio by the block randomisation method to receive standard care with methylprednisolone pulse (intravenous injection, 250 mg·day −1 for 3 days) or standard care alone. The study end-point was the time of clinical improvement or death, whichever came first. Primary and safety analysis was done in the intention-to-treat (ITT) population.  Results 68 eligible patients underwent randomisation (34 patients in each group) from April 20, 2020 to June 20, 2020. In the standard care group, six patients received corticosteroids by the attending physician before the treatment and were excluded from the overall analysis. The percentage of improved patients was higher in the methylprednisolone group than in the standard care group (94.1%  versus 57.1%) and the mortality rate was significantly lower in the methylprednisolone group (5.9%  versus 42.9%; p&lt;0.001). We demonstrated that patients in the methylprednisolone group had a significantly increased survival time compared with patients in the standard care group (log-rank test: p&lt;0.001; hazard ratio 0.293, 95% CI 0.154–0.556). Two patients (5.8%) in the methylprednisolone group and two patients (7.1%) in the standard care group showed severe adverse events between initiation of treatment and the end of the study.  Conclusions Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.	['Prednisona']	['Prednisone']	Our results suggest that methylprednisolone pulse could be an efficient therapeutic agent for hospitalised severe COVID-19 patients at the pulmonary phase.	32943404	The European respiratory journal	1399-3003	10.1183/13993003.02808-2020	Pulso de metilprednisolona intravenoso como tratamento para pacientes graves hospitalizados com COVID-19: resultados de um ensaio clínico controlado randomizado 	Nossos resultados sugerem que o pulso de metilprednisolona pode ser um agente terapêutico eficiente para pacientes graves hospitalizados com COVID-19 na fase pulmonar.
Treatment of COVID-19 Patients with Prolonged Post-Symptomatic Viral Shedding with Leflunomide -- a Single-Center, Randomized, Controlled Clinical Trial	https://doi.org/10.1093/cid/ciaa1417	21/09/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1417	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   We aimed to evaluate the efficacy and safety of leflunomide, an approved dihydroorotate dehydrogenase inhibitor, to treat coronavirus disease 2019 (COVID-19) patients with prolonged postsymptomatic viral shedding.                                                  Methods                   We conducted a prospective, randomized controlled, open-label trial involving hospitalized adult COVID-19 patients with prolonged polymerase chain reaction (PCR) positivity. Patients were randomly assigned to receive either leflunomide (50 mg every 12 hours, 3 consecutive times, orally; then 20 mg once daily for 8 days), in addition to nebulized interferon alpha 2a (IFN-α-2a, 3 million IU each time, twice daily for 10 days), or nebulized IFN-α-2a alone for 10 days. The primary endpoint was the duration of viral shedding.                                                  Results                   A total of 50 COVID-19 patients with prolonged PCR positivity were randomized into 2 groups: 26 were assigned to the leflunomide plus IFN-α-2a group, and 24 were assigned to the interferon-alone group. Treatment with leflunomide was not associated with a difference from the interferon-alone group in the duration of viral shedding (hazard ratio for negative reverse-transcription PCR, 0.70 [95% confidence interval, .391–1.256]; P = .186). In addition, the patients given leflunomide did not have a substantially shorter length of hospital stay than patients treated with interferon alone, with median durations of 29.0 (interquartile range [IQR], 19.3–47.3) days and 33.0 (IQR, 29.3–42.8) days, respectively (P = .170). Two leflunomide recipients were unable to complete the full 10-day course of administration due to adverse events.                                                  Conclusions                   In COVID-19 patients with prolonged PCR positivity, no benefit in terms of the duration of viral shedding was observed with the combined treatment of leflunomide and IFN-α-2a beyond IFN-α-2a alone.               	['Leflunomida']	['Leflunomide']	-	-	-	-	-	Tratamento de pacientes com COVID-19 com disseminação viral pós-sintomática prolongada com leflunomida - um ensaio clínico controlado, randomizado e de centro único 	-
Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19	https://link.springer.com/article/10.1007/s40292-020-00409-7	19/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40292-020-00409-7	1120-9879	11209879	HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION	A4	0.749	24	2.45	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Impacto do Tratamento com Inibidores do Sistema Renina-Angiotensina nos Resultados Clínicos em Pacientes Hipertensos Hospitalizados com COVID-19 	-
Glucocorticoid therapy does not delay viral clearance in COVID-19 patients.	https://doi.org/10.1186/s13054-020-03287-6	21/09/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03287-6	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	A terapia com glicocorticóides não atrasa a depuração viral em pacientes com COVID-19. 	-
Interventions for treatment of COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING Project)	https://doi.org/10.1186/s13643-020-01371-0	09/05/2020	Artigo completo publicado em periódico científico	10.1186/s13643-020-01371-0	2046-4053	20464053	SYSTEMATIC REVIEWS	A2	0.947	68	3.24	 Abstract                  Background                 COVID-19 is a rapidly spreading virus infection that has quickly caused extensive burden to individual, families, countries, and the globe. No intervention has yet been proven effective for the treatment of COVID-19. Some randomized clinical trials assessing the effects of different drugs have been published, and more are currently underway. There is an urgent need for a living, dynamic systematic review that continuously evaluates the beneficial and harmful effects of all available interventions for COVID-19.                                Methods/design                 We will conduct a living systematic review based on searches of major medical databases (e.g., MEDLINE, EMBASE, CENTRAL) and clinical trial registries from their inception onwards to identify relevant randomized clinical trials. We will update the literature search once a week to continuously assess if new evidence is available. Two review authors will independently extract data and perform risk of bias assessment. We will include randomized clinical trials comparing any intervention for the treatment of COVID-19 (e.g., pharmacological interventions, fluid therapy, invasive or noninvasive ventilation, or similar interventions) with any comparator (e.g., an “active” comparator, standard care, placebo, no intervention, or “active placebo”) for participants in all age groups with a diagnosis of COVID-19. Primary outcomes will be all-cause mortality and serious adverse events. Secondary outcomes will be admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and non-serious adverse events. The living systematic review will include aggregate data meta-analyses, Trial Sequential Analyses, network meta-analysis, and individual patient data meta-analyses. Risk of bias will be assessed with domains, an eight-step procedure will be used to assess if the thresholds for clinical significance are crossed, and the certainty of the evidence will be assessed by Grading of Recommendations, Assessment, Development and Evaluations (GRADE).                                Discussion                 COVID-19 has become a pandemic with substantial mortality. A living systematic review evaluating the beneficial and harmful effects of pharmacological and other interventions is urgently needed. This review will continuously inform best practice in treatment and clinical research of this highly prevalent disease.                                Systematic review registration                 PROSPERO CRD42020178787              	['Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', ' Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir' ]	PROSPERO CRD42020178787.	32386514	Systematic reviews	2046-4053	10.1186/s13643-020-01371-0	Intervenções para tratamento de COVID-19: um protocolo para uma revisão sistemática viva com meta-análise de rede incluindo dados individuais de pacientes (The LIVING Project) 	PROSPERO CRD42020178787.
Palliative Care Utilization Among Patients With COVID-19 in an Underserved Population: A Single-Center Retrospective Study	https://doi.org/10.1016/j.jpainsymman.2020.05.022	23/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jpainsymman.2020.05.022	0885-3924	8853924	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT	A1	1.527	147	4.2	-	['Cuidados paliativos']	['Palliative care']	-	-	-	-	-	Utilização de cuidados paliativos entre pacientes com COVID-19 em uma população carente: um estudo retrospectivo de centro único 	-
Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a singlecenter descriptive study	https://doi.org/10.1186/s12879-020-05252-8	29/07/2020	Artigo completo publicado em periódico científico	10.1186/s12879-020-05252-8	1471-2334	14712334	BMC INFECTIOUS DISEASES (ONLINE)	A3	1.042	112	3.75	 Abstract  Background We aimed to report the epidemiological and clinical characteristics of hospitalized patients with coronavirus disease-19 (COVID-19) in Zengdu District, Hubei Province, China.  Methods Clinical data on COVID-19 inpatients in Zengdu Hospital from January 27 to March 11, 2020 were collected; this is a community hospital in an area surrounding Wuhan and supported by volunteer doctors. All hospitalized patients with COVID-19 were included in this study. The epidemiological findings, clinical features, laboratory findings, radiologic manifestations, and clinical outcomes of these patients were analyzed. The patients were followed up for clinical outcomes until March 22, 2020. Severe COVID-19 cases include severe and critical cases diagnosed according to the seventh edition of China’s COVID-19 diagnostic guidelines. Severe and critical COVID-19 cases were diagnosed according to the seventh edition of China’s COVID-19 diagnostic guidelines.  Results All hospitalized COVID-19 patients, 276 (median age: 51.0 years), were enrolled, including 262 non-severe and 14 severe patients. The proportion of patients aged over 60 years was higher in the severe group (78.6%) than in the non-severe group (18.7%,  p &lt; 0.01). Approximately a quarter of the patients (24.6%) had at least one comorbidity, such as hypertension, diabetes, or cancer, and the proportion of patients with comorbidities was higher in the severe group (85.7%) than in the non-severe group (21.4%,  p &lt; 0.01). Common symptoms included fever (82.2% [227/276]) and cough (78.0% [218/276]). 38.4% (106/276) of the patients had a fever at the time of admission. Most patients (94.9% [204/276]) were cured and discharged; 3.6% (10/276) deteriorated to a critical condition and were transferred to another hospital. The median COVID-19 treatment duration and hospital stay were 14.0 and 18.0 days, respectively.  Conclusions Most of the COVID-19 patients in Zengdu had mild disease. Older patients with underlying diseases were at a higher risk of progression to severe disease. The length of hospital-stay and antiviral treatment duration for COVID-19 were slightly longer than those in Wuhan. This work will contribute toward an understanding of COVID-19 characteristics in the areas around the core COVID-19 outbreak region and serve as a reference for decision-making for epidemic prevention and control in similar areas.	['Antivirais', 'Corticosteroides']	['Antivirals', 'Corticosteroids']	-	-	-	-	-	Características clínicas de 276 pacientes hospitalizados com doença de coronavírus 2019 no distrito de Zengdu, província de Hubei: um estudo descritivo de centro único 	-
A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients	https://doi.org/10.1016/j.jcrc.2020.08.025	02/09/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.08.025	0883-9441	8839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Solução salina heparinizada']	['Heparinized saline']	A LDHS protocol was associated with a clinically significant improvement in a-line patency duration in COVID-19 patients, without increased bleeding risk.	32920504	Journal of critical care	1557-8615	10.1016/j.jcrc.2020.08.025	Um protocolo de solução salina heparinizada de baixa dose está associado a uma melhor duração da permeabilidade da linha arterial em pacientes com COVID-19 criticamente enfermos 	Um protocolo LDHS foi associado a uma melhora clinicamente significativa na duração da permeabilidade da linha em pacientes com COVID-19, sem aumento do risco de sangramento.
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	https://doi.org/10.1038/s41591-020-1088-9	15/09/2020	Artigo completo publicado em periódico científico	10.1038/s41591-020-1088-9	1078-8956	10788956	NATURE MEDICINE (PRINT)	A1	24.161	576	34.05	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Tratamento com plasma convalescente de COVID-19 grave: um estudo de controle combinado com escore de propensão 	-
Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region	https://doi.org/10.1371/journal.pone.0238827	09/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0238827	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Dexametasona', 'Hidrocortisona', 'Prednisona']	['Dexamethasone', 'Hydrocortisone', 'Prednisone']	Among non-ICU patients hospitalized with COVID-19 pneumonia complicated by AHRF, treatment with corticosteroid was associated with a significantly lower risk of the primary composite outcome of ICU transfer, intubation, or in-hospital death, composite of intubation or death and individual components of the primary outcome.	32903258	PloS one	1932-6203	10.1371/journal.pone.0238827	Eficácia dos corticosteróides em pacientes com pneumonia por COVID-19 fora da unidade de terapia intensiva da região metropolitana de Nova York 	Entre os pacientes não internados em UTI com pneumonia por COVID-19 complicada por HARF, o tratamento com corticosteróide foi associado a um risco significativamente menor do composto primário desfecho de transferência para UTI, intubação ou óbito hospitalar, composto de intubação ou óbito e componentes individuais do desfecho primário.
The effect of antivirals on COVID-19: a systematic review	https://www.tandfonline.com/doi/abs/10.1080/14787210.2021.1823832	12/09/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2021.1823832	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Hidroxicloroquina', 'Interferon beta', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Hydroxychloroquine', 'Interferon beta', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	-	-	-	-	-	O efeito dos antivirais no COVID-19: uma revisão sistemática 	-
Biological, Molecular and Pharmacological Characteristics of Chloroquine, Hydroxychloroquine, Convalescent Plasma, and Remdesivir for COVID-19 Pandemic: A Comparative Analysis	https://doi.org/10.1016/j.jksus.2020.09.002	06/09/2020	Artigo completo publicado em periódico científico	10.1016/j.jksus.2020.09.002	1018-3647	10183647	JOURNAL OF KING SAUD UNIVERSITY - SCIENCE	A1	0.513	45	4.07	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Plasma convalescent', 'Plasma convalescent', 'Remdesivir', 'Remdesivir']	All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.	32921965	Journal of King Saud University. Science	2213-686X	10.1016/j.jksus.2020.09.002	Características biológicas, moleculares e farmacológicas da cloroquina, hidroxicloroquina, plasma convalescente e remdesivir para a pandemia de COVID-19: uma análise comparativa 	Todas as três modalidades de tratamento têm características favoráveis e desfavoráveis, mas nenhuma mostrou evidência clara de benefício para doença ambulatorial precoce ou profilaxia. Com base nos dados atuais disponíveis, a terapia com plasma convalescente parece mostrar vantagens clínicas para uso em pacientes internados. No futuro, os ensaios clínicos controlados randomizados de grandes amostras em andamento podem esclarecer ainda mais a eficácia e a segurança comparativas dessas três classes de tratamento, para determinar conclusivamente com quem tratar com qual medicamento e quando tratá-los.
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System	https://doi.org/10.3389/fimmu.2020.02072	14/08/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.02072	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Conestate alfa']	['Conestate alpha']	A dysregulated immune response with hyperinflammation is observed in patients with severe coronavirus disease 2019 (COVID-19). The aim of the present study was to assess the safety and potential benefits of human recombinant C1 esterase inhibitor (conestat alfa), a complement, contact activation and kallikrein-kinin system regulator, in severe COVID-19. Patients with evidence of progressive disease after 24 h including an oxygen saturation <93% at rest in ambient air were included at the University Hospital Basel, Switzerland in April 2020. Conestat alfa was administered by intravenous injections of 8400 IU followed by 3 additional doses of 4200 IU in 12-h intervals. Five patients (age range, 53-85 years; one woman) with severe COVID-19 pneumonia (11-39% lung involvement on computed tomography scan of the chest) were treated a median of 1 day (range 1-7 days) after admission. Treatment was well-tolerated. Immediate defervescence occurred, and inflammatory markers and oxygen supplementation decreased or stabilized in 4 patients (e.g., median C-reactive protein 203 (range 31-235) mg/L before vs. 32 (12-72) mg/L on day 5). Only one patient required mechanical ventilation. All patients recovered. C1INH concentrations were elevated before conestat alfa treatment. Levels of complement activation products declined after treatment. Viral loads in nasopharyngeal swabs declined in 4 patients. In this uncontrolled case series, targeting multiple inflammatory cascades by conestat alfa was safe and associated with clinical improvements in the majority of severe COVID-19 patients. Controlled clinical trials are needed to assess its safety and efficacy in preventing disease progression.	32922409	Frontiers in immunology	1664-3224	10.3389/fimmu.2020.02072	Tratamento do COVID-19 com Conestat Alfa, um regulador do sistema complemento, ativação de contato e calicreína-cinina 	Uma resposta imune desregulada com hiperinflamação é observada em pacientes com doença grave por coronavírus 2019 (COVID-19). O objetivo do presente estudo foi avaliar a segurança e os benefícios potenciais do inibidor de esterase C1 recombinante humano (conestat alfa), um complemento, ativação de contato e regulador do sistema calicreína-cinina, em COVID-19 grave. Pacientes com evidência de doença progressiva após 24 h, incluindo saturação de oxigênio <93% em repouso em ar ambiente, foram incluídos no Hospital Universitário Basel, Suíça, em abril de 2020. Conestat alfa foi administrado por injeções intravenosas de 8.400 UI seguidas de 3 doses adicionais de 4200 UI em intervalos de 12 horas. Cinco pacientes (faixa etária, 53-85 anos; uma mulher) com pneumonia grave por COVID-19 (11-39% de envolvimento pulmonar na tomografia computadorizada do tórax) foram tratados em mediana de 1 dia (intervalo de 1-7 dias) após admissão. O tratamento foi bem tolerado. Ocorreu defervescência imediata e marcadores inflamatórios e suplementação de oxigênio diminuíram ou estabilizaram em 4 pacientes (por exemplo, proteína C reativa mediana 203 (intervalo 31-235) mg/L antes vs. 32 (12-72) mg/L no dia 5) . Apenas um paciente necessitou de ventilação mecânica. Todos os pacientes se recuperaram. As concentrações de C1INH foram elevadas antes do tratamento com conestate alfa. Os níveis de produtos de ativação do complemento diminuíram após o tratamento. As cargas virais em swabs nasofaríngeos diminuíram em 4 pacientes. Nesta série de casos não controlados, o direcionamento de múltiplas cascatas inflamatórias pelo conestate alfa foi seguro e associado a melhorias clínicas na maioria dos pacientes graves com COVID-19. Ensaios clínicos controlados são necessários para avaliar sua segurança e eficácia na prevenção da progressão da doença.
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial	https://doi.org/10.1016/j.intimp.2020.106869	04/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106869	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Tocilizumabe']	['Tocilizumab']	Based on the current results, tocilizumab may be a promising agent for patients with severe or critical SARS-CoV-2 infection, if promptly initiated during the severe stage.	32889241	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.106869	Efeitos promissores do tocilizumabe no COVID-19: um ensaio clínico prospectivo não controlado 	Com base nos resultados atuais, o tocilizumabe pode ser um agente promissor para pacientes com infecção grave ou crítica por SARS-CoV-2, se iniciado imediatamente durante o estágio grave.
COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study	https://doi.org/10.1186/s12979-020-00194-w	14/08/2020	Artigo completo publicado em periódico científico	10.1186/s12979-020-00194-w	1742-4933	17424933	IMMUNITY & AGEING	A2	1.697	50	7.3	 Abstract  Background The SARS-CoV-2 infection has widely spread to become the greatest public health challenge to date, the COVID-19 pandemic. Different fatality rates among countries are probably due to non-standardized records being carried out by local health authorities. The Spanish case-fatality rate is 11.22%, far higher than those reported in Asia or by other European countries. A multicentre retrospective study of demographic, clinical, laboratory and immunological features of 584 Spanish COVID-19 hospitalized patients and their outcomes was performed. The use of renin-angiotensin system blockers was also analysed as a risk factor.  Results In this study, 27.4% of cases presented a mild course, 42.1% a moderate one and for 30.5% of cases, the course was severe. Ages ranged from 18 to 98 (average 63). Almost 60 % (59.8%) of patients were male. Interleukin 6 was higher as severity increased. On the other hand, CD8 lymphocyte count was significantly lower as severity grew and subpopulations CD4, CD8, CD19, and NK showed concordant lowering trends. Severity-related natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of CD4 lymphocytes was found in males. The use of angiotensin-converting enzyme inhibitors was associated with a better prognosis. The angiotensin II receptor blocker use was associated with a more severe course.  Conclusions Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and the clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for the hampering of immune system effectors. The adaptive immunity would become exhausted and a strong but ineffective and almost deleterious innate response would account for COVID-19 severity. Angiotensin-converting enzyme inhibitors used by hypertensive patients have a protective effect in regards to COVID-19 severity in our series. Conversely, patients on angiotensin II receptor blockers showed a severer disease.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older than those so far reported and the clinical course of the disease is found to be impaired by age. Immunosenescence might be therefore a suitable explanation for the hampering of immune system effectors. The adaptive immunity would become exhausted and a strong but ineffective and almost deleterious innate response would account for COVID-19 severity. Angiotensin-converting enzyme inhibitors used by hypertensive patients have a protective effect in regards to COVID-19 severity in our series. Conversely, patients on angiotensin II receptor blockers showed a severer disease.	32802142	Immunity & ageing : I & A	1742-4933	10.1186/s12979-020-00194-w	COVID-19: idade, interleucina-6, proteína C reativa e linfócitos como pistas-chave de um estudo retrospectivo multicêntrico 	Idade e comorbidades relacionadas à idade, como dislipidemia, hipertensão ou diabetes, determinaram formas graves mais frequentes da doença neste estudo do que em coortes de literatura anteriores. Nossos casos são mais antigos do que os relatados até agora e o curso clínico da doença é prejudicado pela idade. A imunossenescência pode ser, portanto, uma explicação adequada para o impedimento dos efetores do sistema imunológico. A imunidade adaptativa se esgotaria e uma resposta inata forte, mas ineficaz e quase deletéria, seria responsável pela gravidade do COVID-19. Os inibidores da enzima conversora de angiotensina usados por pacientes hipertensos têm um efeito protetor em relação à gravidade da COVID-19 em nossa série. Por outro lado, os pacientes em uso de bloqueadores dos receptores da angiotensina II apresentaram uma doença mais grave.
No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials	https://doi.org/10.1016/j.dsx.2020.08.033	01/09/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.08.033	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Hidroxicloroquina']	['Hydroxychloroquine']	Repurposed drugs like hydroxycloroquine (HCQ) and chloroquine (CQ) are being tested for potential therapeutic role in COVID-19. We aimed to evaluate efficacy and safety of HCQ and CQ in COVID-19. Using PubMed, EMBASE, medRxiv, Google Scholar, clinicaltrials.gov, electronic search was carried out to identify relevant articles till June 2020 with re-evaluation in last week of November 2020. Observational and interventional clinical studies comparing efficacy of CQ or HCQ to standard management or other drug/s for SARS-CoV-2 infection patients were included. Cochrane review manager version 5.3 was used for synthesis of meta-analysis results. For randomized controlled trials, risk of bias was assessed using Cochrane Collaboration risk of bias assessment tool, version 2.0 (ROB-2). ROBINS-I was used for quality assessment of observational studies. Overall evidence quality generated by review was graded as per GRADE Recommendation. A total of 903 studies were screened. Nineteen studies were included in synthesis of meta-analysis with total of 4,693, 1,626, and 6,491 patients in HCQ/CQ, HCQ/CQ + AZ and control groups, respectively. HCQ/CQ treatment was associated with significantly increased rates of virological cure (OR = 2.08, 95%CI = 1.36-3.17; 	34322403	Journal of family medicine and primary care	2249-4863	10.4103/jfmpc.jfmpc_2338_20	Nenhum benefício da hidroxicloroquina no COVID-19: resultados da revisão sistemática e meta-análise de ensaios controlados randomizados 	Medicamentos reaproveitados como hidroxicloroquina (HCQ) e cloroquina (CQ) estão sendo testados para potencial papel terapêutico no COVID-19. Nosso objetivo foi avaliar a eficácia e segurança do HCQ e CQ no COVID-19. Usando PubMed, EMBASE, medRxiv, Google Scholar, clinicaltrials.gov, a pesquisa eletrônica foi realizada para identificar artigos relevantes até junho de 2020 com reavaliação na última semana de novembro de 2020. Estudos clínicos observacionais e intervencionistas comparando a eficácia do CQ ou HCQ ao padrão gestão ou outros medicamentos para pacientes com infecção por SARS-CoV-2 foram incluídos. O gerenciador de revisão Cochrane versão 5.3 foi usado para a síntese dos resultados da meta-análise. Para ensaios clínicos randomizados, o risco de viés foi avaliado usando a ferramenta de avaliação de risco de viés da Colaboração Cochrane, versão 2.0 (ROB-2). ROBINS-I foi usado para avaliação da qualidade de estudos observacionais. A qualidade geral da evidência gerada pela revisão foi classificada de acordo com a Recomendação GRADE. Um total de 903 estudos foram selecionados. Dezenove estudos foram incluídos na síntese da meta-análise com total de 4.693, 1.626 e 6.491 pacientes nos grupos HCQ/CQ, HCQ/CQ + AZ e controle, respectivamente. O tratamento com HCQ/CQ foi associado a taxas significativamente aumentadas de cura virológica (OR = 2,08, IC 95% = 1,36-3,17;
Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis	https://doi.org/10.1007/s00210-020-01964-5	06/09/2020	Artigo completo publicado em periódico científico	10.1007/s00210-020-01964-5	0028-1298	281298	NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY	A4	0.566	93	2.99	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Uso de hidroxicloroquina e progressão ou prognóstico de COVID-19: uma revisão sistemática e meta-análise 	-
Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review	https://doi.org/10.1016/j.intimp.2020.106942	29/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106942	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Agentes anti-interleucinas', 'Esteroides', 'Hidroxicloroquina', 'Imunoglobulina', 'Plasma convalescente', 'Terapia celular', 'Terapia de purificação do sangue']	['Anti-Interleukin Agents', 'Steroidal', 'Hydroxychloroquine', 'Immunoglobulin', 'Convalescent Plasma', 'Cell Therapy', 'Blood Purification Therapy']	The global panic of the novel coronavirus disease 2019 (COVID-19) triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent requirement for effective therapy. COVID-19 infection, especially in severely ill patients, is likely to be associated with immune dysregulation, prompting the development of novel treatment approaches. Therefore, this systematic review was designed to assess the available data regarding the efficacy of the immunomodulatory drugs used to manage COVID-19. A systematic literature search was carried out up to May 27, 2020, in four databases (PubMed, Scopus, Web of Science, and Embase) and also Clinicaltrials.gov. Sixty-six publications and 111 clinical trials were recognized as eligible, reporting the efficacy of the immunomodulatory agents, including corticosteroids, hydroxychloroquine, passive and cytokine-targeted therapies, mesenchymal stem cells, and blood-purification therapy, in COVID-19 patients. The data were found to be heterogeneous, and the clinical trials were yet to post any findings. Medicines were found to regulate the immune system by boosting the innate responses or suppressing the inflammatory reactions. Passive and cytokine-targeted therapies and mesenchymal stem cells were mostly safe and could regulate the disease much better. These studies underscored the significance of severity profiling in COVID-19 patients, along with appropriate timing, duration, and dosage of the therapies. Therefore, this review indicates that immunomodulatory therapies are potentially effective for COVID-19 and provides comprehensive information for clinicians to fight this outbreak. However, there is no consensus on the optimal therapy for COVID-19, reflecting that the immunomodulatory therapies still warrant further investigations.	32896750	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.106942	Terapia baseada em imunomoduladores como uma estratégia de tratamento potencialmente promissora contra pacientes graves com COVID-19: uma revisão sistemática 	O pânico global da doença do novo coronavírus 2019 (COVID-19) desencadeada pela síndrome respiratória aguda grave coronavírus 2 (SARS-CoV-2) levou a uma necessidade urgente de terapia eficaz. A infecção por COVID-19, especialmente em pacientes graves, provavelmente está associada à desregulação imunológica, levando ao desenvolvimento de novas abordagens de tratamento. Portanto, esta revisão sistemática foi projetada para avaliar os dados disponíveis sobre a eficácia dos medicamentos imunomoduladores usados para gerenciar o COVID-19. Uma busca sistemática da literatura foi realizada até 27 de maio de 2020, em quatro bases de dados (PubMed, Scopus, Web of Science e Embase) e também Clinicaltrials.gov. Sessenta e seis publicações e 111 ensaios clínicos foram reconhecidos como elegíveis, relatando a eficácia dos agentes imunomoduladores, incluindo corticosteroides, hidroxicloroquina, terapias passivas e direcionadas a citocinas, células-tronco mesenquimais e terapia de purificação do sangue, em pacientes com COVID-19. Os dados foram considerados heterogêneos e os ensaios clínicos ainda não publicaram nenhum resultado. Medicamentos foram encontrados para regular o sistema imunológico, aumentando as respostas inatas ou suprimindo as reações inflamatórias. Terapias passivas e direcionadas a citocinas e células-tronco mesenquimais eram seguras e poderiam regular a doença muito melhor. Esses estudos ressaltaram a importância do perfil de gravidade em pacientes com COVID-19, juntamente com o tempo, duração e dosagem apropriados das terapias. Portanto, esta revisão indica que as terapias imunomoduladoras são potencialmente eficazes para o COVID-19 e fornece informações abrangentes para os médicos combaterem esse surto. No entanto, não há consenso sobre a terapia ideal para COVID-19, refletindo que as terapias imunomoduladoras ainda merecem mais investigações.
Systemic corticosteroids and mortality in severe and critical COVID-19 patients in Wuhan, China	https://doi.org/10.1210/clinem/dgaa627	03/09/2020	Artigo completo publicado em periódico científico	10.1210/clinem/dgaa627	0021-972X	0021972X	THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM	A1	1.746	363	5.01	 Abstract                                   Background                   Systemic corticosteroids are now recommended in many treatment guidelines, although supporting evidence is limited to 1 randomized controlled clinical trial (RECOVERY).                                                  Objective                   To identify whether corticosteroids were beneficial to COVID-19 patients.                                                  Methods                   A total of 1514 severe and 249 critical hospitalized COVID-19 patients from 2 medical centers in Wuhan, China. Multivariable Cox models, Cox model with time-varying exposure and propensity score analysis (inverse-probability-of-treatment-weighting [IPTW] and propensity score matching [PSM]) were used to estimate the association of corticosteroid use with risk of in-hospital mortality in severe and critical cases.                                                  Results                   Corticosteroids were administered in 531 (35.1%) severe and 159 (63.9%) critical patients. Compared to the non-corticosteroid group, systemic corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality in either severe cases (HR = 1.77; 95% CI, 1.08-2.89; P = 0.023), or critical cases (HR = 2.07; 95% CI, 1.08–3.98; P = 0.028). Findings were similar in time-varying Cox analysis. For patients with severe COVID-19 at admission, corticosteroid use was not associated with improved or harmful outcome in either PSM or IPTW analysis. For critical COVID-19 patients at admission, results were consistent with multivariable Cox model analysis.                                                  Conclusion                   Corticosteroid use was not associated with beneficial effect in reducing in-hospital mortality for severe or critical cases in Wuhan. Absence of the beneficial effect in our study in contrast to that observed in the RECOVERY clinical trial may be due to biases in observational data, in particular prescription by indication bias, differences in clinical characteristics of patients, choice of corticosteroid used, timing of initiation of treatment, and duration of treatment.               	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Corticosteróides sistêmicos e mortalidade em pacientes graves e críticos com COVID-19 em Wuhan, China 	-
Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective Cohort Study	https://link.springer.com/article/10.1007/s40121-020-00332-3	02/09/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00332-3	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Corticosteroides']	['Corticosteroids']	In adult patients with non-severe COVID-19 pneumonia, early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes.	32880102	Infectious diseases and therapy	2193-8229	10.1007/s40121-020-00332-3	Avaliação da eficácia de corticosteróides precoces, de baixa dose e de curto prazo em adultos hospitalizados com pneumonia não grave por COVID-19: um estudo de coorte retrospectivo 	Em pacientes adultos com pneumonia não grave por COVID-19, precoce, de baixa dose e curto a terapia com corticosteróides a termo foi associada a piores desfechos clínicos.
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial	https://doi.org/10.1016/S0140-6736(20)31862-6	04/09/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31862-6	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Azitromicina']	['Azithromycin']	-	-	-	-	-	Azitromicina adicionada ao padrão de atendimento versus padrão de atendimento isolado no tratamento de pacientes internados no hospital com COVID-19 grave no Brasil (COALITION II): um ensaio clínico randomizado 	-
Observational study of azithromycin in hospitalized patients with COVID-19	https://doi.org/10.1371/journal.pone.0238681	03/09/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0238681	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Azitromicina']	['Azithromycin']	-	-	-	-	-	Estudo observacional de azitromicina em pacientes hospitalizados com COVID-19 	-
Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study	https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1749	03/09/2020	Artigo completo publicado em periódico científico	10.1002/jcph.1749	0091-2700	912700	JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.687	121	2.9	-	['Heparina']	['Heparin']	The pathophysiology of respiratory failure associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains under investigation. One hypothesis is that progressive endothelial damage from the virus leads to microvascular thrombosis. It is uncertain if empiric therapeutic anticoagulation provides benefit over standard deep vein thrombosis (DVT) prophylaxis in critically ill patients with SARS-CoV-2. A retrospective cohort study was performed to evaluate adult patients admitted to the intensive care unit at 3 hospitals with polymerase chain reaction-confirmed SARS-CoV-2-associated respiratory failure requiring invasive mechanical ventilation. A Kaplan-Meier survival analysis was used to compare patients who were initiated on therapeutic anticoagulation prior to the time of intubation and those receiving standard DVT prophylaxis doses. The primary outcome was the difference in the 28-day mortality of patients between the 2 groups. Twenty-eight-day mortality did not differ between groups, occurring in 26.1% of patients who received therapeutic anticoagulation and 29.5% of those who received a prophylactic dose only (hazard ratio, 0.52; P = .055). There was no difference in 28-day mortality between groups in patients who were admitted with a serum D-dimer ≥ 2 µg/mL (hazard ratio, 0.67; P = .41). Empiric therapeutic anticoagulation in patients who require invasive mechanical ventilation for confirmed SARS-CoV-2 infection does not improve 28-day mortality compared with standard DVT prophylaxis, even among those with elevated D-dimer levels.	32885463	Journal of clinical pharmacology	1552-4604	10.1002/jcph.1749	Anticoagulação terapêutica empírica e mortalidade em pacientes críticos com insuficiência respiratória por SARS-CoV-2: um estudo de coorte retrospectivo 	A fisiopatologia da insuficiência respiratória associada ao coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) permanece sob investigação. Uma hipótese é que o dano endotelial progressivo do vírus leva à trombose microvascular. É incerto se a anticoagulação terapêutica empírica oferece benefício sobre a profilaxia padrão de trombose venosa profunda (TVP) em pacientes criticamente enfermos com SARS-CoV-2. Um estudo de coorte retrospectivo foi realizado para avaliar pacientes adultos admitidos na unidade de terapia intensiva em 3 hospitais com insuficiência respiratória associada a SARS-CoV-2 confirmada por reação em cadeia da polimerase que requer ventilação mecânica invasiva. Uma análise de sobrevida de Kaplan-Meier foi usada para comparar pacientes que iniciaram anticoagulação terapêutica antes do momento da intubação e aqueles que receberam doses padrão de profilaxia para TVP. O desfecho primário foi a diferença na mortalidade em 28 dias dos pacientes entre os 2 grupos. A mortalidade em 28 dias não diferiu entre os grupos, ocorrendo em 26,1% dos pacientes que receberam anticoagulação terapêutica e 29,5% daqueles que receberam apenas uma dose profilática (hazard ratio, 0,52; P = 0,055). Não houve diferença na mortalidade em 28 dias entre os grupos em pacientes que foram admitidos com um dímero D sérico ≥ 2 µg/mL (razão de risco, 0,67; P = 0,41). A anticoagulação terapêutica empírica em pacientes que necessitam de ventilação mecânica invasiva para infecção confirmada por SARS-CoV-2 não melhora a mortalidade em 28 dias em comparação com a profilaxia de TVP padrão, mesmo entre aqueles com níveis elevados de dímero D.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	https://doi.org/10.1016/S0140-6736(20)31866-3	04/09/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31866-3	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Vacina (rAd26 and rAd5)']	['Vaccine (rAd26 and rAd5)']	Ministry of Health of the Russian Federation.	32896291	Lancet (London, England)	1474-547X	10.1016/S0140-6736(20)31866-3	Segurança e imunogenicidade de uma vacina heteróloga prime-boost COVID-19 baseada em vetor rAd26 e rAd5 em duas formulações: dois estudos de fase 1/2 abertos e não randomizados do 	Ministério da Saúde da Rússia da Federação Russa.
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes	https://doi.org/10.1016/j.cmet.2020.08.013	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cmet.2020.08.013	1550-4131	15504131	CELL METABOLISM	A1	9.297	292	22.01	-	['Metformina']	['Metformin']	-	-	-	-	-	A metformina está associada à maior incidência de acidose, mas não à mortalidade, em indivíduos com COVID-19 e diabetes tipo 2 pré-existente 	-
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir	https://doi.org/10.1007/s40199-020-00369-2	28/08/2020	Artigo completo publicado em periódico científico	10.1007/s40199-020-00369-2	2008-2231	20082231	DARU JOURNAL OF PHARMACEUTICAL SCIENCES	A4	0.580	47	4.19	-	['Atazanavir', 'Hidroxicloroquina', 'Ritonavir']	['Atazanavir', 'Hydroxychloroquine', 'Ritonavir']	Our study did not support the use of hydroxychloroquine plus atazanavir/ritonavir in patients who had SpO	32857301	Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences	2008-2231	10.1007/s40199-020-00369-2	Comparando os resultados de pacientes hospitalizados com COVID-19 moderado e grave após tratamento com hidroxicloroquina mais atazanavir/ritonavir 	Nosso estudo não apoiou o uso de hidroxicloroquina mais atazanavir/ritonavir em pacientes que tiveram SpO
Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak	https://doi.org/10.1016/j.jaad.2020.07.089	23/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaad.2020.07.089	0190-9622	1909622	JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY	A1	1.948	217	4.29	-	['Imunossupressores']	['Immunosuppressants']	IS therapies for IMIDs are not associated with a significantly greater risk of SARS-CoV-2 or severe sequelae when controlling for other factors, and tumor necrosis factor α inhibitors may decrease the odds of severe infection.	32735965	Journal of the American Academy of Dermatology	1097-6787	10.1016/j.jaad.2020.07.089	Terapia imunossupressora antecedente para doenças inflamatórias imunomediadas no cenário de um surto de COVID-19 As 	terapias IS para IMIDs não estão associadas a um risco significativamente maior de SARS-CoV-2 ou sequelas graves ao controlar outros fatores e fator de necrose tumoral α inibidores podem diminuir as chances de infecção grave.
Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19	https://doi.org/10.1016/j.ijantimicag.2020.106142	24/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106142	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']	This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57-79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3-5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08-117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03-1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36-12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring.	32853675	International journal of antimicrobial agents	1872-7913	10.1016/j.ijantimicag.2020.106142	Fatores preditivos para anormalidades da condução cardíaca 	com combinações contendo hidroxicloroquina para COVID-19 O prolongamento QTc moderado a grave durante a terapia foi definido como um intervalo QTc > 470 ms em homens ou > 480 ms em mulheres. Os pacientes foram tratados sob estrita supervisão cardíaca. Um total de 105 adultos foram incluídos [56% do sexo masculino; mediana (IQR) idade 69 (57-79) anos]. Todos os pacientes receberam terapia com HCQ em combinação com azitromicina (AZM), e 95 (90%) também com lopinavir/ritonavir (LPV/r). Medicamentos concomitantes classificados como de risco para desenvolver torsades de pointes (TdP) foram usados simultaneamente em 81 pacientes (77%). Prolongamento QTc moderado a grave foi observado em 14 pacientes (13%), principalmente nos dias 3-5 da linha de base, com 6 (6%) desenvolvendo prolongamento grave (> 500 ms). Não houve evidência de arritmia TdP ou morte associada à TdP. A adição de LPV/r a HCQ+AZM não prolongou significativamente o intervalo QTc. A regressão multivariável de Cox revelou que os medicamentos com risco conhecido de TdP (HR = 11,28, IC 95% 1,08-117,41), razão neutrófilo-linfócito (NLR) mais alta (HR = 1,10, IC 95% 1,03-1,18 por unidade de aumento) e níveis séricos mais elevados de troponina I cardíaca (HR = 4,09, IC 95% 1,36-12,2 por unidade de aumento) foram os principais contribuintes para o prolongamento QTc moderado a grave. Nesta coorte rastreada e monitorada de perto, não foram observadas complicações derivadas do prolongamento do QTc durante a terapia farmacológica contendo HCQ para COVID-19. Evidência de lesão miocárdica com troponina elevada e forte resposta inflamatória, especificamente NLR mais alta, são condições que requerem monitoramento cuidadoso do intervalo QTc.
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)	https://doi.org/10.1016/j.cmi.2020.08.010	26/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.08.010	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides', 'Tocilizumabe']	['Corticosteroids', 'Tocilizumab']	Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situation.	32860964	Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases	1469-0691	10.1016/j.cmi.2020.08.010	Tratamento com tocilizumabe ou corticosteroides para pacientes com COVID-19 com estado hiperinflamatório: um estudo de coorte multicêntrico (SAM-COVID-19) O 	tocilizumabe pode ser útil em pacientes com COVID-19 com estado hiperinflamatório e deve ser priorizado para ensaios randomizados nessa situação.
High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients	https://doi.org/10.1016/j.jaut.2020.102537	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102537	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Anakinra']	['Anakinra']	Overall, 55.6% of COVID-19 ARDS CSS patients treated with ANK exhibited favorable outcome, not inferior to a TCZ treated matched cohort. ANK may be a potential alternative to TCZ for patients with elevated aminotransferases, and may be useful in non-responders to TCZ.	32843231	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102537	Anakinra subcutâneo de alta dose para tratar a síndrome do desconforto respiratório agudo secundária à síndrome da tempestade de citocinas em pacientes com COVID-19 gravemente doentes 	No geral, 55,6% dos pacientes com COVID-19 ARDS CSS tratados com ANK exibiram resultado favorável, não inferior a uma coorte pareada tratada com TCZ. ANK pode ser uma alternativa potencial ao TCZ para pacientes com aminotransferases elevadas e pode ser útil em não respondedores ao TCZ.
Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study	https://doi.org/10.1016/j.jsbmb.2020.105751	29/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jsbmb.2020.105751	0960-0760	9600760	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY	A2	1.072	133	4.92	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Efeito do tratamento com calcifediol e melhor terapia disponível versus melhor terapia disponível na admissão na unidade de terapia intensiva e mortalidade entre pacientes hospitalizados por COVID-19: um estudo clínico randomizado piloto 	-
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5	18/08/2020	Artigo completo publicado em periódico científico	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01875-5	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract  Background COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19.  Objectives To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19.  Methods Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups.  Measurements and main results The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group.  Conclusions Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.  Trial registration Chinese Clinical Trial Registration; ChiCTR2000031494; Registered on 2 April 2020; http://<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.medresman.org/">www.medresman.org</jats:ext-link>	['Terapia celular']	['Cell Therapy']	Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020-Retrospectively registered, http://www.medresman.org.	35842684	Stem cell research & therapy	1757-6512	10.1186/s13287-022-02972-3	Tratamento de COVID-19 grave com células-tronco mesenquimais de cordão umbilical humano 	Registro de Ensaio Clínico Chinês; ChiCTR2000031494; Registrado em 02 de abril de 2020 - Registrado retrospectivamente, http://www.medresman.org.
Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial	https://doi.org/10.1016/j.intimp.2020.106903	24/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106903	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon beta']	['Interferon beta']	-	-	-	-	-	Interferon β-1b no tratamento de COVID-19 grave: um ensaio clínico randomizado 	-
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	https://www.nejm.org/doi/full/10.1056/NEJMoa2026920	02/09/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2026920	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina NVX-CoV2373', 'Vacina NVX-CoV2373']	['Vaccine NVX-CoV2373', 'Vaccine NVX-CoV2373']	-	-	-	-	-	Ensaio de Fase 1-2 de uma Vacina de Nanopartículas de Proteína de Espiga Recombinante SARS-CoV-2 	-
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review	https://doi.org/10.1016/j.jiph.2020.07.013	03/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jiph.2020.07.013	1876-0341	18760341	JOURNAL OF INFECTION AND PUBLIC HEALTH	A3	1.277	46	6.31	-	['Favipiravir', 'Lopinavir', 'Ostalmovir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Favipiravir', 'Lopinavir', 'Ostalmovir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	-	-	-	-	-	Eficácia clínica de antivirais contra o novo coronavírus (COVID-19): Uma revisão 	-
Renin–angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study	https://doi.org/10.1038/s41440-020-00535-8	21/08/2020	Artigo completo publicado em periódico científico	10.1038/s41440-020-00535-8	0916-9636	9169636	HYPERTENSION RESEARCH	A2	1.119	95	3.97	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Since the beginning of the coronavirus disease 2019 (COVID-19) outbreak initiated on the Diamond Princess Cruise Ship at Yokohama harbor in February 2020, we have been doing our best to treat COVID-19 patients. In animal experiments, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs) are reported to suppress the downregulation of angiotensin converting enzyme 2 (ACE2), and they may inhibit the worsening of pathological conditions. We aimed to examine whether preceding use of ACEIs and ARBs affected the clinical manifestations and prognosis of COVID-19 patients. One hundred fifty-one consecutive patients (mean age 60 ± 19 years) with polymerase-chain-reaction proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were admitted to six hospitals in Kanagawa Prefecture, Japan, were analyzed in this multicenter retrospective observational study. Among all COVID-19 patients, in the multiple regression analysis, older age (age ≥ 65 years) was significantly associated with the primary composite outcome (odds ratio (OR) 6.63, 95% confidence interval (CI) 2.28-22.78, P < 0.001), which consisted of (i) in-hospital death, (ii) extracorporeal membrane oxygenation, (iii) mechanical ventilation, including invasive and noninvasive methods, and (iv) admission to the intensive care unit. In COVID-19 patients with hypertension, preceding ACEI/ARB use was significantly associated with a lower occurrence of new-onset or worsening mental confusion (OR 0.06, 95% CI 0.002-0.69, P = 0.02), which was defined by the confusion criterion, which included mild disorientation or hallucination with an estimation of medical history of mental status, after adjustment for age, sex, and diabetes. In conclusion, older age was a significant contributor to a worse prognosis in COVID-19 patients, and ACEIs/ARBs could be beneficial for the prevention of confusion in COVID-19 patients with hypertension.	32820236	Hypertension research : official journal of the Japanese Society of Hypertension	1348-4214	10.1038/s41440-020-00535-8	Inibidores do sistema renina-angiotensina e a gravidade da doença de coronavírus 2019 em Kanagawa, Japão: um estudo de coorte 	retrospectivo temos feito o nosso melhor para tratar os pacientes com COVID-19. Em experimentos com animais, os inibidores da enzima de conversão da angiotensina (IECAs) e os bloqueadores dos receptores do tipo 1 da angiotensina II (BRAs) são relatados para suprimir a regulação negativa da enzima de conversão da angiotensina 2 (ACE2), e podem inibir o agravamento de condições patológicas. Nosso objetivo foi examinar se o uso anterior de IECAs e BRAs afetou as manifestações clínicas e o prognóstico de pacientes com COVID-19. Cento e cinquenta e um pacientes consecutivos (idade média de 60 ± 19 anos) com reação em cadeia da polimerase comprovada infecção por coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) que foram internados em seis hospitais na província de Kanagawa, Japão, foram analisados neste estudo observacional retrospectivo multicêntrico. Entre todos os pacientes com COVID-19, na análise de regressão múltipla, a idade mais avançada (idade ≥ 65 anos) foi significativamente associada ao resultado composto primário (razão de chances (OR) 6,63, intervalo de confiança de 95% (IC) 2,28-22,78, P < 0,001), que consistiu em (i) óbito hospitalar, (ii) oxigenação por membrana extracorpórea, (iii) ventilação mecânica, incluindo métodos invasivos e não invasivos, e (iv) internação em unidade de terapia intensiva. Em pacientes com COVID-19 com hipertensão, o uso anterior de IECA/BRA foi significativamente associado a uma menor ocorrência de novo início ou piora da confusão mental (OR 0,06, IC 95% 0,002-0,69, P = 0,02), que foi definida pela confusão critério, que incluiu leve desorientação ou alucinação com uma estimativa do histórico médico do estado mental, após ajuste para idade, sexo e diabetes. Em conclusão, a idade avançada foi um contribuinte significativo para um pior prognóstico em pacientes com COVID-19, e IECAs/BRAs podem ser benéficos para a prevenção de confusão em pacientes com COVID-19 com hipertensão.
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study	https://doi.org/10.1038/s41375-020-01018-y	19/08/2020	Artigo completo publicado em periódico científico	10.1038/s41375-020-01018-y	0887-6924	8876924	LEUKEMIA	A1	4.030	202	9.5	 Abstract Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71–93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 &lt; 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.	['Ruxolitinibe']	['Ruxolitinib']	Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor with potent anti-inflammatory properties. We report on a prospective, observational study in 34 patients with COVID-19 who received ruxolitinib on a compassionate-use protocol. Patients had severe pulmonary disease defined by pulmonary infiltrates on imaging and an oxygen saturation ≤ 93% in air and/or PaO2/FiO2 ratio ≤ 300 mmHg. Median age was 80.5 years, and 85.3% had ≥ 2 comorbidities. Median exposure time to ruxolitinib was 13 days, median dose intensity was 20 mg/day. Overall survival by day 28 was 94.1%. Cumulative incidence of clinical improvement of ≥2 points in the ordinal scale was 82.4% (95% confidence interval, 71-93). Clinical improvement was not affected by low-flow versus high-flow oxygen support but was less frequent in patients with PaO2/FiO2 < 200 mmHg. The most frequent adverse events were anemia, urinary tract infections, and thrombocytopenia. Improvement of inflammatory cytokine profile and activated lymphocyte subsets was observed at day 14. In this prospective cohort of aged and high-risk comorbidity patients with severe COVID-19, compassionate-use ruxolitinib was safe and was associated with improvement of pulmonary function and discharge home in 85.3%. Controlled clinical trials are necessary to establish efficacy of ruxolitinib in COVID-19.	32814839	Leukemia	1476-5551	10.1038/s41375-020-01018-y	Uso compassivo do inibidor de JAK1/2 ruxolitinibe para COVID-19 grave: um estudo observacional prospectivo 	Reações inflamatórias esmagadoras contribuem para o desconforto respiratório em pacientes com COVID-19. Ruxolitinib é um inibidor de JAK1/JAK2 com potentes propriedades anti-inflamatórias. Relatamos um estudo prospectivo e observacional em 34 pacientes com COVID-19 que receberam ruxolitinibe em um protocolo de uso compassivo. Os pacientes apresentavam doença pulmonar grave definida por infiltrados pulmonares na imagem e saturação de oxigênio ≤ 93% no ar e/ou relação PaO2/FiO2 ≤ 300 mmHg. A idade mediana foi de 80,5 anos e 85,3% tinham ≥ 2 comorbidades. O tempo médio de exposição ao ruxolitinib foi de 13 dias, a intensidade da dose média foi de 20 mg/dia. A sobrevida global no dia 28 foi de 94,1%. A incidência cumulativa de melhora clínica de ≥2 pontos na escala ordinal foi de 82,4% (intervalo de confiança de 95%, 71-93). A melhora clínica não foi afetada pelo suporte de oxigênio de baixo fluxo versus alto fluxo, mas foi menos frequente em pacientes com PaO2/FiO2 < 200 mmHg. Os eventos adversos mais frequentes foram anemia, infecções do trato urinário e trombocitopenia. A melhora do perfil de citocinas inflamatórias e subconjuntos de linfócitos ativados foi observada no dia 14. Nesta coorte prospectiva de pacientes idosos e com comorbidade de alto risco com COVID-19 grave, o uso compassivo de ruxolitinibe foi seguro e foi associado à melhora da função pulmonar e alta hospitalar em 85,3%. Ensaios clínicos controlados são necessários para estabelecer a eficácia do ruxolitinibe no COVID-19.
Effect of a Previous History of Antiretroviral Treatment on Clinical Picture of Patients with Co-infection of SARS-CoV-2 and HIV: A Preliminary Study	https://doi.org/10.1016/j.ijid.2020.08.045	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.08.045	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Efavirenz', 'Fumarato de tenofovir desoproxila', 'Lamivudina', 'Lopinavir', 'Ritonavir', 'Zidovudina']	['Efavirenz', 'Tenofovir disoproxil fumarate', 'Lamivudine', 'Lopinavir', 'Ritonavir', 'Zidovudine']	Most patients with SARS-CoV-2 and HIV co-infection exhibited mild to moderate symptoms. The milder extent of inflammatory response to SARS-CoV-2 infection might be associated with a previous history of ART in HIV-infected patients.	32829051	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.08.045	Efeito de um histórico prévio de tratamento antirretroviral no quadro clínico de pacientes com coinfecção por SARS-CoV-2 e HIV: um estudo preliminar A 	maioria dos pacientes com coinfecção por SARS-CoV-2 e HIV exibiu sintomas leves a moderados. A extensão mais branda da resposta inflamatória à infecção por SARS-CoV-2 pode estar associada a uma história prévia de TARV em pacientes infectados pelo HIV.
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study	https://doi.org/10.1016/j.ejim.2020.08.019	25/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ejim.2020.08.019	0953-6205	9536205	EUROPEAN JOURNAL OF INTERNAL MEDICINE (LEICESTER)	A2	1.210	79	3.28	-	['Hidroxicloroquina']	['Hydroxychloroquine']	HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within the limits of an observational study and awaiting results from randomized controlled trials, these data do not discourage the use of HCQ in inpatients with COVID-19.	32859477	European journal of internal medicine	1879-0828	10.1016/j.ejim.2020.08.019	O uso de hidroxicloroquina em pacientes hospitalizados com COVID-19 está associado à redução da mortalidade: achados do estudo observacional multicêntrico italiano CORIST 	O uso de HCQ foi associado a um risco 30% menor de morte em pacientes hospitalizados com COVID-19. Dentro dos limites de um estudo observacional e aguardando resultados de ensaios clínicos randomizados, esses dados não desencorajam o uso de HCQ em pacientes internados com COVID-19.
Is there any potential management against COVID-19? A systematic review and meta-analysis	https://doi.org/10.1007/s40199-020-00367-4	18/08/2020	Artigo completo publicado em periódico científico	10.1007/s40199-020-00367-4	2008-2231	20082231	DARU JOURNAL OF PHARMACEUTICAL SCIENCES	A4	0.580	47	4.19	-	['Anakinra', 'Azitromicina', 'Baloxavir marboxil', 'Favipiravir', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Meplazumabe', 'Plasma convalescente', 'Prednisona', 'Remdesivir', 'Ritonavir', 'Ruxolitinibe', 'Tocilizumabe', 'Umifenovir']	['Anakinra', 'Azithromycin', 'Baloxavir marboxil', 'Favipiravir', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Meplazumab', 'Convalescent plasma', 'Prednisone', 'Remdesivir', 'Ritonavir' , 'Ruxolitinib', 'Tocilizumab', 'Umifenovir']	-	-	-	-	-	Existe alguma gestão potencial contra o COVID-19? Uma revisão sistemática e meta-análise 	-
Application of methylene blue -vitamin C –N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinicaltrial	https://doi.org/10.1016/j.ejphar.2020.173494	20/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ejphar.2020.173494	0014-2999	142999	EUROPEAN JOURNAL OF PHARMACOLOGY	A2	0.930	189	4.95	-	[]	[]	-	-	-	-	-	Aplicação de azul de metileno -vitamina C -N-acetil cisteína para tratamento de pacientes criticamente doentes com COVID-19, relato de um ensaio clínico de fase I 	-
Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition	https://doi.org/10.1016/j.ijid.2020.08.047	25/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.08.047	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Corticosteroides', 'Favipiravir', 'Nafamostato']	['Corticosteroids', 'Favipiravir', 'Nafamostat']	-	-	-	-	-	Estudos de caso de SARS-CoV-2 tratados com favipiravir entre pacientes em estado crítico ou grave 	-
Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants	https://doi.org/10.1016/j.ijantimicag.2020.106144	24/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106144	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Terapia com hidroxicloroquina em baixas doses e mortalidade em pacientes hospitalizados com COVID-19: um estudo observacional nacional de 8.075 participantes 	-
Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients	https://doi.org/10.1007/s11883-020-00880-6	24/08/2020	Artigo completo publicado em periódico científico	10.1007/s11883-020-00880-6	1523-3804	15233804	CURRENT ATHEROSCLEROSIS REPORTS	A4	1.284	79	5.21	 Abstract  Purpose of Review The role of renin-angiotensin-aldosterone system (RAAS) inhibitors, notably angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), in the COVID-19 pandemic has not been fully evaluated. With an increasing number of COVID-19 cases worldwide, it is imperative to better understand the impact of RAAS inhibitors in hypertensive COVID patients. PubMed, Embase and the pre-print database Medrxiv were searched, and studies with data on patients on ACEi/ARB with COVID-19 were included. Random effects models were used to estimate the pooled mean difference with 95% confidence interval using Open Meta[Analyst] software.  Recent Findings A total of 28,872 patients were included in this meta-analysis. The use of any RAAS inhibition for any conditions showed a trend to lower risk of death/critical events (OR 0.671, CI 0.435 to 1.034,  p = 0.071). Within the hypertensive cohort, however, there was a significant lower association with deaths (OR 0.664, CI 0.458 to 0.964,  p = 0.031) or the combination of death/critical outcomes (OR 0.670, CI 0.495 to 0.908,  p = 0.010). There was no significant association of critical/death outcomes within ACEi vs non-ACEi (OR 1.008, CI 0.822 to 1.235,  p = 0.941) and ARB vs non-ARB (OR 0.946, CI 0.735 to 1.218,  p = 0.668).  Summary This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic.	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	A total of 28,872 patients were included in this meta-analysis. The use of any RAAS inhibition for any conditions showed a trend to lower risk of death/critical events (OR 0.671, CI 0.435 to 1.034, p = 0.071). Within the hypertensive cohort, however, there was a significant lower association with deaths (OR 0.664, CI 0.458 to 0.964, p = 0.031) or the combination of death/critical outcomes (OR 0.670, CI 0.495 to 0.908, p = 0.010). There was no significant association of critical/death outcomes within ACEi vs non-ACEi (OR 1.008, CI 0.822 to 1.235, p = 0.941) and ARB vs non-ARB (OR 0.946, CI 0.735 to 1.218, p = 0.668). This is the largest meta-analysis including critical events and mortality data on patients prescribed ACEi/ARB and found evidence of beneficial effects of chronic ACEi/ARB use especially in hypertensive cohort with COVID-19. As such, we would strongly encourage patients to continue with RAAS inhibitor pharmacotherapy during the COVID-19 pandemic.	32830286	Current atherosclerosis reports	1534-6242	10.1007/s11883-020-00880-6	Efeito dos inibidores do sistema renina-angiotensina-aldosterona em pacientes com COVID-19: uma revisão sistemática e meta-análise de 28.872 pacientes 	Um total de 28.872 pacientes foram incluídos nesta meta-análise. O uso de qualquer inibição do SRAA para qualquer condição mostrou tendência a menor risco de morte/eventos críticos (OR 0,671, IC 0,435 a 1,034, p = 0,071). Dentro da coorte de hipertensos, no entanto, houve uma associação significativamente menor com óbitos (OR 0,664, IC 0,458 a 0,964, p = 0,031) ou a combinação de óbito/resultados críticos (OR 0,670, IC 0,495 a 0,908, p = 0,010). Não houve associação significativa de desfechos críticos/morte entre IECA vs não IECA (OR 1,008, IC 0,822 a 1,235, p = 0,941) e BRA vs não BRA (OR 0,946, IC 0,735 a 1,218, p = 0,668). Esta é a maior meta-análise que inclui eventos críticos e dados de mortalidade em pacientes com prescrição de IECA/BRA e encontrou evidências de efeitos benéficos do uso crônico de IECA/BRA, especialmente na coorte de hipertensos com COVID-19. Como tal, incentivamos fortemente os pacientes a continuarem com a farmacoterapia com inibidores de RAAS durante a pandemia de COVID-19.
A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19	http://doi.org/10.2147/DDDT.S261154	06/08/2020	Artigo completo publicado em periódico científico	10.2147/DDDT.S261154	1177-8881	11778881	DRUG DESIGN, DEVELOPMENT AND THERAPY	A2	0.784	71	4.63	-	['Remdesivir']	['Remdesivir']	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus strain and the causative agent of COVID-19 was emerged in Wuhan, China, in December 2019 [1]. This pandemic situation and magnitude of suffering have led to global effort to find out effective measures for discovery of new specific drugs and vaccines to combat this deadly disease. In addition to many initiatives to develop vaccines for protective immunity against SARS-CoV-2, some of which are at various stages of clinical trials, researchers worldwide are currently using available conventional therapeutic drugs with the potential to combat the disease effectively in other viral infections and it is believed that these antiviral drugs could act as a promising immediate alternative. Remdesivir (RDV), a broad-spectrum anti-viral agent, initially developed for the treatment of Ebola virus (EBOV) and known to showed promising efficiency in in vitro and in vivo studies against SARS and MERS coronaviruses, is now being investigated against SARS-CoV-2. On May 1, 2020, The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for RDV to treat COVID- 19 patients [2]. A number of multicentre clinical trials are on-going to check the safety and efficacy of RDV for the treatment of COVID-19. Results of published double blind, and placebo-controlled trial on RDV against SARS-CoV-2, showed that RDV administration led to faster clinical improvement in severe COVID-19 patients compared to placebo. This review highlights the available knowledge about RDV as a therapeutic drug for coronaviruses and its preclinical and clinical trials against COVID-19.	33596800	Mini reviews in medicinal chemistry	1875-5607	10.2174/1389557521666210217093004	Uma revisão sobre o remdesivir: um possível agente promissor para o tratamento do COVID-19 	Síndrome respiratória aguda grave coronavírus-2 (SARS-CoV-2), uma nova cepa de coronavírus e o agente causador do COVID-19 surgiu em Wuhan, China, em dezembro de 2019 [1]. Essa situação pandêmica e a magnitude do sofrimento levaram a um esforço global para encontrar medidas eficazes para a descoberta de novos medicamentos e vacinas específicas para combater essa doença mortal. Além de muitas iniciativas para desenvolver vacinas para imunidade protetora contra SARS-CoV-2, algumas das quais estão em vários estágios de ensaios clínicos, pesquisadores em todo o mundo estão atualmente usando medicamentos terapêuticos convencionais disponíveis com potencial para combater a doença de forma eficaz em outras infecções virais e acredita-se que esses antivirais possam atuar como uma alternativa imediata promissora. O remdesivir (RDV), um agente antiviral de amplo espectro, inicialmente desenvolvido para o tratamento do vírus Ebola (EBOV) e conhecido por mostrar eficiência promissora em estudos in vitro e in vivo contra os coronavírus SARS e MERS, agora está sendo investigado contra SARS -CoV-2. Em 1º de maio de 2020, a Food and Drug Administration (FDA) dos EUA concedeu a Autorização de Uso de Emergência (EUA) para RDV para tratar pacientes com COVID-19 [2]. Vários ensaios clínicos multicêntricos estão em andamento para verificar a segurança e eficácia do RDV para o tratamento do COVID-19. Os resultados do estudo duplo-cego e controlado por placebo publicado no RDV contra SARS-CoV-2 mostraram que a administração de RDV levou a uma melhora clínica mais rápida em pacientes graves com COVID-19 em comparação com o placebo. Esta revisão destaca o conhecimento disponível sobre o RDV como medicamento terapêutico para coronavírus e seus ensaios pré-clínicos e clínicos contra o COVID-19.
Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia	https://doi.org/10.1186/s13287-020-01866-6	14/08/2020	Artigo completo publicado em periódico científico	10.1186/s13287-020-01866-6	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract  Background The outbreak of a new virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now become the main health concern all over the world. Since effective antiviral treatments have not been developed until now, SARS-CoV-2 is severely affecting countries and territories around the world.  Methods At the present review, articles in PubMed were searched with the following terms: mesenchymal stem cells, exosomes, coronavirus, and SARS-CoV-2, either alone or in a combination form. The most relevant selected functions were mesenchymal stem cell-derived exosomes and SARS-CoV-2 virus infection.  Results SARS-CoV-2 could damage pulmonary cells and induce secretion of different types of inflammatory cytokines. In the following, these cytokines trigger inflammation that damages the lungs and results in lethal acute respiratory distress syndrome (ARDS). The main characteristic of ARDS is the onset of inflammation in pulmonary, hyaline formation, pulmonary fibrosis, and edema. Mesenchymal stem cell-derived exosomes (MSC-Exo) are believed to have anti-inflammatory effects and immune-modulating capacity as well as the ability to induce tissue regeneration, suggesting a significant therapeutic opportunity that could be used to SARS-CoV-2 pneumonia treatment. Besides, exosomes may serve as a biomarker, drug delivery system, and vaccine for the management of the patient with SARS-CoV-2.  Conclusion MSC-Exo may serve as a promising tool in the treatment of SARS-CoV-2 pneumonia. However, further work needs to be carried out to confirm the efficacy of exosomes in the treatment of SARS-CoV-2 pneumonia.	['Exossomos derivados de células-tronco mesenquimais']	['Mesenchymal stem cell-derived exosomes']	-	-	-	-	-	Potencial aplicação terapêutica de exossomos derivados de células-tronco mesenquimais na pneumonia por SARS-CoV-2 	-
Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study	https://doi.org/10.1093/cid/ciaa1239	21/08/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1239	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Antibacterials may be initiated out of concern for bacterial coinfection in coronavirus disease 2019 (COVID-19). We determined prevalence and predictors of empiric antibacterial therapy and community-onset bacterial coinfections in hospitalized patients with COVID-19.                                                  Methods                   A randomly sampled cohort of 1705 patients hospitalized with COVID-19 in 38 Michigan hospitals between 3/13/2020 and 6/18/2020. Data were collected on early (within 2 days of hospitalization) empiric antibacterial therapy and community-onset bacterial coinfections (positive microbiologic test ≤3 days). Poisson generalized estimating equation models were used to assess predictors.                                                  Results                   Of 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy; 3.5% (59/1705) had a confirmed community-onset bacterial infection. Across hospitals, early empiric antibacterial use varied from 27% to 84%. Patients were more likely to receive early empiric antibacterial therapy if they were older (adjusted rate ratio [ARR]: 1.04 [1.00–1.08] per 10 years); had a lower body mass index (ARR: 0.99 [0.99–1.00] per kg/m2), more severe illness (eg, severe sepsis; ARR: 1.16 [1.07–1.27]), a lobar infiltrate (ARR: 1.21 [1.04–1.42]); or were admitted to a for-profit hospital (ARR: 1.30 [1.15–1.47]). Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs April [85.2%, 628/737], P &amp;lt; .001) and empiric antibacterial use (ARR: 0.71 [0.63–0.81] April vs March) decreased.                                                  Conclusions                   The prevalence of confirmed community-onset bacterial coinfections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.               	['Ampicilina', 'Antibióticos', 'Cefotaxima', 'Ceftarolina', 'Ceftriaxona', 'Levofloxacina', 'Moxifloxacina', 'Sulbactam']	['Ampicillin', 'Antibiotics', 'Cefotaxime', 'Ceftaroline', 'Ceftriaxone', 'Levofloxacin', 'Moxifloxacin', 'Sulbactam']	The prevalence of confirmed community-onset bacterial coinfections was low. Despite this, half of patients received early empiric antibacterial therapy. Antibacterial use varied widely by hospital. Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use.	32820807	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa1239	Terapia antibacteriana empírica e coinfecção bacteriana de início na comunidade em pacientes hospitalizados com COVID-19: um estudo de coorte multi-hospitalar 	A prevalência de coinfecções bacterianas confirmadas de início na comunidade foi baixa. Apesar disso, metade dos pacientes recebeu terapia antibacteriana empírica precocemente. O uso de antibacterianos variou amplamente de acordo com o hospital. Reduzir o tempo de resposta do teste COVID-19 e apoiar a administração pode melhorar o uso de antibacterianos.
Tocilizumab and steroid treatment in patients with COVID-19 pneumonia	https://doi.org/10.1371/journal.pone.0237831	20/08/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0237831	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Prednisona', 'Tocilizumabe']	['Prednisone', 'Tocilizumab']	-	-	-	-	-	Tratamento com tocilizumabe e esteroides em pacientes com pneumonia por COVID-19 	-
Finding the Best Antiviral Regimen for COVID-19: A Double-Center Retrospective Cohort Study of 207 Cases in Hunan, China	https://doi.org/10.1177/1559325820949740	14/08/2020	Artigo completo publicado em periódico científico	10.1177/1559325820949740	1559-3258	15593258	DOSE-RESPONSE	A2	0.453	41	2.52	  Objective:  To compare the efficacy of 3/4-drugs’ group with 1-drug’s or 2-drugs’ groups in coronavirus disease 2019 (COVID-19).   Methods:  We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs.   Results:  The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug’s or 2-drugs’ groups (P &lt; 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug’s or 2-drugs’ groups (both were 9 days) (P &lt; 0.001). The patients’ discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug’s or 2 drugs’ group (P &lt; 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P &lt; 0.05).   Conclusion:  The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients’discharge. 	['Interferon alfa', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	['Interferon alpha', 'Lopinavir', 'Novaferon', 'Ritonavir', 'Umifenovir']	The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients'discharge.	32855629	Dose-response : a publication of International Hormesis Society	1559-3258	10.1177/1559325820949740	Encontrando o melhor regime antiviral para COVID-19: um estudo de coorte retrospectivo em dois centros de 207 casos em Hunan, 	China melhora clínica. O tratamento com corticosteróides e doenças mais graves também foram fatores de risco para eliminação viral e alta dos pacientes.
Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit	https://doi.org/10.1016/j.thromres.2020.07.035	21/07/2020	Artigo completo publicado em periódico científico	10.1016/j.thromres.2020.07.035	0049-3848	493848	THROMBOSIS RESEARCH	A3	1.678	118	5.91	-	['Nadroparina']	['Nadroparin']	Anti Xa activity was within the target range of pharmacodynamic endpoint for covid-19 patients but viscoelastic tests still demonstrated a procoagulant pattern.	32805623	Thrombosis research	1879-2472	10.1016/j.thromres.2020.07.035	covid 19 na unidade de terapia intensiva	
COVID-19 and multisystem inflammatory syndrome in children and adolescents	https://doi.org/10.1016/S1473-3099(20)30651-4	17/08/2020	Artigo completo publicado em periódico científico	10.1016/S1473-3099(20)30651-4	1473-3099	14733099	LANCET. INFECTIOUS DISEASES (PRINT)	A1	10.236	255	13.38	-	['Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Ácido acetilsalicílico', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dexametasona', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Dobutamina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Epinefrina', 'Heparina', 'Heparina', 'Heparina', 'Heparina', 'Heparina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Imunoglobulina', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Infliximabe', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Norepinefrina', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Prednisona', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Acetylsalicylic acid', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Anakinra', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dexamethasone', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Dobutamine', 'Epinephrine', 'Epinephrine', 'Epinephrine', 'Epinephrine ', 'Epinephrine', 'Heparin', 'Heparin', 'Heparin', 'Heparin', 'Heparin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Immunoglobulin', 'Infliximab', 'Infliximab', 'Infliximab', 'Infliximab', 'Infliximab', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Norepinephrine', 'Prednisone', 'Prednisone', 'Prednisone', 'Prednisone ', 'Prednisone', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']	In this cohort of 42 adolescents with a previous multisystem inflammatory syndrome (MIS-C) diagnosis, 32 (76.2%) were vaccinated with COVID-19 vaccines, with a low incidence of relevant adverse events. More importantly, no new MIS-C or myocarditis occurred after a median of 10 weeks (range 5.3-19.7) post-vaccination.	35904132	Journal of the Pediatric Infectious Diseases Society	2048-7207	10.1093/jpids/piac076	COVID-19 e síndrome inflamatória multissistêmica em crianças e adolescentes 	Nesta coorte de 42 adolescentes com diagnóstico prévio de síndrome inflamatória multissistêmica (MIS-C), 32 (76,2%) foram vacinados com vacinas COVID-19, com baixa incidência de efeitos adversos relevantes eventos. Mais importante, nenhum novo MIS-C ou miocardite ocorreu após uma mediana de 10 semanas (intervalo 5,3-19,7) pós-vacinação.
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients	https://link.springer.com/article/10.1007/s11239-020-02243-z	13/08/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11239-020-02243-z	0929-5305	9295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Enoxaparina']	['Enoxaparin']	-	-	-	-	-	Segurança da dose intermediária de heparina de baixo peso molecular em pacientes com COVID-19 	-
Baricitinib restrains the immune dysregulation in severe COVID-19 patients	https://doi.org/10.1172/JCI141772	18/08/2020	Artigo completo publicado em periódico científico	10.1172/JCI141772	0021-9738	219738	THE JOURNAL OF CLINICAL INVESTIGATION	A1	5.527	505	14.12	-	['Baricitinibe', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Baricitinib', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules.METHODSWe treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an observational, longitudinal trial and approved by the local ethics committee. The patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4 mg per day for the remaining 7 days. Changes in the immune phenotype and expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and correlated with serum-derived cytokine levels and antibodies against severe acute respiratory syndrome-coronavirus 2 (anti-SARS-CoV-2). In a single treated patient, we also evaluated the alteration of myeloid cell functional activity.RESULTSWe provide evidence that patients treated with baricitinib had a marked reduction in serum levels of IL-6, IL-1β, and TNF-α, a rapid recovery of circulating T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein, all of which were clinically associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired oxygen) ratio.CONCLUSIONThese data suggest that baricitinib prevented the progression to a severe, extreme form of the viral disease by modulating the patients' immune landscape and that these changes were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia.TRIAL REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGThis work was supported by the Fondazione Cariverona (ENACT Project) and the Fondazione TIM.	32809969	The Journal of clinical investigation	1558-8238	141772	O baricitinibe restringe a desregulação imunológica em pacientes graves com COVID-19 	ANTECEDENTES Pacientes com doença por coronavírus 2019 (COVID-19) desenvolvem pneumonia geralmente associada à linfopenia e uma resposta inflamatória grave devido à liberação descontrolada de citocinas. Esses mediadores são transcricionalmente regulados pelas vias de sinalização JAK/STAT, que podem ser desativadas por pequenas moléculas. MÉTODOS Tratamos um grupo de pacientes (n = 20) com baricitinibe de acordo com o uso off-label do medicamento. O estudo foi desenhado como um estudo observacional, longitudinal e aprovado pelo comitê de ética local. Os pacientes foram tratados com 4 mg de baricitinibe duas vezes ao dia por 2 dias, seguidos de 4 mg por dia pelos 7 dias restantes. Alterações no fenótipo imunológico e expressão de STAT3 fosforilado (p-STAT3) em células do sangue foram avaliadas e correlacionadas com os níveis de citocinas derivadas do soro e anticorpos contra a síndrome respiratória aguda grave-coronavírus 2 (anti-SARS-CoV-2). Em um único paciente tratado, também avaliamos a alteração da atividade funcional das células mieloides. RESULTADOS Fornecemos evidências de que os pacientes tratados com baricitinibe tiveram uma redução acentuada nos níveis séricos de IL-6, IL-1β e TNF-α, uma rápida recuperação de frequências de células T e B circulantes e aumento da produção de anticorpos contra a proteína spike SARS-CoV-2, todos clinicamente associados a uma redução na necessidade de oxigenoterapia e um aumento progressivo na P/F (PaO2, oxigênio parcial pressão/FiO2, fração inspirada de oxigênio) . para pacientes com pneumonia por COVID-19.TRIAL REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGEste trabalho foi apoiado pela Fondazione Cariverona (Projeto ENACT) e pela Fondazione TIM.
Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis	https://onlinelibrary.wiley.com/doi/10.1111/eci.13383	18/08/2020	Artigo completo publicado em periódico científico	10.1111/eci.13383	0014-2972	142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Anticorpo (47D11)', 'Anticorpos n3086/n3113', 'Auranofina', 'Azitromicina', 'Beta-d-N4-hydroxycytidine', 'Cloroquina', 'Corticosteroides', 'Darunavir', 'Emetine', 'Hidroxicloroquina', 'Homoharringtonina (HHT)', 'Interferon alfa', 'Interferon beta', 'Ivermectina', 'Lianhua Qingwen (Medicina Tradicional Chinesa)', 'Lopinavir', 'Pudilan Xiaoyan', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Antibody (47D11)', 'N3086/n3113 antibodies', 'Auranofin', 'Azithromycin', 'Beta-d-N4-hydroxycytidine', 'Chloroquine', 'Corticosteroids', 'Darunavir', 'Emetine', ' Hydroxychloroquine', 'Homoharringtonine (HHT)', 'Interferon alpha', 'Interferon beta', 'Ivermectin', 'Lianhua Qingwen (Traditional Chinese Medicine)', 'Lopinavir', 'Pudilan Xiaoyan', 'Remdesivir', 'Ritonavir' , 'Tocilizumab', 'Umifenovir']	Our meta-analysis suggests that except in vitro studies, no treatment has shown overall favourable outcomes in nCOV-2019 patients. Lopinavir-ritonavir, remdesivir and tocilizumab may have some benefits, while hydroxychloroquine administration may cause harm in nCOV-2019 patients. Results from upcoming large clinical trials may further clarify role of these drugs.	32810285	European journal of clinical investigation	1365-2362	10.1111/eci.13383	Eficácia de várias modalidades de tratamento para nCOV-2019: uma revisão sistemática e meta-análise 	Nossa meta-análise sugere que, exceto estudos in vitro, nenhum tratamento mostrou resultados gerais favoráveis em pacientes com nCOV-2019. Lopinavir-ritonavir, remdesivir e tocilizumab podem ter alguns benefícios, enquanto a administração de hidroxicloroquina pode causar danos em pacientes com nCOV-2019. Os resultados dos próximos grandes ensaios clínicos podem esclarecer ainda mais o papel desses medicamentos.
Severe arterial thromboembolism in patients with Covid- 19	https://doi.org/10.1016/j.jcrc.2020.08.002	08/08/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.08.002	0883-9441	8839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Tromboembolismo arterial grave em pacientes com Covid-19 	-
Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan	https://doi.org/10.1016/j.jfma.2020.07.033	29/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jfma.2020.07.033	0929-6646	9296646	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (PRINT)	A1	0.779	59	2.92	-	['Azitromicina', 'Ceftriaxona', 'Hidroxicloroquina', 'Teicoplanina']	['Azithromycin', 'Ceftriaxone', 'Hydroxychloroquine', 'Teicoplanin']	-	-	-	-	-	Tratamento bem-sucedido de 28 pacientes com doença de coronavírus 2019 em um centro médico em Taiwan 	-
Lopinavir-ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia	https://www.ahajournals.org/doi/10.1161/CIRCEP.120.008798	09/07/2020	Artigo completo publicado em periódico científico	10.1161/CIRCEP.120.008798	1941-3149	19413149	CIRCULATION. ARRHYTHMIA AND ELECTROPHYSIOLOGY	A1	2.471	113	5.0	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	Rationale Due to the cluster and associated comorbidities in residents of long-term care facilities (LTCFs), COVID-19-associated morbidity and mortality are significantly increased. Multiple therapeutic options, including hydroxychloroquine (HCQ) and azithromycin (AZI), were tried initially to treat moderate to severe COVID-19 and high-risk patients in LTCFs, but they were abandoned due to unfavorable reports. As a less toxic option, we initiated treatment with doxycycline (DOXY) very early in the course of illness. DOXY has antiviral, cardioprotective, immunomodulatory, and anti-inflammatory properties, but the efficacy of early intervention with DOXY in high-risk COVID-19 patients in LTCFs is unknown. Objective The goal of this retrospective study is to describe the clinical outcomes of high-risk COVID-19 patients with moderate to severe symptoms in LTCFs after early intervention with DOXY. Design Case-series analysis Setting LTCFs in New York Participants This observational study examines 89 patients who were diagnosed with COVID-19 from March 18 to May 13, 2020. Exposure All patients who were diagnosed with COVID-19 received DOXY and regular standard of care within 12 hours of the onset of symptoms. Additionally, four patients received meropenem, three patients received Zosyn, two patients received linezolid, and two patients received Bactrim DS. Four patients were on chronic ventilator support. No patients received any steroids or any other antiviral or immunomodulatory agents. The majority of the patients received zinc and calcium supplements as well. Main outcomes and measures Assessed measures were patients' characteristics, fever, shortness of breath (SOB), cough, oxygen saturation/pulse oximetry (POX), radiologic improvements, laboratory tests, DOXY side effects, hospital transfers, and death. Results Eighty-nine (89) high-risk patients, who developed a sudden onset of fever, cough, SOB, and hypoxia and were diagnosed with COVID-19, were treated with DOXY (100 mg PO or intravenous (IV) for seven days) and regular standard of care. Eighty-five percent (85%) of patients (n=76) demonstrated clinical recovery that is defined as resolution of fever (average 3.7 days, Coeff = -0.96, p = 0.0001), resolution of SOB (average 4.2 days), and improvement of POX: average 84% before treatment and average 95% after treatment (84.7 ± 7% vs. 95 ± 2.6%, p = 0.0001). Higher pre- and post-treatment POX is associated with lower mortality (oxygen saturation (Spo2) vs. Death, Coeff = -0.01, p = 0.023; post-Spo2 vs. Death, Coeff = -0.05, p = 0.0002). Within 10 days of symptom onset, 3% of patients (n=3) were transferred to hospital due to clinical deterioration and 11% of patients (n=10) died. The result was followed for 30 days from the onset of symptoms in each patient. Conclusion Early treatment with DOXY for high-risk patients with moderate to severe COVID-19 infections in non-hospital settings, such as LTCFs, is associated with early clinical recovery, decreased hospitalization, and decreased mortality.	32809882	Circulation. Arrhythmia and electrophysiology	1941-3084	10.1161/CIRCEP.120.008798	Lopinavir-ritonavir Tratamento para infecção por COVID-19 em Unidade de Terapia Intensiva: Risco de Bradicardia 	Racional Várias opções terapêuticas, incluindo hidroxicloroquina (HCQ) e azitromicina (AZI), foram tentadas inicialmente para tratar COVID-19 moderado a grave e pacientes de alto risco em LTCFs, mas foram abandonadas devido a relatos desfavoráveis. Como uma opção menos tóxica, iniciamos o tratamento com doxiciclina (DOXY) muito cedo no curso da doença. DOXY tem propriedades antivirais, cardioprotetoras, imunomoduladoras e anti-inflamatórias, mas a eficácia da intervenção precoce com DOXY em pacientes com COVID-19 de alto risco em LTCFs é desconhecida. Objetivo O objetivo deste estudo retrospectivo é descrever os resultados clínicos de pacientes com COVID-19 de alto risco com sintomas moderados a graves em ILPIs após intervenção precoce com DOXY. Projeto Análise de série de casos Configurando LTCFs em Nova York Participantes Este estudo observacional examina 89 pacientes diagnosticados com COVID-19 de 18 de março a 13 de maio de 2020. Exposição Todos os pacientes diagnosticados com COVID-19 receberam DOXY e tratamento padrão regular dentro de 12 horas do início dos sintomas. Além disso, quatro pacientes receberam meropenem, três pacientes receberam Zosyn, dois pacientes receberam linezolida e dois pacientes receberam Bactrim DS. Quatro pacientes estavam em suporte ventilatório crônico. Nenhum paciente recebeu esteróides ou quaisquer outros agentes antivirais ou imunomoduladores. A maioria dos pacientes recebeu suplementos de zinco e cálcio também. Principais desfechos e medidas As medidas avaliadas foram características dos pacientes, febre, falta de ar (SOB), tosse, saturação de oxigênio/oximetria de pulso (POX), melhorias radiológicas, exames laboratoriais, efeitos colaterais DOXY, transferências hospitalares e óbito. Resultados Oitenta e nove (89) pacientes de alto risco, que desenvolveram um início súbito de febre, tosse, SOB e hipóxia e foram diagnosticados com COVID-19, foram tratados com DOXY (100 mg PO ou intravenoso (IV) por sete dias ) e padrão regular de cuidados. Oitenta e cinco por cento (85%) dos pacientes (n = 76) demonstraram recuperação clínica definida como resolução da febre (média de 3,7 dias, Coeff = -0,96, p = 0,0001), resolução de SOB (média de 4,2 dias) e melhora da POX: média de 84% antes do tratamento e média de 95% após o tratamento (84,7 ± 7% vs. 95 ± 2,6%, p = 0,0001). Maior POX pré e pós-tratamento está associado a menor mortalidade (saturação de oxigênio (Spo2) vs. Morte, Coeff = -0,01, p = 0,023; pós-Spo2 vs. Morte, Coeff = -0,05, p = 0,0002). Dentro de 10 dias do início dos sintomas, 3% dos pacientes (n=3) foram transferidos para o hospital devido à deterioração clínica e 11% dos pacientes (n=10) morreram. O resultado foi acompanhado por 30 dias a partir do início dos sintomas em cada paciente. Conclusão O tratamento precoce com DOXY para pacientes de alto risco com infecções moderadas a graves por COVID-19 em ambientes não hospitalares, como ILPIs, está associado à recuperação clínica precoce, diminuição da hospitalização e diminuição da mortalidade.
Corticosteroid prevents COVID-19 progressionwithin its therapeutic window: a multicenter, proof-of-concept, observational study	https://doi.org/10.1080/22221751.2020.1807885	14/08/2020	Artigo completo publicado em periódico científico	10.1080/22221751.2020.1807885	2222-1751	22221751	EMERGING MICROBES & INFECTIONS (ONLINE)	A1	3.322	68	13.11	-	[]	[]	-	-	-	-	-	O corticosteroide previne a progressão do COVID-19 dentro de sua janela terapêutica: um estudo observacional multicêntrico, de prova de conceito 	-
Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients	https://doi.org/10.1161/JAHA.120.017736	18/08/2020	Artigo completo publicado em periódico científico	10.1161/JAHA.120.017736	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             Background            <jats:p xml:lang="en">There has been significant controversy about the effects of pre‐hospitalization use of renin‐angiotensin system (RAS) inhibitors on the prognosis of patients with hypertension and coronavirus disease 2019.                    <jats:sec xml:lang="en">             Methods and Results            <jats:p xml:lang="en">              We retrospectively assessed 2297 hospitalized patients with coronavirus disease 2019 at Tongji Hospital in Wuhan, China, from January 10 to March 30, 2020; and identified 1182 patients with known hypertension on pre‐hospitalization therapy. We compared the baseline characteristics and in‐hospital mortality between patients with hypertension taking RAS inhibitors (n=355) versus non‐RAS inhibitors (n=827). Of the 1182 patients with hypertension (median age 68 years, 49.1% male), 12/355 (3.4%) patients died in the RAS inhibitors group versus 95/827 (11.5%) patients in the non‐RAS inhibitors group (               P              &lt;0.0001). Adjusted hazard ratio for mortality was 0.28 (95% CI 0.15–0.52,               P              &lt;0.0001) at 45 days in the RAS inhibitors group compared with non‐RAS inhibitors group. Similar findings were observed when patients taking angiotensin receptor blockers (n=289) or angiotensin‐converting enzyme inhibitors (n=66) were separately compared with non‐RAS inhibitors group. The RAS inhibitors group compared with non‐RAS inhibitors group had lower levels of C‐reactive protein (median 13.5 versus 24.4 pg/mL;               P              =0.007) and interleukin‐6 (median 6.0 versus 8.5 pg/mL;               P              =0.026) on admission. The protective effect of RAS inhibitors on mortality was confirmed in a meta‐analysis of published data when our data were added to previous studies (odd ratio 0.44, 95% CI 0.29–0.65,               P              &lt;0.0001).                                <jats:sec xml:lang="en">             Conclusions            <jats:p xml:lang="en">In a large single center retrospective analysis, we observed a protective effect of pre‐hospitalization use of RAS inhibitors on mortality in patients with hypertension and coronavirus disease 2019, which might be associated with reduced inflammatory response.          	['Antagonistas do Receptor da Angiotensina II', 'Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Background There has been significant controversy regarding the effects of pre-hospitalization use of renin-angiotensin system (RAS) inhibitors on the prognosis of hypertensive COVID-19 patients. Methods and Results We retrospectively assessed 2,297 hospitalized COVID-19 patients at Tongji Hospital in Wuhan, China, from January 10	32807002	Journal of the American Heart Association	2047-9980	10.1161/JAHA.120.017736	Mortalidade e uso pré-hospitalização de inibidores do sistema renina-angiotensina em pacientes hipertensos com COVID-19 	Histórico Existe uma controvérsia significativa sobre os efeitos do uso pré-hospitalar de inibidores do sistema renina-angiotensina (RAS) no prognóstico de pacientes hipertensos com COVID-19 . Métodos e Resultados Avaliamos retrospectivamente 2.297 pacientes hospitalizados com COVID-19 no Hospital Tongji em Wuhan, China, a partir de 10 de janeiro
Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: a new challenge overcome?	https://doi.org/10.1016/j.ijcard.2020.07.041	29/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.07.041	0167-5273	1675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	A role for the renin-angiotensin-aldosterone-system in Severe Acute Respiratory Syndrome-Coronavirus-2 infection and in the development of COronaVIrus Disease-19 disease has generated remarkable concerns among physicians and patients. Even though a suggestive pathophysiological link between renin-angiotensin-aldosterone-system and the virus has been proposed, its pathogenic role remains very difficult to be defined. Although COronaVIrus Disease-19 targets preferentially older people with high prevalence of hypertension and extensive use of renin-angiotensin-aldosterone-system inhibitors, an independent role for hypertension and its therapies is not defined. In this article, we scrutinize evidence from the most representative available studies in which the potential role of renin-angiotensin system inhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, was evaluated in the COronaVIrus Disease-19 disease course, with regard to severity of the disease and mortality. We conclude that at this time, the overall available evidence fails to support a pathogenetic speaks against any harmful role for of renin-angiotensin-aldosterone-system inhibitors in COronaVIrus Disease-19. Consequently, we conclude that treatment with renin-angiotensin-aldosterone-system inhibitors should not be discontinued and, therefore, these therapies should not be interrupted.	32738257	International journal of cardiology	1874-1754	10.1016/j.ijcard.2020.07.041	Revisão sistemática do papel dos inibidores do sistema renina-angiotensina em estudos tardios sobre Covid-19: um novo desafio superado? 	O papel do sistema renina-angiotensina-aldosterona na infecção por Síndrome Respiratória Aguda Grave-Coronavírus-2 e no desenvolvimento da doença da Doença de COronavírus-19 gerou preocupações notáveis entre médicos e pacientes. Embora tenha sido proposta uma sugestiva ligação fisiopatológica entre o sistema renina-angiotensina-aldosterona e o vírus, seu papel patogênico permanece muito difícil de ser definido. Embora a doença de COronavírus-19 tenha como alvo preferencial pessoas idosas com alta prevalência de hipertensão e uso extensivo de inibidores do sistema renina-angiotensina-aldosterona, um papel independente para a hipertensão e suas terapias não está definido. Neste artigo, examinamos as evidências dos estudos disponíveis mais representativos nos quais o papel potencial dos inibidores do sistema renina-angiotensina, especificamente inibidores da enzima conversora de angiotensina e bloqueadores dos receptores da angiotensina, foi avaliado no curso da doença de COronavírus-19, no que diz respeito a gravidade da doença e mortalidade. Concluímos que, neste momento, a evidência geral disponível não suporta uma patogenia fala contra qualquer papel prejudicial dos inibidores do sistema renina-angiotensina-aldosterona na doença de COronavírus-19. Consequentemente, concluímos que o tratamento com inibidores do sistema renina-angiotensina-aldosterona não deve ser descontinuado e, portanto, essas terapias não devem ser interrompidas.
Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients	https://doi.org/10.1016/j.ijid.2020.08.024	12/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.08.024	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Impacto do Tocilizumab na mortalidade e/ou necessidade de ventilação mecânica invasiva em uma coorte de 206 pacientes com COVID-19 	-
Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study	https://doi.org/10.1016/j.intimp.2020.106873	06/08/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106873	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Timosina']	['Thymosin']	-	-	-	-	-	Terapia com timosina α1 em pacientes críticos com COVID-19: um estudo de coorte retrospectivo multicêntrico 	-
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy	https://doi.org/10.1136/jitc-2020-001089	11/08/2020	Artigo completo publicado em periódico científico	10.1136/jitc-2020-001089	2051-1426	20511426	JOURNAL FOR IMMUNOTHERAPY OF CANCER	A1	3.450	80	12.01	  Background The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing.  Study description In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease.  Conclusions This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.	['Sarilumabe']	['Sarilumab']	-	-	-	-	-	Resultados e análises de biomarcadores entre pacientes com COVID-19 tratados com sarilumab, antagonista do receptor de interleucina 6 (IL-6) em uma única instituição na Itália 	-
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study	https://doi.org/10.1371/journal.pone.0237693	13/08/2020	Artigo completo publicado em periódico científico	10.1371/journal.pone.0237693	1932-6203	19326203	PLOS ONE	A1	0.852	367	3.8	-	['Hidroxicloroquina', 'Tocilizumabe']	['Hydroxychloroquine', 'Tocilizumab']	Hydroxychloroquine has been touted as a potential COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has also been proposed as a treatment of critically ill patients. In this retrospective observational cohort study drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Patients were hospitalized at a 13-hospital network spanning New Jersey USA between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). The 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively. Among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57-1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. This observational cohort study suggests hydroxychloroquine, either alone or in combination with azithromycin, was not associated with a survival benefit among hospitalized COVID-19 patients. Tocilizumab demonstrated a trend association towards reduced mortality among ICU patients. Our findings are limited to hospitalized patients and must be interpreted with caution while awaiting results of randomized trials. Trial Registration: Clinicaltrials.gov Identifier: NCT04347993.	32790733	PloS one	1932-6203	10.1371/journal.pone.0237693	Terapia com hidroxicloroquina e tocilizumabe em pacientes com COVID-19 – Um estudo observacional A 	hidroxicloroquina foi apontada como um potencial tratamento para COVID-19. O tocilizumab, um inibidor de IL-6, também foi proposto como tratamento de pacientes críticos. Neste estudo de coorte observacional retrospectivo extraído de registros eletrônicos de saúde, procuramos descrever a associação entre mortalidade e terapia com hidroxicloroquina ou tocilizumabe entre pacientes hospitalizados com COVID-19. Os pacientes foram hospitalizados em uma rede de 13 hospitais em Nova Jersey, EUA, entre 1º de março de 2020 e 22 de abril de 2020, com resultados positivos de reação em cadeia da polimerase para SARS-CoV-2. O acompanhamento foi até 5 de maio de 2020. Entre 2.512 pacientes hospitalizados com COVID-19, houve 547 mortes (22%), 1.539 (61%) altas e 426 (17%) permanecem internados. 1.914 (76%) receberam pelo menos uma dose de hidroxicloroquina e 1.473 (59%) receberam hidroxicloroquina com azitromicina. Após o ajuste para desequilíbrios por meio de modelagem de propensão, em comparação a não receber nenhum medicamento, não houve diferenças significativas na mortalidade associada para pacientes que receberam qualquer hidroxicloroquina durante a hospitalização (HR, 0,99 [IC 95%, 0,80-1,22]), hidroxicloroquina isolada (HR, 1,02 [IC 95%, 0,83-1,27]), ou hidroxicloroquina com azitromicina (HR, 0,98 [IC 95%, 0,75-1,28]). A mortalidade não ajustada em 30 dias para pacientes que receberam hidroxicloroquina sozinha, azitromicina sozinha, a combinação ou nenhuma das drogas foi de 25%, 20%, 18% e 20%, respectivamente. Entre 547 pacientes de UTI avaliáveis, incluindo 134 recebendo tocilizumabe na UTI, uma análise exploratória encontrou uma tendência para uma melhor associação de sobrevida com o tratamento com tocilizumabe (HR ajustado, 0,76 [IC 95%, 0,57-1,00]), com mortalidade não ajustada em 30 dias com e sem tocilizumab de 46% versus 56%. Este estudo observacional de coorte sugere que a hidroxicloroquina, isoladamente ou em combinação com azitromicina, não foi associada a um benefício de sobrevida entre pacientes hospitalizados com COVID-19. O tocilizumabe demonstrou uma tendência de associação à redução da mortalidade entre os pacientes de UTI. Nossos achados são limitados a pacientes hospitalizados e devem ser interpretados com cautela enquanto aguardamos os resultados de estudos randomizados. Registro do teste: Clinicaltrials.gov Identificador: NCT04347993.
Análisis de la relación entre los inhibidores del sistema renina-angiotensina y la evolución de pacientes hospitalizados por infección respiratoria COVID-19	https://doi.org/10.1016/j.medcli.2020.07.004	25/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.07.004	0025-7753	257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Análise da relação entre os inibidores do sistema renina-angiotensina e a evolução de pacientes hospitalizados por infecção respiratória COVID-19 	-
Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?	https://doi.org/10.1097/CRD.0000000000000329	13/08/2020	Artigo completo publicado em periódico científico	10.1097/CRD.0000000000000329	1061-5377	10615377	CARDIOLOGY IN REVIEW (PRINT)	A4	0.622	59	2.39	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Cloroquina ou hidroxicloroquina para o gerenciamento da doença de coronavírus 2019: amigo ou inimigo? 	-
Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019	https://doi.org/10.1007/s11239-020-02248-8	11/08/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02248-8	0929-5305	9295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Argatrobana']	['Argatroban']	-	-	-	-	-	Terapia com argatroban para trombocitopenia induzida por heparina em paciente com doença de coronavírus 2019 	-
Prolonged QT Interval in a PatientWith Coronavirus Disease-2019: Beyond Hydroxychloroquine and Azithromycin	https://doi.org/10.1177/2324709620948407	12/08/2020	Artigo completo publicado em periódico científico	10.1177/2324709620948407	2324-7096	23247096	JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS (ONLINE)	A4	0.296	15	1.13	  Recent reports have suggested an increased risk of QT prolongation and subsequent life-threatening ventricular arrhythmias, particularly torsade de pointes, in patients with coronavirus disease-2019 (COVID-19) treated with hydroxychloroquine and azithromycin. In this article, we report the case of a 75-year-old female with a baseline prolonged QT interval in whom the COVID-19 illness resulted in further remarkable QT prolongation (&gt;700 ms), precipitating recurrent self-terminating episodes of torsade de pointes that necessitated temporary cardiac pacing. Despite the correction of hypoxemia and the absence of reversible factors, such as adverse medication effects, electrolyte derangements, and usage of hydroxychloroquine/azithromycin, the QT interval remained persistently prolonged compared with the baseline with subsequent degeneration into ventricular tachycardia and death. Thus, we highlight that COVID-19 illness itself can potentially lead to further prolongation of QT interval and unmask fatal ventricular arrhythmias in patients who have a prolonged QT and low repolarization reserve at baseline. 	[]	[]	-	-	-	-	-	Intervalo QT prolongado em um paciente com doença de coronavírus-2019: além da hidroxicloroquina e da azitromicina 	-
Plasma exchange in critically ill COVID-19 patients	https://doi.org/10.1186/s13054-020-03171-3	04/08/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03171-3	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Plasmaferese']	['Plasmapheresis']	-	-	-	-	-	Troca de plasma em pacientes criticamente doentes com COVID-19 	-
Impact of implementation of an individualised thromboprophylaxis protocol T in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study	https://doi.org/10.1016/j.thromres.2020.07.038	22/07/2020	Artigo completo publicado em periódico científico	10.1016/j.thromres.2020.07.038	0049-3848	493848	THROMBOSIS RESEARCH	A3	1.678	118	5.91	-	['Nadroparina']	['Nadroparin']	-	-	-	-	-	Impacto da implementação de um protocolo de tromboprofilaxia T individualizado em pacientes críticos de UTI com COVID-19: Um estudo longitudinal controlado antes-depois 	-
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results	https://doi.org/10.1016/j.ijantimicag.2020.106136	08/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106136	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Efeitos da Hidroxicloroquina no Covid-19 em Pacientes de Unidade de Terapia Intensiva: Resultados Preliminares 	-
Vitamin D deficiency as a predictor of poor prognosis in patients with acute  respiratory failure due to COVID-19	https://link.springer.com/article/10.1007/s40618-020-01370-x	09/08/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40618-020-01370-x	1720-8386	17208386	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (ONLINE)	A3	0.936	87	4.35	 Abstract                  Purpose                 Hypovitaminosis D is a highly spread condition correlated with increased risk of respiratory tract infections. Nowadays, the world is in the grip of the Coronavirus disease 19 (COVID 19) pandemic. In these patients, cytokine storm is associated with disease severity. In consideration of the role of vitamin D in the immune system, aim of this study was to analyse vitamin D levels in patients with acute respiratory failure due to COVID-19 and to assess any correlations with disease severity and prognosis.                                Methods                 In this retrospective, observational study, we analysed demographic, clinical and laboratory data of 42 patients with acute respiratory failure due to COVID-19, treated in Respiratory Intermediate Care Unit (RICU) of the Policlinic of Bari from March, 11 to April 30, 2020.                                Results                 Eighty one percent of patients had hypovitaminosis D. Based on vitamin D levels, the population was stratified into four groups: no hypovitaminosis D, insufficiency, moderate deficiency, and severe deficiency. No differences regarding demographic and clinical characteristics were found. A survival analysis highlighted that, after 10 days of hospitalization, severe vitamin D deficiency patients had a 50% mortality probability, while those with vitamin D ≥ 10 ng/mL had a 5% mortality risk ( p = 0.019).                                Conclusions                 High prevalence of hypovitaminosis D was found in COVID-19 patients with acute respiratory failure, treated in a RICU. Patients with severe vitamin D deficiency had a significantly higher mortality risk. Severe vitamin D deficiency may be a marker of poor prognosis in these patients, suggesting that adjunctive treatment might improve disease outcomes.              	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Deficiência de vitamina D como preditor de mau prognóstico em pacientes com insuficiência respiratória aguda por COVID-19 	-
Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials	https://doi.org/10.1007/s00228-020-02962-5	11/08/2020	Artigo completo publicado em periódico científico	10.1007/s00228-020-02962-5	0031-6970	316970	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.732	114	2.61	-	['Hidroxicloroquina']	['Hydroxychloroquine']	HCQ is associated with a high total risk of AEs compared with the placebo or no intervention in the overall population. Given the small number of COVID-19 participants included, we should be cautious regarding the conclusion stating that HCQ is linked with an increase incidence of AEs in patients with COVID-19, which we hope to confirm in the future through well-designed and larger sample size studies.	32780229	European journal of clinical pharmacology	1432-1041	10.1007/s00228-020-02962-5	Segurança da hidroxicloroquina em COVID-19 e outras doenças: uma revisão sistemática e meta-análise de 53 ensaios randomizados 	HCQ está associada a um alto risco total de EAs em comparação com o placebo ou nenhuma intervenção na população geral. Dado o pequeno número de participantes COVID-19 incluídos, devemos ser cautelosos quanto à conclusão de que o HCQ está relacionado a um aumento da incidência de EAs em pacientes com COVID-19, o que esperamos confirmar no futuro por meio de projetos bem projetados e maiores. estudos de tamanho de amostra.
Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality	https://doi.org/10.1016/j.ajpath.2020.08.001	10/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ajpath.2020.08.001	0002-9440	29440	THE AMERICAN JOURNAL OF PATHOLOGY (PRINT)	A1	1.619	289	4.82	-	['Plasma convalescente']	['Convalescent Plasma']	Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has spread globally, and proven treatments are limited. Transfusion of convalescent plasma collected from donors who have recovered from COVID-19 is among many approaches being studied as potentially efficacious therapy. We are conducting a prospective, propensity score-matched study assessing the efficacy of COVID-19 convalescent plasma transfusion versus standard of care as treatment for severe and/or critical COVID-19. We present herein the results of an interim analysis of 316 patients enrolled at Houston Methodist hospitals from March 28 to July 6, 2020. Of the 316 transfused patients, 136 met a 28-day outcome and were matched to 251 non-transfused control COVID-19 patients. Matching criteria included age, sex, body mass index, comorbidities, and baseline ventilation requirement 48 hours from admission, and in a second matching analysis, ventilation status at day 0. Variability in the timing of transfusion relative to admission and titer of antibodies of plasma transfused allowed for analysis in specific matched cohorts. The analysis showed a significant reduction (P = 0.047) in mortality within 28 days, specifically in patients transfused within 72 hours of admission with plasma with an anti-spike protein receptor binding domain titer of ≥1:1350. These data suggest that treatment of COVID-19 with high anti-receptor binding domain IgG titer convalescent plasma is efficacious in early-disease patients.	32795424	The American journal of pathology	1525-2191	10.1016/j.ajpath.2020.08.001	Tratamento de pacientes com COVID-19 com plasma convalescente revela um sinal de mortalidade significativamente diminuída A 	doença por coronavírus 2019 (COVID-19), causada pela síndrome respiratória aguda grave coronavírus 2, se espalhou globalmente e os tratamentos comprovados são limitados. A transfusão de plasma convalescente coletado de doadores que se recuperaram do COVID-19 está entre as muitas abordagens que estão sendo estudadas como terapia potencialmente eficaz. Estamos realizando um estudo prospectivo, com pontuação de propensão, avaliando a eficácia da transfusão de plasma convalescente de COVID-19 versus o padrão de atendimento como tratamento para COVID-19 grave e/ou crítico. Apresentamos aqui os resultados de uma análise interina de 316 pacientes matriculados nos hospitais Metodistas de Houston de 28 de março a 6 de julho de 2020. Dos 316 pacientes transfundidos, 136 obtiveram um resultado de 28 dias e foram pareados com 251 controles não transfundidos COVID- 19 pacientes. Os critérios de correspondência incluíram idade, sexo, índice de massa corporal, comorbidades e necessidade de ventilação basal 48 horas após a admissão e, em uma segunda análise de correspondência, status de ventilação no dia 0. Variabilidade no momento da transfusão em relação à admissão e título de anticorpos do plasma transfundido permitiu a análise em coortes pareadas específicas. A análise mostrou uma redução significativa (P = 0,047) na mortalidade em 28 dias, especificamente em pacientes transfundidos dentro de 72 horas da admissão com plasma com um título de domínio de ligação ao receptor de proteína anti-pico de ≥1:1350. Esses dados sugerem que o tratamento de COVID-19 com plasma convalescente de alto título de domínio de ligação anti-receptor é eficaz em pacientes com doença precoce.
Potential new treatment strategies for COVID‐19: is there a role for bromhexine as add‐on therapy?	https://doi.org/10.1007/s11739-020-02383-3	26/05/2020	Artigo completo publicado em periódico científico	10.1007/s11739-020-02383-3	1828-0447	18280447	INTERN EMERG MED	A2	0.861	51	2.77	-	['Bromexina', 'Bromexina', 'Bromexina', 'Bromexina', 'Bromexina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	['Bromhexine', 'Bromhexine', 'Bromhexine', 'Bromhexine', 'Bromhexine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', ' Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir' , 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir']	-	-	-	-	-	Potenciais novas estratégias de tratamento para COVID-19: existe um papel para a bromexina como terapia complementar? 	-
Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects	https://doi.org/10.1080/14712598.2020.1796963	03/08/2020	Artigo completo publicado em periódico científico	10.1080/14712598.2020.1796963	1471-2598	14712598	EXPERT OPINION ON BIOLOGICAL THERAPY	A2	1.001	91	4.61	-	['Anticorpos', 'Imunoglobulina', 'Plasma convalescente']	['Antibodies', 'Immunoglobulin', 'Convalescent Plasma']	In a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19.	32744917	Expert opinion on biological therapy	1744-7682	10.1080/14712598.2020.1796963	Imunoterapia à base de anticorpos e uso de plasma convalescente para combater a COVID-19: avanços e perspectivas 	Em uma situação de pandemia como a da COVID-19, o desenvolvimento de novos medicamentos deve focar e agilizar as estratégias onde a segurança e a eficácia sejam comprovadas. As abordagens imunoterapêuticas baseadas em anticorpos, como plasma convalescente, imunoglobulinas intravenosas e mAbs, têm um histórico comprovado de segurança e eficácia e estão em uso há décadas. Alguns deles já estão sendo usados para gerenciar pacientes com COVID-19 e considerados úteis. No entanto, os mAbs com potencial de neutralização de vírus são a necessidade da hora durante esta pandemia de COVID-19 para serem mais específicos e direcionados ao vírus. A pesquisa e o investimento precisam ser acelerados para colocá-los em uso clínico para fins profiláticos e terapêuticos contra o COVID-19.
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19	https://doi.org/10.1016/j.intimp.2020.106749	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106749	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Baricitinibe']	['Baricitinib']	In December 2019, a novel coronavirus pneumonia (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) suddenly broke out in China and rapidly spread all over the world. Recently, a cell surface protein, known as angiotensin-converting enzyme II (ACE2), has been identified to be involved in receptor-mediated endocytosis for SARS-CoV-2 entry to the cells. Many studies have reported the clinical characteristics of COVID-19: sudden deterioration of disease around 1-2 weeks after onset; much lower level of lymphocytes, especially natural killer (NK) cells in peripheral blood; extremely high pro-inflammatory cytokines and C reactive protein (CRP). About 15.7% of patients develop severe pneumonia, and cytokine storm is an important factor leading to rapid disease progression. Currently, there are no specific drugs for COVID-19 and the cytokine storm it causes. Baricitinib intracellularly inhibits the proinflammatory signal of several cytokines by suppressing Janus kinase (JAK) JAK1/JAK2. It has been demonstrated clinical benefits for the patients with rheumatoid arthritis (RA), active systemic lupus erythematosus and atopic dermatitis with good efficacy and safety records. Baricitinib is expected to interrupt the passage and intracellular assembly of SARS-CoV-2 into the target cells mediated by ACE2 receptor, and treat cytokine storm caused by COVID-19. Several clinical trials are currently investigating the drug, and one of which has been completed with encouraging results. In this paper, we will elaborate the role of cytokine storm mediated by JAK-STAT pathway in severe COVID-19, the possible mechanisms of baricitinib on reducing the viral entry into the target cells and cytokine storm, the key points of pharmaceutical care based on the latest research reports, clinical trials progress and drug instruction from the US FDA, so as to provide reference for the treatment of severe COVID-19.	32645632	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.106749	Baricitinib, um medicamento com efeito potencial para impedir que o SARS-COV-2 entre nas células-alvo e controlar a tempestade de citocinas induzida por COVID-19 	Em dezembro de 2019, uma nova pneumonia por coronavírus (COVID-19) causada pela síndrome respiratória aguda grave coronavírus 2 (SARS -CoV-2) de repente eclodiu na China e rapidamente se espalhou por todo o mundo. Recentemente, uma proteína de superfície celular, conhecida como enzima conversora de angiotensina II (ACE2), foi identificada como envolvida na endocitose mediada por receptor para entrada de SARS-CoV-2 nas células. Muitos estudos relataram as características clínicas do COVID-19: deterioração súbita da doença cerca de 1-2 semanas após o início; nível muito mais baixo de linfócitos, especialmente células natural killer (NK) no sangue periférico; citocinas pró-inflamatórias extremamente altas e proteína C reativa (PCR). Cerca de 15,7% dos pacientes desenvolvem pneumonia grave, e a tempestade de citocinas é um fator importante que leva à rápida progressão da doença. Atualmente, não existem medicamentos específicos para o COVID-19 e a tempestade de citocinas que ele causa. O baricitinib inibe intracelularmente o sinal pró-inflamatório de várias citocinas ao suprimir a Janus quinase (JAK) JAK1/JAK2. Foram demonstrados benefícios clínicos para os pacientes com artrite reumatoide (AR), lúpus eritematoso sistêmico ativo e dermatite atópica com bons registros de eficácia e segurança. Espera-se que o baricitinibe interrompa a passagem e a montagem intracelular do SARS-CoV-2 nas células-alvo mediadas pelo receptor ACE2 e trate a tempestade de citocinas causada pelo COVID-19. Vários ensaios clínicos estão atualmente investigando a droga, e um dos quais foi concluído com resultados encorajadores. Neste artigo, vamos elaborar o papel da tempestade de citocinas mediada pela via JAK-STAT na COVID-19 grave, os possíveis mecanismos do baricitinibe na redução da entrada viral nas células-alvo e a tempestade de citocinas, os pontos-chave da atenção farmacêutica baseada na os últimos relatórios de pesquisa, progresso de ensaios clínicos e instruções de medicamentos do FDA dos EUA, de modo a fornecer referência para o tratamento de COVID-19 grave.
Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients	http://doi.org/10.2147/DDDT.S259058	28/07/2020	Artigo completo publicado em periódico científico	10.2147/DDDT.S259058	1177-8881	11778881	DRUG DESIGN, DEVELOPMENT AND THERAPY	A2	0.784	71	4.63	-	['Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Interferon alfa', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Interferon alfa', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.	32801640	Drug design, development and therapy	1177-8881	10.2147/DDDT.S259058	Otimização da terapia com agentes antivirais em populações especiais de pacientes com COVID-19 A 	doença de coronavírus 2019 (COVID-19) causada pelo coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) é agora um surto global da doença. O tratamento antiviral atua como um dos meios mais importantes de infecção por SARS-CoV-2. A alteração das características fisiológicas em populações especiais pode levar à alteração na farmacocinética do medicamento, o que pode resultar em falha do tratamento ou aumento das reações adversas ao medicamento. Alguns medicamentos em potencial mostraram efeitos antivirais em infecções por SARS-CoV-2, como cloroquina, hidroxicloroquina, favipiravir, lopinavir/ritonavir, arbidol, interferon alfa e remedsivir. Aqui, revisamos a literatura sobre os efeitos clínicos desses agentes antivirais em pacientes com COVID-19 e fornecemos as possíveis opções de agentes antivirais para mulheres grávidas, pacientes idosos, pacientes com disfunção hepática ou renal e pacientes graves ou criticamente doentes que recebem terapia de substituição renal ou ECMO após a infecção por SARS-CoV-2.
Stem cell therapy for Covid‐19: possibilities and challenges	https://doi.org/10.1002/cbin.11440	07/08/2020	Artigo completo publicado em periódico científico	10.1002/cbin.11440	1065-6995	10656995	CELL BIOLOGY INTERNATIONAL (PRINT)	A4	0.762	81	4.0	-	['Terapia celular']	['Cell Therapy']	-	-	-	-	-	Terapia com células-tronco para Covid-19: possibilidades e desafios 	-
Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells	https://doi.org/10.1097/MD.0000000000021429	31/07/2020	Artigo completo publicado em periódico científico	10.1097/MD.0000000000021429	0025-7974	257974	MEDICINE (BALTIMORE, MD.)	A2	0.470	155	1.94	-	['Terapia celular']	['Cell Therapy']	These results indicated the clinical outcome and good tolerance of allogenic hUCMSCs transfer.	32756149	Medicine	1536-5964	10.1097/MD.0000000000021429	Remissão clínica de um paciente COVID-19 gravemente doente tratado por células-tronco mesenquimais de cordão umbilical humano 	Esses resultados indicaram o resultado clínico e boa tolerância da transferência alogênica de hUCMSCs.
Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19	https://doi.org/10.1111/trf.15975	08/08/2020	Artigo completo publicado em periódico científico	10.1111/trf.15975	0041-1132	411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente', 'Plasma convalescente']	['Convalescent Plasma', 'Convalescent Plasma']	We recommend extreme caution in using CP in critically ill patients more than 2 weeks after the onset of COVID-19 pneumonia.	32770691	Transfusion	1537-2995	10.1111/trf.15975	Lições aprendidas com o uso precoce compassivo de plasma convalescente em pacientes críticos com Covid-19 	Recomendamos extrema cautela no uso de CP em pacientes críticos mais de 2 semanas após o início da pneumonia por COVID-19.
BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?	https://doi.org/10.1038/s41419-020-2720-9	08/07/2020	Artigo completo publicado em periódico científico	10.1038/s41419-020-2720-9	2041-4889	20414889	CELL DEATH & DISEASE	A2	2.099	128	9.13	 Abstract Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2). In the light of its rapid global spreading, on 11 March 2020, the World Health Organization has declared it a pandemic. Interestingly, the global spreading of the disease is not uniform, but has so far left some countries relatively less affected. The reason(s) for this anomalous behavior are not fully understood, but distinct hypotheses have been proposed. Here we discuss the plausibility of two of them: the universal vaccination with  Bacillus Calmette–Guerin (BCG) and the widespread use of the antimalarial drug chloroquine (CQ). Both have been amply discussed in the recent literature with positive and negative conclusions: we felt that a comprehensive presentation of the data available on them would be useful. The analysis of data for countries with over 1000 reported COVID-19 cases has shown that the incidence and mortality were higher in countries in which BCG vaccination is either absent or has been discontinued, as compared with the countries with universal vaccination. We have performed a similar analysis of the data available for CQ, a widely used drug in the African continent and in other countries in which malaria is endemic; we discuss it here because CQ has been used as the drug to treat COVID-19 patients. Several African countries no longer recommend it officially for the fight against malaria, due to the development of resistance to  Plasmodium, but its use across the continent is still diffuse. Taken together, the data in the literature have led to the suggestion of a possible inverse correlation between BCG immunization and COVID-19 disease incidence and severity.	['Cloroquina', 'Cloroquina', 'Vacina BCG', 'Vacina BCG']	['Chloroquine', 'Chloroquine', 'BCG Vaccine', 'BCG Vaccine']	Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2). In the light of its rapid global spreading, on 11 March 2020, the World Health Organization has declared it a pandemic. Interestingly, the global spreading of the disease is not uniform, but has so far left some countries relatively less affected. The reason(s) for this anomalous behavior are not fully understood, but distinct hypotheses have been proposed. Here we discuss the plausibility of two of them: the universal vaccination with Bacillus Calmette-Guerin (BCG) and the widespread use of the antimalarial drug chloroquine (CQ). Both have been amply discussed in the recent literature with positive and negative conclusions: we felt that a comprehensive presentation of the data available on them would be useful. The analysis of data for countries with over 1000 reported COVID-19 cases has shown that the incidence and mortality were higher in countries in which BCG vaccination is either absent or has been discontinued, as compared with the countries with universal vaccination. We have performed a similar analysis of the data available for CQ, a widely used drug in the African continent and in other countries in which malaria is endemic; we discuss it here because CQ has been used as the drug to treat COVID-19 patients. Several African countries no longer recommend it officially for the fight against malaria, due to the development of resistance to Plasmodium, but its use across the continent is still diffuse. Taken together, the data in the literature have led to the suggestion of a possible inverse correlation between BCG immunization and COVID-19 disease incidence and severity.	32641762	Cell death & disease	2041-4889	10.1038/s41419-020-2720-9	Política de vacinação BCG e uso preventivo de cloroquina: eles têm impacto na pandemia de COVID-19? 	A doença de coronavírus 2019 (COVID-19) é uma síndrome respiratória aguda grave causada pelo Coronavírus 2 (SARS-CoV-2). À luz de sua rápida disseminação global, em 11 de março de 2020, a Organização Mundial da Saúde declarou uma pandemia. Curiosamente, a disseminação global da doença não é uniforme, mas até agora deixou alguns países relativamente menos afetados. A(s) razão(ões) para este comportamento anômalo não são totalmente compreendidos, mas hipóteses distintas foram propostas. Aqui discutimos a plausibilidade de dois deles: a vacinação universal com Bacillus Calmette-Guerin (BCG) e o uso generalizado do medicamento antimalárico cloroquina (CQ). Ambos foram amplamente discutidos na literatura recente com conclusões positivas e negativas: sentimos que uma apresentação abrangente dos dados disponíveis sobre eles seria útil. A análise de dados para países com mais de 1.000 casos notificados de COVID-19 mostrou que a incidência e a mortalidade foram maiores em países em que a vacinação BCG está ausente ou foi descontinuada, em comparação com os países com vacinação universal. Fizemos uma análise semelhante dos dados disponíveis para CQ, um medicamento amplamente utilizado no continente africano e em outros países onde a malária é endêmica; discutimos isso aqui porque o CQ tem sido usado como medicamento para tratar pacientes com COVID-19. Vários países africanos já não o recomendam oficialmente para o combate à malária, devido ao desenvolvimento de resistência ao Plasmodium, mas a sua utilização em todo o continente ainda é difusa. Em conjunto, os dados da literatura levaram à sugestão de uma possível correlação inversa entre a imunização BCG e a incidência e gravidade da doença COVID-19.
Early Identification of COVID-19 Cytokine Storm and Treatment with Anakinra or Tocilizumab	https://doi.org/10.1016/j.ijid.2020.07.081	05/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.081	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra', 'Tocilizumabe']	['Anakinra', 'Tocilizumab']	-	-	-	-	-	Identificação precoce da tempestade de citocinas COVID-19 e tratamento com anakinra ou tocilizumab 	-
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial	https://doi.org/10.1093/cid/ciaa1176	09/08/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa1176	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.                Clinical Trials Registration. NCT04434248.	['Favipiravir']	['Favipiravir']	In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.	32770240	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa1176	AVIFAVIR para tratamento de pacientes com COVID-19 moderado: resultados provisórios de um ensaio clínico randomizado multicêntrico de fase II/III 	-19 pacientes. Na fase piloto do ensaio clínico de Fase II/III, o AVIFAVIR permitiu a eliminação viral do SARS-CoV-2 em 62,5% dos pacientes em 4 dias e foi seguro e bem tolerado. Registro de Ensaios Clínicos. NCT04434248.
SARS-CoV-2 Clearance in COVID-19 Patients with Novaferon Treatment: A Randomized, Open-label, Parallel Group Trial	https://doi.org/10.1016/j.ijid.2020.07.053	02/08/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.053	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Lopinavir', 'Novaferon', 'Ritonavir']	['Lopinavir', 'Novaferon', 'Ritonavir']	Number ChiCTR2000029496 at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/).	32758689	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.07.053	Liberação de SARS-CoV-2 em pacientes com COVID-19 com tratamento com Novaferon: um número de ensaio de grupo paralelo randomizado, aberto e paralelo 	ChiCTR2000029496 no Registro de Ensaios Clínicos da China (http://www.chictr.org.cn/).
Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis	https://doi.org/10.1002/clc.23421	05/08/2020	Artigo completo publicado em periódico científico	10.1002/clc.23421	0160-9289	1609289	CLINICAL CARDIOLOGY (MAHWAH, N.J.)	A2	0.983	77	2.8	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	An association among the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID-19) is unclear. PubMed, EMBASE, MedRxiv, and BioRxiv were searched for relevant studies that assessed the association between application of ACEI/ARB and risk of COVID-19, inflammation level, severity COVID-19 infection, and death in patients with COVID-19. Eleven studies were included with 33 483 patients. ACEI/ARB therapy might be associated with the reduced inflammatory factor (interleukin-6) and elevated immune cells counts (CD3, CD8). Meta-analysis showed no significant increase in the risk of COVID-19 infection (odds ratio [OR]: 0.95, 95%CI: 0.89-1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID-19 (OR: 0.75, 95%CI: 0.59-0.96) and mortality (OR: 0.52, 95%CI: 0.35-0.79). Subgroup analyses showed among the general population, ACEI/ARB therapy was associated with reduced severe COVID-19 infection (OR: 0.79, 95%CI: 0.60-1.05) and all-cause mortality (OR: 0.31, 95%CI: 0.13-0.75), and COVID-19 infection (OR: 0.85, 95% CI: 0.66-1.08) were not increased. Among patients with hypertension, the use of an ACEI/ARB was associated with a lower severity of COVID-19 (OR: 0.73, 95%CI: 0.51-1.03) and lower mortality (OR: 0.57, 95%CI: 0.37-0.87), without evidence of an increased risk of COVID-19 infection (OR: 1.00). On the basis of the available evidence, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID-19, either in general population or hypertension patients. Our results need to be interpreted with caution considering the potential for residual confounders, and more well-designed studies that control the clinical confounders are necessary to confirm our findings.	32757246	Clinical cardiology	1932-8737	10.1002/clc.23421	Associação de inibidores da enzima conversora da angiotensina e bloqueadores dos receptores da angiotensina II com risco de COVID-19, nível de inflamação, gravidade e morte em pacientes com COVID-19: Uma revisão sistemática rápida e metanálise 	Uma associação entre o uso da enzima conversora de angiotensina ( inibidores da ECA) e bloqueadores dos receptores da angiotensina (BRAs) com os resultados clínicos da doença por coronavírus 2019 (COVID-19) não é claro. PubMed, EMBASE, MedRxiv e BioRxiv foram pesquisados por estudos relevantes que avaliaram a associação entre a aplicação de IECA/BRA e risco de COVID-19, nível de inflamação, gravidade da infecção por COVID-19 e morte em pacientes com COVID-19. Onze estudos foram incluídos com 33.483 pacientes. A terapia com IECA/BRA pode estar associada à redução do fator inflamatório (interleucina-6) e contagem elevada de células imunes (CD3, CD8). A metanálise não mostrou aumento significativo no risco de infecção por COVID-19 (odds ratio [OR]: 0,95, IC 95%: 0,89-1,05) em pacientes que receberam terapia com IECA/BRA, e a terapia com IECA/BRA foi associada a uma diminuição risco de COVID-19 grave (OR: 0,75, IC 95%: 0,59-0,96) e mortalidade (OR: 0,52, IC 95%: 0,35-0,79). Análises de subgrupo mostraram que entre a população geral, a terapia com IECA/BRA foi associada à redução da infecção grave por COVID-19 (OR: 0,79, IC 95%: 0,60-1,05) e mortalidade por todas as causas (OR: 0,31, IC 95%: 0,13- 0,75) e a infecção por COVID-19 (OR: 0,85, IC 95%: 0,66-1,08) não aumentaram. Entre os pacientes com hipertensão, o uso de IECA/BRA foi associado a menor gravidade de COVID-19 (OR: 0,73, IC 95%: 0,51-1,03) e menor mortalidade (OR: 0,57, IC 95%: 0,37-0,87 ), sem evidência de risco aumentado de infecção por COVID-19 (OR: 1,00). Com base nas evidências disponíveis, a terapia com IECA/BRA deve ser continuada em pacientes com risco ou com COVID-19, seja na população geral ou em pacientes com hipertensão. Nossos resultados precisam ser interpretados com cautela, considerando o potencial de confundidores residuais, e estudos mais bem desenhados que controlam os confundidores clínicos são necessários para confirmar nossos achados.
Therapeutic response to corticosteroids in a critically ill patient with COVID-19	https://doi.org/10.1097/MD.0000000000021597	31/07/2020	Artigo completo publicado em periódico científico	10.1097/MD.0000000000021597	0025-7974	257974	MEDICINE (BALTIMORE, MD.)	A2	0.470	155	1.94	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Resposta terapêutica aos corticosteróides em paciente crítico com COVID-19 	-
The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective,single-center trial	https://doi.org/10.1016/j.medcli.2020.06.007	11/06/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.007	0025-7753	257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']	Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms.	33043142	Medicina clinica (English ed.)	2387-0206	10.1016/j.medcle.2020.06.007	Os efeitos dos inibidores do sistema renina-angiotensina (RASI) na doença de coronavírus (COVID-19) com hipertensão: um estudo retrospectivo de centro 	único Pacientes COVID-19. Análises adicionais com um tamanho de amostragem maior são necessárias para explorar os mecanismos subjacentes.
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review	https://doi.org/10.1007/s11239-020-02235-z	03/08/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02235-z	0929-5305	9295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	 Abstract Many aspects of care such as management of hypercoagulable state in COVID-19 patients, especially those admitted to intensive care units is challenging in the rapidly evolving pandemic of novel coronavirus disease 2019 (COVID-19). We seek to systematically review the available evidence regarding the anticoagulation approach to prevent venous thromboembolism (VTE) among COVID-19 patients admitted to intensive care units. Electronic databases were searched for studies reporting venous thromboembolic events in patients admitted to the intensive care unit receiving any type of anticoagulation (prophylactic or therapeutic). The pooled prevalence (and 95% confidence interval [CI]) of VTE among patients receiving anticoagulant were calculated using the random-effects model. Subgroup pooled analyses were performed with studies reported prophylactic anticoagulation alone and with studies reported mixed prophylactic and therapeutic anticoagulation. We included twelve studies (8 Europe; 2 UK; 1 each from the US and China) in our systematic review and meta-analysis. All studies utilized LMWH or unfractionated heparin as their pharmacologic thromboprophylaxis, either prophylactic doses or therapeutic doses. Seven studies reported on the proportion of patients with the previous history of VTE (range 0–10%). The pooled prevalence of VTE among ICU patients receiving prophylactic or therapeutic anticoagulation across all studies was 31% (95% CI 20–43%). Subgroup pooled analysis limited to studies reported prophylactic anticoagulation alone and mixed (therapeutic and prophylactic anticoagulation) reported pooled prevalences of VTE of 38% (95% CI 10–70%) and 27% (95% CI 17–40%) respectively. With a high prevalence of thromboprophylaxis failure among COVID-19 patients admitted to intensive care units, individualised rather than protocolised VTE thromboprophylaxis would appear prudent at interim.	['Heparina', 'Heparina']	['Heparin', 'Heparin']	-	-	-	-	-	Tromboembolismo venoso em pacientes críticos com COVID-19 recebendo anticoagulação profilática ou terapêutica: uma revisão sistemática 	-
COVID-19, asthma, and biologic therapies: What we need to know	https://doi.org/10.1016/j.waojou.2020.100126	16/05/2020	Artigo completo publicado em periódico científico	10.1016/j.waojou.2020.100126	1939-4551	19394551	THE WORLD ALLERGY ORGANIZATION JOURNAL	A1	1.140	44	4.79	-	['Benralizumabe', 'Corticosteroides', 'Dupilumabe', 'Mepolizumabe', 'Omalizumabe', 'Reslizumabe']	['Benralizumab', 'Corticosteroids', 'Dupilumab', 'Mepolizumab', 'Omalizumab', 'Reslizumab']	Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a challenge. Authorities and physicians are still learning how COVID-19 affects people with underlying diseases, and severe asthma is not an exception. Unless relevant data emerge that change our understanding of the relative safety of medications indicated in patients with asthma during this pandemic, clinicians must follow the recommendations of current evidence-based guidelines for preventing loss of control and exacerbations. Also, with the absence of data that would indicate any potential harm, current advice is to continue the administration of biological therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-2, the decision to maintain or postpone biological therapy until the patient recovers should be a case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-19 in patients with severe asthma, including those treated with biologics, will help to address a clinical challenge in which we have more questions than answers.	32426090	The World Allergy Organization journal	1939-4551	10.1016/j.waojou.2020.100126	COVID-19, asma e terapias biológicas: o que precisamos saber 	Gerenciar pacientes com asma grave durante a pandemia de coronavírus e COVID-19 é um desafio. Autoridades e médicos ainda estão aprendendo como o COVID-19 afeta pessoas com doenças subjacentes, e a asma grave não é exceção. A menos que surjam dados relevantes que mudem nossa compreensão sobre a segurança relativa dos medicamentos indicados em pacientes com asma durante esta pandemia, os médicos devem seguir as recomendações das diretrizes atuais baseadas em evidências para prevenir a perda de controle e exacerbações. Além disso, com a ausência de dados que indiquem qualquer dano potencial, o conselho atual é continuar a administração de terapias biológicas durante a pandemia de COVID-19 em pacientes com asma para os quais tais terapias são claramente indicadas e têm sido eficazes. Para pacientes com asma grave infectados por SARS-CoV-2, a decisão de manter ou adiar a terapia biológica até que o paciente se recupere deve ser uma decisão baseada caso a caso e apoiada por uma equipe multidisciplinar. Um registro de casos de COVID-19 em pacientes com asma grave, incluindo aqueles tratados com produtos biológicos, ajudará a enfrentar um desafio clínico em que temos mais perguntas do que respostas.
Abordaje terapéutico del SARS-CoV-2 (COVID-19) mediante células mesenquimales de médula ósea alogénica expandidas. Conceptos a propósito de un primer caso en España	https://doi.org/10.1016/j.medcli.2020.06.018	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.018	0025-7753	257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Terapia celular']	['Cell Therapy']	-	-	-	-	-	Abordaje terapêutica do SARS-CoV-2 (COVID-19) através de células mesenquimales de médula ósea alogénica expandidas. Conceitos a propósito de un primer caso en España 	-
Clinical outcomes of COVID‑19 in Wuhan, China: a large cohort study	https://doi.org/10.1186/s13613-020-00706-3	31/07/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00706-3	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	 Abstract  Background Since December 2019, an outbreak of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) initially emerged in Wuhan, China, and has spread worldwide now. Clinical features of patients with COVID-19 have been described. However, risk factors leading to in-hospital deterioration and poor prognosis in COVID-19 patients with severe disease have not been well identified.  Methods In this retrospective, single-center cohort study, 1190 adult inpatients (≥ 18 years old) with laboratory-confirmed COVID-19 and determined outcomes (discharged or died) were included from Wuhan Infectious Disease Hospital from December 29, 2019 to February 28, 2020. The final follow-up date was March 2, 2020. Clinical data including characteristics, laboratory and imaging information as well as treatments were extracted from electronic medical records and compared. A multivariable logistic regression model was used to explore the potential predictors associated with in-hospital deterioration and death.  Results 1190 patients with confirmed COVID-19 were included. Their median age was 57 years (interquartile range 47–67 years). Two hundred and sixty-one patients (22%) developed a severe illness after admission. Multivariable logistic regression demonstrated that higher SOFA score (OR 1.32, 95% CI 1.22–1.43, per score increase,  p &lt; 0.001 for deterioration and OR 1.30, 95% CI 1.11–1.53, per score increase,  p = 0.001 for death), lymphocytopenia (OR 1.81, 95% CI 1.13–2.89  p = 0.013 for deterioration; OR 4.44, 95% CI 1.26–15.87,  p = 0.021 for death) on admission were independent risk factors for in-hospital deterioration from not severe to severe disease and for death in severe patients. On admission D-dimer greater than 1 μg/L (OR 3.28, 95% CI 1.19–9.04,  p = 0.021), leukocytopenia (OR 5.10, 95% CI 1.25–20.78), thrombocytopenia (OR 8.37, 95% CI 2.04–34.44) and history of diabetes (OR 11.16, 95% CI 1.87–66.57,  p = 0.008) were also associated with higher risks of in-hospital death in severe COVID-19 patients. Shorter time interval from illness onset to non-invasive mechanical ventilation in the survivors with severe disease was observed compared with non-survivors (10.5 days, IQR 9.25–11.0 vs. 16.0 days, IQR 11.0–19.0 days,  p = 0.030). Treatment with glucocorticoids increased the risk of progression from not severe to severe disease (OR 3.79, 95% CI 2.39–6.01,  p &lt; 0.001). Administration of antiviral drugs especially oseltamivir or ganciclovir is associated with a decreased risk of death in severe patients (OR 0.17, 95% CI 0.05–0.64,  p &lt; 0.001).  Conclusions High SOFA score and lymphocytopenia on admission could predict that not severe patients would develop severe disease in-hospital. On admission elevated D-dimer, leukocytopenia, thrombocytopenia and diabetes were independent risk factors of in-hospital death in severe patients with COVID-19. Administration of oseltamivir or ganciclovir might be beneficial for reducing mortality in severe patients.	['Corticosteroides', 'Ganciclovir', 'Oseltamivir']	['Corticosteroids', 'Ganciclovir', 'Oseltamivir']	-	-	-	-	-	Resultados clínicos do COVID-19 em Wuhan, China: um grande estudo de coorte 	-
The characteristics and outcomes of 681 severe cases with COVID-19 in China.	https://doi.org/10.1016/j.jcrc.2020.07.003	08/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.07.003	0883-9441	8839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Ácido ascórbico', 'Antibióticos', 'Antifúngicos', 'Antivirais', 'Corticosteroides', 'Ganciclovir', 'Imunoglobulina', 'Interferon alfa', 'Oseltamivir', 'Ribavirina', 'Umifenovir']	['Ascorbic acid', 'Antibiotics', 'Antifungals', 'Antivirals', 'Corticosteroids', 'Ganciclovir', 'Immunoglobulin', 'Interferon alpha', 'Oseltamivir', 'Ribavirin', 'Umifenovir']	The combination of NLR and acute myocardial injury on admission was highly predictive of mortality and survival. Clinicians should adopt more aggressive strategies for patients with a high NLR (>6.66) combined with myocardial injury. β-blockers and ACEI/ARB, as well as arbidol and ribavirin, were effective in COVID-19 patients with cardiovascular disease.	32736197	Journal of critical care	1557-8615	10.1016/j.jcrc.2020.07.003	As características e resultados de 681 casos graves com COVID-19 na China. 	A combinação de RNL e lesão miocárdica aguda na admissão foi altamente preditiva de mortalidade e sobrevida. Os médicos devem adotar estratégias mais agressivas para pacientes com alta RNL (>6,66) combinada com lesão miocárdica. Betabloqueadores e IECA/BRA, bem como arbidol e ribavirina, foram eficazes em pacientes com COVID-19 com doença cardiovascular.
High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects	https://doi.org/10.3389/fimmu.2020.01660	14/07/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.01660	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Imunoglobulina']	['Immunoglobulin']	The current outbreak of viral pneumonia, caused by novel coronavirus SARS-CoV-2, is the focus of worldwide attention. The WHO declared the COVID-19 outbreak a pandemic event on Mar 12, 2020, and the number of confirmed cases is still on the rise worldwide. While most infected individuals only experience mild symptoms or may even be asymptomatic, some patients rapidly progress to severe acute respiratory failure with substantial mortality, making it imperative to develop an efficient treatment for severe SARS-CoV-2 pneumonia alongside supportive care. So far, the optimal treatment strategy for severe COVID-19 remains unknown. Intravenous immunoglobulin (IVIg) is a blood product pooled from healthy donors with high concentrations of immunoglobulin G (IgG) and has been used in patients with autoimmune and inflammatory diseases for more than 30 years. In this review, we aim to highlight the known mechanisms of immunomodulatory effects of high-dose IVIg therapy, the immunopathological hypothesis of viral pneumonia, and the clinical evidence of IVIg therapy in viral pneumonia. We then make cautious therapeutic inferences about high-dose IVIg therapy in treating severe COVID-19. These inferences may provide relevant and useful insights in order to aid treatment for COVID-19.	32760407	Frontiers in immunology	1664-3224	10.3389/fimmu.2020.01660	Imunoglobulinas intravenosas de alta dose no tratamento da pneumonia viral aguda grave: os mecanismos conhecidos e os efeitos clínicos 	O atual surto de pneumonia viral, causado pelo novo coronavírus SARS-CoV-2, é o foco da atenção mundial. A OMS declarou o surto de COVID-19 um evento pandêmico em 12 de março de 2020, e o número de casos confirmados ainda está aumentando em todo o mundo. Embora a maioria dos indivíduos infectados apresente apenas sintomas leves ou possa até ser assintomática, alguns pacientes evoluem rapidamente para insuficiência respiratória aguda grave com mortalidade substancial, tornando imperativo desenvolver um tratamento eficiente para pneumonia grave por SARS-CoV-2 juntamente com cuidados de suporte. Até agora, a estratégia de tratamento ideal para COVID-19 grave permanece desconhecida. A imunoglobulina intravenosa (IVIg) é um produto sanguíneo reunido de doadores saudáveis com altas concentrações de imunoglobulina G (IgG) e tem sido usada em pacientes com doenças autoimunes e inflamatórias há mais de 30 anos. Nesta revisão, pretendemos destacar os mecanismos conhecidos dos efeitos imunomoduladores da terapia com altas doses de IVIg, a hipótese imunopatológica da pneumonia viral e a evidência clínica da terapia de IVIg na pneumonia viral. Em seguida, fazemos inferências terapêuticas cautelosas sobre a terapia com altas doses de IVIg no tratamento de COVID-19 grave. Essas inferências podem fornecer informações relevantes e úteis para ajudar no tratamento do COVID-19.
Prolonged asymptomatic SARS-CoV-2 infection in a child receiving immunosuppressive therapy	https://doi.org/10.1002/ppul.24983	31/07/2020	Artigo completo publicado em periódico científico	10.1002/ppul.24983	8755-6863	87556863	PEDIATRIC PULMONOLOGY	A1	0.927	111	3.21	-	['Metotrexato', 'Prednisona']	['Methotrexate', 'Prednisone']	-	-	-	-	-	Infecção prolongada assintomática por SARS-CoV-2 em uma criança recebendo terapia imunossupressora 	-
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19	https://doi.org/10.1016/j.lfs.2020.118185	01/08/2020	Artigo completo publicado em periódico científico	10.1016/j.lfs.2020.118185	0024-3205	243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Anticorpos', 'Imunoglobulina', 'Interferon', 'Plasma convalescente', 'Terapia celular']	['Antibodies', 'Immunoglobulin', 'Interferon', 'Convalescent Plasma', 'Cell Therapy']	Based on the available evidence, it seems that treatment with immunotherapy along with other standard cares could be an effective and safe approach to modulate the immune system and improvement of clinical outcomes.	32750438	Life sciences	1879-0631	10.1016/j.lfs.2020.118185	O sistema imunológico como alvo para terapia de SARS-CoV-2: uma revisão sistemática das imunoterapias atuais para COVID-19 	Com base nas evidências disponíveis, parece que o tratamento com imunoterapia juntamente com outros cuidados padrão pode ser uma abordagem eficaz e segura modular o sistema imunológico e melhorar os resultados clínicos.
Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection	https://doi.org/10.1016/j.mayocp.2020.05.005	19/05/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.05.005	0025-6196	256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Among candidate drugs to treat coronavirus disease 2019 (COVID-19), the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense worldwide attention. Even as the efficacy of this combination is under evaluation, clinicians have begun to use it largely. As these medications are known to prolong the QT interval, we analyzed serial electrocardiograms recorded in patients hospitalized for COVID-19 pneumonia and treated with HCQ + AZ. Fifty consecutive patients received the combination of HCQ (600 mg/d for 10 days) and AZ (500 mg/d on day 1 and 250 mg/d from day 2 to day 5). Twelve-lead electrocardiograms were recorded before treatment, at day 3, at day 5, and at discharge. The median age of patients was 68 years (interquartile range, 53-81 years); 28 (56%) were men. The main comorbidities were hypertension (36%; n=18) and diabetes (16%; n=8). The mean corrected QT (QTc) interval was 408 ms at baseline and increased up to 437 ms at day 3 and to 456 ms at day 5. Thirty-eight patients (76%) presented short-term modifications of the QTc duration (>30 ms). Treatment discontinuation was decided in 6 patients (12%), leading to QTc normalization in 5 of them. No deaths and no cardiac arrhythmic events were observed in this cohort. Our report confirms that a short duration treatment with HCQ + AZ modifies the QTc interval. The treatment had to be discontinued for QTc modifications in 12% of patients. Nevertheless, in inpatients hospitalized for COVID-19, we did not observe any clinically relevant consequences of these transitory modifications. In conclusion, when patients are treated with HCQ + AZ, cardiac monitoring should be regularly performed and hospital settings allow monitoring under in safe conditions.	32753141	Mayo Clinic proceedings	1942-5546	10.1016/j.mayocp.2020.05.005	Modificações agudas do intervalo QT durante o tratamento com hidroxicloroquina-azitromicina no contexto da infecção por COVID- 	19 Mesmo que a eficácia dessa combinação esteja sendo avaliada, os médicos começaram a usá-la amplamente. Como esses medicamentos são conhecidos por prolongar o intervalo QT, analisamos eletrocardiogramas seriados registrados em pacientes hospitalizados por pneumonia por COVID-19 e tratados com HCQ + AZ. Cinquenta pacientes consecutivos receberam a combinação de HCQ (600 mg/d por 10 dias) e AZ (500 mg/d no dia 1 e 250 mg/d do dia 2 ao dia 5). Eletrocardiogramas de doze derivações foram registrados antes do tratamento, no dia 3, no dia 5 e na alta. A idade mediana dos pacientes foi de 68 anos (intervalo interquartil, 53-81 anos); 28 (56%) eram homens. As principais comorbidades foram hipertensão (36%; n=18) e diabetes (16%; n=8). A média do intervalo QT corrigido (QTc) foi de 408 ms na linha de base e aumentou para 437 ms no dia 3 e para 456 ms no dia 5. Trinta e oito pacientes (76%) apresentaram modificações de curto prazo na duração do QTc (>30 EM). A descontinuação do tratamento foi decidida em 6 pacientes (12%), levando à normalização do QTc em 5 deles. Nenhuma morte e nenhum evento arrítmico cardíaco foram observados nesta coorte. Nosso relato confirma que um tratamento de curta duração com HCQ + AZ modifica o intervalo QTc. O tratamento teve que ser descontinuado para modificações do QTc em 12% dos pacientes. No entanto, em pacientes internados por COVID-19, não observamos nenhuma consequência clinicamente relevante dessas modificações transitórias. Em conclusão, quando os pacientes são tratados com HCQ + AZ, o monitoramento cardíaco deve ser realizado regularmente e as configurações hospitalares permitem o monitoramento em condições seguras.
Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients	https://onlinelibrary.wiley.com/doi/10.1111/joim.13163	03/08/2020	Artigo completo publicado em periódico científico	10.1111/joim.13163	0954-6820	9546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Uso do Antagonista de IL-6R Tocilizumab em Pacientes Hospitalizados com COVID-19 	-
Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study	https://onlinelibrary.wiley.com/doi/abs/10.1111/joim.13162	03/08/2020	Artigo completo publicado em periódico científico	10.1111/joim.13162	0954-6820	9546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Tocilizumabe']	['Tocilizumab']	Treatment with COX-2 inhibitors was not associated with an increase in adverse outcomes. Its potential for therapeutic use as an immune modulator warrants further evaluation in a large randomised controlled trial.	32744399	Journal of internal medicine	1365-2796	10.1111/joim.13162	O tocilizumab reduz o tempo de ventilação mecânica e o tempo de internação hospitalar em pacientes com COVID-19 grave: um estudo de coorte retrospectivo 	O tratamento com inibidores de COX-2 não foi associado a um aumento de desfechos adversos. Seu potencial para uso terapêutico como modulador imunológico merece avaliação adicional em um grande estudo controlado randomizado.
Effect of favipiravir and an anti- inflammatory strategy for COVID-19	https://doi.org/10.1186/s13054-020-03137-5	09/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03137-5	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Favipiravir']	['Favipiravir']	-	-	-	-	-	Efeito do favipiravir e uma estratégia anti-inflamatória para COVID-19 	-
Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis	https://www.tandfonline.com/doi/full/10.1080/17476348.2020.1804365	31/07/2020	Artigo completo publicado em periódico científico	10.1080/17476348.2020.1804365	1747-6348	17476348	EXPERT REVIEW OF RESPIRATORY MEDICINE	A3	0.939	47	3.79	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Mortalidade em pacientes com COVID-19 com síndrome do desconforto respiratório agudo e uso de corticosteróides: uma revisão sistemática e metanálise 	-
BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data	https://doi.org/10.1111/lam.13365	30/07/2020	Artigo completo publicado em periódico científico	10.1111/lam.13365	0266-8254	2668254	LETTERS IN APPLIED MICROBIOLOGY	A4	0.593	116	3.35	-	['Vacina BCG', 'Vacina BCG']	['BCG vaccine', 'BCG vaccine']	-	-	-	-	-	A vacinação com BCG no início da vida não melhora o resultado COVID-19 das populações idosas, com base em dados relatados nacionalmente 	-
Remdesivir: A beacon of hope from Ebola virus disease to COVID-19	https://doi.org/10.1002/rmv.2133	30/07/2020	Artigo completo publicado em periódico científico	10.1002/rmv.2133	1052-9276	10529276	REVIEWS IN MEDICAL VIROLOGY (PRINT)	A1	2.371	96	9.42	-	['Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir']	Since the emergence of coronavirus disease 2019 (Covid-19), many studies have been performed to characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and find the optimum way to combat this virus. After suggestions and assessments of several therapeutic options, remdesivir (GS-5734), a direct-acting antiviral drug previously tested against Ebola virus disease, was found to be moderately effective and probably safe for inhibiting SARS-CoV-2 replication. Finally, on 1 May 2020, remdesivir (GS-5734) was granted emergency use authorization as an investigational drug for the treatment of Covid-19 by the Food and Drug Administration. However, without a doubt, there are challenging days ahead. Here, we provide a review of the latest findings (based on preprints, post-prints, and news releases in scientific websites) related to remdesivir efficacy and safety for the treatment of Covid-19, along with covering remdesivir history from bench-to-bedside, as well as an overview of its mechanism of action. In addition, active clinical trials, as well as challenging issues related to the future of remdesivir in Covid-19, are covered. Up to the date of writing this review (19 May 2020), there is one finished randomized clinical trial and two completed non-randomized studies, in addition to some ongoing studies, including three observational studies, two expanded access studies, and seven active clinical trials registered on the clinicaltrials.gov and isrctn.com websites. Based on these studies, it seems that remdesivir could be an effective and probably safe treatment option for Covid-19. However, more randomized controlled studies are required.	33210457	Reviews in medical virology	1099-1654	10.1002/rmv.2133	Remdesivir: um farol de esperança da doença do vírus Ebola para o COVID-19 	Desde o surgimento da doença por coronavírus 2019 (Covid-19), muitos estudos foram realizados para caracterizar o coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) e encontrar o a melhor forma de combater este vírus. Após sugestões e avaliações de várias opções terapêuticas, o remdesivir (GS-5734), um medicamento antiviral de ação direta previamente testado contra a doença do vírus Ebola, mostrou-se moderadamente eficaz e provavelmente seguro para inibir a replicação do SARS-CoV-2. Finalmente, em 1º de maio de 2020, o remdesivir (GS-5734) recebeu autorização de uso emergencial como medicamento experimental para o tratamento do Covid-19 pela Food and Drug Administration. No entanto, sem dúvida, há dias desafiadores pela frente. Aqui, fornecemos uma revisão das descobertas mais recentes (com base em pré-impressões, pós-impressões e comunicados de imprensa em sites científicos) relacionadas à eficácia e segurança do remdesivir para o tratamento do Covid-19, além de cobrir o histórico do remdesivir de bancada a beira do leito, bem como uma visão geral de seu mecanismo de ação. Além disso, são abordados ensaios clínicos ativos, bem como questões desafiadoras relacionadas ao futuro do remdesivir no Covid-19. Até a data de redação desta revisão (19 de maio de 2020), há um ensaio clínico randomizado concluído e dois estudos não randomizados concluídos, além de alguns estudos em andamento, incluindo três estudos observacionais, dois estudos de acesso expandido e sete estudos clínicos ativos ensaios registrados nos sites clinicaltrials.gov e isrctn.com. Com base nesses estudos, parece que o remdesivir pode ser uma opção de tratamento eficaz e provavelmente segura para o Covid-19. No entanto, mais estudos controlados randomizados são necessários.
Liver injury in remdesivir-treated COVID-19 patients	https://doi.org/10.1007/s12072-020-10077-3	28/07/2020	Artigo completo publicado em periódico científico	10.1007/s12072-020-10077-3	1936-0533	19360533	HEPATOLOGY INTERNATIONAL	A3	1.555	52	6.63	-	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Lesão hepática em pacientes com COVID-19 tratados com remdesivir 	-
Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19)	https://doi.org/10.1016/j.cgh.2020.07.050	02/08/2020	Artigo completo publicado em periódico científico	10.1016/j.cgh.2020.07.050	1542-3565	15423565	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY	A1	2.691	183	5.19	-	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Distúrbios hepáticos com uso de remdesivir para coronavírus 2019 (COVID-19) 	-
Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge	https://doi.org/10.1016/j.ijid.2020.07.023	25/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.023	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Sarilumabe', 'Tocilizumabe']	['Sarilumab', 'Tocilizumab']	IL6ri administration prior to >45% FiO	32721528	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.07.023	A administração precoce de inibidores da interleucina-6 para pacientes com doença grave de Covid-19 está associada à diminuição da intubação, redução da mortalidade e aumento 	da administração de IL6ri na alta antes de > 45% de FiO
Appropriate use of Tocilizumab in COVID-19 Infection	https://doi.org/10.1016/j.ijid.2020.07.036	26/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.07.036	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Uso apropriado de Tocilizumab na infecção por COVID-19 	-
Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia	https://doi.org/10.1177/1074248420935740	23/07/2020	Artigo completo publicado em periódico científico	10.1177/1074248420935740	1074-2484	10742484	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS	A2	0.685	52	2.63	  In recent months, the new coronavirus SARS-CoV-2 has emerged as a worldwide threat with about 4.2 million confirmed cases and almost 300 000 deaths. Its major clinical presentation is characterized by respiratory symptoms ranging from mild cough to serve pneumonia with fever and potentially even death. Until today, there is no known medication to improve clinical symptoms or even prevent or fight the infection. The search for a useful vaccination is ongoing and it will probably not be available before the end of 2020. In this review, we highlight hydroxychloroquine (HCQ) as a potential agent to prevent coronavirus disease 2019 (COVID-19) and reduce as well as shorten clinical symptoms. Moreover, it might serve as a potential post-exposition prophylaxis. Although it has been used in the treatment of rheumatoid arthritis, discoid or systemic lupus erythematosus, and malaria prophylaxis and therapy for decades, knowledge on HCQ as a potential treatment for COVID-19 is limited and multiple clinical trials have just emerged. Especially, rare HCQ side effects which were of minor importance for use in selected indications might gain major relevance with population-wide application. These rare side effects include retinopathy and—even more important—QT prolongation leading to sudden cardiac death by malignant arrhythmias. 	['Hidroxicloroquina']	['Hydroxychloroquine']	In recent months, the new coronavirus SARS-CoV-2 has emerged as a worldwide threat with about 4.2 million confirmed cases and almost 300 000 deaths. Its major clinical presentation is characterized by respiratory symptoms ranging from mild cough to serve pneumonia with fever and potentially even death. Until today, there is no known medication to improve clinical symptoms or even prevent or fight the infection. The search for a useful vaccination is ongoing and it will probably not be available before the end of 2020. In this review, we highlight hydroxychloroquine (HCQ) as a potential agent to prevent coronavirus disease 2019 (COVID-19) and reduce as well as shorten clinical symptoms. Moreover, it might serve as a potential post-exposition prophylaxis. Although it has been used in the treatment of rheumatoid arthritis, discoid or systemic lupus erythematosus, and malaria prophylaxis and therapy for decades, knowledge on HCQ as a potential treatment for COVID-19 is limited and multiple clinical trials have just emerged. Especially, rare HCQ side effects which were of minor importance for use in selected indications might gain major relevance with population-wide application. These rare side effects include retinopathy and-even more important-QT prolongation leading to sudden cardiac death by malignant arrhythmias.	32700555	Journal of cardiovascular pharmacology and therapeutics	1940-4034	10.1177/1074248420935740	Hidroxicloroquina na terapia COVID-19: proteção versus proarritmia 	Nos últimos meses, o novo coronavírus SARS-CoV-2 surgiu como uma ameaça mundial com cerca de 4,2 milhões de casos confirmados e quase 300 mil mortes. Sua principal apresentação clínica é caracterizada por sintomas respiratórios que vão desde tosse leve até pneumonia com febre e potencialmente até óbito. Até hoje, não há medicação conhecida para melhorar os sintomas clínicos ou mesmo prevenir ou combater a infecção. A busca por uma vacina útil está em andamento e provavelmente não estará disponível antes do final de 2020. Nesta revisão, destacamos a hidroxicloroquina (HCQ) como um agente potencial para prevenir a doença de coronavírus 2019 (COVID-19) e reduzir, bem como encurtar os sintomas clínicos. Além disso, pode servir como uma potencial profilaxia pós-exposição. Embora tenha sido usado no tratamento da artrite reumatóide, lúpus eritematoso sistêmico ou discóide e na profilaxia e terapia da malária há décadas, o conhecimento sobre o HCQ como um tratamento potencial para COVID-19 é limitado e vários ensaios clínicos acabaram de surgir. Especialmente, os efeitos colaterais raros da HCQ, que eram de menor importância para uso em indicações selecionadas, podem ganhar grande relevância com a aplicação em toda a população. Esses efeitos colaterais raros incluem retinopatia e, ainda mais importante, prolongamento do intervalo QT levando à morte súbita cardíaca por arritmias malignas.
Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir	https://doi.org/10.1016/j.medcli.2020.06.026	09/07/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.026	0025-7753	257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	-	-	-	-	-	Interações medicamentosas potenciais em pacientes COVID 19 em tratamento com lopinavir/ritonavir 	-
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients	https://doi.org/10.1016/j.jaut.2020.102511	08/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102511	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']	In cases of COVID-19 acute respiratory distress syndrome, an excessive host inflammatory response has been reported, with elevated serum interleukin-6 levels. In this multicenter retrospective cohort study we included adult patients with COVID-19, need of respiratory support, and elevated C-reactive protein who received intravenous tocilizumab in addition to standard of care. Control patients not receiving tocilizumab were matched for sex, age and respiratory support. We selected survival as the primary endpoint, along with need for invasive ventilation, thrombosis, hemorrhage, and infections as secondary endpoints at 30 days. We included 64 patients with COVID-19 in the tocilizumab group and 64 matched controls. At baseline the tocilizumab group had longer symptom duration (13 ± 5 vs. 9 ± 5 days) and received hydroxychloroquine more often than controls (100% vs. 81%). The mortality rate was similar between groups (27% with tocilizumab vs. 38%) and at multivariable analysis risk of death was not significantly influenced by tocilizumab (hazard ratio 0.61, 95% confidence interval 0.33-1.15), while being associated with the use at baseline of non invasive mechanical or invasive ventilation, and the presence of comorbidities. Among secondary outcomes, tocilizumab was associated with a lower probability of requiring invasive ventilation (hazard ratio 0.36, 95% confidence interval 0.16-0.83; P = 0.017) but not with the risk of thrombosis, bleeding, or infections. The use of intravenous tocilizumab was not associated with changes in 30-day mortality in patients with COVID-19 severe respiratory impairment. Among the secondary outcomes there was less use of invasive ventilation in the tocilizumab group.	32713677	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102511	Bloqueio do receptor de interleucina-6 com tocilizumabe intravenoso na síndrome do desconforto respiratório agudo COVID-19: Uma análise retrospectiva de sobrevida de 128 pacientes 	Em casos de síndrome do desconforto respiratório agudo COVID-19, uma resposta inflamatória excessiva do hospedeiro foi relatada, com níveis séricos de interleucina-6. Neste estudo de coorte retrospectivo multicêntrico, incluímos pacientes adultos com COVID-19, necessidade de suporte respiratório e proteína C reativa elevada que receberam tocilizumabe intravenoso além do tratamento padrão. Os pacientes controle que não receberam tocilizumabe foram pareados por sexo, idade e suporte respiratório. Selecionamos a sobrevivência como o desfecho primário, juntamente com a necessidade de ventilação invasiva, trombose, hemorragia e infecções como desfechos secundários em 30 dias. Incluímos 64 pacientes com COVID-19 no grupo tocilizumabe e 64 controles pareados. No início do estudo, o grupo de tocilizumab teve maior duração dos sintomas (13 ± 5 vs. 9 ± 5 dias) e recebeu hidroxicloroquina com mais frequência do que os controles (100% vs. 81%). A taxa de mortalidade foi semelhante entre os grupos (27% com tocilizumab vs. 38%) e na análise multivariada o risco de morte não foi significativamente influenciado pelo tocilizumab (hazard ratio 0,61, intervalo de confiança de 95% 0,33-1,15), estando associado ao uso na linha de base de ventilação mecânica não invasiva ou invasiva e a presença de comorbidades. Entre os desfechos secundários, o tocilizumabe foi associado a uma menor probabilidade de necessitar de ventilação invasiva (taxa de risco 0,36, intervalo de confiança de 95% 0,16-0,83; P = 0,017), mas não com o risco de trombose, sangramento ou infecções. O uso de tocilizumabe intravenoso não foi associado a alterações na mortalidade em 30 dias em pacientes com insuficiência respiratória grave por COVID-19. Entre os desfechos secundários houve menor uso de ventilação invasiva no grupo tocilizumab.
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients	https://doi.org/10.1016/j.chom.2020.07.005	18/07/2020	Artigo completo publicado em periódico científico	10.1016/j.chom.2020.07.005	1931-3128	19313128	CELL HOST & MICROBE	A1	9.373	201	19.72	-	['Interferon alfa']	['Interferon alpha']	Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.	32707096	Cell host & microbe	1934-6069	10.1016/j.chom.2020.07.005	Estudo de coorte multicêntrico retrospectivo mostra que a terapia precoce com interferon está associada a respostas clínicas favoráveis em pacientes com COVID-19 Os 	interferons (IFNs) são amplamente utilizados no tratamento de pacientes com doença de coronavírus 2019 (COVID-19). No entanto, um relatório recente do ACE2, o fator do hospedeiro mediando a infecção por SARS-Cov-2, identificando-o como estimulado por interferon, levantou uma preocupação de segurança considerável. Para examinar a associação entre o uso e o momento do IFN-α2b e os resultados clínicos, analisamos em um estudo de coorte multicêntrico retrospectivo de 446 pacientes com COVID-19 em Hubei, China. Modelos de regressão estimaram que a administração precoce (≤ 5 dias após a admissão) de IFN-α2b foi associada à redução da mortalidade hospitalar em comparação com a não admissão de IFN-α2b, enquanto a administração tardia de IFN-α2b foi associada a aumento da mortalidade. Entre os sobreviventes, o IFN-α2b precoce não foi associado à alta hospitalar ou melhora na tomografia computadorizada (TC), enquanto o IFN-α2b tardio foi associado à recuperação tardia. Além disso, IFN-α2b precoce e umifenovir sozinhos ou em conjunto foram associados com mortalidade reduzida e recuperação acelerada em comparação com o tratamento com lopinavir/ritonavir (LPV/r) sozinho. Concluímos que a administração de IFN-α2b durante o estágio inicial de COVID-19 pode induzir respostas clínicas favoráveis.
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine	https://doi.org/10.1016/j.clim.2020.108544	22/07/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108544	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['N-acetilcisteína']	['N-acetylcysteine']	-	-	-	-	-	Bloqueio terapêutico da inflamação na infecção grave por COVID-19 com n-acetilcisteína intravenosa 	-
Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report	https://link.springer.com/article/10.1007/s10557-020-07044-3	30/07/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s10557-020-07044-3	0920-3206	9203206	CARDIOVASCULAR DRUGS AND THERAPY	A2	0.860	71	3.51	-	['Anakinra', 'Anakinra']	['Anakinra', 'Anakinra']	The Shanghai panel, and a parallel medical group in Guangzhou, are advising the use of high-dose IV ascorbate for the treatment of ARDS, along with other supportive therapies, including Vitamin D and zinc. We report preliminary progress in using this treatment for 50 consecutive cases treated in Shanghai hospitals, consistent with earlier reports from a meta-analysis of the use of IV ascorbate to treat sepsis. We provide an instructive clinical anecdote regarding a single family where one elderly member with cardiac and other major comorbidities developed and survived ARDS-related sepsis following daily treatments that included 15 g of IV ascorbate. None of her adult caregivers who had ingested between 2 and 10 g of ascorbate daily developed COVID-19.	32734502	Cardiovascular drugs and therapy	1573-7241	10.1007/s10557-020-07044-3	Anakinra para o tratamento da pericardite associada ao COVID-19: um relato de caso 	O painel de Xangai e um grupo médico paralelo em Guangzhou estão aconselhando o uso de ascorbato IV de alta dose para o tratamento da SDRA, juntamente com outras terapias de suporte, incluindo Vitamina D e zinco. Relatamos o progresso preliminar no uso deste tratamento para 50 casos consecutivos tratados em hospitais de Xangai, consistentes com relatos anteriores de uma meta-análise do uso de ascorbato IV para tratar a sepse. Fornecemos uma história clínica instrutiva sobre uma única família onde um membro idoso com comorbidades cardíacas e outras comorbidades importantes desenvolveu e sobreviveu à sepse relacionada à SDRA após tratamentos diários que incluíam 15 g de ascorbato IV. Nenhum de seus cuidadores adultos que ingeriram entre 2 e 10 g de ascorbato diariamente desenvolveu COVID-19.
COVID-19 and multiple sclerosis: a description of two cases on alemtuzumab	https://doi.org/10.1016/j.msard.2020.102402	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102402	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Alemtuzumabe']	['Alemtuzumab']	In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab.	32711297	Multiple sclerosis and related disorders	2211-0356	10.1016/j.msard.2020.102402	COVID-19 e esclerose múltipla: uma descrição de dois casos em alemtuzumab 	Em pacientes selecionados (jovens, sem comorbidades e com alta atividade), a própria EM pode ser mais perigosa que a COVID-19, portanto, devemos considerar a continuação do tratamento da EM conforme planejado anteriormente , incluindo alentuzumabe.
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure – a cautionary case series	https://doi.org/10.1186/s13054-020-03158-0	17/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03158-0	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Infliximabe']	['Infliximab']	-	-	-	-	-	Infliximabe contra a síndrome grave da tempestade de citocinas induzida por COVID-19 com falência de órgãos - uma série de casos de advertência 	-
High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection	https://onlinelibrary.wiley.com/doi/10.1111/eci.13358	23/07/2020	Artigo completo publicado em periódico científico	10.1111/eci.13358	0014-2972	142972	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (PRINT)	A2	1.229	112	4.98	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Altas doses de hidroxicloroquina não afetam a depuração viral em pacientes com infecção por SARS-CoV-2 	-
Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study	https://doi.org/10.1016/j.ijantimicag.2020.106114	23/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106114	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Ribavirina']	['Ribavirin']	-	-	-	-	-	Terapia com ribavirina para COVID-19 grave: um estudo de coorte retrospectivo 	-
BCG vaccination and COVID-19: Much ado about nothing?	https://doi.org/10.1016/j.mehy.2020.110109	15/07/2020	Artigo completo publicado em periódico científico	10.1016/j.mehy.2020.110109	0306-9877	3069877	MEDICAL HYPOTHESES	A4	0.569	94	3.3	-	['Vacina BCG']	['BCG vaccine']	For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.	32758899	Medical hypotheses	1532-2777	10.1016/j.mehy.2020.110109	Vacinação BCG e COVID-19: muito barulho por nada? 	Para a terapia medicamentosa COVID-19, existem várias opções que são suficientemente apoiadas por evidências. A orientação viva será atualizada à medida que novas evidências surgirem.
Management of immunosuppression in kidney transplant recipients with COVID-19 pneumonia: A summary of 41 confirmed cases reported worldwide	https://doi.org/10.1111/tid.13425	23/07/2020	Artigo completo publicado em periódico científico	10.1111/tid.13425	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Imunossupressores']	['Immunosuppressants']	There is no consensus on immunosuppression management for kidney transplant recipients (KTRs) with SARS-CoV-2 pneumonia. Therefore, we conducted a search in English database from October 2019 to July 2020 and extracted data from cases with treatment details worldwide, and total of 41 recipients with a median age of 50 years were enrolled in this study. Most of them were males (75.8%). The most common presenting symptoms were fever (80.5%), cough (63.4%), and fatigue (41.5%). Patients were classified into three catalogs according to severity of pneumonia: 17 (41.5%) were mild, 15 (36.6%) severe, and 9 (21.9%) critical disease. Laboratory tests revealed that serum creatinine of critical patients was significantly higher than that of mild or severe patients. 68.3% received oxygen support; all patients received antiviral therapy, and 15 (36.6%) recipients were additionally treated with intravenous immunoglobulin and interferon-α. 19.5% of patients maintained immunosuppressive therapy; 36.6% suspended antimetabolite; and 43.9% only treated with corticosteroid. Six (14.6%) patients died (severe: 2, critical: 4); high creatinine with low lymphocyte count was the biggest challenge of immunosuppression management. In all, it is necessary to pay close attention to renal function and lymphocyte count in KTRs infected with COVID-19 and choose appropriate medication programs according to the specific situations.	32702153	Transplant infectious disease : an official journal of the Transplantation Society	1399-3062	10.1111/tid.13425	Manejo da imunossupressão em receptores de transplante renal com pneumonia por COVID-19: um resumo de 41 casos confirmados relatados em todo o 	mundo Portanto, realizamos uma pesquisa no banco de dados em inglês de outubro de 2019 a julho de 2020 e extraímos dados de casos com detalhes de tratamento em todo o mundo, e um total de 41 receptores com idade média de 50 anos foram incluídos neste estudo. A maioria era do sexo masculino (75,8%). Os sintomas de apresentação mais comuns foram febre (80,5%), tosse (63,4%) e fadiga (41,5%). Os pacientes foram classificados em três catálogos de acordo com a gravidade da pneumonia: 17 (41,5%) eram doença leve, 15 (36,6%) grave e 9 (21,9%) doença crítica. Os exames laboratoriais revelaram que a creatinina sérica dos pacientes críticos foi significativamente maior do que a dos pacientes leves ou graves. 68,3% receberam suporte de oxigênio; todos os pacientes receberam terapia antiviral e 15 (36,6%) receptores foram tratados adicionalmente com imunoglobulina intravenosa e interferon-α. 19,5% dos pacientes mantiveram terapia imunossupressora; 36,6% de antimetabólito suspenso; e 43,9% tratados apenas com corticoide. Seis (14,6%) pacientes morreram (grave: 2, crítico: 4); alta creatinina com baixa contagem de linfócitos foi o maior desafio do manejo da imunossupressão. Em suma, é necessário estar atento à função renal e à contagem de linfócitos em KTRs infectados com COVID-19 e escolher programas de medicação adequados de acordo com as situações específicas.
Therapeutic Plasma Exchange: a potential management strategy for critically III COVID-19 patients. 2020	https://doi.org/10.1177/0885066620940259	15/07/2020	Artigo completo publicado em periódico científico	10.1177/0885066620940259	0885-0666	8850666	JOURNAL OF INTENSIVE CARE MEDICINE (PRINT)	A4	0.807	62	3.05	 In the 5 months since initial reports of COVID-19 came to light, the death toll due to SARS-CoV-2 has rapidly increased. The morbidity and mortality of the infection varies based upon patient age, comorbid conditions, viral load, and the availability of effective treatments. Findings from limited autopsies, clinical observations, and laboratory data suggest that high cytokine levels and a procoagulant state can precipitate acute respiratory distress syndrome and multi-organ dysfunction syndrome in critically ill patients. To complicate matters, comorbidities may affect the response to medical treatments currently in use, all of which are still in trial phase. Therapeutic plasma exchange (TPE) merits consideration in the treatment of critically ill COVID-19 patients and is an avenue for clinical trials to pursue. If efficacious, faster recovery of patients may lead to shorter intensive care unit stays and less time on mechanical ventilation. Herein, we briefly discuss some of the various approaches currently being investigated for the treatment of SARS-CoV-2 with a focus on potential benefits of TPE for selected critically ill patients.	['Plasmaferese']	['Plasmapheresis']	-	-	-	-	-	Troca de Plasma Terapêutico: uma estratégia potencial de gerenciamento para pacientes criticamente III com COVID-19. 2020 	-
Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy	https://doi.org/10.1093/infdis/jiaa446	23/07/2020	Artigo completo publicado em periódico científico	10.1093/infdis/jiaa446	0022-1899	221899	THE JOURNAL OF INFECTIOUS DISEASES	A1	2.509	261	5.29	 Abstract                The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.	['Remdesivir']	['Remdesivir']	-	-	-	-	-	COVID-19 persistente em um paciente imunocomprometido temporariamente responsivo a dois cursos de terapia com remdesivir 	-
Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study	https://doi.org/10.1016/j.jaut.2020.102523	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102523	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']	In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay.	32690352	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102523	Experiência com tocilizumabe em pneumonia grave por COVID-19 após 80 dias de acompanhamento: um estudo de coorte retrospectivo 	Em uma coorte mediterrânea, o uso de tocilizumabe para COVID-19 grave mostra 12,9% de mortalidade. A resposta precoce ao TCZ pelo BCRSS e a baixa comorbidade foram associadas ao aumento da sobrevida. A resposta precoce ao TCZ foi relacionada a uma mediana de internação hospitalar mais curta.
Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study	https://doi.org/10.1186/s13054-020-03164-2	19/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03164-2	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Agentes bloqueadores neuromusculares']	['Neuromuscular blocking agents']	In a Mediterranean cohort, use of tocilizumab for severe COVID-19 show 12.9% of mortality. Early TCZ-response by BCRSS and low comorbidity were associated with increased survival. Early TCZ-response was related to shorter median hospital stay.	32684169	Critical care (London, England)	1466-609X	10.1186/s13054-020-03164-2	Agentes bloqueadores neuromusculares (NMBA) para síndrome do desconforto respiratório agudo de COVID-19: um estudo observacional multicêntrico 	Em uma coorte do Mediterrâneo, o uso de tocilizumabe para COVID-19 grave mostra 12,9% de mortalidade. A resposta precoce ao TCZ pelo BCRSS e a baixa comorbidade foram associadas ao aumento da sobrevida. A resposta precoce ao TCZ foi relacionada a uma mediana de internação hospitalar mais curta.
Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study	https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.15495	23/07/2020	Artigo completo publicado em periódico científico	10.1111/febs.15495	1742-464X	1742464X	THE FEBS JOURNAL (PRINT)	A2	1.611	212	5.67	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	Vitamin D deficiency is a worldwide pandemic. The aim of this study was to evaluate associations of plasma 25(OH)D levels with the likelihood of coronavirus disease 2019 (COVID-19) infection and hospitalization. The study population included the 14 000 members of Leumit Health Services, who were tested for COVID-19 infection from February 1	32700398	The FEBS journal	1742-4658	10.1111/febs.15495	Baixo nível plasmático de 25 (OH) vitamina D está associado ao aumento do risco de infecção por COVID-19: um estudo de base populacional israelense A deficiência de 	vitamina D é uma pandemia mundial. O objetivo deste estudo foi avaliar as associações dos níveis plasmáticos de 25(OH)D com a probabilidade de infecção e hospitalização pela doença de coronavírus 2019 (COVID-19). A população do estudo incluiu os 14.000 membros do Leumit Health Services, que foram testados para infecção por COVID-19 a partir de 1º de fevereiro
Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology	https://doi.org/10.1016/j.rec.2020.04.025	19/06/2020	Artigo completo publicado em periódico científico	10.1016/j.rec.2020.04.025	1885-5857	18855857	REVISTA ESPAÑOLA DE CARDIOLOGÍA (INTERNET. ENGLISH ED.)	A4	0.385	7	0.98	-	['Clopidogrel', 'Heparina', 'Ticagrelor']	['Clopidogrel', 'Heparin', 'Ticagrelor']	-	-	-	-	-	Recomendações sobre o tratamento antitrombótico durante a pandemia de COVID-19. Declaração de posição do Grupo de Trabalho sobre Trombose Cardiovascular da Sociedade Espanhola de Cardiologia 	-
Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state	https://onlinelibrary.wiley.com/doi/full/10.1111/resp.13912	21/07/2020	Artigo completo publicado em periódico científico	10.1111/resp.13912	1323-7799	13237799	RESPIROLOGY (CARLTON SOUTH. PRINT)	A2	1.265	94	3.08	-	['Tocilizumabe']	['Tocilizumab']	The global COVID-19 pandemic has led to a race to find medications that can improve the prognosis of the disease. Azithromycin, in association with hydroxychloroquine or chloroquine, has been proposed as one such medication. The aim of this review is to describe the pharmacological mechanism, clinical evidence and prescribing guidelines concerning azithromycin in COVID-19 patients. There is weak evidence on the antiviral and immunomodulating effects of azithromycin, which in addition is not based on results from COVID-19 patients specifically. Therefore, this antibacterial should be considered only as empirical treatment of community-acquired pneumonia (CAP), although not all current treatment guidelines are in agreement. After the initial expectations raised by a small trial, more recent evidence has raised serious safety concerns on the use of hydroxychloroquine or chloroquine with azithromycin to treat COVID-19 patients, as all these drugs have arrhythmogenic potential. The World Health Organization has not made recommendations suggesting the use of azithromycin with hydroxychloroquine or chloroquine as treatment for COVID-19, but some national organisations have taken a different position, recommending this as first-line treatment. Several scientific societies, including the American College of Cardiology, have cautioned about the risks of this treatment in view of the lack of evidence concerning its benefits.	32696570	Respirology (Carlton, Vic.)	1440-1843	10.1111/resp.13912	Terapia com tocilizumabe em indivíduos com infecção por COVID-19 e estado hiperinflamatório 	A pandemia global de COVID-19 levou a uma corrida para encontrar medicamentos que possam melhorar o prognóstico da doença. A azitromicina, em associação com hidroxicloroquina ou cloroquina, tem sido proposta como um desses medicamentos. O objetivo desta revisão é descrever o mecanismo farmacológico, as evidências clínicas e as diretrizes de prescrição da azitromicina em pacientes com COVID-19. Há evidências fracas sobre os efeitos antivirais e imunomoduladores da azitromicina, que, além disso, não se baseiam nos resultados de pacientes com COVID-19 especificamente. Portanto, esse antibacteriano deve ser considerado apenas como tratamento empírico da pneumonia adquirida na comunidade (PAC), embora nem todas as diretrizes atuais de tratamento estejam de acordo. Após as expectativas iniciais levantadas por um pequeno estudo, evidências mais recentes levantaram sérias preocupações de segurança sobre o uso de hidroxicloroquina ou cloroquina com azitromicina para tratar pacientes com COVID-19, pois todos esses medicamentos têm potencial arritmogênico. A Organização Mundial da Saúde não fez recomendações sugerindo o uso de azitromicina com hidroxicloroquina ou cloroquina como tratamento para COVID-19, mas algumas organizações nacionais adotaram uma posição diferente, recomendando isso como tratamento de primeira linha. Diversas sociedades científicas, incluindo o American College of Cardiology, têm alertado sobre os riscos desse tratamento devido à falta de evidências sobre seus benefícios.
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3‐mutated acute myeloid leukaemia and severe COVID‐19	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16962	25/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16962	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Gilteritinibe']	['Gilteritinib']	-	-	-	-	-	Terapia de indução de remissão bem-sucedida com gilteritinibe em um paciente com leucemia mieloide aguda de novo com mutação no FLT3 e COVID-19 grave 	-
High-dose chemotherapy in a patient with coronavirus disease (COVID-19)	https://doi.org/10.1016/j.ejca.2020.06.026	04/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ejca.2020.06.026	0959-8049	9598049	EUROPEAN JOURNAL OF CANCER	A1	2.865	224	7.68	-	['Darunavir', 'Hidroxicloroquina', 'Ritonavir']	['Darunavir', 'Hydroxychloroquine', 'Ritonavir']	-	-	-	-	-	Quimioterapia de alta dose em um paciente com doença por coronavírus (COVID-19) 	-
Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia	https://doi.org/10.1186/s13054-020-03142-8	11/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03142-8	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Terapia celular']	['Cell Therapy']	Administration of 100 million mesenchymal stem cells in combination with standard treatment was found to be safe and resulted in prevention of the cytokine storm, halting of the disease progression and acceleration of recovery in moderate COVID-19. This clinical trial has been registered with the Clinical Trial Registry- India (CTRI) as CTRI/2020/08/027043. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43175.	35873716	American journal of stem cells	2160-4150	10.2450/2020.0164-20	Administração de células-tronco mesenquimais do cordão umbilical em pacientes com pneumonia grave por COVID-19 	A administração de 100 milhões de células-tronco mesenquimais em combinação com o tratamento padrão mostrou-se segura e resultou na prevenção da tempestade de citocinas, interrupção da progressão da doença e aceleração da recuperação em COVID-19 moderado. Este ensaio clínico foi registrado no Clinical Trial Registry- India (CTRI) como CTRI/2020/08/027043. http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43175.
Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study	https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1800453	01/08/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2020.1800453	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tocilizumab para pacientes com COVID-19 grave: um estudo retrospectivo multicêntrico 	-
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19.	https://doi.org/10.1056/NEJMoa2019014	23/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2019014	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	Hidroxicloroquina com ou sem azitromicina em COVID-19 leve a moderado. 	-
Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)	https://doi.org/10.1016/j.dsx.2020.07.011	11/07/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.07.011	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Estatina']	['Statin']	COVID-19, transmitted by SARS-CoV-2, is one of the most serious pandemic situations in the history of mankind, and has already infected a huge population across the globe. This horrendously contagious viral outbreak was first identified in China and within a very short time it affected the world's health, transport, economic, and academic sectors. Despite the recent approval of a few anti-COVID-19 vaccines, their unavailability and insufficiency along with the lack of other potential therapeutic options are continuing to worsen the situation, with valuable lives continuing to be lost. In this situation, researchers across the globe are focusing on repurposing prospective drugs and prophylaxis such as favipiravir, remdesivir, chloroquine, hydroxychloroquine, ivermectin, lopinavir-ritonavir, azithromycin, doxycycline, ACEIs/ARBs, rivaroxaban, and protease inhibitors, which were preliminarily based on 	33279832	Diabetes & metabolic syndrome	1878-0334	10.1016/j.dsx.2020.11.017	Prós e contras do uso de estatinas em pessoas com doença por coronavírus-19 (COVID-19) 	A COVID-19, transmitida pelo SARS-CoV-2, é uma das situações de pandemia mais graves da história da humanidade, e já infectou um enorme população em todo o mundo. Este surto viral terrivelmente contagioso foi identificado pela primeira vez na China e em muito pouco tempo afetou os setores de saúde, transporte, economia e acadêmico do mundo. Apesar da recente aprovação de algumas vacinas anti-COVID-19, sua indisponibilidade e insuficiência, juntamente com a falta de outras opções terapêuticas potenciais, continuam a piorar a situação, com vidas valiosas sendo perdidas. Nessa situação, pesquisadores de todo o mundo estão se concentrando em redirecionar medicamentos e profilaxia prospectivos, como favipiravir, remdesivir, cloroquina, hidroxicloroquina, ivermectina, lopinavir-ritonavir, azitromicina, doxiciclina, IECAs/BRAs, rivaroxabana e inibidores de protease, que foram preliminarmente baseados sobre
Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03058-3	10/06/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03058-3	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Heparina']	['Heparin']	COVID-19, transmitted by SARS-CoV-2, is one of the most serious pandemic situations in the history of mankind, and has already infected a huge population across the globe. This horrendously contagious viral outbreak was first identified in China and within a very short time it affected the world's health, transport, economic, and academic sectors. Despite the recent approval of a few anti-COVID-19 vaccines, their unavailability and insufficiency along with the lack of other potential therapeutic options are continuing to worsen the situation, with valuable lives continuing to be lost. In this situation, researchers across the globe are focusing on repurposing prospective drugs and prophylaxis such as favipiravir, remdesivir, chloroquine, hydroxychloroquine, ivermectin, lopinavir-ritonavir, azithromycin, doxycycline, ACEIs/ARBs, rivaroxaban, and protease inhibitors, which were preliminarily based on 	32522226	Critical care (London, England)	1466-609X	10.1186/s13054-020-03058-3	Heparinas de baixo peso molecular em pacientes com COVID-19: cuidado com a depuração renal aumentada! 	A COVID-19, transmitida pelo SARS-CoV-2, é uma das situações de pandemia mais graves da história da humanidade, e já infectou uma enorme população em todo o mundo. Este surto viral terrivelmente contagioso foi identificado pela primeira vez na China e em muito pouco tempo afetou os setores de saúde, transporte, economia e acadêmico do mundo. Apesar da recente aprovação de algumas vacinas anti-COVID-19, sua indisponibilidade e insuficiência, juntamente com a falta de outras opções terapêuticas potenciais, continuam a piorar a situação, com vidas valiosas sendo perdidas. Nessa situação, pesquisadores de todo o mundo estão se concentrando em redirecionar medicamentos e profilaxia prospectivos, como favipiravir, remdesivir, cloroquina, hidroxicloroquina, ivermectina, lopinavir-ritonavir, azitromicina, doxiciclina, IECAs/BRAs, rivaroxabana e inibidores de protease, que foram preliminarmente baseados sobre
Low- dose systemic steroids, an emerging therapeutic option for COVID-19 related urticaria	https://www.tandfonline.com/doi/full/10.1080/09546634.2020.1795062	16/07/2020	Artigo completo publicado em periódico científico	10.1080/09546634.2020.1795062	0954-6634	9546634	JOURNAL OF DERMATOLOGICAL TREATMENT (PRINT)	A3	0.737	56	2.62	-	['Anti-histamínicos', 'Esteroides']	['Antihistamines', 'Ssteroids']	Dermatologists around the world are still doing their best to report more cutaneous manifestations of the emerging COVID-19 infection. New-onset acute or relapsing chronic urticaria may result from the body's overreacting inflammatory response to infection. The cytokine storm hits different organs in the body, including the skin, leading to activation and degranulation of mast cells with resultant urticaria. Low-dose systemic steroids combined with antihistamines can combat the COVID-19 inflammatory insult and play a role in the control of COVID-19 related severe urticarial attack.	32649228	The Journal of dermatological treatment	1471-1753	10.1080/09546634.2020.1795062	Esteróides sistêmicos de baixa dose, uma opção terapêutica emergente para urticária relacionada à COVID-19 	Dermatologistas em todo o mundo ainda estão fazendo o possível para relatar mais manifestações cutâneas da infecção emergente por COVID-19. A urticária aguda ou crônica recidivante de início recente pode resultar da resposta inflamatória exagerada do corpo à infecção. A tempestade de citocinas atinge diferentes órgãos do corpo, incluindo a pele, levando à ativação e degranulação de mastócitos com urticária resultante. Esteróides sistêmicos de baixa dose combinados com anti-histamínicos podem combater o insulto inflamatório do COVID-19 e desempenhar um papel no controle do ataque de urticária grave relacionado ao COVID-19.
Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer	https://doi.org/10.1111/bjh.16966	25/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16966	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Ruxolitinibe', 'Tocilizumabe']	['Ruxolitinib', 'Tocilizumab']	-	-	-	-	-	Terapia combinada de inibição de IL-6 e JAK-STAT no sHLH relacionado ao COVID-19, potencial divisor de águas 	-
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection	https://doi.org/10.1111/bjh.17014	11/07/2020	Artigo completo publicado em periódico científico	10.1111/bjh.17014	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Remdesivir']	['Remdesivir']	Dermatologists around the world are still doing their best to report more cutaneous manifestations of the emerging COVID-19 infection. New-onset acute or relapsing chronic urticaria may result from the body's overreacting inflammatory response to infection. The cytokine storm hits different organs in the body, including the skin, leading to activation and degranulation of mast cells with resultant urticaria. Low-dose systemic steroids combined with antihistamines can combat the COVID-19 inflammatory insult and play a role in the control of COVID-19 related severe urticarial attack.	32652563	British journal of haematology	1365-2141	10.1111/bjh.17014	Remdesivir durante a quimioterapia de indução para leucemia linfoblástica aguda pediátrica recém-diagnosticada com infecção concomitante por SARS-CoV-2 	Dermatologistas em todo o mundo ainda estão fazendo o possível para relatar mais manifestações cutâneas da infecção emergente por COVID-19. A urticária aguda ou crônica recidivante de início recente pode resultar da resposta inflamatória exagerada do corpo à infecção. A tempestade de citocinas atinge diferentes órgãos do corpo, incluindo a pele, levando à ativação e degranulação de mastócitos com urticária resultante. Esteróides sistêmicos de baixa dose combinados com anti-histamínicos podem combater o insulto inflamatório do COVID-19 e desempenhar um papel no controle do ataque de urticária grave relacionado ao COVID-19.
SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor	https://doi.org/10.1016/j.mehy.2020.110040	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.mehy.2020.110040	0306-9877	3069877	MEDICAL HYPOTHESES	A4	0.569	94	3.3	-	['Secuquinumabe']	['Secukinumab']	-	-	-	-	-	Infecção por SARS-CoV-2 em um paciente com artrite psoriática tratado com inibidor de IL-17 	-
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection	https://doi.org/10.1007/s00380-020-01671-4	16/07/2020	Artigo completo publicado em periódico científico	10.1007/s00380-020-01671-4	0910-8327	9108327	HEART AND VESSELS	A3	0.551	49	1.82	-	['Azitromicina', 'Darunavir', 'Hidroxicloroquina', 'Ritonavir']	['Azithromycin', 'Darunavir', 'Hydroxychloroquine', 'Ritonavir']	-	-	-	-	-	Efeitos no intervalo QT da hidroxicloroquina associada a ritonavir/darunavir ou azitromicina em pacientes com infecção por SARS-CoV-2 	-
Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)	https://doi.org/10.1016/j.mayocp.2020.04.027	29/04/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.04.027	0025-6196	256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Anticorpos', 'Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Inibidores de interleucina-6', 'Lenzilumabe', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Sarilumabe', 'Tocilizumabe']	['Antibodies', 'Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Interleukin-6 inhibitors', 'Lenzilumab', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Sarilumab', 'Tocilizumab']	The novel severe acute respiratory syndrome coronavirus 2 is causing a worldwide pandemic that may lead to a highly morbid and potentially fatal coronavirus disease 2019 (COVID-19). There is currently no drug that has been proven as an effective therapy for COVID-19. Several candidate drugs are being considered and evaluated for treatment. This includes clinically available drugs, such as chloroquine, hydroxychloroquine, and lopinavir/ritonavir, which are being repurposed for the treatment of COVID-19. Novel experimental therapies, such as remdesivir and favipiravir, are also actively being investigated for antiviral efficacy. Clinically available and investigational immunomodulators, such as the interleukin 6 inhibitors tocilizumab and sarilumab and the anti-granulocyte-macrophage colony-stimulating factor lenzilumab, are being tested for their anticipated effect in counteracting the pro-inflammatory cytokine environment that characterizes severe and critical COVID-19. This review article examines the evidence behind the potential use of these leading drug candidates for the treatment of COVID-19. The authors conclude, based on this review, that there is still no high-quality evidence to support any of these proposed drug therapies. The authors, therefore, encourage the enrollment of eligible patients to multiple ongoing clinical trials that assess the efficacy and safety of these candidate therapies. Until the results of controlled trials are available, none of the suggested therapeutics is clinically proven as an effective therapy for COVID-19.	32561148	Mayo Clinic proceedings	1942-5546	10.1016/j.mayocp.2020.04.027	Considerações de tratamento para COVID-19: uma revisão crítica das evidências (ou falta 	delas) Atualmente, nenhum medicamento foi comprovado como uma terapia eficaz para o COVID-19. Vários medicamentos candidatos estão sendo considerados e avaliados para tratamento. Isso inclui medicamentos clinicamente disponíveis, como cloroquina, hidroxicloroquina e lopinavir/ritonavir, que estão sendo reaproveitados para o tratamento do COVID-19. Novas terapias experimentais, como remdesivir e favipiravir, também estão sendo investigadas ativamente quanto à eficácia antiviral. Os imunomoduladores clinicamente disponíveis e em investigação, como os inibidores da interleucina 6 tocilizumab e sarilumab e o fator estimulador de colônias antigranulócitos-macrófagos lenzilumab, estão sendo testados quanto ao seu efeito antecipado na neutralização do ambiente de citocinas pró-inflamatórias que caracteriza a COVID-19 grave e crítica. 19. Este artigo de revisão examina as evidências por trás do uso potencial desses principais candidatos a medicamentos para o tratamento do COVID-19. Os autores concluem, com base nesta revisão, que ainda não há evidências de alta qualidade para apoiar qualquer uma dessas terapias medicamentosas propostas. Os autores, portanto, incentivam a inscrição de pacientes elegíveis para vários ensaios clínicos em andamento que avaliam a eficácia e a segurança dessas terapias candidatas. Até que os resultados dos ensaios controlados estejam disponíveis, nenhuma das terapêuticas sugeridas é clinicamente comprovada como uma terapia eficaz para o COVID-19.
Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib	https://doi.org/10.1111/tid.13401	06/07/2020	Artigo completo publicado em periódico científico	10.1111/tid.13401	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Ruxolitinibe']	['Ruxolitinib']	-	-	-	-	-	COVID-19 grave em paciente com doença crônica do enxerto versus hospedeiro após transplante de células-tronco hematopoiéticas tratado com sucesso com ruxolitinibe 	-
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16798	07/05/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16798	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Pembrolizumabe']	['Pembrolizumab']	Extracorporeal membrane oxygenation (ECMO) is an established part of the treatment algorithm for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome. An intense inflammatory response may cause an imbalance in the coagulation cascade making both thrombosis and bleeding common and notable features of the clinical management of these patients. Large observational and retrospective studies provide a better understanding of the pathophysiology and management of bleeding and thrombosis in COVID-19 patients requiring ECMO. Clinically significant bleeding, including intracerebral hemorrhage, is an independent predictor of mortality, and thrombosis (particularly pulmonary embolism) is associated with mortality, especially if occurring with right ventricular dysfunction. The incidence of heparin-induced thrombocytopenia is higher than the general patient cohort with acute respiratory distress syndrome or other indications for ECMO. The use of laboratory parameters to predict bleeding or thrombosis has a limited role. In this review, the authors discuss the complex pathophysiology of bleeding and thrombosis observed in patients with COVID-19 during ECMO support, and their effects on outcomes.	32379903	British journal of haematology	1365-2141	10.1111/bjh.16798	O resultado de um paciente com linfoma de Hodgkin refratário em pembrolizumab, infectado com SARS-CoV-2 A oxigenação por 	membrana extracorpórea (ECMO) é uma parte estabelecida do algoritmo de tratamento para a síndrome do desconforto respiratório agudo relacionado à doença de coronavírus 2019 (COVID-19). Uma resposta inflamatória intensa pode causar um desequilíbrio na cascata de coagulação, tornando a trombose e o sangramento características comuns e notáveis no manejo clínico desses pacientes. Grandes estudos observacionais e retrospectivos fornecem uma melhor compreensão da fisiopatologia e manejo de sangramento e trombose em pacientes com COVID-19 que necessitam de ECMO. Sangramento clinicamente significativo, incluindo hemorragia intracerebral, é um preditor independente de mortalidade, e trombose (particularmente embolia pulmonar) está associada à mortalidade, especialmente se ocorrer com disfunção ventricular direita. A incidência de trombocitopenia induzida por heparina é maior do que a coorte geral de pacientes com síndrome do desconforto respiratório agudo ou outras indicações para ECMO. O uso de parâmetros laboratoriais para prever sangramento ou trombose tem um papel limitado. Nesta revisão, os autores discutem a complexa fisiopatologia do sangramento e da trombose observada em pacientes com COVID-19 durante o suporte com ECMO e seus efeitos nos resultados.
Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14489	21/07/2020	Artigo completo publicado em periódico científico	10.1111/bcp.14489	0306-5251	3065251	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (PRINT)	A1	1.055	153	3.73	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	It is not known whether the adverse events (AEs) associated with the administration of lopinavir and ritonavir (LPV/r) in the treatment of COVID-19 are concentration-dependent. In a retrospective study of 65 patients treated with LPV/r and therapeutic drug monitoring (TDM) for severe forms of COVID-19 (median age: 67; males: 41 [63.1%]), 33 (50.8%) displayed a grade ≥2 increase in plasma levels of hepatobiliary markers, lipase and/or triglycerides. A causal relationship between LPV/r and the AE was suspected in 9 of the 65 patients (13.8%). At 400 mg b.i.d., the plasma trough concentrations of LPV/r were high and showed marked interindividual variability (median [interquartile range]: 16,600 [11,430-20,842] ng/ml for lopinavir and 501 [247-891] ng/ml for ritonavir). The trough lopinavir concentration was negatively correlated with body mass index, while the trough ritonavir concentration was positively correlated with age and negatively correlated with prothrombin activity. However, the occurrence of abnormal laboratory values was not associated with higher trough plasma concentrations of LPV/r. Further studies will be needed to determine the value of TDM in LPV/r-treated patients with COVID-19.	32692462	British journal of clinical pharmacology	1365-2125	10.1111/bcp.14489	Achados laboratoriais anormais e monitoramento da concentração plasmática de lopinavir e ritonavir em COVID-19 	Não se sabe se os eventos adversos (EAs) associados à administração de lopinavir e ritonavir (LPV/r) no tratamento de COVID-19 são dependentes da concentração . Em um estudo retrospectivo de 65 pacientes tratados com LPV/r e monitoramento de drogas terapêuticas (TDM) para formas graves de COVID-19 (idade média: 67; homens: 41 [63,1%]), 33 (50,8%) apresentaram um grau ≥ 2 aumento dos níveis plasmáticos de marcadores hepatobiliares, lipase e/ou triglicerídeos. Suspeita-se de relação causal entre LPV/r e EA em 9 dos 65 pacientes (13,8%). Na dose de 400 mg duas vezes, as concentrações plasmáticas mínimas de LPV/r foram altas e mostraram marcada variabilidade interindividual (mediana [intervalo interquartil]: 16.600 [11.430-20.842] ng/ml para lopinavir e 501 [247-891] ng/ml para ritonavir ). A concentração mínima de lopinavir foi negativamente correlacionada com o índice de massa corporal, enquanto a concentração mínima de ritonavir foi positivamente correlacionada com a idade e negativamente correlacionada com a atividade da protrombina. No entanto, a ocorrência de valores laboratoriais anormais não foi associada a maiores concentrações plasmáticas mínimas de LPV/r. Mais estudos serão necessários para determinar o valor do TDM em pacientes tratados com LPV/r com COVID-19.
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience	https://doi.org/10.1080/09546634.2020.1789041	09/07/2020	Artigo completo publicado em periódico científico	10.1080/09546634.2020.1789041	0954-6634	9546634	JOURNAL OF DERMATOLOGICAL TREATMENT (PRINT)	A3	0.737	56	2.62	-	['Rituximabe']	['Rituximab']	The most suitable timing and dosage for the use of corticosteroids to maximize its effect during the worsening of COVID-19 pneumonia are discussed. One of the main pathophysiological hypotheses for severe COVID-19 patients is related to cytokine storm and virus load, which can be effectively treated with corticosteroid therapy.	32594787	The Journal of dermatological treatment	1471-1753	10.1080/09546634.2020.1789041	COVID-19 em pacientes com pênfigo vulgar com terapia prévia com rituximabe: uma experiência 	de telemedicina São discutidos o momento e a dosagem mais adequados para o uso de corticosteroides para maximizar seu efeito durante o agravamento da pneumonia por COVID-19. Uma das principais hipóteses fisiopatológicas para pacientes graves com COVID-19 está relacionada à tempestade de citocinas e carga viral, que pode ser tratada efetivamente com corticoterapia.
Use of tocilizumab in kidney transplant recipients with COVID-19	https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16192	12/07/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16192	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Uso de tocilizumabe em receptores de transplante renal com COVID-19 	-
Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with pcr positive SARS-Cov-2 infection including drug induced changes in the corrected qt interval (QTc) (2020)	https://doi.org/10.1016/j.hrthm.2020.06.033	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.06.033	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	In pediatric patients with PCR-positive active COVID-19 infection, significant arrhythmias are infrequent, but are more common than expected in a general pediatric population. Comorbidities are not more common in patients with arrhythmias than in patients without arrhythmias. COVID-19 treatment using HCQ is associated with QTc prolongation but was not associated with arrhythmias in pediatric patients.	32621881	Heart rhythm	1556-3871	10.1016/j.hrthm.2020.06.033	Cov -2 PCR positiva, incluindo alterações induzidas por drogas no intervalo qt corrigido (QTc) (2020) 	infrequentes, mas são mais comuns do que o esperado em uma população pediátrica geral. As comorbidades não são mais comuns em pacientes com arritmias do que em pacientes sem arritmias. O tratamento com COVID-19 usando HCQ está associado ao prolongamento do intervalo QTc, mas não foi associado a arritmias em pacientes pediátricos.
Remdesivir for the Treatment of Covid-19 - Preliminary Report	https://www.nejm.org/doi/full/10.1056/NEJMoa2007764	22/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007764	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Remdesivir para o Tratamento da Covid-19 - Relatório Preliminar 	-
Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.14482	20/07/2020	Artigo completo publicado em periódico científico	10.1111/bcp.14482	0306-5251	3065251	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (PRINT)	A1	1.055	153	3.73	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Although patients who received HCQ/Az were more severely ill the administration of these repurposed drugs did not result in clinical improvement and was associated with a significant increase in toxicity. This descriptive study highlights the importance of monitoring all repurposed agents for adverse events.	32687645	British journal of clinical pharmacology	1365-2125	10.1111/bcp.14482	Resultados clínicos e eventos adversos em pacientes hospitalizados com COVID-19, tratados com hidroxicloroquina e azitromicina off label 	Embora os pacientes que receberam HCQ/Az estivessem mais gravemente doentes, a administração desses medicamentos reaproveitados não resultou em melhora clínica e foi associada a um aumento da toxicidade. Este estudo descritivo destaca a importância de monitorar todos os agentes reaproveitados para eventos adversos.
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19	https://doi.org/10.1016/j.jcrc.2020.06.019	11/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jcrc.2020.06.019	0883-9441	8839441	JOURNAL OF CRITICAL CARE	A4	1.123	89	3.31	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	Patients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed.	32683212	Journal of critical care	1557-8615	10.1016/j.jcrc.2020.06.019	Atualização I. Uma revisão sistemática sobre a eficácia e segurança da cloroquina/hidroxicloroquina para COVID-19 	Pacientes com COVID-19 devem ser tratados com CQ/HCQ somente se monitorados e no contexto de ECRs de alta qualidade. Dados de alta qualidade sobre eficácia/segurança são urgentemente necessários.
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial	https://doi.org/10.1016/S0140-6736(20)31605-6	20/07/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31605-6	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Ad5-nCoV']	['Ad5-nCoV']	-	-	-	-	-	Imunogenicidade e segurança de uma vacina COVID-19 com vetor de adenovírus recombinante tipo 5 em adultos saudáveis com 18 anos ou mais: um estudo de fase 2 randomizado, duplo-cego, controlado por placebo 	-
A critical evaluation of glucocorticoids in the management of severe COVID19	https://doi.org/10.1016/j.cytogfr.2020.06.012	24/06/2020	Artigo completo publicado em periódico científico	10.1016/j.cytogfr.2020.06.012	1359-6101	13596101	CYTOKINE & GROWTH FACTOR REVIEWS	A1	2.756	168	14.32	-	['Dexametasona', 'Prednisona']	['Dexamethasone', 'Prednisone']	-	-	-	-	-	Uma avaliação crítica de glicocorticóides no manejo de COVID19 grave 	-
The cardiovascular effects of treatment with hydroxychloroquine and azithromycin	https://doi.org/10.1002/phar.2445	16/07/2020	Artigo completo publicado em periódico científico	10.1002/phar.2445	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	Os efeitos cardiovasculares do tratamento com hidroxicloroquina e azitromicina 	-
A pandemic center's experience of managing pregnant women with COVID-19 infection in Turkey: A prospective cohort study	https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13318	18/07/2020	Artigo completo publicado em periódico científico	10.1002/ijgo.13318	0020-7292	207292	INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS	A3	0.956	103	3.59	-	['Azitromicina', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	The clinical course of COVID 19 during pregnancy appears to be mild in the present study.	32682342	International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics	1879-3479	10.1002/ijgo.13318	A experiência de um centro pandêmico no manejo de mulheres grávidas com infecção por COVID-19 na Turquia: um estudo de coorte prospectivo 	O curso clínico do COVID 19 durante a gravidez parece ser leve no presente estudo.
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report	https://www.nejm.org/doi/10.1056/NEJMoa2021436	17/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021436	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Dexametasona']	['Dexamethasone']	-	-	-	-	-	Dexametasona em Pacientes Hospitalizados com Covid-19 — Relatório Preliminar 	-
Mild COVID‐19 infection in an NMO patient treated with tocilizumab: a confrmation of anti‐IL‐6 protective role?	https://doi.org/10.1007/s00415-020-10039-7	07/07/2020	Artigo completo publicado em periódico científico	10.1007/s00415-020-10039-7	0340-5354	3405354	JOURNAL OF NEUROLOGY (PRINT)	A2	1.359	144	4.75	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Infecção leve por COVID-19 em um paciente NMO tratado com tocilizumabe: uma confirmação do papel protetor anti-IL-6? 	-
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?	https://doi.org/10.1016/j.ijantimicag.2020.106056	13/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106056	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	The severity of COVID-19 has resulted in a global rush to find the right antiviral treatment to conquer the pandemic and to treat patients. This requires reliable studies to support treatment. In a recently published study by Gautret et al. the authors concluded that hydroxychloroquine monotherapy and hydroxychloroquine in combination with azithromycin reduced viral load. However, this trial has several major methodological issues, including the design, outcome measure and the statistical analyses. In this paper we discuss the background, clinical evidence, pharmacology and methodological issues related to this clinical trial. We understand the rush to release results, however in case conclusions are far reaching the evidence needs to be robust.	32674929	International journal of antimicrobial agents	1872-7913	10.1016/j.ijantimicag.2020.106056	Responder a Gautret et al: sulfato de hidroxicloroquina e azitromicina para COVID-19: quais são as evidências e quais são os riscos? 	A gravidade do COVID-19 resultou em uma corrida global para encontrar o tratamento antiviral certo para vencer a pandemia e tratar os pacientes. Isso requer estudos confiáveis para apoiar o tratamento. Em um estudo recentemente publicado por Gautret et al. os autores concluíram que a monoterapia com hidroxicloroquina e hidroxicloroquina em combinação com azitromicina reduziram a carga viral. No entanto, este estudo tem várias questões metodológicas importantes, incluindo o design, a medida do resultado e as análises estatísticas. Neste artigo discutimos os antecedentes, evidências clínicas, farmacologia e questões metodológicas relacionadas a este ensaio clínico. Entendemos a pressa em divulgar os resultados, no entanto, caso as conclusões sejam de longo alcance, as evidências precisam ser robustas.
Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors	https://doi.org/10.1016/j.medcli.2020.06.013	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.06.013	0025-7753	257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Risco de COVID-19 grave em pacientes hipertensos tratados com inibidores do sistema renina-angiotensina-aldosterona 	-
A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01802-8	16/07/2020	Artigo completo publicado em periódico científico	https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01802-8	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-α, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.	['Plasma convalescente', 'Terapia celular']	['Convalescent Plasma', 'Cell Therapy']	Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-α, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.	32678017	Stem cell research & therapy	1757-6512	10.1186/s13287-020-01802-8	Um papel sinérgico de plasma convalescente e células-tronco mesenquimais no tratamento de pacientes gravemente enfermos com COVID-19: relato de caso clínico 	Vírus da síndrome do desconforto respiratório agudo-2 (SARS-CoV-2) responsável pela infecção por doença de coronavírus 2019 (COVID-19) , que causa emergências globais de saúde pública, acelerou amplamente por mais de 5 meses e tem o risco de transmissão a longo prazo. Nenhum tratamento eficaz foi descoberto até o momento. Nos casos relatados, o paciente continuou a piorar mesmo após a administração de medicamentos antivirais, como lopinavir/ritonavir, interferon-α e ribavirina, bem como injeção intravenosa de meropenem, metilprednisolona e imunoglobulina. Assim, infundimos o paciente com plasma convalescente (CP), e a contagem absoluta de linfócitos aumentou no dia seguinte e voltou ao normal no quarto dia. Seguido de infusão intravenosa de células-tronco mesenquimais (MSCs), os infiltrados bilaterais foram absorvidos e a função pulmonar melhorou significativamente. Observamos que a infusão intravenosa de CP e MSCs para o tratamento de pacientes graves com COVID-19 pode ter características sinérgicas na inibição da tempestade de citocinas, promovendo o reparo da lesão pulmonar e recuperando a função pulmonar. Esperamos fornecer uma referência para a direção de pesquisa de estratégias clínicas COVID-19.
Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock	https://www.nejm.org/doi/full/10.1056/NEJMcpc2004975	15/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMcpc2004975	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonista de β-adrenérgico', 'Cefepima', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Vancomicina']	['β-Adrenergic Antagonist', 'Cefepime', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Vancomycin']	The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health. In the current paper, we describe our successful treatment of one COVID-19 pneumonia patient case with high mortality risk factors. Our experience underlines the importance of the use of a multidisciplinary therapeutic approach in order to achieve a favorable clinical outcome. Further, enhancing the capability of the COVID-19 diagnosis with the use of the chest imaging modalities is discussed.	32668103	The New England journal of medicine	1533-4406	10.1056/NEJMcpc2004975	Caso 24-2020: Mulher de 44 anos com dor torácica, dispneia e 	choque ameaçando a saúde pública global. No artigo atual, descrevemos nosso tratamento bem-sucedido de um caso de paciente com pneumonia por COVID-19 com fatores de risco de alta mortalidade. A nossa experiência sublinha a importância da utilização de uma abordagem terapêutica multidisciplinar para alcançar um resultado clínico favorável. Além disso, é discutido o aprimoramento da capacidade do diagnóstico de COVID-19 com o uso das modalidades de imagem do tórax.
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial	https://doi.org/10.7326/M20-4207	16/07/2020	Artigo completo publicado em periódico científico	10.7326/M20-4207	0003-4819	34819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']	Private donors.	32673060	Annals of internal medicine	1539-3704	10.7326/M20-4207	Hidroxicloroquina em adultos não hospitalizados com COVID-19 precoce: um estudo randomizado 	Doadores privados.
Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19	https://doi.org/10.1093/ofid/ofaa241	21/06/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa241	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract                                   Background                   We aimed to evaluate the antiviral activity and safety of darunavir/cobicistat (DRV/c) in treating COVID-19 patients.                                                  Methods                   In this single-center, randomized, and open-label trial, mild patients with polymerase chain reaction (PCR)–confirmed COVID-19 were enrolled in Shanghai, China. Participants were randomized to receive DRV/c for 5 days on the top of interferon alpha 2b inhaling or interferon alpha 2b inhaling alone. The primary end point was the virological clearance rate of oropharyngeal swabs at day 7 after randomization in the intention-to-treat population (clinicaltrials.gov: NCT04252274).                                                  Results                   From January 30, 2020, to February 6, 2020, a total of 30 patients were enrolled, of whom 18 (60%) were male, aged 47.2 ± 2.8 years; 63.3% (19/30) of the participants had fever, and 46.7% (14/30) had cough at enrollment. The participants were randomized (range) at 4 (2–5) days after onset of symptoms. The proportion of negative PCR results at day 7 was 46.7% (7/15) and 60.0% (9/15) in the DRV/c and control groups (P = .72), respectively. The viral clearance rate at day 3 was 20% (3/15) in both study groups, while the number increased to 26.7% (4/15) in the DRV/c group and remained 20% (3/15) in the control group at day 5. Fourteen days after randomization, 1 participant in the DRV/c group progressed to critical illness and discontinued DRV/c, while all the patients in the control group were stable (P = 1.0). The frequencies of adverse events in the 2 groups were comparable.                                                  Conclusions                   Five days of DRV/c did not increase the proportion of negative conversion vs standard of care alone, although it was well tolerated.               	['Cobicistato', 'Darunavir']	['Cobicistat', 'Darunavir']	For the French translation of the abstract see Supplementary Materials section.	32855991	Open forum infectious diseases	2328-8957	10.1093/ofid/ofaa321	Atividade antiviral e segurança do darunavir/cobicistat para o tratamento do COVID-19 	Para a tradução francesa do resumo, consulte a seção Materiais Suplementares.
Corticosteroid administration for viral pneumonia: COVID-19 and beyond	https://doi.org/10.1016/j.cmi.2020.06.020	16/07/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.06.020	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Administração de corticosteróides para pneumonia viral: COVID-19 e além 	-
Rethinking interleukin-6 blockade for treatment of COVID-19	https://doi.org/10.1016/j.mehy.2020.110053	27/06/2020	Artigo completo publicado em periódico científico	10.1016/j.mehy.2020.110053	0306-9877	3069877	MEDICAL HYPOTHESES	A4	0.569	94	3.3	-	['Inibidores de interleucina-6']	['Interleukin-6 inhibitors']	Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been proposed as a treatment for patients with Coronavirus Disease 2019 (COVID-19). The rationale for this approach includes commitment to the concept that inflammation is a cause of lung damage in COVID-19 and belief that IL-6 is a pro-inflammatory molecule. Observational data thought to support IL-6 inhibition include elevated circulating IL-6 levels in COVID-19 patients and association between elevated IL-6 and poor clinical outcomes. However, IL-6 has significant anti-inflammatory properties, which calls into question the rationale for employing IL-6 blockade to suppress inflammation-induced tissue injury. Also, studies suggesting a beneficial role for IL-6 in the host response to infection challenge the strategy of using IL-6 blockade to treat COVID-19. In studies of recombinant IL-6 injected into human volunteers, IL-6 levels exceeding those measured in COVID-19 patients have been observed with no pulmonary adverse events or other organ damage. These observations question the role of IL-6 as a contributing factor in COVID-19. Clinical experience with IL-6 receptor antagonists such as tocilizumab demonstrates increase in severe and opportunistic infections, raising concern about using tocilizumab and similar agents to treat COVID-19. Trials of drugs to inhibit IL-6 activity in COVID-19 are ongoing and will shed light on the role of IL-6 in COVID-19 pathogenesis. However, until more information is available, providers should exercise caution in prescribing these therapies given the potential for patient harm.	32758889	Medical hypotheses	1532-2777	10.1016/j.mehy.2020.110053	Repensando o bloqueio da interleucina-6 para o tratamento da COVID-19 	A interleucina-6 (IL-6) é uma citocina pleiotrópica com efeitos na regulação imunológica, inflamação e infecção. O uso de medicamentos que inibem a atividade biológica da IL-6 tem sido proposto como tratamento para pacientes com Doença de Coronavírus 2019 (COVID-19). A justificativa para essa abordagem inclui o compromisso com o conceito de que a inflamação é uma causa de dano pulmonar no COVID-19 e a crença de que a IL-6 é uma molécula pró-inflamatória. Os dados observacionais pensados para apoiar a inibição de IL-6 incluem níveis elevados de IL-6 circulante em pacientes com COVID-19 e associação entre IL-6 elevada e resultados clínicos ruins. No entanto, a IL-6 tem propriedades anti-inflamatórias significativas, o que põe em causa a razão para empregar o bloqueio de IL-6 para suprimir a lesão tecidual induzida por inflamação. Além disso, estudos que sugerem um papel benéfico para IL-6 na resposta do hospedeiro à infecção desafiam a estratégia de uso do bloqueio de IL-6 para tratar COVID-19. Em estudos de IL-6 recombinante injetada em voluntários humanos, foram observados níveis de IL-6 superiores aos medidos em pacientes com COVID-19 sem eventos adversos pulmonares ou danos a outros órgãos. Essas observações questionam o papel da IL-6 como fator contribuinte no COVID-19. A experiência clínica com antagonistas do receptor de IL-6, como o tocilizumabe, demonstra aumento de infecções graves e oportunistas, aumentando a preocupação com o uso de tocilizumabe e agentes similares no tratamento de COVID-19. Ensaios de medicamentos para inibir a atividade da IL-6 na COVID-19 estão em andamento e esclarecerão o papel da IL-6 na patogênese da COVID-19. No entanto, até que mais informações estejam disponíveis, os profissionais devem ter cautela ao prescrever essas terapias, devido ao potencial de dano ao paciente.
Could anti‐hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID‐19 infection? Data from centers of southern Italy	https://doi.org/10.1161/JAHA.120.016948	07/07/2020	Artigo completo publicado em periódico científico	10.1161/JAHA.120.016948	2047-9980	20479980	JOURNAL OF THE AMERICAN HEART ASSOCIATION	A1	2.237	100	5.51	<jats:sec xml:lang="en">             BACKGROUND            <jats:p xml:lang="en">Coronavirus disease 2019 (COVID‐19) is the cause of a pandemic disease, with severe acute respiratory syndrome by binding target epithelial lung cells through angiotensin‐converting enzyme 2 in humans. Thus, patients with hypertension with COVID‐19 could have worse prognosis. Indeed, angiotensin‐converting enzyme inhibitors and/or angiotensin receptor blockers may interfere with angiotensin‐converting enzyme 2 expression/activity. Thus, patients with hypertension undergoing angiotensin‐converting enzyme inhibitor and/or angiotensin receptor blockers drug therapy may be at a higher risk of contracting a serious COVID‐19 infection and should be monitored. Moreover, in the present study we investigated the effects of angiotensin‐converting enzyme inhibitor versus angiotensin receptor blockers versus calcium channel blockers on clinical outcomes as mechanical ventilation, intensive care unit admissions, heart injury, and death in 62 patients with hypertension hospitalized for COVID‐19 infection.                    <jats:sec xml:lang="en">             METHODS AND RESULTS            <jats:p xml:lang="en">              The multicenter study was prospectively conducted at Department of Infectious Diseases of Sant'Anna Hospital of Caserta, and of University of Campania "Luigi Vanvitelli" of Naples, at Department of Advanced Surgical and Medical Sciences of University of Campania "Luigi Vanvitelli," Naples, and at General Medical Assistance Unit "FIMG," Naples, Italy. Lowest values of left ventricle ejection fraction predicted deaths (1.142, 1.008–1.294,               P              &lt;0.05), while highest values of interleukin‐6 predicted the admission to intensive care unit (1.617, 1.094–2.389), mechanical ventilation (1.149, 1.082–1.219), heart injuries (1.367, 1.054–1.772), and deaths (4.742, 1.788–8.524).                                <jats:sec xml:lang="en">             CONCLUSIONS            <jats:p xml:lang="en">Anti‐hypertensive drugs didn't affect the prognosis in patients with COVID‐19. Consequently, tailored anti‐inflammatory and immune therapies in addition to chronic antihypertensive therapy, could prevent a worse prognosis, as well as improve the clinical outcomes in patients with hypertension with COVID‐19 infection.          	['Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	BACKGROUND Coronavirus disease 2019 (COVID-19) is the cause of a pandemic disease, with severe acute respiratory syndrome by binding target epithelial lung cells through angiotensin-converting enzyme 2 in humans. Thus, patients with hypertension with COVID-19 could have worse prognosis. Indeed, angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers may interfere with angiotensin-converting enzyme 2 expression/activity. Thus, patients with hypertension undergoing angiotensin-converting enzyme inhibitor and/or angiotensin receptor blockers drug therapy may be at a higher risk of contracting a serious COVID-19 infection and should be monitored. Moreover, in the present study we investigated the effects of angiotensin-converting enzyme inhibitor versus angiotensin receptor blockers versus calcium channel blockers on clinical outcomes as mechanical ventilation, intensive care unit admissions, heart injury, and death in 62 patients with hypertension hospitalized for COVID-19 infection. METHODS AND RESULTS The multicenter study was prospectively conducted at Department of Infectious Diseases of Sant'Anna Hospital of Caserta, and of University of Campania "Luigi Vanvitelli" of Naples, at Department of Advanced Surgical and Medical Sciences of University of Campania "Luigi Vanvitelli," Naples, and at General Medical Assistance Unit "FIMG," Naples, Italy. Lowest values of left ventricle ejection fraction predicted deaths (1.142, 1.008-1.294, 	32633594	Journal of the American Heart Association	2047-9980	10.1161/JAHA.120.016948	A terapia medicamentosa anti-hipertensiva pode afetar o prognóstico clínico de pacientes hipertensos com infecção por COVID-19? Dados de centros do sul da Itália 	ANTECEDENTES A doença de coronavírus 2019 (COVID-19) é a causa de uma doença pandêmica, com síndrome respiratória aguda grave, ligando células epiteliais pulmonares alvo através da enzima conversora de angiotensina 2 em humanos. Assim, pacientes com hipertensão com COVID-19 poderiam ter pior prognóstico. De fato, os inibidores da enzima conversora da angiotensina e/ou bloqueadores do receptor da angiotensina podem interferir na expressão/atividade da enzima conversora da angiotensina 2. Assim, pacientes com hipertensão submetidos à terapia medicamentosa com inibidores da enzima conversora de angiotensina e/ou bloqueadores dos receptores da angiotensina podem ter maior risco de contrair uma infecção grave por COVID-19 e devem ser monitorados. Além disso, no presente estudo, investigamos os efeitos do inibidor da enzima conversora da angiotensina versus bloqueadores dos receptores da angiotensina versus bloqueadores dos canais de cálcio em desfechos clínicos como ventilação mecânica, internações em unidades de terapia intensiva, lesão cardíaca e morte em 62 pacientes com hipertensão hospitalizados por COVID- 19 infecção. MÉTODOS E RESULTADOS O estudo multicêntrico foi realizado prospectivamente no Departamento de Doenças Infecciosas do Hospital Sant'Anna de Caserta, e da Universidade da Campânia "Luigi Vanvitelli" de Nápoles, no Departamento de Ciências Médicas e Cirúrgicas Avançadas da Universidade da Campânia "Luigi Vanvitelli, " Nápoles, e na Unidade de Assistência Médica Geral "FIMG", Nápoles, Itália. Os valores mais baixos da fração de ejeção do ventrículo esquerdo previram mortes (1,142, 1,008-1,294,
Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study	https://doi.org/10.1186/s13054-020-03154-4	14/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03154-4	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Atorvastatina']	['Atorvastatin']	-	-	-	-	-	Atorvastatina associada à diminuição do risco de morte em pacientes com COVID-19 internados em uma UTI: um estudo de coorte retrospectivo 	-
The Use of IV vitamin C for patients with COVID-19: a single center observational study	https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1794819	14/07/2020	Artigo completo publicado em periódico científico	10.1080/14787210.2020.1794819	1478-7210	14787210	EXPERT REVIEW OF ANTI-INFECTIVE THERAPY	A2	1.078	84	5.45	-	['Ácido ascórbico']	['Ascorbic acid']	-	-	-	-	-	O uso de vitamina C IV para pacientes com COVID-19: um estudo observacional de centro único 	-
First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test	https://doi.org/10.1111/cod.13657	12/07/2020	Artigo completo publicado em periódico científico	10.1111/cod.13657	0105-1873	1051873	CONTACT DERMATITIS	A1	0.810	100	1.97	-	['Hidroxicloroquina']	['Hydroxychloroquine']	The COVID-19, actual pandemic due to SARS COV 2 is associated with numerous thromboembolic complications. Although venous thrombosis including pulmonary embolisms have been widely described, arterial localization seems rarely reported. Acute limb ischemia and myocardial infarction are two major consequences of arterial thrombosis and their concomitant occurrence among COVID-19 patients is extremely rare. It is an evident aspect of hypercoagulability and a real challenge to physicians. We herein describe the management of a 77 years old COVID-19 patient presenting an acute lower limb ischemia with concomitant myocardial infarction. He underwent coronary angiography with subsequent stent placement then was transferred to the operating room where a thrombectomy was performed. The outcome was poor as the cardiogenic shock persisted in addition to a reperfusion syndrome with multiorgan failure.	32654163	Contact dermatitis	1600-0536	10.1111/cod.13657	Primeiro caso de síndrome DRESS causada por hidroxicloroquina com teste 	de contato positivo Embora a trombose venosa incluindo embolia pulmonar tenha sido amplamente descrita, a localização arterial parece raramente relatada. A isquemia aguda do membro e o infarto do miocárdio são duas das principais consequências da trombose arterial e sua ocorrência concomitante entre pacientes com COVID-19 é extremamente rara. É um aspecto evidente da hipercoagulabilidade e um verdadeiro desafio para os médicos. Descrevemos o manejo de um paciente de 77 anos com COVID-19 apresentando isquemia aguda de membros inferiores com infarto do miocárdio concomitante. Foi submetido a cineangiocoronariografia com posterior colocação de stent e foi transferido para a sala de cirurgia onde foi realizada trombectomia. O resultado foi ruim, pois o choque cardiogênico persistiu, além de uma síndrome de reperfusão com falência de múltiplos órgãos.
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19	https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.120.15464	13/07/2020	Artigo completo publicado em periódico científico	10.1161/HYPERTENSIONAHA.120.15464	0194-911X	0194911X	HYPERTENSION (DALLAS, TEX. 1979)	A1	3.395	276	7.36	             The severe acute respiratory syndrome coronavirus 2 is known to infect host cells by interacting with ACE2 (angiotensin-converting enzyme 2) expressed in the respiratory epithelium. There have been concerns on whether alterations of ACE2 expression by renin-angiotensin-aldosterone system (RAAS) inhibitors would contribute to the infectivity and severity of coronavirus disease 2019 (COVID-19). We performed a case-control study to investigate the association between RAAS inhibitors and risk and severity of COVID-19 infection in South Korea using the population-based data provided by the Korean National Health Insurance System. Of 16 281 subjects with hypertension, there were 950 (5.8%) confirmed COVID-19 cases. After case-control matching, multivariable-adjusted conditional logistic regression analysis was performed. The adjusted odds ratio and 95% CIs for COVID-19 infection and long-term hospitalization comparing exposure to RAAS inhibitors and nonexposure to RAAS inhibitors was 1.161 (0.958–1.407) and 0.863 (0.533–1.397), respectively. When comparing exposure to RAAS inhibitors and nonexposure to RAAS inhibitors for intensive care unit admission, high-flow oxygen therapy, and death, the adjusted odds ratios (95% CIs) were 1.515 (0.402–5.701), 0.663 (0.272–1.619), and 1.363 (0.513–3.662), respectively. In all analyses,             P            values were not significant (             P            &gt;0.05). The present study demonstrates the absence of an identifiable association between the exposure to RAAS inhibitors and risk and severity of COVID-19 infection, supporting the current medical guidelines and recommendations that patients should not discontinue RAAS inhibitors out of a concern that they are at increased risk for infection or severe illness of COVID-19.          	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']	-	-	-	-	-	Associação entre inibidores do sistema renina-angiotensina-aldosterona e COVID-19 	-
Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients	https://doi.org/10.1161/HYPERTENSIONAHA.120.15289	13/07/2020	Artigo completo publicado em periódico científico	10.1161/HYPERTENSIONAHA.120.15289	0194-911X	0194911X	HYPERTENSION (DALLAS, TEX. 1979)	A1	3.395	276	7.36	             Hypertension is one of the most common comorbidities in patients with coronavirus disease 2019 (COVID-19). This study aimed to clarify the impact of hypertension on COVID-19 and investigate whether the prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of COVID-19. A total of 996 patients with COVID-19 were enrolled, including 282 patients with hypertension and 714 patients without hypertension. Propensity score-matched analysis (1:1 matching) was used to adjust the imbalanced baseline variables between the 2 groups. Patients with hypertension were further divided into the RAAS inhibitor group (n=41) and non-RAAS inhibitor group (n=241) according to their medication history. The results showed that COVID-19 patients with hypertension had more severe secondary infections, cardiac and renal dysfunction, and depletion of CD8             +            cells on admission. Patients with hypertension were more likely to have comorbidities and complications and were more likely to be classified as critically ill than those without hypertension. Cox regression analysis revealed that hypertension (hazard ratio, 95% CI, unmatched cohort [1.80, 1.20–2.70]; matched cohort [2.24, 1.36–3.70]) was independently associated with all-cause mortality in patients with COVID-19. In addition, hypertensive patients with a history of RAAS inhibitor treatment had lower levels of C-reactive protein and higher levels of CD4             +            cells. The mortality of patients in the RAAS inhibitor group (9.8% versus 26.1%) was significantly lower than that of patients in the non-RAAS inhibitor group. In conclusion, hypertension may be an independent risk factor for all-cause mortality in patients with COVID-19. Patients who previously used RAAS inhibitors may have a better prognosis.          	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Hypertension is one of the most common comorbidities in patients with coronavirus disease 2019 (COVID-19). This study aimed to clarify the impact of hypertension on COVID-19 and investigate whether the prior use of renin-angiotensin-aldosterone system (RAAS) inhibitors affects the prognosis of COVID-19. A total of 996 patients with COVID-19 were enrolled, including 282 patients with hypertension and 714 patients without hypertension. Propensity score-matched analysis (1:1 matching) was used to adjust the imbalanced baseline variables between the 2 groups. Patients with hypertension were further divided into the RAAS inhibitor group (n=41) and non-RAAS inhibitor group (n=241) according to their medication history. The results showed that COVID-19 patients with hypertension had more severe secondary infections, cardiac and renal dysfunction, and depletion of CD8	32654555	Hypertension (Dallas, Tex. : 1979)	1524-4563	10.1161/HYPERTENSIONAHA.120.15289	Características clínicas da COVID-19 em pacientes com hipertensão essencial e os impactos dos inibidores do sistema renina-angiotensina-aldosterona no prognóstico de pacientes com COVID-19 A 	hipertensão é uma das comorbidades mais comuns em pacientes com doença por coronavírus 2019 (COVID-19). Este estudo teve como objetivo esclarecer o impacto da hipertensão na COVID-19 e investigar se o uso prévio de inibidores do sistema renina-angiotensina-aldosterona (SRAA) afeta o prognóstico da COVID-19. Um total de 996 pacientes com COVID-19 foram inscritos, incluindo 282 pacientes com hipertensão e 714 pacientes sem hipertensão. A análise de correspondência de pontuação de propensão (correspondência de 1:1) foi usada para ajustar as variáveis basais desequilibradas entre os 2 grupos. Os pacientes com hipertensão foram divididos em grupo inibidor de RAAS (n=41) e grupo não inibidor de RAAS (n=241) de acordo com seu histórico de medicação. Os resultados mostraram que pacientes com COVID-19 com hipertensão tiveram infecções secundárias mais graves, disfunção cardíaca e renal e depleção de CD8
Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?	https://doi.org/10.1111/joim.13121	01/07/2020	Artigo completo publicado em periódico científico	10.1111/joim.13121	0954-6820	9546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Esomeprazol', 'Omeprazol', 'Pantoprazol']	['Esomeprazole', 'Omeprazole', 'Pantoprazole']	-	-	-	-	-	O tratamento com inibidores da bomba de prótons aumenta o risco de infecções secundárias e SDRA em pacientes hospitalizados com COVID-19: coincidência ou fator de risco subestimado? 	-
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?	https://doi.org/10.1016/j.ejca.2020.06.017	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejca.2020.06.017	0959-8049	9598049	EUROPEAN JOURNAL OF CANCER	A1	2.865	224	7.68	-	['Obinutuzumabe', 'Obinutuzumabe', 'Ocrelizumabe', 'Ocrelizumabe', 'Ofatumumabe', 'Ofatumumabe', 'Rituximabe', 'Rituximabe']	['Obinutuzumab', 'Obinutuzumab', 'Ocrelizumab', 'Ocrelizumab', 'Ofatumumab', 'Ofatumumab', 'Rituximab', 'Rituximab']	A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic.	32619884	European journal of cancer (Oxford, England : 1990)	1879-0852	10.1016/j.ejca.2020.06.017	A terapia anti-CD20 pode comprometer a eficácia de uma vacina SARS-CoV-2? 	Uma vacina contra SARS-CoV-2 pode representar a abordagem mais promissora para interromper de forma durável a atual pandemia de COVID-19. Acreditamos que a terapia anti-CD20 pode comprometer a eficácia de tal vacina. Isso é lamentável porque os pacientes que recebem terapia anti-CD20 (ou seja, aqueles com malignidades hematológicas ou distúrbios autoimunes) estão particularmente em risco de COVID-19 grave e, como tal, são os que mais precisam de uma vacina. Aqui, revisamos as razões pelas quais a terapia anti-CD20 pode anular ou diminuir a eficácia de uma vacina contra SARS-CoV-2 e chamamos a atenção dos médicos para esse risco potencial para que possa ser considerado ao avaliar a relação risco/benefício de terapia anti-CD20 durante a atual pandemia.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report	https://doi.org/10.1056/NEJMoa2022483	14/07/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2022483	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Vacina mRNA-1273']	['mRNA-1273 vaccine']	-	-	-	-	-	Uma vacina de mRNA contra SARS-CoV-2 - Relatório Preliminar 	-
Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic	https://doi.org/10.1007/s11845-020-02291-7	06/07/2020	Artigo completo publicado em periódico científico	10.1007/s11845-020-02291-7	0021-1265	211265	IRISH JOURNAL OF MEDICAL SCIENCE	A4	0.410	36	1.68	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), has rapidly spread since December 2019 to become the focus of healthcare systems worldwide. Its highly contagious nature and significant mortality has led to its prioritization as a public health issue. The race to prevent and treat this disease has led to "off-label" prescribing of medications such as hydroxychloroquine, azithromycin, and Kaletra (lopinavir/ritonavir). Currently, there is no robust clinical evidence for the use of these drugs in the treatment of COVID-19, with most, if not all of these medications associated with the potential for QT interval prolongation, torsades de pointes, and resultant drug-induced sudden cardiac death. The aim of this document is to help healthcare providers mitigate the potential deleterious effects of drug-induced QTc prolongation.	32627127	Irish journal of medical science	1863-4362	10.1007/s11845-020-02291-7	Orientação clínica para navegar no prolongamento do QTc e no potencial arritmogênico da farmacoterapia durante a pandemia de 	COVID-19 2019 para se tornar o foco dos sistemas de saúde em todo o mundo. Sua natureza altamente contagiosa e mortalidade significativa levaram à sua priorização como questão de saúde pública. A corrida para prevenir e tratar esta doença levou à prescrição "off-label" de medicamentos como hidroxicloroquina, azitromicina e Kaletra (lopinavir/ritonavir). Atualmente, não há evidências clínicas robustas para o uso desses medicamentos no tratamento de COVID-19, com a maioria, se não todos esses medicamentos associados ao potencial de prolongamento do intervalo QT, torsades de pointes e resultantes súbitos induzidos por medicamentos. morte cardíaca. O objetivo deste documento é ajudar os profissionais de saúde a mitigar os potenciais efeitos deletérios do prolongamento do intervalo QTc induzido por drogas.
Pros and cons of corticosteroid therapy for COVID-19 patients	https://doi.org/10.1016/j.resp.2020.103492	10/07/2020	Artigo completo publicado em periódico científico	10.1016/j.resp.2020.103492	1569-9048	15699048	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY	A4	0.635	102	2.53	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']	-	-	-	-	-	Prós e contras da terapia com corticosteróides para pacientes com COVID-19 	-
Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection	https://doi.org/10.1016/j.clinre.2020.05.014	10/06/2020	Artigo completo publicado em periódico científico	10.1016/j.clinre.2020.05.014	2210-7401	22107401	CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY	A4	0.585	59	2.14	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	-	-	-	-	-	Características clínicas e manejo de um paciente transplantado de fígado admitido com infecção por SARS-CoV-2 	-
Bacillus Calmette–Guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study	https://www.cambridge.org/core/journals/epidemiology-and-infection/article/bacillus-calmetteguerin-vaccination-and-clinical-characteristics-and-outcomes-of-covid19-in-rhode-island-united-states-a-cohort-study/2A472746C49A1AB2C6AC698711C5049F	09/07/2020	Artigo completo publicado em periódico científico	https://www.cambridge.org/core/journals/epidemiology-and-infection/article/bacillus-calmetteguerin-vaccination-and-clinical-characteristics-and-outcomes-of-covid19-in-rhode-island-united-states-a-cohort-study/2A472746C49A1AB2C6AC698711C5049F	-	-	-	-	-	-	-	-	['Vacina BCG']	['BCG vaccine']	Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, and there is limited data on effective therapies. Bacillus Calmette-Guérin (BCG) vaccine, a live-attenuated strain derived from an isolate of Mycobacterium bovis and originally designed to prevent tuberculosis, has shown some efficacy against infection with unrelated pathogens. In this study, we reviewed 120 consecutive adult patients (≥18 years old) with COVID-19 at a major federally qualified health centre in Rhode Island, United States from 19 March to 29 April 2020. Median age was 39.5 years (interquartile range, 27.0-50.0), 30% were male and 87.5% were Latino/Hispanics. Eighty-two (68.3%) patients had BCG vaccination. Individuals with BCG vaccination were less likely to require hospital admission during the disease course (3.7% vs. 15.8%, P = 0.019). This association remained unchanged after adjusting for demographics and comorbidities (P = 0.017) using multivariate regression analysis. The finding from our study suggests the potential of BCG in preventing more severe COVID-19.	32641191	Epidemiology and infection	1469-4409	10.1017/S0950268820001569	Vacinação com Bacillus Calmette-Guérin e características clínicas e resultados da COVID-19 em Rhode Island, Estados Unidos: um estudo de coorte 	A doença de coronavírus 2019 (COVID-19) resultou em uma pandemia global e há dados limitados sobre terapias eficazes. A vacina Bacillus Calmette-Guérin (BCG), uma cepa viva atenuada derivada de um isolado de Mycobacterium bovis e originalmente projetada para prevenir a tuberculose, mostrou alguma eficácia contra a infecção por patógenos não relacionados. Neste estudo, revisamos 120 pacientes adultos consecutivos (≥18 anos) com COVID-19 em um importante centro de saúde federal qualificado em Rhode Island, Estados Unidos, de 19 de março a 29 de abril de 2020. A idade média foi de 39,5 anos (intervalo interquartil, 27,0-50,0), 30% eram do sexo masculino e 87,5% eram latinos/hispânicos. Oitenta e dois (68,3%) pacientes foram vacinados com BCG. Indivíduos com vacinação BCG foram menos propensos a necessitar de internação hospitalar durante o curso da doença (3,7% vs. 15,8%, P = 0,019). Essa associação permaneceu inalterada após o ajuste para dados demográficos e comorbidades (P = 0,017) usando análise de regressão multivariada. A descoberta do nosso estudo sugere o potencial do BCG na prevenção de COVID-19 mais grave.
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis	https://doi.org/10.1186/s13054-020-03117-9	11/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03117-9	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	 Abstract  Background The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients.  Methods The present report took the opportunity of compassionate use and successive drug shortages to compare the effects of two therapeutic options, lopinavir/ritonavir and hydroxychloroquine, as compared to standard of care only. The primary outcomes were treatment escalation (intubation, extra-corporeal membrane oxygenation support, or renal replacement therapy) after day 1 until day 28. Secondary outcomes included ventilator-free days at day 28, mortality at day 14 and day 28, treatment safety issues and changes in respiratory tracts, and plasma viral load (as estimated by cycle threshold value) between admission and day 7.  Results Eighty patients were treated during a 4-week period and included in the analysis: 22 (28%) received standard of care only, 20 (25%) patients received lopinavir/ritonavir associated to standard of care, and 38 (47%) patients received hydroxychloroquine and standard of care. Baseline characteristics were well balanced between the 3 groups. Treatment escalation occurred in 9 (41%), 10 (50%), and 15 (39%) patients who received standard of care only, standard of care and lopinavir/ritonavir, and standard of care and hydroxychloroquine, respectively ( p = 0.567). There was no significant difference between groups regarding the number of ventilator-free days at day 28 and mortality at day 14 and day 28. Finally, there was no significant change between groups in viral respiratory or plasma load between admission and day 7.  Conclusion In critically ill patients admitted for SARS-CoV-2-related pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir as compared to standard of care only on the proportion of patients who needed treatment escalation at day 28. Further randomized controlled trials are required to demonstrate whether these drugs may be useful in this context.	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	In critically ill patients admitted for SARS-CoV-2-related pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir as compared to standard of care only on the proportion of patients who needed treatment escalation at day 28. Further randomized controlled trials are required to demonstrate whether these drugs may be useful in this context.	32653015	Critical care (London, England)	1466-609X	10.1186/s13054-020-03117-9	Comparação de hidroxicloroquina, lopinavir/ritonavir e padrão de atendimento em pacientes críticos com pneumonia por SARS-CoV-2: uma análise retrospectiva 	oportunista lopinavir/ritonavir em comparação com o tratamento padrão apenas na proporção de pacientes que necessitaram de tratamento escalonado no dia 28. São necessários mais ensaios clínicos randomizados para demonstrar se esses medicamentos podem ser úteis neste contexto.
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19	https://link.springer.com/article/10.1007/s40121-020-00318-1	10/07/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s40121-020-00318-1	2193-8229	21938229	INFECTIOUS DISEASES AND THERAPY	A4	1.141	33	4.82	-	['Remdesivir']	['Remdesivir']	Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.	32651941	Infectious diseases and therapy	2193-8229	10.1007/s40121-020-00318-1	Isso escalou rapidamente: o lugar do remdesivir na terapia para o COVID-19 	O remdesivir é um antiviral nucleosídeo recentemente estudado em vários ensaios randomizados para o tratamento do COVID-19. Os dados observacionais e prospectivos disponíveis são conflitantes, exigindo que os médicos avaliem e reconciliem criticamente os resultados para determinar as populações de pacientes que podem se beneficiar da terapia com remdesivir, especialmente quando a oferta de medicamentos é escassa. Nesta revisão, analisamos dados clínicos pertinentes do remdesivir para pacientes com COVID-19 de 1º de janeiro de 2020 a 31 de maio de 2020.
An adult with Kawasaki-like multisystem inflammatory syndrome associated with COVID-19	https://doi.org/10.1016/S0140-6736(20)31526-9	10/07/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31526-9	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Um adulto com síndrome inflamatória multissistêmica do tipo Kawasaki associada ao COVID-19 	-
SAFETY AND EFFICACY OF ANTI-IL6-RECEPTOR TOCILIZUMAB USE IN SEVERE AND CRITICAL PATIENTS AFFECTED BY CORONAVIRUS DISEASE 2019: A COMPARATIVE ANALYSIS	https://doi.org/10.1016/j.jinf.2020.07.008	08/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.07.008	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Tocilizumabe']	['Tocilizumab']	Some of the tocilizumab doses used in the subjects included in this analysis were provided by the "Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia" (EudraCT Number: 2020-001110-38) supported by the Italian National Agency for Drugs (AIFA). No specific funding support was planned for study design, data collection and analysis and manuscript writing of this paper.	32652164	The Journal of infection	1532-2742	10.1016/j.jinf.2020.07.008	SEGURANÇA E EFICÁCIA DO USO DO ANTI-IL6-RECEPTOR TOCILIZUMAB EM PACIENTES GRAVES E CRÍTICOS AFETADOS PELA DOENÇA POR CORONAVÍRUS 2019: UMA ANÁLISE COMPARATIVA 	Algumas das doses de tocilizumab usadas nos indivíduos incluídos nesta análise foram fornecidas pelo "Estudo multicêntrico sobre a eficácia e tolerabilidade de tocilizumab no tratamento de pacientes com pneumonia por COVID-19" (Número EudraCT: 2020-001110-38) apoiado pela Agência Nacional Italiana de Medicamentos (AIFA). Nenhum apoio financeiro específico foi planejado para o desenho do estudo, coleta e análise de dados e redação do manuscrito deste artigo.
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab	https://doi.org/10.1016/j.jaut.2020.102512	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.jaut.2020.102512	0896-8411	8968411	JOURNAL OF AUTOIMMUNITY (PRINT)	A1	2.751	121	12.06	-	['Tocilizumabe']	['Tocilizumab']	Coronavirus disease 2019 (COVID-19) can progress to cytokine storm that is associated with organ dysfunction and death. The purpose of the present study is to determine clinical characteristics associated with 28 day in-hospital survival in patients with coronavirus disease 2019 (COVID-19) that received tocilizumab. This was a retrospective observational cohort study conducted at a five hospital health system in Michigan, United States. Adult patients with confirmed COVID-19 that were admitted to the hospital and received tocilizumab for cytokine storm from March 1, 2020 through April 3, 2020 were included. Patients were grouped into survivors and non-survivors based on 28 day in-hospital mortality. Study day 0 was defined as the day tocilizumab was administered. Factors independently associated with in-hospital survival at 28 days after tocilizumab administration were assessed. Epidemiologic, demographic, laboratory, prognostic scores, treatment, and outcome data were collected and analyzed. Clinical response was collected and defined as a decline of two levels on a six-point ordinal scale of clinical status or discharged alive from the hospital. Of the 81 patients included, the median age was 64 (58-71) years and 56 (69.1%) were male. The 28 day in-hospital mortality was 43.2%. There were 46 (56.8%) patients in the survivors and 35 (43.2%) in the non-survivors group. On study day 0 no differences were noted in demographics, clinical characteristics, severity of illness scores, or treatments received between survivors and non-survivors. C-reactive protein was significantly higher in the non-survivors compared to survivors. Compared to non-survivors, recipients of tocilizumab within 12 days of symptom onset was independently associated with survival (adjusted OR: 0.296, 95% CI: 0.098-0.889). SOFA score ≥8 on day 0 was independently associated with mortality (adjusted OR: 2.842, 95% CI: 1.042-7.753). Clinical response occurred more commonly in survivors than non-survivors (80.4% vs. 5.7%; p < 0.001). Improvements in the six-point ordinal scale and SOFA score were observed in survivors after tocilizumab. Early receipt of tocilizumab in patients with severe COVID-19 was an independent predictor for in-hospital survival at 28 days.	32646770	Journal of autoimmunity	1095-9157	10.1016/j.jaut.2020.102512	Características clínicas e preditores de sobrevivência em adultos com doença de coronavírus 2019 recebendo tocilizumab 	A doença de coronavírus 2019 (COVID-19) pode progredir para tempestade de citocinas associada à disfunção orgânica e morte. O objetivo do presente estudo é determinar as características clínicas associadas à sobrevida hospitalar de 28 dias em pacientes com doença por coronavírus 2019 (COVID-19) que receberam tocilizumabe. Este foi um estudo de coorte observacional retrospectivo realizado em um sistema de saúde de cinco hospitais em Michigan, Estados Unidos. Pacientes adultos com COVID-19 confirmado que foram admitidos no hospital e receberam tocilizumab para tempestade de citocinas de 1º de março de 2020 a 3 de abril de 2020 foram incluídos. Os pacientes foram agrupados em sobreviventes e não sobreviventes com base na mortalidade hospitalar em 28 dias. O dia 0 do estudo foi definido como o dia em que o tocilizumabe foi administrado. Fatores independentemente associados à sobrevida hospitalar em 28 dias após a administração de tocilizumab foram avaliados. Dados epidemiológicos, demográficos, laboratoriais, prognósticos, tratamento e resultados foram coletados e analisados. A resposta clínica foi coletada e definida como um declínio de dois níveis em uma escala ordinal de seis pontos do estado clínico ou alta viva do hospital. Dos 81 pacientes incluídos, a mediana de idade foi de 64 (58-71) anos e 56 (69,1%) eram do sexo masculino. A mortalidade hospitalar em 28 dias foi de 43,2%. Havia 46 (56,8%) pacientes no grupo de sobreviventes e 35 (43,2%) no grupo de não sobreviventes. No dia 0 do estudo, não foram observadas diferenças nos dados demográficos, características clínicas, gravidade dos escores da doença ou tratamentos recebidos entre sobreviventes e não sobreviventes. A proteína C reativa foi significativamente maior nos não sobreviventes em comparação com os sobreviventes. Em comparação com os não sobreviventes, os receptores de tocilizumabe dentro de 12 dias do início dos sintomas foram independentemente associados à sobrevida (OR ajustado: 0,296, IC 95%: 0,098-0,889). A pontuação SOFA ≥8 no dia 0 foi independentemente associada à mortalidade (OR ajustado: 2,842, IC 95%: 1,042-7,753). A resposta clínica ocorreu mais comumente em sobreviventes do que não sobreviventes (80,4% vs. 5,7%; p < 0,001). Melhorias na escala ordinal de seis pontos e pontuação SOFA foram observadas em sobreviventes após tocilizumab. O recebimento precoce de tocilizumabe em pacientes com COVID-19 grave foi um preditor independente de sobrevida hospitalar em 28 dias.
Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysi	https://doi.org/10.1016/j.intimp.2020.106740	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106740	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon recombinante tipo 1']	['Type 1 recombinant interferon']	-	-	-	-	-	Avaliação da segurança, eficácia, tolerabilidade e resultados relacionados ao tratamento de interferons tipo I para infecção por coronavírus humano (HCoVs) na prática clínica: uma revisão sistemática crítica atualizada e meta-análise 	-
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses	https://doi.org/10.1016/j.intimp.2020.106717	18/06/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106717	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Agonistas de TLRs', 'AS01B', 'AS03A', 'Delta inulin', 'Hidróxido de alumínio', 'MF59', 'Montanide ISA-51', 'Protollin', 'rOv-ASP-1']	['TLR agonists', 'AS01B', 'AS03A', 'Delta inulin', 'Aluminium hydroxide', 'MF59', 'Montanide ISA-51', 'Protollin', 'rOv-ASP-1']	-	-	-	-	-	Potenciais adjuvantes para o desenvolvimento de uma vacina SARS-CoV-2 com base em resultados experimentais de coronavírus semelhantes 	-
Role of vitamin D in preventing of COVID-19 infection, progression and severity	https://doi.org/10.1016/j.jiph.2020.06.021	20/06/2020	Artigo completo publicado em periódico científico	10.1016/j.jiph.2020.06.021	1876-0341	18760341	JOURNAL OF INFECTION AND PUBLIC HEALTH	A3	1.277	46	6.31	-	['Vitamina D (25-hidroxivitamina D)']	['Vitamin D (25-hydroxyvitamin D)']	-	-	-	-	-	Papel da vitamina D na prevenção da infecção, progressão e gravidade por COVID-19 	-
COVID-19 among fit patients with CLL treated with venetoclax-based combinations	http://dx.doi.org/10.1038/s41375-020-0941-7	29/06/2020	Artigo completo publicado em periódico científico	10.1038/s41375-020-0941-7	0887-6924	8876924	LEUKEMIA	A1	4.030	202	9.5	-	['Venetoclax', 'Venetoclax', 'Venetoclax']	['Venetoclax', 'Venetoclax', 'Venetoclax']	The role of disease-modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease-2019 (COVID-19) due to the absence of an adequate immune response against the SARS-CoV-2. However, therapies that act on immune response could play a protective role by dampening the cytokine-release syndrome. Fingolimod is a drug used for immune therapy in patients with multiple sclerosis (MS) through the sequestration of activated lymphocytes in the lymph nodes. We report the case of a 57-year-old man with relapsing-remitting MS treated with fingolimod that showed a reactivation of COVID-19 with signs of hyperinflammation syndrome after fingolimod withdrawal. Our case suggests that discontinuation of fingolimod during COVID-19 could imply a worsening of SARS-CoV2 infection.	32601378	Leukemia	1476-5551	10.1038/s41375-020-0941-7	COVID-19 entre pacientes aptos com LLC tratados com combinações à base 	de venetoclax Pacientes imunocomprometidos podem ter uma doença de coronavírus-2019 mais grave (COVID-19) devido à ausência de uma resposta imune adequada contra o SARS-CoV-2. No entanto, as terapias que atuam na resposta imune podem desempenhar um papel protetor ao amortecer a síndrome de liberação de citocinas. O fingolimode é um medicamento utilizado para terapia imunológica em pacientes com esclerose múltipla (EM) por meio do sequestro de linfócitos ativados nos linfonodos. Relatamos o caso de um homem de 57 anos com EM recorrente-remitente tratado com fingolimode que apresentou reativação de COVID-19 com sinais de síndrome de hiperinflamação após a retirada de fingolimode. Nosso caso sugere que a descontinuação do fingolimode durante o COVID-19 pode implicar no agravamento da infecção por SARS-CoV2.
Severe refractory COVID-19 patients responding to convalescent plasma; A case series	https://doi.org/10.1016/j.amsu.2020.06.018	24/06/2020	Artigo completo publicado em periódico científico	10.1016/j.amsu.2020.06.018	2049-0801	20490801	ANNALS OF MEDICINE AND SURGERY	A4	0.373	30	1.78	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Pacientes com COVID-19 refratários graves que respondem ao plasma convalescente; Uma série de casos 	-
Hydroxychloroquine safety: A meta-analysis of randomized controlled trials	https://doi.org/10.1016/j.tmaid.2020.101812	06/07/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101812	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Segurança da hidroxicloroquina: uma meta-análise de ensaios clínicos randomizados 	-
SARS-CoV-2: Virology, epidemiology, immunology and vaccine development	https://doi.org/10.1016/j.biologicals.2020.06.005	23/06/2020	Artigo completo publicado em periódico científico	10.1016/j.biologicals.2020.06.005	1045-1056	10451056	BIOLOGICALS (LONDON. PRINT)	A4	0.460	60	2.0	-	['Vacina (SCB-2019)', 'Vacina (SCB-2019)', 'Vacina (SCB-2019)', 'Vacina (SCB-2019)', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina Curevac', 'Vacina Curevac', 'Vacina Curevac', 'Vacina Curevac', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina NVX-CoV2373', 'Vacina NVX-CoV2373', 'Vacina NVX-CoV2373', 'Vacina NVX-CoV2373']	['Vaccine (SCB-2019)', 'Vaccine (SCB-2019)', 'Vaccine (SCB-2019)', 'Vaccine (SCB-2019)', 'Vaccine ChAdOx1 nCoV-19', 'Vaccine ChAdOx1 nCoV- 19', 'Vaccina ChAdOx1 nCoV-19', 'Vaccina ChAdOx1 nCoV-19', 'Vaccina Curevac', 'Vaccina Curevac', 'Vaccina Curevac', 'Vaccina Curevac', 'Vaccina INO-4800', 'Vaccina INO- 4800', 'INO-4800 vaccine', 'INO-4800 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'NVX-CoV2373 vaccine ', 'NVX-CoV2373 vaccine', 'NVX-CoV2373 vaccine', 'NVX-CoV2373 vaccine']	-	-	-	-	-	SARS-CoV-2: Virologia, epidemiologia, imunologia e desenvolvimento de vacinas 	-
Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline	https://www.frontiersin.org/article/10.3389/fimmu.2020.01294	05/06/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fimmu.2020.01294	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Convalescent Plasma', 'Remdesivir', 'Ritonavir']	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of CoV disease 2019 (COVID-19) is a highly pathogenic and transmissible CoV that is presently plaguing the global human population and economy. No proven effective antiviral therapy or vaccine currently exists, and supportive care remains to be the cornerstone treatment. Through previous lessons learned from SARS-CoV-1 and MERS-CoV studies, scientific groups worldwide have rapidly expanded the knowledge pertaining to SARS-CoV-2 virology that includes in vitro and in vivo models for testing of antiviral therapies and randomized clinical trials. In the present narrative, we review SARS-CoV-2 virology, clinical features, pathophysiology, and animal models with a specific focus on the antiviral and adjunctive therapies currently being tested or that require testing in animal models and randomized clinical trials.	32582221	Frontiers in immunology	1664-3224	10.3389/fimmu.2020.01294	A doença de coronavírus 2019 (COVID-19) pode tornar a imunidade natural a reinfecções? Um destaque sobre o coronavírus 2 da síndrome respiratória aguda grave do pipeline terapêutico 	(SARS-CoV-2), o agente causador da doença CoV 2019 (COVID-19) é um CoV altamente patogênico e transmissível que atualmente está assolando a população e a economia humana global. Atualmente, não existe terapia antiviral ou vacina comprovadamente eficaz, e os cuidados de suporte continuam a ser o tratamento fundamental. Por meio de lições anteriores aprendidas com estudos SARS-CoV-1 e MERS-CoV, grupos científicos em todo o mundo expandiram rapidamente o conhecimento referente à virologia SARS-CoV-2, que inclui modelos in vitro e in vivo para testes de terapias antivirais e ensaios clínicos randomizados. Na presente narrativa, revisamos a virologia, as características clínicas, a fisiopatologia e os modelos animais do SARS-CoV-2 com foco específico nas terapias antivirais e adjuvantes atualmente sendo testadas ou que requerem testes em modelos animais e ensaios clínicos randomizados.
Convalescent Plasma Therapy: Helpful Treatment of COVID-19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications	https://onlinelibrary.wiley.com/doi/abs/10.1111/ctr.14025	30/06/2020	Artigo completo publicado em periódico científico	10.1111/ctr.14025	0902-0063	9020063	CLINICAL TRANSPLANTATION	A4	0.901	80	2.87	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Terapia de plasma convalescente: tratamento útil de COVID-19 em um receptor de transplante renal apresentando manifestação clínica e complicações complexas 	-
Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era	https://doi.org/10.1016/j.ejim.2020.06.006	06/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejim.2020.06.006	0953-6205	9536205	EUROPEAN JOURNAL OF INTERNAL MEDICINE (LEICESTER)	A2	1.210	79	3.28	-	['Apixabana', 'Dabigatrana', 'Edoxabana', 'Heparina', 'Rivaroxabana']	['Apixaban', 'Dabigatran', 'Edoxaban', 'Heparin', 'Rivaroxaban']	COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease continues to pose a major therapeutic challenge. Patient mortality is ultimately caused by acute respiratory distress syndrome (ARDS). Cytokine release syndrome (or "cytokine storm") is likely to be a contributing factor to ARDS in many patients. Because interleukin 6 (IL-6) is known to play a key role in inflammation, IL-6 receptor inhibitors such as tocilizumab may potentially treat COVID-19 by attenuating cytokine release. We present the case of a 48-year-old male with severe COVID-19, on the verge of meeting intubation requirements, who needed progressive oxygen support for respiratory distress. The patient was treated with a non-weight-based dosage of tocilizumab to prevent the onset of a cytokine storm. We chose to administer an IL-6 inhibitor because of the gradually increasing levels of acute phase reactants identified on serial blood draws, as well as his declining respiratory status. The treatment was well-tolerated in conjunction with standard drug therapies for COVID-19 (hydroxychloroquine, azithromycin, and zinc). The patient subsequently experienced marked improvements in his respiratory symptoms and overall clinical status over the following days. We believe that tocilizumab played a substantial role in his ability to avert clinical decline, particularly the need for mechanical ventilation. Ultimately, the patient was downgraded from the ICU and discharged within days. We highlight the potential of IL-6 inhibitors to prevent the progression of respiratory disease to a point requiring ventilator support. This case underscores the potential importance of early serial measurements of IL-6 and cytokine storm-associated acute phase reactants, such as ferritin, D-dimer, and C-reactive protein, in guiding clinical decision-making in the management of patients with suspected COVID-19. 	32564905	European journal of internal medicine	1879-0828	10.1016/j.ejim.2020.06.006	Papel protetor do tratamento crônico com anticoagulantes orais diretos em pacientes idosos afetados por pneumonia intersticial na era 	COVID-19 A COVID-19, causada pelo novo coronavírus respiratório agudo grave 2 (SARS-CoV-2), surgiu em Wuhan, China, em 2019 e resultou na atual pandemia. A doença continua a representar um grande desafio terapêutico. A mortalidade do paciente é, em última análise, causada pela síndrome do desconforto respiratório agudo (SDRA). A síndrome de liberação de citocinas (ou "tempestade de citocinas") provavelmente é um fator que contribui para a SDRA em muitos pacientes. Como a interleucina 6 (IL-6) é conhecida por desempenhar um papel fundamental na inflamação, os inibidores do receptor de IL-6, como o tocilizumabe, podem tratar o COVID-19 atenuando a liberação de citocinas. Apresentamos o caso de um homem de 48 anos com COVID-19 grave, prestes a atender aos requisitos de intubação, que necessitou de suporte progressivo de oxigênio para desconforto respiratório. O paciente foi tratado com uma dosagem não baseada no peso de tocilizumabe para evitar o início de uma tempestade de citocinas. Optamos por administrar um inibidor de IL-6 devido aos níveis gradualmente crescentes de reagentes de fase aguda identificados em coletas seriadas de sangue, bem como seu estado respiratório em declínio. O tratamento foi bem tolerado em conjunto com terapias medicamentosas padrão para COVID-19 (hidroxicloroquina, azitromicina e zinco). O paciente posteriormente experimentou melhorias acentuadas em seus sintomas respiratórios e estado clínico geral nos dias seguintes. Acreditamos que o tocilizumabe tenha desempenhado um papel substancial em sua capacidade de evitar o declínio clínico, particularmente a necessidade de ventilação mecânica. Em última análise, o paciente foi rebaixado da UTI e recebeu alta em poucos dias. Destacamos o potencial dos inibidores de IL-6 para prevenir a progressão da doença respiratória a ponto de exigir suporte ventilatório. Este caso ressalta a importância potencial de medições seriadas precoces de IL-6 e reagentes de fase aguda associados à tempestade de citocinas, como ferritina, dímero D e proteína C reativa, na orientação da tomada de decisão clínica no manejo de pacientes com suspeita COVID-19.
Obstetric Management of COVID-19 in Pregnant Women	https://www.frontiersin.org/article/10.3389/fmicb.2020.01186	26/05/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fmicb.2020.01186	1664-302X	1664302X	FRONTIERS IN MICROBIOLOGY (ONLINE)	A1	1.314	166	6.11	-	['Cloroquina', 'Cloroquina', 'Interferon alfa', 'Interferon alfa', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir']	['Chloroquine', 'Chloroquine', 'Interferon alfa', 'Interferon alfa', 'Lopinavir', 'Lopinavir', 'Ritonavir', 'Ritonavir']	-	-	-	-	-	Manejo Obstétrico do COVID-19 em Gestantes 	-
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report	https://doi.org/10.1016/j.msard.2020.102323	21/06/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102323	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Ocrelizumabe']	['Ocrelizumab']	The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.	32593961	Multiple sclerosis and related disorders	2211-0356	10.1016/j.msard.2020.102323	A resposta sorológica ao SARS-CoV-2 é preservada em pacientes com EM em tratamento com ocrelizumabe? Relato de caso 	A emergência representada pela pandemia de COVID-19 representa um novo desafio para os clínicos que lidam com doenças autoimunes por causa de pacientes submetidos à terapia imunossupressora. Poucos casos de pacientes com esclerose múltipla (EM) recebendo ocrelizumabe que contraíram COVID-19 com curso benigno foram publicados recentemente. Apresentamos o caso de um paciente com EM com COVID-19 leve que desenvolveu IgA específica para SARS-CoV-2 sem IgG dez semanas após a infecção. Pacientes em uso de drogas depletoras de células B têm uma resposta imune de anticorpos reduzida aos neoantígenos virais. Uma relativa preservação de tecidos linfoides associados à mucosa (MALT) pode ser responsável pela resposta de IgA em nosso paciente.
Mortality and the use of antithrombotic therapies among nursing home residents with COVID ‐19	https://doi.org/10.1111/jgs.16664	07/07/2020	Artigo completo publicado em periódico científico	10.1111/jgs.16664	0002-8614	28614	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY	A1	2.133	241	4.78	-	['Antagonistas da vitamina K (AVK)', 'Anticoagulantes']	['Vitamin K antagonists (VKA)', 'Anticoagulants']	-	-	-	-	-	Mortalidade e uso de terapias antitrombóticas entre residentes de asilos com COVID ‐19 	-
Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)	https://doi.org/10.1016/j.micinf.2020.06.005	20/06/2020	Artigo completo publicado em periódico científico	10.1016/j.micinf.2020.06.005	1286-4579	12864579	MICROBES AND INFECTION	A2	1.586	148	6.22	-	['Tocilizumabe']	['Tocilizumab']	COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: "Death" and "Recovery". Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O	32574789	Microbes and infection	1769-714X	10.1016/j.micinf.2020.06.005	Fatores preditivos de mortalidade em pacientes tratados com tocilizumabe para síndrome do desconforto respiratório agudo relacionada à doença por coronavírus 2019 (COVID-19) 	Pacientes com COVID-19 (n = 34) que sofrem de SDRA foram tratados com tocilizumabe (TCZ). O desfecho foi classificado em dois grupos: "Morte" e "Recuperação". Fatores preditivos de mortalidade foram estudados. A média de idade foi de 75,3 anos, a média de oxigênio (O
An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can’t Get No) Satisfaction	https://doi.org/10.1016/j.ijid.2020.06.095	02/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.095	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	COVID-19 patients (n = 34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: "Death" and "Recovery". Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O	32623080	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.06.095	Um estudo de coorte observacional de hidroxicloroquina e azitromicina para COVID-19: (não é possível obter não) Satisfação 	Pacientes com COVID-19 (n = 34) que sofrem de SDRA foram tratados com tocilizumab (TCZ). O desfecho foi classificado em dois grupos: "Morte" e "Recuperação". Fatores preditivos de mortalidade foram estudados. A média de idade foi de 75,3 anos, a média de oxigênio (O
Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk	https://doi.org/10.1016/j.hrthm.2020.07.001	02/07/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.07.001	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Hidroxicloroquina']	['Hydroxychloroquine']	(Hydroxy)chloroquine ((H)CQ) is being investigated as a treatment for COVID-19, but studies have so far demonstrated either no or a small benefit. However, these studies have been mostly performed in patients admitted to the hospital and hence likely already (severely) affected. Another suggested approach uses prophylactic (H)CQ treatment aimed at preventing either severe acute respiratory syndrome coronavirus 2 infection or the development of disease. A substantial number of clinical trials are planned or underway aimed at assessing the prophylactic benefit of (H)CQ. However, (H)CQ may lead to QT prolongation and potentially induce life-threatening arrhythmias. This may be of particular relevance to patients with preexisting cardiovascular disease and those taking other QT-prolonging drugs. In addition, it is known that a certain percentage of the population carries genetic variant(s) that reduces their repolarization reserve, predisposing them to (H)CQ-induced QT prolongation, and this may be more relevant to female patients who already have a longer QT interval to start with. This review provides an overview of the current evidence on (H)CQ therapy in patients with COVID-19 and discusses different strategies for prophylactic (H)CQ therapy (ie, preinfection, postexposure, and postinfection). In particular, the potential cardiac effects, including QT prolongation and arrhythmias, will be addressed. Based on these insights, recommendations will be presented as to which preventive measures should be taken when giving (H)CQ prophylactically, including electrocardiographic monitoring.	32622993	Heart rhythm	1556-3871	10.1016/j.hrthm.2020.07.001	A (hidroxi)cloroquina profilática na COVID-19: potencial relevância para o risco de arritmia cardíaca 	(Hidroxi)cloroquina ((H)CQ) está sendo investigada como tratamento para COVID-19, mas os estudos até agora demonstraram nenhum ou um pequeno benefício. No entanto, esses estudos foram realizados principalmente em pacientes internados no hospital e, portanto, provavelmente já (gravemente) afetados. Outra abordagem sugerida usa o tratamento profilático (H)CQ destinado a prevenir a infecção por coronavírus 2 da síndrome respiratória aguda grave ou o desenvolvimento da doença. Um número substancial de ensaios clínicos está planejado ou em andamento com o objetivo de avaliar o benefício profilático de (H)CQ. No entanto, (H)CQ pode levar ao prolongamento do intervalo QT e potencialmente induzir arritmias com risco de vida. Isso pode ser de particular relevância para pacientes com doença cardiovascular preexistente e para aqueles que tomam outros medicamentos que prolongam o intervalo QT. Além disso, sabe-se que certa porcentagem da população é portadora de variante(s) genética(s) que reduz sua reserva de repolarização, predispondo-a ao prolongamento do intervalo QT induzido por (H)CQ, e isso pode ser mais relevante para pacientes do sexo feminino que já apresentam intervalo QT mais longo para começar. Esta revisão fornece uma visão geral das evidências atuais sobre a terapia com (H)CQ em pacientes com COVID-19 e discute diferentes estratégias para a terapia profilática (H)CQ (ou seja, pré-infecção, pós-exposição e pós-infecção). Em particular, serão abordados os potenciais efeitos cardíacos, incluindo prolongamento do intervalo QT e arritmias. Com base nesses insights, serão apresentadas recomendações sobre quais medidas preventivas devem ser tomadas ao administrar (H)CQ profilaticamente, incluindo monitoramento eletrocardiográfico.
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.	https://doi.org/10.1016/j.drudis.2020.06.030	03/07/2020	Artigo completo publicado em periódico científico	10.1016/j.drudis.2020.06.030	1359-6446	13596446	DRUG DISCOVERY TODAY	A1	1.470	185	8.45	-	['Cloroquina']	['Chloroquine']	-	-	-	-	-	Reposicionando a cloroquina como profilaxia antiviral contra COVID-19: potencial e desafios. 	-
Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19	https://doi.org/10.1016/j.ijid.2020.06.091	30/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.091	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Cloroquina', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Lopinavir', 'Oseltamivir', 'Ritonavir', 'Umifenovir']	Early detection and timely hospital admission may be warranted for symptomatic COVID-19 patients, especially for older patients and patients with diarrhea. Corticosteroid treatment is associated with prolonged viral RNA shedding and should be used with caution. Lopinavir/ritonavir use may be associated with prolonged viral RNA shedding in non-severe patients; further randomized controlled trials are needed to confirm this finding.	32619760	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.06.091	Associações de características clínicas e regimes de tratamento com a duração do derramamento de RNA viral em pacientes com COVID-19 	A detecção precoce e a admissão hospitalar oportuna podem ser justificadas para pacientes sintomáticos com COVID-19, especialmente para pacientes idosos e pacientes com diarreia. O tratamento com corticosteroides está associado à liberação prolongada de RNA viral e deve ser usado com cautela. O uso de lopinavir/ritonavir pode estar associado à liberação prolongada de RNA viral em pacientes não graves; mais ensaios clínicos randomizados são necessários para confirmar este achado.
Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy	https://doi.org/10.1016/j.eplepsyres.2020.106399	11/06/2020	Artigo completo publicado em periódico científico	10.1016/j.eplepsyres.2020.106399	0920-1211	9201211	EPILEPSY RESEARCH	A3	0.767	117	3.03	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Avaliar o risco de convulsões com terapia com cloroquina ou hidroxicloroquina para COVID-19 em pessoas com epilepsia 	-
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series	https://doi.org/10.1186/s13054-020-03078-z	03/07/2020	Artigo completo publicado em periódico científico	10.1186/s13054-020-03078-z	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Favipiravir', 'Nafamostato']	['Favipiravir', 'Nafamostat']	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe pneumonia related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse transcription PCR was used to monitor SARS-CoV-2 in blood plasma and the lower and upper respiratory tract. Among the five patients treated, two needed mechanical ventilation and one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load in the upper respiratory tract was observed in most cases, but two patients died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted before the initialy planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement. This case series of five COVID-19 patients requiring intensive care unit treatment for respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients.	32620147	Critical care (London, England)	1466-609X	10.1186/s13054-020-03078-z	Tratamento com mesilato de nafamostat em combinação com favipiravir para pacientes criticamente doentes com Covid-19: uma série de casos 	O coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) foi identificado como o vírus responsável pelo surto da doença de coronavírus 2019 (COVID-19) no mundo todo. Os dados sobre o tratamento são assustadores e foram feitos paralelos entre o SARS-CoV-2 e outros coronavírus. O remdesivir é um antiviral de amplo espectro com atividade in vitro eficiente contra o SARS-CoV-2. A evidência de melhora clínica em pacientes com COVID-19 grave tratados com remdesivir é controversa. O objetivo deste estudo foi descrever os resultados clínicos e o monitoramento virológico dos primeiros cinco pacientes com COVID-19 admitidos na unidade de terapia intensiva do Hospital Universitário Bichat-Claude Bernard, Paris, França, por pneumonia grave relacionada ao SARS-CoV-2 e tratados com remdesivir. A PCR de transcrição reversa quantitativa foi usada para monitorar SARS-CoV-2 no plasma sanguíneo e no trato respiratório inferior e superior. Entre os cinco pacientes atendidos, dois necessitaram de ventilação mecânica e um de oxigênio de alto fluxo por cânula. Uma diminuição significativa na carga viral do SARS-CoV-2 no trato respiratório superior foi observada na maioria dos casos, mas dois pacientes morreram com replicação ativa do SARS-CoV-2 no trato respiratório inferior. As amostras de plasma foram positivas para SARS-CoV-2 em apenas um paciente. O remdesivir foi interrompido antes da duração inicialmente planejada em quatro pacientes, dois por causa de elevações da alanina aminotransferase (3 a 5 intervalo normal) e dois por causa de insuficiência renal com necessidade de substituição renal. Esta série de casos de cinco pacientes com COVID-19 que necessitam de tratamento em unidade de terapia intensiva por desconforto respiratório e tratados com remdesivir destaca a complexidade do uso de remdesivir nesses pacientes graves.
Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19	https://doi.org/10.1016/j.ijid.2020.06.099	01/07/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.099	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	Tratamento com Hidroxicloroquina, Azitromicina e Combinação em Pacientes Hospitalizados com COVID-19 	-
Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19	https://doi.org/10.1002/sctm.20-0186	11/06/2020	Artigo completo publicado em periódico científico	10.1002/sctm.20-0186	2157-6564	21576564	STEM CELLS TRANSLATIONAL MEDICINE	A1	1.412	80	7.67	 Abstract                The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID-19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Because there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID-19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft-vs-host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious—including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis—as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials—including for COVID-19—of MSCT for these diseases, with some perspectives and comment on MSCT for COVID-19.                                  <jats:title />               	['Terapia celular']	['Cell Therapy']	The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID-19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Because there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID-19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft-vs-host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious-including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis-as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials-including for COVID-19-of MSCT for these diseases, with some perspectives and comment on MSCT for COVID-19.	32526079	Stem cells translational medicine	2157-6580	10.1002/sctm.20-0186	mesenquimais para distúrbios pulmonares imunológicos/inflamatórios: Obtendo insights para possível uso no COVID-19 	, incluindo uso alogênico incomparável. A doença do novo coronavírus COVID-19 desencadeou uma pandemia em tempo recorde acompanhada por uma taxa de mortalidade alarmante principalmente devido a lesão pulmonar e síndrome do desconforto respiratório agudo. Como atualmente não existem terapias preventivas ou curativas eficazes, a terapia MSC (MSCT) surgiu como um possível candidato, apesar da falta de dados pré-clínicos de MSCs para COVID-19. Curiosamente, os dados pré-clínicos de MSCT especificamente sobre distúrbios imunológicos/inflamatórios dos pulmões estavam entre os primeiros a serem relatados em 2003, com o primeiro uso clínico de MSCT para doença do enxerto versus hospedeiro relatado em 2004. Desde esses primeiros relatórios, dados pré-clínicos mostrando os efeitos benéficos da imunomodulação de MSC acumularam-se substancialmente e, como consequência, mais de um terço dos ensaios clínicos de MSCT agora têm como alvo doenças imunológicas/inflamatórias. Há muitas evidências pré-clínicas para MSCT em não infecciosas - incluindo doença pulmonar obstrutiva crônica, asma e fibrose pulmonar idiopática - bem como em doenças pulmonares infecciosas bacterianas/inflamatórias, com dados geralmente demonstrando efeitos terapêuticos; no entanto, para condições pulmonares virais infecciosas, a evidência pré-clínica é mais escassa com alguns resultados inconsistentes. Neste artigo, revisamos as evidências mecanicistas para o uso clínico de MSCs em distúrbios imunológicos/inflamatórios pulmonares e pesquisamos os ensaios clínicos em andamento - incluindo para COVID-19 - de MSCT para essas doenças, com algumas perspectivas e comentários sobre MSCT para COVID- 19.
Effects of Hydroxychloroquine Treatment on QT Interval	https://doi.org/10.1016/j.hrthm.2020.06.029	28/06/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.06.029	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Efeitos do tratamento com hidroxicloroquina no intervalo QT 	-
Use of Baricitinib in Patients with Moderate and Severe COVID-19	https://doi.org/10.1093/cid/ciaa879	29/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa879	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.	['Baricitinibe', 'Hidroxicloroquina']	['Baricitinib', 'Hydroxychloroquine']	-	-	-	-	-	Uso de Baricitinibe em Pacientes com COVID-19 Moderado e Grave 	-
Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with Pglycoprotein inhibitors	https://doi.org/10.1093/cid/ciaa883	28/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa883	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                We report a case of a man with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details on this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy.	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Lesão hepática induzida por drogas em um paciente com COVID-19: potencial interação do remdesivir com inibidores da Pglicoproteína 	-
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	https://doi.org/10.1016/j.msard.2020.102180	06/05/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102180	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Fingolimode']	['Fingolimod']	-	-	-	-	-	Infecção grave por COVID-19 em paciente com esclerose múltipla tratado com fingolimode 	-
Belatacept, kidney transplantation and COVID-19: successful management of the first reported case within the United Kingdom	https://doi.org/10.1111/ctr.14026	30/06/2020	Artigo completo publicado em periódico científico	10.1111/ctr.14026	0902-0063	9020063	CLINICAL TRANSPLANTATION	A4	0.901	80	2.87	-	['Belatacept']	['Belatacept']	The offset effect between CML and SARS-CoV-2 infection was supposed to be the underlying mechanism for the absence of leukocytosis or splenomegaly. The impact of immune network by SARS-CoV-2 preserved and disrupted the patient's response to TKIs despite the virus' ablation. We suggest that a continued elevation of basophils may be a useful indicator for CML concurrent with COVID-19, and individualized treatment with adjusted dosage and suitable type of TKIs should be considered to improve the patient's health outcome.	32603010	Clinical transplantation	1399-0012	10.1111/ctr.14026	Belatacept, transplante renal e COVID-19: manejo bem-sucedido do primeiro caso relatado no Reino Unido 	O efeito de compensação entre a infecção por LMC e SARS-CoV-2 deveria ser o mecanismo subjacente para a ausência de leucocitose ou esplenomegalia. O impacto da rede imunológica pelo SARS-CoV-2 preservou e interrompeu a resposta do paciente aos TKIs, apesar da ablação do vírus. Sugerimos que uma elevação contínua de basófilos pode ser um indicador útil para LMC concomitante com COVID-19, e o tratamento individualizado com dosagem ajustada e tipo adequado de TKIs deve ser considerado para melhorar o desfecho de saúde do paciente.
Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry	https://doi.org/10.1016/j.rec.2020.05.018	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.rec.2020.05.018	1885-5857	18855857	REVISTA ESPAÑOLA DE CARDIOLOGÍA (INTERNET. ENGLISH ED.)	A4	0.385	7	0.98	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Impacto dos inibidores da enzima conversora da angiotensina e bloqueadores dos receptores da angiotensina no COVID-19 em uma população ocidental. Registro CARDIOVIDO 	-
Role of corticosteroid in the management of COVID-19: A systemic review and a clinician’s perspective.	https://doi.org/10.1016/j.dsx.2020.06.054	27/06/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.06.054	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Papel do corticosteroide no manejo do COVID-19: uma revisão sistêmica e a perspectiva do clínico. 	-
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen	https://doi.org/10.1038/s41429-020-0336-z	12/06/2020	Artigo completo publicado em periódico científico	10.1038/s41429-020-0336-z	0021-8820	218820	JOURNAL OF ANTIBIOTICS (TOKYO. 1968)	A4	0.514	84	3.09	-	['Ivermectina']	['Ivermectin']	Ivermectin proposes many potentials effects to treat a range of diseases, with its antimicrobial, antiviral, and anti-cancer properties as a wonder drug. It is highly effective against many microorganisms including some viruses. In this comprehensive systematic review, antiviral effects of ivermectin are summarized including in vitro and in vivo studies over the past 50 years. Several studies reported antiviral effects of ivermectin on RNA viruses such as Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2. Furthermore, there are some studies showing antiviral effects of ivermectin against DNA viruses such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin plays a role in several biological mechanisms, therefore it could serve as a potential candidate in the treatment of a wide range of viruses including COVID-19 as well as other types of positive-sense single-stranded RNA viruses. In vivo studies of animal models revealed a broad range of antiviral effects of ivermectin, however, clinical trials are necessary to appraise the potential efficacy of ivermectin in clinical setting.	32533071	The Journal of antibiotics	1881-1469	10.1038/s41429-020-0336-z	Ivermectina: uma revisão sistemática dos efeitos antivirais ao regime complementar COVID-19 A 	ivermectina propõe muitos efeitos potenciais para tratar uma série de doenças, com suas propriedades antimicrobianas, antivirais e anticancerígenas como um medicamento maravilhoso. É altamente eficaz contra muitos microorganismos, incluindo alguns vírus. Nesta revisão sistemática abrangente, os efeitos antivirais da ivermectina são resumidos, incluindo estudos in vitro e in vivo nos últimos 50 anos. Vários estudos relataram efeitos antivirais da ivermectina em vírus de RNA, como Zika, dengue, febre amarela, Nilo Ocidental, Hendra, Newcastle, encefalite equina venezuelana, chikungunya, Semliki Forest, Sindbis, gripe aviária A, Síndrome Reprodutiva e Respiratória Suína, vírus da imunodeficiência humana tipo 1 e síndrome respiratória aguda grave coronavírus 2. Além disso, existem alguns estudos que mostram os efeitos antivirais da ivermectina contra vírus de DNA, como herpes eqüino tipo 1, poliomavírus BK, pseudo-raiva, circovírus suíno 2 e herpesvírus bovino 1. A ivermectina desempenha um papel em vários mecanismos biológicos, portanto, pode servir como potencial candidato no tratamento de uma ampla gama de vírus, incluindo COVID-19, bem como outros tipos de vírus de RNA de fita simples de sentido positivo. Estudos in vivo de modelos animais revelaram uma ampla gama de efeitos antivirais da ivermectina, no entanto, são necessários ensaios clínicos para avaliar a eficácia potencial da ivermectina no ambiente clínico.
Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment	https://doi.org/10.1007/s11886-020-01327-9	11/06/2020	Artigo completo publicado em periódico científico	10.1007/s11886-020-01327-9	1523-3782	15233782	CURRENT CARDIOLOGY REPORTS (PRINT)	A4	0.916	54	3.55	-	['Heparina', 'Heparina']	['Heparin', 'Heparin']	In this article, we review currently available clinical data, and mechanisms for COVID-associated coagulopathy, and propose algorithms for screening, prevention (including extended-duration prophylaxis), and treatment of these patients. Although these recommendations are subject to change given rapidly evolving data, we provide a framework that can guide clinicians in managing thrombotic complications in this challenging condition.	32529517	Current cardiology reports	1534-3170	10.1007/s11886-020-01327-9	Tromboembolismo venoso no COVID-19: em direção a uma abordagem ideal para tromboprofilaxia, triagem e 	tratamento ) e tratamento desses pacientes. Embora essas recomendações estejam sujeitas a alterações devido aos dados em rápida evolução, fornecemos uma estrutura que pode orientar os médicos no manejo de complicações trombóticas nessa condição desafiadora.
A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient	https://doi.org/10.1111/tid.13388	25/06/2020	Artigo completo publicado em periódico científico	10.1111/tid.13388	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Favipiravir', 'Tocilizumabe']	['Favipiravir', 'Tocilizumab']	We report a case of COVID-19 in kidney transplant patient in Thailand. A 58-year-old 2 years post-kidney transplant recipient, with maintenance immunosuppression of tacrolimus, mycophenolate mofetil (MMF), and prednisolone, presented with acute diarrhea which followed by fever on day 12. Symptoms of pneumonia together with lymphopenia from complete blood count were developed on day 7 after onset of fever with the x-ray finding of bilateral multifocal patchy infiltration. COVID-19 infection has been confirmed by reverse real-time polymerase chain reaction (PCR) in nasal swab as well as found in stool. Darunavir together with ritonavir, hydroxychloroquine, azithromycin, and favipiravir was initiated on the first day of admission at primary hospital. Patient has been transferred to our hospital on day 2 of admission in which tacrolimus together with MMF was discontinued. High-flow nasal cannula oxygen therapy was required on days 4-5 of hospitalization. Tocilizumab was administered after rising of serum IL-6 level. Symptoms of pneumonia were improved in which no oxygen treatment required from day 10 of hospitalization. Drug interaction between tacrolimus and anti-viral treatment leads to severely high level of tacrolimus which caused reversible acute kidney injury (AKI) after supportive treatment.	32585765	Transplant infectious disease : an official journal of the Transplantation Society	1399-3062	10.1111/tid.13388	Um caso de tratamento bem-sucedido de pneumonia grave por COVID-19 com favipiravir e tocilizumabe em receptor pós-transplante renal 	Relatamos um caso de COVID-19 em paciente de transplante renal na Tailândia. Paciente de 58 anos, 2 anos pós-transplante renal, com imunossupressão de manutenção de tacrolimus, micofenolato de mofetil (MMF) e prednisolona, apresentou diarreia aguda seguida de febre no dia 12. Sintomas de pneumonia juntamente com linfopenia de sangue completo contagem foram desenvolvidos no dia 7 após o início da febre com o achado radiográfico de infiltração irregular multifocal bilateral. A infecção por COVID-19 foi confirmada por reação em cadeia da polimerase (PCR) reversa em tempo real em swab nasal, bem como encontrada nas fezes. Darunavir junto com ritonavir, hidroxicloroquina, azitromicina e favipiravir foi iniciado no primeiro dia de internação no hospital primário. O paciente foi transferido para o nosso hospital no dia 2 de admissão em que o tacrolimus em conjunto com MMF foi descontinuado. A oxigenoterapia com cânula nasal de alto fluxo foi necessária nos dias 4-5 de internação. O tocilizumab foi administrado após elevação do nível sérico de IL-6. Os sintomas de pneumonia foram melhorados em que nenhum tratamento de oxigênio necessário a partir do dia 10 de internação. A interação medicamentosa entre o tacrolimus e o tratamento antiviral leva a um nível gravemente alto de tacrolimus que causou lesão renal aguda reversível (LRA) após tratamento de suporte.
Methylprednisolone added to tocilizumab reduces mortality in SARS‐CoV‐2 pneumonia: an observational study	https://doi.org/10.1111/joim.13145	30/06/2020	Artigo completo publicado em periódico científico	10.1111/joim.13145	0954-6820	9546820	JOURNAL OF INTERNAL MEDICINE (PRINT)	A1	3.193	170	9.41	-	['Prednisona', 'Tocilizumabe']	['Prednisone', 'Tocilizumab']	Our data suggest that anakinra could be beneficial in treating COVID-19 patients with evidence of cytokine storm syndrome when initiated early after onset of acute hypoxemic respiratory failure. Our patient selection and treatment approach should be considered for investigation in a clinical trial to determine the safety and efficacy of anakinra in treating patients with COVID-19 and symptoms of cytokine storm syndrome.	32603493	Journal of internal medicine	1365-2796	10.1111/joim.13145	tocilizumab reduz a mortalidade na pneumonia por SARS-CoV-2: um estudo observacional 	Nossa seleção de pacientes e abordagem de tratamento devem ser consideradas para investigação em um ensaio clínico para determinar a segurança e eficácia de anakinra no tratamento de pacientes com COVID-19 e sintomas da síndrome da tempestade de citocinas.
Association of Hydroxychloroquine with QTc Interval in Patients	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048476	05/06/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.048476	0009-7322	97322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	-	['Hidroxicloroquina']	['Hydroxychloroquine']	Early QTc prolongation is frequent in COVID-19 patients treated with hydroxychloroquine or chloroquine in association with azithromycin.	35892438	Clinics and practice	2039-7275	10.3390/clinpract12040052	Associação de hidroxicloroquina com intervalo QTc em pacientes 	O prolongamento precoce do QTc é frequente em pacientes com COVID-19 tratados com hidroxicloroquina ou cloroquina em associação com azitromicina.
Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial	https://onlinelibrary.wiley.com/doi/10.1111/ijcp.13600	30/06/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13600	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Febuxostato']	['Febuxostat']	This trial suggests that FBX is as an alternative treatment to HCQ for COVID-19 infection and may be considered in patients with a contraindication or precaution to HCQ.	32603531	International journal of clinical practice	1742-1241	10.1111/ijcp.13600	Terapia com febuxostat em pacientes ambulatoriais com suspeita de COVID-19: um ensaio clínico 	Este estudo sugere que o FBX é um tratamento alternativo ao HCQ para infecção por COVID-19 e pode ser considerado em pacientes com contraindicação ou precaução ao HCQ.
Nanotechnology for COVID-19: Therapeutics and Vaccine Research	https://doi.org/10.1021/acsnano.0c04006	22/06/2020	Artigo completo publicado em periódico científico	10.1021/acsnano.0c04006	1936-0851	19360851	ACS NANO	A1	4.611	413	17.04	-	['Ad5-nCoV', 'Ad5-nCoV', 'Ad5-nCoV', 'Vacina BNT162', 'Vacina BNT162', 'Vacina BNT162', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina ChAdOx1 nCoV-19', 'Vacina de DNA', 'Vacina de DNA', 'Vacina de DNA', 'Vacina de RNA', 'Vacina de RNA', 'Vacina de RNA', 'Vacina de vírus inativado', 'Vacina de vírus inativado', 'Vacina de vírus inativado', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina INO-4800', 'Vacina mRNA-1273', 'Vacina mRNA-1273', 'Vacina mRNA-1273']	['Ad5-nCoV', 'Ad5-nCoV', 'Ad5-nCoV', 'BNT162 Vaccine', 'BNT162 Vaccine', 'BNT162 Vaccine', 'ChAdOx1 Vaccine nCoV-19', 'ChAdOx1 Vaccine nCoV-19', 'ChAdOx1 nCoV-19 vaccine', 'DNA vaccine', 'DNA vaccine', 'DNA vaccine', 'RNA vaccine', 'RNA vaccine', 'RNA vaccine', 'inactivated virus vaccine' , 'Inactivated virus vaccine', 'Inactivated virus vaccine', 'INO-4800 vaccine', 'INO-4800 vaccine', 'INO-4800 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine', 'mRNA-1273 vaccine']	-	-	-	-	-	Nanotecnologia para COVID-19: Terapia e Pesquisa de Vacinas 	-
Pneumococcal superinfection in COVID-19 patients: a series of 5 cases	https://doi.org/10.1016/j.medcli.2020.05.022	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.medcli.2020.05.022	0025-7753	257753	MEDICINA CLÍNICA (ED. IMPRESA)	A4	0.325	67	0.99	-	['Anakinra', 'Antibióticos', 'Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Anakinra', 'Antibiotics', 'Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']	International guidelines do not include the universal screening for bacterial co-infection. Radiological pattern of COVID-19 can be indistinguishable from that of pneumococcus pneumonia and frequency of co-infection is not well stablished, therefore clinicians should be aware of the possible SARS-CoV-2-pneumococcus association to avoid misdiagnosis and delay antibiotic therapy.	33521301	Medicina clinica (English ed.)	2387-0206	10.1016/j.medcle.2020.05.028	Superinfecção pneumocócica em pacientes com COVID-19: uma série de 5 casos 	As diretrizes internacionais não incluem a triagem universal para coinfecção bacteriana. O padrão radiológico do COVID-19 pode ser indistinguível do da pneumonia por pneumococo e a frequência de coinfecção não está bem estabelecida, portanto, os médicos devem estar cientes da possível associação SARS-CoV-2-pneumococo para evitar erros de diagnóstico e retardar a antibioticoterapia.
Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID‐19 pneumonia	https://doi.org/10.1111/bjh.16978	27/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16978	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Hidroxicarbamida']	['Hydroxycarbamide']	-	-	-	-	-	Tratamento bem sucedido da leucemia mielomonocítica crônica com hidroxicarbamida em um paciente com insuficiência respiratória hipóxica aguda devido à pneumonia por COVID-19 	-
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents	https://doi.org/10.1056/NEJMoa2021680	29/06/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021680	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Anakinra', 'Corticosteroides', 'Imunoglobulina', 'Siltuximabe', 'Tocilizumabe']	['Anakinra', 'Corticosteroids', 'Immunoglobulin', 'Siltuximab', 'Tocilizumab']	-	-	-	-	-	Síndrome Inflamatória Multissistêmica em Crianças e Adolescentes nos EUA 	-
Prior treatment with immunosuppressants among COVID‐19 inpatients at one hospital in Spain	https://onlinelibrary.wiley.com/doi/10.1111/jdv.16798	28/06/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16798	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Imunossupressores']	['Immunosuppressants']	Eight weeks after having laboratory-confirmed SARS-CoV-2 breakthrough infections, 2 otherwise healthy, fully immunized adolescent patients in the United States who were experiencing related signs and symptoms were diagnosed with multisystem inflammatory syndrome in children. Our findings indicate that COVID-19 vaccination does not completely protect adolescents against multisystem inflammatory syndrome.	32594619	Journal of the European Academy of Dermatology and Venereology : JEADV	1468-3083	10.1111/jdv.16798	Tratamento prévio com imunossupressores entre pacientes internados com COVID-19 em um hospital na Espanha 	Oito semanas após a confirmação laboratorial de infecções por SARS-CoV-2, 2 pacientes adolescentes saudáveis e totalmente imunizados nos Estados Unidos que apresentavam sinais e sintomas relacionados foram diagnosticados com síndrome inflamatória multissistêmica em crianças. Nossos achados indicam que a vacinação contra COVID-19 não protege completamente os adolescentes contra a síndrome inflamatória multissistêmica.
Multisystem Inflammatory Syndrome in Children in New York State	https://doi.org/10.1056/NEJMoa2021756	29/06/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2021756	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Corticosteroides', 'Imunoglobulina']	['Corticosteroids', 'Immunoglobulin']	-	-	-	-	-	Síndrome Inflamatória Multissistêmica em Crianças no Estado de Nova York 	-
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19	https://doi.org/10.1016/j.cmet.2020.06.015	24/06/2020	Artigo completo publicado em periódico científico	10.1016/j.cmet.2020.06.015	1550-4131	15504131	CELL METABOLISM	A1	9.297	292	22.01	-	['Estatina']	['Statin']	-	-	-	-	-	O uso hospitalar de estatinas está associado a um risco reduzido de mortalidade entre indivíduos com COVID-19 	-
TB infection and BCG vaccination: are we protected from COVID-19?	https://doi.org/10.1016/j.puhe.2020.05.042	30/05/2020	Artigo completo publicado em periódico científico	10.1016/j.puhe.2020.05.042	0033-3506	333506	PUBLIC HEALTH (LONDON)	A4	0.973	80	3.65	-	['Vacina BCG']	['BCG vaccine']	-	-	-	-	-	Infecção por TB e vacinação BCG: estamos protegidos do COVID-19? 	-
Ruxolitinib for Tocilizumab-Refractory Severe COVID-19 Infection	https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16979	27/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16979	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Ruxolitinibe']	['Ruxolitinib']	Previous studies reported that coronavirus disease 2019 (COVID-19) was likely to result in liver injury. However, few studies reported the impacts of COVID-19 on liver function in patients with chronic liver diseases. We aimed to describe a case series of COVID-19 patients with chronic hepatitis B virus (HBV) infection. Confirmed hospitalized COVID-19 patients from hospitals in 10 cities of Jiangsu province, China, were retrospectively included between 18 January 2020 and 26 February 2020. Demographic information, epidemiologic data, clinical features, and treatment data were extracted from medical records. Seven COVID-19 patients with chronic HBV infection were included. Six (85.7%) patients were male. The patients aged from 33 to 49 years. Two patients had HBV-related cirrhosis. One patient (14.3%) was positive for serum HBV e-antigen. On admission, 1 (14.3%) patient had mildly elevated alanine aminotransferase (ALT) level (>40 U/L) and 1 (14.3%) had elevated aspartate aminotransferase (AST) level (>40 U/L). The serum albumin level and platelet counts were decreased in two patients with HBV-related liver cirrhosis. Three (42.9%) patients had elevated ALT level and 2 (28.6%) patients had elevated AST level in hospitalization. However, the peak ALT and AST level during hospitalization was 51 U/L and 44 U/L, respectively. As of 29 February 2020, all patients were discharged. No patient was admitted to the intensive care units or developed liver failure during hospitalization. The abnormalities of liver function are not uncommon on COVID-19 patients with chronic HBV infection in our case series. However, no patient developed severe liver-related complications during hospitalization.	32593183	British journal of haematology	1365-2141	10.1111/bjh.16979	Ruxolitinibe para infecção grave por COVID-19 refratária a tocilizumabe 	Estudos anteriores relataram que a doença por coronavírus 2019 (COVID-19) provavelmente resultaria em lesão hepática. No entanto, poucos estudos relataram os impactos do COVID-19 na função hepática em pacientes com doenças hepáticas crônicas. Nosso objetivo foi descrever uma série de casos de pacientes com COVID-19 com infecção crônica pelo vírus da hepatite B (HBV). Pacientes hospitalizados confirmados com COVID-19 de hospitais em 10 cidades da província de Jiangsu, China, foram incluídos retrospectivamente entre 18 de janeiro de 2020 e 26 de fevereiro de 2020. Informações demográficas, dados epidemiológicos, características clínicas e dados de tratamento foram extraídos de prontuários médicos. Sete pacientes com COVID-19 com infecção crônica por HBV foram incluídos. Seis (85,7%) pacientes eram do sexo masculino. Os pacientes com idade de 33 a 49 anos. Dois pacientes tiveram cirrose relacionada ao HBV. Um paciente (14,3%) foi positivo para e-antígeno HBV sérico. Na admissão, 1 (14,3%) paciente apresentava nível levemente elevado de alanina aminotransferase (ALT) (>40 U/L) e 1 (14,3%) tinha nível elevado de aspartato aminotransferase (AST) (>40 U/L). O nível de albumina sérica e a contagem de plaquetas estavam diminuídos em dois pacientes com cirrose hepática relacionada ao HBV. Três (42,9%) pacientes apresentaram nível elevado de ALT e 2 (28,6%) pacientes apresentaram nível elevado de AST na internação. No entanto, o nível de pico de ALT e AST durante a hospitalização foi de 51 U/L e 44 U/L, respectivamente. Em 29 de fevereiro de 2020, todos os pacientes receberam alta. Nenhum paciente foi admitido nas unidades de terapia intensiva ou desenvolveu insuficiência hepática durante a internação. As anormalidades da função hepática não são incomuns em pacientes com COVID-19 com infecção crônica por HBV em nossa série de casos. No entanto, nenhum paciente desenvolveu complicações hepáticas graves durante a hospitalização.
Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome	https://doi.org/10.1111/bjh.16961	25/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16961	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Tocilizumabe']	['Tocilizumab']	Previous studies reported that coronavirus disease 2019 (COVID-19) was likely to result in liver injury. However, few studies reported the impacts of COVID-19 on liver function in patients with chronic liver diseases. We aimed to describe a case series of COVID-19 patients with chronic hepatitis B virus (HBV) infection. Confirmed hospitalized COVID-19 patients from hospitals in 10 cities of Jiangsu province, China, were retrospectively included between 18 January 2020 and 26 February 2020. Demographic information, epidemiologic data, clinical features, and treatment data were extracted from medical records. Seven COVID-19 patients with chronic HBV infection were included. Six (85.7%) patients were male. The patients aged from 33 to 49 years. Two patients had HBV-related cirrhosis. One patient (14.3%) was positive for serum HBV e-antigen. On admission, 1 (14.3%) patient had mildly elevated alanine aminotransferase (ALT) level (>40 U/L) and 1 (14.3%) had elevated aspartate aminotransferase (AST) level (>40 U/L). The serum albumin level and platelet counts were decreased in two patients with HBV-related liver cirrhosis. Three (42.9%) patients had elevated ALT level and 2 (28.6%) patients had elevated AST level in hospitalization. However, the peak ALT and AST level during hospitalization was 51 U/L and 44 U/L, respectively. As of 29 February 2020, all patients were discharged. No patient was admitted to the intensive care units or developed liver failure during hospitalization. The abnormalities of liver function are not uncommon on COVID-19 patients with chronic HBV infection in our case series. However, no patient developed severe liver-related complications during hospitalization.	32584416	British journal of haematology	1365-2141	10.1111/bjh.16961	Melhoria da síndrome da tempestade de citocinas relacionada ao COVID-19: paralelos à síndrome de liberação de citocinas de células T do receptor de antígeno quimérico 	Estudos anteriores relataram que a doença de coronavírus 2019 (COVID-19) provavelmente resultaria em lesão hepática. No entanto, poucos estudos relataram os impactos do COVID-19 na função hepática em pacientes com doenças hepáticas crônicas. Nosso objetivo foi descrever uma série de casos de pacientes com COVID-19 com infecção crônica pelo vírus da hepatite B (HBV). Pacientes hospitalizados confirmados com COVID-19 de hospitais em 10 cidades da província de Jiangsu, China, foram incluídos retrospectivamente entre 18 de janeiro de 2020 e 26 de fevereiro de 2020. Informações demográficas, dados epidemiológicos, características clínicas e dados de tratamento foram extraídos de prontuários médicos. Sete pacientes com COVID-19 com infecção crônica por HBV foram incluídos. Seis (85,7%) pacientes eram do sexo masculino. Os pacientes com idade de 33 a 49 anos. Dois pacientes tiveram cirrose relacionada ao HBV. Um paciente (14,3%) foi positivo para e-antígeno HBV sérico. Na admissão, 1 (14,3%) paciente apresentava nível levemente elevado de alanina aminotransferase (ALT) (>40 U/L) e 1 (14,3%) tinha nível elevado de aspartato aminotransferase (AST) (>40 U/L). O nível de albumina sérica e a contagem de plaquetas estavam diminuídos em dois pacientes com cirrose hepática relacionada ao HBV. Três (42,9%) pacientes apresentaram nível elevado de ALT e 2 (28,6%) pacientes apresentaram nível elevado de AST na internação. No entanto, o nível de pico de ALT e AST durante a hospitalização foi de 51 U/L e 44 U/L, respectivamente. Em 29 de fevereiro de 2020, todos os pacientes receberam alta. Nenhum paciente foi admitido nas unidades de terapia intensiva ou desenvolveu insuficiência hepática durante a internação. As anormalidades da função hepática não são incomuns em pacientes com COVID-19 com infecção crônica por HBV em nossa série de casos. No entanto, nenhum paciente desenvolveu complicações hepáticas graves durante a hospitalização.
Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery	https://doi.org/10.1111/bjh.16981	27/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16981	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Plasma convalescente']	['Convalescent Plasma']	Previous studies reported that coronavirus disease 2019 (COVID-19) was likely to result in liver injury. However, few studies reported the impacts of COVID-19 on liver function in patients with chronic liver diseases. We aimed to describe a case series of COVID-19 patients with chronic hepatitis B virus (HBV) infection. Confirmed hospitalized COVID-19 patients from hospitals in 10 cities of Jiangsu province, China, were retrospectively included between 18 January 2020 and 26 February 2020. Demographic information, epidemiologic data, clinical features, and treatment data were extracted from medical records. Seven COVID-19 patients with chronic HBV infection were included. Six (85.7%) patients were male. The patients aged from 33 to 49 years. Two patients had HBV-related cirrhosis. One patient (14.3%) was positive for serum HBV e-antigen. On admission, 1 (14.3%) patient had mildly elevated alanine aminotransferase (ALT) level (>40 U/L) and 1 (14.3%) had elevated aspartate aminotransferase (AST) level (>40 U/L). The serum albumin level and platelet counts were decreased in two patients with HBV-related liver cirrhosis. Three (42.9%) patients had elevated ALT level and 2 (28.6%) patients had elevated AST level in hospitalization. However, the peak ALT and AST level during hospitalization was 51 U/L and 44 U/L, respectively. As of 29 February 2020, all patients were discharged. No patient was admitted to the intensive care units or developed liver failure during hospitalization. The abnormalities of liver function are not uncommon on COVID-19 patients with chronic HBV infection in our case series. However, no patient developed severe liver-related complications during hospitalization.	32593180	British journal of haematology	1365-2141	10.1111/bjh.16981	Plasma convalescente para Covid-19 persistente após a depleção de linfócitos terapêuticos: um relatório de recuperação rápida 	Estudos anteriores relataram que a doença por coronavírus 2019 (COVID-19) provavelmente resultaria em lesão hepática. No entanto, poucos estudos relataram os impactos do COVID-19 na função hepática em pacientes com doenças hepáticas crônicas. Nosso objetivo foi descrever uma série de casos de pacientes com COVID-19 com infecção crônica pelo vírus da hepatite B (HBV). Pacientes hospitalizados confirmados com COVID-19 de hospitais em 10 cidades da província de Jiangsu, China, foram incluídos retrospectivamente entre 18 de janeiro de 2020 e 26 de fevereiro de 2020. Informações demográficas, dados epidemiológicos, características clínicas e dados de tratamento foram extraídos de prontuários médicos. Sete pacientes com COVID-19 com infecção crônica por HBV foram incluídos. Seis (85,7%) pacientes eram do sexo masculino. Os pacientes com idade de 33 a 49 anos. Dois pacientes tiveram cirrose relacionada ao HBV. Um paciente (14,3%) foi positivo para e-antígeno HBV sérico. Na admissão, 1 (14,3%) paciente apresentava nível levemente elevado de alanina aminotransferase (ALT) (>40 U/L) e 1 (14,3%) tinha nível elevado de aspartato aminotransferase (AST) (>40 U/L). O nível de albumina sérica e a contagem de plaquetas estavam diminuídos em dois pacientes com cirrose hepática relacionada ao HBV. Três (42,9%) pacientes apresentaram nível elevado de ALT e 2 (28,6%) pacientes apresentaram nível elevado de AST na internação. No entanto, o nível de pico de ALT e AST durante a hospitalização foi de 51 U/L e 44 U/L, respectivamente. Em 29 de fevereiro de 2020, todos os pacientes receberam alta. Nenhum paciente foi admitido nas unidades de terapia intensiva ou desenvolveu insuficiência hepática durante a internação. As anormalidades da função hepática não são incomuns em pacientes com COVID-19 com infecção crônica por HBV em nossa série de casos. No entanto, nenhum paciente desenvolveu complicações hepáticas graves durante a hospitalização.
A case of Covid-19 patient with acute limb ischemia and heparin resistance	https://doi.org/10.1016/j.avsg.2020.06.046	23/06/2020	Artigo completo publicado em periódico científico	10.1016/j.avsg.2020.06.046	0890-5096	8905096	ANNALS OF VASCULAR SURGERY (PRINT)	A4	0.511	75	1.53	-	['Heparina']	['Heparin']	-	-	-	-	-	Um caso de paciente Covid-19 com isquemia aguda de membro e resistência à heparina 	-
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis	https://doi.org/10.1016/j.tmaid.2020.101791	25/06/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101791	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Although this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.	32593867	Travel medicine and infectious disease	1873-0442	10.1016/j.tmaid.2020.101791	Resultados de 3.737 pacientes com COVID-19 tratados com hidroxicloroquina/azitromicina e outros regimes em Marselha, França: Uma análise retrospectiva 	Embora esta seja uma análise retrospectiva, os resultados sugerem que o diagnóstico precoce, isolamento precoce e tratamento precoce de pacientes com COVID-19, com pelo menos 3 dias de HCQ-AZ levam a um resultado clínico significativamente melhor e uma redução da carga viral mais rápida do que outros tratamentos.
QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection	https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1968	26/06/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1968	0009-9236	99236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Association between Hydroxychloroquine (HCQ) and Azithromycin (AZT) is under evaluation for patients with lower respiratory tract infection (LRTI) caused by the Severe Acute Respiratory Syndrome (SARS-CoV-2). Both drugs have a known torsadogenic potential, but sparse data are available concerning QT prolongation induced by this association. Our objective was to assess for COVID-19 LRTI variations of QT interval under HCQ/AZT in patients hospitalized, and to compare manual versus automated QT measurements. Before therapy initiation, a baseline 12 lead-ECG was electronically sent to our cardiology department for automated and manual QT analysis (Bazett and Fridericia's correction), repeated 2 days after initiation. According to our institutional protocol (Pasteur University Hospital), HCQ/AZT was initiated only if baseline QTc ≤ 480ms and potassium level> 4.0 mmol/L. From March 24	32588427	Clinical pharmacology and therapeutics	1532-6535	10.1002/cpt.1968	Prolongamento do intervalo QT sob associação hidroxicloroquina/azitromicina para pacientes internados com infecção do trato respiratório inferior por SARS-CoV- 	2 Síndrome (SARS-CoV-2). Ambas as drogas têm um potencial torsadogênico conhecido, mas dados escassos estão disponíveis sobre o prolongamento do intervalo QT induzido por essa associação. Nosso objetivo foi avaliar as variações de LRTI COVID-19 do intervalo QT sob HCQ/AZT em pacientes hospitalizados e comparar medições QT manuais versus automatizadas. Antes do início da terapia, um ECG de 12 derivações de linha de base foi enviado eletronicamente ao nosso departamento de cardiologia para análise QT automática e manual (correção de Bazett e Fridericia), repetida 2 dias após o início. De acordo com nosso protocolo institucional (Hospital Universitário Pasteur), HCQ/AZT era iniciado apenas se QTc basal ≤ 480ms e nível de potássio > 4,0 mmol/L. A partir de 24 de março
Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review	https://www.frontiersin.org/article/10.3389/fpubh.2020.00252	29/06/2020	Artigo completo publicado em periódico científico	https://www.frontiersin.org/article/10.3389/fpubh.2020.00252	2296-2565	22962565	FRONTIERS IN PUBLIC HEALTH	A3	1.298	64	5.87	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	At this time of the COVID-19 pandemic, potentially effective treatments are currently under urgent investigation. Benefits of chloroquine and hydroxychloroquine for the treatment of COVID-19 infection have been proposed and clinical trials are underway. Chloroquine and hydroxychloroquine, typically used for the treatment of malaria and autoimmune diseases, have been considered for off-label use in several countries. In the literature, there are reports of ototoxic effects of the drugs causing damage to the inner ear structures, which then result in hearing loss, tinnitus, and/or imbalance. This mini-review represents a summary of the findings from a systematic search regarding ototoxicity of chloroquine and hydroxychloroquine in the published literature. The characteristics of sensorineural hearing loss and/or tinnitus after chloroquine or hydroxychloroquine treatment can be temporary but reports of persistent auditory and vestibular dysfunction exist. These are not frequent, but the impact can be substantial. Additionally, abnormal cochleovestibular development in the newborn was also reported after chloroquine treatment in pregnant women. The suggested dose of chloroquine for COVID-19 infection is considerably higher than the usual dosage for malaria treatment; therefore, it is plausible that the ototoxic effects will be greater. There are potential implications from this review for survivors of COVID-19 treated with chloroquine or hydroxychloroquine. Patient reports of hearing loss, tinnitus, or imbalance should be noted. Those with troublesome hearing loss, tinnitus and/or imbalance are encouraged to be referred for hearing evaluation and interventions once they are stable. Clinical trials of chloroquine or hydroxychloroquine should also consider including audiological monitoring in the protocol.	32574312	Frontiers in public health	2296-2565	10.3389/fpubh.2020.00252	Implicações clínicas da ototoxicidade da cloroquina e da hidroxicloroquina para o tratamento com COVID-19: uma mini-revisão 	Neste momento da pandemia de COVID-19, tratamentos potencialmente eficazes estão atualmente sob investigação urgente. Os benefícios da cloroquina e da hidroxicloroquina para o tratamento da infecção por COVID-19 foram propostos e os ensaios clínicos estão em andamento. A cloroquina e a hidroxicloroquina, normalmente usadas para o tratamento de malária e doenças autoimunes, foram consideradas para uso off-label em vários países. Na literatura, há relatos de efeitos ototóxicos das drogas causando danos às estruturas da orelha interna, resultando em perda auditiva, zumbido e/ou desequilíbrio. Esta mini-revisão representa um resumo dos resultados de uma pesquisa sistemática sobre ototoxicidade da cloroquina e hidroxicloroquina na literatura publicada. As características da perda auditiva neurossensorial e/ou zumbido após o tratamento com cloroquina ou hidroxicloroquina podem ser temporárias, mas existem relatos de disfunção auditiva e vestibular persistente. Estes não são frequentes, mas o impacto pode ser substancial. Além disso, o desenvolvimento cocleovestibular anormal no recém-nascido também foi relatado após o tratamento com cloroquina em mulheres grávidas. A dose sugerida de cloroquina para infecção por COVID-19 é consideravelmente maior do que a dose usual para tratamento da malária; portanto, é plausível que os efeitos ototóxicos sejam maiores. Existem implicações potenciais desta revisão para sobreviventes de COVID-19 tratados com cloroquina ou hidroxicloroquina. Os relatos dos pacientes de perda auditiva, zumbido ou desequilíbrio devem ser anotados. Aqueles com perda auditiva incômoda, zumbido e/ou desequilíbrio são incentivados a serem encaminhados para avaliação e intervenções auditivas, uma vez que estejam estáveis. Ensaios clínicos de cloroquina ou hidroxicloroquina também devem considerar a inclusão de monitoramento audiológico no protocolo.
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)	https://doi.org/10.1038/s41375-020-0907-9	17/06/2020	Artigo completo publicado em periódico científico	10.1038/s41375-020-0907-9	0887-6924	8876924	LEUKEMIA	A1	4.030	202	9.5	-	['Ruxolitinibe']	['Ruxolitinib']	-	-	-	-	-	Ruxolitinibe para o tratamento da síndrome do desconforto respiratório agudo (SDRA) induzida por SARS-CoV-2 	-
Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia	https://doi.org/10.1093/cid/ciaa812	23/06/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa812	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Preliminary data from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine storm may increase morbidity and mortality. Tocilizumab (anti-IL-6R) is approved by the Food and Drug Administration for treatment of cytokine storm associated with chimeric antigen receptor T-cell therapy. Here we examined compassionate use of tocilizumab in patients with SARS-CoV-2 pneumonia.                                                  Methods                   We report on a single-center study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia. All patients had confirmed SARS-CoV-2 pneumonia and oxygen saturations &amp;lt;90% on oxygen support with most intubated. We examined clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre- and post-tocilizumab treatment.                                                  Results                   Twenty-seven SARS-CoV-2 pneumonia patients received one 400 mg dose of tocilizumab. Interleukin (IL)-6 was the predominant cytokine detected at tocilizumab treatment. Significant reductions in temperature and CRP were seen post-tocilizumab. However, 4 patients did not show rapid CRP declines, of whom 3 had poorer outcomes. Oxygen and vasopressor requirements diminished over the first week post-tocilizumab. Twenty-two patients required mechanical ventilation; at last follow-up, 16 were extubated. Adverse events and serious adverse events were minimal, but 2 deaths (7.4%) occurred that were felt unrelated to tocilizumab.                                                  Conclusions                   Compared to published reports on the morbidity and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflammation, oxygen requirements, vasopressor support, and mortality. The rationale for tocilizumab treatment is supported by detection of IL-6 in pathogenic levels in all patients. Additional doses of tocilizumab may be needed for those showing slow declines in CRP. Proof of efficacy awaits randomized, placebo-controlled clinical trials.               	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Uso compassivo de tocilizumab para tratamento de pneumonia por SARS-CoV-2 	-
The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study	https://doi.org/10.1007/s40199-020-00353-w	19/06/2020	Artigo completo publicado em periódico científico	10.1007/s40199-020-00353-w	2008-2231	20082231	DARU JOURNAL OF PHARMACEUTICAL SCIENCES	A4	0.580	47	4.19	-	['Azitromicina', 'Lopinavir', 'Naproxeno', 'Prednisolona', 'Ritonavir']	['Azithromycin', 'Lopinavir', 'Naproxen', 'Prednisolone', 'Ritonavir']	This study revealed the beneficial effect of the short-term use of low-dose prednisolone in combination with azithromycin, naproxen and lopinavir/ritonavir (regimen I), in decreasing ALOS compared to regimen II. Since there is still lack of evidence for safety of this regimen, further investigation in our ongoing follow-up to deal with COVID-19 pneumonia is underway. Graphical abstract.	32562159	Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences	2008-2231	10.1007/s40199-020-00353-w	Covid -19: um estudo observacional, retrospectivo e centrado único 	e lopinavir/ritonavir (regime I), em ALOS decrescente em relação ao regime II. Como ainda há falta de evidências para a segurança desse regime, mais investigações em nosso acompanhamento contínuo para lidar com a pneumonia por COVID-19 estão em andamento. Resumo gráfico.
SARS-CoV-2 infection and stem cells: Interaction and intervention.	https://doi.org/10.1016/j.scr.2020.101859	01/06/2020	Artigo completo publicado em periódico científico	10.1016/j.scr.2020.101859	1873-5061	18735061	STEM CELL RESEARCH (AMSTERDAM. PRINT)	A2	0.482	70	1.67	-	['Terapia celular']	['Cell Therapy']	-	-	-	-	-	Infecção por SARS-CoV-2 e células-tronco: interação e intervenção. 	-
Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment. Rheumatology.	https://doi.org/10.1093/rheumatology/keaa318	22/06/2020	Artigo completo publicado em periódico científico	10.1093/rheumatology/keaa318	1462-0324	14620324	RHEUMATOLOGY (OXFORD. PRINT)	A1	1.563	181	3.96	-	['Anakinra']	['Anakinra']	Through bioinformatics method analysis, this study provides a new perspective to explore the pathogenesis, gene regulatory networks and provide drug compounds as a reference for COVID-19 Myocarditis. It is worth highlighting that critical genes (CDK1, KIF20A, PBK, KIF2C, CDC20, UBE2C) may be potential biomarkers and treatment targets of COVID-19 Myocarditis for future study.	32568376	Rheumatology (Oxford, England)	1462-0332	10.1093/rheumatology/keaa318	Tratamento bem-sucedido de COVID-19 grave com anakinra subcutâneo como tratamento único. Reumatologia. 	Por meio da análise do método de bioinformática, este estudo fornece uma nova perspectiva para explorar a patogênese, as redes reguladoras de genes e fornecer compostos de medicamentos como referência para a miocardite COVID-19. Vale ressaltar que genes críticos (CDK1, KIF20A, PBK, KIF2C, CDC20, UBE2C) podem ser potenciais biomarcadores e alvos de tratamento da miocardite COVID-19 para estudo futuro.
Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis	https://doi.org/10.1007/s10072-020-04522-2	20/06/2020	Artigo completo publicado em periódico científico	10.1007/s10072-020-04522-2	1590-1874	15901874	NEUROLOGICAL SCIENCES (TESTO STAMPATO)	A3	0.847	76	2.69	-	['Rituximabe']	['Rituximab']	-	-	-	-	-	Doença de coronavírus 2019: desfecho favorável em paciente imunossuprimido com esclerose múltipla 	-
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab	https://doi.org/10.1007/s10067-020-05234-w	19/06/2020	Artigo completo publicado em periódico científico	10.1007/s10067-020-05234-w	0770-3198	7703198	CLINICAL RHEUMATOLOGY (PRINTED)	A4	0.873	88	3.38	 Abstract Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA). Tocilizumab was applied and intended to target both COVID-19 and RA. However, disease of this patient aggravated after usage of tocilizumab. After the discussion of a multiple disciplinary team (MDT) including rheumatologists, antimicrobial treatments were applied to target the potential opportunistic infections ( Pneumocystis jirovecii and  Aspergillus fumigatus), which were authenticated several days later via high throughput sequencing. As an important cytokine in immune responses, IL-6 can be a double-edged sword: interference in the IL-6-IL-6 receptor signaling may save patients from cytokine release storm (CRS), but can also weaken the anti-infectious immunity, particularly in rheumatic patients, who may have received a long-term treatment with immunosuppressive/modulatory agents. Thus, we suggest careful considerations before and close monitoring in the administration of tocilizumab in rheumatic patients with COVID-19. Besides tocilizumab, several disease-modifying antirheumatic drugs (DMARDs) can also be applied in the treatment of COVID-19. Therefore, we also reviewed and discussed the application of these DMARDs in COVID-19 condition.	['Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']	Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA). Tocilizumab was applied and intended to target both COVID-19 and RA. However, disease of this patient aggravated after usage of tocilizumab. After the discussion of a multiple disciplinary team (MDT) including rheumatologists, antimicrobial treatments were applied to target the potential opportunistic infections (Pneumocystis jirovecii and Aspergillus fumigatus), which were authenticated several days later via high throughput sequencing. As an important cytokine in immune responses, IL-6 can be a double-edged sword: interference in the IL-6-IL-6 receptor signaling may save patients from cytokine release storm (CRS), but can also weaken the anti-infectious immunity, particularly in rheumatic patients, who may have received a long-term treatment with immunosuppressive/modulatory agents. Thus, we suggest careful considerations before and close monitoring in the administration of tocilizumab in rheumatic patients with COVID-19. Besides tocilizumab, several disease-modifying antirheumatic drugs (DMARDs) can also be applied in the treatment of COVID-19. Therefore, we also reviewed and discussed the application of these DMARDs in COVID-19 condition.	32562070	Clinical rheumatology	1434-9949	10.1007/s10067-020-05234-w	Um caso complexo de COVID-19 com artrite reumatoide tratado com tocilizumabe 	Recorrências de COVID-19 foram observadas em uma paciente com uso prolongado de hidroxicloroquina, leflunomida e glicocorticoides devido a seu histórico de 30 anos de artrite reumatoide (AR). O tocilizumab foi aplicado e destinado a atingir tanto o COVID-19 quanto a AR. No entanto, a doença deste paciente agravou-se após o uso de tocilizumab. Após a discussão de uma equipe disciplinar múltipla (MDT), incluindo reumatologistas, tratamentos antimicrobianos foram aplicados para direcionar as possíveis infecções oportunistas (Pneumocystis jirovecii e Aspergillus fumigatus), que foram autenticadas vários dias depois por meio de sequenciamento de alto rendimento. Como uma citocina importante nas respostas imunes, a IL-6 pode ser uma faca de dois gumes: a interferência na sinalização do receptor de IL-6-IL-6 pode salvar os pacientes da tempestade de liberação de citocinas (CRS), mas também pode enfraquecer o anti-infeccioso imunidade, particularmente em pacientes reumáticos, que podem ter recebido um tratamento de longo prazo com agentes imunossupressores/moduladores. Assim, sugerimos cuidadosa consideração antes e monitoramento próximo na administração de tocilizumabe em pacientes reumáticos com COVID-19. Além do tocilizumabe, vários medicamentos antirreumáticos modificadores da doença (DMARDs) também podem ser aplicados no tratamento da COVID-19. Portanto, também revisamos e discutimos a aplicação desses DMARDs na condição COVID-19.
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19	https://doi.org/10.1111/JDV.16761	21/06/2020	Artigo completo publicado em periódico científico	10.1111/JDV.16761	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Acitretina', 'Adalimumabe', 'Apremilast', 'Brodalumabe', 'Certolizumabe Pegol', 'Ciclosporina', 'Etanercepte', 'Guselkumabe', 'Infliximabe', 'Ixequizumab', 'Metotrexato', 'Risankizumabe', 'Secuquinumabe', 'Ustekinumabe']	['Acitretin', 'Adalimumab', 'Apremilast', 'Brodalumab', 'Certolizumab Pegol', 'Cyclosporin', 'Etanercept', 'Guselkumabe', 'Infliximab', 'Ixequizumab', 'Methotrexate', 'Risankizumabe', 'Secukinumab', 'Ustekinumab']	-	-	-	-	-	O tratamento sistêmico ou biológico em pacientes com psoríase não aumenta o risco de uma forma grave de COVID-19 	-
Imatinib for COVID-19: A case report	https://doi.org/10.1016/j.clim.2020.108518	27/06/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108518	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Imatinibe']	['Imatinib']	-	-	-	-	-	Imatinibe para COVID-19: Relato de caso 	-
Vaccine development and therapeutic design for 2019‐ncov/SARS‐cov‐2: challenges and chances.	https://doi.org/10.1002/jcp.29771	18/06/2020	Artigo completo publicado em periódico científico	10.1002/jcp.29771	0021-9541	219541	JOURNAL OF CELLULAR PHYSIOLOGY (PRINT)	A2	1.308	183	6.77	-	['Vacina']	['Vaccine']	The ongoing outbreak of the recently emerged 2019 novel coronavirus (nCoV), which has seriously threatened global health security, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high morbidity and mortality. Despite the burden of the disease worldwide, still, no licensed vaccine or any specific drug against 2019-nCoV is available. Data from several countries show that few repurposed drugs using existing antiviral drugs have not (so far) been satisfactory and more recently were proven to be even highly toxic. These findings underline an urgent need for preventative and therapeutic interventions designed to target specific aspects of 2019-nCoV. Again the major factor in this urgency is that the process of data acquisition by physical experiment is time-consuming and expensive to obtain. Scientific simulations and more in-depth data analysis permit to validate or refute drug repurposing opportunities predicted via target similarity profiling to speed up the development of a new more effective anti-2019-nCoV therapy especially where in vitro and/or in vivo data are not yet available. In addition, several research programs are being developed, aiming at the exploration of vaccines to prevent and treat the 2019-nCoV. Computational-based technology has given us the tools to explore and identify potentially effective drug and/or vaccine candidates which can effectively shorten the time and reduce the operating cost. The aim of the present review is to address the available information on molecular determinants in disease pathobiology modules and define the computational approaches employed in systematic drug repositioning and vaccine development settings for SARS-CoV-2.	32557648	Journal of cellular physiology	1097-4652	10.1002/jcp.29771	Desenvolvimento de vacinas e design terapêutico para 2019-ncov/SARS-cov-2: desafios e chances. 	O surto em andamento do novo coronavírus de 2019 (nCoV), que ameaçou seriamente a segurança da saúde global, é causado pelo coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) com alta morbidade e mortalidade. Apesar da carga da doença em todo o mundo, ainda não há vacina licenciada ou qualquer medicamento específico contra 2019-nCoV. Dados de vários países mostram que poucos medicamentos reaproveitados usando medicamentos antivirais existentes não foram (até agora) satisfatórios e, mais recentemente, provaram ser altamente tóxicos. Essas descobertas sublinham a necessidade urgente de intervenções preventivas e terapêuticas destinadas a abordar aspectos específicos do 2019-nCoV. Novamente, o principal fator nessa urgência é que o processo de aquisição de dados por experimento físico é demorado e caro para obter. Simulações científicas e análises de dados mais aprofundadas permitem validar ou refutar oportunidades de redirecionamento de medicamentos previstas por meio de perfis de similaridade de alvos para acelerar o desenvolvimento de uma nova terapia anti-2019-nCoV mais eficaz, especialmente quando os dados in vitro e/ou in vivo não são ainda disponível. Além disso, vários programas de pesquisa estão sendo desenvolvidos, visando a exploração de vacinas para prevenir e tratar o 2019-nCoV. A tecnologia baseada em computação nos deu as ferramentas para explorar e identificar candidatos a medicamentos e/ou vacinas potencialmente eficazes que podem efetivamente encurtar o tempo e reduzir o custo operacional. O objetivo da presente revisão é abordar as informações disponíveis sobre determinantes moleculares nos módulos de patobiologia da doença e definir as abordagens computacionais empregadas no reposicionamento sistemático de medicamentos e configurações de desenvolvimento de vacinas para SARS-CoV-2.
A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.	https://doi.org/10.1002/jcph.1693	18/06/2020	Artigo completo publicado em periódico científico	10.1002/jcph.1693	0091-2700	912700	JOURNAL OF CLINICAL PHARMACOLOGY	A3	0.687	121	2.9	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Uma revisão abrangente sobre o tocilizumab na síndrome do desconforto respiratório agudo COVID-19. 	-
Coagulopathy, thromboembolic complications and the use of heparin in COVID-19 Pneumonia,	https://doi.org/10.1016/j.jvsv.2020.05.018	17/06/2020	Artigo completo publicado em periódico científico	10.1016/j.jvsv.2020.05.018	2213-333X	2213333X	JOURNAL OF VASCULAR SURGERY: VENOUS AND LYMPHATIC DISORDERS	A3	0.774	34	2.45	-	['Heparina']	['Heparin']	-	-	-	-	-	Coagulopatia, complicações tromboembólicas e uso de heparina na pneumonia por COVID-19, 	-
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.	https://doi.org/10.1001/jama.2020.11301	19/06/2020	Artigo completo publicado em periódico científico	10.1001/jama.2020.11301	0098-7484	987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Associação do uso de inibidor da enzima conversora de angiotensina ou bloqueador do receptor de angiotensina com diagnóstico e mortalidade por COVID-19. 	-
Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020.	https://doi.org/10.1016/j.onehlt.2020.100141	19/06/2020	Artigo completo publicado em periódico científico	10.1016/j.onehlt.2020.100141	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Hidroxicloroquina']	['Hydroxychloroquine']	In the absence of a vaccine the medical and scientific community is looking intensely at utilizing a pre or post exposure drug that could decrease viremia. The search for a medication that could reduce risk of serious disease, and ideally of any manifestation of disease from SARS-CoV2, and of asymptomatic shedding of SARS-CoV2 is of urgent interest. Repurposing existing pharmaceuticals is among the approaches to achieve these ends. We performed a systematic review of all interventional studies registered in ClinicalTrials.gov with a focus on one repurposed drug, Hydroxychloroquine (HCQ). The detailed analysis of these studies, some of them already recruiting, provide an overall picture of HCQ use as a COVID-19 prophylaxis around the world. Among the included studies, all but three were randomized and parallel and most of them (74%, 23/31) were double-blinded to quadruple-blinded studies. We found a great diversity in dosing and nearly all the possible scientifically reasonable regimens are under evaluation. This diversity offers benefits as well as challenges. Importantly, the final analysis of these trials should be done through an extensive reading of the results in regard to the clinical design, it will be crucial to carefully read and evaluate the results of each study in regards to the clinical design rather than quickly glancing a 140 characters-based social media message announcing the failure or success of a drug against a disease.	32562480	One health (Amsterdam, Netherlands)	2352-7714	10.1016/j.onehlt.2020.100141	Revisão sistemática de ensaios registrados de profilaxia com hidroxicloroquina para profissionais de saúde COVID-19 no primeiro terço de 2020. 	Na ausência de uma vacina, a comunidade médica e científica está analisando intensamente a utilização de um medicamento pré ou pós-exposição que possa diminuir a viremia. A busca por um medicamento que possa reduzir o risco de doença grave e, idealmente, de qualquer manifestação da doença por SARS-CoV2 e de disseminação assintomática de SARS-CoV2 é de interesse urgente. O reaproveitamento de produtos farmacêuticos existentes está entre as abordagens para atingir esses objetivos. Realizamos uma revisão sistemática de todos os estudos de intervenção registrados no ClinicalTrials.gov com foco em um medicamento reaproveitado, a hidroxicloroquina (HCQ). A análise detalhada desses estudos, alguns deles já recrutando, fornece uma visão geral do uso de HCQ como profilaxia da COVID-19 em todo o mundo. Entre os estudos incluídos, todos, exceto três, eram randomizados e paralelos e a maioria deles (74%, 23/31) eram estudos duplo-cegos para estudos quádruplos-cegos. Encontramos uma grande diversidade na dosagem e quase todos os regimes cientificamente razoáveis estão sob avaliação. Essa diversidade oferece benefícios e também desafios. É importante ressaltar que a análise final desses ensaios deve ser feita por meio de uma extensa leitura dos resultados em relação ao desenho clínico, será crucial ler e avaliar cuidadosamente os resultados de cada estudo quanto ao desenho clínico ao invés de olhar rapidamente um Mensagem de mídia social baseada em 140 caracteres anunciando o fracasso ou o sucesso de um medicamento contra uma doença.
Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.	https://doi.org/10.1186/s12985-020-01354-6	19/06/2020	Artigo completo publicado em periódico científico	10.1186/s12985-020-01354-6	1743-422X	1743422X	VIROLOGY JOURNAL	A3	1.091	88	4.9	 Abstract  Background Convalescent plasma (CP) transfusion was reported to be effective in treating critically ill patients with COVID-19, and hydroxychloroquine could potently inhibit SARS-CoV-2 in vitro. Herein, we reported a case receiving combination therapy with CP transfusion and hydroxychloroquine for the first time.  Case presentation Laboratory findings showed high lactic acid level (2.1 mmol/L) and C-reactive protein (CRP, 48.8 mg/L), and low white blood cell count (1.96 × 10 9/L) in a 65-year-old Chinese man, who was diagnosed with severe COVID-19. CP was intravenously given twice, and hydroxychloroquine was orally administrated for a week (0.2 g, three times a day). The lactic acid and C-reactive protein levels remained high (2.1 mmol/L and 73.23 mg/L, respectively), while the arterial oxyhemoglobin saturation decreased to 86% with a low oxygenation index (OI, 76 mmHg) on day 4 after CP transfusion. His temperature returned to normal and the OI ascended above 300 on day 11. Moreover, the RNA test remained positive in throat swab, and computed tomography revealed severe pulmonary lesions on day 11 after admission.  Conclusion These findings suggested that the effectiveness of combination therapy with CP and hydroxychloroquine may be non-optimal, and specific therapy needs to be explored.	['Hidroxicloroquina', 'Plasma convalescente']	['Hydroxychloroquine', 'Convalescent Plasma']	These findings suggested that the effectiveness of combination therapy with CP and hydroxychloroquine may be non-optimal, and specific therapy needs to be explored.	32560646	Virology journal	1743-422X	10.1186/s12985-020-01354-6	Eficácia não ideal da transfusão de plasma convalescente e hidroxicloroquina no tratamento de COVID-19: relato de caso. 	Esses achados sugeriram que a eficácia da terapia combinada com CP e hidroxicloroquina pode não ser a ideal, e a terapia específica precisa ser explorada.
Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.	https://doi.org/10.1002/phar.2438	15/06/2020	Artigo completo publicado em periódico científico	10.1002/phar.2438	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Baricitinibe']	['Baricitinib']	-	-	-	-	-	Baricitinib: Uma revisão de farmacologia, segurança e experiência clínica emergente em COVID-19. 	-
Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.	https://doi.org/10.2147/DDDT.S254354	29/05/2020	Artigo completo publicado em periódico científico	10.2147/DDDT.S254354	1177-8881	11778881	DRUG DESIGN, DEVELOPMENT AND THERAPY	A2	0.784	71	4.63	-	['Antimaláricos', 'Antivirais']	['Antimalarials', 'Antivirals']	This study is the first snapshot of the landscape of COVID-19 clinical trials registered in China and provided the basic features of clinical trial designs for the treatment and prevention of COVID-19 to offer useful information to guide future clinical trials on COVID-19 in other countries.	32581514	Drug design, development and therapy	1177-8881	10.2147/DDDT.S254354	Características dos ensaios clínicos COVID-19 na China com base nos dados de registro no ChiCTR e ClinicalTrials.gov. 	Este estudo é o primeiro instantâneo do cenário de ensaios clínicos COVID-19 registrados na China e forneceu os recursos básicos de projetos de ensaios clínicos para o tratamento e prevenção do COVID-19 para oferecer informações úteis para orientar futuros ensaios clínicos sobre COVID-19 em outros países.
Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.	https://doi.org/10.1177/1753466620933510	16/06/2020	Artigo completo publicado em periódico científico	10.1177/1753466620933510	1753-4666	17534666	THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE	A2	1.219	41	5.26	-	['Óxido nítrico']	['Nitric oxide']	-	-	-	-	-	Tratamento com óxido nítrico inalado em pacientes com COVID-19 com respiração espontânea. 	-
Withdrawing mycophenolate mofetil in treating a young kidney transplant recipient with COVID-19.	http://dx.doi.org/10.1097/MD.0000000000020481	12/06/2020	Artigo completo publicado em periódico científico	10.1097/MD.0000000000020481	0025-7974	257974	MEDICINE (BALTIMORE, MD.)	A2	0.470	155	1.94	-	['Antibióticos', 'Interferon alfa', 'Medicina Tradicional Chinesa']	['Antibiotics', 'Interferon alpha', 'Traditional Chinese Medicine']	-	-	-	-	-	Retirada de micofenolato mofetil no tratamento de um jovem receptor de transplante renal com COVID-19. 	-
Subcutaneous administrationof interferon beta-1a for COVID-19: A noncontrolled prospective trial.	https://doi.org/10.1016/j.intimp.2020.106688	07/06/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106688	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Interferon beta']	['Interferon beta']	-	-	-	-	-	Administração subcutânea de interferon beta-1a para COVID-19: um estudo prospectivo não controlado. 	-
Vaccination strategies to combat novel corona virus SARS-CoV-2.	https://doi.org/10.1016/j.lfs.2020.117956	12/06/2020	Artigo completo publicado em periódico científico	10.1016/j.lfs.2020.117956	0024-3205	243205	LIFE SCIENCES (1973)	A1	1.132	174	6.25	-	['Vacina de DNA', 'Vacina de RNA']	['DNA vaccine', 'RNA vaccine']	The 2019-novel coronavirus disease (COVID-19) is caused by SARS-CoV-2 is transmitted from human to human has recently reported in China. Now COVID-19 has been spread all over the world and declared epidemics by WHO. It has caused a Public Health Emergency of International Concern. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Due to the rapid increase of SARS-CoV-2 infections and unavailability of antiviral therapeutic agents, developing an effective SAR-CoV-2 vaccine is urgently required. SARS-CoV-2 which is genetically similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) is an enveloped, single and positive-stranded RNA virus with a genome comprising 29,891 nucleotides, which encode the 12 putative open reading frames responsible for the synthesis of viral structural and nonstructural proteins which are very similar to SARS-CoV and MERS-CoV proteins. In this review we have summarized various vaccine candidates i.e., nucleotide, subunit and vector based as well as attenuated and inactivated forms, which have already been demonstrated their prophylactic efficacy against MERS-CoV and SARS-CoV, so these candidates could be used as a potential tool for the development of a safe and effective vaccine against SARS-CoV-2.	32535078	Life sciences	1879-0631	10.1016/j.lfs.2020.117956	Estratégias de vacinação para combater o novo vírus corona SARS-CoV-2. 	A nova doença de coronavírus de 2019 (COVID-19) é causada por SARS-CoV-2 é transmitida de humano para humano, relatada recentemente na China. Agora o COVID-19 foi espalhado por todo o mundo e declarado epidemia pela OMS. Isso causou uma Emergência de Saúde Pública de Importância Internacional. Os idosos e pessoas com doenças subjacentes são suscetíveis à infecção e propensos a desfechos graves, que podem estar associados à síndrome do desconforto respiratório agudo (SDRA) e à tempestade de citocinas. Devido ao rápido aumento de infecções por SARS-CoV-2 e indisponibilidade de agentes terapêuticos antivirais, é urgentemente necessário desenvolver uma vacina eficaz contra SAR-CoV-2. O SARS-CoV-2, que é geneticamente semelhante ao SARS-CoV e ao coronavírus da síndrome respiratória do Oriente Médio (MERS-CoV), é um vírus de RNA de fita simples e positiva com um genoma composto por 29.891 nucleotídeos, que codificam os 12 quadros de leitura aberta putativos responsável pela síntese de proteínas estruturais e não estruturais virais que são muito semelhantes às proteínas SARS-CoV e MERS-CoV. Nesta revisão, resumimos vários candidatos a vacina, ou seja, nucleotídeos, subunidades e vetores, bem como formas atenuadas e inativadas, que já demonstraram sua eficácia profilática contra MERS-CoV e SARS-CoV, para que esses candidatos possam ser usados como um ferramenta potencial para o desenvolvimento de uma vacina segura e eficaz contra SARS-CoV-2.
Promising Antiviral Candidate Drug for the COVID-19 Pandemic: A Mini-Review of Remdesivir.	https://doi.org/10.1016/j.ejmech.2020.112527	06/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejmech.2020.112527	0223-5234	2235234	EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY	A1	1.054	175	6.74	-	['Remdesivir']	['Remdesivir']	Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed.	32563812	European journal of medicinal chemistry	1768-3254	10.1016/j.ejmech.2020.112527	Medicamento candidato antiviral promissor para a pandemia de COVID-19: uma mini-revisão do remdesivir. 	Espera-se que o remdesivir (GS-5734), um inibidor da RNA polimerase viral dependente de RNA (RdRP) que pode ser usado para tratar uma variedade de infecções por vírus de RNA, seja um tratamento eficaz para o coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV- 2) infecção. Em 1º de maio de 2020, a Food and Drug Administration (FDA) dos EUA concedeu a Autorização de Uso de Emergência (EUA) para o remdesivir no tratamento de pacientes com COVID-19. À luz da pandemia de COVID-19, esta revisão apresenta informações abrangentes sobre o remdesivir, incluindo informações sobre os marcos, propriedades intelectuais, mecanismos anti-coronavírus, pesquisas pré-clínicas e ensaios clínicos e, em particular, síntese química, farmacologia, toxicologia, farmacodinâmica e farmacocinética do remdesivir. Além disso, também são discutidas as perspectivas sobre o uso do remdesivir para o tratamento da COVID-19.
Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors.	https://doi.org/10.1111/TRF.15927	13/06/2020	Artigo completo publicado em periódico científico	10.1111/TRF.15927	0041-1132	411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente']	['Convalescent Plasma']	We found evidence of persistent viral shedding in nasopharyngeal secretions more than 2 weeks after resolution of symptoms from confirmed COVID-19 infection. Persistent shedding was more common in older participants, and viral load was higher among older positive participants. These results underscore the necessity of testing COVID-19 convalescent plasma donors less than 28 days after symptom resolution.	32533556	Transfusion	1537-2995	10.1111/trf.15927	Derramamento persistente de RNA viral após a resolução dos sintomas de COVID-19 em doadores de plasma convalescentes mais velhos. 	Encontramos evidências de disseminação viral persistente nas secreções nasofaríngeas mais de 2 semanas após a resolução dos sintomas da infecção confirmada por COVID-19. A eliminação persistente foi mais comum em participantes mais velhos, e a carga viral foi maior entre os participantes positivos mais velhos. Esses resultados ressaltam a necessidade de testar doadores de plasma convalescentes COVID-19 menos de 28 dias após a resolução dos sintomas.
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.	https://doi.org/10.1016/j.ijantimicag.2020.106053	10/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106053	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Azitromicina']	['Azithromycin']	The emergence of the new COVID-19 virus is proving to be a challenge in seeking effective therapies. Since the most severe clinical manifestation of COVID-19 appears to be a severe acute respiratory syndrome, azithromycin has been proposed as a potential treatment. Azithromycin is known to have immunomodulating and antiviral properties. In vitro studies have demonstrated the capacity of azithromycin in reducing production of pro-inflammatory cytokines such as IL-8, IL-6, TNF alpha, reduce oxidative stress, and modulate T-helper functions. At the same time there are multiple clinical evidences of the role of azithromycin in acute respiratory distress syndrome and against Middle East Respiratory syndrome (MERS). Some preliminary evidence has demonstrated controversial results regarding efficacy of azithromycin in combination with hydroxychloroquine in COVID-19. First, a French trial demonstrated 100% virological negativizing of six patients treated with azithromycin plus hydroxychloroquine vs. 57.1% of patients treated with only hydroxychloroquine and 12.5% of the control group (P < 0.05). On the other hand, another case series revealed no efficacy at all on 11 patients treated with the same combination and doses. Furthermore, there are some concerns regarding the association of azithromycin and hydroxychloroquine because of potential QT prolongation. In fact, both drugs have this as a potential side effect and evidence regarding the safe use of this combination is controversial. Despite the necessity to quickly find solutions for COVID-19, extreme caution must be used in evaluating the risk-benefit balance. However, based on preclinical and clinical evidence and some preliminary results in COVID-19, azithromycin could have potential in the fight against this new disease.	32534189	International journal of antimicrobial agents	1872-7913	10.1016/j.ijantimicag.2020.106053	Macrolídeos e infecções virais: foco na azitromicina na patologia COVID-19. 	O surgimento do novo vírus COVID-19 está se mostrando um desafio na busca de terapias eficazes. Como a manifestação clínica mais grave do COVID-19 parece ser uma síndrome respiratória aguda grave, a azitromicina foi proposta como um tratamento potencial. A azitromicina é conhecida por ter propriedades imunomoduladoras e antivirais. Estudos in vitro demonstraram a capacidade da azitromicina em reduzir a produção de citocinas pró-inflamatórias como IL-8, IL-6, TNF alfa, reduzir o estresse oxidativo e modular as funções T-helper. Ao mesmo tempo, existem múltiplas evidências clínicas do papel da azitromicina na síndrome do desconforto respiratório agudo e contra a síndrome respiratória do Oriente Médio (MERS). Algumas evidências preliminares demonstraram resultados controversos sobre a eficácia da azitromicina em combinação com a hidroxicloroquina no COVID-19. Primeiro, um estudo francês demonstrou 100% de negativização virológica de seis pacientes tratados com azitromicina mais hidroxicloroquina versus 57,1% dos pacientes tratados apenas com hidroxicloroquina e 12,5% do grupo controle (P < 0,05). Por outro lado, outra série de casos não revelou nenhuma eficácia em 11 pacientes tratados com a mesma combinação e doses. Além disso, existem algumas preocupações em relação à associação de azitromicina e hidroxicloroquina devido ao potencial prolongamento do intervalo QT. De fato, ambas as drogas têm isso como um potencial efeito colateral e as evidências sobre o uso seguro dessa combinação são controversas. Apesar da necessidade de encontrar rapidamente soluções para o COVID-19, deve-se ter extrema cautela na avaliação da relação risco-benefício. No entanto, com base em evidências pré-clínicas e clínicas e alguns resultados preliminares no COVID-19, a azitromicina pode ter potencial no combate a essa nova doença.
COVID-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role?	https://doi.org/10.1016/j.msard.2020.102250	03/06/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102250	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Natalizumabe']	['Natalizumab']	-	-	-	-	-	COVID-19 em paciente com esclerose múltipla tratado com natalizumabe: o bloqueio das integrinas pode ter um papel protetor? 	-
Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?	https://doi.org/10.1111/ajt.16141	12/06/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16141	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Ciclosporina']	['Cyclosporin']	Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19.	32529737	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons	1600-6143	10.1111/ajt.16141	A ciclosporina deve ser útil em receptores de transplante renal afetados por SARS-CoV-2? 	A minimização da imunossupressão e a administração de antirretrovirais foram recomendadas para receptores de transplante renal (KTRs) com doença de coronavírus 2019 (COVID-19). No entanto, os resultados continuam ruins. Dado o provável benefício da ciclosporina devido ao seu efeito antiviral e imunomodulador, nós a usamos como estratégia em KTRs diagnosticados com coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2). Estudamos 29 receptores de transplante renal (KTRs) que foram admitidos em nossa instituição com COVID-19 entre 15 de março e 24 de abril de 2020. Micofenolato e/ou alvo mamífero de inibidores de rapamicina (mTORi) foram descontinuados em todos os pacientes. Duas estratégias terapêuticas foram comparadas: Grupo 1, minimização de inibidores de calcineurina (N = 6); e Grupo 2, terapia à base de ciclosporina (N = 23), com 15 pacientes trocados de tacrolimus. A hidroxicloroquina foi considerada em ambas as estratégias, mas antivirais em nenhuma. Seis pacientes morreram após desconforto respiratório (20,6%). Cinco necessitaram de ventilação mecânica (17,2%) e 3 puderam ser desmamados. Dezenove pacientes tiveram uma recuperação sem intercorrências (65,5%). No grupo 1, 3 de 6 pacientes morreram (50%) e 1 de 6 necessitou de ventilação mecânica invasiva (16,7%). No grupo 2, 3 dos 23 pacientes morreram (12,5%). A função renal não se deteriorou e não foram observados sinais de rejeição em nenhum paciente no segundo regime de tratamento. Em conclusão, o tratamento imunossupressor baseado em ciclosporina pode ser seguro e eficaz para KTRs diagnosticados com COVID-19.
Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.	https://journals.physiology.org/doi/abs/10.1152/ajplung.00199.2020	10/06/2020	Artigo completo publicado em periódico científico	10.1152/ajplung.00199.2020	1040-0605	10400605	AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY	A1	1.639	169	5.36	  Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every country in the world. Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacotherapies against this disease. Because of this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. Observed hypercoagulability in patients with COVID-19 has created debate within the critical care community on the therapeutic utility of heparin. We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through antiviral and anti-inflammatory effects. Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy. 	['Heparina']	['Heparin']	Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every country in the world. Despite an unprecedented focus of scientific investigation, there is a paucity of evidence-based pharmacotherapies against this disease. Because of this lack of data-driven treatment strategies, broad variations in practice patterns have emerged. Observed hypercoagulability in patients with COVID-19 has created debate within the critical care community on the therapeutic utility of heparin. We seek to provide an overview of the data supporting the therapeutic use of heparin, both unfractionated and low molecular weight, as an anticoagulant for the treatment of SARS-CoV-2 infection. Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through antiviral and anti-inflammatory effects. Finally, we discuss known adverse effects and theoretical off-target effects that may temper enthusiasm for the adoption of heparin as a therapy in COVID-19 without confirmatory prospective randomized controlled trials. Despite previous failures of anticoagulants in critical illness, plausibility of heparin for COVID-19 is sufficiently robust to justify urgent randomized controlled trials to determine the safety and effectiveness of this therapy.	32519894	American journal of physiology. Lung cellular and molecular physiology	1522-1504	10.1152/ajplung.00199.2020	Heparina como terapia para COVID-19: evidências atuais e possibilidades futuras. 	A doença de coronavírus 2019 (COVID-19), a síndrome clínica associada à infecção pelo coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2), impactou quase todos os países do mundo. Apesar de um foco de investigação científica sem precedentes, há uma escassez de farmacoterapias baseadas em evidências contra esta doença. Devido a essa falta de estratégias de tratamento baseadas em dados, surgiram amplas variações nos padrões de prática. A hipercoagulabilidade observada em pacientes com COVID-19 criou um debate na comunidade de cuidados intensivos sobre a utilidade terapêutica da heparina. Procuramos fornecer uma visão geral dos dados que suportam o uso terapêutico da heparina, não fracionada e de baixo peso molecular, como anticoagulante para o tratamento da infecção por SARS-CoV-2. Além disso, revisamos as evidências pré-clínicas que estabelecem a plausibilidade biológica da heparina e medicamentos sintéticos semelhantes à heparina como terapias para COVID-19 por meio de efeitos antivirais e anti-inflamatórios. Por fim, discutimos os efeitos adversos conhecidos e os efeitos teóricos fora do alvo que podem moderar o entusiasmo pela adoção da heparina como terapia no COVID-19 sem estudos prospectivos controlados randomizados confirmatórios. Apesar de falhas anteriores de anticoagulantes em doenças críticas, a plausibilidade da heparina para COVID-19 é suficientemente robusta para justificar ensaios controlados randomizados urgentes para determinar a segurança e a eficácia dessa terapia.
COVID-19 in a severe eosinophilic asthmatic receiving benralizumab – a case study.	https://doi.org/10.1080/02770903.2020.1781165	07/06/2020	Artigo completo publicado em periódico científico	10.1080/02770903.2020.1781165	0277-0903	2770903	THE JOURNAL OF ASTHMA	A3	0.554	73	2.11	-	['Benralizumabe']	['Benralizumab']	-	-	-	-	-	COVID-19 em asmático eosinofílico grave recebendo benralizumabe – um estudo de caso. 	-
Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients	https://doi.org/10.1016/j.ijid.2020.06.006	03/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.06.006	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Zinco']	['Zinc']	Coronavirus 2019 (COVID-19) is a pandemic with substantial mortality and no accepted therapy. We report here on four consecutive outpatients with clinical characteristics (CDC case definition) of and/or laboratory-confirmed COVID-19 who were treated with high dose zinc salt oral lozenges. All four patients experienced significant improvement in objective and symptomatic disease measures after one day of high dose therapy suggesting that zinc therapy was playing a role in clinical recovery. A mechanism for zinc's effects is proposed based on previously published studies on SARS- CoV-1, and randomized controlled trials assessing zinc shortening of common cold duration. The limited sample size and study design preclude a definitive statement about the effectiveness of zinc as a treatment for COVID-19 but suggest the variables to be addressed to confirm these initial findings in future trials.	32522597	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.06.006	Tratamento do SARS-CoV-2 com altas doses de sais de zinco orais: um relatório sobre quatro pacientes O 	coronavírus 2019 (COVID-19) é uma pandemia com mortalidade substancial e sem terapia aceita. Relatamos aqui quatro pacientes ambulatoriais consecutivos com características clínicas (definição de caso do CDC) de COVID-19 e/ou confirmado laboratorialmente que foram tratados com pastilhas orais de sal de zinco em altas doses. Todos os quatro pacientes apresentaram melhora significativa nas medidas objetivas e sintomáticas da doença após um dia de terapia com altas doses, sugerindo que a terapia com zinco estava desempenhando um papel na recuperação clínica. Um mecanismo para os efeitos do zinco é proposto com base em estudos publicados anteriormente sobre SARS-CoV-1 e ensaios controlados randomizados avaliando o encurtamento do zinco na duração do resfriado comum. O tamanho limitado da amostra e o desenho do estudo impedem uma declaração definitiva sobre a eficácia do zinco como tratamento para COVID-19, mas sugerem as variáveis a serem abordadas para confirmar essas descobertas iniciais em ensaios futuros.
Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.	https://doi.org/10.1111/all.14452	10/06/2020	Artigo completo publicado em periódico científico	10.1111/all.14452	0105-4538	1054538	ALLERGY (COPENHAGEN)	A1	3.122	183	8.1	-	['Antibióticos', 'Interferon alfa', 'Medicina Tradicional Chinesa']	['Antibiotics', 'Interferon alpha', 'Traditional Chinese Medicine']	Pediatric COVID-19 patients tended to have a mild clinical course. Patients with pneumonia had higher proportion of fever and cough and increased inflammatory biomarkers than those without pneumonia. There was no difference between allergic and nonallergic COVID-19 children in disease incidence, clinical features, and laboratory and immunological findings. Allergy was not a risk factor for developing and severity of SARS-CoV-2 infection and hardly influenced the disease course of COVID-19 in children.	32524611	Allergy	1398-9995	10.1111/all.14452	Características clínicas de 182 pacientes pediátricos com COVID-19 com diferentes gravidades e estado alérgico. 	Pacientes pediátricos com COVID-19 tendem a ter um curso clínico leve. Pacientes com pneumonia apresentaram maior proporção de febre e tosse e biomarcadores inflamatórios aumentados do que aqueles sem pneumonia. Não houve diferença entre crianças alérgicas e não alérgicas com COVID-19 na incidência da doença, características clínicas e achados laboratoriais e imunológicos. A alergia não foi um fator de risco para o desenvolvimento e gravidade da infecção por SARS-CoV-2 e dificilmente influenciou o curso da doença de COVID-19 em crianças.
Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review.	https://link.springer.com/article/10.1007/s11481-020-09930-x	09/06/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s11481-020-09930-x	1557-1890	15571890	JOURNAL OF NEUROIMMUNE PHARMACOLOGY	A2	1.381	77	5.86	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	A adição de hidroxicloroquina ao tratamento padrão oferece algum benefício na redução da mortalidade entre pacientes com COVID-19?: uma revisão sistemática. 	-
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.	https://doi.org/10.3389/fimmu.2020.01091	19/06/2020	Artigo completo publicado em periódico científico	10.3389/fimmu.2020.01091	1664-3224	16643224	FRONTIERS IN IMMUNOLOGY (ONLINE)	A1	2.331	155	8.54	-	['Terapia celular']	['Cell Therapy']	Numerous clinical trials of mesenchymal stromal/stem cells (MSCs) as a new treatment for coronavirus-induced disease (COVID-19) have been registered recently, most of them based on intravenous (IV) infusion. There is no approved effective therapy for COVID-19, but MSC therapies have shown first promise in the treatment of acute respiratory distress syndrome (ARDS) pneumonia, inflammation, and sepsis, which are among the leading causes of mortality in COVID-19 patients. Many of the critically ill COVID-19 patients are in a hypercoagulable procoagulant state and at high risk for disseminated intravascular coagulation, thromboembolism, and thrombotic multi-organ failure, another cause of high fatality. It is not yet clear whether IV infusion is a safe and effective route of MSC delivery in COVID-19, since MSC-based products express variable levels of highly procoagulant tissue factor (TF/CD142), compromising the cells' hemocompatibility and safety profile. Of concern, IV infusions of poorly characterized MSC products with unchecked (high) TF/CD142 expression could trigger blood clotting in COVID-19 and other vulnerable patient populations and further promote the risk for thromboembolism. In contrast, well-characterized products with robust manufacturing procedures and optimized modes of clinical delivery hold great promise for ameliorating COVID-19 by exerting their beneficial immunomodulatory effects, inducing tissue repair and organ protection. While the need for MSC therapy in COVID-19 is apparent, integrating both innate and adaptive immune compatibility testing into the current guidelines for cell, tissue, and organ transplantation is critical for safe and effective therapies. It is paramount to only use well-characterized, safe MSCs even in the most urgent and experimental treatments. We here propose three steps to mitigate the risk for these vulnerable patients: (1) updated clinical guidelines for cell and tissue transplantation, (2) updated minimal criteria for characterization of cellular therapeutics, and (3) updated cell therapy routines reflecting specific patient needs.	32574263	Frontiers in immunology	1664-3224	10.3389/fimmu.2020.01091	Terapias MSC para COVID-19: Importância da coagulopatia do paciente, tromboprofilaxia, qualidade do produto celular e modo de entrega para segurança e eficácia do tratamento. 	Numerosos ensaios clínicos de células-tronco/estromais mesenquimais (MSCs) como um novo tratamento para a doença induzida por coronavírus (COVID-19) foram registrados recentemente, a maioria deles baseados em infusão intravenosa (IV). Não há terapia eficaz aprovada para o COVID-19, mas as terapias com MSC mostraram-se promissoras no tratamento da pneumonia, inflamação e sepse da síndrome do desconforto respiratório agudo (SDRA), que estão entre as principais causas de mortalidade em pacientes com COVID-19. Muitos dos pacientes criticamente doentes com COVID-19 estão em um estado pró-coagulável hipercoagulável e com alto risco de coagulação intravascular disseminada, tromboembolismo e falência multiorgânica trombótica, outra causa de alta letalidade. Ainda não está claro se a infusão intravenosa é uma via segura e eficaz de entrega de MSC na COVID-19, uma vez que os produtos à base de MSC expressam níveis variáveis de fator tecidual altamente pró-coagulante (TF/CD142), comprometendo a hemocompatibilidade e o perfil de segurança das células. Preocupante, as infusões intravenosas de produtos MSC mal caracterizados com expressão descontrolada (alta) de TF/CD142 podem desencadear a coagulação do sangue em COVID-19 e outras populações de pacientes vulneráveis e promover ainda mais o risco de tromboembolismo. Por outro lado, produtos bem caracterizados com procedimentos de fabricação robustos e modos otimizados de entrega clínica são uma grande promessa para melhorar o COVID-19, exercendo seus efeitos imunomoduladores benéficos, induzindo reparo de tecidos e proteção de órgãos. Embora a necessidade de terapia de MSC no COVID-19 seja aparente, a integração de testes de compatibilidade imunológica inata e adaptativa às diretrizes atuais para transplante de células, tecidos e órgãos é fundamental para terapias seguras e eficazes. É primordial usar apenas CTMs bem caracterizadas e seguras mesmo nos tratamentos mais urgentes e experimentais. Propomos aqui três etapas para mitigar o risco para esses pacientes vulneráveis: (1) diretrizes clínicas atualizadas para transplante de células e tecidos, (2) critérios mínimos atualizados para caracterização de terapêutica celular e (3) rotinas de terapia celular atualizadas refletindo as necessidades específicas do paciente .
COVID-19 related coagulopathy: a distinct entity?	https://doi.org/10.3390/jcm9061651	28/04/2020	Artigo completo publicado em periódico científico	10.3390/jcm9061651	2077-0383	20770383	JOURNAL OF CLINICAL MEDICINE	A1	1.040	75	4.84	 The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.	['Heparina']	['Heparin']	The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.	32486469	Journal of clinical medicine	2077-0383	10.3390/jcm9061651	Coagulopatia relacionada ao COVID-19: uma entidade distinta? 	A pandemia da doença de coronavírus 2019 (COVID-19) impactou as comunidades de saúde em todo o mundo em uma escala sem precedentes. Os pacientes tiveram diversos desfechos clínicos, mas aqueles que desenvolveram coagulopatia relacionada ao COVID-19 mostraram um desfecho desproporcionalmente pior. Esta revisão narrativa resume as evidências atuais sobre a epidemiologia, características clínicas, modelos baseados em fisiopatologia conhecidos e presumidos e orientações de tratamento em relação à coagulopatia COVID-19.
Anticoagulation with Argatroban in patients with acute antithrombin deficiency in severe COVID -19.	https://doi.org/10.1111/bjh.16927	09/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16927	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Argatrobana']	['Argatroban']	Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality worldwide. Though previous coronaviruses have caused substantial epidemics in recent years, effective therapies remained limited at the start of the Coronavirus disease 19 (COVID-19) pandemic. The emergence and rapid spread throughout the globe of the novel SARS-CoV-2 virus necessitated a rapid development of therapeutics. Given the multitude of therapies that have emerged over the last two years and the evolution of data surrounding the efficacy of these therapies, we aim to provide an update on the major clinical trials that influenced clinical utilization of various COVID-19 therapeutics. This review focuses on currently used therapies in the United States and discusses the molecular mechanisms by which these therapies target the SARS-CoV-2 virus or the COVID-19 disease process. PubMed and EMBASE were used to find trials assessing the efficacy of various COVID-19 therapies. The keywords SARS-CoV-2, COVID-19, and the names of the various therapies included in this review were searched in different combinations to find large-scale randomized controlled trials performed since the onset of the COVID-19 pandemic. Multiple therapeutic options are currently approved for the treatment of SARS-CoV-2 and prevention of severe disease in high-risk individuals in both in the inpatient and outpatient settings. In severe disease, a combination of antiviral and immunomodulatory treatments is currently recommended for treatment. Additionally, anti-viral agents have shown promise in preventing severe disease and hospitalization for those in the outpatient setting. More recently, current therapeutic approaches are directed toward early treatment with monoclonal antibodies directed against the SARS-CoV-2 virus. Despite this, no treatment to date serves as a definitive cure and vaccines against the SARS-CoV-2 virus remain our best defense to prevent further morbidity and mortality.	32516429	British journal of haematology	1365-2141	10.1111/bjh.16927	Anticoagulação com Argatroban em pacientes com deficiência aguda de antitrombina em COVID-19 grave. 	A síndrome respiratória aguda grave-coronavírus 2 (SARS-CoV-2) causou morbidade e mortalidade significativas em todo o mundo. Embora os coronavírus anteriores tenham causado epidemias substanciais nos últimos anos, as terapias eficazes permaneceram limitadas no início da pandemia da doença de coronavírus 19 (COVID-19). O surgimento e a rápida disseminação em todo o mundo do novo vírus SARS-CoV-2 exigiu um rápido desenvolvimento da terapêutica. Dada a multiplicidade de terapias que surgiram nos últimos dois anos e a evolução dos dados em torno da eficácia dessas terapias, nosso objetivo é fornecer uma atualização sobre os principais ensaios clínicos que influenciaram a utilização clínica de várias terapêuticas para COVID-19. Esta revisão se concentra nas terapias atualmente usadas nos Estados Unidos e discute os mecanismos moleculares pelos quais essas terapias visam o vírus SARS-CoV-2 ou o processo da doença COVID-19. PubMed e EMBASE foram usados para encontrar ensaios avaliando a eficácia de várias terapias COVID-19. As palavras-chave SARS-CoV-2, COVID-19 e os nomes das várias terapias incluídas nesta revisão foram pesquisados em diferentes combinações para encontrar ensaios controlados randomizados em larga escala realizados desde o início da pandemia de COVID-19. Atualmente, várias opções terapêuticas estão aprovadas para o tratamento de SARS-CoV-2 e prevenção de doenças graves em indivíduos de alto risco, tanto em regime de internação quanto ambulatorial. Na doença grave, uma combinação de tratamentos antivirais e imunomoduladores é atualmente recomendada para o tratamento. Além disso, os agentes antivirais mostraram-se promissores na prevenção de doenças graves e hospitalização para aqueles em regime ambulatorial. Mais recentemente, as abordagens terapêuticas atuais são direcionadas para o tratamento precoce com anticorpos monoclonais direcionados contra o vírus SARS-CoV-2. Apesar disso, nenhum tratamento até o momento serve como cura definitiva e as vacinas contra o vírus SARS-CoV-2 continuam sendo nossa melhor defesa para evitar mais morbidade e mortalidade.
Diagnosis and management of the drug hypersensitivity reactions in coronavirus disease 19	https://onlinelibrary.wiley.com/doi/full/10.1111/all.14439	08/06/2020	Artigo completo publicado em periódico científico	10.1111/all.14439	0105-4538	1054538	ALLERGY (COPENHAGEN)	A1	3.122	183	8.1	-	['Agentes anti-interleucinas', 'Agentes anti-interleucinas', 'Agentes anti-interleucinas', 'Anti-inflamatórios', 'Anti-inflamatórios', 'Anti-inflamatórios', 'Anticoagulantes', 'Anticoagulantes', 'Anticoagulantes', 'Antiplaquetários', 'Antiplaquetários', 'Antiplaquetários', 'Antivirais', 'Antivirais', 'Antivirais', 'Imunomoduladores', 'Imunomoduladores', 'Imunomoduladores']	['Anti-interleukin agents', 'Anti-interleukin agents', 'Anti-interleukin agents', 'Anti-inflammatory', 'Anti-inflammatory', 'Anti-inflammatory', 'Anticoagulant', 'Anticoagulant', 'Anticoagulant ', 'Antiplatelet agents', 'Antiplatelet agents', 'Antiplatelet agents', 'Antivirals', 'Antivirals', 'Antivirals', 'Immunomodulators', 'Immunomodulators', 'Immunomodulators']	-	-	-	-	-	Diagnóstico e manejo das reações de hipersensibilidade a medicamentos na doença de coronavírus 19 	-
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2.	https://doi.org/10.1001/jama.2020.10369	08/06/2020	Artigo completo publicado em periódico científico	10.1001/jama.2020.10369	0098-7484	987484	JAMA (CHICAGO, ILL.)	A1	6.076	709	12.28	-	['Anakinra', 'Corticosteroides', 'Imunoglobulina', 'Infliximabe']	['Anakinra', 'Corticosteroids', 'Immunoglobulin', 'Infliximab']	-	-	-	-	-	Características clínicas de 58 crianças com síndrome multissistêmica inflamatória pediátrica temporariamente associada ao SARS-CoV-2. 	-
Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives.	https://doi.org/10.1093/ajh/hpaa096	08/06/2020	Artigo completo publicado em periódico científico	10.1093/ajh/hpaa096	0895-7061	8957061	AMERICAN JOURNAL OF HYPERTENSION	A3	0.862	141	2.38	 Abstract                                   BACKGROUND                   The effect of chronic use of renin–angiotensin–aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients.                                                  METHODS                   A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020.                                                  RESULTS                   All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09–0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17–1.83, P = 0.341).                                                  CONCLUSIONS                   Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.	32511678	American journal of hypertension	1941-7225	10.1093/ajh/hpaa096	Uso de inibidores de RAAS e risco de deterioração clínica no COVID-19: resultados de uma coorte italiana de 133 hipertensos. 	Nossos dados sugerem que o uso crônico de inibidores do SRAA não afeta negativamente o curso clínico da COVID-19 em pacientes hipertensos. Mais estudos são necessários para confirmar esse achado e determinar se os inibidores do SRAA podem ter um efeito protetor na morbidade e mortalidade relacionadas ao COVID-19.
Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome	https://doi.org/10.1016/j.chest.2020.05.573	05/06/2020	Artigo completo publicado em periódico científico	10.1016/j.chest.2020.05.573	0012-3692	123692	CHEST (AMERICAN COLLEGE OF CHEST PHYSICIANS)	A1	2.264	302	4.41	-	['Almitrina']	['Almitrine']	Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality.	32512007	Chest	1931-3543	10.1016/j.chest.2020.05.573	Eficácia da Almitrina no Tratamento da Hipoxemia na Síndrome do Desconforto Respiratório Agudo Sars-Cov-2 	Nossos dados sugerem que o uso crônico de inibidores do SRAA não afeta negativamente o curso clínico da COVID-19 em pacientes hipertensos. Mais estudos são necessários para confirmar esse achado e determinar se os inibidores do SRAA podem ter um efeito protetor na morbidade e mortalidade relacionadas ao COVID-19.
Flight of the COVID-19 patient: experience with a Wuhan evacuee: a case report.	https://doi.org/10.1186/s13256-020-02396-8	11/06/2020	Artigo completo publicado em periódico científico	10.1186/s13256-020-02396-8	1752-1947	17521947	JOURNAL OF MEDICAL CASE REPORTS	A4	0.289	34	1.13	 Abstract  Background Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2, was declared a global pandemic by the World Health Organization in March 2020.  Case presentation We report a case of a 51-year-old Chinese woman who was evacuated from Wuhan, China and diagnosed with coronavirus disease 2019 infection at a Southern California quarantine facility. Her clinical course was notable for high fevers, night sweats, productive cough, transient leukopenia, lymphopenia, thrombocytopenia, and transaminitis. Evolving hypoxia and infiltrates on chest imaging warranted the trial of an investigational antiviral drug - remdesivir. Our patient recovered and was discharged after 2 weeks of hospitalization.  Conclusions This case highlights our patient’s clinical course, including diagnostic work-up, medical management, and challenges in defining non-infectivity in a relatively unknown disease.	['Remdesivir']	['Remdesivir']	This case highlights our patient's clinical course, including diagnostic work-up, medical management, and challenges in defining non-infectivity in a relatively unknown disease.	32527327	Journal of medical case reports	1752-1947	10.1186/s13256-020-02396-8	Vôo do paciente COVID-19: experiência com evacuado de Wuhan: relato de caso. 	Este caso destaca o curso clínico de nosso paciente, incluindo investigação diagnóstica, manejo médico e desafios na definição de não infectividade em uma doença relativamente desconhecida.
Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.	https://doi.org/10.1111/tid.13348	05/06/2020	Artigo completo publicado em periódico científico	10.1111/tid.13348	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Tocilizumabe']	['Tocilizumab']	Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: All were of male gender, with a mean age of 55.5 ± 8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had cardiovascular comorbidities, 1/6 had diabetes, and 3/6 have one or more previous KTs. Four out of six patients died, at an average time of 9.75 ± 2.4 days after tocilizumab administration, 3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 and 21 days, respectively; in both patient, a significant increase of total lymphocyte count was observed. In conclusion, KTs, where the role of peculiar factors such as chronic immunosuppression is still undetermined, represent a high-risk group with significant COVID-19-associated mortality. The evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) in this specific population.	32500936	Transplant infectious disease : an official journal of the Transplantation Society	1399-3062	10.1111/tid.13348	Série de casos de seis pacientes transplantados renais com pneumonia por COVID-19 tratados com tocilizumabe. 	Poucos relatos descreveram o resultado de pacientes transplantados renais (KTs) afetados por COVID-19 tratados com inibidor do receptor de interleucina-6 tocilizumab (TCZ). Relatamos nossa série de casos de 6 KTs com pneumonia por COVID-19 que receberam TCZ: Todos eram do sexo masculino, com idade média de 55,5 ± 8,4 anos, tempo médio de transplante de 3.611 dias (1.465-5.757); 5/6 tinham comorbidades cardiovasculares, 1/6 tinham diabetes e 3/6 tinham um ou mais KTs prévios. Quatro em cada seis pacientes morreram, em um tempo médio de 9,75 ± 2,4 dias após a administração de tocilizumab, 3/6 devido a um choque séptico coexistente. Dois pacientes melhoraram após TCZ e receberam alta em 20 e 21 dias, respectivamente; em ambos os pacientes, observou-se um aumento significativo da contagem total de linfócitos. Em conclusão, os KTs, onde o papel de fatores peculiares como a imunossupressão crônica ainda é indeterminado, representam um grupo de alto risco com mortalidade significativa associada ao COVID-19. A avaliação do efeito do TCZ na pneumonia por COVID-19 requer estudos controlados (idealmente ECRs) nessa população específica.
Tocilizumab administration in a refractory case of COVID-19.	https://doi.org/10.1016/j.ijantimicag.2020.106043	02/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106043	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Administração de tocilizumabe em caso refratário de COVID-19. 	-
Severe exacerbation of immune thrombocytopenia and COVID-19: the favorable response to corticosteroid-based therapy—a case report.	https://doi.org/10.1007/s00277-020-04070-x	04/06/2020	Artigo completo publicado em periódico científico	10.1007/s00277-020-04070-x	0939-5555	9395555	ANNALS OF HEMATOLOGY (PRINT)	A4	0.994	84	2.75	-	['Imunoglobulina', 'Prednisona', 'Umifenovir']	['Immunoglobulin', 'Prednisone', 'Umifenovir']	The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.	32500224	Annals of hematology	1432-0584	10.1007/s00277-020-04070-x	Exacerbação grave de trombocitopenia imune e COVID-19: a resposta favorável à terapia baseada em corticosteróides - relato de caso. 	Os resultados desta série de casos sugerem que a famotidina oral em altas doses é bem tolerada e associada a melhores resultados relatados pelos pacientes em pacientes não hospitalizados com COVID-19.
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.	https://doi.org/10.1016/j.tmaid.2020.101738	05/05/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101738	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	The viral shedding exhibited different patterns during treatment. Immune insufficiency is responsible for the delayed viral clearance, suggesting that an immunomodulator should be considered to promote viral clearance in patients with low lymphocyte counts.	32889105	Travel medicine and infectious disease	1873-0442	10.1016/j.tmaid.2020.101861	Tratamento precoce de pacientes com COVID-19 com hidroxicloroquina e azitromicina: uma análise retrospectiva de 1.061 casos em Marselha, França. 	A excreção viral exibiu diferentes padrões durante o tratamento. A insuficiência imunológica é responsável pelo atraso na depuração viral, sugerindo que um imunomodulador deva ser considerado para promover a depuração viral em pacientes com baixa contagem de linfócitos.
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19	https://doi.org/10.1056/NEJMoa2016638	03/06/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2016638	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina', 'Hidroxicloroquina']	['Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Um ensaio randomizado de hidroxicloroquina como profilaxia pós-exposição para Covid-19 	-
Use of corticosteroids in asthma and COPD patients with or without COVID-19.	https://doi.org/10.1016/j.rmed.2020.106045	24/05/2020	Artigo completo publicado em periódico científico	10.1016/j.rmed.2020.106045	0954-6111	9546111	RESPIRATORY MEDICINE	A2	1.112	127	3.99	-	['Corticosteroides', 'Corticosteroides']	['Corticosteroids', 'Corticosteroids']	-	-	-	-	-	Uso de corticosteróides em pacientes com asma e DPOC com ou sem COVID-19. 	-
Persisting SARS-CoV-2 viremia after rituximab therapy: Two cases with fatal outcome and a review of literature.	https://doi.org/10.1111/bjh.16896	01/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16896	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Rituximabe']	['Rituximab']	-	-	-	-	-	Viremia persistente de SARS-CoV-2 após terapia com rituximabe: dois casos com desfecho fatal e uma revisão da literatura. 	-
Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.	https://doi.org/10.1111/jce.14594	02/06/2020	Artigo completo publicado em periódico científico	10.1111/jce.14594	1045-3873	10453873	JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY (PRINT)	A3	1.019	143	2.1	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Psoriasis is a chronic inflammatory skin disease that is characterized by well-demarcated erythematous plaques with a silver scale. Although many new and emerging therapeutic agents are often sufficient to control the disease, there is still a need for alternative treatment options in challenging cases. Extracorporeal photopheresis (ECP) has been applied to many T-cell-mediated diseases to restore immune homeostasis and treat psoriasis effectively. In this paper, we present a psoriasis patient who did not respond to methotrexate, narrowband ultraviolet B, or acitretin. Because of a diagnosis of non-Hodgkin lymphoma, the patient had contraindications for cyclosporine, fumaric acid esters, and biologics but achieved remission with a total of 12 sessions of ECP in two and a half months. Although exacerbation was recorded after polymerase chain reaction (PCR) confirmed coronavirus 2019 (COVID-19) disease infection at the end of the first month, scores from the psoriasis area severity index (PASI) and dermatological life quality index (DLQI) were regressed significantly within two and a half months. ECP seems to provide an effective and rapid response for psoriasis and should be considered for psoriasis patients who fail to respond or have contraindications to existing treatments.	32485061	Journal of cardiovascular electrophysiology	1540-8167	10.1111/jce.14594	Incidência e determinantes do prolongamento do intervalo QT em pacientes com COVID-19 tratados com hidroxicloroquina e azitromicina. 	A psoríase é uma doença inflamatória crônica da pele que se caracteriza por placas eritematosas bem demarcadas com escamas prateadas. Embora muitos agentes terapêuticos novos e emergentes sejam muitas vezes suficientes para controlar a doença, ainda há necessidade de opções alternativas de tratamento em casos desafiadores. A fotoférese extracorpórea (ECP) tem sido aplicada a muitas doenças mediadas por células T para restaurar a homeostase imunológica e tratar a psoríase de forma eficaz. Neste artigo, apresentamos um paciente com psoríase que não respondeu ao metotrexato, ultravioleta B de banda estreita ou acitretina. Devido ao diagnóstico de linfoma não-Hodgkin, o paciente teve contraindicações para ciclosporina, ésteres de ácido fumárico e biológicos, mas obteve remissão com um total de 12 sessões de PCE em dois meses e meio. Embora a exacerbação tenha sido registrada após a reação em cadeia da polimerase (PCR) confirmar a infecção por coronavírus 2019 (COVID-19) no final do primeiro mês, as pontuações do índice de gravidade da área de psoríase (PASI) e do índice de qualidade de vida dermatológica (DLQI) foram regredidos significativamente em dois meses e meio. A ECP parece fornecer uma resposta eficaz e rápida para a psoríase e deve ser considerada para pacientes com psoríase que não respondem ou têm contraindicações aos tratamentos existentes.
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.	https://doi.org/10.1016/j.ejim.2020.05.021	01/06/2020	Artigo completo publicado em periódico científico	10.1016/j.ejim.2020.05.021	0953-6205	9536205	EUROPEAN JOURNAL OF INTERNAL MEDICINE (LEICESTER)	A2	1.210	79	3.28	-	['Tocilizumabe']	['Tocilizumab']	At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials.	32482597	European journal of internal medicine	1879-0828	10.1016/j.ejim.2020.05.021	Eficácia e segurança do tocilizumab em pacientes graves com COVID-19: um estudo de coorte retrospectivo de centro único. 	No dia 28, a melhora clínica e a mortalidade não foram estatisticamente diferentes entre o tocilizumabe e os pacientes do tratamento padrão em nossa coorte. Infecções bacterianas ou fúngicas foram registradas em 13% dos pacientes com tocilizumabe e em 12% dos pacientes com tratamento padrão. A confirmação da eficácia e segurança exigirá estudos controlados em andamento.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.	https://doi.org/10.1053/j.gastro.2020.05.066	23/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.066	0016-5085	165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Corticosteroides']	['Corticosteroids']	At day 28, clinical improvement and mortality were not statistically different between tocilizumab and standard treatment patients in our cohort. Bacterial or fungal infections were recorded in 13% of tocilizumab patients and in 12% of standard treatment patients. Confirmation of efficacy and safety will require ongoing controlled trials.	32479824	Gastroenterology	1528-0012	10.1053/j.gastro.2020.05.066	Atividade da doença basal e terapia com esteróides estratificam o risco de COVID-19 em pacientes com doença inflamatória intestinal. 	No dia 28, a melhora clínica e a mortalidade não foram estatisticamente diferentes entre o tocilizumabe e os pacientes do tratamento padrão em nossa coorte. Infecções bacterianas ou fúngicas foram registradas em 13% dos pacientes com tocilizumabe e em 12% dos pacientes com tratamento padrão. A confirmação da eficácia e segurança exigirá estudos controlados em andamento.
Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.	https://doi.org/10.1016/j.phrs.2020.104872	30/04/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104872	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Cloroquina', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Umifenovir']	The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I	32360583	Pharmacological research	1096-1186	10.1016/j.phrs.2020.104872	Eficácia e segurança das opções terapêuticas atuais para COVID-19 - lições a serem aprendidas com a epidemia de SARS e MERS: uma revisão sistemática e meta-análise. 	A rápida progressão da pandemia da doença de coronavírus 2019 (COVID-19) tornou-se uma preocupação global. Esta meta-análise teve como objetivo avaliar a eficácia e segurança da opção atual de terapias para síndrome respiratória aguda grave (SARS), síndrome respiratória do Oriente Médio (MERS) além de COVID-19, na tentativa de identificar terapia promissora para síndrome respiratória aguda grave coronavírus 2 (SARS-CoV-2) pacientes infectados. Pesquisamos PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP) e WANFANG DATA para estudos controlados randomizados (RCTs), coorte prospectiva e estudos de coorte retrospectivos que avaliaram terapias (hidroxicloroquina , terapia à base de lopinavir/ritonavir e terapia à base de ribavirina, etc.) para SARS, MERS e COVID-19. Os desfechos primários foram mortalidade, erradicação virológica e melhora clínica, e os desfechos secundários foram melhora dos sintomas e resultados da radiografia de tórax, incidência de síndrome da doença respiratória aguda (SDRA), utilização de ventilação mecânica e eventos adversos (EAs). Riscos relativos resumidos (RRs) e intervalos de confiança de 95% (ICs) foram calculados usando modelos de efeitos aleatórios, e a qualidade da evidência foi avaliada usando GRADEpro. Dezoito artigos (5 ECRs, 2 estudos de coorte prospectivos e 11 estudos de coorte retrospectivos) envolvendo 4.941 pacientes foram incluídos. Em comparação com o tratamento de controle, as intervenções anti-vírus coronarianos reduziram significativamente a mortalidade (RR 0,65, IC 95% 0,44-0,96; I
Trials and tribulations: so many potential treatments, so few answers	https://link.springer.com/article/10.1007/s00264-020-04625-7	24/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s00264-020-04625-7	0341-2695	3412695	INTERNATIONAL ORTHOPAEDICS	A2	0.956	96	3.4	-	['Antimaláricos']	['Antimalarials']	The relatively small sample sizes and the number of independent trials investigating similar therapies are concerning. Resources may not be being allocated based on scientific merit and may be driven by public consciousness and speculation. Moving forward, a concerted effort focused on implementing large, well-coordinated and carefully designed multi-armed clinical trials will help to ensure that the most promising therapeutic options are rigorously studied and clinically meaningful results produced.	32447429	International orthopaedics	1432-5195	10.1007/s00264-020-04625-7	Ensaios e tribulações: tantos tratamentos potenciais, tão poucas respostas 	Os tamanhos de amostra relativamente pequenos e o número de ensaios independentes investigando terapias semelhantes são preocupantes. Os recursos podem não estar sendo alocados com base no mérito científico e podem ser impulsionados pela consciência pública e pela especulação. No futuro, um esforço concentrado focado na implementação de grandes ensaios clínicos multi-armados, bem coordenados e cuidadosamente projetados, ajudará a garantir que as opções terapêuticas mais promissoras sejam rigorosamente estudadas e resultados clinicamente significativos sejam produzidos.
Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.	https://doi.org/10.1111/bjh.16901	01/06/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16901	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tratamento com bloqueio de interleucina-6 para síndrome de liberação de citocinas associada a COVID-19 em um paciente com leucemia mielóide crônica mal controlada. 	-
First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19.	https://doi.org/10.1111/liv.14516	17/05/2020	Artigo completo publicado em periódico científico	10.1111/liv.14516	1478-3223	14783223	LIVER INTERNATIONAL (PRINT)	A2	2.064	118	6.49	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Primeiro caso de lesão hepática induzida por drogas associada ao uso de tocilizumabe em paciente com COVID-19. 	-
Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2.	https://doi.org/10.1111/ajt.16080	31/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16080	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Terapia com tocilizumabe em cinco receptores de transplante de tecido sólido e composto com SDRA precoce devido a SARS-CoV-2. 	-
Successful use of methylprednisolone for treating severe COVID-19.	https://doi.org/10.1016/j.jaci.2020.05.021	28/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.021	0091-6749	916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Prednisona']	['Prednisone']	-	-	-	-	-	Uso bem-sucedido de metilprednisolona no tratamento de COVID-19 grave. 	-
Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome.	https://doi.org/10.1186/s13613-020-00678-4	24/05/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00678-4	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	The efficient transmission of severe acute respiratory syndrome-2 coronavirus (SARS-CoV-2) from patients to health care workers or family members has been a worrisome and prominent feature of the ongoing outbreak. On the basis of clinical practice and in-vitro studies, we postulated that post-exposure prophylaxis (PEP) using Arbidol is associated with decreased infection among individuals exposed to confirmed cases of COVID-19 infection. We conducted a retrospective cohort study on family members and health care workers who were exposed to patients confirmed to have SARS-CoV-2 infection by real-time RT-PCR and chest computed tomography (CT) from January 1 to January 16, 2020. The last follow-up date was Feb. 26, 2020. The emergence of fever and/or respiratory symptoms after exposure to the primary case was collected. The correlations between post-exposure prophylaxis and infection in household contacts and health care workers were respectively analyzed. A total of 66 members in 27 families and 124 health care workers had evidence of close exposure to patients with confirmed COVID-19. The Cox regression based on the data of the family members and health care workers with Arbidol or not showed that Arbidol PEP was a protective factor against the development of COVID-19 (HR 0.025, 95% CI 0.003-0.209, P=0.0006 for family members and HR 0.056, 95% CI 0.005-0.662, P=0.0221 for health care workers). Our findings suggest Arbidol could reduce the infection risk of the novel coronavirus in hospital and family settings. This treatment should be promoted for PEP use and should be the subject of further investigation.	32449091	Annals of intensive care	2110-5820	10.1186/s13613-020-00678-4	Falta de depuração viral pela combinação de hidroxicloroquina e azitromicina ou lopinavir e ritonavir na síndrome do desconforto respiratório agudo relacionada ao SARS-CoV-2. 	A transmissão eficiente do coronavírus da síndrome respiratória aguda grave-2 (SARS-CoV-2) de pacientes para profissionais de saúde ou familiares tem sido uma característica preocupante e proeminente do surto em andamento. Com base na prática clínica e estudos in vitro, postulamos que a profilaxia pós-exposição (PEP) usando Arbidol está associada à diminuição da infecção entre indivíduos expostos a casos confirmados de infecção por COVID-19. Realizamos um estudo de coorte retrospectivo em familiares e profissionais de saúde que foram expostos a pacientes com infecção confirmada por SARS-CoV-2 por RT-PCR em tempo real e tomografia computadorizada (TC) de tórax de 1º de janeiro a 16 de janeiro de 2020. A última data de acompanhamento foi 26 de fevereiro de 2020. Foi coletado o surgimento de febre e/ou sintomas respiratórios após a exposição ao caso primário. Foram analisadas as correlações entre profilaxia pós-exposição e infecção em contatos domiciliares e profissionais de saúde, respectivamente. Um total de 66 membros em 27 famílias e 124 profissionais de saúde tiveram evidências de exposição próxima a pacientes com COVID-19 confirmado. A regressão de Cox com base nos dados dos familiares e profissionais de saúde com Arbidol ou não mostrou que Arbidol PEP foi um fator de proteção contra o desenvolvimento de COVID-19 (HR 0,025, IC 95% 0,003-0,209, P=0,0006 para membros e HR 0,056, IC 95% 0,005-0,662, P=0,0221 para profissionais de saúde). Nossas descobertas sugerem que o Arbidol pode reduzir o risco de infecção do novo coronavírus em ambientes hospitalares e familiares. Este tratamento deve ser promovido para uso de PEP e deve ser objeto de investigação adicional.
Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.	https://doi.org/10.1186/s13287-020-01725-4	27/05/2020	Artigo completo publicado em periódico científico	10.1186/s13287-020-01725-4	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton’s jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People’s Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2 days after hWJC transplantation, and recovered and discharged in 7 days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein is significantly decreased after hWJC treatment. Thus, the intravenous transplantation of hWJCs was safe and effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in a critically severe condition. This report highlights the potential of hWJC infusions as an effective treatment for COVID-19 pneumonia.	['Terapia celular']	['Cell Therapy']	The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton's jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People's Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2 days after hWJC transplantation, and recovered and discharged in 7 days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3	32460839	Stem cell research & therapy	1757-6512	10.1186/s13287-020-01725-4	Infusão intravenosa de células-tronco mesenquimais derivadas de geleia de Wharton do cordão umbilical humano como um tratamento potencial para pacientes com pneumonia por COVID-19. 	A nova doença de coronavírus 2019 (COVID-19) tornou-se uma emergência global de saúde pública desde que os pacientes foram detectados pela primeira vez em Wuhan, na China. Até o momento, não há medicamentos ou vacinas específicos disponíveis para curar os pacientes com infecção por COVID-19. O sistema imunológico e a inflamação são propostos para desempenhar um papel central na patogênese do COVID-19. As células-tronco mesenquimais (MSCs) demonstraram possuir uma poderosa função imunomoduladora abrangente. A infusão intravenosa de MSCs mostrou resultados promissores no tratamento da COVID-19. Aqui, relatamos um caso de um paciente grave com COVID-19 tratado com MSCs derivadas de geléia de Wharton (hWJCs) de cordão umbilical humano de um doador saudável no Hospital Popular de Liaocheng, China, a partir de 24 de fevereiro de 2020. A função pulmonar e os sintomas do paciente com pneumonia por COVID-19 melhorou significativamente em 2 dias após o transplante de hWJC e se recuperou e recebeu alta em 7 dias após o tratamento. Após o tratamento, a porcentagem e a contagem de subconjuntos de linfócitos (CD3
Treatment of COVID-19 Patients with Convalescent Plasma	https://doi.org/10.1016/j.ajpath.2020.05.014	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ajpath.2020.05.014	0002-9440	29440	THE AMERICAN JOURNAL OF PATHOLOGY (PRINT)	A1	1.619	289	4.82	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Tratamento de pacientes com COVID-19 com plasma convalescente 	-
A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois	https://www.liebertpub.com/doi/10.1089/APC.2020.0103	29/05/2020	Artigo completo publicado em periódico científico	10.1089/APC.2020.0103	1087-2914	10872914	AIDS PATIENT CARE AND STDS	A1	2.544	87	4.91	-	['Azitromicina', 'Cefalosporina', 'Hidroxicloroquina']	['Azithromycin', 'Cephalosporin', 'Hydroxychloroquine']	The risk of COVID-19 among people living with HIV (PLWH) is largely unknown and there have been very few reported cases in the literature. We report a case series of five PLWH with COVID-19. We identified all patients with a diagnosis of HIV who tested positive for SARS-CoV-2 at University of Chicago Medicine between March 1, 2020, and April 7, 2020. We retrospectively collected data regarding demographics, comorbidities, medications, laboratory test results, radiology results, and outcomes associated with COVID-19. All five PLWH with COVID-19 were African American; 80% (4/5) were cisgender females. The mean age of patients was 48 years old (range 38-53). The majority of patients presented with cough, fever, and shortness of breath. Three patients had diarrhea. One patient presented with predominantly cardiac symptoms. All were taking antiretroviral therapy (ART) with CD4 count >200 cells/mm	32469614	AIDS patient care and STDs	1557-7449	10.1089/apc.2020.0103	COVID -19 em Chicago, Illinois 	Relatamos uma série de casos de cinco PVHA com COVID-19. Identificamos todos os pacientes com diagnóstico de HIV que testaram positivo para SARS-CoV-2 na Universidade de Chicago Medicine entre 1º de março de 2020 e 7 de abril de 2020. Coletamos retrospectivamente dados sobre dados demográficos, comorbidades, medicamentos, resultados de exames laboratoriais, resultados de radiologia e resultados associados ao COVID-19. Todas as cinco PVHA com COVID-19 eram afro-americanas; 80% (4/5) eram mulheres cisgênero. A idade média dos pacientes foi de 48 anos (variação 38-53). A maioria dos pacientes apresentou tosse, febre e falta de ar. Três pacientes tiveram diarreia. Um paciente apresentou sintomas predominantemente cardíacos. Todos estavam em terapia antirretroviral (ART) com contagem de CD4 > 200 células/mm
Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study	https://doi.org/10.1016/j.phrs.2020.104965	29/05/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104965	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Ácido acetilsalicílico', 'Anticoagulantes']	['Acetylsalicylic acid', 'Anticoagulants']	Little is still known about the clinical features associated with the occurrence of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus disease 2019 (COVID-19). The aim of the present study was to describe the prevalence of pre-admission antithrombotic therapies in patients with COVID-19 and to investigate the potential association between antithrombotic therapy and ARDS, as disease clinical presentation, or in-hospital mortality. We enrolled 192 consecutive patients with laboratory-confirmed COVID-19 admitted to emergency department of five Italian hospitals. The study population was divided in two groups according to the evidence of ARDS at chest computed tomography at admission. Propensity score weighting adjusted regression analysis was performed to assess the risk ARDS at admission, and death during hospitalization, in patients treated or not with antiplatelet and anticoagulant agents. ARDS was reported in 73 cases (38 %), who showed more likely hypertension compared to those without ARDS (57.8 % vs 49.6 %; P = 0.005). Thirty-five patients (18.5 %) died during the hospitalization. Not survived COVID-19 patients showed a statistically significant increased age (77 ± 8.31 vs 65.57 ± 8.31; P = 0.001), hypertension (77.1 % vs 53.5 %; P = 0.018) and coronary artery disease prevalence (28.6 % vs 10.2 %; P = 0.009). Both unadjusted and adjusted regression analyses showed no difference in the risk of ARDS at admission, or death during hospitalization, between patients treated or not with antiplatelets or anticoagulants. Pre-admission antithrombotic therapy, both antiplatelet and anticoagulant, does not seem to show a protective effect in severe forms of COVID-19 with ARDS at presentation and rapidly evolving toward death.	32474087	Pharmacological research	1096-1186	10.1016/j.phrs.2020.104965	Impacto clínico da terapia antitrombótica pré-admissão em pacientes hospitalizados com COVID-19: um estudo observacional multicêntrico 	Pouco ainda se sabe sobre as características clínicas associadas à ocorrência de síndrome do desconforto respiratório agudo (SDRA) em pacientes hospitalizados com doença de Coronavírus 2019 (COVID- 19). O objetivo do presente estudo foi descrever a prevalência de terapias antitrombóticas pré-admissão em pacientes com COVID-19 e investigar a potencial associação entre terapia antitrombótica e SDRA, como apresentação clínica da doença ou mortalidade hospitalar. Inscrevemos 192 pacientes consecutivos com COVID-19 confirmado laboratorialmente admitidos no departamento de emergência de cinco hospitais italianos. A população do estudo foi dividida em dois grupos de acordo com a evidência de SDRA na tomografia computadorizada de tórax na admissão. A análise de regressão ajustada por ponderação do escore de propensão foi realizada para avaliar o risco de SDRA na admissão e óbito durante a internação, em pacientes tratados ou não com antiplaquetários e anticoagulantes. SDRA foi relatada em 73 casos (38%), que apresentaram hipertensão mais provável em comparação com aqueles sem SDRA (57,8% vs 49,6%; P = 0,005). Trinta e cinco pacientes (18,5%) morreram durante a internação. Os pacientes que não sobreviveram à COVID-19 apresentaram um aumento estatisticamente significativo da idade (77 ± 8,31 vs 65,57 ± 8,31; P = 0,001), hipertensão (77,1 % vs 53,5 %; P = 0,018) e prevalência de doença arterial coronariana (28,6 % vs 10,2 %; P = 0,009). Ambas as análises de regressão não ajustada e ajustada não mostraram diferença no risco de SDRA na admissão, ou morte durante a hospitalização, entre pacientes tratados ou não com antiplaquetários ou anticoagulantes. A terapia antitrombótica pré-admissão, tanto antiplaquetária quanto anticoagulante, não parece mostrar um efeito protetor nas formas graves de COVID-19 com SDRA na apresentação e evoluindo rapidamente para a morte.
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort	https://doi.org/10.1016/S2352-3018(20)30164-8	28/05/2020	Artigo completo publicado em periódico científico	10.1016/S2352-3018(20)30164-8	2352-3018	23523018	THE LANCET HIV	A1	5.296	62	4.76	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	None.	32473657	The lancet. HIV	2352-3018	10.1016/S2352-3018(20)30164-8	Descrição do COVID-19 em indivíduos infectados pelo HIV: uma coorte prospectiva de centro único 	Nenhum.
COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome	https://doi.org/10.1016/j.jinf.2020.05.056	28/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.05.056	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Pacientes com COVID-19 com hipertensão têm maior gravidade e o tratamento com IECA/BRA não tem influência sobre a gravidade e o desfecho clínico 	-
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, singleblind, randomized controlled trial	https://doi.org/10.1016/j.jaci.2020.05.019	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.019	0091-6749	916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Ruxolitinibe']	['Ruxolitinib']	-	-	-	-	-	Ruxolitinib no tratamento da doença grave por coronavírus 2019 (COVID-19): Um estudo multicêntrico, simples-cego, randomizado controlado 	-
Ramipril in High Risk Patients with COVID-19	https://doi.org/10.1016/j.jacc.2020.05.040	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jacc.2020.05.040	0735-1097	7351097	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (PRINT)	A1	9.756	451	9.53	-	['Ramipril']	['Ramipril']	-	-	-	-	-	Ramipril em Pacientes de Alto Risco com COVID-19 	-
Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review	https://doi.org/10.1016/j.cmi.2020.05.016	26/05/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.05.016	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Evidências clínicas para o reaproveitamento de cloroquina e hidroxicloroquina como agentes antivirais: uma revisão sistemática 	-
Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome	https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0146	29/05/2020	Artigo completo publicado em periódico científico	10.1002/sctm.20-0146	2157-6564	21576564	STEM CELLS TRANSLATIONAL MEDICINE	A1	1.412	80	7.67	 Abstract                Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2/FiO2 ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.                                  <jats:title />                   Significance statement The potential benefits of mesenchymal stromal cell (MSC) therapy for patients with COVID-19 acute respiratory distress syndrome support the rapid commencement of clinical trials, as well as the compassionate use of MSCs that already have documented safety profiles from FDA-approved studies.               	['Terapia celular']	['Cell Therapy']	Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO	32472653	Stem cells translational medicine	2157-6580	10.1002/sctm.20-0146	Terapia baseada em células para reduzir a mortalidade por COVID-19: Revisão sistemática e meta-análise de estudos humanos sobre síndrome do desconforto respiratório agudo 	Casos graves de infecção por COVID-19, muitas vezes levando à morte, foram associados a variantes da síndrome do desconforto respiratório agudo ( ARDS). A terapia celular com células estromais mesenquimais (MSCs) é um tratamento potencial para a SDRA COVID-19 com base em estudos pré-clínicos e clínicos que apoiam o conceito de que as MSCs modulam os processos inflamatórios e de remodelação e restauram as barreiras alvéolo-capilares. Os autores realizaram uma revisão sistemática da literatura e meta-análise de efeitos aleatórios para determinar o valor potencial da terapia com MSC para o tratamento de pacientes infectados com COVID-19 com SDRA. Publicações em todos os idiomas de 1990 a 31 de março de 2020 foram revisadas, resultando em 2.691 estudos, dos quais nove foram incluídos. MSCs foram administrados por via intravenosa ou intratraqueal em 117 participantes, que foram acompanhados por 14 dias a 5 anos. Todas as MSCs eram alogênicas de medula óssea, cordão umbilical, sangue menstrual, tecido adiposo ou fontes não relatadas. A mortalidade combinada apresentou tendência favorável, mas não atingiu significância estatística. Nenhum evento adverso grave relacionado foi relatado e eventos adversos leves foram resolvidos espontaneamente. Foi encontrada uma tendência de melhora dos achados radiográficos, função pulmonar (complacência pulmonar, volumes correntes, PaO
An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease‑19 (COVID‑19)	https://doi.org/10.1007/s40261-020-00927-1	28/05/2020	Artigo completo publicado em periódico científico	10.1007/s40261-020-00927-1	1173-2563	11732563	CLINICAL DRUG INVESTIGATION	A4	0.718	60	2.86	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Uma revisão sistemática atualizada do papel terapêutico da hidroxicloroquina na doença de coronavírus-19 (COVID-19) 	-
COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?	https://doi.org/10.1016/j.phrs.2020.104906	13/05/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104906	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)', 'Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)']	-	-	-	-	-	COVID-19, hipertensão e doenças cardiovasculares: devemos mudar a terapia? 	-
Early outpatient treatment of symptomatic, high-risk Covid-19 patients that should be ramped-up immediately as key to the pandemic crisis	https://doi.org/10.1093/aje/kwaa093	27/05/2020	Artigo completo publicado em periódico científico	10.1093/aje/kwaa093	0002-9262	29262	AMERICAN JOURNAL OF EPIDEMIOLOGY	A1	1.831	267	3.68	 Abstract More than 1.6 million Americans have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and more than 10 times that number carry antibodies to it. High-risk patients with progressing symptomatic disease currently have only hospitalization treatment, with its high mortality, available to them. An outpatient treatment that prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir and hydroxychloroquine (HCQ) + azithromycin (AZ). Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials in outpatients have been registered. HCQ + AZ has been widely misrepresented in both clinical reports and public media, and results of outpatient trials are not expected until September. Early outpatient illness is very different from later florid disease requiring hospitalization, and the treatments differ. Evidence about use of HCQ alone, or of HCQ + AZ in inpatients, is irrelevant with regard to the efficacy of HCQ + AZ in early high-risk outpatient disease. Five studies, including 2 controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. HCQ + AZ has been used as the standard of care in more than 300,000 older adults with multiple comorbid conditions; the estimated proportion of such patients diagnosed with cardiac arrhythmia attributable to the medications is 47 per 100,000 users, among whom estimated mortality is less than 20% (9/100,000 users), as compared with the 10,000 Americans now dying each week. These medications need to be made widely available and promoted immediately for physicians to prescribe.	['Azitromicina', 'Hidroxicloroquina', 'Remdesivir']	['Azithromycin', 'Hydroxychloroquine', 'Remdesivir']	-	-	-	-	-	Tratamento ambulatorial precoce de pacientes sintomáticos e de alto risco Covid-19 que devem ser intensificados imediatamente como chave para a crise pandêmica 	-
Can Zn Be a Critical Element in COVID-19 Treatment?	https://link.springer.com/article/10.1007/s12011-020-02194-9	26/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s12011-020-02194-9	0163-4984	1634984	BIOLOGICAL TRACE ELEMENT RESEARCH	A3	0.649	88	4.18	-	['Zinco']	['Zinc']	The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale and evidence have been presented to use chloroquine for the treatment of COVID-19. Furthermore, Zn has the ability to enhance innate and adaptive immunity in the course of a viral infection. Besides, Zn supplement can favour COVID-19 treatment using those suggested and/or recommended drugs. Again, the effectiveness of Zn can be enhanced by using chloroquine as an ionophore while Zn inside the infected cell can stop SARS-CoV-2 replication. Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19.	32458149	Biological trace element research	1559-0720	10.1007/s12011-020-02194-9	O Zn pode ser um elemento crítico no tratamento do COVID-19? 	A atual pandemia de COVID-19 causada pelo SARS-CoV-2 levou pesquisadores em todo o mundo a procurar um tratamento antiviral eficaz. Vários medicamentos antivirais, como ribavirina, remdesivir, lopinavir/ritonavir, antibióticos como azitromicina e doxiciclina e antiparasitários, como ivermectina, foram recomendados para o tratamento da COVID-19. Além disso, foram apresentadas justificativas e evidências pré-clínicas suficientes para o uso da cloroquina no tratamento da COVID-19. Além disso, o Zn tem a capacidade de aumentar a imunidade inata e adaptativa no curso de uma infecção viral. Além disso, o suplemento de Zn pode favorecer o tratamento da COVID-19 com os medicamentos sugeridos e/ou recomendados. Novamente, a eficácia do Zn pode ser aprimorada usando a cloroquina como ionóforo, enquanto o Zn dentro da célula infectada pode interromper a replicação do SARS-CoV-2. Dados esses benefícios, este artigo de perspectiva descreve como e por que o Zn pode ser considerado como um complemento ao tratamento prescrito do COVID-19.
Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes.	https://doi.org/10.1111/dom.14097	28/05/2020	Artigo completo publicado em periódico científico	10.1111/dom.14097	1462-8902	14628902	DIABETES, OBESITY AND METABOLISM (PRINT)	A1	2.356	135	6.08	-	['Inibidores da DPP-4']	['DPP-4 Inhibitors']	Because other coronaviruses enter the cells by binding to dipeptidyl-peptidase-4 (DPP-4), it has been speculated that DPP-4 inhibitors (DPP-4is) may exert an activity against severe acute respiratory syndrome coronavirus 2. In the absence of clinical trial results, we analysed epidemiological data to support or discard such a hypothesis. We retrieved information on exposure to DPP-4is among patients with type 2 diabetes (T2D) hospitalized for COVID-19 at an outbreak hospital in Italy. As a reference, we retrieved information on exposure to DPP-4is among matched patients with T2D in the same region. Of 403 hospitalized COVID-19 patients, 85 had T2D. The rate of exposure to DPP-4is was similar between T2D patients with COVID-19 (10.6%) and 14 857 matched patients in the region (8.8%), or 793 matched patients in the local outpatient clinic (15.4%), 8284 matched patients hospitalized for other reasons (8.5%), and when comparing 71 patients hospitalized for COVID-19 pneumonia (11.3%) with 351 matched patients with pneumonia of another aetiology (10.3%). T2D patients with COVID-19 who were on DPP-4is had a similar disease outcome as those who were not. In summary, we found no evidence that DPP-4is might affect hospitalization for COVID-19.	32463179	Diabetes, obesity & metabolism	1463-1326	10.1111/dom.14097	Exposição a inibidores de DPP-4 e COVID-19 entre pessoas com diabetes tipo 2. 	Como outros coronavírus entram nas células ligando-se à dipeptidil-peptidase-4 (DPP-4), especulou-se que os inibidores de DPP-4 (DPP-4is) podem exercer uma atividade contra o coronavírus 2 da síndrome respiratória aguda grave. resultados de ensaios clínicos, analisamos dados epidemiológicos para apoiar ou descartar tal hipótese. Recuperamos informações sobre a exposição ao DPP-4is entre pacientes com diabetes tipo 2 (T2D) hospitalizados por COVID-19 em um hospital de surto na Itália. Como referência, recuperamos informações sobre a exposição ao DPP-4is entre pacientes pareados com DM2 na mesma região. Dos 403 pacientes hospitalizados com COVID-19, 85 tinham DM2. A taxa de exposição ao DPP-4is foi semelhante entre pacientes com DM2 com COVID-19 (10,6%) e 14.857 pacientes pareados na região (8,8%), ou 793 pacientes pareados no ambulatório local (15,4%), 8.284 pareados pacientes internados por outros motivos (8,5%) e ao comparar 71 pacientes internados por pneumonia por COVID-19 (11,3%) com 351 pacientes pareados com pneumonia de outra etiologia (10,3%). Pacientes com DM2 com COVID-19 que estavam em DPP-4is tiveram um resultado de doença semelhante aos que não estavam. Em resumo, não encontramos evidências de que o DPP-4is possa afetar a hospitalização por COVID-19.
QT Interval Prolongation and Torsade de Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin	https://doi.org/10.1016/j.hrthm.2020.05.014	11/05/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.05.014	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Azitromicina', 'Azitromicina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Azithromycin', 'Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Prolongamento do intervalo QT e Torsade de Pointes em pacientes com COVID-19 tratados com Hidroxicloroquina/Azitromicina 	-
Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence	https://doi.org/10.1111/ijcp.13557	27/05/2020	Artigo completo publicado em periódico científico	10.1111/ijcp.13557	1368-5031	13685031	INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ESHER)	A2	0.646	103	2.5	-	['Ácido acetilsalicílico', 'Brometo de ipratrópio', 'Claritromicina', 'Ibuprofeno', 'Interferon alfa', 'Naproxeno', 'Oseltamivir', 'Paracetamol']	['Acetylsalicylic acid', 'Ipratropium bromide', 'Clarithromycin', 'Ibuprofen', 'Interferon alpha', 'Naproxen', 'Oseltamivir', 'Paracetamol']	-	-	-	-	-	Anti-inflamatórios não esteroides no manejo da COVID-19; uma revisão sistemática sobre evidências atuais 	-
A case of cefditoren-induced Acute Generalized Exanthematous Pustulosis during COVID-19 pandemics	https://doi.org/10.1111/jdv.16664	26/05/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16664	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Azitromicina', 'Cefditoren', 'Ceftriaxona', 'Hidroxicloroquina', 'Interferon beta', 'Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Azithromycin', 'Cefditoren', 'Ceftriaxone', 'Hydroxychloroquine', 'Interferon beta', 'Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']	Adult-onset Still's disease (AOSD)-like syndrome has rarely been reported as a complication of COVID-19 vaccination. This study reports a 31-year-old female patient who presented with fever, myalgia, arthralgia, pleuropericarditis, leukocytosis, and transaminitis following ChAdOx1 vaccination, and met Yamaguchi's criteria. A PubMed literature search, performed up until March 2022, identified 10 such cases. A total of 11 cases, including the one in this report, developed AOSD-like syndrome after administration of the viral vector (ChAdOx1) vaccine (six patients) and mRNA vaccine (five patients: BNT162b2 in four and mRNA-1273 in one). There were four male and seven female patients, with their median (Q1, Q3) age and the onset of symptoms after vaccination being 36 years (29, 45) and 10 days (6, 13), respectively. Fever (100%), arthralgia/arthritis (90.9%), skin rashes (81.8%), and sore throat (81.8%) were the main clinical findings. Pericarditis (45.5%), myocarditis/cardiac dysfunction (36.4%), pleuritis (54.6%), and pulmonary infiltrations (36.4%) were also common. One patient developed macrophage activation syndrome. One patient responded well to non-steroidal anti-inflammatory drugs, and the other six showed a good response to high-dose corticosteroids alone. Of the remaining four patients, who showed partial responses to high dose corticosteroids, showed good responses to biological agents. AOSD-like syndrome following COVID-19 vaccination shared many similar clinical features and treatment outcomes to those of idiopathic AOSD (but with a higher prevalence of cardiopulmonary involvement in the former). Physicians should be aware of this extremely rare complication to achieve early diagnosis and provide proper management.	32455478	Journal of the European Academy of Dermatology and Venereology : JEADV	1468-3083	10.1111/jdv.16664	Um caso de pustulose exantematosa generalizada aguda induzida por cefditoreno durante pandemias de COVID-19 	A síndrome semelhante à doença de Still do adulto (AOSD) raramente foi relatada como uma complicação da vacinação para COVID-19. Este estudo relata uma paciente do sexo feminino de 31 anos que apresentou febre, mialgia, artralgia, pleuropericardite, leucocitose e transaminite após vacinação com ChAdOx1 e preenchia os critérios de Yamaguchi. Uma pesquisa bibliográfica no PubMed, realizada até março de 2022, identificou 10 desses casos. Um total de 11 casos, incluindo o deste relato, desenvolveu síndrome semelhante a AOSD após administração da vacina de vetor viral (ChAdOx1) (seis pacientes) e vacina de mRNA (cinco pacientes: BNT162b2 em quatro e mRNA-1273 em um). Havia quatro pacientes do sexo masculino e sete do sexo feminino, com idade mediana (Q1, Q3) e início dos sintomas após a vacinação, sendo 36 anos (29, 45) e 10 dias (6, 13), respectivamente. Febre (100%), artralgia/artrite (90,9%), erupções cutâneas (81,8%) e dor de garganta (81,8%) foram os principais achados clínicos. Pericardite (45,5%), miocardite/disfunção cardíaca (36,4%), pleurite (54,6%) e infiltrações pulmonares (36,4%) também foram comuns. Um paciente desenvolveu síndrome de ativação macrofágica. Um paciente respondeu bem aos anti-inflamatórios não esteroides e os outros seis apresentaram boa resposta apenas aos corticosteroides em altas doses. Dos quatro pacientes restantes, que apresentaram respostas parciais aos corticosteróides em altas doses, apresentaram boas respostas aos agentes biológicos. A síndrome semelhante a AOSD após a vacinação com COVID-19 compartilhou muitas características clínicas e resultados de tratamento semelhantes aos da AOSD idiopática (mas com maior prevalência de envolvimento cardiopulmonar na primeira). Os médicos devem estar cientes dessa complicação extremamente rara para obter o diagnóstico precoce e fornecer o tratamento adequado.
COVID‐SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults	https://onlinelibrary.wiley.com/doi/full/10.1111/jgs.16623	22/05/2020	Artigo completo publicado em periódico científico	10.1111/jgs.16623	0002-8614	28614	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY	A1	2.133	241	4.78	-	['Hidroxicloroquina']	['Hydroxychloroquine']	The COVID-19 pandemic highlights the importance of medication optimization and deprescribing PIMs in older adults. By acting now to reduce polypharmacy and use of PIMs, we can better prepare this vulnerable population for inclusion in trials and, if substantiated, pharmacologic treatment or prevention of COVID-19. J Am Geriatr Soc 68:1636-1646, 2020.	32441771	Journal of the American Geriatrics Society	1532-5415	10.1111/jgs.16623	COVID-SAFER: Orientação de desprescrição para interações medicamentosas com hidroxicloroquina em idosos 	A pandemia de COVID-19 destaca a importância da otimização de medicamentos e desprescrição de PIMs em idosos. Ao agir agora para reduzir a polifarmácia e o uso de PIMs, podemos preparar melhor essa população vulnerável para inclusão em ensaios e, se comprovado, tratamento farmacológico ou prevenção de COVID-19. J Am Geriatr Soc 68:1636-1646, 2020.
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19	https://doi.org/10.1056/NEJMoa2015301	27/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2015301	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	-	-	-	-	-	Remdesivir por 5 ou 10 dias em pacientes com Covid-19 grave 	-
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review	https://www.acpjournals.org/doi/10.7326/M20-2496	27/05/2020	Artigo completo publicado em periódico científico	10.7326/M20-2496	0003-4819	34819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Hidroxicloroquina ou cloroquina para tratamento ou profilaxia de COVID-19: uma revisão sistemática viva 	-
A review on possible modes of actions of Chloroquine / Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic	https://doi.org/10.1016/j.ijantimicag.2020.106028	22/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.106028	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Uma revisão sobre os possíveis modos de ação da Cloroquina / Hidroxicloroquina: Reaproveitamento contra a pandemia de SAR-COV-2 (COVID 19) 	-
Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury	https://doi.org/10.1186/s13287-020-01699-3	24/05/2020	Artigo completo publicado em periódico científico	10.1186/s13287-020-01699-3	1757-6512	17576512	STEM CELL RESEARCH & THERAPY	A1	1.330	90	7.89	 Abstract Acute lung injury (ALI), an increasingly devastating human disorder, is characterized by a multitude of lung changes arising from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. In particular, influenza virus, coronavirus, and other respiratory viruses circulate in nature in various animal species and can cause severe and rapidly spread human infections. Although scientific advancements have allowed for rapid progress to be made to understand the pathogenesis and develop therapeutics after each viral pandemic, few effective methods to treat virus-induced ALI have been described. Recently, stem cell therapy has been widely used in the treatment of various diseases, including ALI. In this review, we detail the present stem cell-based therapeutics for lung injury caused by influenza virus and the outlook for the future state of stem cell therapy to deal with emerging influenza and coronaviruses.	['Terapia celular']	['Cell Therapy']	Acute lung injury (ALI), an increasingly devastating human disorder, is characterized by a multitude of lung changes arising from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. In particular, influenza virus, coronavirus, and other respiratory viruses circulate in nature in various animal species and can cause severe and rapidly spread human infections. Although scientific advancements have allowed for rapid progress to be made to understand the pathogenesis and develop therapeutics after each viral pandemic, few effective methods to treat virus-induced ALI have been described. Recently, stem cell therapy has been widely used in the treatment of various diseases, including ALI. In this review, we detail the present stem cell-based therapeutics for lung injury caused by influenza virus and the outlook for the future state of stem cell therapy to deal with emerging influenza and coronaviruses.	32448377	Stem cell research & therapy	1757-6512	10.1186/s13287-020-01699-3	Terapia com células-tronco: uma abordagem potencial para o tratamento do vírus influenza e lesão pulmonar aguda induzida por coronavírus A lesão 	pulmonar aguda (LPA), um distúrbio humano cada vez mais devastador, é caracterizada por uma infinidade de alterações pulmonares decorrentes de uma ampla variedade de lesões pulmonares. A infecção viral é a principal causa de morbidade e mortalidade em pacientes com LPA e síndrome do desconforto respiratório agudo (SDRA). Em particular, o vírus da gripe, o coronavírus e outros vírus respiratórios circulam na natureza em várias espécies animais e podem causar infecções humanas graves e rapidamente disseminadas. Embora os avanços científicos tenham permitido um rápido progresso para entender a patogênese e desenvolver terapêutica após cada pandemia viral, poucos métodos eficazes para tratar a LPA induzida por vírus foram descritos. Recentemente, a terapia com células-tronco tem sido amplamente utilizada no tratamento de diversas doenças, incluindo a LPA. Nesta revisão, detalhamos as atuais terapias baseadas em células-tronco para lesão pulmonar causada pelo vírus influenza e as perspectivas para o estado futuro da terapia com células-tronco para lidar com influenza e coronavírus emergentes.
Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review	https://link.springer.com/article/10.1007/s10067-020-05172-7	25/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s10067-020-05172-7	0770-3198	7703198	CLINICAL RHEUMATOLOGY (PRINTED)	A4	0.873	88	3.38	-	['Prednisona']	['Prednisone']	-	-	-	-	-	Tratamento com corticosteroides na pneumonia grave por COVID-19: dois casos e revisão de literatura 	-
Efficacy of therapeutic plasma exchange in severe COVID-19 patients	https://onlinelibrary.wiley.com/doi/10.1111/bjh.16890	26/05/2020	Artigo completo publicado em periódico científico	10.1111/bjh.16890	0007-1048	71048	BRITISH JOURNAL OF HAEMATOLOGY (PRINT)	A2	1.677	194	3.8	-	['Plasmaferese']	['Plasmapheresis']	-	-	-	-	-	Eficácia da troca de plasma terapêutica em pacientes graves com COVID-19 	-
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: the interplay between immunosuppression and novel therapy including tocilizumab	https://doi.org/10.1111/tid.13334	25/05/2020	Artigo completo publicado em periódico científico	10.1111/tid.13334	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Esteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tocilizumabe']	['Steroidal', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tocilizumab']	Although immunosuppressed patients may be more prone to SARS-CoV-2 infection with atypical presentation, long-term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID-19. The interaction between immunosuppression and new antiviral drugs in the treatment of transplanted patients contracting COVID-19 has not yet been fully investigated. Moreover, data regarding the optimal management of these patients are still very limited. We report a case of the successful recovery from severe COVID-19 of a kidney-transplanted patient treated with hydroxychloroquine, lopinavir/ritonavir, steroid, and tocilizumab.	32449235	Transplant infectious disease : an official journal of the Transplantation Society	1399-3062	10.1111/tid.13334	Recuperação bem-sucedida de pneumonia grave por COVID-19 após transplante renal: a interação entre imunossupressão e nova terapia, 	incluindo tocilizumabe para complicações clínicas graves do COVID-19. A interação entre imunossupressão e novos medicamentos antivirais no tratamento de pacientes transplantados contraindo COVID-19 ainda não foi totalmente investigada. Além disso, os dados sobre o manejo ideal desses pacientes ainda são muito limitados. Relatamos um caso de recuperação bem-sucedida de COVID-19 grave de um paciente transplantado de rim tratado com hidroxicloroquina, lopinavir/ritonavir, esteroide e tocilizumabe.
Acetic acid disinfection as a potential adjunctive therapy for non-severe COVID-19	https://doi.org/10.1007/s00405-020-06067-8	24/05/2020	Artigo completo publicado em periódico científico	10.1007/s00405-020-06067-8	0937-4477	9374477	EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY	A3	0.926	76	3.14	-	['Ácido acético']	['Acetic Acid']	Considering its potential benefits and high availability, acetic acid disinfection appears to be a promising adjunctive therapy in cases of non-severe COVID-19 and deserves further investigation.	32449022	European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery	1434-4726	10.1007/s00405-020-06067-8	Desinfecção com ácido acético como terapia adjuvante potencial para COVID-19 não grave 	Considerando seus potenciais benefícios e alta disponibilidade, a desinfecção com ácido acético parece ser uma terapia adjuvante promissora em casos de COVID-19 não grave e merece mais investigação.
COVID-19 and Liver Transplantation: lessons learned from three reported cases	https://doi.org/10.1111/TID.13335	21/05/2020	Artigo completo publicado em periódico científico	10.1111/TID.13335	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Corticosteroides', 'Imunossupressores']	['Corticosteroids', 'Immunosuppressants']	Considering its potential benefits and high availability, acetic acid disinfection appears to be a promising adjunctive therapy in cases of non-severe COVID-19 and deserves further investigation.	32438464	Transplant infectious disease : an official journal of the Transplantation Society	1399-3062	10.1111/tid.13335	COVID-19 e transplante de fígado: lições aprendidas de três casos relatados 	Considerando seus potenciais benefícios e alta disponibilidade, a desinfecção com ácido acético parece ser uma terapia adjuvante promissora em casos de COVID-19 não grave e merece mais investigação.
Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients	https://doi.org/doi:10.1016/j.diabet.2020.05.005	21/05/2020	Artigo completo publicado em periódico científico	doi:10.1016/j.diabet.2020.05.005	1262-3636	12623636	DIABETES & METABOLISM	A2	1.834	94	4.51	-	['Tocilizumabe']	['Tocilizumab']	Tocilizumab (TCZ) is used for treating moderate-to-severe Covid-19 pneumonia by targeting interleukin-6 receptors (IL-6Rs) and reducing cytokine release. Yet, in spite of this therapy, patients with vs. patients without diabetes have an adverse disease course. In fact, glucose homoeostasis has influenced the outcomes of diabetes patients with infectious diseases. Of the 475 Covid-19-positive patients admitted to infectious disease departments (University of Bologna, University Vanvitelli of Napoli, San Sebastiano Caserta Hospital) in Italy since 1 March 2020, 31 (39.7%) hyperglycaemic and 47 (60.3%) normoglycaemic patients (blood glucose levels ≥140mg/dL) were retrospectively evaluated at admission and during their hospital stay. Of note, 20 (64%) hyperglycaemic and 11 (23.4%) normoglycaemic patients had diabetes (P<0.01). At admission, hyperglycaemic vs. normoglycaemic patients had fivefold higher IL-6 levels, which persisted even after TCZ administration (P<0.05). Intriguingly, in a risk-adjusted Cox regression analysis, TCZ in hyperglycaemic patients failed to attenuate risk of severe outcomes as it did in normoglycaemic patients (P<0.009). Also, in hyperglycaemic patients, higher IL-6 plasma levels reduced the effects of TCZ, while adding IL-6 levels to the Cox regression model led to loss of significance (P<0.07) of its effects. Moreover, there was evidence that optimal Covid-19 infection management with TCZ is not achieved during hyperglycaemia in both diabetic and non-diabetic patients. These data may be of interest to currently ongoing clinical trials of TCZ effects in Covid-19 patients and of optimal control of glycaemia in this patient subset.	32447102	Diabetes & metabolism	1878-1780	10.1016/j.diabet.2020.05.005	Impacto negativo da hiperglicemia na terapia com tocilizumabe em pacientes com Covid- 	19 No entanto, apesar desta terapia, pacientes com vs. pacientes sem diabetes têm um curso adverso da doença. De fato, a homeostase da glicose influenciou os resultados de pacientes diabéticos com doenças infecciosas. Dos 475 pacientes positivos para Covid-19 admitidos em departamentos de doenças infecciosas (Universidade de Bolonha, Universidade Vanvitelli de Napoli, Hospital San Sebastiano Caserta) na Itália desde 1º de março de 2020, 31 (39,7%) pacientes hiperglicêmicos e 47 (60,3%) normoglicêmicos (níveis de glicose no sangue ≥140mg/dL) foram avaliados retrospectivamente na admissão e durante a internação. Vale ressaltar que 20 (64%) pacientes hiperglicêmicos e 11 (23,4%) normoglicêmicos apresentavam diabetes (P<0,01). Na admissão, pacientes hiperglicêmicos versus normoglicêmicos apresentavam níveis de IL-6 cinco vezes mais elevados, que persistiram mesmo após a administração de TCZ (P<0,05). Curiosamente, em uma análise de regressão de Cox ajustada ao risco, o TCZ em pacientes hiperglicêmicos não conseguiu atenuar o risco de desfechos graves como fez em pacientes normoglicêmicos (P <0,009). Além disso, em pacientes hiperglicêmicos, níveis plasmáticos mais altos de IL-6 reduziram os efeitos do TCZ, enquanto a adição de níveis de IL-6 ao modelo de regressão de Cox levou à perda de significância (P<0,07) de seus efeitos. Além disso, houve evidências de que o gerenciamento ideal da infecção por Covid-19 com TCZ não é alcançado durante a hiperglicemia em pacientes diabéticos e não diabéticos. Esses dados podem ser de interesse para os ensaios clínicos atualmente em andamento dos efeitos do TCZ em pacientes com Covid-19 e do controle ideal da glicemia neste subgrupo de pacientes.
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin	https://doi.org/10.1016/j.ijcard.2020.05.036	18/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijcard.2020.05.036	0167-5273	1675273	INTERNATIONAL JOURNAL OF CARDIOLOGY (PRINT)	A3	1.195	129	2.55	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	Therapy with hydroxychloroquine and azithromycin prolongs QTc interval in patients with COVID-19, particularly in those with high levels of transaminases. Because QTc duration remains stable during the 24 h, multiple daily ECG are not recommendable.	32439366	International journal of cardiology	1874-1754	10.1016/j.ijcard.2020.05.036	Perfil arrítmico e variabilidade do intervalo QT de 24 horas em pacientes com COVID-19 tratados com hidroxicloroquina e azitromicina A 	terapia com hidroxicloroquina e azitromicina prolonga o intervalo QTc em pacientes com COVID-19, particularmente naqueles com altos níveis de transaminases. Como a duração do QTc permanece estável durante as 24 h, múltiplos ECGs diários não são recomendáveis.
Convalescent plasma: A possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases	https://doi.org/10.1016/j.dsx.2020.05.023	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.05.023	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Plasma convalescente: um possível protocolo de tratamento para pacientes com COVID-19 que sofrem de diabetes ou doenças hepáticas subjacentes 	-
Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19	https://accpjournals.onlinelibrary.wiley.com/doi/full/10.1002/phar.2429	23/05/2020	Artigo completo publicado em periódico científico	10.1002/phar.2429	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir']	The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals. Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being evaluated in COVID-19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre-clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic β-coronaviruses, including SARS-CoV-2. In this article, we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics, and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID-19 clinical trials.	32446287	Pharmacotherapy	1875-9114	10.1002/phar.2429	Remdesivir: Revisão de farmacologia, dados pré-clínicos e experiência clínica emergente para COVID-19 	A pandemia global da doença do novo coronavírus 2019 (COVID-19) causada pelo coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) criou um necessidade de antivirais eficazes. O remdesivir (anteriormente GS-5734) é um pró-fármaco análogo de nucleosídeo atualmente sendo avaliado em ensaios clínicos de COVID-19. Suas características estruturais únicas permitem que altas concentrações do metabólito trifosfato ativo sejam entregues intracelularmente e evita a revisão para inibir com sucesso a síntese de RNA viral. Em modelos pré-clínicos, o remdesivir demonstrou potente atividade antiviral contra diversos β-coronavírus humanos e zoonóticos, incluindo SARS-CoV-2. Neste artigo, revisamos criticamente os dados disponíveis sobre o remdesivir com ênfase em bioquímica, farmacologia, farmacocinética e atividade in vitro contra coronavírus, bem como a experiência clínica e o progresso atual nos ensaios clínicos de COVID-19.
COVID-19 vaccines: knowing the unknown	https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202048663	21/05/2020	Artigo completo publicado em periódico científico	10.1002/eji.202048663	0014-2980	142980	EUROPEAN JOURNAL OF IMMUNOLOGY	A2	1.831	209	4.89	-	['Vacina', 'Vacina']	['Vaccine', 'Vaccine']	-	-	-	-	-	Vacinas COVID-19: conhecendo o desconhecido 	-
Heparin resistance in COVID-19 patients in the intensive care unit	https://doi.org/10.1007/s11239-020-02145-0	22/05/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02145-0	0929-5305	9295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Heparina']	['Heparin']	-	-	-	-	-	Resistência à heparina em pacientes com COVID-19 na unidade de terapia intensiva 	-
Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study	https://doi.org/10.1093/cid/ciaa624	22/05/2020	Artigo completo publicado em periódico científico	10.1093/cid/ciaa624	1058-4838	10584838	CLINICAL INFECTIOUS DISEASES	A1	4.394	353	8.72	 Abstract                                   Background                   Renin-angiotensin-aldosterone system (RAAS) inhibitors may facilitate host cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or attenuate organ injury via RAAS blockade. We aimed to assess the associations between prior use of RAAS inhibitors and clinical outcomes among Korean patients with coronavirus disease 2019 (COVID-19).                                                  Methods                   We performed a nationwide population-based cohort study using the Korean Health Insurance Review and Assessment database. Claim records were screened for 69 793 individuals who were tested for COVID-19 until 8 April 2020. Adjusted odds ratios (ORs) were used to compare the clinical outcomes between RAAS inhibitor users and nonusers.                                                  Results                   Among 5179 confirmed COVID-19 cases, 762 patients were RAAS inhibitor users and 4417 patients were nonusers. Relative to nonusers, RAAS inhibitor users were more likely to be older, male, and have comorbidities. Among 1954 hospitalized patients with COVID-19, 377 patients were RAAS inhibitor users, and 1577 patients were nonusers. In-hospital mortality was observed for 33 RAAS inhibitor users (9%) and 51 nonusers (3%) (P &amp;lt; .001). However, after adjustment for age, sex, Charlson comorbidity index, immunosuppression, and hospital type, the use of RAAS inhibitors was not associated with a higher risk of mortality (adjusted OR, 0.88; 95% confidence interval, 0.53–1.44; P = .60). No significant differences were observed between RAAS inhibitor users and nonusers in terms of vasopressor use, modes of ventilation, extracorporeal membrane oxygenation, renal replacement therapy, and acute cardiac events.                                                  Conclusions                   Our findings suggest that prior use of RAAS inhibitors was not independently associated with mortality among COVID-19 patients in Korea.               	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Our findings suggest that prior use of RAAS inhibitors was not independently associated with mortality among COVID-19 patients in Korea.	32442285	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	1537-6591	10.1093/cid/ciaa624	Associação de inibidores do sistema renina-angiotensina-aldosterona com desfechos relacionados ao COVID-19 na Coreia: um estudo de coorte nacional de base 	populacional
Remdesivir for the Treatment of Covid-19 — Preliminary Report	https://doi.org/10.1056/NEJMoa2007764	22/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007764	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	-	-	-	-	-	Remdesivir para o Tratamento da Covid-19 — Relatório Preliminar 	-
QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review	https://doi.org/10.1016/j.hrthm.2020.05.008	10/05/2020	Artigo completo publicado em periódico científico	10.1016/j.hrthm.2020.05.008	1547-5271	15475271	HEART RHYTHM	A2	2.402	140	4.93	-	['Cloroquina', 'Cloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Chloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Prolongamento do intervalo QT, torsades de pointes e morte súbita com cursos curtos de cloroquina ou hidroxicloroquina, conforme usado no COVID-19: uma revisão sistemática 	-
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	https://doi.org/10.1016/S0140-6736(20)31180-6	22/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31180-6	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Cloroquina', 'Hidroxicloroquina', 'Macrolídeos']	['Chloroquine', 'Hydroxychloroquine', 'Macrolides']	-	-	-	-	-	Hidroxicloroquina ou cloroquina com ou sem macrolídeo para tratamento de COVID-19: uma análise de registro multinacional 	-
Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection	https://doi.org/10.1183/13993003.00799-2020	08/05/2020	Artigo completo publicado em periódico científico	10.1183/13993003.00799-2020	0903-1936	9031936	THE EUROPEAN RESPIRATORY JOURNAL	A1	4.336	255	9.39	  Background The duration of viral shedding is central to the guidance of decisions about isolation precautions and antiviral treatment. However, studies regarding the risk factors associated with prolonged shedding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the impact of lopinavir/ritonavir (LPV/r) treatment on viral shedding remain scarce.  Methods Data were collected from all SARS-CoV-2 infected patients who were admitted to isolation wards and had reverse transcription PCR conversion at the No. 3 People's Hospital of Hubei province, China, between 31 January and 9 March 2020. We compared clinical characteristics and SARS-CoV-2 RNA shedding between patients initiated with LPV/r treatment and those without. Logistic regression analysis was employed to evaluate the risk factors associated with prolonged viral shedding.  Results Of 120 patients, the median age was 52 years, 54 (45%) were male and 78 (65%) received LPV/r treatment. The median duration of SARS-CoV-2 RNA detection from symptom onset was 23 days (interquartile range 18–32 days). Older age (OR 1.03, 95% CI 1.00–1.05; p=0.03) and the lack of LPV/r treatment (OR 2.42, 95% CI 1.10–5.36; p=0.029) were independent risk factors for prolonged SARS-CoV-2 RNA shedding. Patients who initiated LPV/r treatment within 10 days from symptom onset, but not initiated from day 11 onwards, had significantly shorter viral shedding duration compared with those without LPV/r treatment (median 19 days  versus 28.5 days; log-rank p&lt;0.001).  Conclusion Older age and the lack of LPV/r treatment were independently associated with prolonged SARS-CoV-2 RNA shedding in patients with coronavirus disease 2019 (COVID-19). Earlier administration of LPV/r treatment could shorten viral shedding duration.	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	Older age and the lack of LPV/r treatment were independently associated with prolonged SARS-CoV-2 RNA shedding in patients with coronavirus disease 2019 (COVID-19). Earlier administration of LPV/r treatment could shorten viral shedding duration.	32430428	The European respiratory journal	1399-3003	10.1183/13993003.00799-2020	Fatores associados à disseminação viral prolongada e impacto do tratamento com Lopinavir/Ritonavir em pacientes não críticos hospitalizados com infecção 	por SARS-CoV-2 pacientes com doença de coronavírus 2019 (COVID-19). A administração precoce do tratamento com LPV/r pode encurtar a duração da disseminação viral.
SARS2-CoV-2 and Stroke in a New York Healthcare System	https://www.ahajournals.org/doi/10.1161/STROKEAHA.120.030335	20/05/2020	Artigo completo publicado em periódico científico	10.1161/STROKEAHA.120.030335	0039-2499	392499	STROKE (DALLAS. 1970)	A1	3.245	330	6.52	              Background and Purpose:             With the spread of coronavirus disease 2019 (COVID-19) during the current worldwide pandemic, there is mounting evidence that patients affected by the illness may develop clinically significant coagulopathy with thromboembolic complications including ischemic stroke. However, there is limited data on the clinical characteristics, stroke mechanism, and outcomes of patients who have a stroke and COVID-19.                                  Methods:             We conducted a retrospective cohort study of consecutive patients with ischemic stroke who were hospitalized between March 15, 2020, and April 19, 2020, within a major health system in New York, the current global epicenter of the pandemic. We compared the clinical characteristics of stroke patients with a concurrent diagnosis of COVID-19 to stroke patients without COVID-19 (contemporary controls). In addition, we compared patients to a historical cohort of patients with ischemic stroke discharged from our hospital system between March 15, 2019, and April 15, 2019 (historical controls).                                  Results:                           During the study period in 2020, out of 3556 hospitalized patients with diagnosis of COVID-19 infection, 32 patients (0.9%) had imaging proven ischemic stroke. Cryptogenic stroke was more common in patients with COVID-19 (65.6%) as compared to contemporary controls (30.4%,               P              =0.003) and historical controls (25.0%,               P              &lt;0.001). When compared with contemporary controls, COVID-19 positive patients had higher admission National Institutes of Health Stroke Scale score and higher peak D-dimer levels. When compared with historical controls, COVID-19 positive patients were more likely to be younger men with elevated troponin, higher admission National Institutes of Health Stroke Scale score, and higher erythrocyte sedimentation rate. Patients with COVID-19 and stroke had significantly higher mortality than historical and contemporary controls.                                              Conclusions:             We observed a low rate of imaging-confirmed ischemic stroke in hospitalized patients with COVID-19. Most strokes were cryptogenic, possibly related to an acquired hypercoagulability, and mortality was increased. Studies are needed to determine the utility of therapeutic anticoagulation for stroke and other thrombotic event prevention in patients with COVID-19.          	['Anticoagulantes']	['Anticoagulants']	-	-	-	-	-	SARS2-CoV-2 e acidente vascular cerebral em um sistema de saúde de Nova York 	-
Adjuvant corticosteroid therapy for critically ill patients with COVID-19	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02964-w	19/05/2020	Artigo completo publicado em periódico científico	https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02964-w	1364-8535	13648535	CRITICAL CARE (LONDON. PRINT)	A1	3.218	185	8.76	-	['Corticosteroides']	['Corticosteroids']	-	-	-	-	-	Corticoterapia adjuvante para pacientes críticos com COVID-19 	-
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	https://doi.org/10.1016/S0140-6736(20)31208-3	22/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31208-3	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Ad5-nCoV']	['Ad5-nCoV']	National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.	32450106	Lancet (London, England)	1474-547X	10.1016/S0140-6736(20)31208-3	Segurança, tolerabilidade e imunogenicidade de uma vacina COVID-19 vetorizada de adenovírus recombinante do tipo 5: um ensaio de escalonamento de dose, aberto, não randomizado, primeiro em humanos 	Programa Nacional de P&D da China, Major Nacional de Ciência e Tecnologia Projeto, e CanSino Biologics.
Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry	https://doi.org/10.1053/j.gastro.2020.05.032	18/05/2020	Artigo completo publicado em periódico científico	10.1053/j.gastro.2020.05.032	0016-5085	165085	GASTROENTEROLOGY (NEW YORK, N.Y. 1943)	A1	7.689	423	10.76	-	['Antagonistas de TNF', 'Azatioprina', 'Corticosteroides', 'Mercaptopurina', 'Metotrexato']	['TNF antagonists', 'Azathioprine', 'Corticosteroids', 'Mercaptopurine', 'Methotrexate']	-	-	-	-	-	Corticosteróides, mas não antagonistas de TNF, estão associados a resultados adversos de COVID-19 em pacientes com doenças inflamatórias intestinais: resultados de um registro internacional 	-
Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome	https://doi.org/10.1161/CIRCULATIONAHA.120.046702	18/05/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.046702	0009-7322	97322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	              Background:             To investigate deep vein thrombosis (DVT) in hospitalized patients with coronavirus disease 2019 (COVID-19), we performed a single institutional study to evaluate its prevalence, risk factors, prognosis, and potential thromboprophylaxis strategies in a large referral and treatment center.                                  Methods:             We studied a total of 143 patients with COVID-19 from January 29, 2020 to February 29, 2020. Demographic and clinical data, laboratory data, including ultrasound scans of the lower extremities, and outcome variables were obtained, and comparisons were made between groups with and without DVT.                                  Results:                           Of the 143 patients hospitalized with COVID-19 (age 63±14 years, 74 [51.7%] men), 66 patients developed lower extremity DVT (46.1%: 23 [34.8%] with proximal DVT and 43 [65.2%] with distal DVT). Compared with patients who did not have DVT, patients with DVT were older and had a lower oxygenation index, a higher rate of cardiac injury, and worse prognosis, including an increased proportion of deaths (23 [34.8%] versus 9 [11.7%];               P              =0.001) and a decreased proportion of patients discharged (32 [48.5%] versus 60 [77.9%];               P              &lt;0.001). Multivariant analysis showed an association only between CURB-65 (confusion status, urea, respiratory rate, and blood pressure) score 3 to 5 (odds ratio, 6.122;               P              =0.031), Padua prediction score ≥4 (odds ratio, 4.016;               P              =0.04), D-dimer &gt;1.0 μg/mL (odds ratio, 5.818;               P              &lt;0.014), and DVT in this cohort, respectively. The combination of a CURB-65 score 3 to 5, a Padua prediction score ≥4, and D-dimer &gt;1.0 μg/mL has a sensitivity of 88.52% and a specificity of 61.43% for screening for DVT. In the subgroup of patients with a Padua prediction score ≥4 and whose ultrasound scans were performed &gt;72 hours after admission, DVT was present in 18 (34.0%) patients in the subgroup receiving venous thromboembolism prophylaxis versus 35 (66.0%) patients in the nonprophylaxis group (               P              =0.010).                                              Conclusions:             The prevalence of DVT is high and is associated with adverse outcomes in hospitalized patients with COVID-19. Prophylaxis for venous thromboembolism may be protective in patients with a Padua protection score ≥4 after admission. Our data seem to suggest that COVID-19 is probably an additional risk factor for DVT in hospitalized patients.          	['Antagonistas do Receptor da Angiotensina II', 'Antivirais', 'Heparina', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Antivirals', 'Heparin', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	The treatment of psoriasis is mainly based on anti-inflammatory and/or anti-hyperproliferative agents. The topical steroids appeared in the fifties and were the first therapeutic breakthrough for psoriasis, followed by methotrexate and phototherapy in the sixties, photochemotherapy (PUVA) in the seventies and acitretin and cyclosporine in the eighties. The targeted biologic therapies represent a whole new era of therapeutic possibilities with a highly beneficial safety record. The choice of treatment depends on a large series of factors, including the type and extend of the psoriasis, the patient's preferences, co-medications, comorbidities and drug tolerance. This overview presents the currently available topical and systemic agents for treating psoriasis, including topical corticosteroids, vitamin D derivatives, UV-light based therapies, methotrexate, cyclosporine, acitretin, and the biologic agents such as the TNF antagonists etanercept, adalimumab and infliximab, as well as the anti-p40 IL12/23 agent ustekinumab. Newer, very promising, agents aiming the Th17 pathway are under development for psoriasis. 	33523727	Circulation	1524-4539	10.1161/CIRCULATIONAHA.120.050551	Trombose Venosa Profunda em Pacientes Hospitalizados com Doença de Coronavírus 2019 (COVID-19) em Wuhan, China: Prevalência, Fatores de Risco e Resultado 	O tratamento da psoríase é baseado principalmente em agentes anti-inflamatórios e/ou anti-hiperproliferativos. Os esteróides tópicos surgiram na década de 50 e foram o primeiro avanço terapêutico para a psoríase, seguidos pelo metotrexato e fototerapia na década de 60, fotoquimioterapia (PUVA) na década de 70 e acitretina e ciclosporina na década de 80. As terapias biológicas direcionadas representam uma nova era de possibilidades terapêuticas com um histórico de segurança altamente benéfico. A escolha do tratamento depende de uma grande série de fatores, incluindo o tipo e extensão da psoríase, preferências do paciente, co-medicações, comorbidades e tolerância medicamentosa. Esta visão geral apresenta os agentes tópicos e sistêmicos atualmente disponíveis para o tratamento da psoríase, incluindo corticosteroides tópicos, derivados da vitamina D, terapias à base de luz UV, metotrexato, ciclosporina, acitretina e os agentes biológicos, como os antagonistas do TNF etanercept, adalimumabe e infliximabe, como bem como o agente anti-p40 IL12/23 ustekinumab. Agentes mais novos e muito promissores visando a via Th17 estão em desenvolvimento para a psoríase.
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care	https://doi.org/10.1016/j.jcv.2020.104444	15/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jcv.2020.104444	1386-6532	13866532	JOURNAL OF CLINICAL VIROLOGY	A3	3.355	114	10.59	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Perfil da pneumonia COVID-19 progredindo para a síndrome da tempestade de citocinas: resultados de um único estudo do Centro Italiano sobre tocilizumab versus padrão de atendimento 	-
Unique skin manifestations of COVID-19: Is drug eruption specific to COVID-19?	https://doi.org/10.1016/j.jdermsci.2020.05.002	16/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jdermsci.2020.05.002	0923-1811	9231811	JOURNAL OF DERMATOLOGICAL SCIENCE (AMSTERDAM)	A2	1.097	99	3.97	-	['Ampicilina', 'Anti-inflamatórios não esteroidais', 'Claritromicina', 'Levofloxacina', 'Prednisolona', 'Sulbactam']	['Ampicillin', 'Non-steroidal anti-inflammatory drugs', 'Clarithromycin', 'Levofloxacin', 'Prednisolone', 'Sulbactam']	In light of their ineffectiveness against COVID-19 as evident in large clinical studies, drugs including hydroxychloroquine, lopinavir/ritonavir, and ivermectin should neither be used routinely nor in clinical studies. While lack of sufficient data, it creates doubt regarding the reliability of chloroquine and favipiravir use in COVID-19 patients. Hence, these two drugs can only be used in clinical studies. In contrast, ample well-conducted studies have approved the use of remdesivir, tocilizumab, and dexamethasone under certain conditions in COVID-19 patients. Consequently, it is significant to establish a strong surveillance system in order to monitor the proper safety and toxicity profile of the potential anti-COVID-19 drugs with good clinical outcomes.	32425356	Journal of dermatological science	1873-569X	10.1016/j.jdermsci.2020.05.002	Manifestações cutâneas únicas do COVID-19: a erupção medicamentosa é específica do COVID-19? 	À luz de sua ineficácia contra o COVID-19, como evidenciado em grandes estudos clínicos, medicamentos como hidroxicloroquina, lopinavir/ritonavir e ivermectina não devem ser usados rotineiramente nem em estudos clínicos. Embora não haja dados suficientes, gera dúvidas sobre a confiabilidade do uso de cloroquina e favipiravir em pacientes com COVID-19. Portanto, esses dois medicamentos só podem ser usados em estudos clínicos. Em contraste, amplos estudos bem conduzidos aprovaram o uso de remdesivir, tocilizumabe e dexametasona sob certas condições em pacientes com COVID-19. Consequentemente, é importante estabelecer um forte sistema de vigilância para monitorar o perfil adequado de segurança e toxicidade dos potenciais medicamentos anti-COVID-19 com bons resultados clínicos.
Mesenchymal stem cell therapy in severe COVID-19: a retrospective study of short-term treatment efficacy and side effects	https://doi.org/10.1016/j.jinf.2020.05.020	15/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.05.020	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Terapia celular']	['Cell Therapy']	Off-label use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious.	32422152	The Journal of infection	1532-2742	10.1016/j.jinf.2020.05.020	Terapia com células-tronco mesenquimais no COVID-19 grave: um estudo retrospectivo da eficácia do tratamento de curto prazo e efeitos colaterais 	O uso off-label de tratamentos no COVID-19 aumenta o risco de RAMs cardíacas, algumas delas evitáveis. Mesmo que esses medicamentos sejam percebidos como familiares, eles são usados em pacientes com fatores de risco adicionais causados por infecção. Devem ser tomadas precauções para mitigar o risco, mesmo que sejam comprovadamente eficazes.
Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048360	17/05/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.048360	0009-7322	97322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	              Background:             Cardiac injury and myocarditis have been described in adults with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children is typically minimally symptomatic. We report a series of febrile pediatric patients with acute heart failure potentially associated with SARS-CoV-2 infection and the multisystem inflammatory syndrome in children as defined by the US Centers for Disease Control and Prevention.                                  Methods:             Over a 2-month period, contemporary with the SARS-CoV-2 pandemic in France and Switzerland, we retrospectively collected clinical, biological, therapeutic, and early outcomes data in children who were admitted to pediatric intensive care units in 14 centers for cardiogenic shock, left ventricular dysfunction, and severe inflammatory state.                                  Results:             Thirty-five children were identified and included in the study. Median age at admission was 10 years (range, 2–16 years). Comorbidities were present in 28%, including asthma and overweight. Gastrointestinal symptoms were prominent. Left ventricular ejection fraction was &lt;30% in one-third; 80% required inotropic support with 28% treated with extracorporeal membrane oxygenation. Inflammation markers were suggestive of cytokine storm (interleukin-6 median, 135 pg/mL) and macrophage activation (D-dimer median, 5284 ng/mL). Mean BNP (B-type natriuretic peptide) was elevated (5743 pg/mL). Thirty-one of 35 patients (88%) tested positive for SARS-CoV-2 infection by polymerase chain reaction of nasopharyngeal swab or serology. All patients received intravenous immunoglobulin, with adjunctive steroid therapy used in one-third. Left ventricular function was restored in the 25 of 35 of those discharged from the intensive care unit. No patient died, and all patients treated with extracorporeal membrane oxygenation were successfully weaned.                                  Conclusions:             Children may experience an acute cardiac decompensation caused by severe inflammatory state after SARS-CoV-2 infection (multisystem inflammatory syndrome in children). Treatment with immunoglobulin appears to be associated with recovery of left ventricular systolic function.          	['Imunoglobulina']	['Immunoglobulin']	-	-	-	-	-	Insuficiência cardíaca aguda na síndrome inflamatória multissistêmica em crianças (MIS-C) no contexto da pandemia global de SARS-CoV-2 	-
Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids	https://doi.org/10.1016/j.intimp.2020.106560	08/05/2020	Artigo completo publicado em periódico científico	10.1016/j.intimp.2020.106560	1567-5769	15675769	INTERNATIONAL IMMUNOPHARMACOLOGY (PRINT)	A2	1.059	119	5.61	-	['Anticorpos', 'Corticosteroides', 'Imunoglobulina', 'Interferon recombinante tipo 1', 'Plasma convalescente', 'Tocilizumabe']	['Antibodies', 'Corticosteroids', 'Immunoglobulin', 'Recombinant Interferon Type 1', 'Convalescent Plasma', 'Tocilizumab']	The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. Here, we will provide an overview of therapeutic options for COVID-19. Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. Evidence links COVID-19 to variable degrees of inflammation. Studies show that the use of corticosteroids might accelerate recovery from COVID-19. There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.	32413736	International immunopharmacology	1878-1705	10.1016/j.intimp.2020.106560	Para o planejamento do tratamento do COVID-19: Fundamentação e hipótese para o uso de vários agentes imunossupressores: Anti-anticorpos, imunoglobulinas e corticosteróides 	O novo coronavírus, SARS-CoV2, pode causar uma doença potencialmente fatal, COVID-19, em humanos. Aqui, forneceremos uma visão geral das opções terapêuticas para o COVID-19. O plasma de pacientes recuperados de COVID-19 que contém anticorpos contra SARS-CoV2 mostrou resultados promissores em pacientes com COVID-19 grave. Além disso, a IGIV, combinada com doses moderadas de corticosteróides, pode melhorar os resultados dos pacientes. Evidências ligam o COVID-19 a graus variáveis de inflamação. Estudos mostram que o uso de corticosteroides pode acelerar a recuperação do COVID-19. No entanto, não há ensaios clínicos controlados que mostrem se o uso de corticosteroides pode reduzir a morte relacionada ao COVID-19. Além disso, a citocina pró-inflamatória IL6 é a citocina mais bem documentada em COVID-19 correlacionada com gravidade, criticidade, carga viral e prognóstico de pacientes com COVID-19. Tocilizumab, um anticorpo monoclonal contra IL6, pode conferir benefício clínico em pacientes com altos níveis de IL6. Elementos essenciais que processam a entrada de células SARS-CoV2 e características específicas que permitem que o SARS-CoV2 escape do sistema imunológico têm potencial como alvos para a terapia COVID-19.
Advances in the Relationship Between Coronavirus Infection and Cardiovascular Diseases	https://doi.org/10.1016/j.biopha.2020.110230	13/05/2020	Artigo completo publicado em periódico científico	10.1016/j.biopha.2020.110230	0753-3322	7533322	BIOMEDICINE & PHARMACOTHERAPY	A2	1.194	109	7.17	-	['Antagonistas do Receptor da Angiotensina II', 'Antiarrítmicos', 'Antifúngicos', 'Azitromicina', 'Corticosteroides', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Levofloxacina', 'Lopinavir', 'Moxifloxacina', 'Prednisona', 'Remdesivir', 'Ritonavir']	['Angiotensin II Receptor Antagonists', 'Antiarrhythmics', 'Antifungals', 'Azithromycin', 'Corticosteroids', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Levofloxacin', 'Lopinavir', 'Moxifloxacin ', 'Prednisone', 'Remdesivir', 'Ritonavir']	-	-	-	-	-	Avanços na relação entre infecção por coronavírus e doenças cardiovasculares 	-
A late onset widespread skin rash in a previous Covid-19 infected patient: viral or multidrug effect?	https://doi.org/10.1111/jdv.16633	18/05/2020	Artigo completo publicado em periódico científico	10.1111/jdv.16633	0926-9959	9269959	JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY	A1	1.613	116	3.95	-	['Anti-histamínicos', 'Antibióticos', 'Anticoagulantes', 'Antivirais', 'Esteroides']	['Antihistamines', 'Antibiotics', 'Anticoagulants', 'Antivirals', 'Steroidal']	-	-	-	-	-	Uma erupção cutânea generalizada de início tardio em um paciente anterior infectado por Covid-19: efeito viral ou multidrogas? 	-
Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report	https://doi.org/10.1016/j.ijid.2020.05.050	15/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.05.050	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra', 'Anakinra', 'Remdesivir', 'Remdesivir']	['Anakinra', 'Anakinra', 'Remdesivir', 'Remdesivir']	We report the first successful treatment with the IL-1 receptor antagonist anakinra, in association with the most promising and available antiviral therapy, of a severe case of novel coronavirus disease 2019 (COVID-19). We describe the diagnosis, clinical course, and management of the case, including the respiratory failure at presentation, the progression to a scenario characterized by profound inflammatory dysregulation similar to that observed during macrophage activation syndrome, and the clinical improvement after treatment with the IL-1 receptor antagonist anakinra. This case highlights the high tolerability and the interesting immunomodulatory profile of the IL-1 receptor antagonist anakinra in the setting of severe COVID-19 associated with remdesivir therapy. Further studies are needed to confirm the safety and efficacy of this combination strategy in the treatment of this emerging infection.	32422376	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	1878-3511	10.1016/j.ijid.2020.05.050	Antagonista do receptor de interleucina-1 anakinra em associação com remdesivir na doença grave de Coronavírus 2019: Relato de caso Relatamos 	o primeiro tratamento bem sucedido com o antagonista do receptor de IL-1 anakinra, em associação com a terapia antiviral mais promissora e disponível, de um caso grave de doença do novo coronavírus 2019 (COVID-19). Descrevemos o diagnóstico, o curso clínico e o manejo do caso, incluindo a insuficiência respiratória na apresentação, a progressão para um quadro caracterizado por desregulação inflamatória profunda semelhante à observada durante a síndrome de ativação macrofágica e a melhora clínica após o tratamento com IL- 1 antagonista do receptor anakinra. Este caso destaca a alta tolerabilidade e o interessante perfil imunomodulador do antagonista do receptor de IL-1 anakinra no cenário de COVID-19 grave associado à terapia com remdesivir. Mais estudos são necessários para confirmar a segurança e eficácia desta estratégia de combinação no tratamento desta infecção emergente.
COVID-19 infection in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab	https://doi.org/10.1016/j.jaci.2020.05.005	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.005	0091-6749	916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Dupilumabe']	['Dupilumab']	-	-	-	-	-	Infecção por COVID-19 em paciente com rinossinusite crônica grave com pólipos nasais durante terapia com dupilumabe 	-
Early experience with remdesivir in SARS-CoV-2 pneumonia	https://link.springer.com/article/10.1007/s15010-020-01448-x	16/05/2020	Artigo completo publicado em periódico científico	https://link.springer.com/article/10.1007/s15010-020-01448-x	0300-8126	3008126	INFECTION	A4	1.119	80	4.01	-	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Experiência inicial com remdesivir na pneumonia por SARS-CoV-2 	-
Coronavirus disease 2019 in renal transplant recipients: report of two cases	https://doi.org/10.1111/tid.13329	16/05/2020	Artigo completo publicado em periódico científico	10.1111/tid.13329	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Prednisona']	['Prednisone']	-	-	-	-	-	Doença por coronavírus 2019 em receptores de transplante renal: relato de dois casos 	-
A Case of Coronavirus Disease 2019 Treated With Ciclesonide	https://doi.org/10.1016/j.mayocp.2020.04.007	15/04/2020	Artigo completo publicado em periódico científico	10.1016/j.mayocp.2020.04.007	0025-6196	256196	MAYO CLINIC PROCEEDINGS	A1	2.186	191	4.51	-	['Ciclesonida']	['Cyclesonide']	-	-	-	-	-	Um caso de doença de coronavírus 2019 tratado com ciclesonida 	-
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran	https://doi.org/10.1016/j.msard.2020.102195	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102195	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Imunomoduladores', 'Imunomoduladores', 'Imunossupressores', 'Imunossupressores']	['Immunomodulators', 'Immunomodulators', 'Immunosuppressants', 'Immunosuppressants']	The course of infection in patients with MS suspected of having COVID-19 was mild to moderate, and all patients had a full recovery. B-cell depleting antibodies may increase the susceptibility to contracting COVID-19.	32460086	Multiple sclerosis and related disorders	2211-0356	10.1016/j.msard.2020.102195	Terapias de depleção de células B podem afetar a suscetibilidade à doença respiratória aguda entre pacientes com esclerose múltipla durante a epidemia inicial de COVID-19 no Irã 	O curso da infecção em pacientes com EM com suspeita de COVID-19 foi leve a moderado e todos os pacientes tiveram recuperação total. Anticorpos de depleção de células B podem aumentar a suscetibilidade de contrair COVID-19.
First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study	https://doi.org/10.1111/ajt.16062	15/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.16062	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	-	-	-	-	-	Primeira experiência de infecções por SARS-CoV-2 em receptores de transplante de órgãos sólidos no Swiss Transplant Cohort Study 	-
Complement activation in patientswith COVID-19: A novel therapeutictarget	https://doi.org/10.1016/j.jaci.2020.05.006	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.jaci.2020.05.006	0091-6749	916749	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY	A1	3.810	307	8.93	-	['Sistema complemento']	['Add-on system']	-	-	-	-	-	Ativação do complemento em pacientes com COVID-19: um novo alvo terapêutico 	-
The role of passive immunization in the age of SARS‑CoV‑2: an update	https://doi.org/10.1186/s40001-020-00414-5	13/05/2020	Artigo completo publicado em periódico científico	10.1186/s40001-020-00414-5	2047-783X	2047783X	EUROPEAN JOURNAL OF MEDICAL RESEARCH	A3	0.725	60	3.84	 Abstract The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.	['Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente']	['Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma', 'Convalescent plasma']	-	-	-	-	-	O papel da imunização passiva na era do SARS-CoV-2: uma atualização 	-
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19	http://doi.org/10.1016/j.msard.2020.102182	07/05/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102182	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Um bom equilíbrio: imunossupressão e imunoterapia em um paciente com esclerose múltipla e COVID-19 	-
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic	https://doi.org/10.1016/j.sapharm.2020.04.031	30/04/2020	Artigo completo publicado em periódico científico	10.1016/j.sapharm.2020.04.031	1551-7411	15517411	RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY	A3	0.674	54	2.88	-	['Amoxicilina', 'Azitromicina', 'Cloroquina']	['Amoxicillin', 'Azithromycin', 'Chloroquine']	Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions.	32409150	Research in social & administrative pharmacy : RSAP	1934-8150	10.1016/j.sapharm.2020.04.031	Uma avaliação do uso concomitante de cloroquina ou hidroxicloroquina mais azitromicina em desfechos cardíacos: um estudo farmacoepidemiológico para informar o uso durante a pandemia de COVID19 O 	uso combinado de cloroquina e azitromicina em doses de rotina não mostrou aumentos pronunciados nas arritmias nesta população do mundo real, embora o pequeno tamanho da amostra e as taxas de resultados limitam as conclusões.
Clinical characteristics and drug therapies in patients with the common‑type coronavirus disease 2019 in Hunan, China	https://doi.org/10.1007/s11096-020-01031-2	14/05/2020	Artigo completo publicado em periódico científico	10.1007/s11096-020-01031-2	2210-7703	22107703	INTERNATIONAL JOURNAL OF CLINICAL PHARMACY	A4	0.501	63	2.41	-	['Corticosteroides', 'Fluoroquinolona', 'Interferon alfa', 'Lopinavir', 'Novaferon', 'Ritonavir']	['Corticosteroids', 'Fluoroquinolone', 'Interferon alpha', 'Lopinavir', 'Novaferon', 'Ritonavir']	-	-	-	-	-	Características clínicas e terapias medicamentosas em pacientes com a doença de coronavírus do tipo comum 2019 em Hunan, China 	-
Compassionate  remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status	https://doi.org/10.1016/j.phrs.2020.104899	11/05/2020	Artigo completo publicado em periódico científico	10.1016/j.phrs.2020.104899	1043-6618	10436618	PHARMACOLOGICAL RESEARCH	A1	1.738	147	8.88	-	['Remdesivir']	['Remdesivir']	SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses and is a possible antiviral treatment for SARS-CoV-2 infection. This prospective (compassionate), open-label study of remdesivir, which was conducted at Luigi Sacco Hospital, Milan, Italy, between February 23 and March 20, 2020, involved patients with SARS-CoV-2 pneumonia aged ≥18 years undergoing mechanical ventilation or with an oxygen saturation level of ≤94 % in air or a National Early Warning Score 2 of ≥4. The primary outcome was the change in clinical status based on a 7-category ordinal scale (1 = not hospitalised, resuming normal daily activities; 7 = deceased). The 35 patients enrolled from February 23 to March 20, 2020, included 18 in intensive care unit (ICU), and 17 in our infectious diseases ward (IDW). The 10-day course of remdesivir was completed by 22 patients (63 %) and discontinued by 13, of whom eight (22.8 %) discontinued because of adverse events. The median follow-up was 39 days (IQR 25-44). At day 28, 14 (82.3 %) patients from IDW were discharged, two were still hospitalized and one died (5.9 %), whereas in ICU 6 (33.3 %) were discharged, 8 (44.4 %) patients died, three (16.7 %) were still mechanically ventilated and one (5.6 %) was improved but still hospitalized. Hypertransaminasemia and acute kidney injury were the most frequent severe adverse events observed (42.8 % and 22.8 % of the cases, respectively). Our data suggest that remdesivir can benefit patients with SARS-CoV-2 pneumonia hospitalised outside ICU where clinical outcome was better and adverse events are less frequently observed. Ongoing randomised controlled trials will clarify its real efficacy and safety, who to treat, and when.	32407959	Pharmacological research	1096-1186	10.1016/j.phrs.2020.104899	Tratamento compassivo com remdesivir de pneumonia grave por Covid-19 em pacientes de unidade de terapia intensiva (UTI) e não-UTI: resultado clínico e diferenças no status de hospitalização pós-tratamento 	SARS-CoV-2 está causando um número crescente de mortes em todo o mundo porque nenhum tratamento eficaz é disponível atualmente. O remdesivir mostrou atividade in vitro contra os coronavírus e é um possível tratamento antiviral para a infecção por SARS-CoV-2. Este estudo prospectivo (compassivo), aberto de remdesivir, realizado no Hospital Luigi Sacco, Milão, Itália, entre 23 de fevereiro e 20 de março de 2020, envolveu pacientes com pneumonia por SARS-CoV-2 com idade ≥18 anos em ventilação mecânica ou com um nível de saturação de oxigênio ≤94% no ar ou um National Early Warning Score 2 de ≥4. O desfecho primário foi a mudança no estado clínico com base em uma escala ordinal de 7 categorias (1 = não hospitalizado, retomando as atividades diárias normais; 7 = falecido). Os 35 pacientes matriculados de 23 de fevereiro a 20 de março de 2020, incluíram 18 na unidade de terapia intensiva (UTI) e 17 em nossa enfermaria de doenças infecciosas (IDW). O curso de 10 dias de remdesivir foi concluído por 22 pacientes (63%) e descontinuado por 13, dos quais oito (22,8%) descontinuaram devido a eventos adversos. O acompanhamento médio foi de 39 dias (IQR 25-44). No dia 28, 14 (82,3%) pacientes do IDW receberam alta, dois ainda estavam internados e um faleceu (5,9%), enquanto na UTI 6 (33,3%) receberam alta, 8 (44,4%) pacientes morreram, três (16,7%) ) ainda foram ventilados mecanicamente e um (5,6%) melhorou, mas ainda hospitalizado. Hipertransaminasemia e lesão renal aguda foram os eventos adversos graves mais frequentes observados (42,8% e 22,8% dos casos, respectivamente). Nossos dados sugerem que o remdesivir pode beneficiar pacientes com pneumonia por SARS-CoV-2 hospitalizados fora da UTI, onde o resultado clínico foi melhor e os eventos adversos são observados com menos frequência. Ensaios controlados randomizados em andamento esclarecerão sua real eficácia e segurança, quem tratar e quando.
Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19?	https://doi.org/10.7326/M20-1998	18/05/2020	Artigo completo publicado em periódico científico	10.7326/M20-1998	0003-4819	34819	ANNALS OF INTERNAL MEDICINE	A1	4.621	403	6.43	-	['Azitromicina', 'Cloroquina', 'Hidroxicloroquina']	['Azithromycin', 'Chloroquine', 'Hydroxychloroquine']	-	-	-	-	-	Os médicos devem usar cloroquina ou hidroxicloroquina isoladamente ou em combinação com azitromicina para a profilaxia ou tratamento do COVID-19? 	-
Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies	https://doi.org/10.1016/j.dsx.2020.05.018	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.05.018	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Remdesivir']	['Remdesivir']	Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials.	32428865	Diabetes & metabolic syndrome	1878-0334	10.1016/j.dsx.2020.05.018	Remdesivir no COVID-19: Uma revisão crítica de estudos farmacológicos, pré-clínicos e clínicos 	O remdesivir mostrou um resultado misto em pacientes com COVID-19 com um efeito colateral aceitável. No entanto, o júri ainda está fora enquanto aguarda os resultados dos próximos julgamentos.
Combating COVID-19 with Mesenchymal Stem Cell therapy	https://doi.org/10.1016/j.btre.2020.e00467	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.btre.2020.e00467	2215-017X	2215017X	BIOTECHNOLOGY REPORTS	A2	0.854	43	6.09	-	['Terapia celular']	['Cell Therapy']	-	-	-	-	-	Combate ao COVID-19 com terapia com células-tronco mesenquimais 	-
Allogeneic cardiosphere‐derived cells (CAP‐1002) in critically ill COVID‐19 patients: compassionate‐use case series	https://doi.org/10.1007/s00395-020-0795-1	12/05/2020	Artigo completo publicado em periódico científico	10.1007/s00395-020-0795-1	0300-8428	3008428	BASIC RESEARCH IN CARDIOLOGY (PRINT)	A1	1.615	100	11.01	 Abstract There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients ( n = 6; age range 19–75 years, 1 female) required ventilatory support (invasive mechanical ventilation,  n = 5) with PaO 2/FiO 2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients ( n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43–2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89–1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26–0.82 × 10 3/µl) but had increased in three of these five patients at last follow-up (range 0.23–1.02 × 10 3/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.	['Terapia celular']	['Cell Therapy']	-	-	-	-	-	Células derivadas de cardiosfera alogênica (CAP-1002) em pacientes criticamente doentes com COVID-19: série de casos de uso compassivo 	-
Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report	https://onlinelibrary.wiley.com/doi/10.1111/ajt.15985	02/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.15985	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Curso Clínico de COVID-19 em Receptor de Transplante Hepático em Hemodiálise e Resposta à Terapia com Tocilizumabe: Relato de Caso 	-
Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis	https://doi.org/10.1016/j.chom.2020.05.007	14/05/2020	Artigo completo publicado em periódico científico	10.1016/j.chom.2020.05.007	1931-3128	19313128	CELL HOST & MICROBE	A1	9.373	201	19.72	-	['Anakinra', 'Anakinra', 'Anakinra']	['Anakinra', 'Anakinra', 'Anakinra']	-	-	-	-	-	Respostas favoráveis de anakinra em pacientes graves com COVID-19 com linfohistiocitose hemofagocítica secundária 	-
Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study	https://doi.org/10.1016/S0140-6736(20)31030-8	14/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31030-8	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Renin-Angiotensin-Aldosterone System Inhibitors (ISRAA)']	Instituto de Salud Carlos III.	32416785	Lancet (London, England)	1474-547X	10.1016/S0140-6736(20)31030-8	Uso de inibidores do sistema renina-angiotensina-aldosterona e risco de COVID-19 requerendo internação hospitalar: um estudo caso-população 	Instituto de Salud Carlos III.
Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis	https://doi.org/10.1016/j.dsx.2020.05.017	12/05/2020	Artigo completo publicado em periódico científico	10.1016/j.dsx.2020.05.017	1871-4021	18714021	DIABETES & METABOLIC SYNDROME (PRINT)	A3	1.587	56	7.53	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Hidroxicloroquina em pacientes com COVID-19: uma revisão sistemática e meta-análise 	-
SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors	https://doi.org/10.1016/S2213-2600(20)30224-1	13/05/2020	Artigo completo publicado em periódico científico	10.1016/S2213-2600(20)30224-1	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Expressão do gene ACE2 do receptor SARS-CoV-2 e inibidores de RAAS 	-
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury	https://www.nejm.org/doi/full/10.1056/NEJMcpc2002418	13/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMcpc2002418	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Anticoagulantes', 'Cloroquina', 'Favipiravir', 'Hidroxicloroquina', 'Remdesivir', 'Tocilizumabe']	['Anticoagulants', 'Chloroquine', 'Favipiravir', 'Hydroxychloroquine', 'Remdesivir', 'Tocilizumab']	The emerging coronavirus disease (COVID-19) swept across the world, affecting more than 200 countries and territories. Genomic analysis suggests that the COVID-19 virus originated in bats and transmitted to humans through unknown intermediate hosts in the Wuhan seafood market, China, in December of 2019. This virus belongs to the 	32402156	The New England journal of medicine	1533-4406	10.1056/NEJMcpc2002418	Caso 17-2020: Um homem de 68 anos com Covid-19 e lesão renal aguda 	A doença emergente do coronavírus (COVID-19) varreu o mundo, afetando mais de 200 países e territórios. A análise genômica sugere que o vírus COVID-19 se originou em morcegos e foi transmitido a humanos por meio de hospedeiros intermediários desconhecidos no mercado de frutos do mar de Wuhan, China, em dezembro de 2019.
Use of anakinra in severe COVID-19: a case report	https://doi.org/10.1016/j.ijid.2020.05.026	10/05/2020	Artigo completo publicado em periódico científico	10.1016/j.ijid.2020.05.026	1201-9712	12019712	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES	A3	2.433	104	9.39	-	['Anakinra']	['Anakinra']	-	-	-	-	-	Uso de anakinra em COVID-19 grave: relato de caso 	-
COVID‐19 in people living with human immunodefciency virus: a case series of 33 patients	https://doi.org/10.1007/s15010-020-01438-z	11/05/2020	Artigo completo publicado em periódico científico	10.1007/s15010-020-01438-z	0300-8126	3008126	INFECTION	A4	1.119	80	4.01	-	['Darunavir', 'Emtricitabina', 'Lamivudina', 'Ritonavir', 'Tenofovir']	['Darunavir', 'Emtricitabine', 'Lamivudine', 'Ritonavir', 'Tenofovir']	-	-	-	-	-	COVID-19 em pessoas vivendo com o vírus da imunodeficiência humana: uma série de casos de 33 pacientes 	-
A global treatments for coronaviruses including COVID-19	https://doi.org/10.1002/jcp.29785	11/05/2020	Artigo completo publicado em periódico científico	10.1002/jcp.29785	0021-9541	219541	JOURNAL OF CELLULAR PHYSIOLOGY (PRINT)	A2	1.308	183	6.77	-	['Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Ribavirina', 'Ritonavir', 'Teicoplanina', 'Umifenovir']	['Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Ribavirin', 'Ritonavir', 'Teicoplanin', 'Umifenovir']	-	-	-	-	-	Tratamentos globais para coronavírus, incluindo COVID-19 	-
Plasmapheresis treatment in COVID-19–related autoimmune meningoencephalitis: Case series	https://doi.org/10.1016/j.bbi.2020.05.022	07/05/2020	Artigo completo publicado em periódico científico	10.1016/j.bbi.2020.05.022	0889-1591	8891591	BRAIN, BEHAVIOR, AND IMMUNITY	A1	3.046	170	12.52	-	['Plasmaferese']	['Plasmapheresis']	Severe SARS-CoV-2 (COVID-19) infection has the potential for a high mortality rate. In this paper, we report the results of plasmapheresis treatment in a series of severely ill patients with COVID-19-related autoimmune meningoencephalitis in the Intensive Care Unit (ICU).	32389697	Brain, behavior, and immunity	1090-2139	10.1016/j.bbi.2020.05.022	Tratamento com plasmaférese na meningoencefalite autoimune relacionada ao COVID-19: Série de casos 	A infecção grave por SARS-CoV-2 (COVID-19) tem potencial para uma alta taxa de mortalidade. Neste artigo, relatamos os resultados do tratamento com plasmaferese em uma série de pacientes gravemente enfermos com meningoencefalite autoimune relacionada à COVID-19 na Unidade de Terapia Intensiva (UTI).
Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units	https://doi.org/10.1001/jamapediatrics.2020.1948	11/05/2020	Artigo completo publicado em periódico científico	10.1001/jamapediatrics.2020.1948	2168-6203	21686203	JAMA PEDIATRICS (PRINT)	A1	3.450	196	5.81	-	['Azitromicina', 'Hidroxicloroquina', 'Plasma convalescente', 'Remdesivir', 'Tocilizumabe']	['Azithromycin', 'Hydroxychloroquine', 'Convalescent Plasma', 'Remdesivir', 'Tocilizumab']	This early report describes the burden of COVID-19 infection in North American PICUs and confirms that severe illness in children is significant but far less frequent than in adults. Prehospital comorbidities appear to be an important factor in children. These preliminary observations provide an important platform for larger and more extensive studies of children with COVID-19 infection.	32392288	JAMA pediatrics	2168-6211	10.1001/jamapediatrics.2020.1948	Características e resultados de crianças com infecção por coronavírus 2019 (COVID-19) admitidas em unidades de terapia intensiva pediátrica dos EUA e 	Canadá menos frequente do que em adultos. As comorbidades pré-hospitalares parecem ser um fator importante em crianças. Essas observações preliminares fornecem uma plataforma importante para estudos maiores e mais extensos de crianças com infecção por COVID-19.
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach	https://doi.org/10.1016/j.msard.2020.102165	30/04/2020	Artigo completo publicado em periódico científico	10.1016/j.msard.2020.102165	2211-0348	22110348	MULTIPLE SCLEROSIS AND RELATED DISORDERS	A3	1.006	45	3.6	-	['Natalizumabe']	['Natalizumab']	-	-	-	-	-	COVID-19 ocorrendo durante o tratamento com Natalizumabe: relato de caso em paciente com abordagem de dosagem de intervalo estendido 	-
Early Experience of COVID-19 in Two Heart Transplant Recipients: Case Reports and Review of Treatment Options	https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.15982	07/05/2020	Artigo completo publicado em periódico científico	10.1111/ajt.15982	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Hidroxicloroquina', 'Imunoglobulina', 'Lopinavir', 'Prednisona', 'Ritonavir', 'Tocilizumabe']	['Hydroxychloroquine', 'Immunoglobulin', 'Lopinavir', 'Prednisone', 'Ritonavir', 'Tocilizumab']	-	-	-	-	-	Experiência inicial de COVID-19 em dois receptores de transplante cardíaco: relatos de casos e revisão de opções de tratamento 	-
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy	https://doi.org/10.1016/j.autrev.2020.102568	03/05/2020	Artigo completo publicado em periódico científico	10.1016/j.autrev.2020.102568	1568-9972	15689972	AUTOIMMUNITY REVIEWS	A1	3.168	130	11.48	-	['Tocilizumabe']	['Tocilizumab']	A hyperinflammatory syndrome (HIS) may cause a life-threatening acute respiratory distress syndrome (ARDS) in patients with COVID-19 pneumonia. A prospective series of 100 consecutive patients admitted to the Spedali Civili University Hospital in Brescia (Italy) between March 9th and March 20th with confirmed COVID-19 pneumonia and ARDS requiring ventilatory support was analyzed to determine whether intravenous administration of tocilizumab (TCZ), a monoclonal antibody that targets the interleukin 6 (IL-6) receptor, was associated with improved outcome. Tocilizumab was administered at a dosage of 8 mg/kg by two consecutive intravenous infusions 12 h apart. A third infusion was optional based on clinical response. The outcome measure was an improvement in acute respiratory failure assessed by means of the Brescia COVID Respiratory Severity Score (BCRSS 0 to 8, with higher scores indicating higher severity) at 24-72 h and 10 days after tocilizumab administration. Out of 100 treated patients (88 M, 12 F; median age: 62 years), 43 received TCZ in the intensive care unit (ICU), while 57 in the general ward as no ICU beds were available. Of these 57 patients, 37 (65%) improved and suspended noninvasive ventilation (NIV) (median BCRSS: 1 [IQR 0-2]), 7 (12%) patients remained stable in NIV, and 13 (23%) patients worsened (10 died, 3 were admitted to ICU). Of the 43 patients treated in the ICU, 32 (74%) improved (17 of them were taken off the ventilator and were discharged to the ward), 1 (2%) remained stable (BCRSS: 5) and 10 (24%) died (all of them had BCRSS≥7 before TCZ). Overall at 10 days, the respiratory condition was improved or stabilized in 77 (77%) patients, of whom 61 showed a significant clearing of diffuse bilateral opacities on chest x-ray and 15 were discharged from the hospital. Respiratory condition worsened in 23 (23%) patients, of whom 20 (20%) died. All the patients presented with lymphopenia and high levels of C-reactive protein (CRP), fibrinogen, ferritin and IL-6 indicating a HIS. During the 10-day follow-up, three cases of severe adverse events were recorded: two patients developed septic shock and died, one had gastrointestinal perforation requiring urgent surgery and was alive at day 10. In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized by HIS. The response to TCZ was rapid, sustained, and associated with significant clinical improvement.	32376398	Autoimmunity reviews	1873-0183	10.1016/j.autrev.2020.102568	Tocilizumab para o tratamento de pneumonia grave por COVID-19 com síndrome hiperinflamatória e insuficiência respiratória aguda: Um estudo de centro único de 100 pacientes em Brescia, Itália 	Uma síndrome hiperinflamatória (HIS) pode causar uma síndrome do desconforto respiratório agudo (SDRA) com risco de vida em pacientes com pneumonia por COVID-19. Uma série prospectiva de 100 pacientes consecutivos internados no Hospital Universitário Spedali Civili em Brescia (Itália) entre 9 e 20 de março com pneumonia confirmada por COVID-19 e SDRA com necessidade de suporte ventilatório foi analisada para determinar se a administração intravenosa de tocilizumab (TCZ), um anticorpo monoclonal que tem como alvo o receptor de interleucina 6 (IL-6), foi associado a um melhor resultado. Tocilizumab foi administrado na dose de 8 mg/kg por duas infusões intravenosas consecutivas com 12 h de intervalo. Uma terceira infusão era opcional com base na resposta clínica. A medida de resultado foi uma melhora na insuficiência respiratória aguda avaliada por meio do Brescia COVID Respiratory Severity Score (BCRSS 0 a 8, com pontuações mais altas indicando maior gravidade) em 24-72 h e 10 dias após a administração de tocilizumab. Dos 100 pacientes tratados (88 M, 12 F; idade mediana: 62 anos), 43 receberam TCZ na unidade de terapia intensiva (UTI), enquanto 57 na enfermaria geral, pois não havia leitos de UTI disponíveis. Destes 57 pacientes, 37 (65%) melhoraram e suspenderam a ventilação não invasiva (VNI) (mediana BCRSS: 1 [IQR 0-2]), 7 (12%) pacientes permaneceram estáveis em VNI e 13 (23%) pacientes pioraram (10 morreram, 3 foram internados na UTI). Dos 43 pacientes atendidos na UTI, 32 (74%) melhoraram (17 deles foram retirados do ventilador e receberam alta para a enfermaria), 1 (2%) permaneceu estável (BCRSS: 5) e 10 (24%) morreram (todos tinham BCRSS≥7 antes do TCZ). Em geral, em 10 dias, a condição respiratória melhorou ou estabilizou em 77 (77%) pacientes, dos quais 61 apresentaram uma resolução significativa de opacidades bilaterais difusas na radiografia de tórax e 15 receberam alta hospitalar. A condição respiratória piorou em 23 (23%) pacientes, dos quais 20 (20%) morreram. Todos os pacientes apresentavam linfopenia e níveis elevados de proteína C reativa (PCR), fibrinogênio, ferritina e IL-6 indicando SIH. Durante o seguimento de 10 dias, três casos de eventos adversos graves foram registrados: dois pacientes desenvolveram choque séptico e morreram, um teve perfuração gastrointestinal com necessidade de cirurgia de urgência e estava vivo no dia 10. Em conclusão, nossa série mostrou que o COVID-19 pneumonia com SDRA foi caracterizada por HIS. A resposta ao TCZ foi rápida, sustentada e associada a melhora clínica significativa.
Triple combination of interferon beta-1b , lopinavir – ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial	http://dx.doi.org/10.1016/S0140-6736(20)31042-4	08/05/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)31042-4	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Interferon beta', 'Lopinavir', 'Ribavirina', 'Ritonavir']	['Interferon beta', 'Lopinavir', 'Ribavirin', 'Ritonavir']	The Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine.	32401715	Lancet (London, England)	1474-547X	10.1016/S0140-6736(20)31042-4	Combinação tripla de interferon beta-1b, lopinavir – ritonavir e ribavirina no tratamento de pacientes internados com COVID-19: um estudo aberto, randomizado, fase 2 	The Shaw-Foundation, Richard e Carol Yu, May Tam Mak Mei Yin e Projeto Sanming de Medicina.
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19	https://www.nejm.org/doi/full/10.1056/nejmoa2012410	07/05/2020	Artigo completo publicado em periódico científico	10.1056/nejmoa2012410	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Estudo observacional da hidroxicloroquina em pacientes hospitalizados com Covid-19 	-
Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2	https://doi.org/10.1111/bph.15092	05/05/2020	Artigo completo publicado em periódico científico	10.1111/bph.15092	0007-1188	71188	BRITISH JOURNAL OF PHARMACOLOGY	A1	1.993	223	8.41	-	['Antagonistas do Receptor da Angiotensina II', 'Camostato', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)', 'Lopinavir', 'Medicina Tradicional Chinesa', 'Meplazumabe', 'Metuximabe', 'Metuzumabe', 'Plasma convalescente', 'Proteína spike', 'Ribavirina', 'Ritonavir', 'Soro convalescente', 'Tocilizumabe', 'Vacina']	['Angiotensin II Receptor Antagonists', 'Camostat', 'Transmembrane Serine Protease Inhibitor 2 (TMPRSS2)', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors', 'Lopinavir', 'Traditional Chinese Medicine', 'Meplazumab', 'Metuximab', 'Metuzumab', 'Convalescent plasma', 'Spike protein', 'Ribavirin', 'Ritonavir', 'Convalescent serum', 'Tocilizumab', 'Vaccine']	-	-	-	-	-	Potenciais Alvos Terapêuticos e Medicamentos Promissores para Combater o SARS-CoV-2 	-
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061cases in Marseille, France	https://doi.org/10.1016/j.tmaid.2020.101738	05/05/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101738	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	-	-	-	-	-	Tratamento precoce de pacientes com COVID-19 com hidroxicloroquina e azitromicina: uma análise retrospectiva de 1061 casos em Marselha, França 	-
Evidence for Use or Disuse of Renin–Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder	https://journals.sagepub.com/doi/10.1177/1074248420921720	30/04/2020	Artigo completo publicado em periódico científico	10.1177/1074248420921720	1074-2484	10742484	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS	A2	0.685	52	2.63	  Coronavirus disease 19 (COVID-19) originated in Wuhan, China, in December 2019 has been declared pandemic by World Health Organization due to an exponential rise in the number of infected and deceased persons across the globe. Emerging reports suggest that susceptibility and mortality rates are higher in patients with certain comorbidities when compared to the average population. Cardiovascular diseases and diabetes are important risk factors for a lethal outcome of COVID-19. Extensive research ensuing the outbreak of coronavirus-related severe acute respiratory syndrome in the year 2003, and COVID-19 recently revealed a role of renin–angiotensin system (RAS) components in the entry of coronavirus wherein angiotensin-converting enzyme 2 (ACE2) had garnered the significant attention. This raises the question whether the use of RAS inhibitors, the backbone of treatment of cardiovascular, neurovascular, and kidney diseases could increase the susceptibility for coronavirus infection or unfortunate outcomes of COVID-19. Thus, currently, there is a lack of consensus regarding the effects of RAS inhibitors in such patients. Moreover, expert bodies like American Heart Association, American College of Cardiology, and so on have now released official statements that RAS inhibitors must be continued, unless suggested otherwise by a physician. In this brief review, we will elaborate on the role of RAS and ACE2 in pathogenesis of COVID-19. Moreover, we will discuss the potential effect of the use and disuse of RAS inhibitors in patients having COVID-19 with cardiometabolic comorbidities. 	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Evidência para uso ou desuso de moduladores do sistema renina-angiotensina em pacientes com COVID-19 com um distúrbio cardiorrenal subjacente 	-
Rethinking the role of hydroxychloroquine in the treatment of COVID-19	https://faseb.onlinelibrary.wiley.com/doi/10.1096/fj.202000919	29/04/2020	Artigo completo publicado em periódico científico	10.1096/fj.202000919	0892-6638	8926638	THE FASEB JOURNAL	A1	1.385	287	5.11	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	There are currently no proven or approved treatments for coronavirus disease 2019 (COVID-19). Early anecdotal reports and limited in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease. As an increasing number of patients with COVID-19 are treated with these agents and more evidence accumulates, there continues to be no high-quality clinical data showing a clear benefit of these agents for this disease. Moreover, these agents have the potential to cause harm, including a broad range of adverse events including serious cardiac side effects when combined with other agents. In addition, the known and potent immunomodulatory effects of these agents which support their use in the treatment of auto-immune conditions, and provided a component in the original rationale for their use in patients with COVID-19, may, in fact, undermine their utility in the context of the treatment of this respiratory viral infection. Specifically, the impact of HCQ on cytokine production and suppression of antigen presentation may have immunologic consequences that hamper innate and adaptive antiviral immune responses for patients with COVID-19. Similarly, the reported in vitro inhibition of viral proliferation is largely derived from the blockade of viral fusion that initiates infection rather than the direct inhibition of viral replication as seen with nucleoside/tide analogs in other viral infections. Given these facts and the growing uncertainty about these agents for the treatment of COVID-19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease. In this article, we review the datasets that support or detract from the use of these agents for the treatment of COVID-19 and render a data informed opinion that they should only be used with caution and in the context of carefully thought out clinical trials, or on a case-by-case basis after rigorous consideration of the risks and benefits of this therapeutic approach.	32350928	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	1530-6860	10.1096/fj.202000919	Repensando o papel da hidroxicloroquina no tratamento da COVID-19 	Atualmente, não há tratamentos comprovados ou aprovados para a doença de coronavírus 2019 (COVID-19). Relatórios anedóticos iniciais e dados in vitro limitados levaram à absorção significativa de hidroxicloroquina (HCQ) e, em menor grau, cloroquina (CQ), para muitos pacientes com esta doença. À medida que um número crescente de pacientes com COVID-19 é tratado com esses agentes e mais evidências se acumulam, continua a não haver dados clínicos de alta qualidade mostrando um benefício claro desses agentes para essa doença. Além disso, esses agentes têm o potencial de causar danos, incluindo uma ampla gama de eventos adversos, incluindo efeitos colaterais cardíacos graves quando combinados com outros agentes. Além disso, os efeitos imunomoduladores conhecidos e potentes desses agentes, que apoiam seu uso no tratamento de doenças autoimunes e constituíram um componente na justificativa original para seu uso em pacientes com COVID-19, podem, de fato, prejudicar sua utilidade no contexto do tratamento desta infecção viral respiratória. Especificamente, o impacto do HCQ na produção de citocinas e na supressão da apresentação de antígenos pode ter consequências imunológicas que dificultam as respostas imunes antivirais inatas e adaptativas para pacientes com COVID-19. Da mesma forma, a inibição da proliferação viral relatada in vitro é em grande parte derivada do bloqueio da fusão viral que inicia a infecção, em vez da inibição direta da replicação viral, como visto com análogos de nucleosídeo/maré em outras infecções virais. Dados esses fatos e a crescente incerteza sobre esses agentes para o tratamento da COVID-19, fica claro que, no mínimo, planejamento cuidadoso e coleta de dados de ensaios clínicos randomizados são necessários para entender qual é o papel desses agentes nessa doença. . Neste artigo, revisamos os conjuntos de dados que apoiam ou prejudicam o uso desses agentes para o tratamento do COVID-19 e emitimos uma opinião informada de que eles devem ser usados apenas com cautela e no contexto de ensaios clínicos cuidadosamente pensados, ou caso a caso após análise rigorosa dos riscos e benefícios desta abordagem terapêutica.
COVID-19: Immunology and treatment options	https://doi.org/10.1016/j.clim.2020.108448	27/04/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108448	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Azitromicina', 'Corticosteroides', 'Enzima Conversora de Angiotensina 2 recombinante', 'Hidroxicloroquina', 'Imunoglobulina', 'Inibidores de Janus Kinase (JAK)', 'Interferon recombinante tipo 1', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Tocilizumabe']	['Azithromycin', 'Corticosteroids', 'Recombinant Angiotensin 2 Converting Enzyme', 'Hydroxychloroquine', 'Immunoglobulin', 'Janus Kinase (JAK) Inhibitors', 'Recombinant Interferon Type 1', 'Lopinavir', 'Convalescent Plasma ', 'Remdesivir', 'Ritonavir', 'Tocilizumab']	-	-	-	-	-	COVID-19: Imunologia e opções de tratamento 	-
Convalescent plasma: possible therapy for novel coronavirus disease 2019	https://onlinelibrary.wiley.com/doi/full/10.1111/trf.15797	02/05/2020	Artigo completo publicado em periódico científico	10.1111/trf.15797	0041-1132	411132	TRANSFUSION (ARLINGTON, VA.)	A3	0.919	138	2.44	-	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Plasma convalescente: possível terapia para a doença do novo coronavírus 2019 	-
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2007621	01/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007621	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Doença cardiovascular, terapia medicamentosa e mortalidade no Covid-19 	-
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2006923	01/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2006923	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Bloqueadores do sistema renina-angiotensina-aldosterona e o risco de Covid-19 	-
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19	https://doi.org/10.1056/NEJMoa2008975	01/05/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2008975	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Antagonista de β-adrenérgico', 'Antagonistas do Receptor da Angiotensina II', 'Bloqueadores do Canal de Cálcio', 'Diuréticos', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['β-Adrenergic Antagonist', 'Angiotensin II Receptor Antagonists', 'Calcium Channel Blockers', 'Diuretics', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Inibidores do Sistema Renina-Angiotensina-Aldosterona e Risco de Covid-19 	-
A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19	https://onlinelibrary.wiley.com/doi/full/10.1111/acem.14005	02/05/2020	Artigo completo publicado em periódico científico	10.1111/acem.14005	1069-6563	10696563	ACADEMIC EMERGENCY MEDICINE	A1	1.374	130	3.05	-	['Cloroquina', 'Hidroxicloroquina']	['Chloroquine', 'Hydroxychloroquine']	There are currently not enough data available to support the routine use of HCQ and CQ as therapies for COVID-19. Pending further results from more extensive studies with more stringent study parameters, clinicians should defer from routine use of HCQ and CQ. There are several clinical trials currently under way with results expected soon.	32359203	Academic emergency medicine : official journal of the Society for Academic Emergency Medicine	1553-2712	10.1111/acem.14005	Uma revisão sistemática rápida de ensaios clínicos utilizando cloroquina e hidroxicloroquina como tratamento para COVID-19 	Atualmente, não há dados suficientes disponíveis para apoiar o uso rotineiro de HCQ e CQ como terapias para COVID-19. Na pendência de mais resultados de estudos mais extensos com parâmetros de estudo mais rigorosos, os médicos devem adiar o uso rotineiro de HCQ e CQ. Existem vários ensaios clínicos em andamento com resultados esperados em breve.
Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review	https://doi.org/10.1016/j.jcv.2020.104380	21/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jcv.2020.104380	1386-6532	13866532	JOURNAL OF CLINICAL VIROLOGY	A3	3.355	114	10.59	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Tratamento de suporte com tocilizumabe para COVID-19: uma revisão sistemática 	-
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMsr2005760	23/04/2020	Artigo completo publicado em periódico científico	10.1056/NEJMsr2005760	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)', 'Inibidores do Sistema Renina-Angiotensina-Aldosterona (ISRAA)']	['Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)', 'Inhibitors of the Renin-Angiotensin-Aldosterone System (ISRAA)']	-	-	-	-	-	Inibidores do Sistema Renina-Angiotensina-Aldosterona em Pacientes com Covid-19 	-
Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study	https://doi.org/10.1161/HYPERTENSIONAHA.120.15143	01/05/2020	Artigo completo publicado em periódico científico	10.1161/HYPERTENSIONAHA.120.15143	0194-911X	0194911X	HYPERTENSION (DALLAS, TEX. 1979)	A1	3.395	276	7.36	             With the capability of inducing elevated expression of ACE2 (angiotensin-converting enzyme 2), the cellular receptor for severe acute respiratory syndrome coronavirus 2, angiotensin II receptor blockers (ARBs) or ACE inhibitors treatment may have a controversial role in both facilitating virus infection and reducing pathogenic inflammation. We aimed to evaluate the effects of ARBs/ACE inhibitors on coronavirus disease 2019 (COVID-19) in a retrospective, single-center study. One hundred twenty-six patients with COVID-19 and preexisting hypertension at Hubei Provincial Hospital of Traditional Chinese Medicine in Wuhan from January 5 to February 22, 2020, were retrospectively allocated to ARBs/ACE inhibitors group (n=43) and non-ARBs/ACE inhibitors group (n=83) according to their antihypertensive medication. One hundred twenty-five age- and sex-matched patients with COVID-19 without hypertension were randomly selected as nonhypertension controls. In addition, the medication history of 1942 patients with hypertension that were admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from November 1 to December 31, 2019, before the COVID-19 outbreak were also reviewed for external comparison. Epidemiological, demographic, clinical, and laboratory data were collected, analyzed, and compared between these groups. The frequency of ARBs/ACE inhibitors usage in patients with hypertension with or without COVID-19 were comparable. Among patients with COVID-19 and hypertension, those received either ARBs/ACE inhibitors or non-ARBs/ACE inhibitors had comparable blood pressure. However, ARBs/ACE inhibitors group had significantly lower concentrations of hs-CRP (high-sensitivity C-reactive protein;             P            =0.049) and PCT (procalcitonin,             P            =0.008). Furthermore, a lower proportion of critical patients (9.3% versus 22.9%;             P            =0.061) and a lower death rate (4.7% versus 13.3%;             P            =0.216) were observed in ARBs/ACE inhibitors group than non-ARBs/ACE inhibitors group, although these differences failed to reach statistical significance. Our findings thus support the use of ARBs/ACE inhibitors in patients with COVID-19 and preexisting hypertension.          	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Efeitos de BRAs e IECAs na infecção por vírus, estado inflamatório e resultados clínicos em pacientes com COVID-19 com hipertensão: um estudo retrospectivo de centro único 	-
Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients	https://doi.org/10.1093/infdis/jiaa228	29/04/2020	Artigo completo publicado em periódico científico	10.1093/infdis/jiaa228	0022-1899	221899	THE JOURNAL OF INFECTIOUS DISEASES	A1	2.509	261	5.29	 Abstract                Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier.	['Plasma convalescente']	['Convalescent Plasma']	-	-	-	-	-	Efeito da terapia de plasma convalescente na disseminação e sobrevivência viral em pacientes com COVID-19 	-
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development	https://doi.org/10.1016/j.ebiom.2020.102768	26/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ebiom.2020.102768	2352-3964	23523964	EBIOMEDICINE	A1	2.663	79	7.76	-	['Plasma convalescente', 'Vacina']	['Convalescent Plasma', 'Vaccine']	The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.	32344202	EBioMedicine	2352-3964	10.1016/j.ebiom.2020.102768	Impacto do aprimoramento imunológico na terapia com globulina hiperimune policlonal Covid-19 e desenvolvimento de vacinas 	A disseminação pandêmica de um novo coronavírus - SARS coronavírus-2 (SARS-CoV-2) como causa de doença respiratória aguda, denominada Covid-19, está colocando o sistemas de saúde de muitos países sob estresse sem precedentes. As economias globais também estão em espiral em direção a uma recessão com medo dessa nova doença com risco de vida. Vacinas que previnem a infecção por SARS-CoV-2 e terapias que reduzem o risco de Covid-19 grave são, portanto, urgentemente necessárias. Um método rápido para derivar o tratamento antiviral para o Covid-19 é o uso de globulina hiperimune derivada do plasma convalescente. No entanto, tanto a globulina hiperimune quanto o desenvolvimento de vacinas enfrentam um obstáculo comum - o risco de aumento da doença mediada por anticorpos. O objetivo desta revisão é examinar o corpo de evidências que apoia a hipótese de aprimoramento imunológico que pode ser pertinente ao Covid-19. Também discutimos como esse risco pode ser mitigado para que tanto a globulina hiperimune quanto as vacinas possam ser traduzidas rapidamente para superar a atual crise global de saúde.
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study	https://doi.org/10.1016/j.cmi.2020.04.026	25/04/2020	Artigo completo publicado em periódico científico	10.1016/j.cmi.2020.04.026	1198-743X	1198743X	CLINICAL MICROBIOLOGY AND INFECTION (PRINT)	A1	3.111	167	7.73	-	['Umifenovir']	['Umifenovir']	-	-	-	-	-	O tratamento com umifenovir não está associado a melhores resultados em pacientes com doença por coronavírus 2019: um estudo retrospectivo 	-
Two distinct cases with COVID-19 in kidney transplant recipients	https://doi.org/10.1111/ajt.15947	26/04/2020	Artigo completo publicado em periódico científico	10.1111/ajt.15947	1600-6135	16006135	AMERICAN JOURNAL OF TRANSPLANTATION (PRINT)	A1	3.311	198	6.32	-	['Azitromicina', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir']	['Azithromycin', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir']	-	-	-	-	-	Dois casos distintos com COVID-19 em receptores de transplante renal 	-
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia	https://doi.org/10.1007/s40261-020-00917-3	26/04/2020	Artigo completo publicado em periódico científico	10.1007/s40261-020-00917-3	1173-2563	11732563	CLINICAL DRUG INVESTIGATION	A4	0.718	60	2.86	-	['Tocilizumabe']	['Tocilizumab']	-	-	-	-	-	Uso Racional de Tocilizumabe no Tratamento da Nova Pneumonia por Coronavírus 	-
Combating Devastating COVID -19 by Drug Repurposing	https://doi.org/10.1016/j.ijantimicag.2020.105984	20/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105984	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Hidroxicloroquina', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Hydroxychloroquine', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ribavirin', 'Ritonavir']	-	-	-	-	-	Combatendo a devastadora COVID-19 pelo reaproveitamento de medicamentos 	-
A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance	https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.15082	24/04/2020	Artigo completo publicado em periódico científico	10.1111/bph.15082	0007-1188	71188	BRITISH JOURNAL OF PHARMACOLOGY	A1	1.993	223	8.41	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Angiotensin Converting Enzyme2 is the cell surface binding site for the coronavirus SARS-CoV-2, which causes COVID-19. We propose that an imbalance in the action of ACE1- and ACE2-derived peptides, thereby enhancing angiotensin II (Ang II) signalling is primary driver of COVID-19 pathobiology. ACE1/ACE2 imbalance occurs due to the binding of SARS-CoV-2 to ACE2, reducing ACE2-mediated conversion of Ang II to Ang peptides that counteract pathophysiological effects of ACE1-generated ANG II. This hypothesis suggests several approaches to treat COVID-19 by restoring ACE1/ACE2 balance: (a) AT receptor antagonists; (b) ACE1 inhibitors (ACEIs); (iii) agonists of receptors activated by ACE2-derived peptides (e.g. Ang (1-7), which activates MAS1); (d) recombinant human ACE2 or ACE2 peptides as decoys for the virus. Reducing ACE1/ACE2 imbalance is predicted to blunt COVID-19-associated morbidity and mortality, especially in vulnerable patients. Importantly, approved AT antagonists and ACEIs can be rapidly repurposed to test their efficacy in treating COVID-19. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.	32333398	British journal of pharmacology	1476-5381	10.1111/bph.15082	Uma hipótese para patobiologia e tratamento de COVID-19: a centralidade do desequilíbrio ACE1/ACE2 	A Enzima de Conversão de Angiotensina2 é o local de ligação da superfície celular para o coronavírus SARS-CoV-2, que causa o COVID-19. Propomos que um desequilíbrio na ação dos peptídeos derivados de ACE1 e ACE2, aumentando assim a sinalização da angiotensina II (Ang II), é o principal fator da patobiologia do COVID-19. O desequilíbrio ACE1/ACE2 ocorre devido à ligação do SARS-CoV-2 ao ACE2, reduzindo a conversão mediada por ACE2 de Ang II em peptídeos Ang que neutralizam os efeitos fisiopatológicos da ANG II gerada por ACE1. Essa hipótese sugere várias abordagens para tratar o COVID-19 restaurando o equilíbrio ACE1/ACE2: (a) antagonistas do receptor AT; (b) inibidores de ACE1 (ACEIs); (iii) agonistas de receptores ativados por peptídeos derivados de ACE2 (por exemplo, Ang (1-7), que ativa MAS1); (d) péptidos ACE2 ou ACE2 humanos recombinantes como chamarizes para o vírus. Prevê-se que a redução do desequilíbrio ACE1/ACE2 reduza a morbidade e a mortalidade associadas ao COVID-19, especialmente em pacientes vulneráveis. É importante ressaltar que os antagonistas de AT e IECAs aprovados podem ser rapidamente reaproveitados para testar sua eficácia no tratamento do COVID-19. ARTIGOS LINKADOS: Este artigo faz parte de uma edição temática sobre A Farmacologia do COVID-19. Para ver os outros artigos desta seção, visite http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
COVID-19: lambda interferon against viral load and hyperinflammation	https://www.embopress.org/doi/10.15252/emmm.202012465	25/04/2020	Artigo completo publicado em periódico científico	10.15252/emmm.202012465	1757-4676	17574676	EMBO MOLECULAR MEDICINE	A1	4.039	119	10.64	-	['Interferon lambda']	['Interferon lambda']	Coronavirus disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 250,000 deaths (JHU data-05/06/2020, https://coronavirus.jhu.edu/). Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon-lambda (IFNλ), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNλ in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNλ induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNλ and potential safety considerations. We conclude that IFNλ constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).	32333818	EMBO molecular medicine	1757-4684	10.15252/emmm.202012465	COVID-19: interferon lambda contra carga viral e hiperinflamação 	A doença do coronavírus 2019 (COVID-19), desencadeada pelo betacoronavírus SARS-CoV-2, tornou-se uma das piores pandemias do nosso tempo que já causou mais de 250.000 mortes (JHU data-05/06/2020, https://coronavirus.jhu.edu/). Abordagens terapêuticas eficazes são urgentemente necessárias para reduzir a propagação do vírus e seu número de mortes. Aqui, avaliamos a possibilidade de usar interferon-lambda (IFNλ), um terceiro tipo de interferon que compartilha baixa homologia com IFNs tipo I e IL-10, para o tratamento de pacientes com COVID-19. Discutimos o papel exclusivo do IFNλ no ajuste fino da imunidade antiviral no trato respiratório para obter proteção ideal e danos mínimos ao hospedeiro e revisamos evidências iniciais de que o SARS-CoV-2 pode prejudicar a indução de IFNλ, levando a uma resposta tardia dominada pelo IFN do tipo I que desencadeia hiperinflamação e doença grave. Também consideramos as potenciais janelas de oportunidade para intervenção terapêutica com IFNλ e possíveis considerações de segurança. Concluímos que o IFNλ constitui um agente terapêutico promissor para reduzir a presença viral e a hiperinflamação em uma única injeção para prevenir as consequências devastadoras do COVID-19, como pneumonia e síndrome do desconforto respiratório agudo (SDRA).
Current pharmacological treatments for COVID-19: what’s next?	https://doi.org/10.1111/bph.15072	24/04/2020	Artigo completo publicado em periódico científico	10.1111/bph.15072	0007-1188	71188	BRITISH JOURNAL OF PHARMACOLOGY	A1	1.993	223	8.41	-	['Favipiravir', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Favipiravir', 'Lopinavir', 'Remdesivir', 'Ritonavir', 'Tocilizumab', 'Umifenovir']	Since December 2019 SARS-Cov-2 was found responsible for the disease COVID-19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID-19, focusing on their antiviral, immune-modulatory and/or anti-inflammatory actions. Where available, data from clinical trials involving patients with COVID-19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.	32329520	British journal of pharmacology	1476-5381	10.1111/bph.15072	Tratamentos farmacológicos atuais para COVID-19: o que vem a seguir? 	Desde dezembro de 2019, o SARS-Cov-2 foi considerado responsável pela doença COVID-19, que se espalhou pelo mundo. Ainda não há terapias/vacinas específicas para o tratamento da COVID-19. O reposicionamento de medicamentos pode oferecer uma estratégia e vários medicamentos foram reaproveitados, incluindo lopinavir/ritonavir, remdesivir, favipiravir e tocilizumab. Este artigo descreve as principais propriedades farmacológicas desses medicamentos administrados a pacientes com COVID-19, com foco em suas ações antivirais, imunomoduladoras e/ou anti-inflamatórias. Quando disponíveis, são relatados dados de ensaios clínicos envolvendo pacientes com COVID-19. Ensaios clínicos preliminares parecem apoiar seu benefício. No entanto, esses medicamentos em pacientes com COVID-19 têm perfis de segurança peculiares. Assim, são necessários ensaios clínicos adequados para esses compostos. No entanto, enquanto se espera por medidas preventivas eficazes, ou seja, vacinas, muitos ensaios clínicos com medicamentos pertencentes a diferentes classes terapêuticas estão em andamento. Seus resultados nos ajudarão a definir a melhor maneira de tratar o COVID-19 e reduzir seus sintomas e complicações. ARTIGOS LINKADOS: Este artigo faz parte de uma edição temática sobre A Farmacologia do COVID-19. Para ver os outros artigos desta seção, visite http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1863	22/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1863	0009-9236	99236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	Concerns have been raised regarding the safety of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with coronavirus disease of 2019 (COVID-19), based on the hypothesis that such medications may raise expression of ACE2, the receptor for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). We conducted a literature review of studies (n = 12) in experimental animals and human subjects (n = 12) and evaluated the evidence regarding the impact of administration of ACEIs and ARBs on ACE2 expression. We prioritized studies that assessed ACE2 protein expression data, measured directly or inferred from ACE2 activity assays. The findings in animals are inconsistent with respect to an increase in ACE2 expression in response to treatment with ACEIs or ARBs. Control/sham animals show little to no effect in the plurality of studies. Those studies that report increases in ACE2 expression tend to involve acute injury models and/or higher doses of ACEIs or ARBs than are typically administered to patients. Data from human studies overwhelmingly imply that administration of ACEIs/ARBs does not increase ACE2 expression. Available evidence, in particular, data from human studies, does not support the hypothesis that ACEI/ARB use increases ACE2 expression and the risk of complications from COVID-19. We conclude that patients being treated with ACEIs and ARBs should continue their use for approved indications.	32320478	Clinical pharmacology and therapeutics	1532-6535	10.1002/cpt.1863	Riscos do uso de inibidores da ECA e BRA no COVID-19: avaliando as evidências Surgiram 	preocupações sobre a segurança dos inibidores da enzima conversora da angiotensina (IECAs) e bloqueadores dos receptores da angiotensina (BRAs) em pacientes com doença por coronavírus de 2019 (COVID-19), com base na hipótese de que tais medicamentos podem aumentar a expressão de ACE2, o receptor para a síndrome respiratória aguda grave-coronavírus 2 (SARS-CoV-2). Realizamos uma revisão da literatura de estudos (n = 12) em animais experimentais e seres humanos (n = 12) e avaliamos as evidências sobre o impacto da administração de IECAs e BRAs na expressão de ECA2. Priorizamos estudos que avaliaram dados de expressão da proteína ACE2, medidos diretamente ou inferidos de ensaios de atividade de ACE2. Os achados em animais são inconsistentes em relação a um aumento na expressão de ACE2 em resposta ao tratamento com IECAs ou BRAs. Animais de controle/sham mostram pouco ou nenhum efeito na pluralidade de estudos. Os estudos que relatam aumentos na expressão de ACE2 tendem a envolver modelos de lesão aguda e/ou doses mais altas de IECAs ou BRAs do que normalmente são administrados aos pacientes. Os dados de estudos em humanos implicam esmagadoramente que a administração de IECAs/BRA não aumenta a expressão de ACE2. As evidências disponíveis, em particular, dados de estudos em humanos, não suportam a hipótese de que o uso de IECA/BRA aumenta a expressão de ACE2 e o risco de complicações do COVID-19. Concluímos que os pacientes em tratamento com IECAs e BRAs devem continuar seu uso para as indicações aprovadas.
Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes	https://doi.org/10.1016/S0140-6736(20)30912-0	23/04/2020	Artigo completo publicado em periódico científico	10.1016/S0140-6736(20)30912-0	0140-6736	1406736	LANCET (BRITISH EDITION)	A1	15.652	807	18.73	-	['Hidrocortisona']	['Hydrocortisone']	-	-	-	-	-	Miocardite em paciente com COVID-19: uma causa de troponina elevada e alterações no ECG 	-
Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1866	23/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1866	0009-9236	99236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Cloroquina', 'Lopinavir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Lopinavir', 'Ritonavir', 'Umifenovir']	To evaluate the incidence, type, and risk factors associated with adverse drug reactions (ADRs) among patients with coronavirus disease 2019 (COVID-19) by Hospital Pharmacovigilance System (CHPS). A retrospective analysis was performed on 217 patients with COVID-19 admitted to the First Hospital of Changsha in China, from January 17, 2020, to February 29, 2020. The active monitoring model in CHPS was used to detect ADR signals of the hospital information system. The risk factors for the ADRs were classified using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system. Univariate and multivariate logistic regressions were carried out to analyze the risk factors of ADRs. Our results showed that the prevalence of ADRs was 37.8% in the patients, which was predominated by drug-induced gastrointestinal disorders and liver system disorders (23.0% vs. 13.8%). The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively. There were 96.8% of ADRs that occurred within 14 days of hospitalization. Multivariable analysis showed that length of stay (odds ratio (OR): 2.02; 95% confidence interval (CI) 1.03-3.96; P = 0.04), number of drugs used in the hospital (OR: 3.17; 95% CI 1.60-6.27; P = 0.001) and underlying basic diseases (OR: 2.07; 95% CI 1.02-4.23; P = 0.04) were independent risk factor for ADRs in the patients. Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID-19 treatment in the real world, which provided reference for safe medication in the clinic.	32324898	Clinical pharmacology and therapeutics	1532-6535	10.1002/cpt.1866	Incidência de reações adversas a medicamentos em pacientes com COVID-19 na China: um estudo de monitoramento ativo do Hospital Pharmacovigilance System 	Para avaliar a incidência, tipo e fatores de risco associados a reações adversas a medicamentos (RAMs) entre pacientes com doença de coronavírus 2019 (COVID-19) pelo Sistema de Farmacovigilância Hospitalar (CHPS). Uma análise retrospectiva foi realizada em 217 pacientes com COVID-19 internados no Primeiro Hospital de Changsha na China, de 17 de janeiro de 2020 a 29 de fevereiro de 2020. O modelo de monitoramento ativo no CHPS foi usado para detectar sinais de RAM das informações do hospital sistema. Os fatores de risco para as RAMs foram classificados usando o sistema World Health Organization-Uppsala Monitoring Center (WHO-UMC). Regressões logísticas univariadas e multivariadas foram realizadas para analisar os fatores de risco de RAM. Nossos resultados mostraram que a prevalência de RAM foi de 37,8% nos pacientes, com predomínio de distúrbios gastrointestinais induzidos por drogas e distúrbios do sistema hepático (23,0% vs. 13,8%). A RAM pode ser explicada pelo uso de lopinavir/ritonavir e umifenovir em 63,8% e 18,1%, respectivamente. Houve 96,8% das RAMs que ocorreram em até 14 dias de internação. A análise multivariada mostrou que o tempo de permanência (odds ratio (OR): 2,02; intervalo de confiança de 95% (IC) 1,03-3,96; P = 0,04), número de medicamentos usados no hospital (OR: 3,17; IC 95% 1,60-6,27 ; P = 0,001) e doenças básicas de base (OR: 2,07; IC 95% 1,02-4,23; P = 0,04) foram fatores de risco independentes para RAM nos pacientes. Juntos, a incidência de RAMs foi significativamente alta durante o período de tratamento. Além disso, o monitoramento ativo do sistema CHPS refletiu as RAMs durante o tratamento com COVID-19 no mundo real, o que forneceu referência para medicação segura na clínica.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2001282	18/03/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2001282	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	-	-	-	-	-	Um ensaio de Lopinavir-Ritonavir em adultos hospitalizados com COVID-19 grave 	-
COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency	https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.13432	23/04/2020	Artigo completo publicado em periódico científico	10.1111/ejh.13432	0902-4441	9024441	EUROPEAN JOURNAL OF HAEMATOLOGY	A3	1.057	88	3.2	-	['Hidroxicloroquina']	['Hydroxychloroquine']	-	-	-	-	-	Infecção por COVID-19 e tratamento com hidroxicloroquina causam crise grave de hemólise em paciente com deficiência de glicose-6-fosfato desidrogenase 	-
Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1710019	21/04/2020	Artigo completo publicado em periódico científico	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1710019	0340-6245	3406245	THROMBOSIS AND HAEMOSTASIS	A1	1.745	195	5.58	 Abstract Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions.	['Anticoagulantes', 'Anticoagulantes']	['Anticoagulants', 'Anticoagulants']	-	-	-	-	-	Prevenção e tratamento do tromboembolismo venoso associado à infecção por doença de coronavírus 2019: uma declaração de consenso antes das diretrizes 	-
A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report	https://doi.org/10.1016/j.jiac.2020.03.018	18/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jiac.2020.03.018	1341-321X	1341321X	JOURNAL OF INFECTION AND CHEMOTHERAPY	A4	0.588	64	2.23	-	['Lopinavir', 'Oxigenação por membrana extracorpórea (ECMO)', 'Ritonavir']	['Lopinavir', 'Extracorporeal membrane oxygenation (ECMO)', 'Ritonavir']	Strict infection control precautions are not always an easy task, especially under urgent care in an intensive care unit. However, severe cases of COVID-19 pneumonia, or another novel infectious disease, could present at any moment and would be a continuing challenge to pursue appropriate measures. We need to be well prepared to secure healthcare workers from exposure to infectious diseases and nosocomial spread, as well as to provide necessary intensive care.	32317225	Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy	1437-7780	10.1016/j.jiac.2020.03.018	Uma pneumonia esporádica por COVID-19 tratada com oxigenação por membrana extracorpórea em Tóquio, Japão: Relato de caso 	Precauções rigorosas de controle de infecção nem sempre são uma tarefa fácil, especialmente sob cuidados urgentes em uma unidade de terapia intensiva. No entanto, casos graves de pneumonia por COVID-19, ou outra nova doença infecciosa, podem se apresentar a qualquer momento e seria um desafio contínuo adotar medidas apropriadas. Precisamos estar bem preparados para proteger os profissionais de saúde da exposição a doenças infecciosas e disseminação nosocomial, bem como fornecer os cuidados intensivos necessários.
Therapeutic strategies for critically ill patients with COVID-19	https://doi.org/10.1186/s13613-020-00661-z	20/04/2020	Artigo completo publicado em periódico científico	10.1186/s13613-020-00661-z	2110-5820	21105820	ANNALS OF INTENSIVE CARE	A1	2.219	60	7.23	 Abstract Since the 2019 novel coronavirus disease (COVID-19) outbreak originated from Wuhan, Hubei Province, China, at the end of 2019, it has become a clinical threat to the general population worldwide. Among people infected with the novel coronavirus (2019-nCoV), the intensive management of the critically ill patients in intensive care unit (ICU) needs substantial medical resource. In the present article, we have summarized the promising drugs, adjunctive agents, respiratory supportive strategies, as well as circulation management, multiple organ function monitoring and appropriate nutritional strategies for the treatment of COVID-19 in the ICU based on the previous experience of treating other viral infections and influenza. These treatments are referable before the vaccine and specific drugs are available for COVID-19.	['Ciclosporina', 'Corticosteroides', 'Favipiravir', 'Gamaglobulina', 'Interferon', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Timosina', 'Tocilizumabe', 'Umifenovir']	['Cyclosporin', 'Corticosteroids', 'Favipiravir', 'Gamaglobulin', 'Interferon', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Thymosin', 'Tocilizumab', 'Umifenovir']	-	-	-	-	-	Estratégias terapêuticas para pacientes críticos com COVID-19 	-
Treatment options for COVID-19: The reality and challenges	https://doi.org/10.1016/j.jmii.2020.03.034	04/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jmii.2020.03.034	1684-1182	16841182	JOURNAL OF MICROBIOLOGY, IMMUNOLOGY AND INFECTION	A4	1.748	63	7.83	-	['Azitromicina', 'Cloroquina', 'Favipiravir', 'Heparina', 'Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Prednisona', 'Remdesivir', 'Ribavirina', 'Ritonavir']	['Azithromycin', 'Chloroquine', 'Favipiravir', 'Heparin', 'Hydroxychloroquine', 'Lopinavir', 'Convalescent Plasma', 'Prednisone', 'Remdesivir', 'Ribavirin', 'Ritonavir']	-	-	-	-	-	Opções de tratamento para COVID-19: a realidade e os desafios 	-
Natural products and their derivatives against coronavirus: A review of the non-clinical and pre-clinical data	https://doi.org/10.1002/ptr.6700	04/04/2020	Artigo completo publicado em periódico científico	10.1002/ptr.6700	0951-418X	0951418X	PTR. PHYTOTHERAPY RESEARCH	A2	1.046	140	7.29	-	['Produtos naturais', 'Produtos naturais', 'Produtos naturais']	['Natural products', 'Natural products', 'Natural products']	Several corona viral infections have created serious threats in the last couple of decades claiming the death of thousands of human beings. Recently, corona viral epidemic raised the issue of developing effective antiviral agents at the earliest to prevent further losses. Natural products have always played a crucial role in drug development process against various diseases, which resulted in screening of such agents to combat emergent mutants of corona virus. This review focuses on those natural compounds that showed promising results against corona viruses. Although inhibition of viral replication is often considered as a general mechanism for antiviral activity of most of the natural products, studies have shown that some natural products can interact with key viral proteins that are associated with virulence. In this context, some of the natural products have antiviral activity in the nanomolar concentration (e.g., lycorine, homoharringtonine, silvestrol, ouabain, tylophorine, and 7-methoxycryptopleurine) and could be leads for further drug development on their own or as a template for drug design. In addition, a good number of natural products with anti-corona virus activity are the major constituents of some common dietary supplements, which can be exploited to improve the immunity of the general population in certain epidemics.	32248575	Phytotherapy research : PTR	1099-1573	10.1002/ptr.6700	Produtos naturais e seus derivados contra o coronavírus: uma revisão dos dados não clínicos e pré-clínicos 	Várias infecções virais por corona criaram sérias ameaças nas últimas duas décadas, alegando a morte de milhares de seres humanos. Recentemente, a epidemia viral de corona levantou a questão do desenvolvimento de agentes antivirais eficazes o mais cedo possível para evitar mais perdas. Os produtos naturais sempre tiveram um papel crucial no processo de desenvolvimento de medicamentos contra diversas doenças, o que resultou na triagem desses agentes para combater mutantes emergentes do corona vírus. Esta revisão se concentra nos compostos naturais que mostraram resultados promissores contra os vírus corona. Embora a inibição da replicação viral seja frequentemente considerada como um mecanismo geral para a atividade antiviral da maioria dos produtos naturais, estudos mostraram que alguns produtos naturais podem interagir com proteínas virais chave associadas à virulência. Nesse contexto, alguns dos produtos naturais têm atividade antiviral na concentração nanomolar (por exemplo, licorina, homoharringtonina, silvestrol, ouabaína, tiloforina e 7-metoxicriptopleurina) e podem ser pistas para o desenvolvimento de medicamentos por conta própria ou como modelo para projeto de drogas. Além disso, um bom número de produtos naturais com atividade anti-corona vírus são os principais constituintes de alguns suplementos alimentares comuns, que podem ser explorados para melhorar a imunidade da população em geral em certas epidemias.
Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies	https://doi.org/10.1016/j.ijantimicag.2020.105982	16/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105982	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Cloroquina', 'Hidroxicloroquina', 'Prednisona', 'Tocilizumabe', 'Ulinastatina']	['Chloroquine', 'Hydroxychloroquine', 'Prednisone', 'Tocilizumab', 'Ulinastatin']	TCM has a systemic theoretical understanding on the pathological evolution and a positive clinical efficacy on NCP. The CMs of ISRD improved patients' recovery, suggesting the importance of regulating intestinal function and keeping microenvironmental balance in TCM treatment of NCP. The active compounds from QFPDD and NHC-recommended formulas contribute to recovery of varied disease progresses during TCM treating NCP.	32305588	International journal of antimicrobial agents	1872-7913	10.1016/j.ijantimicag.2020.105982	Tempestade de citocinas e terapia imunomoduladora no COVID-19: papel da cloroquina e anticorpos monoclonais anti-IL-6 A 	MTC tem uma compreensão teórica sistêmica sobre a evolução patológica e uma eficácia clínica positiva na PCN. Os MCs do ISRD melhoraram a recuperação dos pacientes, sugerindo a importância de regular a função intestinal e manter o equilíbrio microambiental no tratamento da MTC da NCP. Os compostos ativos das fórmulas recomendadas por QFPDD e NHC contribuem para a recuperação de vários progressos da doença durante o tratamento de NCP com MTC.
American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplantation and Cellular Therapy Patients in the United States	https://doi.org/10.1016/j.bbmt.2020.04.005	16/04/2020	Artigo completo publicado em periódico científico	10.1016/j.bbmt.2020.04.005	1083-8791	10838791	BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION	A1	1.397	126	4.17	-	['Cloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Plasma convalescente', 'Remdesivir', 'Ritonavir', 'Ruxolitinibe', 'Terapia celular', 'Tocilizumabe']	['Chloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Convalescent plasma', 'Remdesivir', 'Ritonavir', 'Ruxolitinib', 'Cell therapy', 'Tocilizumab']	-	-	-	-	-	American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Q1 Cell Transplant and Cellular Therapy Patients in the United States 	-
Clinical Implications of SARS-CoV-2 Interaction with Renin Angiotensin System	https://doi.org/10.1016/j.jacc.2020.04.028	09/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jacc.2020.04.028	0735-1097	7351097	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (PRINT)	A1	9.756	451	9.53	-	['Antagonistas do Receptor da Angiotensina II', 'Inibidores da Enzima Conversora da Angiotensina 2 (IECA 2)']	['Angiotensin II Receptor Antagonists', 'Angiotensin Converting Enzyme 2 (ACEI 2) Inhibitors']	-	-	-	-	-	Implicações Clínicas da Interação SARS-CoV-2 com o Sistema Renina Angiotensina 	-
Antiplatelet Therapy Following Percutaneous Coronary Intervention in Patients Complicated by COVID-19: Implications from Clinical Features to Pathological Findings	https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046988	16/04/2020	Artigo completo publicado em periódico científico	10.1161/CIRCULATIONAHA.120.046988	0009-7322	97322	CIRCULATION (NEW YORK, N.Y.)	A1	8.281	630	12.78	-	['Antagonista de P2Y12', 'Heparina', 'Ticagrelor']	['P2Y12 antagonist', 'Heparin', 'Ticagrelor']	-	-	-	-	-	Terapia Antiplaquetária Após Intervenção Coronária Percutânea em Pacientes Complicados por COVID-19: Implicações de Características Clínicas a Achados Patológicos 	-
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1857	17/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1857	0009-9236	99236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Azitromicina']	['Azithromycin']	Azithromycin (AZ) is a broad-spectrum macrolide antibiotic with a long half-life and a large volume of distribution. It is primarily used for the treatment of respiratory, enteric, and genitourinary bacterial infections. AZ is not approved for the treatment of viral infections, and there is no well-controlled, prospective, randomized clinical evidence to support AZ therapy in coronavirus disease 2019 (COVID-19). Nevertheless, there are anecdotal reports that some hospitals have begun to include AZ in combination with hydroxychloroquine or chloroquine (CQ) for treatment of COVID-19. It is essential that the clinical pharmacology (CP) characteristics of AZ be considered in planning and conducting clinical trials of AZ alone or in combination with other agents, to ensure safe study conduct and to increase the probability of achieving definitive answers regarding efficacy of AZ in the treatment of COVID-19. The safety profile of AZ used as an antibacterial agent is well established.	32302411	Clinical pharmacology and therapeutics	1532-6535	10.1002/cpt.1857	Perspectivas da farmacologia clínica sobre a atividade antiviral da azitromicina e uso na COVID-19 A 	azitromicina (AZ) é um antibiótico macrolídeo de amplo espectro com meia-vida longa e grande volume de distribuição. É usado principalmente para o tratamento de infecções bacterianas respiratórias, entéricas e geniturinárias. O AZ não está aprovado para o tratamento de infecções virais e não há evidências clínicas bem controladas, prospectivas e randomizadas para apoiar a terapia com AZ na doença de coronavírus 2019 (COVID-19). No entanto, há relatos anedóticos de que alguns hospitais começaram a incluir AZ em combinação com hidroxicloroquina ou cloroquina (CQ) para o tratamento de COVID-19. É essencial que as características de farmacologia clínica (CP) da AZ sejam consideradas no planejamento e condução de ensaios clínicos da AZ isoladamente ou em combinação com outros agentes, para garantir a condução segura do estudo e aumentar a probabilidade de obter respostas definitivas sobre a eficácia da AZ em o tratamento da COVID-19. O perfil de segurança do AZ usado como agente antibacteriano está bem estabelecido.
The epidemiology and clinical information about COVID-19	https://doi.org/10.1007/s10096-020-03874-z	04/04/2020	Artigo completo publicado em periódico científico	10.1007/s10096-020-03874-z	0934-9723	9349723	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (PRINT)	A3	1.205	111	4.42	-	['Cloroquina', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	['Chloroquine', 'Interferon', 'Lopinavir', 'Oseltamivir', 'Remdesivir', 'Ritonavir', 'Umifenovir']	-	-	-	-	-	A epidemiologia e as informações clínicas sobre o COVID-19 	-
Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection	https://doi.org/10.1016/j.ijantimicag.2020.105974	13/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105974	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Imunoglobulina', 'Plasmaferese']	['Immunoglobulin', 'Plasmapheresis']	-	-	-	-	-	Tratamento bem-sucedido de troca de plasma seguido de imunogloblina intravenosa em um paciente gravemente doente com nova infecção por coronavírus de 2019 	-
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment	https://doi.org/10.1002/jia2.25489	26/03/2020	Artigo completo publicado em periódico científico	10.1002/jia2.25489	1758-2652	17582652	JOURNAL OF THE INTERNATIONAL AIDS SOCIETY	A1	2.162	69	4.42	-	['Lopinavir', 'Ritonavir']	['Lopinavir', 'Ritonavir']	-	-	-	-	-	Revisão sistemática da eficácia e segurança dos medicamentos antirretrovirais contra SARS, MERS ou COVID-19: avaliação inicial 	-
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options	https://doi.org/10.1093/ofid/ofaa105	04/04/2020	Artigo completo publicado em periódico científico	10.1093/ofid/ofaa105	2328-8957	23288957	OPEN FORUM INFECTIOUS DISEASES	A3	1.317	45	3.66	 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.	['Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Lopinavir', 'Nitazoxanida', 'Remdesivir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe']	['Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Lopinavir', 'Nitazoxanide', 'Remdesivir', 'Ribavirin', 'Ritonavir', 'Tocilizumab']	-	-	-	-	-	Tratamento da doença de coronavírus 2019: uma revisão das opções iniciais e emergentes 	-
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study	https://doi.org/10.1016/j.tmaid.2020.101663	11/04/2020	Artigo completo publicado em periódico científico	10.1016/j.tmaid.2020.101663	1477-8939	14778939	TRAVEL MEDICINE AND INFECTIOUS DISEASE	A1	2.225	60	7.19	-	['Azitromicina', 'Hidroxicloroquina']	['Azithromycin', 'Hydroxychloroquine']	We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.	32289548	Travel medicine and infectious disease	1873-0442	10.1016/j.tmaid.2020.101663	Efeito clínico e microbiológico de uma combinação de hidroxicloroquina e azitromicina em 80 pacientes com COVID-19 com pelo menos seis dias de acompanhamento: um estudo observacional piloto 	Acreditamos que há urgência em avaliar a eficácia dessa estratégia terapêutica potencialmente salvadora de vidas em um em maior escala, tanto para tratar e curar pacientes em um estágio inicial, antes que complicações respiratórias graves irreversíveis se instalem, quanto para diminuir a duração do transporte e evitar a propagação da doença. Além disso, o custo do tratamento é insignificante.
Cytokine Storm in COVID-19 and Treatment	https://doi.org/10.1016/j.jinf.2020.03.037	10/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.03.037	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Anakinra', 'Antagonistas de TNF', 'Cloroquina', 'Corticosteroides', 'Imunoglobulina', 'Inibidores de IFN-αβ', 'Interferon lambda', 'Tocilizumabe', 'Ulinastatina']	['Anakinra', 'TNF Antagonists', 'Chloroquine', 'Corticosteroids', 'Immunoglobulin', 'IFN-αβ Inhibitors', 'Interferon lambda', 'Tocilizumab', 'Ulinastatin']	-	-	-	-	-	Tempestade de citocinas no COVID-19 e tratamento 	-
Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19	https://doi.org/10.1016/j.jinf.2020.03.039	14/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.03.039	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Prednisona']	['Prednisone']	-	-	-	-	-	A terapia com corticosteróides em baixas doses não atrasa a depuração viral em pacientes com COVID-19 	-
Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19	https://doi.org/10.1016/j.jinf.2020.03.044	10/04/2020	Artigo completo publicado em periódico científico	10.1016/j.jinf.2020.03.044	0163-4453	1634453	THE JOURNAL OF INFECTION	A2	5.027	119	15.14	-	['Imunoglobulina']	['Immunoglobulin']	This meta-analysis concurs with the previous reports regarding the use of corticosteroid in COVID 19 in comparison to usual care. However, for both the primary and secondary outcome, the study did not find any statistically significant difference between the use of pulse dose methyl prednisolone and low dose corticosteroid to treat COVID 19 patients.	32283154	The Journal of infection	1532-2742	10.1016/j.jinf.2020.03.044	Efeito da terapia regular com imunoglobulina intravenosa no prognóstico de pneumonia grave em pacientes com COVID- 	19 No entanto, tanto para o desfecho primário quanto para o secundário, o estudo não encontrou diferença estatisticamente significativa entre o uso de metil prednisolona em dose de pulso e corticosteróide em baixa dose para tratar pacientes com COVID 19.
Drug repositioning an alternative for the treatment of coronavirus COVID-19	https://doi.org/10.1016/j.ijantimicag.2020.105969	09/04/2020	Artigo completo publicado em periódico científico	10.1016/j.ijantimicag.2020.105969	0924-8579	9248579	INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (PRINT)	A1	2.121	137	10.76	-	['Cloroquina', 'Hidroxicloroquina', 'Metformina', 'Nitazoxanida', 'Remdesivir', 'Teicoplanina', 'Vancomicina']	['Chloroquine', 'Hydroxychloroquine', 'Metformin', 'Nitazoxanide', 'Remdesivir', 'Teicoplanin', 'Vancomycin']	-	-	-	-	-	Reposicionamento de medicamentos uma alternativa para o tratamento do coronavírus COVID-19 	-
Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.	https://doi.org/10.1002/phar.2403	13/04/2020	Artigo completo publicado em periódico científico	10.1002/phar.2403	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Remdesivir']	['Remdesivir']	-	-	-	-	-	Atraso no início do remdesivir em um paciente positivo para COVID-19. 	-
Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19)	https://onlinelibrary.wiley.com/doi/abs/10.1111/tid.13286	12/04/2020	Artigo completo publicado em periódico científico	10.1111/tid.13286	1398-2273	13982273	TRANSPLANT INFECTIOUS DISEASE (PRINT)	A4	0.536	70	2.33	-	['Cobicistato', 'Darunavir', 'Hidroxicloroquina', 'Lopinavir', 'Ritonavir', 'Tacrolimus']	['Cobicistat', 'Darunavir', 'Hydroxychloroquine', 'Lopinavir', 'Ritonavir', 'Tacrolimus']	-	-	-	-	-	Interação medicamentosa ameaçadora em um paciente de transplante renal com doença de coronavírus 2019 (COVID-19) 	-
Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience	https://doi.org/10.1016/j.sapharm.2020.03.027	03/04/2020	Artigo completo publicado em periódico científico	10.1016/j.sapharm.2020.03.027	1551-7411	15517411	RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY	A3	0.674	54	2.88	-	['Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Interferon', 'Lopinavir', 'Ribavirina', 'Ritonavir', 'Tocilizumabe', 'Umifenovir']	['Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Interferon', 'Lopinavir', 'Ribavirin', 'Ritonavir', 'Tocilizumab', 'Umifenovir']	-	-	-	-	-	Atenção Farmacêutica Hospitalar a Pacientes Hospitalizados com COVID-19: Recomendações e Orientações da Experiência Clínica 	-
Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic	https://doi.org/10.1016/j.clim.2020.108409	07/04/2020	Artigo completo publicado em periódico científico	10.1016/j.clim.2020.108409	1521-6616	15216616	CLINICAL IMMUNOLOGY (ORLANDO, FLA. PRINT)	A3	1.609	130	6.8	-	['Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Ácido ascórbico', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Anticorpos', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Emodina', 'Emodina', 'Emodina', 'Emodina', 'Emodina', 'Emodina', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Ervas com atividade inibitória de protease quimiotripsina-like 3', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Inibidor de protease transmembrana serina 2 (TMPRSS2)', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Promazina', 'Promazina', 'Promazina', 'Promazina', 'Promazina', 'Promazina', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Selênio', 'Selênio', 'Selênio', 'Selênio', 'Selênio', 'Selênio', 'Viperina', 'Viperina', 'Viperina', 'Viperina', 'Viperina', 'Viperina', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina A', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Vitamina D (25-hidroxivitamina D)', 'Zinco', 'Zinco', 'Zinco', 'Zinco', 'Zinco', 'Zinco']	['Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Ascorbic acid', 'Antibodies', 'Antibodies', 'Antibodies', 'Antibodies', 'Antibodies' , 'Antibodies', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', 'Darunavir', ' Darunavir', 'Emodin', 'Emodin', 'Emodin', 'Emodin', 'Emodin', 'Emodin', 'Herbs with chymotrypsin-like 3 protease inhibitory activity', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin-like protease inhibitory activity 3', 'Herbs with chymotrypsin protease inhibitory activity 3' -like 3', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychlor oquina', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Transmembrane serine protease 2 (TMPRSS2) inhibitor', 'Transmembrane serine protease 2 (TMPRSS2) inhibitor', 'Transmembrane serine protease 2 (TMPRSS2) inhibitor', 'Inhibitor of transmembrane serine protease 2 (TMPRSS2)', 'Transmembrane serine protease inhibitor 2 (TMPRSS2)', 'Transmembrane serine protease inhibitor 2 (TMPRSS2)', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', ' Lopinavir', 'Lopinavir', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Promazine', 'Promazine', 'Promazine', ' Promazine', 'Promazine', 'Promazine', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir' , 'Ritonavir', 'Ritonavir', 'Selenium', 'Selenium', 'Selenium', 'Selenium', 'Selenium', 'Selenium', 'Viperine', 'Viperine', 'Viperine', 'Viperine', ' Viperina', 'Viperina', 'Vitami in A', 'Vitamin A', 'Vitamin A', 'Vitamin A', 'Vitamin A', 'Vitamin A', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)' , 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)', 'Vitamin D (25-hydroxyvitamin D)', 'Zinc', ' Zinc', 'Zinc', 'Zinc', 'Zinc', 'Zinc']	It is an ugly fact that a significant amount of the world's population will contract SARS-CoV-II infection with the current spreading. While a specific treatment is not yet coming soon, individual risk assessment and management strategies are crucial. The individual preventive and protective measures drive the personal risk of getting the disease. Among the virus-contracted hosts, their different metabolic status, as determined by their diet, nutrition, age, sex, medical conditions, lifestyle, and environmental factors, govern the personal fate toward different clinical severity of COVID-19, from asymptomatic, mild, moderate, to death. The careful individual assessment for the possible dietary, nutritional, medical, lifestyle, and environmental risks, together with the proper relevant risk management strategies, is the sensible way to deal with the pandemic of SARS-CoV-II.	32276137	Clinical immunology (Orlando, Fla.)	1521-7035	10.1016/j.clim.2020.108409	Estratégia de gerenciamento de risco individual e possíveis opções terapêuticas para a pandemia de COVID-19 	É um fato feio que uma quantidade significativa da população mundial contraia a infecção por SARS-CoV-II com a disseminação atual. Embora um tratamento específico ainda não esteja disponível em breve, a avaliação de risco individual e as estratégias de gerenciamento são cruciais. As medidas preventivas e protetivas individuais impulsionam o risco pessoal de contrair a doença. Entre os hospedeiros contraídos pelo vírus, seus diferentes estados metabólicos, determinados por sua dieta, nutrição, idade, sexo, condições médicas, estilo de vida e fatores ambientais, governam o destino pessoal em relação à gravidade clínica diferente do COVID-19, de assintomático, leve , moderado, até a morte. A avaliação individual cuidadosa dos possíveis riscos dietéticos, nutricionais, médicos, de estilo de vida e ambientais, juntamente com as estratégias adequadas de gerenciamento de riscos relevantes, é a maneira sensata de lidar com a pandemia de SARS-CoV-II.
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19	https://doi.org/10.1093/qjmed/hcaa121	10/04/2020	Artigo completo publicado em periódico científico	10.1093/qjmed/hcaa121	1460-2725	14602725	QJM (OXFORD. 1994. PRINT)	A2	0.755	123	2.1	 Abstract                                   Background                   Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin and ‘ground-glass’ opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection.                                                  Aim                   We aimed to investigate whether plasminogen can improve lung lesions and hypoxemia of COVID-19.                                                  Design                   Thirteen clinically moderate, severe or critical COVID-19 patients were treated with atomization inhalation of freeze-dried plasminogen.                                                  Methods                   Levels of their lung lesions, oxygen saturation and heart rates were compared before and after treatment by computed tomography scanning images and patient monitor.                                                  Results                   After plasminogen inhalation, conditions of lung lesions in five clinically moderate patients have quickly improved, shown as the decreased range and density of ‘ground glass’ opacity. Improvements of oxygen saturation were observed in six clinically severe patients. In the two patients with critical conditions, the oxygen levels have significantly increased from 79–82% to 91% just about 1 h after the first inhalation. In 8 of 13 patients, the heart rates had slowed down. For the five clinically moderate patients, the difference is even statistically significant. Furthermore, a general relief of chest tightness was observed.                                                  Conclusion                   Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, this study suggests that additional plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Although further studies are needed, this study highlights a possible hope of efficiently combating this rapid epidemic emergency.               	['Ativador do plasminogênio tecidual (tPA)']	['Tissue Plasminogen Activator (tPA)']	Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, this study suggests that additional plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Although further studies are needed, this study highlights a possible hope of efficiently combating this rapid epidemic emergency.	32275753	QJM : monthly journal of the Association of Physicians	1460-2393	10.1093/qjmed/hcaa121	Plasminogênio melhora lesões pulmonares e hipoxemia em pacientes com COVID-19 	Embora seja relatado que o plasminogênio está dramaticamente aumentado em adultos com SDRA, este estudo sugere que plasminogênio adicional pode ser eficaz e eficiente no tratamento de lesões pulmonares e hipoxemia durante infecções por COVID-19. Embora mais estudos sejam necessários, este estudo destaca uma possível esperança de combater eficientemente essa rápida emergência epidêmica.
Compassionate Use of Remdesivir for Patients with Severe Covid-19	https://www.nejm.org/doi/full/10.1056/NEJMoa2007016	10/04/2020	Artigo completo publicado em periódico científico	10.1056/NEJMoa2007016	0028-4793	284793	New England Journal of Medicine	A1	24.907	1079	31.87	-	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	['Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir']	-	-	-	-	-	Uso compassivo do remdesivir para pacientes com Covid-19 grave 	-
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses	https://doi.org/10.1016/j.onehlt.2020.100128	27/03/2020	Artigo completo publicado em periódico científico	10.1016/j.onehlt.2020.100128	2352-7714	23527714	ONE HEALTH	A4	1.149	29	7.65	-	['Remdesivir']	['Remdesivir']	Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734™) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on 	32258351	One health (Amsterdam, Netherlands)	2352-7714	10.1016/j.onehlt.2020.100128	O conhecimento atual sobre os antivirais remdesivir (GS-5734) e GS-441524 como opções terapêuticas para coronavírus 	As recentes epidemias internacionais de doenças associadas ao coronavírus ressaltam a necessidade urgente de saúde pública e médica para o desenvolvimento de vacinas e terapias aprovadas por órgãos reguladores. Em particular, a atual pandemia da doença de coronavírus 2019 (COVID-19) intensificou rapidamente o interesse no desenvolvimento de opções de tratamento para mitigar o impacto na vida humana. O remdesivir (GS-5734™) é um medicamento antiviral de amplo espectro que agora está sendo testado como um tratamento potencial para COVID-19 em ensaios clínicos internacionais em vários locais. As evidências atualmente disponíveis sobre os efeitos antivirais do remdesivir contra os coronavírus são baseadas principalmente em
Heavner MS. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019	https://doi.org/10.1002/phar.2398	07/02/2020	Artigo completo publicado em periódico científico	10.1002/phar.2398	0277-0008	2770008	PHARMACOTHERAPY (CARLISLE, MA.)	A2	1.308	114	4.82	-	['Baricitinibe', 'Cloroquina', 'Corticosteroides', 'Hidroxicloroquina', 'Interferon alfa', 'Lopinavir', 'Nelfinavir', 'Nitazoxanida', 'Plasma convalescente', 'Remdesivir', 'Ribavirina', 'Tocilizumabe']	['Baricitinib', 'Chloroquine', 'Corticosteroids', 'Hydroxychloroquine', 'Interferon alfa', 'Lopinavir', 'Nelfinavir', 'Nitazoxanide', 'Convalescent plasma', 'Remdesivir', 'Ribavirin', 'Tocilizumab' ]	The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into an emergent global pandemic. Coronavirus disease 2019 (COVID-19) can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. As the incidence continues to rise at a rapid pace, critical care teams are faced with challenging treatment decisions. There is currently no widely accepted standard of care in the pharmacologic management of patients with COVID-19. Urgent identification of potential treatment strategies is a priority. Therapies include novel agents available in clinical trials or through compassionate use, and other drugs, repurposed antiviral and immunomodulating therapies. Many have demonstrated in vitro or in vivo potential against other viruses that are similar to SARS-CoV-2. Critically ill patients with COVID-19 have additional considerations related to adjustments for organ impairment and renal replacement therapies, complex lists of concurrent medications, limitations with drug administration and compatibility, and unique toxicities that should be evaluated when utilizing these therapies. The purpose of this review is to summarize practical considerations for pharmacotherapy in patients with COVID-19, with the intent of serving as a resource for health care providers at the forefront of clinical care during this pandemic.	32259313	Pharmacotherapy	1875-9114	10.1002/phar.2398	Heavner MS. Revisão da Farmacoterapia Emergente para o Tratamento da Doença de Coronavírus 2019 	O surto da síndrome respiratória aguda grave coronavírus 2 (SARS-CoV-2) evoluiu para uma pandemia global emergente. A doença de coronavírus 2019 (COVID-19) pode se manifestar em um espectro de doenças, desde doença leve até insuficiência respiratória grave, exigindo internação na unidade de terapia intensiva. À medida que a incidência continua a aumentar em ritmo acelerado, as equipes de cuidados intensivos enfrentam decisões de tratamento desafiadoras. Atualmente, não existe um padrão de atendimento amplamente aceito no manejo farmacológico de pacientes com COVID-19. A identificação urgente de potenciais estratégias de tratamento é uma prioridade. As terapias incluem novos agentes disponíveis em ensaios clínicos ou por meio de uso compassivo, e outros medicamentos, terapias antivirais e imunomoduladoras reaproveitadas. Muitos demonstraram potencial in vitro ou in vivo contra outros vírus semelhantes ao SARS-CoV-2. Pacientes em estado crítico com COVID-19 têm considerações adicionais relacionadas a ajustes para comprometimento de órgãos e terapias de substituição renal, listas complexas de medicamentos concomitantes, limitações com administração e compatibilidade de medicamentos e toxicidades únicas que devem ser avaliadas ao utilizar essas terapias. O objetivo desta revisão é resumir as considerações práticas para a farmacoterapia em pacientes com COVID-19, com a intenção de servir como um recurso para os profissionais de saúde na vanguarda do atendimento clínico durante essa pandemia.
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations	https://doi.org/10.1016/S2213-2600(20)30161-2	06/04/2020	Artigo completo publicado em periódico científico	10.1016/S2213-2600(20)30161-2	2213-2600	22132600	THE LANCET RESPIRATORY MEDICINE	A1	11.120	138	14.48	-	['Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Cloroquina', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Hidroxicloroquina', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Plasma convalescente', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe', 'Tocilizumabe']	['Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Chloroquine', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', 'Favipiravir', ' Favipiravir', 'Favipiravir', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Hydroxychloroquine', 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Lopinavir' , 'Lopinavir', 'Lopinavir', 'Lopinavir', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Plasma convalescent', 'Remdesivir ', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Remdesivir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Ritonavir', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab', 'Tocilizumab']	-	-	-	-	-	Gestão de cuidados intensivos da doença de coronavírus 2019 (COVID-19): desafios e recomendações 	-
Infuenza and obesity: its odd relationship and the lessons for COVID‑19 pandemic	https://doi.org/10.1007/s00592-020-01522-8	05/04/2020	Artigo completo publicado em periódico científico	10.1007/s00592-020-01522-8	0940-5429	9405429	ACTA DIABETOLOGICA (PRINT)	A2	1.048	73	3.71	-	['Metformina', 'Pioglitazona']	['Metformin', 'Pioglitazone']	-	-	-	-	-	Infuenza e obesidade: sua estranha relação e as lições para a pandemia de COVID-19 	-
Diference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2	https://doi.org/10.1007/s11239-020-02105-8	03/04/2020	Artigo completo publicado em periódico científico	10.1007/s11239-020-02105-8	0929-5305	9295305	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	A2	0.974	72	3.8	-	['Heparina']	['Heparin']	-	-	-	-	-	Diferença das características de coagulação entre pneumonia grave induzida por SARS-CoV2 e não-SARS-CoV2 	-
Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection	https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1844	04/04/2020	Artigo completo publicado em periódico científico	10.1002/cpt.1844	0009-9236	99236	CLINICAL PHARMACOLOGY AND THERAPEUTICS	A1	1.689	195	5.36	-	['Favipiravir']	['Favipiravir']	-	-	-	-	-	Favipiravir: farmacocinética e preocupações sobre ensaios clínicos para infecção por 2019-nCoV 	-